A O
randomized O
, O
prospective O
study O
of O
endometrial B-intervention
resection I-intervention
to O
prevent O
recurrent B-condition
endometrial I-condition
polyps I-condition
in O
women B-eligibility
with I-eligibility
breast I-eligibility
cancer I-eligibility
receiving I-eligibility
tamoxifen I-eligibility
. O
To O
assess O
the O
role O
of O
endometrial O
resection O
in O
preventing O
recurrence O
of O
tamoxifen O
- O
associated O
endometrial O
polyps O
in O
women O
with O
breast O
cancer O
. O
Randomized O
, O
prospective O
study O
( O
Canadian B-ethinicity
Task O
Force O
classification O
I O
) O
. O
Tertiary O
university O
- O
affiliated O
medical O
center O
. O
Twenty B-total-participants
consecutive O
women O
( O
age O
range O
43 B-age
- I-age
61 I-age
yrs I-age
) O
. O
Hysteroscopic O
removal O
of O
tamoxifen O
- O
associated O
endometrial O
polyps O
with O
or O
without O
simultaneous O
resection O
of O
the O
endometrium O
. O
Patients O
were O
randomized O
to O
undergo O
( O
10 B-intervention-participants
women O
) O
or O
not B-control
undergo I-control
( O
10 B-control-participants
) O
concomitant O
endometrial O
resection O
. O
They O
were O
followed O
for O
at O
least O
18 O
months O
( O
range O
18 O
- O
24 O
mo O
) O
, O
including O
transvaginal O
ultrasonography O
every O
6 O
months O
and O
hysteroscopy O
when O
endometrial O
irregularity O
was O
noted O
. O
The O
main O
outcome O
variable O
was O
recurrence B-outcome-measure
of I-outcome-measure
endometrial I-outcome-measure
polyps I-outcome-measure
; O
occurrence B-outcome-measure
of I-outcome-measure
uterine I-outcome-measure
bleeding I-outcome-measure
was O
also O
noted O
. O
In O
women O
who O
underwent O
endometrial O
resection O
, O
only O
one B-iv-bin-abs
had O
a O
1 O
x O
1 O
- O
cm O
endometrial B-outcome
polyp I-outcome
diagnosed O
and O
removed O
during O
follow O
- O
up O
. O
Seven B-iv-bin-abs
women O
remained O
amenorrheic B-outcome
, O
and O
three B-iv-bin-abs
experienced O
spotting B-outcome
for O
a O
few O
days O
every O
month O
. O
In O
the O
control O
group O
, O
six B-cv-bin-abs
women O
had O
recurrent B-outcome
endometrial I-outcome
polyps I-outcome
requiring I-outcome
hysteroscopic I-outcome
removal I-outcome
( O
two O
- O
tail O
Fisher O
's O
exact O
test O
p O
< O
0.06 O
) O
. O
Recurrence O
of O
endometrial O
polyps O
, O
one O
of O
the O
most O
common O
problems O
in O
patients O
with O
breast O
cancer O
receiving O
long O
- O
term O
treatment O
with O
tamoxifen O
, O
may O
be O
reduced O
by O
performing O
endometrial O
resection O
at O
the O
time O
of O
hysteroscopic O
removal O
of O
polyps O
. O
The O
possible O
risk O
of O
occult O
endometrial O
cancer O
is O
yet O
to O
be O
determined O
. O
( O
J O
Am O
Assoc O
Gynecol O
Laparosc O
6 O
( O
3 O
): O
285 O
- O
288 O
, O
1999 O
) O

Randomized O
trial O
of O
fenretinide B-intervention
to O
prevent O
second B-condition
breast I-condition
malignancy I-condition
in O
women O
with O
early O
breast O
cancer O
. O
Fenretinide O
, O
a O
vitamin O
A O
analogue O
, O
has O
been O
shown O
to O
inhibit O
breast O
carcinogenesis O
in O
preclinical O
studies O
. O
We O
determined O
the O
efficacy O
of O
fenretinide O
in O
preventing O
a O
second O
breast O
malignancy O
in O
women O
with O
breast O
cancer O
. O
We O
randomly O
assigned O
2972 B-total-participants
women O
, O
aged O
30 B-age
- I-age
70 I-age
years I-age
, O
with B-eligibility
surgically I-eligibility
removed I-eligibility
stage I-eligibility
I I-eligibility
breast I-eligibility
cancer I-eligibility
or I-eligibility
ductal I-eligibility
carcinoma I-eligibility
in I-eligibility
situ I-eligibility
to O
receive O
for O
5 O
years O
either O
fenretinide O
orally O
( O
200 O
mg O
/ O
day O
) O
or O
no B-control
treatment I-control
. O
The O
primary O
end O
point O
was O
the O
incidence B-outcome-measure
of I-outcome-measure
contralateral I-outcome-measure
breast I-outcome-measure
cancer I-outcome-measure
or I-outcome-measure
ipsilateral I-outcome-measure
breast I-outcome-measure
cancer I-outcome-measure
7 O
years O
after O
randomization O
. O
Other O
end O
points O
considered O
post O
hoc O
were O
the O
same O
outcomes O
stratified O
by O
menopausal B-outcome-measure
status I-outcome-measure
, O
incidence B-outcome-measure
of I-outcome-measure
distant I-outcome-measure
metastases I-outcome-measure
, O
overall B-outcome-measure
mortality I-outcome-measure
, O
and O
tumors B-outcome-measure
in I-outcome-measure
other I-outcome-measure
organs I-outcome-measure
. O
The O
hazards O
of O
breast O
cancer O
occurrence O
were O
determined O
by O
Cox O
proportional O
hazards O
regression O
analysis O
. O
Statistical O
tests O
were O
two O
- O
sided O
. O
At O
a O
median O
observation O
time O
of O
97 O
months O
, O
there O
were O
no O
statistically O
significant O
differences O
in O
the O
occurrence B-outcome
of I-outcome
contralateral I-outcome
breast I-outcome
cancer I-outcome
( O
P O
= O
.642 O
) O
or O
ipsilateral B-outcome
breast I-outcome
cancer I-outcome
( O
P O
= O
.177 O
) O
between O
the O
two O
arms O
. O
However O
, O
an O
interaction O
was O
detected O
between O
fenretinide O
treatment O
and O
menopausal O
status O
in O
both O
outcomes O
( O
P O
for O
interaction O
in O
both O
outcomes O
= O
.045 O
) O
, O
with O
a O
possible O
beneficial O
effect O
in O
premenopausal B-outcome
women I-outcome
( O
contralateral B-outcome
breast I-outcome
cancer I-outcome
: O
adjusted O
hazard O
ratio O
[ O
HR O
] O
= O
0.66 O
, O
and O
95 O
% O
confidence O
interval O
[ O
CI O
] O
= O
0.41 O
- O
1.07 O
; O
ipsilateral B-outcome
breast I-outcome
cancer I-outcome
: O
adjusted O
HR O
= O
0.65 O
, O
and O
95 O
% O
CI O
= O
0.46 O
- O
0 O
. O
92 O
) O
and O
an O
opposite O
effect O
in O
postmenopausal B-outcome
women I-outcome
( O
contralateral B-outcome
breast I-outcome
cancer I-outcome
: O
adjusted O
HR O
= O
1.32 O
, O
and O
95 O
% O
CI O
= O
0.82 O
- O
2.15 O
; O
ipsilateral B-outcome
breast I-outcome
cancer I-outcome
: O
adjusted O
HR O
= O
1.19 O
, O
and O
95 O
% O
CI O
= O
0.75 O
- O
1 O
. O
89 O
) O
. O
There O
were O
no O
statistically O
significant O
differences O
between O
the O
two O
arms O
in O
tumors B-outcome
in I-outcome
other I-outcome
organs I-outcome
, O
incidence B-outcome
of I-outcome
distant I-outcome
metastasis I-outcome
, O
and O
all B-outcome
- I-outcome
cause I-outcome
mortality I-outcome
. O
Fenretinide O
treatment O
of O
women O
with O
breast O
cancer O
for O
5 O
years O
appears O
to O
have O
no O
statistically O
significant O
effect O
on O
the O
incidence O
of O
second O
breast O
malignancies O
overall O
, O
although O
a O
possible O
benefit O
was O
detected O
in O
premenopausal O
women O
. O
These O
studies O
, O
particularly O
the O
post O
hoc O
analyses O
, O
are O
considered O
exploratory O
and O
need O
to O
be O
confirmed O
. O

Cardiovascular O
effects O
of O
tamoxifen B-intervention
in O
women O
with O
and O
without O
heart O
disease O
: O
breast O
cancer O
prevention O
trial O
. O
National O
Surgical O
Adjuvant O
Breast O
and O
Bowel O
Project O
Breast O
Cancer O
Prevention O
Trial O
Investigators O
. O
The O
overall O
effect O
of O
prophylactic O
tamoxifen O
in O
women O
depends O
on O
the O
balance O
between O
the O
effects O
of O
the O
drug O
, O
which O
include O
preventing O
breast O
cancer O
and O
altering O
cardiovascular O
risk O
. O
In O
a O
recent O
clinical O
trial O
, O
postmenopausal O
estrogen O
- O
progestin O
therapy O
was O
shown O
to O
increase O
the O
risk O
of O
early O
cardiovascular O
events O
among O
women O
with O
a O
history O
of O
coronary B-condition
heart I-condition
disease I-condition
( I-condition
CHD I-condition
) I-condition
. O
The O
cardiovascular O
effects O
of O
tamoxifen O
in O
women O
with O
and O
without O
CHD O
are O
not O
known O
. O
The O
National O
Surgical O
Adjuvant O
Breast O
and O
Bowel O
Project O
Breast O
Cancer O
Prevention O
Trial O
( O
BCPT O
) O
is O
the O
only O
clinical O
trial O
that O
provides O
data O
to O
assess O
the O
cardiovascular O
effects O
of O
tamoxifen O
in O
women O
with O
and O
without O
CHD O
. O
A O
total O
of O
13 B-total-participants
388 I-total-participants
women B-eligibility
at I-eligibility
increased I-eligibility
risk I-eligibility
for I-eligibility
breast I-eligibility
cancer I-eligibility
were O
randomly O
assigned O
in O
the O
BCPT O
to O
receive O
either O
tamoxifen O
( O
20 O
mg O
/ O
day O
) O
or O
placebo B-control
. O
Cardiovascular O
follow O
- O
up O
was O
available O
for O
13 B-total-participants
194 I-total-participants
women O
, O
1048 O
of O
whom O
had O
prior O
clinical O
CHD O
. O
Fatal O
and O
nonfatal O
myocardial O
infarction O
, O
unstable O
angina O
, O
and O
severe O
angina O
were O
tabulated O
( O
mean O
follow O
- O
up O
: O
49 O
months O
) O
. O
All O
statistical O
tests O
were O
two O
- O
sided O
. O
Cardiovascular B-outcome
event I-outcome
rates I-outcome
were O
not O
statistically O
significantly O
different O
between O
women O
assigned O
to O
receive O
tamoxifen O
and O
those O
assigned O
to O
receive O
placebo O
, O
independent O
of O
pre O
- O
existing O
CHD O
. O
Among O
women O
without O
CHD O
( O
6074 B-intervention-participants
on O
tamoxifen O
versus O
6072 B-control-participants
on O
placebo O
) O
, O
risk O
ratios O
( O
95 O
% O
confidence O
intervals O
[ O
CIs O
] O
) O
for O
tamoxifen O
users O
were O
1.75 O
( O
0.44 O
to O
8.13 O
) O
for O
fatal B-outcome
myocardial I-outcome
infarction I-outcome
, I-outcome
1.11 O
( O
0.55 O
to O
2.28 O
) O
for O
nonfatal B-outcome
myocardial I-outcome
infarction I-outcome
, O
0.69 O
( O
0.29 O
to O
1.57 O
) O
for O
unstable B-outcome
angina I-outcome
, O
and O
0.83 O
( O
0.32 O
to O
2.10 O
) O
for O
severe B-outcome
angina I-outcome
. O
In O
women O
with O
CHD O
( O
516 B-intervention-participants
on O
tamoxifen O
versus O
532 B-control-participants
on O
placebo O
) O
, O
risk O
ratios O
( O
95 O
% O
CIs O
) O
for O
tamoxifen O
users O
were O
0.00 O
( O
0 O
to O
1.58 O
) O
for O
fatal B-outcome
myocardial I-outcome
infarction I-outcome
, O
1.25 O
( O
0.32 O
to O
5.18 O
) O
for O
nonfatal B-outcome
myocardial I-outcome
infarction I-outcome
, O
2.26 O
( O
0.87 O
to O
6.55 O
) O
for O
unstable B-outcome
angina I-outcome
, O
and O
1.39 O
( O
0.23 O
to O
9.47 O
) O
for O
severe B-outcome
angina I-outcome
. O
There O
was O
no O
evidence O
that O
the O
lack O
of O
association O
between O
tamoxifen O
and O
cardiovascular O
events O
was O
related O
to O
an O
early O
increase O
in O
risk O
that O
may O
have O
been O
offset O
by O
a O
late O
decrease O
in O
risk O
. O
When O
used O
for O
breast O
cancer O
prevention O
in O
women O
with O
or O
without O
heart O
disease O
, O
tamoxifen O
is O
not O
associated O
with O
beneficial O
or O
adverse O
cardiovascular O
effects O
. O

Tamoxifen B-intervention
for O
the O
prevention O
of O
breast O
cancer O
: O
psychosocial O
impact O
on O
women O
participating O
in O
two O
randomized O
controlled O
trials O
. O
The O
purpose O
of O
this O
study O
was O
to O
evaluate O
the O
psychosocial O
implications O
of O
tamoxifen O
versus O
placebo B-control
in O
women B-eligibility
who I-eligibility
are I-eligibility
at I-eligibility
increased I-eligibility
risk I-eligibility
of I-eligibility
breast I-eligibility
cancer I-eligibility
. O
The O
488 B-total-participants
women O
in O
the O
psychosocial O
study O
were O
recruited O
from O
participants O
in O
two O
placebo O
- O
controlled O
, O
double O
- O
blind O
, O
randomized O
, O
controlled O
trials O
that O
investigated O
the O
efficacy O
of O
tamoxifen O
in O
the O
prevention O
of O
breast O
cancer O
in O
women O
who O
are O
at O
high O
familial O
risk O
. O
During O
a O
5 O
- O
year O
period O
, O
repeated O
assessments O
were O
made O
of O
anxiety O
, O
psychological O
distress O
, O
and O
sexual O
functioning O
using O
standardized O
questionnaires O
before O
treatment O
at O
baseline O
and O
at O
6 O
- O
month O
intervals O
during O
the O
trial O
. O
Questionnaire O
completion O
over O
5 O
years O
was O
good O
, O
with O
71.1 O
% O
of O
women O
returning O
at O
least O
8 O
of O
10 O
follow O
- O
up O
assessments O
. O
Although O
scores O
from O
individuals O
showed O
considerable O
fluctuation O
and O
variation O
over O
time O
, O
changes B-outcome
in I-outcome
anxiety I-outcome
, O
mood B-outcome
, O
and O
sexual B-outcome
functioning I-outcome
were O
not O
associated O
with O
treatment O
group O
. O
The O
number O
of O
symptoms O
reported O
at O
48 O
months O
via O
a O
self O
- O
report O
checklist O
were O
not O
associated O
with O
treatment O
group O
, O
but O
vasomotor B-outcome
symptoms I-outcome
were O
more O
frequent O
among O
tamoxifen O
- O
treated O
women O
. O
Symptoms O
of O
low B-outcome
energy I-outcome
, O
breast B-outcome
sensitivity I-outcome
, O
and O
visual B-outcome
blurring I-outcome
were O
reported O
most O
frequently O
in O
the O
placebo O
group O
. O
In O
general O
, O
these O
results O
are O
comparable O
to O
those O
from O
the O
National O
Surgical O
Adjuvant O
Breast O
and O
Bowel O
Project O
psychosocial O
study O
despite O
differences O
in O
study O
populations O
, O
methodology O
, O
and O
instruments O
. O
The O
long O
- O
term O
use O
of O
tamoxifen O
and O
other O
selective O
estrogen O
response O
modulators O
as O
preventive O
agents O
in O
high O
- O
risk O
groups O
has O
been O
questioned O
, O
but O
we O
found O
no O
evidence O
of O
treatment O
- O
related O
side O
effects O
that O
affect O
women O
's O
psychosocial O
and O
sexual O
functioning O
. O

A O
phase O
II O
breast O
cancer O
chemoprevention O
trial O
of O
oral O
alpha B-intervention
- I-intervention
difluoromethylornithine I-intervention
: O
breast O
tissue O
, O
imaging O
, O
and O
serum O
and O
urine O
biomarkers O
. O
A O
double O
- O
blind O
randomized O
Phase O
II O
chemoprevention O
trial O
of O
alpha O
- O
difluoromethylornithine O
( O
DFMO O
) O
was O
conducted O
in O
a O
group O
of O
women B-eligibility
at I-eligibility
high I-eligibility
risk I-eligibility
for I-eligibility
development I-eligibility
of I-eligibility
breast I-eligibility
cancer I-eligibility
. O
DFMO O
is O
an O
irreversible O
inhibitor O
of O
ornithine O
decarboxylase O
, O
the O
limiting O
enzyme O
of O
polyamine O
synthesis O
that O
is O
often O
up O
- O
regulated O
in O
breast O
cancer O
. O
Study O
entrants O
were O
required O
to O
have O
random O
periareolar O
fine O
- O
needle O
aspiration O
cytology O
prior O
to O
entry O
that O
exhibited O
hyperplasia O
or O
hyperplasia O
with O
atypia O
, O
as O
well O
as O
a O
mammogram O
and O
clinical O
breast O
exam O
judged O
as O
not O
suspicious O
for O
breast O
cancer O
and O
no O
clinical O
hearing O
loss O
. O
Subjects O
were O
randomized O
to O
6 O
months O
of O
oral O
DFMO O
( O
0.5 O
g O
/ O
m O
( O
2 O
) O
/day O
) O
or O
placebo B-control
, O
followed O
by O
repeat O
fine O
- O
needle O
aspiration O
and O
biomarker O
assessment O
. O
The O
main O
study O
end O
point O
was O
an O
improvement B-outcome-measure
in I-outcome-measure
cytologic I-outcome-measure
pattern I-outcome-measure
. O
Of O
119 B-total-participants
subjects O
entered O
, O
96 O
% O
completed O
the O
study O
and O
were O
evaluable O
for O
the O
main O
study O
end O
point O
. O
A O
modest O
reduction O
( O
28 O
% O
) O
in O
average O
total B-outcome
urine I-outcome
polyamines I-outcome
was O
obtained O
in O
the O
DFMO O
group O
, O
but O
there O
was O
no O
reduction B-outcome
in I-outcome
the I-outcome
spermidine I-outcome
: I-outcome
spermine I-outcome
ratio I-outcome
. O
There O
was O
no O
difference O
in O
cytologic B-outcome
improvement I-outcome
between O
DFMO O
and O
placebo O
. O
Likewise O
, O
there O
was O
no O
difference O
between O
DFMO O
and O
placebo O
for O
the O
secondary O
end O
points O
of O
breast B-outcome
molecular I-outcome
marker I-outcome
changes I-outcome
( O
immunocytochemical O
expression O
of O
proliferating O
cell O
nuclear O
antigen O
, O
p53 O
, O
and O
epidermal O
growth O
factor O
receptor O
) O
, O
mammographic B-outcome
breast I-outcome
density I-outcome
, O
serum B-outcome
insulin I-outcome
- I-outcome
like I-outcome
growth I-outcome
factor I-outcome
I I-outcome
: O
insulin O
- O
like O
growth O
factor O
binding O
protein O
3 O
ratio O
, O
adverse B-outcome
events I-outcome
, O
quality B-outcome
of I-outcome
life I-outcome
indices I-outcome
, O
or O
subsequent B-outcome
cancer I-outcome
development I-outcome
. O
DFMO O
at O
a O
dose O
level O
of O
0.5 O
g O
/ O
m O
( O
2 O
) O
/day O
administered O
for O
6 O
months O
does O
not O
modulate O
breast O
risk O
biomarkers O
tested O
in O
this O
study O
. O

Tamoxifen B-intervention
, I-intervention
radiation I-intervention
therapy I-intervention
, I-intervention
or I-intervention
both I-intervention
for O
prevention O
of O
ipsilateral B-condition
breast I-condition
tumor I-condition
recurrence I-condition
after O
lumpectomy O
in O
women B-eligibility
with I-eligibility
invasive I-eligibility
breast I-eligibility
cancers I-eligibility
of I-eligibility
one I-eligibility
centimeter I-eligibility
or I-eligibility
less I-eligibility
. O
This O
trial O
was O
prompted O
by O
uncertainty O
about O
the O
need O
for O
breast O
irradiation O
after O
lumpectomy O
in O
node O
- O
negative O
women O
with O
invasive O
breast O
cancers O
of O
< O
/ O
= O
1 O
cm O
, O
by O
speculation O
that O
tamoxifen O
( O
TAM O
) O
might O
be O
as O
or O
more O
effective O
than O
radiation O
therapy O
( O
XRT O
) O
in O
reducing O
the O
rate O
of O
ipsilateral O
breast O
tumor O
recurrence O
( O
IBTR O
) O
in O
such O
women O
, O
and O
by O
the O
thesis O
that O
both O
modalities O
might O
be O
more O
effective O
than O
either O
alone O
. O
After O
lumpectomy O
, O
1,009 B-total-participants
women O
were O
randomly O
assigned O
to O
TAM O
( O
n O
= O
336 B-intervention-participants
) O
, O
XRT B-control
and I-control
placebo I-control
( O
n O
= O
336 B-control-participants
) O
, O
or O
XRT O
and O
TAM O
( O
n O
= O
337 B-intervention-participants
) O
. O
Rates B-outcome-measure
of I-outcome-measure
IBTR I-outcome-measure
, O
distant B-outcome-measure
recurrence I-outcome-measure
, O
and O
contralateral B-outcome-measure
breast I-outcome-measure
cancer I-outcome-measure
( I-outcome-measure
CBC I-outcome-measure
) I-outcome-measure
were O
among O
the O
end O
points O
for O
analysis O
. O
Cumulative O
incidence O
of O
IBTR O
and O
of O
CBC O
was O
computed O
accounting O
for O
competing O
risks O
. O
Results O
with O
two O
- O
sided O
P O
values O
of.05 O
or O
less O
were O
statistically O
significant O
. O
XRT O
and O
placebo O
resulted O
in O
a O
49 B-cv-bin-percent
% I-cv-bin-percent
lower O
hazard B-outcome
rate I-outcome
of I-outcome
IBTR I-outcome
than O
did O
TAM O
alone O
; O
XRT O
and O
TAM O
resulted O
in O
a O
63 B-iv-bin-percent
% I-iv-bin-percent
lower O
rate O
than O
did O
XRT O
and O
placebo O
. O
When O
compared O
with O
TAM O
alone O
, O
XRT O
plus O
TAM O
resulted O
in O
an O
81 B-iv-bin-percent
% I-iv-bin-percent
reduction B-outcome
in I-outcome
hazard I-outcome
rate I-outcome
of I-outcome
IBTR I-outcome
. O
Cumulative B-outcome
incidence I-outcome
of I-outcome
IBTR I-outcome
through O
8 O
years O
was O
16.5 B-iv-bin-percent
% I-iv-bin-percent
with O
TAM O
, O
9.3 B-cv-bin-percent
% I-cv-bin-percent
with O
XRT O
and O
placebo O
, O
and O
2.8 B-iv-bin-percent
% I-iv-bin-percent
with O
XRT O
and O
TAM O
. O
XRT O
reduced O
IBTR O
below O
the O
level O
achieved O
with O
TAM O
alone O
, O
regardless O
of O
estrogen O
receptor O
( O
ER O
) O
status O
. O
Distant B-outcome
treatment I-outcome
failures I-outcome
were O
infrequent O
and O
not O
significantly O
different O
among O
the O
groups O
( O
P O
= O
.28 O
) O
. O
When O
TAM O
- O
treated O
women O
were O
compared O
with O
those O
who O
received O
XRT O
and O
placebo O
, O
there O
was O
a O
significant O
reduction B-outcome
in I-outcome
CBC I-outcome
( O
hazard O
ratio O
, O
0.45 O
; O
95 O
% O
confidence O
interval O
, O
0.21 O
to O
0.95 O
; O
P O
= O
.039 O
) O
. O
Survival B-outcome
in O
the O
three O
groups O
was O
93 B-iv-bin-percent
% I-iv-bin-percent
, O
94 B-cv-bin-percent
% I-cv-bin-percent
, O
and O
93 B-iv-bin-percent
% I-iv-bin-percent
, O
respectively O
( O
P O
= O
.93 O
) O
. O
In O
women O
with O
tumors O
< O
/ O
= O
1 O
cm O
, O
IBTR O
occurs O
with O
enough O
frequency O
after O
lumpectomy O
to O
justify O
considering O
XRT O
, O
regardless O
of O
tumor O
ER O
status O
, O
and O
TAM O
plus O
XRT O
when O
tumors O
are O
ER O
positive O
. O

Twenty O
- O
year O
follow O
- O
up O
of O
a O
randomized O
study O
comparing O
breast B-intervention
- I-intervention
conserving I-intervention
surgery I-intervention
with O
radical B-control
mastectomy I-control
for O
early O
breast O
cancer O
. O
We O
conducted O
20 O
years O
of O
follow O
- O
up O
of O
women O
enrolled O
in O
a O
randomized O
trial O
to O
compare O
the O
efficacy O
of O
radical O
( O
Halsted O
) O
mastectomy O
with O
that O
of O
breast O
- O
conserving O
surgery O
. O
From O
1973 O
to O
1980 O
, O
701 B-total-participants
women B-eligibility
with I-eligibility
breast I-eligibility
cancers I-eligibility
measuring I-eligibility
no I-eligibility
more I-eligibility
than I-eligibility
2 I-eligibility
cm I-eligibility
in O
diameter O
were O
randomly O
assigned O
to O
undergo O
radical O
mastectomy O
( O
349 B-control-participants
patients O
) O
or O
breast O
- O
conserving O
surgery O
( O
quadrantectomy O
) O
followed O
by O
radiotherapy O
to O
the O
ipsilateral O
mammary O
tissue O
( O
352 B-intervention-participants
patients O
) O
. O
After O
1976 O
, O
patients O
in O
both O
groups O
who O
had O
positive O
axillary O
nodes O
also O
received O
adjuvant O
chemotherapy O
with O
cyclophosphamide O
, O
methotrexate O
, O
and O
fluorouracil O
. O
Thirty B-iv-bin-abs
women O
in O
the O
group O
that O
underwent O
breast O
- O
conserving O
therapy O
had O
a O
recurrence B-outcome
of I-outcome
tumor I-outcome
in O
the O
same O
breast O
, O
whereas O
eight B-cv-bin-abs
women O
in O
the O
radical O
- O
mastectomy O
group O
had O
local O
recurrences O
( O
P<0.001 O
) O
. O
The O
crude O
cumulative B-outcome
incidence I-outcome
of O
these O
events O
was O
8.8 B-iv-bin-percent
percent I-iv-bin-percent
and O
2.3 B-cv-bin-percent
percent I-cv-bin-percent
, O
respectively O
, O
after O
20 O
years O
. O
In O
contrast O
, O
there O
was O
no O
significant O
difference O
between O
the O
two O
groups O
in O
the O
rates B-outcome
of I-outcome
contralateral I-outcome
- I-outcome
breast I-outcome
carcinomas I-outcome
, O
distant B-outcome
metastases I-outcome
, O
or O
second B-outcome
primary I-outcome
cancers I-outcome
. O
After O
a O
median O
follow O
- O
up O
of O
20 O
years O
, O
the O
rate O
of O
death B-outcome
from I-outcome
all I-outcome
causes I-outcome
was O
41.7 B-iv-bin-percent
percent I-iv-bin-percent
in O
the O
group O
that O
underwent O
breast O
- O
conserving O
surgery O
and O
41.2 B-cv-bin-percent
percent I-cv-bin-percent
in O
the O
radical O
- O
mastectomy O
group O
( O
P O
= O
1.0 O
) O
. O
The O
respective O
rates O
of O
death B-outcome
from I-outcome
breast I-outcome
cancer I-outcome
were O
26.1 B-iv-bin-percent
percent I-iv-bin-percent
and O
24.3 B-cv-bin-percent
percent I-cv-bin-percent
( O
P O
= O
0.8 O
) O
. O
The O
long B-outcome
- I-outcome
term I-outcome
survival I-outcome
rate I-outcome
among O
women O
who O
undergo O
breast O
- O
conserving O
surgery O
is O
the O
same O
as O
that O
among O
women O
who O
undergo O
radical O
mastectomy O
. O
Breast O
- O
conserving O
surgery O
is O
therefore O
the O
treatment O
of O
choice O
for O
women O
with O
relatively O
small O
breast O
cancers O
. O

Dose O
- O
dense O
biweekly O
doxorubicin B-intervention
/ I-intervention
docetaxel I-intervention
versus O
sequential B-control
neoadjuvant I-control
chemotherapy I-control
with O
doxorubicin O
/ O
cyclophosphamide O
/ O
docetaxel O
in O
operable B-eligibility
breast I-eligibility
cancer I-eligibility
: O
second O
interim O
analysis O
. O
Timing O
of O
systemic O
treatment O
in O
primary O
operable O
breast O
cancer O
is O
subject O
to O
extensive O
investigation O
, O
suggesting O
that O
pathologic O
complete O
remission O
( O
pCR O
) O
might O
improve O
survival O
in O
this O
setting O
. O
The O
German O
Adjuvant O
Breast O
Cancer O
Group O
previously O
demonstrated O
the O
feasibility O
of O
a O
dose O
- O
dense O
biweekly O
schedule O
of O
4 O
cycles O
doxorubicin O
50 O
mg O
/ O
m2 O
and O
docetaxel O
75 O
mg O
/ O
m2 O
( O
ddAT O
) O
+ O
/- O
tamoxifen O
in O
the O
neoadjuvant O
setting O
to O
yield O
a O
pCR O
of O
9.7 O
% O
( O
Gepardo O
trial O
) O
. O
Patients O
assigned O
to O
ddAT O
received O
prophylactic O
granulocyte O
colony O
- O
stimulating O
factor O
support O
( O
5 O
micro O
g O
/ O
kg O
days O
5 O
- O
10 O
) O
. O
The O
current O
study O
( O
GeparDUO O
) O
was O
designed O
to O
assess O
whether O
the O
pCR O
rate O
, O
including O
no O
viable O
invasive O
and O
preinvasive O
tumor O
cells O
, O
achieved O
with O
ddAT O
was O
equivalent O
to O
sequential O
administration O
of O
doxorubicin O
/ O
cyclophosphamide O
followed O
by O
docetaxel O
( O
AC O
- O
DOC O
) O
over O
24 O
weeks O
in O
primary O
operable O
breast O
cancer O
. O
From O
June O
1999 O
to O
September O
2001 O
, O
913 B-total-participants
patients O
were O
enrolled O
in O
this O
trial O
. O
In O
total O
, O
395 B-total-participants
patients O
randomized O
before O
August O
1 O
, O
2000 O
, O
were O
included O
in O
the O
second O
interim O
analysis O
. O
Safety O
data O
were O
available O
from O
369 B-total-participants
patients O
( O
ddAT O
, O
n O
= O
191 B-intervention-participants
; O
AC O
- O
DOC O
, O
n O
= O
178 B-control-participants
) O
demonstrating O
that O
toxicity O
of O
both O
regimens O
was O
tolerable O
. O
Grade B-outcome
3 I-outcome
/ I-outcome
4 I-outcome
neutropenia I-outcome
occurred O
in O
39.8 B-iv-bin-percent
% I-iv-bin-percent
of O
patients O
receiving O
ddAT O
and O
in O
69.3 B-cv-bin-percent
% I-cv-bin-percent
of O
patients O
treated O
with O
AC O
- O
DOC O
. O
Efficacy O
data O
were O
available O
in O
378 B-total-participants
patients O
. O
A O
pCR B-outcome
occurred I-outcome
in O
14.8 O
% O
of O
the O
primary O
breast O
tumors O
. O
According O
to O
the O
recommendations O
of O
the O
data O
monitoring O
committee O
, O
recruitment O
to O
the O
study O
was O
halted O
as O
of O
September O
2001 O
( O
n O
= O
913 O
/ O
1000 O
) O
due O
to O
the O
significant O
difference O
in O
pCR O
rates O
observed O
between O
the O
treatment O
arms O
. O
Surgery O
was O
documented O
in O
380 O
patients O
. O
Breast B-outcome
conservation I-outcome
was O
possible O
in O
288 O
cases O
( O
75.8 O
% O
) O
. O
The O
application O
of O
both O
schedules O
is O
safe O
and O
feasible O
in O
an O
outpatient O
setting O
. O
Although O
, O
results O
obtained O
from O
this O
interim O
analysis O
are O
encouraging O
, O
caution O
is O
recommended O
until O
the O
results O
obtained O
show O
statistical O
difference O
in O
pCR O
. O

Docetaxel B-intervention
vs O
5 B-control
- I-control
fluorouracil I-control
plus I-control
vinorelbine I-control
in O
metastatic O
breast O
cancer O
after O
anthracycline O
therapy O
failure O
. O
This O
multicentre O
, O
randomised O
phase O
III O
study O
compared O
docetaxel O
with O
5 O
- O
fluorouracil+vinorelbine O
in O
patients O
with O
metastatic O
breast O
cancer O
after O
failure O
of O
neo O
/ O
adjuvant O
or O
one O
line O
of O
palliative O
anthracycline O
- O
based O
chemotherapy O
. O
One B-total-participants
hundred I-total-participants
and I-total-participants
seventy I-total-participants
- I-total-participants
six I-total-participants
metastatic B-eligibility
breast I-eligibility
cancer I-eligibility
patients I-eligibility
were O
randomised O
to O
receive O
docetaxel O
( O
100 O
mg O
m O
( O
-2 O
) O
) O
every O
3 O
weeks O
or O
5 O
- O
fluorouracil+vinorelbine O
: O
5 O
- O
fluorouracil O
( O
750 O
mg O
m O
( O
-2 O
) O
per O
day O
continuous O
infusion O
) O
D1 O
- O
5 O
plus O
vinorelbine O
( O
25 O
mg O
m O
( O
-2 O
) O
) O
D1 O
and O
D5 O
of O
each O
3 O
- O
week O
cycle O
. O
Eighty B-intervention-participants
- I-intervention-participants
six I-intervention-participants
patients O
received O
516 O
cycles O
of O
docetaxel O
; O
90 B-control-participants
patients O
received O
476 O
cycles O
of O
5 O
- O
fluorouracil+vinorelbine O
. O
Median B-outcome
time I-outcome
to I-outcome
progression I-outcome
( O
6.5 B-iv-cont-median
vs O
5.1 B-cv-cont-median
months I-cv-cont-median
) O
and O
overall B-outcome
survival I-outcome
( O
16.0 B-iv-cont-median
vs O
15.0 B-cv-cont-median
months I-cv-cont-median
) O
did O
not O
differ O
significantly O
between O
the O
docetaxel O
and O
5 O
- O
fluorouracil+vinorelbine O
arms O
, O
respectively O
. O
Six B-iv-bin-abs
( O
7 B-iv-bin-percent
% I-iv-bin-percent
) O
complete B-outcome
responses I-outcome
and O
31 B-iv-bin-abs
( O
36 B-iv-bin-percent
% I-iv-bin-percent
) O
partial B-outcome
responses I-outcome
occurred O
with O
docetaxel O
( O
overall B-outcome
response I-outcome
rate I-outcome
43 B-iv-bin-percent
% I-iv-bin-percent
, O
95 O
% O
confidence O
interval O
: O
32 O
- O
53 O
% O
) O
, O
while O
4 B-cv-bin-abs
( O
4.4 B-cv-bin-percent
% I-cv-bin-percent
) O
complete B-outcome
responses I-outcome
and O
31 B-cv-bin-abs
( O
34.4 B-cv-bin-percent
% I-cv-bin-percent
) O
partial B-outcome
responses I-outcome
occurred O
with O
5 O
- O
fluorouracil+vinorelbine O
( O
overall B-outcome
response I-outcome
rate I-outcome
38.8 B-cv-bin-percent
% I-cv-bin-percent
, O
95 O
% O
confidence O
interval O
: O
29 O
- O
49 O
% O
) O
. O
Main O
grade B-outcome
3 I-outcome
- I-outcome
4 I-outcome
toxicities I-outcome
were O
( O
docetaxel O
vs O
5 O
- O
fluorouracil+vinorelbine O
): O
neutropenia B-outcome
82 B-iv-bin-percent
% I-iv-bin-percent
vs O
67 B-cv-bin-percent
% I-cv-bin-percent
; O
stomatitis B-outcome
5 B-iv-bin-percent
% I-iv-bin-percent
vs O
40 B-cv-bin-percent
% I-cv-bin-percent
; O
febrile B-outcome
neutropenia I-outcome
13 B-iv-bin-percent
% I-iv-bin-percent
vs O
22 B-cv-bin-percent
% I-cv-bin-percent
; O
and O
infection B-outcome
2 B-iv-bin-percent
% I-iv-bin-percent
vs O
7 B-cv-bin-percent
% I-cv-bin-percent
. O
There O
was O
one B-iv-bin-abs
possible O
treatment B-outcome
- I-outcome
related I-outcome
death I-outcome
in O
the O
docetaxel O
arm O
and O
five B-cv-bin-abs
with O
5 O
- O
fluorouracil+vinorelbine O
. O
In O
anthracycline O
- O
pretreated O
metastatic O
breast O
cancer O
patients O
, O
docetaxel O
showed O
comparable O
efficacy O
to O
5 O
- O
fluorouracil+vinorelbine O
, O
but O
was O
less O
toxic O
. O

Fenretinide B-intervention
breast O
cancer O
prevention O
trial O
: O
drug O
and O
retinol O
plasma O
levels O
in O
relation O
to O
age O
and O
disease O
outcome O
. O
To O
assess O
, O
in O
women O
participating O
in O
a O
breast O
cancer O
prevention O
trialon O
fenretinide O
( O
4 O
- O
HPR O
) O
, O
the O
relationship O
of O
drug O
and O
retinol O
levels O
with O
the O
risk O
of O
second O
breast O
malignancy O
, O
taking O
into O
account O
age O
and O
menopausal O
status O
. O
In O
a O
multicenter O
prevention O
trial O
, O
women B-eligibility
with I-eligibility
early I-eligibility
breast I-eligibility
cancer I-eligibility
were O
randomly O
assigned O
to O
receive O
no B-control
treatment I-control
or O
200 O
mg O
of O
4 O
- O
HPR O
/ O
day O
for O
5 O
years O
. O
Blood O
was O
collected O
at O
baseline O
and O
on O
a O
yearly O
basis O
during O
intervention O
from O
women O
recruited O
at O
the O
Istituto O
Tumori O
( O
Milan B-location
, I-location
Italy I-location
; O
818 B-intervention-participants
and O
756 B-control-participants
in O
the O
4 O
- O
HPR O
and O
control O
arm O
, O
respectively O
, O
who O
accounted O
for O
53 O
% O
of O
the O
participants O
in O
the O
trial O
) O
. O
The O
plasma O
concentrations O
of O
4 O
- O
HPR O
, O
its O
main O
metabolite O
N- O
( O
4 O
- O
methoxyphenyl O
) O
retinamide O
, O
and O
retinol O
were O
assayed O
by O
high O
- O
performance O
liquid O
chromatography O
. O
Three O
age O
ranges O
( O
< O
or O
= O
45 O
, O
46 O
- O
55 O
, O
and O
> O
or O
= O
56 O
years O
) O
, O
menopausal O
status O
at O
baseline O
, O
and O
disease O
outcome O
at O
a O
median O
follow O
- O
up O
of O
97 O
months O
were O
taken O
into O
account O
in O
the O
analysis O
. O
Baseline O
retinol O
levels O
were O
significantly O
lower O
( O
P O
< O
or O
= O
0.05 O
) O
in O
subjects O
< O
or O
= O
45 O
years O
than O
in O
older O
subjects O
, O
and O
among O
subjects O
in O
the O
age O
range O
46 O
- O
55 O
years O
, O
they O
were O
significantly O
higher O
( O
P O
< O
or O
= O
0.001 O
) O
in O
those O
in O
postmenopause O
than O
in O
those O
in O
premenopause O
. O
Baseline O
retinol O
levels O
were O
not O
related O
to O
the O
risk O
of O
a O
second O
breast O
malignancy O
. O
4 B-outcome
- I-outcome
HPR I-outcome
and I-outcome
N- I-outcome
( I-outcome
4 I-outcome
- I-outcome
methoxyphenyl I-outcome
) I-outcome
retinamide I-outcome
levels I-outcome
were O
not O
affected O
by O
menopausal O
status O
. O
They O
slightly O
, O
but O
significantly O
( O
P O
< O
or O
= O
0.05 O
) O
, O
increased O
with O
age O
( O
> O
or O
= O
46 O
years O
versus O
< O
or O
= O
45 O
years O
) O
but O
only O
in O
disease O
- O
free O
subjects O
. O
Among O
subjects O
< O
45 O
years O
, O
they O
were O
slightly O
, O
but O
significantly O
( O
P O
< O
or O
= O
0.05 O
) O
, O
higher O
in O
those O
subjects O
in O
which O
breast O
cancer O
recurred O
. O
4 O
- O
HPR O
treatment O
caused O
a O
retinol B-outcome
level I-outcome
reduction O
, O
which O
was O
strongly O
( O
r O
> O
or O
= O
0.71 O
; O
P O
< O
or O
= O
0.001 O
) O
related O
to O
pretreatment O
retinol O
levels O
. O
Retinol B-outcome
plasma I-outcome
levels I-outcome
increased O
with O
age O
and O
after O
menopause O
and O
were O
not O
related O
to O
breast O
cancer O
recurrence O
. O
4 B-outcome
- I-outcome
HPR I-outcome
levels I-outcome
were O
lower O
in O
subjects O
< O
45 O
years O
than O
in O
older O
subjects O
. O
The O
inverse O
relationship O
between O
drug O
plasma O
levels O
and O
4 O
- O
HPR O
preventive O
effects O
observed O
in O
young O
women O
suggests O
a O
role O
for O
4 O
- O
HPR O
plasma O
sequestration O
in O
4 O
- O
HPR O
biological O
activity O
. O

Tamoxifen B-intervention
alone I-intervention
versus O
adjuvant B-control
tamoxifen I-control
for O
operable B-eligibility
breast I-eligibility
cancer I-eligibility
of I-eligibility
the I-eligibility
elderly I-eligibility
: O
long O
- O
term O
results O
of O
the O
phase O
III O
randomized O
controlled O
multicenter O
GRETA O
trial O
. O
To O
evaluate O
the O
efficacy O
of O
tamoxifen O
as O
primary O
treatment O
in O
women O
aged O
over O
70 B-age
years I-age
with O
operable O
breast O
cancer O
versus O
surgery O
followed O
by O
adjuvant O
tamoxifen O
. O
Patients O
randomly O
received O
tamoxifen O
alone O
( O
160 O
mg O
day O
1 O
, O
then O
20 O
mg O
/ O
day O
) O
for O
5 O
years O
or O
surgery O
followed O
by O
tamoxifen O
( O
20 O
mg O
/ O
day O
) O
for O
5 O
years O
. O
Overall B-outcome-measure
survival I-outcome-measure
was O
the O
main O
study O
end O
point O
; O
secondary O
objectives O
included O
breast B-outcome-measure
cancer I-outcome-measure
survival I-outcome-measure
and O
local B-outcome-measure
control I-outcome-measure
of I-outcome-measure
the I-outcome-measure
disease I-outcome-measure
. O
Between O
1987 O
and O
1992 O
, O
239 B-control-participants
patients O
were O
assigned O
to O
surgery O
plus O
tamoxifen O
and O
235 B-intervention-participants
to O
tamoxifen O
alone O
. O
Treatment O
arms O
were O
comparable O
for O
tumor O
size O
, O
clinical O
nodal O
status O
and O
performance O
status O
. O
At O
a O
median O
follow O
- O
up O
of O
80 O
months O
274 O
patients O
had O
died B-outcome
. O
No O
difference O
between O
groups O
had O
emerged O
in O
overall B-outcome
and I-outcome
breast I-outcome
cancer I-outcome
survival I-outcome
. O
There O
were O
27 B-cv-bin-abs
local B-outcome
progressions I-outcome
in O
the O
surgery O
plus O
tamoxifen O
group O
and O
106 B-iv-bin-abs
in O
the O
tamoxifen O
- O
alone O
group O
( O
P O
= O
0.0001 O
) O
. O
In O
the O
surgery O
plus O
tamoxifen O
group O
, O
no O
difference O
in O
overall B-outcome
survival I-outcome
had O
emerged O
according O
to O
the O
extension O
of O
operation O
. O
The O
long O
- O
term O
results O
of O
the O
study O
confirm O
the O
3 O
- O
year O
interim O
analysis O
already O
reported O
. O
Surgery O
( O
radical O
or O
minimal O
) O
followed O
by O
adjuvant O
tamoxifen O
does O
not O
modify O
overall B-outcome
and I-outcome
breast I-outcome
cancer I-outcome
survival I-outcome
as O
compared O
with O
tamoxifen O
alone O
in O
early O
breast O
cancer O
of O
older O
women O
. O
Because O
of O
the O
high O
rate O
of O
local O
progressions O
with O
tamoxifen O
alone O
, O
minimal O
surgery O
followed O
by O
tamoxifen O
appears O
to O
be O
the O
appropriate O
treatment O
in O
such O
patients O
. O
More O
extensive O
surgery O
is O
not O
useful O
. O
Tamoxifen O
alone O
is O
an O
adequate O
alternative O
treatment O
in O
very O
old O
or O
frail O
patients O
. O

Cimicifuga B-intervention
racemosa I-intervention
for O
the O
treatment O
of O
hot B-condition
flushes I-condition
in O
women B-eligibility
surviving I-eligibility
breast I-eligibility
cancer I-eligibility
. O
To O
examine O
the O
effect O
of O
Cimicifuga O
racemosa O
( O
CR O
BNO O
1055 O
) O
on O
hot O
flushes O
caused O
by O
tamoxifen O
adjuvant O
therapy O
in O
young O
premenopausal O
breast O
cancer O
survivors O
. O
This O
treatment O
presents O
an O
off O
- O
label O
use O
of O
CR O
BNO O
1055 O
. O
Between O
May O
1999 O
and O
December O
2001 O
, O
we O
accrued O
136 B-total-participants
breast O
cancer O
survivors O
aged O
35 O
- O
52 O
years O
. O
After O
treatment O
with O
segmental O
or O
total O
mastectomy O
, O
radiation O
therapy O
and O
adjuvant O
chemotherapy O
, O
participants O
were O
in O
open O
- O
label O
randomly O
assigned O
( O
1 O
- O
2 O
) O
to O
receive O
tamoxifen O
20 O
mg O
per O
day O
orally O
( O
usual B-control
- I-control
care I-control
group I-control
; O
n O
= O
46 B-control-participants
) O
or O
tamoxifen O
( O
same O
dose O
and O
posology O
) O
plus O
CR O
BNO O
1055 O
( O
Menofem O
/ O
Klimadynon O
, O
corresponding O
to O
20 O
mg O
of O
herbal O
drug O
; O
intervention O
group O
n O
= O
90 B-intervention-participants
) O
. O
Duration O
of O
treatment O
was O
5 O
years O
for O
tamoxifen O
, O
according O
to O
international O
standards O
for O
adjuvant O
therapies O
, O
and O
12 O
months O
for O
CR O
BNO O
1055 O
. O
Follow O
- O
up O
included O
clinical O
assessment O
every O
2 O
months O
; O
the O
primary O
endpoint O
was O
to O
record O
the O
number B-outcome-measure
and I-outcome-measure
intensity I-outcome-measure
of I-outcome-measure
hot I-outcome-measure
flushes I-outcome-measure
. O
Comparing O
patients O
assigned O
to O
usual O
- O
care O
group O
with O
those O
assigned O
to O
intervention O
group O
, O
the O
number O
and O
severity O
of O
hot O
flushes O
were O
reduced O
after O
intervention O
. O
Almost O
half O
of O
the O
patients O
of O
the O
intervention O
group O
were O
free O
of O
hot O
flushes O
, O
while O
severe B-outcome
hot I-outcome
flushes I-outcome
were O
reported O
by O
24.4 B-iv-bin-percent
% I-iv-bin-percent
of O
patients O
of O
intervention O
group O
and O
73.9 B-cv-bin-percent
% I-cv-bin-percent
of O
the O
usual O
- O
care O
group O
( O
P<0.01 O
) O
. O
Hot B-outcome
flushes I-outcome
were O
the O
most O
frequent O
adverse O
reaction O
to O
tamoxifen O
adjuvant O
therapy O
in O
breast O
cancer O
survivors O
. O
The O
combined O
administration O
of O
tamoxifen O
plus O
CR O
BNO O
1055 O
for O
a O
period O
of O
12 O
months O
allowed O
satisfactory O
reduction O
in O
the O
number O
and O
severity O
of O
hot O
flushes O
. O

Levofloxacin B-intervention
for O
prophylaxis O
in O
breast O
cancer O
surgery O
compared O
with O
ofloxacin B-control
. O
We O
found O
that O
once O
- O
daily O
use O
of O
ofloxacin O
is O
beneficial O
from O
the O
standpoints O
of O
economy O
and O
patient O
compliance O
. O
Levofloxacin O
, O
has O
twice O
the O
antimicrobial O
activity O
and O
same O
toxicity O
of O
ofloxacin O
. O
We O
investigated O
the O
clinical O
usefulness O
of O
levofloxacin O
compared O
with O
ofloxacin O
in O
breast O
surgery O
. O
Between O
July O
, O
1996 O
and O
April O
, O
1999 O
, O
199 B-total-participants
consecutive O
patients B-eligibility
hospitalized I-eligibility
in I-eligibility
our I-eligibility
department I-eligibility
for I-eligibility
treatment I-eligibility
of I-eligibility
breast I-eligibility
cancer I-eligibility
were O
enrolled O
in O
this O
study O
with O
their O
informed O
consent O
and O
181 B-total-participants
patients O
were O
evaluated O
. O
Four B-iv-bin-abs
( O
4 B-iv-bin-percent
% I-iv-bin-percent
) O
of O
the O
99 B-intervention-participants
patients O
in O
the O
levofloxacin O
group O
had O
wound B-outcome
infections I-outcome
, O
as O
did O
5 B-cv-bin-abs
( O
6 B-cv-bin-percent
% I-cv-bin-percent
) O
of O
the O
82 B-control-participants
patients O
in O
the O
ofloxacin O
group O
. O
The O
median B-outcome
times I-outcome
needed I-outcome
for I-outcome
wound I-outcome
care I-outcome
, O
with O
25th O
and O
75th O
percentiles O
, O
were O
13 B-iv-cont-median
[ O
9 B-iv-cont-q1
, O
16 B-iv-cont-q3
] O
days O
in O
the O
levofloxacin O
group O
and O
11 B-cv-cont-median
[ O
9 B-cv-cont-q1
, O
16 B-cv-cont-q3
] O
days O
in O
the O
ofloxacin O
group O
. O
From O
infected O
wound O
three B-iv-bin-abs
strains O
of O
Staphylococcus B-outcome
aureus I-outcome
were O
detected O
from O
the O
levofloxacin O
group O
and O
two B-cv-bin-abs
strains O
were O
from O
ofloxacin O
group O
, O
but O
no O
methicillin O
- O
resistant O
strains O
were O
isolated O
. O
Multiple O
regression O
analysis O
showed O
that O
only O
wound O
dehiscence O
was O
a O
significant O
factor O
in O
the O
occurrence O
of O
wound O
infection O
and O
the O
period O
of O
wound O
care O
. O
No O
signs O
or O
symptoms O
suggesting O
levofloxacin O
or O
ofloxacin O
toxicity B-outcome
were O
observed O
. O
Laboratory O
test O
changes O
before O
and O
after O
treatment O
were O
similar O
in O
the O
two O
groups O
. O
It O
appears O
that O
levofloxacin O
is O
not O
superior O
to O
ofloxacin O
in O
prophylactic O
efficacy O
for O
postoperative O
wound O
infection O
after O
breast O
surgery O
. O

Phase O
II O
, O
randomized O
, O
double O
- O
blind O
study O
of O
two O
dose O
levels O
of O
arzoxifene B-intervention
in O
patients O
with O
locally O
advanced O
or O
metastatic O
breast O
cancer O
. O
To O
select O
a O
daily O
dose O
of O
arzoxifene O
( O
LY353381 O
) O
, O
a O
selective O
estrogen O
receptor O
modulator O
, O
for O
use O
in O
future O
studies O
in O
women O
with O
locally O
advanced O
or O
metastatic O
breast O
cancer O
who O
are O
either O
potentially O
tamoxifen O
sensitive O
( O
TS O
) O
or O
tamoxifen O
refractory O
( O
TR O
) O
. O
This O
trial O
was O
a O
randomized O
, O
double O
- O
blind O
, O
phase O
II O
study O
of O
arzoxifene O
20 O
mg O
( O
n O
= O
55 B-intervention-participants
) O
and O
50 B-control
mg I-control
( O
n O
= O
57 B-control-participants
) O
in O
women B-eligibility
with I-eligibility
advanced I-eligibility
or I-eligibility
metastatic I-eligibility
breast I-eligibility
cancer I-eligibility
. O
Patients O
were O
randomly O
assigned O
to O
balance O
for O
number O
of O
metastatic O
disease O
sites O
, O
prior O
tamoxifen O
therapy O
, O
and O
estrogen O
receptor O
status O
. O
The O
primary O
end O
point O
was O
tumor B-outcome-measure
response I-outcome-measure
rate I-outcome-measure
( O
RR O
) O
. O
Secondary O
end O
points O
included O
clinical B-outcome-measure
benefit I-outcome-measure
rate I-outcome-measure
( I-outcome-measure
CBR I-outcome-measure
) I-outcome-measure
, O
time B-outcome-measure
to I-outcome-measure
progression I-outcome-measure
( I-outcome-measure
TTP I-outcome-measure
) I-outcome-measure
, O
and O
toxicity B-outcome-measure
. O
Forty B-total-participants
- I-total-participants
nine I-total-participants
patients O
were O
TS O
and O
63 B-total-participants
were O
TR O
. O
According O
to O
independent O
review O
, O
among O
TS O
patients O
, O
RR B-outcome
was O
higher O
in O
the O
20 O
- O
mg O
arm O
than O
the O
50 O
- O
mg O
arm O
( O
26.1 B-iv-bin-percent
% I-iv-bin-percent
v O
8.0 B-cv-bin-percent
% I-cv-bin-percent
) O
, O
with O
a O
longer O
TTP B-outcome
( O
8.3 B-iv-cont-median
v O
3.2 B-cv-cont-median
months I-cv-cont-median
; O
P O
> O
.05 O
) O
. O
Among O
the O
TR O
patients O
, O
response B-outcome
rate I-outcome
was O
the O
same O
in O
the O
20 O
- O
mg O
and O
50 O
- O
mg O
arms O
( O
10.3 B-iv-bin-percent
% I-iv-bin-percent
) O
with O
similar O
TTP B-outcome
( O
2.7 B-iv-cont-mean
and O
2.8 B-cv-cont-mean
months I-cv-cont-mean
, O
respectively O
; O
P O
> O
.05 O
) O
. O
CBR B-outcome
was O
higher O
in O
the O
20 O
- O
mg O
arm O
than O
in O
the O
50 O
- O
mg O
arm O
among O
TS O
patients O
( O
39.1 B-iv-bin-percent
% I-iv-bin-percent
v O
20.0 B-cv-bin-percent
% I-cv-bin-percent
) O
and O
TR B-outcome
patients I-outcome
( O
13.8 B-iv-bin-percent
% I-iv-bin-percent
v O
10.3 B-cv-bin-percent
% I-cv-bin-percent
) O
. O
Arzoxifene O
was O
well O
tolerated O
. O
Dose B-outcome
- I-outcome
dependent I-outcome
toxicity I-outcome
was O
not O
demonstrated O
. O
There O
were O
no B-outcome
deaths I-outcome
during O
study O
. O
Arzoxifene O
is O
effective O
in O
the O
treatment O
of O
TS O
and O
TR O
patients O
with O
advanced O
or O
metastatic O
breast O
cancer O
at O
the O
20 O
- O
mg O
and O
50 O
- O
mg O
dose O
levels O
. O
Toxicities B-outcome
are O
minimal O
, O
and O
the O
therapy O
is O
tolerated O
. O
The O
20 O
- O
mg O
dose O
seems O
to O
be O
at O
least O
as O
effective O
as O
the O
50 O
- O
mg O
dose O
. O
Accordingly O
, O
arzoxifene O
20 O
mg O
/ O
d O
was O
selected O
for O
further O
study O
in O
patients O
with O
breast O
cancer O
. O

Helping O
patients O
make O
informed O
choices O
: O
a O
randomized O
trial O
of O
a O
decision O
aid O
for O
adjuvant O
chemotherapy O
in O
lymph O
node O
- O
negative O
breast O
cancer O
. O
In O
recent O
years O
, O
patients O
have O
indicated O
a O
desire O
for O
more O
information O
about O
their O
disease O
and O
to O
be O
involved O
in O
making O
decisions O
about O
their O
care O
. O
We O
developed O
an O
aid O
called O
the O
" O
Decision O
Board O
" O
to O
help O
clinicians O
inform O
patients O
with O
lymph O
node O
- O
negative O
breast O
cancer O
of O
the O
risks O
and O
benefits O
of O
adjuvant O
chemotherapy O
. O
We O
determined O
whether O
adding O
the O
Decision O
Board O
to O
the O
medical O
consultation O
improved O
patient O
knowledge O
and O
satisfaction O
compared O
with O
the O
medical O
consultation O
alone O
. O
Between O
October O
1995 O
and O
March O
2000 O
, O
176 B-total-participants
women B-eligibility
with I-eligibility
lymph I-eligibility
node I-eligibility
- I-eligibility
negative I-eligibility
breast I-eligibility
cancer I-eligibility
who I-eligibility
were I-eligibility
candidates I-eligibility
for I-eligibility
adjuvant I-eligibility
chemotherapy I-eligibility
were O
randomly O
assigned O
to O
receive O
the O
Decision B-intervention
Board I-intervention
plus I-intervention
the I-intervention
medical I-intervention
consultation I-intervention
( O
83 B-intervention-participants
patients O
) O
or O
the O
medical B-control
consultation I-control
alone I-control
( O
93 B-control-participants
patients O
) O
. O
One O
week O
after O
the O
consultation O
, O
patients O
completed O
a O
questionnaire O
assessing O
their O
knowledge O
about O
breast O
cancer O
and O
chemotherapy O
. O
Satisfaction O
with O
decision O
making O
was O
assessed O
1 O
week O
and O
3 O
, O
6 O
, O
and O
12 O
months O
after O
randomization O
, O
and O
differences O
between O
groups O
were O
analyzed O
by O
a O
repeated O
measures O
analysis O
of O
variance O
. O
All O
statistical O
tests O
were O
two O
- O
sided O
. O
Patients O
in O
the O
Decision O
Board O
arm O
were O
better B-outcome
informed I-outcome
about O
breast O
cancer O
and O
adjuvant O
chemotherapy O
than O
patients O
in O
the O
control O
arm O
( O
mean O
knowledge O
score O
= O
80.2 B-iv-cont-mean
[ O
on O
a O
scale O
of O
0 O
- O
100 O
] O
, O
95 O
% O
confidence O
interval O
[ O
CI O
] O
= O
77.1 O
to O
83.3 O
, O
and O
71.7 B-cv-cont-mean
, O
95 O
% O
CI O
= O
69.0 O
to O
74.4 O
, O
respectively O
; O
P<.001 O
) O
. O
Over O
the O
entire O
study O
period O
, O
satisfaction B-outcome
with O
decision O
making O
was O
higher O
for O
patients O
in O
the O
Decision O
Board O
arm O
than O
for O
patients O
in O
the O
control O
arm O
( O
P O
= O
.032 O
) O
. O
There O
was O
no O
statistically O
significant O
difference O
between O
the O
two O
groups O
in O
the O
number B-outcome
of I-outcome
patients I-outcome
who I-outcome
chose I-outcome
adjuvant I-outcome
chemotherapy I-outcome
( O
77 B-iv-bin-percent
% I-iv-bin-percent
and O
70 B-cv-bin-percent
% I-cv-bin-percent
for O
patients O
in O
the O
Decision O
Board O
arm O
and O
those O
in O
the O
control O
arm O
, O
respectively O
; O
P O
= O
.303 O
) O
. O
When O
making O
decisions O
regarding O
adjuvant O
chemotherapy O
, O
patients O
with O
early O
breast O
cancer O
who O
had O
been O
exposed O
to O
the O
Decision O
Board O
had O
better O
knowledge O
of O
the O
disease O
and O
treatment O
options O
and O
greater O
satisfaction O
with O
their O
decision O
making O
than O
those O
who O
received O
the O
standard O
consultation O
. O

Randomized O
controlled O
trial O
of O
exercise B-intervention
training I-intervention
in O
postmenopausal O
breast O
cancer O
survivors O
: O
cardiopulmonary O
and O
quality O
of O
life O
outcomes O
. O
To O
determine O
the O
effects O
of O
exercise O
training O
on O
cardiopulmonary O
function O
and O
quality O
of O
life O
( O
QOL O
) O
in O
postmenopausal O
breast O
cancer O
survivors O
who O
had O
completed O
surgery O
, O
radiotherapy O
, O
and/or O
chemotherapy O
with O
or O
without O
current O
hormone O
therapy O
use O
. O
Fifty B-total-participants
- I-total-participants
three I-total-participants
postmenopausal B-eligibility
breast I-eligibility
cancer I-eligibility
survivors I-eligibility
were O
randomly O
assigned O
to O
an O
exercise O
( O
n O
= O
25 B-intervention-participants
) O
or O
control B-control
( O
n O
= O
28 B-control-participants
) O
group O
. O
The O
exercise O
group O
trained O
on O
cycle O
ergometers O
three O
times O
per O
week O
for O
15 O
weeks O
at O
a O
power O
output O
that O
elicited O
the O
ventilatory O
equivalent O
for O
carbon O
dioxide O
. O
The O
control O
group O
did O
not O
train O
. O
The O
primary O
outcomes O
were O
changes B-outcome-measure
in I-outcome-measure
peak I-outcome-measure
oxygen I-outcome-measure
consumption I-outcome-measure
and O
overall B-outcome-measure
QOL I-outcome-measure
from I-outcome-measure
baseline I-outcome-measure
to I-outcome-measure
postintervention I-outcome-measure
. O
Peak O
oxygen O
consumption O
was O
assessed O
by O
a O
graded O
exercise O
test O
using O
gas O
exchange O
analysis O
. O
Overall O
QOL O
was O
assessed O
by O
the O
Functional O
Assessment O
of O
Cancer O
Therapy O
- O
Breast O
scale O
. O
Fifty B-total-participants
- I-total-participants
two I-total-participants
participants O
completed O
the O
trial O
. O
The O
exercise O
group O
completed O
98.4 O
% O
of O
the O
exercise O
sessions O
. O
Baseline O
values O
for O
peak B-outcome
oxygen I-outcome
consumption I-outcome
( O
P O
= O
.254 O
) O
and O
overall B-outcome
QOL I-outcome
( O
P O
= O
.286 O
) O
did O
not O
differ O
between O
groups O
. O
Peak B-outcome
oxygen I-outcome
consumption I-outcome
increased O
by O
0.24 O
L O
/ O
min O
in O
the O
exercise O
group O
, O
whereas O
it O
decreased O
by O
0.05 O
L O
/ O
min O
in O
the O
control O
group O
( O
mean O
difference O
, O
0.29 O
L O
/ O
min O
; O
95 O
% O
confidence O
interval O
[ O
CI O
] O
, O
0.18 O
to O
0.40 O
; O
P O
< O
.001 O
) O
. O
Overall B-outcome
QOL I-outcome
increased O
by O
9.1 B-iv-cont-mean
points I-iv-cont-mean
in O
the O
exercise O
group O
compared O
with O
0.3 B-cv-cont-mean
points I-cv-cont-mean
in O
the O
control O
group O
( O
mean O
difference O
, O
8.8 O
points O
; O
95 O
% O
CI O
, O
3.6 O
to O
14.0 O
; O
P O
= O
.001 O
) O
. O
Pearson O
correlations O
indicated O
that O
change O
in O
peak B-outcome
oxygen I-outcome
consumption I-outcome
correlated O
with O
change O
in O
overall B-outcome
QOL I-outcome
( O
r O
= O
0.45 O
; O
P O
< O
.01 O
) O
. O
Exercise O
training O
had O
beneficial O
effects O
on O
cardiopulmonary O
function O
and O
QOL O
in O
postmenopausal O
breast O
cancer O
survivors O
. O

Phase O
III O
study O
of O
letrozole B-intervention
versus O
tamoxifen B-control
as O
first O
- O
line O
therapy O
of O
advanced O
breast O
cancer O
in O
postmenopausal O
women O
: O
analysis O
of O
survival O
and O
update O
of O
efficacy O
from O
the O
International O
Letrozole O
Breast O
Cancer O
Group O
. O
To O
analyze O
overall O
survival O
( O
OS O
) O
and O
update O
efficacy O
data O
for O
letrozole O
versus O
tamoxifen O
as O
first O
- O
line O
therapy O
in O
postmenopausal O
women O
with O
locally O
advanced O
or O
metastatic O
breast O
cancer O
. O
This O
multicenter O
phase O
III O
trial O
randomly O
assigned O
916 B-total-participants
patients B-eligibility
with I-eligibility
hormone I-eligibility
receptor I-eligibility
- I-eligibility
positive I-eligibility
or I-eligibility
unknown I-eligibility
tumors I-eligibility
letrozole O
2.5 O
mg O
( O
n O
= O
458 B-intervention-participants
) O
or O
tamoxifen O
20 O
mg O
( O
n O
= O
458 B-control-participants
) O
daily O
until O
disease O
progression O
. O
Optional O
cross O
- O
over O
was O
permitted O
at O
the O
treating O
physician O
's O
discretion O
. O
This O
report O
updates O
efficacy O
at O
a O
median O
follow O
- O
up O
of O
32 O
months O
. O
The O
superiority O
of O
letrozole O
to O
tamoxifen O
was O
confirmed O
for O
time B-outcome
to I-outcome
progression I-outcome
( O
median O
, O
9.4 B-iv-cont-median
v O
6.0 B-cv-cont-median
months I-cv-cont-median
, O
respectively O
; O
P O
< O
.0001 O
) O
, O
time B-outcome
to I-outcome
treatment I-outcome
failure I-outcome
( O
median O
, O
9 B-iv-cont-median
v O
5.7 B-cv-cont-median
months I-cv-cont-median
, O
respectively O
; O
P O
< O
.0001 O
) O
, O
overall B-outcome
objective I-outcome
response I-outcome
rate I-outcome
( O
32 B-iv-bin-percent
% I-iv-bin-percent
v O
21 B-cv-bin-percent
% I-cv-bin-percent
, O
respectively O
; O
P O
= O
.0002 O
) O
, O
and O
overall B-outcome
clinical I-outcome
benefit I-outcome
. O
Median B-outcome
OS I-outcome
was O
slightly O
prolonged O
for O
the O
randomized O
letrozole O
arm O
( O
34 B-iv-cont-median
v O
30 B-cv-cont-median
months I-cv-cont-median
, O
respectively O
) O
. O
Although O
this O
difference O
in O
OS O
is O
not O
significant O
, O
survival O
was O
improved O
in O
the O
randomized O
letrozole O
arm O
over O
the O
first O
2 O
years O
of O
the O
study O
. O
Approximately O
one O
half O
of O
the O
patients O
in O
each O
arm O
crossed O
over O
. O
Total O
duration O
of O
endocrine O
therapy O
( O
" B-outcome
time I-outcome
to I-outcome
chemotherapy I-outcome
" I-outcome
) O
was O
significantly O
longer O
( O
P O
= O
.005 O
) O
for O
patients O
initially O
on O
letrozole O
( O
median O
, O
16 B-iv-cont-median
months I-iv-cont-median
) O
than O
for O
patients O
initially O
on O
tamoxifen O
( O
median O
, O
9 B-cv-cont-median
months I-cv-cont-median
) O
. O
Time B-outcome
to I-outcome
worsening I-outcome
of O
Karnofsky O
performance O
score O
was O
significantly O
delayed O
with O
letrozole O
compared O
with O
tamoxifen O
( O
P O
= O
.001 O
) O
. O
This O
study O
documents O
the O
superiority O
of O
letrozole O
over O
tamoxifen O
in O
first O
- O
line O
endocrine O
therapy O
in O
postmenopausal O
women O
with O
advanced O
breast O
cancer O
. O

[ O
Treatment O
of O
advanced O
metastatic O
breast O
cancer O
with O
exemestane B-intervention
, O
a O
multicenter O
randomized O
controlled O
study O
of O
195 O
cases O
] O
. O
To O
observe O
the O
efficacy O
of O
exemestane O
for O
postmenopausal O
advanced O
metastatic O
breast O
cancer O
, O
and O
to O
assess O
its O
side O
effects O
. O
A O
randomized O
, O
double O
- O
blind O
, O
and O
parallel O
controlled O
study O
was O
conducted O
among O
195 B-total-participants
patients B-eligibility
with I-eligibility
postmenopausal I-eligibility
advanced I-eligibility
metastatic I-eligibility
breast I-eligibility
cancer I-eligibility
from O
December O
2001 O
to O
June O
2002 O
. O
Except O
for O
the O
4 O
cases O
who O
were O
lost O
to O
follow O
- O
up O
, O
the O
remaining O
191 B-total-participants
patients O
were O
divided O
into O
two O
groups O
: O
study O
group O
( O
n O
= O
96 B-intervention-participants
, O
treated O
with O
exemestane O
capsule O
25 O
mg O
and O
one O
model O
tablet O
of O
letrozole O
orally O
q. O
d. O
for O
8 O
weeks O
) O
, O
and O
control B-control
group I-control
( O
n O
= O
95 B-control-participants
, O
treated O
with O
letrozole O
2.5 O
mg O
and O
one O
model O
capsule O
of O
exemestane O
orally O
q. O
d. O
for O
8 O
weeks O
) O
. O
Physical O
examination O
, O
roentgenography O
and O
CT O
were O
conducted O
to O
observe O
the O
outcome O
of O
the O
tumor O
and O
the O
level O
of O
estrogen O
was O
tested O
2 O
weeks O
before O
and O
4 O
and O
8 O
weeks O
after O
the O
beginning O
of O
treatment O
. O
The O
effective B-outcome
rate I-outcome
was O
44.8 B-iv-bin-percent
% I-iv-bin-percent
in O
the O
study O
group O
and O
45.3 B-cv-bin-percent
% I-cv-bin-percent
in O
the O
control O
group O
( O
P O
= O
0.971 O
) O
. O
The O
level B-outcome
of I-outcome
estradiol I-outcome
was O
5.17 B-iv-cont-mean
+ O
/- O
6.68 B-iv-cont-sd
x I-iv-cont-sd
10 I-iv-cont-sd
( I-iv-cont-sd
4 I-iv-cont-sd
) I-iv-cont-sd
pg I-iv-cont-sd
/ I-iv-cont-sd
L I-iv-cont-sd
and O
4.19 B-cv-cont-mean
+ O
/- O
3.06 B-cv-cont-sd
x I-cv-cont-sd
10 I-cv-cont-sd
( I-cv-cont-sd
4 I-cv-cont-sd
) I-cv-cont-sd
pg I-cv-cont-sd
/ I-cv-cont-sd
L I-cv-cont-sd
in O
the O
study O
group O
and O
control O
group O
respectively O
; O
and O
was O
3.08 B-iv-cont-mean
+ O
/- O
2.80 B-iv-cont-sd
x I-iv-cont-sd
10 I-iv-cont-sd
( I-iv-cont-sd
4 I-iv-cont-sd
) I-iv-cont-sd
pg I-iv-cont-sd
/ I-iv-cont-sd
L I-iv-cont-sd
and O
2.76 B-cv-cont-mean
+ O
/- O
1.98 B-cv-cont-sd
x I-cv-cont-sd
10 I-cv-cont-sd
( I-cv-cont-sd
4 I-cv-cont-sd
) I-cv-cont-sd
pg I-cv-cont-sd
/ I-cv-cont-sd
L I-cv-cont-sd
in O
the O
study O
group O
and O
control O
group O
respectively O
8 O
weeks O
after O
the O
beginning O
of O
treatment O
, O
both O
decreased O
by O
43.7 O
% O
in O
comparison O
with O
those O
before O
treatment O
( O
both O
P O
< O
0.001 O
) O
, O
however O
, O
there O
was O
no O
significant O
difference O
between O
the O
study O
group O
and O
control O
group O
( O
P O
= O
0.141 O
) O
. O
The O
side O
effects O
of O
exemestane O
included O
thirst B-outcome
, O
giddiness B-outcome
, O
and O
nausea B-outcome
. O
An O
effective O
hormonal O
medicine O
, O
exemestane O
has O
good O
therapeutic O
efficacy O
in O
postmenopausal O
advanced O
metastatic O
breast O
cancer O
with O
only O
mild O
side O
effects O
. O

Preoperative B-intervention
FLAC I-intervention
/ I-intervention
granulocyte I-intervention
- I-intervention
colony I-intervention
- I-intervention
stimulating I-intervention
factor I-intervention
chemotherapy I-intervention
for O
stage O
II O
breast O
cancer O
: O
a O
prospective O
randomized O
trial O
. O
Preoperative O
chemotherapy O
for O
stage O
II O
breast O
cancer O
may O
reduce O
locoregional O
tumors O
and O
provides O
initial O
treatment O
for O
systemic O
micrometastases O
. O
We O
conducted O
a O
prospective O
, O
randomized O
trial O
to O
evaluate O
the O
ability O
of O
intensive O
preoperative O
chemotherapy O
to O
enhance O
the O
outcome O
of O
this O
approach O
. O
Patients B-eligibility
with I-eligibility
clinical I-eligibility
stage I-eligibility
II I-eligibility
breast I-eligibility
cancer I-eligibility
( I-eligibility
T2N0 I-eligibility
, I-eligibility
T1N1 I-eligibility
, I-eligibility
and I-eligibility
T2N1 I-eligibility
) I-eligibility
were O
prospectively O
randomized O
to O
receive O
either O
preoperative O
or O
postoperative O
chemotherapy O
with O
five O
21 O
- O
day O
cycles O
of O
fluorouracil O
, O
leucovorin O
calcium O
, O
doxorubicin O
, O
and O
cyclophosphamide O
( O
FLAC O
) O
/granulocyte O
- O
colony O
- O
stimulating O
factor O
. O
Local O
therapy O
consisted O
of O
modified O
radical O
mastectomy O
or O
segmentectomy O
/ O
axillary O
dissection O
/ O
breast O
radiotherapy O
, O
according O
to O
patient O
preference O
. O
Fifty B-total-participants
- I-total-participants
three I-total-participants
women O
were O
randomized O
( O
26 B-intervention-participants
preoperative B-intervention
chemotherapy I-intervention
and O
27 B-control-participants
postoperative B-control
chemotherapy I-control
) O
. O
The O
objective B-outcome
clinical I-outcome
response I-outcome
rate I-outcome
of O
the O
primary O
tumor O
to O
preoperative O
chemotherapy O
was O
80 B-iv-bin-percent
% I-iv-bin-percent
, O
and O
the O
pathologic B-outcome
complete I-outcome
response I-outcome
rate I-outcome
was O
20 B-iv-bin-percent
% I-iv-bin-percent
. O
Preoperative O
chemotherapy O
reduced O
the O
overall B-outcome
incidence I-outcome
and I-outcome
number I-outcome
of I-outcome
axillary I-outcome
lymph I-outcome
node I-outcome
metastases I-outcome
. O
There O
was O
no O
difference O
in O
the O
use B-outcome
of I-outcome
breast I-outcome
- I-outcome
conserving I-outcome
local I-outcome
therapy I-outcome
between O
the O
two O
treatment O
arms O
. O
There O
were O
20 O
local B-outcome
/ I-outcome
regional I-outcome
or I-outcome
distant I-outcome
recurrences I-outcome
( O
9 B-iv-bin-abs
preoperative O
and O
11 B-cv-bin-abs
postoperative O
) O
. O
There O
was O
no O
difference O
in O
the O
overall B-outcome
or I-outcome
disease I-outcome
- I-outcome
free I-outcome
survival I-outcome
between O
the O
preoperative O
and O
postoperative O
chemotherapy O
arms O
. O
Preoperative O
FLAC O
/ O
granulocyte O
- O
colony O
- O
stimulating O
factor O
chemotherapy O
was O
effective O
against O
local O
/ O
regional O
tumors O
in O
stage O
II O
breast O
cancer O
but O
was O
otherwise O
comparable O
to O
postoperative O
chemotherapy O
. O

High B-intervention
- I-intervention
dose I-intervention
chemotherapy I-intervention
with O
hematopoietic O
stem O
- O
cell O
rescue O
for O
high O
- O
risk O
breast O
cancer O
. O
The O
use O
of O
high O
- O
dose O
adjuvant O
chemotherapy O
for O
high O
- O
risk O
primary O
breast O
cancer O
is O
controversial O
. O
We O
studied O
its O
efficacy O
in O
patients O
with O
4 O
to O
9 O
or O
10 O
or O
more O
tumor O
- O
positive O
axillary O
lymph O
nodes O
. O
Patients O
younger B-age
than I-age
56 I-age
years I-age
of O
age O
who B-eligibility
had I-eligibility
undergone I-eligibility
surgery I-eligibility
for I-eligibility
breast I-eligibility
cancer I-eligibility
and I-eligibility
who I-eligibility
had I-eligibility
no I-eligibility
distant I-eligibility
metastases I-eligibility
were O
eligible O
if O
they O
had O
at O
least O
four O
tumor O
- O
positive O
axillary O
lymph O
nodes O
. O
Patients O
in O
the O
conventional O
- O
dose O
group O
received O
fluorouracil O
, O
epirubicin O
, O
and O
cyclophosphamide O
( O
FEC O
) O
every O
three O
weeks O
for O
five O
courses O
, O
followed O
by O
radiotherapy O
and O
tamoxifen O
. O
The O
high O
- O
dose O
treatment O
was O
identical O
, O
except O
that O
high O
- O
dose O
chemotherapy O
( O
6 O
g O
of O
cyclophosphamide O
per O
square O
meter O
of O
body O
- O
surface O
area O
, O
480 O
mg O
of O
thiotepa O
per O
square O
meter O
, O
and O
1600 O
mg O
of O
carboplatin O
per O
square O
meter O
) O
with O
autologous O
peripheral O
- O
blood O
hematopoietic O
progenitor O
- O
cell O
transplantation O
replaced O
the O
fifth O
course O
of O
FEC O
. O
Of O
the O
885 B-total-participants
patients O
, O
442 B-intervention-participants
were O
assigned O
to O
the O
high O
- O
dose O
group O
and O
443 B-control-participants
to O
the O
conventional B-control
- I-control
dose I-control
group I-control
. O
After O
a O
median O
follow O
- O
up O
of O
57 O
months O
, O
the O
actuarial O
5 B-outcome
- I-outcome
year I-outcome
relapse I-outcome
- I-outcome
free I-outcome
survival I-outcome
rates I-outcome
were O
59 B-cv-bin-percent
percent I-cv-bin-percent
in O
the O
conventional O
- O
dose O
group O
and O
65 B-iv-bin-percent
percent I-iv-bin-percent
in O
the O
high O
- O
dose O
group O
( O
hazard O
ratio O
for O
relapse O
in O
the O
high O
- O
dose O
group O
, O
0.83 O
; O
95 O
percent O
confidence O
interval O
, O
0.66 O
to O
1.03 O
; O
P O
= O
0.09 O
) O
. O
In O
the O
group O
with O
10 O
or O
more O
positive O
nodes O
, O
the O
relapse B-outcome
- I-outcome
free I-outcome
survival I-outcome
rates I-outcome
were O
51 B-cv-bin-percent
percent I-cv-bin-percent
in O
the O
conventional O
- O
dose O
group O
and O
61 B-iv-bin-percent
percent I-iv-bin-percent
in O
the O
high O
- O
dose O
group O
( O
P O
= O
0.05 O
by O
the O
log O
- O
rank O
test O
; O
hazard O
ratio O
for O
relapse O
, O
0.71 O
; O
95 O
percent O
confidence O
interval O
, O
0.50 O
to O
1.00 O
) O
. O
High O
- O
dose O
alkylating O
therapy O
improves O
relapse B-outcome
- I-outcome
free I-outcome
survival I-outcome
among O
patients O
with O
stage O
II O
or O
III O
breast O
cancer O
and O
10 O
or O
more O
positive O
axillary O
lymph O
nodes O
. O
This O
benefit O
may O
be O
confined O
to O
patients O
with O
HER-2 O
/ O
neu O
- O
negative O
tumors O
. O

A O
randomized O
comparison O
of O
sentinel B-intervention
- I-intervention
node I-intervention
biopsy I-intervention
with O
routine B-control
axillary I-control
dissection I-control
in O
breast O
cancer O
. O
Although O
numerous O
studies O
have O
shown O
that O
the O
status O
of O
the O
sentinel O
node O
is O
an O
accurate O
predictor O
of O
the O
status O
of O
the O
axillary O
nodes O
in O
breast O
cancer O
, O
the O
efficacy O
and O
safety O
of O
sentinel O
- O
node O
biopsy O
require O
validation O
. O
From O
March O
1998 O
to O
December O
1999 O
, O
we O
randomly O
assigned O
516 B-total-participants
patients B-eligibility
with I-eligibility
primary I-eligibility
breast I-eligibility
cancer I-eligibility
in I-eligibility
whom I-eligibility
the I-eligibility
tumor I-eligibility
was I-eligibility
less I-eligibility
than I-eligibility
or I-eligibility
equal I-eligibility
to I-eligibility
2 I-eligibility
cm I-eligibility
in I-eligibility
diameter I-eligibility
either O
to O
sentinel O
- O
node O
biopsy O
and O
total O
axillary O
dissection O
( O
the O
axillary O
- O
dissection O
group O
) O
or O
to O
sentinel O
- O
node O
biopsy O
followed O
by O
axillary O
dissection O
only O
if O
the O
sentinel O
node O
contained O
metastases O
( O
the O
sentinel O
- O
node O
group O
) O
. O
The O
number B-outcome
of I-outcome
sentinel I-outcome
nodes I-outcome
found O
was O
the O
same O
in O
the O
two O
groups O
. O
A O
sentinel B-outcome
node I-outcome
was I-outcome
positive I-outcome
in O
83 B-cv-bin-abs
of O
the O
257 B-control-participants
patients O
in O
the O
axillary O
- O
dissection O
group O
( O
32.3 B-cv-bin-percent
percent I-cv-bin-percent
) O
, O
and O
in O
92 B-iv-bin-abs
of O
the O
259 B-intervention-participants
patients O
in O
the O
sentinel O
- O
node O
group O
( O
35.5 B-iv-bin-percent
percent I-iv-bin-percent
) O
. O
In O
the O
axillary O
- O
dissection O
group O
, O
the O
overall B-outcome
accuracy I-outcome
of I-outcome
the I-outcome
sentinel I-outcome
- I-outcome
node I-outcome
status I-outcome
was O
96.9 B-cv-bin-percent
percent I-cv-bin-percent
, O
the O
sensitivity B-outcome
91.2 B-cv-bin-percent
percent I-cv-bin-percent
, O
and O
the O
specificity B-outcome
100 B-cv-bin-percent
percent I-cv-bin-percent
. O
There O
was O
less O
pain B-outcome
and O
better O
arm B-outcome
mobility I-outcome
in O
the O
patients O
who O
underwent O
sentinel O
- O
node O
biopsy O
only O
than O
in O
those O
who O
also O
underwent O
axillary O
dissection O
. O
There O
were O
15 B-cv-bin-abs
events B-outcome
associated I-outcome
with I-outcome
breast I-outcome
cancer I-outcome
in O
the O
axillary O
- O
dissection O
group O
and O
10 B-iv-bin-abs
such O
events O
in O
the O
sentinel O
- O
node O
group O
. O
Among O
the O
167 O
patients O
who O
did O
not O
undergo O
axillary O
dissection O
, O
there O
were O
no O
cases B-outcome
of I-outcome
overt I-outcome
axillary I-outcome
metastasis I-outcome
during O
follow O
- O
up O
. O
Sentinel O
- O
node O
biopsy O
is O
a O
safe O
and O
accurate O
method O
of O
screening O
the O
axillary O
nodes O
for O
metastasis O
in O
women O
with O
a O
small O
breast O
cancer O
. O

Effect O
of O
nurse B-intervention
case I-intervention
management I-intervention
on O
the O
treatment O
of O
older B-eligibility
women I-eligibility
with I-eligibility
breast I-eligibility
cancer I-eligibility
. O
To O
evaluate O
the O
effect O
of O
nurse O
case O
management O
on O
the O
treatment O
of O
older O
women O
with O
breast O
cancer O
. O
Randomized O
prospective O
trial O
. O
Sixty O
surgeons O
practicing O
at O
13 O
community O
and O
two O
public O
hospitals O
in O
southeast O
Texas O
. O
Three B-total-participants
hundred I-total-participants
thirty I-total-participants
- I-total-participants
five I-total-participants
women O
( O
166 B-control-participants
control B-control
and O
169 B-intervention-participants
intervention O
) O
aged B-age
65 I-age
and I-age
older I-age
newly O
diagnosed O
with O
breast O
cancer O
. O
Women O
seeing O
surgeons O
randomized O
to O
the O
intervention O
group O
received O
the O
services O
of O
a O
nurse O
case O
manager O
for O
12 O
months O
after O
the O
diagnosis O
of O
breast O
cancer O
. O
The O
primary O
outcome O
was O
the O
type B-outcome-measure
and I-outcome-measure
use I-outcome-measure
of I-outcome-measure
cancer I-outcome-measure
- I-outcome-measure
specific I-outcome-measure
therapies I-outcome-measure
received O
in O
the O
first O
6 O
months O
after O
diagnosis O
. O
Secondary O
outcomes O
were O
patient B-outcome-measure
satisfaction I-outcome-measure
and O
arm B-outcome-measure
function I-outcome-measure
on O
the O
affected O
side O
2 O
months O
after O
diagnosis O
. O
More O
women O
in O
the O
intervention O
group O
received B-outcome
breast I-outcome
- I-outcome
conserving I-outcome
surgery I-outcome
( O
28.6 B-iv-bin-percent
% I-iv-bin-percent
vs O
18.7 B-cv-bin-percent
% I-cv-bin-percent
; O
P O
= O
.031 O
) O
and O
radiation B-outcome
therapy I-outcome
( O
36.0 B-iv-bin-percent
% I-iv-bin-percent
vs O
19.0 B-cv-bin-percent
% I-cv-bin-percent
; O
P O
= O
.003 O
) O
. O
Of O
women O
undergoing O
breast O
- O
conserving O
surgery O
, O
greater O
percentages O
in O
the O
case O
management O
group O
received B-outcome
adjuvant I-outcome
radiation I-outcome
( O
78.3 B-iv-bin-percent
% I-iv-bin-percent
vs O
44.8 B-cv-bin-percent
% I-cv-bin-percent
; O
P O
= O
.001 O
) O
and O
axillary B-outcome
dissection I-outcome
( O
71.4 B-iv-bin-percent
% I-iv-bin-percent
vs O
44.8 B-cv-bin-percent
% I-cv-bin-percent
; O
P O
= O
.057 O
) O
. O
Women O
in O
the O
case O
management O
group O
were O
also O
more O
likely B-outcome
to I-outcome
receive I-outcome
more I-outcome
breast I-outcome
reconstruction I-outcome
surgery I-outcome
( O
9.3 B-iv-bin-percent
% I-iv-bin-percent
vs O
2.6 B-cv-bin-percent
% I-cv-bin-percent
, O
P O
= O
.054 O
) O
, O
and O
women O
in O
the O
case O
management O
group O
with O
advanced O
cancer O
were O
more B-outcome
likely I-outcome
to I-outcome
receive I-outcome
chemotherapy I-outcome
( O
72.7 B-iv-bin-percent
% I-iv-bin-percent
vs O
30.0 B-cv-bin-percent
% I-cv-bin-percent
, O
P O
= O
.057 O
) O
. O
Two O
months O
after O
surgery O
, O
higher O
percentages O
of O
women O
in O
the O
case O
manager O
group O
had O
normal B-outcome
arm I-outcome
function I-outcome
( O
93 B-iv-bin-percent
% I-iv-bin-percent
vs O
84 B-cv-bin-percent
% I-cv-bin-percent
; O
P O
= O
.037 O
) O
and O
were O
more O
likely B-outcome
to I-outcome
state I-outcome
that I-outcome
they I-outcome
had I-outcome
a I-outcome
real I-outcome
choice I-outcome
in I-outcome
their I-outcome
treatment I-outcome
( O
82.2 B-iv-bin-percent
% I-iv-bin-percent
vs O
69.9 B-cv-bin-percent
% I-cv-bin-percent
, O
P O
= O
.020 O
) O
. O
Women O
with O
indicators O
of O
poor O
social O
support O
were O
more O
likely O
to O
benefit O
from O
nurse O
case O
management O
. O
Nurse O
case O
management O
results O
in O
more O
appropriate O
management O
of O
older O
women O
with O
breast O
cancer O
. O

Bone O
turnover O
markers O
and O
insulin O
- O
like O
growth O
factor O
components O
in O
metastatic O
breast O
cancer O
: O
results O
from O
a O
randomised O
trial O
of O
exemestane B-intervention
vs O
megestrol B-control
acetate I-control
. O
The O
aim O
of O
this O
randomised O
study O
was O
to O
compare O
the O
effects O
of O
progestins O
and O
aromatase O
inactivators O
on O
bone O
remodelling O
markers O
and O
the O
components O
of O
insulin O
- O
like O
growth O
factor O
in O
patients B-eligibility
with I-eligibility
metastatic I-eligibility
breast I-eligibility
cancer I-eligibility
. O
Within O
the O
framework O
of O
a O
large O
( O
769 B-total-participants
patients O
) O
, O
randomised O
double O
- O
blind O
clinical O
trial O
comparing O
exemestane O
( O
EXE O
) O
with O
megestrol O
acetate O
( O
MA O
) O
, O
serum O
17 O
beta O
- O
estradiol O
( O
E2 O
) O
, O
estrone O
( O
E1 O
) O
, O
estrone O
sulphate O
( O
E1S O
) O
, O
bone O
alkaline O
phosphatase O
( O
BAP O
) O
, O
carboxy O
- O
terminal O
cross O
- O
linking O
telopeptide O
of O
type O
I O
collagen O
( O
ICTP O
) O
and O
the O
components O
of O
insulin O
- O
like O
growth O
factor O
( O
IGF O
) O
family O
( O
IGF-1 O
, O
IGF-2 O
and O
IGFBP-3 O
) O
were O
determined O
in O
53 B-total-participants
patients O
( O
24 B-intervention-participants
randomised O
to O
EXE O
and O
29 B-control-participants
ramdomised O
to O
MA O
) O
. O
After O
eight O
weeks O
of O
treatment O
, O
both O
ICTP B-outcome
and O
BAP B-outcome
increased O
( O
p O
< O
0.01 O
) O
in O
the O
EXE O
group O
, O
but O
only O
ICTP O
in O
the O
MA O
group O
( O
p O
< O
0.03 O
) O
. O
The O
8 O
- O
week O
suppression B-outcome
of I-outcome
E2 I-outcome
and I-outcome
E1S I-outcome
was O
more O
pronounced O
in O
the O
EXE O
group O
( O
to O
, O
respectively O
, O
11.2 O
% O
and O
9.9 O
% O
of O
baseline O
values O
) O
than O
in O
the O
MA O
group O
( O
33.1 O
% O
and O
29.7 O
% O
) O
. O
IGF-1 B-outcome
increased I-outcome
( O
p O
< O
0.01 O
) O
in O
both O
groups O
, O
but O
more O
so O
in O
the O
patients O
treated O
with O
MA O
. O
Estrogen B-outcome
levels I-outcome
negatively O
correlated O
with O
ICTP O
in O
both O
groups O
, O
but O
were O
not O
related O
to O
BAP O
in O
either O
. O
IGF-1 O
negatively O
correlated O
with O
estrogens O
in O
both O
groups O
. O
The O
results O
of O
this O
study O
indicate O
that O
anti O
- O
aromatase O
therapy O
is O
associated O
with O
increased O
osteoclast O
activity O
, O
and O
suggest O
the O
existence O
of O
possible O
differential O
effects O
of O
different O
hormonal O
therapies O
on O
bone O
remodelling O
markers O
regardless O
of O
the O
estrogen O
suppression O
induced O
by O
EXE O
. O

Locoregional O
recurrence O
after O
doxorubicin B-intervention
- I-intervention
based I-intervention
chemotherapy I-intervention
and O
postmastectomy B-intervention
: O
Implications O
for O
breast B-eligibility
cancer I-eligibility
patients I-eligibility
with I-eligibility
early I-eligibility
- I-eligibility
stage I-eligibility
disease I-eligibility
and O
predictors O
for O
recurrence O
after O
postmastectomy O
radiation O
. O
To O
compare O
rates O
of O
locoregional O
recurrence O
( O
LRR O
) O
after O
mastectomy O
, O
doxorubicin O
- O
based O
chemotherapy O
, O
and O
radiation O
with O
those O
of O
patients O
receiving O
mastectomy B-control
and I-control
doxorubicin I-control
- I-control
based I-control
chemotherapy I-control
without I-control
radiation I-control
and O
to O
determine O
predictors O
of O
LRR O
after O
postmastectomy O
radiation O
. O
Kaplan O
- O
Meier O
freedom O
- O
from O
- O
LRR O
rates O
were O
calculated O
for O
470 B-total-participants
patients O
treated O
with O
mastectomy O
, O
doxorubicin O
- O
based O
chemotherapy O
, O
and O
postmastectomy O
radiation O
in O
five O
single O
- O
institution O
clinical O
trials O
. O
The O
LRR O
rates O
in O
these O
patients O
were O
compared O
to O
previously O
reported O
rates O
in O
1031 O
patients O
treated O
without O
radiation O
in O
the O
same O
trials O
. O
Median O
follow O
- O
up O
was O
14 O
years O
. O
Irradiated O
patients O
had O
significantly O
less O
favorable O
prognostic B-outcome
factors I-outcome
for I-outcome
LRR I-outcome
than O
did O
unirradiated O
patients O
. O
Despite O
this O
, O
in O
all O
subsets O
of O
node O
- O
positive O
patients O
, O
postmastectomy O
radiation O
led O
to O
lower O
rates B-outcome
of I-outcome
LRR I-outcome
. O
This O
included O
patients O
with O
T1 O
or O
T2 O
tumors O
and O
one O
to O
three O
positive O
nodes O
( O
10 B-outcome
- I-outcome
year I-outcome
LRR I-outcome
rates I-outcome
of O
3 O
% O
vs. O
13 O
% O
, O
p O
= O
0.003 O
) O
. O
Multivariate O
analysis O
of O
LRR O
for O
patients O
with O
this O
stage O
of O
disease O
revealed O
that O
no O
radiation O
, O
close O
/ O
positive O
margins O
, O
gross O
extracapsular O
extension O
, O
and O
dissection O
of O
< O
10 O
nodes O
predicted O
for O
increased O
LRR O
( O
hazard O
ratios O
6.25 O
, O
4.61 O
, O
3.27 O
, O
and O
2.66 O
, O
respectively O
) O
. O
Significant O
predictors B-outcome
of I-outcome
LRR I-outcome
for O
patients O
treated O
with O
postmastectomy O
radiation O
were O
higher O
number O
and O
> O
or O
= O
20 O
% O
positive B-outcome
nodes I-outcome
, O
larger O
tumor B-outcome
size I-outcome
, O
lymphovascular B-outcome
space I-outcome
invasion I-outcome
, O
and O
estrogen B-outcome
receptor I-outcome
( I-outcome
ER I-outcome
) I-outcome
-negative I-outcome
disease I-outcome
. O
Recursive O
partitioning O
analysis O
revealed O
ER O
- O
negative O
status O
to O
be O
the O
most O
powerful O
discriminator O
of O
LRR O
in O
irradiated O
patients O
. O
Postmastectomy O
radiation O
decreases O
LRR O
for O
patients O
with O
breast O
cancer O
, O
including O
those O
with O
Stage O
II O
breast O
cancer O
and O
one O
to O
three O
positive O
lymph O
nodes O
. O

Sentinel O
node O
biopsy O
in O
breast O
cancer O
: O
validation O
study O
and O
comparison O
of O
blue B-intervention
dye I-intervention
alone I-intervention
with O
triple B-control
modality I-control
localization I-control
. O
Sentinel O
node O
biopsy O
( O
SNB O
) O
for O
breast O
cancer O
patients O
is O
a O
new O
technique O
with O
the O
potential O
to O
provide O
an O
accurate O
staging O
of O
the O
axillary O
nodal O
status O
while O
avoiding O
the O
morbidity O
of O
an O
axillary O
dissection O
. O
The O
objective O
of O
the O
present O
study O
is O
to O
validate O
the O
use O
of O
sentinel O
node O
biopsy O
in O
a O
New B-location
Zealand I-location
hospital O
and O
to O
compare O
the O
ability O
of O
patent O
blue O
dye O
( O
PB O
) O
alone O
with O
triple O
modality O
( O
TM O
) O
( O
preoperative O
lymphoscintigraphy O
, O
intraoperative O
gamma O
probe O
and O
intraoperative O
blue O
dye O
) O
to O
identify O
the O
sentinel O
node O
. O
A O
total O
of O
104 B-total-participants
patients B-eligibility
who I-eligibility
had I-eligibility
a I-eligibility
palpable I-eligibility
breast I-eligibility
lump I-eligibility
that I-eligibility
was I-eligibility
confirmed I-eligibility
to I-eligibility
be I-eligibility
malignant I-eligibility
by I-eligibility
radiology I-eligibility
and I-eligibility
cytology I-eligibility
and I-eligibility
a I-eligibility
clinical I-eligibility
diagnosis I-eligibility
of I-eligibility
stage I-eligibility
I I-eligibility
or I-eligibility
stage I-eligibility
II I-eligibility
breast I-eligibility
cancer I-eligibility
, O
were O
enrolled O
for O
SNB O
and O
randomly O
assigned O
to O
triple O
modality O
or O
blue O
dye O
alone O
for O
the O
localization O
of O
the O
sentinel O
node O
. O
Axillary O
dissection O
was O
performed O
after O
the O
sentinel O
node O
( O
s O
) O
had O
been O
removed O
. O
There O
were O
63 B-intervention-participants
patients O
in O
the O
PB O
group O
and O
41 B-control-participants
patients O
in O
the O
TM O
group O
. O
Both O
groups O
are O
comparable O
, O
with O
a O
similar O
mean O
age O
and O
primary O
tumour O
size O
. O
A O
sentinel B-outcome
node I-outcome
was O
identified O
in O
57 B-iv-bin-abs
( O
90 B-iv-bin-percent
% I-iv-bin-percent
) O
of O
the O
PB O
group O
patients O
and O
40 B-cv-bin-abs
( O
98 B-cv-bin-percent
% I-cv-bin-percent
) O
of O
the O
TM O
group O
patients O
. O
Of O
these O
23 B-iv-bin-abs
( O
37 B-iv-bin-percent
% I-iv-bin-percent
) O
of O
the O
PB O
group O
and O
23 B-cv-bin-abs
( O
56 B-cv-bin-percent
% I-cv-bin-percent
) O
in O
the O
TM O
group O
had O
axillary B-outcome
nodes I-outcome
positive I-outcome
for I-outcome
malignancy I-outcome
. O
There O
was O
one B-iv-bin-abs
false B-outcome
negative I-outcome
SNB I-outcome
in O
the O
PB O
group O
and O
two B-cv-bin-abs
false O
negative O
results O
in O
the O
TM O
group O
. O
Therefore O
, O
the O
PB O
group O
had O
an O
accuracy B-outcome
of O
98 B-iv-bin-percent
% I-iv-bin-percent
and O
a O
sensitivity B-outcome
of O
96 B-cv-bin-percent
% I-cv-bin-percent
compared O
to O
an O
accuracy B-outcome
of O
95 B-cv-bin-percent
% I-cv-bin-percent
and O
a O
sensitivity B-outcome
of O
91 B-cv-bin-percent
% I-cv-bin-percent
for O
the O
TM O
group O
. O
The O
results O
of O
the O
present O
study O
validate O
the O
use O
of O
SNB O
in O
suitable O
breast O
cancer O
patients O
. O
Identification O
and O
the O
accuracy O
of O
the O
sentinel O
node O
localization O
were O
similar O
between O
the O
two O
groups O
. O
Therefore O
, O
in O
hospital O
centres O
without O
adequate O
access O
to O
a O
nuclear O
medical O
facility O
, O
it O
would O
be O
feasible O
to O
conduct O
SNB O
using O
blue O
dye O
alone O
. O

Efficacy O
of O
tamoxifen B-intervention
following I-intervention
anastrozole I-intervention
( O
' O
Arimidex O
' O
) O
compared O
with O
anastrozole B-control
following I-control
tamoxifen I-control
as O
first O
- O
line O
treatment O
for O
advanced O
breast O
cancer O
in O
postmenopausal O
women O
. O
Anastrozole O
( O
' O
Arimidex O
' O
) O
is O
indicated O
for O
the O
treatment O
of O
advanced O
breast O
cancer O
in O
postmenopausal O
women O
. O
Combined O
analysis O
of O
two O
international O
randomised O
, O
double O
- O
blind O
trials O
( O
n O
= O
1021 B-total-participants
) O
showed O
that O
in O
patients B-eligibility
with I-eligibility
hormone I-eligibility
receptor I-eligibility
- I-eligibility
positive I-eligibility
tumours I-eligibility
, O
first O
- O
line O
treatment O
with O
anastrozole O
significantly O
prolonged O
the O
time B-outcome
to I-outcome
progression I-outcome
( I-outcome
TTP I-outcome
) I-outcome
compared O
with O
tamoxifen O
( O
median O
TTP O
: O
10.7 B-iv-cont-median
versus O
6.4 B-cv-cont-median
months I-cv-cont-median
, O
respectively O
; O
P O
= O
0.022 O
) O
. O
Second O
- O
line O
tamoxifen O
following O
anastrozole O
, O
or O
vice O
versa O
, O
in O
this O
trial O
population O
was O
unblinded O
. O
The O
treatments O
were O
crossed O
over O
and O
then O
efficacy O
was O
assessed O
using O
a O
questionnaire O
. O
Of O
511 B-intervention-participants
patients O
randomised O
to O
anastrozole O
, O
137 B-iv-bin-abs
( O
26.8 B-iv-bin-percent
% I-iv-bin-percent
) O
received B-outcome
second I-outcome
- I-outcome
line I-outcome
tamoxifen I-outcome
. O
Questionnaire O
data O
were O
available O
for O
119 B-total-participants
patients O
; O
58 B-iv-bin-abs
( O
48.7 B-iv-bin-percent
% I-iv-bin-percent
) O
gained B-outcome
clinical I-outcome
benefit I-outcome
( O
CB O
= O
complete+partial O
response O
( O
CR+PR O
) O
+ O
( O
stable O
disease O
( O
SD O
) O
> O
/ O
= O
24 O
weeks O
) O
) O
, O
while O
12 B-iv-bin-abs
( O
10.1 B-iv-bin-percent
% I-iv-bin-percent
) O
had O
an O
objective B-outcome
response I-outcome
( O
OR O
= O
CR+PR O
) O
. O
Of O
510 B-control-participants
patients O
randomised O
to O
tamoxifen O
, O
134 B-cv-bin-abs
( O
26.3 B-cv-bin-percent
% I-cv-bin-percent
) O
received B-outcome
second I-outcome
- I-outcome
line I-outcome
anastrozole I-outcome
. O
Questionnaire O
data O
from O
95 O
patients O
showed O
that O
54 B-cv-bin-abs
( O
56.8 B-cv-bin-percent
% I-cv-bin-percent
) O
gained B-outcome
CB I-outcome
and O
7 B-cv-bin-abs
of O
the O
patients O
gaining O
CB O
( O
7.4 B-cv-bin-percent
% I-cv-bin-percent
) O
had O
an O
OR B-outcome
. O
Previous O
studies O
showed O
anastrozole O
is O
effective O
after O
first O
- O
line O
tamoxifen O
. O
These O
data O
show O
that O
the O
sequential O
administration O
of O
first O
- O
line O
anastrozole O
followed O
by O
tamoxifen O
provides O
effective O
use O
of O
these O
drugs O
in O
the O
treatment O
of O
postmenopausal O
women O
with O
advanced O
breast O
cancer O
. O

" B-intervention
Tumour I-intervention
marker I-intervention
guided I-intervention
" I-intervention
salvage I-intervention
treatment I-intervention
prolongs O
survival O
of O
breast O
cancer O
patients O
: O
final O
report O
of O
a O
7 O
- O
year O
study O
. O
Randomised O
trials O
on O
breast O
cancer O
showed O
no O
significant O
benefit O
from O
post O
- O
operative O
follow O
- O
up O
with O
clinical O
and/or O
conventional O
radiological O
means O
. O
We O
hypothesised O
that O
carcinoembryonic O
antigen O
( O
CEA O
) O
, O
tissue O
polipeptyde O
antigen O
( O
TPA O
) O
, O
breast O
cancer O
associated O
antigen O
115 O
D8 O
/ O
DF3 O
( O
CA15.3 O
) O
tumour O
marker O
panel O
is O
sensitive O
enough O
for O
significantly O
anticipating O
salvage O
treatment O
and O
prolonging O
survival O
of O
relapsing O
breast O
cancer O
patients O
. O
From O
October O
1981 O
to O
May O
1999 O
, O
68 B-total-participants
( O
62 O
% O
) O
of O
109 O
patients B-eligibility
with I-eligibility
distant I-eligibility
metastases I-eligibility
were O
recruited O
. O
Thirty B-intervention-participants
- I-intervention-participants
six I-intervention-participants
( O
53 O
% O
) O
received O
salvage O
treatment O
at O
the O
time O
of O
significant O
increase O
in O
one O
or O
more O
components O
of O
CEA O
- O
TPA O
- O
CA15.3 O
tumour O
marker O
panel O
and O
negative O
instrumental O
examinations O
( O
" O
tumour O
marker O
guided O
" O
treatment O
) O
and O
32 B-control-participants
( O
47 O
% O
) O
were O
treated O
only O
after O
radiological O
confirmation O
of O
metastases O
( O
conventional B-control
treatment I-control
) O
. O
The O
prognostic O
factors O
of O
the O
two O
groups O
did O
not O
show O
any O
statistically O
significant O
difference O
. O
The O
time O
from O
one O
or O
more O
tumour O
marker O
increase O
to O
clear O
clinical O
and/or O
radiological O
signs O
of O
distant O
metastases O
( O
lead B-outcome
time I-outcome
) O
was O
significantly O
prolonged O
in O
the O
36 O
patients O
with O
" O
tumour O
marker O
guided O
" O
treatment O
( O
17.3 B-iv-cont-mean
+ O
/- O
13.1 B-iv-cont-sd
vs. O
2.9 B-cv-cont-mean
+ O
/- O
2.9 B-cv-cont-sd
months I-cv-cont-sd
, O
P O
< O
0.001 O
, O
Wilcoxon O
test O
) O
as O
well O
as O
the O
survival B-outcome
curves I-outcome
from O
salvage O
therapy O
and O
from O
mastectomy O
( O
the O
proportion O
of O
survivors O
was O
: O
at B-outcome
36 I-outcome
months I-outcome
from O
salvage O
therapy O
28 B-iv-bin-percent
% I-iv-bin-percent
vs. O
9 B-cv-bin-percent
% I-cv-bin-percent
, O
P O
= O
0.0094 O
; O
at B-outcome
84 I-outcome
months I-outcome
from O
mastectomy O
42 B-iv-bin-percent
% I-iv-bin-percent
vs. O
19 B-cv-bin-percent
% I-cv-bin-percent
, O
P O
= O
0.0017 O
) O
. O
The O
multivariate O
Cox O
analysis O
showed O
that O
time O
from O
mastectomy O
to O
tumour O
marker O
increase O
and O
" O
tumour O
marker O
guided O
" O
salvage O
treatment O
were O
the O
only O
significantly O
different O
variables O
( O
P O
= O
0.00001 O
and O
0.005 O
, O
respectively O
) O
. O
These O
data O
point O
out O
that O
" O
tumour O
marker O
guided O
" O
salvage O
treatment O
significantly O
prolongs O
disease O
- O
free O
and O
overall O
survivals O
of O
relapsing O
responsive O
patients O
. O

A O
cancer O
research O
( O
UK O
) O
randomized O
phase O
II O
study O
of O
idoxifene B-intervention
in O
patients O
with O
locally O
advanced O
/ O
metastatic O
breast O
cancer O
resistant O
to O
tamoxifen O
. O
Idoxifene O
is O
a O
novel O
selective O
oestrogen O
receptor O
modulator O
( O
SERM O
) O
which O
had O
greater O
binding O
affinity O
for O
the O
oestrogen O
receptor O
( O
ER O
) O
and O
reduced O
agonist O
activity O
compared O
with O
tamoxifen O
in O
preclinical O
studies O
. O
In O
a O
randomized O
phase O
II O
trial O
in O
56 B-total-participants
postmenopausal B-eligibility
patients I-eligibility
with I-eligibility
progressive I-eligibility
locally I-eligibility
advanced I-eligibility
/ I-eligibility
metastatic I-eligibility
breast I-eligibility
cancer I-eligibility
we O
assessed O
whether O
idoxifene O
showed O
evidence O
of O
activity O
compared O
with O
an O
increased O
40 O
mg O
/ O
day O
dose O
of O
tamoxifen B-control
in O
patients O
who O
had O
previously O
demonstrated O
resistance O
to O
the O
standard O
20 O
mg O
/ O
day O
dose O
of O
tamoxifen O
. O
Of O
47 B-total-participants
patients O
eligible O
for O
response O
( O
25 B-intervention-participants
idoxifene O
, O
22 B-control-participants
tamoxifen O
) O
, O
two B-iv-bin-abs
partial B-outcome
responses I-outcome
and O
two B-iv-bin-abs
disease B-outcome
stabilizations I-outcome
( I-outcome
SD I-outcome
) I-outcome
for O
> O
6 O
months O
were O
seen O
with O
idoxifene O
( O
overall B-outcome
clinical I-outcome
benefit I-outcome
rate I-outcome
16 B-iv-bin-percent
% I-iv-bin-percent
, O
95 O
% O
CI O
4.5 O
- O
36.1 O
% O
) O
. O
The O
median B-outcome
duration I-outcome
of I-outcome
clinical I-outcome
benefit I-outcome
was O
9.8 B-iv-cont-median
months I-iv-cont-median
. O
In O
contrast O
, O
no B-cv-bin-abs
objective B-outcome
responses I-outcome
were O
seen O
with O
the O
increased O
40 O
mg O
/ O
day O
dose O
of O
tamoxifen O
, O
although O
two B-cv-bin-abs
patients O
had O
SD B-outcome
for O
7 O
and O
14 O
months O
( O
clinical B-outcome
benefit I-outcome
rate I-outcome
9 B-cv-bin-percent
% I-cv-bin-percent
, O
95 O
% O
CI O
1.1 O
- O
29.2 O
% O
) O
. O
Idoxifene O
was O
well O
tolerated O
and O
the O
reported O
possible O
drug B-outcome
- I-outcome
related I-outcome
toxicities I-outcome
were O
similar O
in O
frequency O
to O
those O
with O
tamoxifen O
( O
hot B-outcome
flushes I-outcome
13 B-iv-bin-percent
% I-iv-bin-percent
vs O
15 B-cv-bin-percent
% I-cv-bin-percent
, O
mild B-outcome
nausea I-outcome
20 B-iv-bin-percent
% I-iv-bin-percent
vs O
15 B-cv-bin-percent
% I-cv-bin-percent
) O
. O
Endocrine O
and O
lipid O
analysis O
in O
both O
groups O
showed O
a O
similar O
significant O
fall O
in O
serum B-outcome
follicle I-outcome
- I-outcome
stimulating I-outcome
hormone I-outcome
and I-outcome
luteinizing I-outcome
hormone I-outcome
after O
4 O
weeks O
, O
together O
with O
a O
significant O
rise O
in O
sex O
hormone O
binding O
globulin O
levels O
and O
11 O
% O
reduction O
in O
serum B-outcome
cholesterol I-outcome
levels I-outcome
. O
In O
conclusion O
, O
while O
idoxifene O
was O
associated O
with O
only O
modest O
evidence O
of O
clinical O
activity O
in O
patients O
with O
tamoxifen O
- O
resistant O
breast O
cancer O
, O
its O
toxicity O
profile O
and O
effects O
on O
endocrine O
/ O
lipid O
parameters O
were O
similar O
to O
those O
of O
tamoxifen O
. O

A O
randomized O
trial O
of O
exemestane B-intervention
after O
two O
to O
three O
years O
of O
tamoxifen O
therapy O
in O
postmenopausal B-eligibility
women I-eligibility
with I-eligibility
primary I-eligibility
breast I-eligibility
cancer I-eligibility
. O
Tamoxifen O
, O
taken O
for O
five O
years O
, O
is O
the O
standard O
adjuvant O
treatment O
for O
postmenopausal O
women O
with O
primary O
, O
estrogen O
- O
receptor O
- O
positive O
breast O
cancer O
. O
Despite O
this O
treatment O
, O
however O
, O
some O
patients O
have O
a O
relapse O
. O
We O
conducted O
a O
double O
- O
blind O
, O
randomized O
trial O
to O
test O
whether O
, O
after O
two O
to O
three O
years O
of O
tamoxifen O
therapy O
, O
switching O
to O
exemestane O
was O
more O
effective O
than O
continuing O
tamoxifen O
therapy O
for O
the O
remainder O
of O
the O
five O
years O
of O
treatment O
. O
The O
primary O
end O
point O
was O
disease B-outcome-measure
- I-outcome-measure
free I-outcome-measure
survival I-outcome-measure
. O
Of O
the O
4742 B-total-participants
patients O
enrolled O
, O
2362 B-intervention-participants
were O
randomly O
assigned O
to O
switch O
to O
exemestane O
, O
and O
2380 B-control-participants
to O
continue O
to O
receive O
tamoxifen B-control
. O
After O
a O
median O
follow O
- O
up O
of O
30.6 O
months O
, O
449 O
first O
events O
( O
local B-outcome
or I-outcome
metastatic I-outcome
recurrence I-outcome
, O
contralateral B-outcome
breast I-outcome
cancer I-outcome
, O
or O
death B-outcome
) O
were O
reported O
-- O
183 B-iv-bin-abs
in O
the O
exemestane O
group O
and O
266 B-cv-bin-abs
in O
the O
tamoxifen O
group O
. O
The O
unadjusted O
hazard O
ratio O
in O
the O
exemestane O
group O
as O
compared O
with O
the O
tamoxifen O
group O
was O
0.68 O
( O
95 O
percent O
confidence O
interval O
, O
0.56 O
to O
0.82 O
; O
P<0.001 O
by O
the O
log O
- O
rank O
test O
) O
, O
representing O
a O
32 B-iv-bin-percent
percent I-iv-bin-percent
reduction B-outcome
in I-outcome
risk I-outcome
and O
corresponding O
to O
an O
absolute O
benefit O
in O
terms O
of O
disease B-outcome
- I-outcome
free I-outcome
survival I-outcome
of O
4.7 B-iv-bin-percent
percent I-iv-bin-percent
( O
95 O
percent O
confidence O
interval O
, O
2.6 O
to O
6.8 O
) O
at O
three O
years O
after O
randomization O
. O
Overall B-outcome
survival I-outcome
was O
not O
significantly O
different O
in O
the O
two O
groups O
, O
with O
93 B-iv-bin-abs
deaths B-outcome
occurring O
in O
the O
exemestane O
group O
and O
106 B-cv-bin-abs
in O
the O
tamoxifen O
group O
. O
Severe B-outcome
toxic I-outcome
effects I-outcome
of O
exemestane O
were O
rare O
. O
Contralateral B-outcome
breast I-outcome
cancer I-outcome
occurred O
in O
20 B-cv-bin-abs
patients O
in O
the O
tamoxifen O
group O
and O
9 B-iv-bin-abs
in O
the O
exemestane O
group O
( O
P O
= O
0.04 O
) O
. O
Exemestane O
therapy O
after O
two O
to O
three O
years O
of O
tamoxifen O
therapy O
significantly O
improved O
disease O
- O
free O
survival O
as O
compared O
with O
the O
standard O
five O
years O
of O
tamoxifen O
treatment O
. O

Oral B-intervention
ibandronate I-intervention
reduces O
the O
risk O
of O
skeletal B-condition
complications I-condition
in O
breast O
cancer O
patients O
with O
metastatic O
bone O
disease O
: O
results O
from O
two O
randomised O
, O
placebo O
- O
controlled O
phase O
III O
studies O
. O
Although O
intravenous O
( O
i. O
v. O
) O
bisphosphonates O
are O
the O
standard O
of O
care O
for O
metastatic O
bone O
disease O
, O
they O
are O
less O
than O
ideal O
for O
many O
patients O
due O
to O
infusion O
- O
related O
adverse O
events O
( O
AEs O
) O
, O
an O
increased O
risk O
of O
renal O
toxicity O
and O
the O
inconvenience O
of O
regular O
hospital O
visits O
. O
The O
use O
of O
oral O
bisphosphonate O
therapy O
is O
limited O
by O
concerns O
over O
efficacy O
and O
gastrointestinal O
( O
GI O
) O
side O
effects O
. O
There O
remains O
a O
clinical O
need O
for O
an O
oral O
bisphosphonate O
that O
offers O
equivalent O
efficacy O
to O
i. O
v. O
bisphosphonates O
, O
good O
tolerability O
and O
dosing O
convenience O
. O
Oral O
ibandronate O
, O
a O
highly O
potent O
, O
third O
- O
generation O
aminobisphosphonate O
, O
has O
been O
evaluated O
in O
phase O
III O
clinical O
trials O
of O
patients O
with O
bone O
metastases O
from O
breast O
cancer O
. O
In O
two O
pooled O
phase O
III O
studies O
, O
patients B-eligibility
with I-eligibility
breast I-eligibility
cancer I-eligibility
and I-eligibility
bone I-eligibility
metastases I-eligibility
were O
randomised O
to O
receive O
oral O
ibandronate O
50 O
mg O
( O
n O
= O
287 B-intervention-participants
) O
or O
placebo B-control
( O
n O
= O
277 B-control-participants
) O
once O
daily O
for O
up O
to O
96 O
weeks O
. O
The O
primary O
end O
point O
was O
the O
skeletal B-outcome-measure
morbidity I-outcome-measure
period I-outcome-measure
rate I-outcome-measure
( I-outcome-measure
SMPR I-outcome-measure
) I-outcome-measure
, O
defined O
as O
the O
number O
of O
12 O
- O
week O
periods O
with O
new O
skeletal O
complications O
. O
Multivariate O
Poisson O
's O
regression O
analysis O
was O
used O
to O
assess O
the O
relative O
risk O
of O
skeletal O
- O
related O
events O
in O
each O
treatment O
group O
during O
the O
study O
period O
. O
Oral O
ibandronate O
50 O
mg O
significantly O
reduced O
the O
mean B-outcome
SMPR I-outcome
compared O
with O
placebo O
( O
0.95 B-iv-cont-mean
vs O
1.18 B-cv-cont-mean
, O
P O
= O
0.004 O
) O
. O
There O
was O
a O
significant O
reduction O
in O
the O
mean B-outcome
number I-outcome
of I-outcome
events I-outcome
requiring I-outcome
radiotherapy I-outcome
( O
0.73 B-iv-cont-mean
vs O
0.98 B-cv-cont-mean
, O
P<0.001 O
) O
and O
events B-outcome
requiring I-outcome
surgery I-outcome
( O
0.47 B-iv-cont-mean
vs O
0.53 B-cv-cont-mean
, O
P O
= O
0.037 O
) O
. O
Poisson O
's O
regression O
analysis O
confirmed O
that O
oral O
ibandronate O
significantly O
reduced O
the O
risk B-outcome
of I-outcome
a I-outcome
skeletal I-outcome
event I-outcome
compared O
with O
placebo O
( O
hazard O
ratio O
0.62 O
, O
95 O
% O
CI O
= O
0.48 O
, O
0.79 O
; O
P O
= O
0.0001 O
) O
. O
The O
incidence O
of O
mild O
treatment O
- O
related O
upper B-outcome
GI I-outcome
AEs I-outcome
was O
slightly O
higher O
in O
the O
oral O
ibandronate O
50 O
mg O
group O
compared O
with O
placebo O
, O
but O
very O
few O
serious O
drug O
- O
related O
AEs O
were O
reported O
. O
Oral O
ibandronate O
50 O
mg O
is O
an O
effective O
, O
well O
- O
tolerated O
and O
convenient O
treatment O
for O
the O
prevention O
of O
skeletal O
complications O
of O
metastatic O
bone O
disease O
. O

Phase O
III O
randomized O
trial O
of O
Calendula B-intervention
officinalis I-intervention
compared O
with O
trolamine B-control
for O
the O
prevention O
of O
acute B-condition
dermatitis I-condition
during O
irradiation O
for O
breast O
cancer O
. O
The O
effectiveness O
of O
nonsteroid O
topical O
agents O
for O
the O
prevention O
of O
acute O
dermatitis O
during O
adjuvant O
radiotherapy O
for O
breast O
carcinoma O
has O
not O
been O
demonstrated O
. O
The O
goal O
of O
this O
study O
was O
to O
compare O
the O
effectiveness O
of O
calendula O
( O
Pommade O
au O
Calendula O
par O
Digestion O
; O
Boiron O
Ltd O
, O
Levallois O
- O
Perret O
, O
France B-location
) O
with O
that O
of O
trolamine O
( O
Biafine O
; O
Genmedix O
Ltd O
, O
France O
) O
, O
which O
is O
considered O
in O
many O
institutions O
to O
be O
the O
reference O
topical O
agent O
. O
Between O
July O
1999 O
and O
June O
2001 O
, O
254 B-total-participants
patients B-eligibility
who I-eligibility
had I-eligibility
been I-eligibility
operated I-eligibility
on I-eligibility
for I-eligibility
breast I-eligibility
cancer I-eligibility
and I-eligibility
who I-eligibility
were I-eligibility
to I-eligibility
receive I-eligibility
postoperative I-eligibility
radiation I-eligibility
therapy I-eligibility
were O
randomly O
allocated O
to O
application O
of O
either O
trolamine O
( O
128 B-control-participants
patients O
) O
or O
calendula O
( O
126 B-intervention-participants
patients O
) O
on O
the O
irradiated O
fields O
after O
each O
session O
. O
The O
primary O
end O
point O
was O
the O
occurrence B-outcome-measure
of I-outcome-measure
acute I-outcome-measure
dermatitis I-outcome-measure
of I-outcome-measure
grade I-outcome-measure
2 I-outcome-measure
or I-outcome-measure
higher I-outcome-measure
. O
Prognostic O
factors O
, O
including O
treatment O
modalities O
and O
patient O
characteristics O
, O
were O
also O
investigated O
. O
Secondary O
end O
points O
were O
the O
occurrence B-outcome-measure
of I-outcome-measure
pain I-outcome-measure
, O
the O
quantity B-outcome-measure
of I-outcome-measure
topical I-outcome-measure
agent I-outcome-measure
used I-outcome-measure
, O
and O
patient B-outcome-measure
satisfaction I-outcome-measure
. O
The O
occurrence B-outcome
of I-outcome
acute I-outcome
dermatitis I-outcome
of I-outcome
grade I-outcome
2 I-outcome
or I-outcome
higher I-outcome
was O
significantly O
lower O
( O
41 B-iv-bin-percent
% I-iv-bin-percent
v O
63 B-cv-bin-percent
% I-cv-bin-percent
; O
P O
< O
.001 O
) O
with O
the O
use O
of O
calendula O
than O
with O
trolamine O
. O
Moreover O
, O
patients O
receiving O
calendula O
had O
less O
frequent O
interruption O
of O
radiotherapy O
and O
significantly O
reduced O
radiation B-outcome
- I-outcome
induced I-outcome
pain I-outcome
. O
Calendula O
was O
considered O
to O
be O
more O
difficult O
to O
apply O
, O
but O
self B-outcome
- I-outcome
assessed I-outcome
satisfaction I-outcome
was O
greater O
. O
Body O
mass O
index O
and O
adjuvant O
chemotherapy O
before O
radiotherapy O
after O
lumpectomy O
were O
significant O
prognostic O
factors O
for O
acute O
dermatitis O
. O
Calendula O
is O
highly O
effective O
for O
the O
prevention O
of O
acute O
dermatitis O
of O
grade O
2 O
or O
higher O
and O
should O
be O
proposed O
for O
patients O
undergoing O
postoperative O
irradiation O
for O
breast O
cancer O
. O

Comparison O
of O
fulvestrant B-intervention
versus O
tamoxifen B-control
for O
the O
treatment O
of O
advanced O
breast O
cancer O
in O
postmenopausal O
women O
previously O
untreated O
with O
endocrine O
therapy O
: O
a O
multinational O
, O
double O
- O
blind O
, O
randomized O
trial O
. O
To O
evaluate O
the O
efficacy O
and O
tolerability O
of O
fulvestrant O
( O
Faslodex O
; O
AstraZeneca O
Pharmaceuticals O
LP O
, O
Wilmington O
, O
DE O
) O
, O
a O
new O
estrogen O
receptor O
( O
ER O
) O
antagonist O
that O
downregulates O
ER O
and O
has O
no O
agonist O
effects O
, O
versus O
tamoxifen O
, O
an O
antiestrogen O
with O
agonist O
and O
antagonist O
effects O
, O
for O
the O
treatment O
of O
advanced O
breast O
cancer O
in O
postmenopausal O
women O
. O
In O
this O
multicenter O
, O
double O
- O
blind O
, O
randomized O
trial O
, O
patients B-eligibility
with I-eligibility
metastatic I-eligibility
/ I-eligibility
locally I-eligibility
advanced I-eligibility
breast I-eligibility
cancer I-eligibility
previously I-eligibility
untreated I-eligibility
for I-eligibility
advanced I-eligibility
disease I-eligibility
were O
randomly O
assigned O
to O
receive O
either O
fulvestrant O
( O
250 O
mg O
, O
via O
intramuscular O
injection O
, O
once O
monthly O
; O
n O
= O
313 B-intervention-participants
) O
or O
tamoxifen O
( O
20 O
mg O
, O
orally O
, O
once O
daily O
; O
n O
= O
274 B-control-participants
) O
. O
Patients O
' O
tumors O
were O
positive O
for O
ER O
( O
ER+ O
) O
and/or O
progesterone O
receptor O
( O
PgR+ O
) O
, O
or O
had O
an O
unknown O
receptor O
status O
. O
At O
a O
median O
follow O
- O
up O
of O
14.5 O
months O
, O
there O
was O
no O
significant O
difference O
between O
fulvestrant O
and O
tamoxifen O
for O
the O
primary O
end O
point O
of O
time B-outcome
to I-outcome
progression I-outcome
( O
TTP O
; O
median O
TTP O
, O
6.8 B-iv-cont-median
months I-iv-cont-median
and O
8.3 B-cv-cont-median
months I-cv-cont-median
, O
respectively O
; O
hazard O
ratio O
, O
1.18 O
; O
95 O
% O
CI O
, O
0.98 O
to O
1.44 O
; O
P O
= O
.088 O
) O
. O
In O
a O
prospectively O
planned O
subset O
analysis O
of O
patients O
with O
known O
ER+ O
and/or O
PgR+ O
tumors O
( O
approximately O
78 O
% O
) O
, O
median B-outcome
TTP I-outcome
was O
8.2 B-iv-cont-median
months I-iv-cont-median
for O
fulvestrant O
and O
8.3 B-cv-cont-median
months I-cv-cont-median
for O
tamoxifen O
( O
hazard O
ratio O
, O
1.10 O
; O
95 O
% O
CI O
, O
0.89 O
to O
1.36 O
; O
P O
= O
.39 O
) O
. O
The O
objective B-outcome
response I-outcome
rate I-outcome
for O
the O
overall O
population O
was O
31.6 B-iv-bin-percent
% I-iv-bin-percent
with O
fulvestrant O
and O
33.9 B-cv-bin-percent
% I-cv-bin-percent
with O
tamoxifen O
, O
and O
33.2 B-iv-bin-percent
% I-iv-bin-percent
and O
31.1 B-cv-bin-percent
% I-cv-bin-percent
, O
respectively O
, O
in O
the O
known O
hormone O
receptor O
- O
positive O
subgroup O
. O
Both O
treatments O
were O
well B-outcome
tolerated I-outcome
. O
In O
the O
overall O
population O
, O
between O
- O
group O
differences O
in O
efficacy O
end O
points O
favored O
tamoxifen O
, O
and O
statistical O
noninferiority O
of O
fulvestrant O
could O
not O
be O
demonstrated O
. O
However O
, O
in O
patients O
with O
hormone O
receptor O
- O
positive O
tumors O
, O
fulvestrant O
had O
similar O
efficacy O
to O
tamoxifen O
and O
was O
well O
tolerated O
. O

Sentinel B-intervention
lymph I-intervention
node I-intervention
biopsy I-intervention
in O
patients O
with O
multifocal O
breast O
cancer O
. O
Multifocal O
or O
multicentric O
breast O
cancer O
has O
been O
suggested O
as O
a O
contraindication O
for O
sentinel O
node O
biopsy O
( O
SNB O
) O
. O
However O
, O
recent O
studies O
have O
demonstrated O
that O
all O
quadrants O
of O
the O
breast O
drain O
through O
common O
afferent O
channels O
to O
a O
common O
axillary O
sentinel O
node O
. O
This O
should O
mean O
that O
the O
presence O
of O
multifocal O
tumour O
should O
not O
affect O
the O
lymphatic O
drainage O
. O
The O
purpose O
of O
this O
study O
was O
to O
evaluate O
the O
feasibility O
and O
accuracy O
of O
SNB O
in O
patients O
with O
multifocal O
breast O
cancer O
using O
a O
peritumoural O
injection O
technique O
for O
sentinel O
lymph O
node O
( O
SN O
) O
mapping O
. O
In O
the O
ALMANAC O
multicentre O
trial O
validation O
phase O
, O
we O
took O
SNB O
samples O
from O
842 B-total-participants
patients B-eligibility
with I-eligibility
node I-eligibility
negative I-eligibility
, I-eligibility
invasive I-eligibility
breast I-eligibility
cancer I-eligibility
with O
use O
of O
a O
blue O
dye O
and O
radiolabelled O
colloid O
mapping O
technique O
at O
the O
peritumoural O
injection O
site O
. O
All O
patients O
underwent O
standard O
axillary O
treatment O
after O
SNB O
. O
Seventy O
- O
five O
of O
the O
842 O
patients O
had O
multifocal O
lesions O
on O
final O
histopathologic O
examination O
. O
The O
following O
analysis O
is O
focused O
on O
patients O
with O
multifocal O
lesions O
. O
A O
mean O
number O
of O
2.4 O
SNs B-outcome
were O
identified O
in O
71 B-iv-bin-abs
of O
75 B-intervention-participants
patients O
( O
identification O
rate O
: O
94.7 B-iv-bin-percent
% I-iv-bin-percent
) O
. O
Thirty B-iv-bin-abs
- I-iv-bin-abs
one I-iv-bin-abs
patients O
had O
a O
positive B-outcome
SN I-outcome
, O
40 B-iv-bin-abs
a O
negative B-outcome
SN I-outcome
. O
Standard O
axillary O
treatment O
confirmed B-outcome
the I-outcome
SN I-outcome
to I-outcome
be I-outcome
negative I-outcome
in O
37 B-iv-bin-abs
of O
40 B-intervention-participants
patients O
, O
whereas O
three B-iv-bin-abs
patients O
revealed O
positive B-outcome
non I-outcome
- I-outcome
sentinel I-outcome
lymph I-outcome
nodes I-outcome
( O
false O
- O
negative O
rate O
: O
8.8 O
% O
) O
. O
Overall O
SN O
biopsy O
accurately B-outcome
predicted I-outcome
axillary I-outcome
lymph I-outcome
node I-outcome
status I-outcome
in O
68 B-iv-bin-abs
of O
71 B-intervention-participants
patients O
( O
95.8 B-iv-bin-percent
% I-iv-bin-percent
) O
. O
SNB O
accurately O
staged O
the O
axilla O
in O
multifocal O
breast O
cancer O
and O
may O
become O
an O
alternative O
to O
complete O
axillary O
lymph O
node O
dissection O
in O
node O
negative O
patients O
with O
multifocal O
breast O
cancer O
. O

Seroma B-condition
prevention O
following O
axillary B-intervention
dissection I-intervention
in O
patients O
with O
breast O
cancer O
by O
using O
ultrasound O
scissors O
: O
a O
prospective O
clinical O
study O
. O
Seroma O
formation O
following O
axillary O
dissection O
is O
a O
common O
complication O
of O
breast O
surgery O
. O
The O
aims O
of O
this O
study O
were O
( O
1 O
) O
to O
analyse O
the O
risk O
factors O
of O
seroma O
formation O
, O
and O
( O
2 O
) O
to O
evaluate O
the O
role O
of O
ultrasound O
scissors O
in O
performing O
axillary O
dissection O
in O
patients O
with O
primary O
breast O
cancer O
undergoing O
mastectomy O
and O
breast O
- O
conserving O
surgery O
. O
Ninety B-total-participants
- I-total-participants
two I-total-participants
women O
( O
median O
age O
55 B-age
years I-age
, O
range O
33 O
- O
73 O
years O
) O
requiring B-eligibility
surgery I-eligibility
for I-eligibility
known I-eligibility
unilateral I-eligibility
primary I-eligibility
breast I-eligibility
cancer I-eligibility
( I-eligibility
pT1a I-eligibility
= I-eligibility
1 I-eligibility
, I-eligibility
pT1b I-eligibility
= I-eligibility
20 I-eligibility
, I-eligibility
pT1c I-eligibility
= I-eligibility
43 I-eligibility
, I-eligibility
pT2 I-eligibility
= I-eligibility
25 I-eligibility
, I-eligibility
pT3 I-eligibility
=3 I-eligibility
) I-eligibility
were O
prospectively O
randomised O
to O
undergo O
axillary O
dissection O
by O
either O
using O
( O
Group O
A O
, O
45 B-intervention-participants
patients O
) O
or O
not B-control
using I-control
( O
Group O
B O
, O
47 B-control-participants
patients O
) O
ultrasound O
scissors O
( O
US O
) O
. O
Thirty O
- O
eight O
( O
41.3 O
% O
) O
patients O
underwent O
modified O
radical O
mastectomy O
, O
while O
54 O
( O
58.7 O
% O
) O
underwent O
breast O
- O
conserving O
surgery O
. O
Twenty O
- O
eight O
( O
30.4 O
% O
) O
patients O
( O
Group O
A O
= O
9 B-iv-bin-abs
out O
of O
45 B-intervention-participants
, O
20 B-iv-bin-percent
% I-iv-bin-percent
; O
Group O
B O
= O
19 B-cv-bin-abs
out O
of O
47 B-control-participants
, O
42 B-cv-bin-percent
% I-cv-bin-percent
; O
P O
= O
NS O
) O
developed B-outcome
a I-outcome
wound I-outcome
seroma I-outcome
. O
Multivariate O
analysis O
using O
a O
logistic O
regression O
model O
showed O
that O
surgical B-outcome
procedure I-outcome
( O
RR O
= O
8.9 O
; O
95 O
% O
CI O
: O
3.2 O
- O
25.3 O
) O
, O
total B-outcome
amount I-outcome
of I-outcome
drainage I-outcome
( O
RR O
= O
7.8 O
; O
95 O
% O
CI O
: O
2.8 O
- O
22.0 O
) O
, O
and O
size B-outcome
of I-outcome
the I-outcome
tumour I-outcome
( O
RR O
= O
6.0 O
; O
95 O
% O
CI O
: O
2.2 O
- O
16.5 O
) O
independently O
correlated O
with O
seroma O
formation O
. O
The O
logistic O
regression O
function O
( O
RR O
= O
19.4 O
; O
95 O
% O
CI O
: O
6 O
- O
62 O
) O
correctly O
allocated O
75 O
out O
of O
92 O
( O
81.5 O
% O
) O
patients O
. O
Size O
of O
the O
tumour O
, O
and O
total O
amount O
of O
drainage O
represent O
the O
principal O
factors O
of O
seroma O
formation O
following O
axillary O
dissection O
in O
patients O
undergoing O
surgery O
for O
breast O
cancer O
. O
Although O
the O
use O
of O
ultrasound O
cutting O
devices O
may O
reduce O
the O
risk O
of O
seroma O
formation O
, O
further O
studies O
are O
need O
to O
verify O
the O
real O
impact O
on O
long O
- O
term O
morbidity O
of O
such O
technique O
. O

Local O
recurrence O
in O
breast O
cancer O
after O
conservative B-intervention
surgery I-intervention
: O
timing O
of O
radiotherapy O
and O
sequencing O
of O
chemotherapy O
. O
A O
randomized O
trial O
was O
conducted O
to O
determine O
( O
a O
) O
the O
role O
of O
radiotherapy O
and O
chemotherapy O
on O
local O
control O
and O
( O
b O
) O
to O
determine O
the O
timing O
of O
radiotherapy O
for O
early B-eligibility
- I-eligibility
stage I-eligibility
breast I-eligibility
cancer I-eligibility
. I-eligibility
Five B-intervention-participants
hundred I-intervention-participants
and I-intervention-participants
ninety I-intervention-participants
patients O
were O
treated O
with O
both O
conservative O
surgery O
and O
radiotherapy O
( O
group O
A O
) O
. O
The O
average O
time O
interval O
between O
surgery O
and O
radiation O
was O
90 O
days O
for O
452 O
patients O
and O
over O
90 O
days O
for O
138 O
patients O
. O
One B-control-participants
hundred I-control-participants
and I-control-participants
ninety I-control-participants
- I-control-participants
four I-control-participants
patients O
underwent O
adjuvant B-control
therapy I-control
based O
on O
CMF O
regimens O
( O
group O
B O
) O
. O
Among O
396 B-intervention-participants
patients O
of O
group O
A O
, O
8.1 B-iv-bin-percent
% I-iv-bin-percent
had O
local B-outcome
failure I-outcome
; O
we O
observed O
7.2 B-iv-bin-percent
% I-iv-bin-percent
local B-outcome
recurrences I-outcome
in O
363 B-intervention-participants
patients O
who O
received O
therapy O
before O
90 O
days O
and O
18.2 B-iv-bin-percent
% I-iv-bin-percent
in O
patients O
who O
received O
therapy O
after O
90 O
days O
. O
Among O
patients O
of O
group O
B O
, O
7.7 B-cv-bin-percent
% I-cv-bin-percent
had O
local B-outcome
failure I-outcome
; O
for O
patients O
who O
underwent O
radiotherapy O
before O
90 O
days O
, O
the O
local B-outcome
recurrence I-outcome
rate I-outcome
was O
6.6 B-cv-bin-percent
% I-cv-bin-percent
, O
compared O
with O
12.3 B-cv-bin-percent
% I-cv-bin-percent
for O
patients O
who O
underwent O
therapy O
more O
than O
90 O
days O
after O
surgery O
. O
In O
patients O
who O
are O
eligible O
to O
receive O
chemotherapy O
, O
it O
is O
possible O
to O
administer O
radiotherapy O
after O
systemic O
treatment O
, O
while O
in O
patients O
who O
have O
to O
be O
treated O
with O
radiotherapy O
more O
then O
90 O
days O
after O
breast O
surgery O
, O
chemotherapy O
can O
reduce O
the O
local O
failure O
rate O
. O

Postoperative O
adjuvant O
use O
of O
carmofur B-intervention
for O
early O
breast O
cancer O
. O
The O
efficacy O
of O
oral O
fluoropyrimidine O
carmofur O
was O
evaluated O
for O
adjuvant O
use O
for O
breast O
cancer O
. O
150 B-total-participants
patients B-eligibility
with I-eligibility
breast I-eligibility
cancer I-eligibility
of I-eligibility
T0N1 I-eligibility
, I-eligibility
T1 I-eligibility
, I-eligibility
N1 I-eligibility
, I-eligibility
T2N0 I-eligibility
, I-eligibility
and I-eligibility
T2N1 I-eligibility
were O
randomized O
to O
100 B-intervention-participants
for O
carmofur O
and O
50 B-control-participants
for O
carboquone B-control
. O
Both O
drugs O
were O
administered O
continuously O
for O
28 O
days O
cyclically O
for O
5 O
years O
with O
a O
cessation O
period O
of O
28 O
days O
for O
carmofur O
and O
56 O
days O
for O
carboquone O
. O
Overall B-outcome
survival I-outcome
excluding O
non O
- O
breast O
cancer O
death O
was O
90 B-iv-bin-percent
% I-iv-bin-percent
for O
the O
carmofur O
group O
and O
88 B-cv-bin-percent
% I-cv-bin-percent
for O
the O
carboquone O
group O
, O
adjusted O
by O
Cox O
's O
regression O
analysis O
. O
Difference O
in O
drug O
never O
affected O
survival O
. O
Leukocyte B-outcome
count I-outcome
was O
decreased O
in O
the O
carboquone O
group O
, O
but O
no O
change O
in O
serum O
transaminase O
was O
found O
in O
either O
group O
. O
Ten O
patients O
, O
5 B-iv-bin-abs
for O
carmofur O
and O
5 B-cv-bin-abs
for O
carboquone O
, O
suffered O
from O
second B-outcome
malignancy I-outcome
, O
more O
than O
expected O
in O
the O
normal O
population O
, O
but O
difference O
in O
the O
cumulative O
rate O
of O
each O
group O
was O
not O
significant O
. O
Adjuvant O
use O
of O
carmofur O
as O
well O
as O
carboquone O
is O
beneficial O
for O
early O
breast O
cancer O
. O

High B-control
- I-control
dose I-control
oral I-control
medroxyprogesterone I-control
acetate I-control
or O
tamoxifen B-intervention
as O
adjuvant O
hormone O
therapy O
for O
node O
- O
negative O
early O
- O
stage O
breast O
cancer O
: O
randomized O
trial O
with O
7 O
- O
year O
update O
. O
A O
randomized O
adjuvant O
trial O
compared O
tamoxifen O
20 O
mg O
daily O
for O
5 O
years O
with O
high O
- O
dose O
oral O
medroxyprogesterone O
acetate O
( O
MPA O
) O
1 O
g O
orally O
for O
9 O
months O
. O
One B-total-participants
hundred I-total-participants
ninety I-total-participants
- I-total-participants
four I-total-participants
patients B-eligibility
with I-eligibility
histologically I-eligibility
proven I-eligibility
primary I-eligibility
node I-eligibility
- I-eligibility
negative I-eligibility
breast I-eligibility
carcinoma I-eligibility
were O
enrolled O
between O
December O
1990 O
and O
October O
1996 O
, O
with O
98 B-intervention-participants
patients O
randomized O
into O
the O
tamoxifen O
arm O
and O
96 B-control-participants
into O
the O
MPA O
arm O
. O
At O
a O
median O
follow O
- O
up O
of O
86 O
months O
, O
25 O
relapses B-outcome
and O
13 O
deaths B-outcome
were O
recorded O
. O
The O
relapse B-outcome
- I-outcome
free I-outcome
survival I-outcome
rate I-outcome
at I-outcome
7 I-outcome
years I-outcome
in O
the O
tamoxifen O
arm O
was O
93 B-iv-bin-percent
% I-iv-bin-percent
, O
versus O
81 B-cv-bin-percent
% I-cv-bin-percent
in O
the O
MPA O
arm O
( O
P O
= O
0.02 O
) O
. O
The O
difference O
was O
observed O
in O
patients O
with O
stage B-outcome
T2 I-outcome
disease I-outcome
( O
100 B-iv-bin-percent
% I-iv-bin-percent
in O
the O
tamoxifen O
group O
vs. O
64 B-cv-bin-percent
% I-cv-bin-percent
in O
the O
MPA O
group O
; O
P O
= O
0.01 O
) O
, O
in O
younger B-outcome
and/or I-outcome
premenopausal I-outcome
patients I-outcome
( O
in O
patients O
< O
50 O
years O
of O
age O
, O
100 B-iv-bin-percent
% I-iv-bin-percent
in O
the O
tamoxifen O
arm O
vs. O
81 B-cv-bin-percent
% I-cv-bin-percent
in O
the O
MPA O
arm O
[ O
P O
= O
0.02 O
] O
, O
and O
in O
patients B-outcome
> I-outcome
or I-outcome
= I-outcome
50 I-outcome
years I-outcome
of I-outcome
age I-outcome
, O
90 B-iv-bin-percent
% I-iv-bin-percent
in O
the O
tamoxifen O
arm O
vs. O
82 B-cv-bin-percent
% I-cv-bin-percent
in O
the O
MPA O
arm O
[ O
P O
= O
0.16 O
] O
) O
. O
Also O
, O
the O
overall B-outcome
survival I-outcome
rate I-outcome
at I-outcome
7 I-outcome
years I-outcome
was O
lower O
in O
women O
< O
50 O
years O
of O
age O
( O
P O
= O
0.04 O
) O
. O

Randomized O
phase O
II O
study O
of O
two O
irinotecan B-intervention
schedules I-intervention
for O
patients O
with O
metastatic O
breast O
cancer O
refractory O
to O
an O
anthracycline O
, O
a O
taxane O
, O
or O
both O
. O
A O
pressing O
need O
exists O
for O
agents O
active O
against O
anthracycline- O
or O
taxane O
- O
refractory O
metastatic O
breast O
cancer O
( O
MBC O
) O
, O
or O
both O
. O
Previous O
clinical O
trials O
suggested O
that O
irinotecan O
might O
have O
such O
activity O
. O
We O
conducted O
this O
multicenter O
phase O
II O
study O
to O
assess O
efficacy O
and O
tolerability O
of O
two O
irinotecan O
schedules O
. O
MBC B-eligibility
patients I-eligibility
who I-eligibility
experienced I-eligibility
disease I-eligibility
progression I-eligibility
after I-eligibility
one I-eligibility
to I-eligibility
three I-eligibility
chemotherapy I-eligibility
regimens I-eligibility
, I-eligibility
including I-eligibility
at I-eligibility
least I-eligibility
one I-eligibility
anthracycline- I-eligibility
or I-eligibility
taxane I-eligibility
- I-eligibility
based I-eligibility
regimen I-eligibility
, O
were O
randomly O
assigned O
to O
irinotecan O
in O
6 O
- O
week O
cycles O
comprising O
100 O
mg O
/ O
m O
( O
2 O
) O
weekly O
for O
4 O
weeks O
, O
then O
a O
2 O
- O
week O
rest O
( O
weekly O
) O
or O
240 O
mg O
/ O
m O
( O
2 O
) O
every O
3 O
weeks O
. O
The O
weekly B-intervention
arm I-intervention
had O
52 B-intervention-participants
assessable O
patients O
; O
the O
every-3 B-control
- I-control
weeks I-control
arm I-control
had O
51 B-control-participants
assessable O
patients O
. O
In O
the O
weekly O
arm O
, O
the O
objective B-outcome
response I-outcome
( O
complete O
regression O
[ O
CR O
] O
+ O
partial O
regression O
[ O
PR O
] O
) O
rate O
was O
23 B-iv-bin-percent
% I-iv-bin-percent
( O
one B-iv-bin-abs
CR B-outcome
, O
11 B-iv-bin-abs
PR B-outcome
; O
95 O
% O
CI O
, O
13 O
% O
to O
37 O
% O
) O
. O
Median B-outcome
response I-outcome
duration I-outcome
was O
4.9 B-iv-cont-median
months I-iv-cont-median
( O
range O
, O
1.9 O
to O
15.9 O
months O
) O
, O
and O
median B-outcome
overall I-outcome
survival I-outcome
was O
9.7 B-iv-cont-median
months I-iv-cont-median
( O
95 O
% O
CI O
, O
8.0 O
to O
14.2 O
months O
) O
. O
In O
the O
every-3 O
- O
weeks O
arm O
, O
the O
objective B-outcome
response I-outcome
rate I-outcome
was O
14 B-cv-bin-percent
% I-cv-bin-percent
( O
nine B-cv-bin-abs
PR B-outcome
; O
95 O
% O
CI O
, O
6 O
% O
to O
26 O
% O
) O
, O
median B-outcome
response I-outcome
duration I-outcome
was O
4.2 B-cv-cont-median
months I-cv-cont-median
( O
range O
, O
3.1 O
to O
13.9 O
months O
) O
, O
and O
median B-outcome
overall I-outcome
survival I-outcome
was O
8.6 B-cv-cont-median
months I-cv-cont-median
( O
95 O
% O
CI O
, O
7.0 O
to O
12.3 O
months O
) O
. O
Treatment O
generally O
was O
well B-outcome
tolerated I-outcome
, O
especially O
in O
the O
weekly O
arm O
. O
Grade B-outcome
3 I-outcome
to I-outcome
4 I-outcome
adverse I-outcome
events I-outcome
with O
> O
or O
= O
10 O
% O
incidence O
included O
neutropenia B-outcome
( O
29 B-iv-bin-percent
% I-iv-bin-percent
) O
and O
diarrhea B-outcome
( O
17 B-iv-bin-percent
% I-iv-bin-percent
) O
in O
the O
weekly O
arm O
and O
neutropenia B-outcome
( O
36 B-cv-bin-percent
% I-cv-bin-percent
) O
, O
vomiting B-outcome
( O
20 B-cv-bin-percent
% I-cv-bin-percent
) O
, O
dyspnea B-outcome
( O
18 B-cv-bin-percent
% I-cv-bin-percent
) O
, O
nausea B-outcome
( O
16 B-cv-bin-percent
% I-cv-bin-percent
) O
, O
and O
diarrhea B-outcome
( O
12 B-cv-bin-percent
% I-cv-bin-percent
) O
in O
the O
every-3 O
- O
weeks O
arm O
. O
Irinotecan O
is O
active O
with O
good B-outcome
tolerability I-outcome
in O
refractory O
MBC O
. O
Irinotecan O
( O
especially O
weekly O
) O
warrants O
additional O
study O
as O
monotherapy O
and O
in O
combination O
regimens O
in O
this O
setting O
. O

Effect O
of O
a O
decision B-intervention
aid I-intervention
on O
knowledge O
and O
treatment O
decision O
making O
for O
breast O
cancer O
surgery O
: O
a O
randomized O
trial O
. O
The O
long O
- O
term O
results O
of O
randomized O
trials O
have O
demonstrated O
equivalent O
survival O
rates O
for O
mastectomy O
and O
breast O
- O
conserving O
therapy O
for O
the O
treatment O
of O
early O
stage O
breast O
cancer O
. O
Consequently O
, O
the O
choice O
of O
treatment O
should O
be O
based O
on O
a O
patient O
's O
preferences O
. O
To O
evaluate O
the O
impact O
of O
a O
decision O
aid O
regarding O
the O
different O
surgical O
treatment O
options O
on O
patient O
decision O
making O
. O
A O
cluster O
randomized O
trial O
for O
which O
general O
surgeons O
in O
the O
communities O
of O
central O
- O
west O
, O
and O
eastern B-location
Ontario I-location
, I-location
Canada I-location
, O
were O
randomly O
assigned O
to O
use O
the O
decision O
aid O
or O
not O
in O
the O
surgical O
consultation O
. O
Patients O
received O
the O
decision O
aid O
or O
not O
based O
on O
the O
surgeon O
seen O
. O
Twenty O
surgeons O
participated O
in O
the O
study O
. O
Of O
the O
208 B-total-participants
eligible O
women B-eligibility
with I-eligibility
newly I-eligibility
diagnosed I-eligibility
clinical I-eligibility
stage I-eligibility
I I-eligibility
or I-eligibility
II I-eligibility
breast I-eligibility
cancer I-eligibility
seen I-eligibility
by I-eligibility
study I-eligibility
surgeons I-eligibility
, O
201 B-total-participants
agreed O
to O
be O
evaluated O
: O
94 B-intervention-participants
were O
assigned O
to O
the O
decision O
board O
and O
107 B-control-participants
to O
usual B-control
practice I-control
. O
Patients O
were O
recruited O
from O
November O
1999 O
to O
April O
2002 O
. O
The O
decision O
board O
is O
a O
decision O
aid O
designed O
to O
help O
physicians O
inform O
their O
patients O
about O
different O
treatment O
options O
and O
to O
enable O
patients O
to O
express O
a O
preference O
for O
treatment O
. O
Patient O
knowledge O
about O
the O
surgical O
treatment O
of O
breast O
cancer O
; O
decisional O
conflict O
; O
satisfaction O
with O
decision O
making O
; O
and O
the O
treatment O
decision O
following O
the O
consultation O
. O
Patients O
in O
the O
decision O
board O
group O
had O
higher O
knowledge B-outcome
scores I-outcome
about I-outcome
their I-outcome
treatment I-outcome
options I-outcome
( O
66.9 B-iv-cont-mean
vs O
58.7 B-cv-cont-mean
; O
P<.001 O
) O
, O
had O
less O
decisional B-outcome
conflict I-outcome
( O
1.40 B-iv-cont-mean
vs O
1.62 B-cv-cont-mean
, O
P O
= O
.02 O
) O
, O
and O
were O
more O
satisfied B-outcome
with I-outcome
decision I-outcome
making I-outcome
( O
4.50 B-iv-cont-mean
vs O
4.32 B-cv-cont-mean
, O
P O
= O
.05 O
) O
following O
the O
consultation O
. O
Patients O
who O
used O
the O
decision O
board O
were O
more B-outcome
likely I-outcome
to I-outcome
choose I-outcome
BCT I-outcome
( O
94 B-iv-bin-percent
% I-iv-bin-percent
vs O
76 B-cv-bin-percent
% I-cv-bin-percent
, O
P O
= O
.03 O
) O
. O
The O
decision O
board O
was O
helpful O
in O
improving O
communication O
and O
enabling O
women O
to O
make O
a O
choice O
regarding O
treatment O
. O
Such O
instruments O
should O
be O
considered O
by O
surgeons O
when O
communicating O
the O
different O
surgical O
options O
to O
women O
with O
breast O
cancer O
. O

Long O
- O
term O
cardiac O
follow O
- O
up O
in O
relapse O
- O
free O
patients O
after O
six O
courses O
of O
fluorouracil B-intervention
, I-intervention
epirubicin I-intervention
, I-intervention
and I-intervention
cyclophosphamide I-intervention
, I-intervention
with I-intervention
either I-intervention
50 I-intervention
or I-intervention
100 I-intervention
mg I-intervention
of I-intervention
epirubicin I-intervention
, O
as O
adjuvant O
therapy O
for O
node B-eligibility
- I-eligibility
positive I-eligibility
breast I-eligibility
cancer I-eligibility
: O
French B-location
adjuvant O
study O
group O
. O
PURPOSE O
To O
evaluate O
long O
- O
term O
cardiac O
function O
in O
patients O
without O
disease O
who O
had O
received O
six O
cycles O
of O
fluorouracil O
500 O
mg O
/ O
m O
( O
2 O
) O
, O
epirubicin O
50 O
mg O
/ O
m O
( O
2 O
) O
, O
and O
cyclophosphamide O
500 O
mg O
/ O
m O
( O
2 O
) O
( O
FEC O
50 O
) O
or O
the O
same O
regimen O
with O
epirubicin O
100 O
mg O
/ O
m O
( O
2 O
) O
( O
FEC O
100 O
) O
as O
adjuvant O
chemotherapy O
for O
node O
- O
positive O
breast O
cancer O
in O
the O
French O
Adjuvant O
Study O
Group-05 O
trial O
. O
PATIENTS O
AND O
METHODS O
One B-total-participants
hundred I-total-participants
fifty I-total-participants
patients I-total-participants
( O
FEC O
50 O
, O
n O
= O
65 B-intervention-participants
; O
FEC B-control
100 I-control
, O
n O
= O
85 B-control-participants
) O
who O
were O
without O
disease O
and O
who O
gave O
their O
informed O
consent O
were O
enrolled O
for O
long O
- O
term O
cardiac O
assessment O
. O
The O
assessment O
included O
cardiac O
events O
occurring O
after O
the O
end O
of O
chemotherapy O
, O
vital O
signs O
, O
concomitant O
disease O
, O
ECG O
, O
isotopic O
left O
ventricular O
ejection O
fraction O
( O
LVEF O
) O
, O
and O
echographic O
parameters O
. O
Abnormal O
files O
were O
blindly O
reviewed O
by O
cardiologists O
and O
oncologists O
. O
Results O
The O
median O
follow O
- O
up O
time O
was O
102 O
months O
. O
After O
FEC O
100 O
, O
LVEF B-outcome
was I-outcome
less I-outcome
than I-outcome
50 I-outcome
% I-outcome
in O
five B-iv-bin-abs
patients O
( O
radioisotopic O
method O
) O
, O
and O
two B-iv-bin-abs
patients O
experienced O
congestive B-outcome
heart I-outcome
failure I-outcome
( I-outcome
CHF I-outcome
) I-outcome
that O
was O
possibly O
related O
to O
treatment O
. O
Asymptomatic B-outcome
left I-outcome
ventricular I-outcome
dysfunction I-outcome
( I-outcome
LVD I-outcome
) I-outcome
was O
experienced O
in O
18 B-iv-bin-abs
patients O
after O
FEC O
100 O
and O
in O
one B-cv-bin-abs
patient O
after O
FEC O
50 O
. O
In O
these O
patients O
, O
treatment B-outcome
causality I-outcome
was O
probable O
in O
eight O
patients O
. O
Two O
additional O
years O
after O
this O
assessment O
, O
all O
18 O
patients O
were O
still O
asymptomatic O
. O
CONCLUSION O
After O
more O
than O
8 O
years O
of O
follow O
- O
up O
, O
the O
cardiac O
toxicity O
observed O
after O
adjuvant O
treatment O
with O
FEC O
100 O
comprised O
two O
cases O
of O
well O
- O
controlled O
CHF O
and O
18 O
cases O
of O
asymptomatic O
LVD O
. O
In O
the O
majority O
of O
women O
with O
primary O
breast O
cancer O
, O
the O
benefits O
of O
treatment O
with O
FEC O
100 O
in O
terms O
of O
disease O
- O
free O
and O
overall O
survival O
outweigh O
the O
risks O
, O
and O
cardiac O
risk O
factors O
should O
be O
carefully O
evaluated O
in O
patient O
selection O
. O

Comparison O
of O
fracture O
, O
cardiovascular O
event O
, O
and O
breast O
cancer O
rates O
at O
3 O
years O
in O
postmenopausal O
women O
with O
osteoporosis O
. O
To O
compare O
event O
rates O
for O
osteoporotic O
fractures O
, O
cardiovascular O
events O
, O
and O
breast O
cancer O
in O
postmenopausal O
women O
with O
osteoporosis O
. O
A O
prospective O
, O
observational O
study O
of O
the O
placebo O
group O
in O
the O
double O
- O
blind O
, O
randomized O
Multiple O
Outcomes O
of O
Raloxifene O
Evaluation O
trial O
. O
One O
hundred O
eighty O
clinical O
research O
centers O
in O
25 O
countries O
. O
Postmenopausal B-eligibility
women I-eligibility
( O
n O
= O
2,565 B-total-participants
, O
mean O
age O
= O
67 B-age
) O
with B-eligibility
osteoporosis I-eligibility
were O
given O
calcium B-intervention
( O
500 O
mg O
/ O
d O
) O
and O
vitamin B-control
D I-control
( O
400 O
- O
600 O
IU O
/ O
d O
) O
supplements O
. O
The O
occurrence O
of O
at O
least O
one O
new B-outcome
fracture I-outcome
, I-outcome
cardiovascular I-outcome
event I-outcome
, I-outcome
or I-outcome
breast I-outcome
cancer I-outcome
diagnosis I-outcome
at O
3 O
years O
was O
identified O
and O
adjudicated O
. O
The O
occurrence O
of O
any O
fracture O
was O
the O
most O
common O
event O
in O
these O
women O
. O
In O
women O
without O
prevalent O
vertebral O
fractures O
( O
n O
= O
1,627 B-total-participants
) O
, O
the O
event B-outcome
rates I-outcome
per O
1,000 O
patient O
- O
years O
were O
45.4 O
for O
any B-outcome
fracture I-outcome
, O
15.2 O
for O
vertebral B-outcome
fracture I-outcome
, O
4.7 O
for O
clinical B-outcome
vertebral I-outcome
fracture I-outcome
, O
0.9 O
for O
hip B-outcome
fracture I-outcome
, O
8.3 O
for O
any B-outcome
cardiovascular I-outcome
event I-outcome
, O
and O
5.2 O
for O
all B-outcome
breast I-outcome
cancer I-outcome
. O
In O
women O
with O
prevalent O
vertebral O
fractures O
( O
n O
= O
938 B-total-participants
) O
, O
the O
event B-outcome
rates I-outcome
per O
1,000 O
patient O
- O
years O
were O
117.4 O
for O
any O
new B-outcome
fracture I-outcome
, O
77.1 O
for O
new B-outcome
vertebral I-outcome
fracture I-outcome
, O
25.7 O
for O
clinical B-outcome
vertebral I-outcome
fracture I-outcome
, O
5.8 O
for O
hip B-outcome
fracture I-outcome
, O
15.1 O
for O
any B-outcome
cardiovascular I-outcome
event I-outcome
, O
and O
2.6 O
for O
all B-outcome
breast I-outcome
cancer I-outcome
. O
The O
effect O
of O
prevalent O
fracture O
status O
on O
event O
rates O
was O
not O
dependent O
on O
whether O
women O
were O
older O
or O
younger O
than O
65 O
, O
but O
women O
aged O
65 O
and O
older O
had O
a O
3.6 O
times O
greater O
occurrence O
of O
cardiovascular O
events O
than O
younger O
women O
, O
irrespective O
of O
prevalent O
fracture O
status O
. O
These O
data O
on O
the O
relative O
incidence O
of O
clinically O
significant O
skeletal O
and O
extra O
- O
skeletal O
outcomes O
may O
be O
useful O
in O
choosing O
an O
agent O
for O
health O
maintenance O
for O
postmenopausal O
women O
with O
osteoporosis O
. O

Tamoxifen B-intervention
with I-intervention
or I-intervention
without I-intervention
breast I-intervention
irradiation I-intervention
in O
women O
50 O
years O
of O
age O
or O
older O
with O
early O
breast O
cancer O
. O
We O
determined O
the O
effect O
of O
breast O
irradiation O
plus O
tamoxifen O
on O
disease O
- O
free O
survival O
and O
local O
relapse O
in O
women O
50 B-age
years I-age
of O
age O
or O
older O
who B-eligibility
had I-eligibility
T1 I-eligibility
or I-eligibility
T2 I-eligibility
node I-eligibility
- I-eligibility
negative I-eligibility
breast I-eligibility
cancer I-eligibility
. O
Between O
December O
1992 O
and O
June O
2000 O
, O
769 B-total-participants
women B-eligibility
with I-eligibility
early I-eligibility
breast I-eligibility
cancer I-eligibility
( I-eligibility
tumor I-eligibility
diameter I-eligibility
, I-eligibility
5 I-eligibility
cm I-eligibility
or I-eligibility
less I-eligibility
) I-eligibility
were O
randomly O
assigned O
to O
receive O
breast O
irradiation O
plus O
tamoxifen O
( O
386 B-intervention-participants
women O
) O
or O
tamoxifen B-control
alone I-control
( O
383 B-control-participants
women O
) O
. O
The O
median O
follow O
- O
up O
was O
5.6 O
years O
. O
The O
rate O
of O
local B-outcome
relapse I-outcome
at I-outcome
five I-outcome
years I-outcome
was O
7.7 B-cv-bin-percent
percent I-cv-bin-percent
in O
the O
tamoxifen O
group O
and O
0.6 B-iv-bin-percent
percent I-iv-bin-percent
in O
the O
group O
given O
tamoxifen O
plus O
irradiation O
( O
hazard O
ratio O
, O
8.3 O
; O
95 O
percent O
confidence O
interval O
, O
3.3 O
to O
21.2 O
; O
P<0.001 O
) O
, O
with O
corresponding O
five B-outcome
- I-outcome
year I-outcome
disease I-outcome
- I-outcome
free I-outcome
survival I-outcome
rates I-outcome
of O
84 B-cv-bin-percent
percent I-cv-bin-percent
and O
91 B-iv-bin-percent
percent I-iv-bin-percent
( O
P O
= O
0.004 O
) O
. O
A O
planned O
subgroup O
analysis O
of O
611 B-total-participants
women O
with O
T1 O
, O
receptor O
- O
positive O
tumors O
indicated O
a O
benefit O
from O
radiotherapy O
( O
five B-outcome
- I-outcome
year I-outcome
rates I-outcome
of I-outcome
local I-outcome
relapse I-outcome
, O
0.4 B-iv-bin-percent
percent I-iv-bin-percent
with O
tamoxifen O
plus O
radiotherapy O
and O
5.9 B-cv-bin-percent
percent I-cv-bin-percent
with O
tamoxifen O
alone O
; O
P<0.001 O
) O
. O
Overall O
, O
there O
was O
a O
significant O
difference O
in O
the O
rate B-outcome
of I-outcome
axillary I-outcome
relapse I-outcome
at I-outcome
five I-outcome
years I-outcome
( O
2.5 B-cv-bin-percent
percent I-cv-bin-percent
in O
the O
tamoxifen O
group O
and O
0.5 B-iv-bin-percent
percent I-iv-bin-percent
in O
the O
group O
given O
tamoxifen O
plus O
irradiation O
, O
P O
= O
0.049 O
) O
, O
but O
no O
significant O
difference O
in O
the O
rates B-outcome
of I-outcome
distant I-outcome
relapse I-outcome
or I-outcome
overall I-outcome
survival I-outcome
. O
As O
compared O
with O
tamoxifen O
alone O
, O
radiotherapy O
plus O
tamoxifen O
significantly O
reduces O
the O
risk O
of O
breast O
and O
axillary O
recurrence O
after O
lumpectomy O
in O
women O
with O
small O
, O
node O
- O
negative O
, O
hormone O
- O
receptor O
- O
positive O
breast O
cancers O
. O

Lumpectomy B-intervention
plus I-intervention
tamoxifen I-intervention
with I-intervention
or I-intervention
without I-intervention
irradiation I-intervention
in O
women O
70 B-age
years I-age
of I-age
age I-age
or I-age
older I-age
with O
early O
breast O
cancer O
. O
In O
women O
70 O
years O
of O
age O
or O
older O
who O
have O
early O
breast O
cancer O
, O
it O
is O
unclear O
whether O
lumpectomy O
plus O
tamoxifen O
is O
as O
effective O
as O
lumpectomy O
followed O
by O
tamoxifen O
plus O
radiation O
therapy O
. O
Between O
July O
1994 O
and O
February O
1999 O
, O
we O
randomly O
assigned O
636 B-total-participants
women B-eligibility
who I-eligibility
were I-eligibility
70 I-eligibility
years I-eligibility
of I-eligibility
age I-eligibility
or I-eligibility
older I-eligibility
and I-eligibility
who I-eligibility
had I-eligibility
clinical I-eligibility
stage I-eligibility
I I-eligibility
( I-eligibility
T1N0M0 I-eligibility
according I-eligibility
to I-eligibility
the I-eligibility
tumor I-eligibility
- I-eligibility
node I-eligibility
- I-eligibility
metastasis I-eligibility
classification I-eligibility
) I-eligibility
, I-eligibility
estrogen I-eligibility
- I-eligibility
receptor I-eligibility
- I-eligibility
positive I-eligibility
breast I-eligibility
carcinoma I-eligibility
treated O
by O
lumpectomy O
to O
receive O
tamoxifen O
plus O
radiation O
therapy O
( O
317 B-intervention-participants
women O
) O
or O
tamoxifen B-control
alone I-control
( O
319 B-control-participants
women O
) O
. O
Primary O
end O
points O
were O
the O
time B-outcome-measure
to I-outcome-measure
local I-outcome-measure
or I-outcome-measure
regional I-outcome-measure
recurrence I-outcome-measure
, O
the O
frequency B-outcome-measure
of I-outcome-measure
mastectomy I-outcome-measure
for I-outcome-measure
recurrence I-outcome-measure
, O
breast B-outcome-measure
- I-outcome-measure
cancer I-outcome-measure
- I-outcome-measure
specific I-outcome-measure
survival I-outcome-measure
, O
the B-outcome-measure
time I-outcome-measure
to I-outcome-measure
distant I-outcome-measure
metastasis I-outcome-measure
, O
and O
overall B-outcome-measure
survival I-outcome-measure
. O
The O
only O
significant O
difference O
between O
the O
two O
groups O
was O
in O
the O
rate B-outcome
of I-outcome
local I-outcome
or I-outcome
regional I-outcome
recurrence I-outcome
at I-outcome
five I-outcome
years I-outcome
( O
1 B-iv-bin-percent
percent I-iv-bin-percent
in O
the O
group O
given O
tamoxifen O
plus O
irradiation O
and O
4 B-cv-bin-percent
percent I-cv-bin-percent
in O
the O
group O
given O
tamoxifen O
alone O
, O
P<0.001 O
) O
. O
There O
were O
no O
significant O
differences O
between O
the O
two O
groups O
with O
regard O
to O
the O
rates B-outcome
of I-outcome
mastectomy I-outcome
for I-outcome
local I-outcome
recurrence I-outcome
, I-outcome
distant I-outcome
metastases I-outcome
, I-outcome
or I-outcome
five I-outcome
- I-outcome
year I-outcome
rates I-outcome
of I-outcome
overall I-outcome
survival I-outcome
( O
87 B-iv-bin-percent
percent I-iv-bin-percent
in O
the O
group O
given O
tamoxifen O
plus O
irradiation O
and O
86 B-cv-bin-percent
percent I-cv-bin-percent
in O
the O
tamoxifen O
group O
, O
P O
= O
0.94 O
) O
. O
Assessment O
by O
physicians O
and O
patients O
of O
cosmetic O
results O
and O
adverse O
events O
uniformly O
rated O
tamoxifen O
plus O
irradiation O
inferior O
to O
tamoxifen O
alone O
. O
Lumpectomy O
plus O
adjuvant O
therapy O
with O
tamoxifen O
alone O
is O
a O
realistic O
choice O
for O
the O
treatment O
of O
women O
70 O
years O
of O
age O
or O
older O
who O
have O
early O
, O
estrogen O
- O
receptor O
- O
positive O
breast O
cancer O
. O

1 B-intervention
- I-intervention
hexylcarbamoyl-5 I-intervention
- I-intervention
fluorouracil I-intervention
+ I-intervention
cyclophosphamide I-intervention
+ I-intervention
tamoxifen I-intervention
versus I-intervention
CMF I-intervention
+ I-intervention
tamoxifen I-intervention
in O
women O
with O
lymph O
node O
- O
positive O
breast O
cancer O
after O
primary O
surgery O
: O
a O
randomized O
controlled O
trial O
. O
We O
studied O
the O
usefulness O
of O
the O
oral O
5 O
- O
FU O
anti O
- O
cancer O
drug O
1 O
- O
hexylcarbamoyl-5 O
- O
fluorouracil O
( O
HCFU O
) O
+ O
cyclophosphamide O
( O
CPM O
) O
+ O
tamoxifen O
( O
TAM O
) O
( O
HCT O
group O
) O
in O
comparison O
with O
CMF B-control
+ I-control
TAM I-control
( O
CMFT O
group O
) O
in O
adjuvant O
therapy O
for O
breast O
cancer O
by O
a O
non O
- O
inferiority O
study O
based O
on O
a O
multi O
- O
institutional O
joint O
study O
. O
Clinical B-eligibility
stage I-eligibility
I I-eligibility
, I-eligibility
II I-eligibility
primary I-eligibility
breast I-eligibility
cancers I-eligibility
with I-eligibility
histologically I-eligibility
positive I-eligibility
axillary I-eligibility
lymph I-eligibility
node I-eligibility
metastasis I-eligibility
were O
randomly O
assigned O
to O
the O
HCT O
group O
or O
the O
CMFT O
group O
after O
primary O
surgery O
. O
We O
registered O
136 B-total-participants
cases O
( O
HCT O
group O
68 B-intervention-participants
cases O
, O
CMFT O
group O
68 B-control-participants
cases O
) O
. O
No O
significant O
difference O
in O
the O
5 B-outcome
- I-outcome
year I-outcome
overall I-outcome
survival I-outcome
rate I-outcome
( I-outcome
OS I-outcome
) I-outcome
and O
the O
5 B-outcome
- I-outcome
year I-outcome
disease I-outcome
- I-outcome
free I-outcome
survival I-outcome
rate I-outcome
( I-outcome
DFS I-outcome
) I-outcome
was O
found O
between O
the O
two O
groups O
. O
In O
the O
stratified O
analysis O
, O
DFS B-outcome
in O
cases O
in O
which O
the O
number O
of O
metastatic O
lymph O
nodes O
was O
1 O
- O
3 O
was O
significantly O
better O
in O
the O
HCT O
group O
( O
HCT O
group O
84.3 B-iv-bin-percent
% I-iv-bin-percent
, O
CMFT O
group O
69.4 B-cv-bin-percent
% I-cv-bin-percent
, O
log O
- O
rank O
test O
p O
= O
0.0496 O
) O
. O
No O
significant O
difference O
in O
the O
total O
incidence O
of O
adverse B-outcome
effects I-outcome
was O
found O
between O
the O
two O
groups O
, O
but O
there O
were O
significantly O
less O
adverse B-outcome
effects I-outcome
of O
grade O
2 O
or O
over O
in O
the O
HCT O
group O
( O
p O
= O
0.034 O
) O
. O
The O
QOL O
survey O
at O
3 O
months O
after O
surgery O
showed O
a O
significant O
decline O
of O
the O
QOL B-outcome
regarding O
lassitude B-outcome
, O
degree B-outcome
of I-outcome
difficulty I-outcome
in I-outcome
daily I-outcome
life I-outcome
, O
satisfaction B-outcome
with I-outcome
treatment I-outcome
and O
present B-outcome
mood I-outcome
in O
the O
CMFT O
group O
. O
Study O
results O
suggest O
that O
2 O
- O
year O
HCT O
therapy O
including O
the O
oral O
5 O
- O
FU O
anti O
- O
cancer O
drug O
HCFU O
is O
a O
useful O
adjuvant O
therapy O
which O
can O
replace O
CMFT O
therapy O
in O
early O
breast O
cancer O
cases O
with O
3 O
or O
lower O
metastatic O
lymph O
nodes O
. O

Efficacy O
of O
first O
- O
line O
letrozole B-intervention
versus O
tamoxifen B-control
as O
a O
function O
of O
age O
in O
postmenopausal O
women O
with O
advanced O
breast O
cancer O
. O
To O
compare O
the O
efficacy O
, O
in O
regard O
to O
time O
to O
progression O
( O
TTP O
) O
and O
objective O
response O
rate O
( O
ORR O
) O
, O
of O
letrozole O
( O
Femara O
; O
Novartis O
Pharma O
AG O
; O
Basel B-location
Switzerland I-location
) O
, O
an O
oral O
aromatase O
inhibitor O
, O
with O
that O
of O
tamoxifen O
( O
Tamofen O
; O
Leiras O
OY O
; O
Turku B-location
, I-location
Finland I-location
) O
as O
first O
- O
line O
therapy O
in O
younger O
( O
< B-age
70 I-age
years I-age
) O
and O
older O
( O
> B-age
/ I-age
= I-age
70 I-age
years I-age
) O
postmenopausal O
women O
with O
advanced O
breast O
cancer O
. O
Nine B-total-participants
hundred I-total-participants
seven I-total-participants
patients B-eligibility
with I-eligibility
advanced I-eligibility
breast I-eligibility
cancer I-eligibility
were O
randomly O
assigned O
to O
receive O
2.5 O
mg O
letrozole O
( O
n O
= O
453 O
) O
or O
20 O
mg O
tamoxifen O
( O
n O
= O
454 O
) O
once O
daily O
in O
a O
double O
- O
blind O
, O
multicenter O
, O
international O
trial O
. O
Among O
the O
prospectively O
planned O
analyses O
were O
analyses O
of O
TTP O
and O
ORR O
by O
age O
( O
< O
70 O
and O
> O
/ O
= O
70 O
years O
) O
. O
The O
results O
of O
these O
prospectively O
planned O
analyses O
are O
reported O
here O
. O
Letrozole O
was O
as O
effective O
in O
older O
postmenopausal O
women O
( O
> O
/ O
= O
70 O
years O
of O
age O
) O
as O
it O
was O
in O
younger O
postmenopausal O
women O
( O
< O
70 O
years O
of O
age O
) O
. O
The O
overall B-outcome
ORR I-outcome
in O
the O
older O
subgroup O
was O
significantly O
higher O
in O
patients O
treated O
with O
letrozole O
( O
38 B-iv-bin-percent
% I-iv-bin-percent
) O
than O
in O
patients O
treated O
with O
tamoxifen O
( O
18 B-cv-bin-percent
% I-cv-bin-percent
) O
. O
In O
the O
younger O
subgroup O
of O
postmenopausal O
patients O
, O
the O
ORRs B-outcome
were O
not O
significantly O
different O
( O
letrozole O
, O
26 B-iv-bin-percent
% I-iv-bin-percent
; O
tamoxifen O
, O
22 B-cv-bin-percent
% I-cv-bin-percent
) O
. O
TTP B-outcome
was O
significantly O
longer O
for O
letrozole O
than O
for O
tamoxifen O
in O
both O
age O
groups O
( O
younger B-outcome
: O
letrozole O
median O
TTP O
, O
8.8 B-iv-cont-median
months I-iv-cont-median
; O
tamoxifen O
, O
6.0 B-cv-cont-median
months I-cv-cont-median
; O
older B-outcome
: O
letrozole O
median O
TTP O
, O
12.2 B-iv-cont-median
months I-iv-cont-median
; O
tamoxifen O
, O
5.8 B-cv-cont-median
months I-cv-cont-median
) O
. O
Although O
age O
was O
independently O
prognostic O
of O
TTP O
, O
there O
was O
no O
significant O
effect O
of O
age O
on O
ORR B-outcome
in O
the O
presence O
of O
other O
factors O
. O
The O
data O
show O
that O
letrozole O
, O
2.5 O
mg O
once O
daily O
, O
is O
as O
effective O
in O
older O
, O
postmenopausal O
women O
as O
it O
is O
in O
younger O
postmenopausal O
women O
with O
advanced O
breast O
cancer O
. O
In O
addition O
, O
letrozole O
was O
more O
effective O
than O
tamoxifen O
in O
both O
younger O
and O
older O
patients O
. O

Disease O
- O
free O
survival O
advantage O
of O
weekly O
epirubicin B-intervention
plus I-intervention
tamoxifen I-intervention
versus O
tamoxifen B-control
alone I-control
as O
adjuvant O
treatment O
of O
operable O
, O
node O
- O
positive O
, O
elderly O
breast O
cancer O
patients O
: O
6 O
- O
year O
follow O
- O
up O
results O
of O
the O
French O
adjuvant O
study O
group O
08 O
trial O
. O
To O
assess O
whether O
an O
epirubicin O
( O
EPI O
) O
-based O
chemotherapy O
plus O
hormonal O
regimen O
improves O
disease O
- O
free O
( O
DFS O
) O
in O
women O
older B-age
than I-age
65 I-age
years I-age
, O
with B-eligibility
node I-eligibility
- I-eligibility
positive I-eligibility
, I-eligibility
operable I-eligibility
breast I-eligibility
cancer I-eligibility
( I-eligibility
BC I-eligibility
) I-eligibility
, O
relative O
to O
tamoxifen O
( O
TAM O
) O
alone O
. O
A O
total O
of O
338 B-total-participants
patients O
were O
randomly O
assigned O
after O
surgery O
to O
receive O
TAM O
30 O
mg O
/ O
d O
for O
3 O
years O
( O
TAM O
, O
n O
= O
164 B-control-participants
) O
, O
or O
EPI O
30 O
mg O
on O
days O
1 O
, O
8 O
, O
and O
15 O
every O
28 O
days O
for O
six O
cycles O
plus O
TAM O
30 O
mg O
/ O
d O
for O
3 O
years O
( O
EPI O
- O
TAM O
, O
n O
= O
174 B-intervention-participants
) O
. O
In O
both O
arms O
, O
patients O
received O
radiotherapy O
, O
delivered O
after O
chemotherapy O
( O
CT O
) O
in O
the O
EPI O
- O
TAM O
group O
. O
The O
6 B-outcome
- I-outcome
year I-outcome
DFS I-outcome
rates O
were O
69.3 B-cv-bin-percent
% I-cv-bin-percent
with O
TAM O
and O
72.6 B-iv-bin-percent
% I-iv-bin-percent
with O
EPI O
- O
TAM O
( O
P O
= O
.14 O
) O
. O
The O
multivariate O
analysis O
shows O
a O
relative O
risk B-outcome
of I-outcome
relapse I-outcome
of O
1.93 O
( O
95 O
% O
CI O
, O
1.70 O
to O
2.17 O
) O
with O
TAM O
compared O
with O
EPI O
- O
TAM O
( O
P O
= O
.005 O
) O
. O
The O
6 B-outcome
- I-outcome
year I-outcome
OS I-outcome
, O
related O
to O
disease O
progression O
, O
was O
79.1 B-cv-bin-percent
% I-cv-bin-percent
and O
79.8 B-iv-bin-percent
% I-iv-bin-percent
, O
respectively O
( O
P O
= O
.41 O
) O
. O
Compliance B-outcome
with O
CT O
was O
good O
: O
96.9 O
% O
of O
patients O
received O
six O
cycles O
. O
The O
acute B-outcome
toxicity I-outcome
per O
patient O
was O
mild O
: O
grade B-outcome
2 I-outcome
neutropenia I-outcome
in O
5.9 O
% O
, O
grade B-outcome
2 I-outcome
anemia I-outcome
in O
2.0 O
% O
, O
grade B-outcome
3 I-outcome
nausea I-outcome
or I-outcome
vomiting I-outcome
in O
4.6 O
% O
, O
and O
grade B-outcome
3 I-outcome
alopecia I-outcome
in O
7.2 O
% O
. O
Five O
cases O
( O
in O
five O
patients O
) O
of O
decreased B-outcome
left I-outcome
ventricular I-outcome
ejection I-outcome
fraction I-outcome
occurred O
after O
CT O
: O
three O
after O
adjuvant O
CT O
, O
and O
two O
after O
anthracycline O
- O
based O
CT O
for O
relapse O
. O
One O
patient O
died B-outcome
as I-outcome
a I-outcome
result I-outcome
of I-outcome
dysrhythmia I-outcome
related O
to O
carcinomatous O
lymphangitis O
. O
No O
secondary B-outcome
leukemia I-outcome
occurred O
. O
This O
study O
conducted O
in O
node O
- O
positive O
elderly O
patients O
demonstrates O
a O
significant O
contribution O
of O
a O
weekly O
EPI O
regimen O
in O
terms O
of O
DFS O
. O
Moreover O
, O
this O
regimen O
is O
safe O
for O
hematologic O
, O
nonhematologic O
, O
and O
cardiac O
toxicities O
. O

The O
effect O
of O
fibrin B-intervention
sealant I-intervention
combined I-intervention
with I-intervention
fibrinolysis I-intervention
inhibitor I-intervention
on O
reducing O
the O
amount B-condition
of I-condition
lymphatic I-condition
leakage I-condition
after I-condition
axillary I-condition
evacuation I-condition
in O
breast O
cancer O
. O
A O
prospective O
randomized O
clinical O
trial O
. O
One O
third O
of O
women O
undergoing O
mastectomy O
with O
axillary O
evacuation O
for O
primary O
breast O
cancer O
suffer O
from O
postoperative O
seromas O
leading O
to O
unnecessary O
costs O
and O
complications O
such O
as O
infections O
and O
new O
operations O
. O
Different O
methods O
to O
prevent O
seroma O
formation O
have O
been O
tried O
without O
permanent O
success O
. O
The O
aim O
of O
this O
prospective O
randomised O
study O
was O
to O
examine O
the O
effect O
of O
fibrin O
sealant O
with O
fibrinolysis O
inhibitor O
firstly O
on O
the O
reduction O
of O
the O
amount O
of O
lymphatic O
leakage O
after O
axillary O
evacuation O
and O
secondly O
on O
the O
reduction O
of O
days O
with O
drains O
and O
postoperative O
seroma O
punctures O
. O
40 B-total-participants
patients B-eligibility
with I-eligibility
primary I-eligibility
breast I-eligibility
cancer I-eligibility
were O
prospectively O
randomised O
to O
the O
treatment O
group O
( O
n O
= O
19 B-intervention-participants
) O
getting O
fibrin O
glue O
combined O
with O
fibrinolysis O
inhibitor O
( O
aprotinin O
) O
sprayed O
into O
the O
axillary O
fossa O
and O
to O
the O
control B-control
group I-control
( O
n O
= O
21 B-control-participants
) O
. O
There O
were O
no O
differences O
in O
the O
incidence B-outcome
of I-outcome
postoperative I-outcome
seromas I-outcome
between O
the O
groups O
. O
However O
, O
the O
seromas O
were O
easier O
to O
treat O
if O
fibrin O
clue O
was O
used O
. O
Total O
quantity O
( O
mean O
+/- O
SD O
) O
of O
lymphorrhea B-outcome
and I-outcome
total I-outcome
number I-outcome
of I-outcome
aspirations I-outcome
( O
mean O
+/- O
SD O
) O
were O
almost O
twice O
as O
high O
in O
the O
patients O
of O
the O
control O
group O
compared O
to O
those O
having O
fibrin O
sealant O
. O
In O
the O
treatment O
group O
seromas O
resolved O
after O
one O
or O
occasionally O
after O
two O
aspirations O
in O
71 B-iv-bin-percent
% I-iv-bin-percent
of O
patients O
, O
while O
in O
the O
control O
group O
90 B-cv-bin-percent
% I-cv-bin-percent
of O
patients O
needed B-outcome
three I-outcome
or I-outcome
more I-outcome
aspirations I-outcome
. O
Potentially O
, O
fibrin O
sealant O
combined O
with O
fibrinolysis O
inhibitor O
might O
be O
used O
for O
the O
treatment O
of O
post- O
axillary O
evacuation O
lymphorrhea O
and O
seroma O
. O

Ten O
- O
year O
follow O
- O
up O
of O
a O
randomized O
controlled O
trial O
of O
adjuvant B-intervention
clodronate I-intervention
treatment O
in O
node O
- O
positive O
breast O
cancer O
patients O
. O
Ten O
- O
year O
follow O
- O
up O
results O
are O
presented O
of O
an O
adjuvant O
clodronate O
trial O
in O
patients O
with O
primary O
breast O
cancer O
. O
Between O
1990 O
and O
1993 O
, O
299 B-total-participants
women B-eligibility
with I-eligibility
primary I-eligibility
node I-eligibility
positive I-eligibility
breast I-eligibility
cancer I-eligibility
were O
randomized O
to O
oral O
clodronate O
1600 O
mg O
daily O
( O
149 B-intervention-participants
) O
or O
controls B-control
( O
150 B-control-participants
) O
for O
3 O
years O
. O
All O
patients O
received O
adjuvant O
chemo- O
or O
endocrine O
therapy O
. O
Within O
10 O
years O
bone B-outcome
metastases I-outcome
were O
detected O
at O
the O
same O
frequency O
in O
the O
clodronate O
and O
control O
groups O
: O
44 B-iv-bin-abs
( O
32 B-iv-bin-percent
% I-iv-bin-percent
) O
vs. O
42 B-cv-bin-abs
( O
29 B-cv-bin-percent
% I-cv-bin-percent
) O
, O
respectively O
, O
( O
p O
= O
0.35 O
) O
. O
The O
frequency B-outcome
of I-outcome
non I-outcome
- I-outcome
skeletal I-outcome
recurrences I-outcome
( O
visceral O
and O
local O
) O
was O
significantly O
higher O
in O
the O
clodronate O
group O
69 B-iv-bin-abs
( O
50 B-iv-bin-percent
% I-iv-bin-percent
) O
as O
compared O
with O
the O
controls O
51 B-cv-bin-abs
( O
36 B-cv-bin-percent
% I-cv-bin-percent
) O
( O
p O
= O
0.005 O
) O
. O
Ten B-outcome
- I-outcome
year I-outcome
disease I-outcome
- I-outcome
free I-outcome
survival I-outcome
( I-outcome
DFS I-outcome
) I-outcome
remained O
significantly O
lower O
in O
the O
clodronate O
group O
( O
45 B-iv-bin-percent
% I-iv-bin-percent
vs. O
58 B-cv-bin-percent
% I-cv-bin-percent
, O
p O
= O
0.01 O
, O
respectively O
) O
. O
This O
was O
especially O
seen O
in O
oestrogen B-outcome
receptor I-outcome
negative I-outcome
patients I-outcome
( O
25 B-iv-bin-percent
% I-iv-bin-percent
vs. O
58 B-cv-bin-percent
% I-cv-bin-percent
, O
p O
= O
0.004 O
, O
respectively O
) O
. O
No O
significant O
overall B-outcome
survival I-outcome
difference O
was O
found O
between O
the O
groups O
. O
As O
previously O
reported O
3 O
- O
year O
adjuvant O
clodronate O
treatment O
did O
not O
prevent O
the O
development O
of O
bone O
metastases O
in O
node O
- O
positive O
breast O
cancer O
patients O
. O
A O
negative O
effect O
of O
clodronate O
on O
DFS O
by O
increasing O
the O
development O
of O
visceral O
metastases O
was O
still O
seen O
at O
10 O
years O
, O
but O
this O
did O
not O
significantly O
compromise O
overall O
survival O
. O

Clinically O
relevant O
pneumonitis B-condition
after O
sequential O
paclitaxel B-intervention
- I-intervention
based I-intervention
chemotherapy I-intervention
and I-intervention
radiotherapy I-intervention
in O
breast O
cancer O
patients O
. O
Taxane O
- O
based O
chemotherapy O
has O
been O
associated O
with O
an O
increased O
risk O
of O
radiation O
pneumonitis O
in O
patients O
with O
breast O
cancer O
. O
To O
obtain O
additional O
information O
about O
this O
association O
, O
we O
investigated O
the O
association O
between O
paclitaxel O
chemotherapy O
and O
radiation O
pneumonitis O
in O
patients O
participating O
in O
a O
phase O
III O
randomized O
study O
. O
Five B-total-participants
hundred I-total-participants
and I-total-participants
twenty I-total-participants
- I-total-participants
four I-total-participants
breast B-eligibility
cancer I-eligibility
patients I-eligibility
were O
prospectively O
and O
randomly O
assigned O
to O
receive O
either O
four O
cycles O
of O
paclitaxel O
followed O
by O
four O
cycles O
of O
5 O
- O
fluorouracil O
, O
doxorubicin O
, O
cyclophosphamide O
( O
FAC O
) O
or O
eight B-control
cycles I-control
of I-control
FAC I-control
. O
One B-total-participants
hundred I-total-participants
and I-total-participants
eighty I-total-participants
- I-total-participants
nine I-total-participants
of O
these O
patients O
( O
100 B-intervention-participants
in O
the O
paclitaxel O
- O
FAC O
group O
and O
89 B-control-participants
in O
the O
FAC O
group O
) O
subsequently O
underwent O
radiation O
therapy O
in O
our O
institution O
and O
had O
medical O
records O
available O
to O
review O
for O
pulmonary O
symptoms O
. O
In O
addition O
, O
a O
radiologist O
who O
was O
unaware O
of O
the O
type O
of O
treatment O
scored O
chest O
x O
- O
ray O
changes O
after O
radiation O
treatment O
. O
Crude O
rates O
of O
radiation O
pneumonitis O
were O
compared O
with O
chi O
- O
square O
or O
Fisher O
's O
exact O
test O
, O
and O
actuarial O
rates O
were O
assessed O
with O
Kaplan O
- O
Meier O
and O
log O
- O
rank O
tests O
. O
All O
statistical O
tests O
were O
two O
- O
sided O
. O
No O
difference O
in O
the O
rate B-outcome
of I-outcome
clinically I-outcome
relevant I-outcome
radiation I-outcome
pneumonitis I-outcome
was O
observed O
between O
the O
two O
groups O
( O
5.0 B-iv-bin-percent
% I-iv-bin-percent
in O
the O
paclitaxel O
- O
FAC O
group O
versus O
4.5 B-cv-bin-percent
% I-cv-bin-percent
in O
the O
FAC O
group O
; O
difference O
= O
0.5 O
% O
, O
95 O
% O
CI O
= O
-6.6 O
% O
to O
5.5 O
% O
; O
P O
= O
1.00 O
) O
. O
Oral B-outcome
steroids I-outcome
for I-outcome
pneumonitis I-outcome
were O
taken O
by O
two B-iv-bin-abs
patients O
in O
the O
paclitaxel O
- O
FAC O
group O
but O
by O
none B-cv-bin-abs
in O
the O
FAC O
group O
, O
and O
no O
patient O
was O
hospitalized B-outcome
for I-outcome
or I-outcome
died I-outcome
of I-outcome
radiation I-outcome
pneumonitis I-outcome
. O
The O
paclitaxel O
- O
FAC O
group O
( O
39.3 B-iv-bin-percent
% I-iv-bin-percent
) O
had O
a O
higher O
rate B-outcome
of I-outcome
radiographic I-outcome
changes I-outcome
after I-outcome
irradiation I-outcome
than O
the O
FAC O
group O
( O
23.7 B-cv-bin-percent
% I-cv-bin-percent
; O
difference O
= O
15.6 O
% O
, O
95 O
% O
CI O
= O
-0.11 O
% O
to O
28.8 O
% O
; O
P O
= O
.034 O
) O
. O
Patients O
with O
breast O
cancer O
treated O
with O
sequential O
paclitaxel O
, O
FAC O
, O
and O
radiation O
therapy O
appeared O
to O
have O
a O
very O
low O
rate O
of O
clinically O
relevant O
radiation O
pneumonitis O
that O
was O
no O
different O
from O
that O
of O
patients O
treated O
with O
FAC O
alone O
. O

Randomized O
phase O
III O
trial O
of O
marimastat B-intervention
versus O
placebo B-control
in O
patients B-eligibility
with I-eligibility
metastatic I-eligibility
breast I-eligibility
cancer I-eligibility
who I-eligibility
have I-eligibility
responding I-eligibility
or I-eligibility
stable I-eligibility
disease I-eligibility
after I-eligibility
first I-eligibility
- I-eligibility
line I-eligibility
chemotherapy I-eligibility
: O
Eastern O
Cooperative O
Oncology O
Group O
trial O
E2196 O
. O
To O
determine O
whether O
a O
matrix O
metalloproteinase O
inhibitor O
improves O
progression O
- O
free O
survival O
( O
PFS O
) O
in O
patients O
with O
metastatic O
breast O
cancer O
who O
have O
responding O
or O
stable O
disease O
after O
first O
- O
line O
chemotherapy O
. O
One B-total-participants
hundred I-total-participants
seventy I-total-participants
- I-total-participants
nine I-total-participants
eligible O
patients O
were O
randomly O
assigned O
to O
receive O
oral O
marimastat O
( O
10 O
mg O
bid O
; O
n O
= O
114 B-intervention-participants
) O
or O
a O
placebo O
( O
n O
= O
65 B-control-participants
) O
within O
3 O
to O
6 O
weeks O
of O
completing O
six O
to O
eight O
cycles O
of O
first O
- O
line O
doxorubicin- O
and/or O
taxane O
- O
containing O
chemotherapy O
for O
metastatic O
disease O
. O
Patients O
were O
evaluated O
every O
3 O
months O
until O
disease O
progression O
. O
When O
comparing O
placebo O
with O
marimastat O
, O
there O
was O
no O
significant O
difference O
in O
PFS B-outcome
( O
median O
, O
3.1 B-iv-cont-median
months I-iv-cont-median
v O
4.7 B-cv-cont-median
months I-cv-cont-median
, O
respectively O
; O
hazard O
ratio O
, O
1.26 O
; O
95 O
% O
CI O
, O
0.91 O
to O
1.74 O
; O
P O
= O
.16 O
) O
or O
overall B-outcome
survival I-outcome
( O
median O
, O
26.6 B-iv-cont-median
months I-iv-cont-median
v O
24.7 B-cv-cont-median
months I-cv-cont-median
, O
respectively O
; O
hazard O
ratio O
, O
1.03 O
; O
95 O
% O
CI O
, O
0.73 O
to O
1.46 O
; O
P O
= O
.86 O
) O
. O
Patients O
treated O
with O
marimastat O
were O
more O
likely O
to O
develop O
grade B-outcome
2 I-outcome
or I-outcome
3 I-outcome
musculoskeletal I-outcome
toxicity I-outcome
( I-outcome
MST I-outcome
) I-outcome
, O
a O
known O
complication O
of O
the O
drug O
indicative O
of O
achieving O
a O
biologic O
effect O
, O
compared O
with O
patients O
administered O
placebo O
( O
63 B-iv-bin-percent
% I-iv-bin-percent
v O
22 B-cv-bin-percent
% I-cv-bin-percent
, O
respectively O
; O
P O
< O
.0001 O
) O
. O
Patients O
with O
grade O
2 O
or O
3 O
MST O
had O
significantly O
inferior O
survival B-outcome
compared O
with O
patients O
who O
had O
grade O
0 O
or O
1 O
MST O
( O
median O
, O
22.5 B-iv-cont-median
months I-iv-cont-median
v O
28.2 B-cv-cont-median
months I-cv-cont-median
; O
P O
= O
.04 O
) O
. O
In O
addition O
, O
patients O
who O
had O
a O
marimastat O
plasma O
concentration O
of O
at O
least O
10 O
ng O
/ O
mL O
at O
month O
1 O
and/or O
3 O
were O
significantly O
more O
likely O
to O
have O
grade B-outcome
2 I-outcome
to I-outcome
3 I-outcome
MST I-outcome
( O
P O
< O
.0001 O
) O
. O
Marimastat O
does O
not O
prolong O
PFS B-outcome
when O
used O
after O
first O
- O
line O
chemotherapy O
for O
metastatic O
breast O
cancer O
. O
Patients O
with O
higher O
marimastat O
levels O
exhibited O
MST O
, O
and O
MST O
was O
associated O
with O
inferior O
survival O
. O

The O
relevance O
of O
intraventricular B-intervention
chemotherapy I-intervention
for O
leptomeningeal O
metastasis O
in O
breast O
cancer O
: O
a O
randomised O
study O
. O
To O
assess O
the O
benefit O
of O
intraventricular O
chemotherapy O
, O
patients B-eligibility
with I-eligibility
leptomeningeal I-eligibility
metastasis I-eligibility
( I-eligibility
LM I-eligibility
) I-eligibility
from I-eligibility
breast I-eligibility
cancer I-eligibility
were O
randomised O
to O
treatment O
including O
intraventricular O
( O
IT O
) O
chemotherapy O
( O
n O
= O
17 B-intervention-participants
) O
or O
to O
non B-control
- I-control
intrathecal I-control
( I-control
non I-control
- I-control
IT I-control
) I-control
treatment I-control
( O
n O
= O
18 B-control-participants
) O
. O
Appropriate O
systemic O
therapy O
and O
involved O
field O
radiation O
therapy O
( O
RT O
) O
were O
given O
in O
both O
arms O
. O
Intention O
- O
to O
- O
treat O
analysis O
showed O
neurological B-outcome
improvement I-outcome
or I-outcome
stabilisation I-outcome
in O
59 B-iv-bin-percent
% I-iv-bin-percent
of O
the O
IT O
and O
in O
67 B-cv-bin-percent
% I-cv-bin-percent
of O
the O
non O
- O
IT O
group O
, O
with O
median B-outcome
time I-outcome
to I-outcome
progression I-outcome
of O
23 B-iv-cont-median
weeks I-iv-cont-median
( O
IT O
) O
and O
24 B-cv-cont-median
weeks I-cv-cont-median
( O
non O
- O
IT O
) O
. O
Median B-outcome
survival I-outcome
of O
IT O
patients O
was O
18.3 B-iv-cont-median
weeks I-iv-cont-median
and O
30.3 B-cv-cont-median
weeks I-cv-cont-median
for O
non O
- O
IT O
patients O
( O
difference O
12.9 O
weeks O
; O
95 O
% O
Confidence O
Interval O
( O
CI O
) O
-5.5 O
to O
+34.3 O
weeks O
; O
P O
= O
0.32 O
) O
. O
Neurological B-outcome
complications I-outcome
of O
treatment O
occurred O
in O
47 B-iv-bin-percent
% I-iv-bin-percent
( O
IT O
) O
vs O
6 B-cv-bin-percent
% I-cv-bin-percent
( O
non O
- O
IT O
) O
( O
P O
= O
0.0072 O
) O
. O
In O
conclusion O
, O
standard O
systemic O
chemotherapy O
with O
involved O
field O
RT O
for O
LM O
from O
breast O
cancer O
is O
feasible O
. O
Addition O
of O
intraventricular O
chemotherapy O
does O
not O
lead O
to O
survival O
benefit O
or O
improved O
neurological O
response O
, O
and O
is O
associated O
with O
an O
increased O
risk O
of O
neurotoxicity O
. O

High B-intervention
- I-intervention
dose I-intervention
chemotherapy I-intervention
with O
haematopoietic O
stem O
cell O
transplantation O
for O
metastatic O
breast O
cancer O
patients O
: O
final O
results O
of O
the O
French B-location
multicentric O
randomised O
CMA O
/ O
PEGASE O
04 O
protocol O
. O
The O
aim O
of O
our O
study O
was O
to O
evaluate O
the O
impact O
on O
time O
to O
progression O
( O
TTP O
) O
and O
overall O
survival O
( O
OS O
) O
of O
high O
- O
dose O
chemotherapy O
( O
HD O
- O
CT O
) O
over O
conventional B-control
CT I-control
in O
metastatic B-eligibility
breast I-eligibility
cancer I-eligibility
patients I-eligibility
. O
Between O
09 O
/ O
92 O
and O
12 O
/ O
96 O
, O
61 B-total-participants
patients B-eligibility
with I-eligibility
chemosensitive I-eligibility
metastatic I-eligibility
breast I-eligibility
cancer I-eligibility
were O
randomised O
between O
HD O
- O
CT O
using O
the O
CMA O
regimen O
( O
Mitoxantrone O
, O
Cyclophosphamide O
, O
Melphalan O
) O
applied O
as O
consolidation O
( O
32 B-intervention-participants
patients O
) O
or O
maintenance O
CT O
( O
29 B-control-participants
patients O
) O
. O
At O
randomisation O
, O
13 O
patients O
were O
in O
complete B-outcome
response I-outcome
, O
47 O
in O
partial B-outcome
response I-outcome
and O
one O
had O
stable B-outcome
disease I-outcome
. O
The O
median B-outcome
TTPs I-outcome
from O
randomisation O
were O
6 B-iv-cont-median
and O
12 B-cv-cont-median
months I-cv-cont-median
in O
the O
standard O
and O
intensive O
groups O
, O
respectively O
( O
P O
< O
0.0056 O
) O
, O
with O
a O
relapse B-outcome
rate I-outcome
of O
86.2 B-iv-bin-percent
% I-iv-bin-percent
vs. O
62.5 B-cv-bin-percent
% I-cv-bin-percent
at B-outcome
2 I-outcome
years I-outcome
, O
and O
100 B-iv-bin-percent
% I-iv-bin-percent
vs. O
81.3 B-cv-bin-percent
% I-cv-bin-percent
at B-outcome
5 I-outcome
years I-outcome
. O
The O
median B-outcome
OS I-outcome
times I-outcome
were O
19.3 B-iv-cont-median
and O
44.1 B-cv-cont-median
months I-cv-cont-median
, O
with O
an O
OS B-outcome
rate I-outcome
of O
13.8 B-iv-bin-percent
% I-iv-bin-percent
vs. O
36.8 B-cv-bin-percent
% I-cv-bin-percent
at B-outcome
5 I-outcome
years I-outcome
( O
P O
< O
0.0294 O
) O
. O
The O
CMA O
regimen O
could O
prolong O
the O
TTP O
of O
patients O
with O
chemosensitive O
metastatic O
breast O
cancer O
. O
Further O
studies O
are O
needed O
to O
determine O
if O
this O
translates O
into O
an O
effect O
on O
OS O
. O

Avoiding O
axillary O
dissection O
in O
breast O
cancer O
surgery O
: O
a O
randomized O
trial O
to O
assess O
the O
role O
of O
axillary B-intervention
radiotherapy I-intervention
. O
The O
need O
to O
dissect O
axillary O
nodes O
in O
patients O
with O
early O
breast O
cancer O
and O
clinically O
negative O
axilla O
remains O
controversial O
. O
The O
aim O
of O
the O
study O
was O
to O
assess O
the O
role O
of O
axillary O
radiotherapy O
( O
RT O
) O
in O
reducing O
axillary O
metastases O
in O
patients B-eligibility
with I-eligibility
early I-eligibility
breast I-eligibility
cancer I-eligibility
who I-eligibility
did I-eligibility
not I-eligibility
receive I-eligibility
axillary I-eligibility
dissection I-eligibility
. O
From O
1995 O
to O
1998 O
, O
435 B-total-participants
patients O
over B-age
45 I-age
years I-age
old O
with O
breast O
cancer O
up O
to O
1.2 O
cm O
and O
no O
palpable O
axillary O
nodes O
were O
randomized O
214 B-control-participants
to O
breast B-control
conservation I-control
without I-control
axillary I-control
treatment I-control
and O
221 B-intervention-participants
to O
breast O
conservation O
plus O
axillary O
RT O
. O
After O
a O
median O
follow O
- O
up O
of O
63 O
months O
, O
overt B-outcome
axillary I-outcome
metastases I-outcome
were O
fewer O
than O
expected O
: O
three B-cv-bin-abs
cases O
in O
the O
no O
axillary O
treatment O
group O
( O
1.5 B-cv-bin-percent
% I-cv-bin-percent
) O
and O
one B-iv-bin-abs
in O
the O
RT O
group O
( O
0.5 B-iv-bin-percent
% I-iv-bin-percent
) O
. O
Expected B-outcome
cases I-outcome
were O
43 B-cv-bin-abs
in O
the O
no O
axillary O
treatment O
group O
and O
10 B-iv-bin-abs
in O
the O
RT O
group O
. O
Rates B-outcome
of I-outcome
distant I-outcome
metastases I-outcome
and O
local B-outcome
failures I-outcome
were O
low O
, O
and O
5 B-outcome
- I-outcome
year I-outcome
disease I-outcome
free I-outcome
survival I-outcome
was O
96.0 O
% O
( O
95 O
% O
confidence O
interval O
, O
94.1%-97.9 O
% O
) O
without O
significant O
differences O
between O
the O
two O
arms O
. O
This O
study O
suggests O
that O
occult O
axillary O
metastases O
might O
never O
become O
clinically O
overt O
and O
axillary O
dissection O
might O
be O
avoided O
in O
patients O
with O
small O
carcinomas O
and O
a O
clinically O
negative O
axilla O
. O
Axillary O
RT O
seems O
to O
protect O
the O
patients O
from O
axillary O
recurrence O
almost O
completely O
. O

Differences O
in O
breast O
cancer O
risk O
factors O
by O
tumor B-intervention
marker I-intervention
subtypes I-intervention
among O
premenopausal O
Vietnamese B-ethinicity
and O
Chinese B-ethinicity
women O
. O
We O
evaluated O
associations O
between O
reproductive O
and O
lifestyle O
risk O
factors O
with O
breast O
cancer O
tumor O
marker O
status O
in O
a O
case O
- O
control O
study O
. O
Cases O
were O
premenopausal B-eligibility
women I-eligibility
living O
in O
Vietnam B-location
and O
China B-location
who O
were O
eligible O
for O
a O
clinical O
trial O
of O
oophorectomy O
and O
tamoxifen O
as O
treatment O
for O
breast O
cancer O
( O
n O
= O
682 B-intervention-participants
) O
. O
Controls B-control
were O
nonrelative O
hospital O
visitors O
, O
matched O
on O
age O
to O
the O
cases O
( O
n O
= O
649 B-control-participants
) O
. O
Immunohistochemical O
analysis O
was O
used O
to O
identify O
the O
presence O
of O
estrogen O
receptor O
( O
ER O
) O
and O
progesterone O
receptor O
and O
the O
overexpression O
of O
HER-2 O
/ O
neu O
oncogene O
. O
Odds O
ratios O
( O
OR O
) O
and O
95 O
% O
confidence O
intervals O
( O
95 O
% O
CI O
) O
were O
estimated O
using O
unconditional O
logistic O
regression O
, O
adjusted O
for O
known O
confounders O
. O
Overall O
, O
280 O
( O
61 O
% O
) O
tumor O
samples O
were O
ER O
positive O
and O
176 O
( O
38 O
% O
) O
were O
ER O
negative O
. O
HER-2 O
/ O
neu O
overexpression O
was O
detected O
in O
161 O
( O
35 O
% O
) O
samples O
, O
whereas O
286 O
( O
26 O
% O
) O
samples O
were O
HER-2 O
/ O
neu O
negative O
. O
We O
observed O
an O
inverse O
trend O
between O
increasing O
parity O
and O
decreasing O
breast B-outcome
cancer I-outcome
risk I-outcome
( O
P O
= O
0.002 O
) O
. O
Women O
ages O
> O
or O
= O
25 O
years O
at O
first O
birth O
had O
increased O
breast B-outcome
cancer I-outcome
risk I-outcome
compared O
with O
women O
ages O
< O
25 O
years O
at O
first O
birth O
( O
OR O
, O
1.53 O
; O
95 O
% O
CI O
, O
1.20 O
- O
1.95 O
) O
. O
Women O
who O
consumed O
alcohol O
had O
increased O
risk B-outcome
of I-outcome
breast I-outcome
cancer I-outcome
compared O
with O
women O
who O
did O
not O
( O
OR,1.85 O
; O
95 O
% O
CI O
, O
1.32 O
- O
2.61 O
) O
. O
Compared O
with O
controls O
, O
OR B-outcome
estimates O
for O
breast O
cancer O
by O
parity O
and O
age O
at O
first O
birth O
were O
significantly O
associated O
with O
ER O
and/or O
HER-2 O
/ O
neu O
tumor O
status O
by O
Wald O
test O
( O
P O
< O
0.05 O
) O
. O
Family O
history O
, O
age O
at O
menarche O
, O
cumulative O
lactation O
, O
body O
mass O
index O
, O
and O
education O
were O
not O
significantly O
related O
to O
breast O
cancer O
risk O
. O
Our O
findings O
support O
the O
hypothesis O
that O
some O
breast O
cancer O
risk O
factors O
differ O
by O
ER O
and O
HER-2 O
/ O
neu O
tumor O
marker O
subtypes O
. O

Effect O
of O
tamoxifen B-intervention
on O
venous B-condition
thromboembolic I-condition
events I-condition
in O
a O
breast O
cancer O
prevention O
trial O
. O
Tamoxifen O
, O
a O
selective O
estrogen O
- O
receptor O
modulator O
, O
increases O
venous O
thromboembolic O
events O
( O
VTE O
) O
, O
but O
the O
factors O
explaining O
this O
risk O
are O
unclear O
. O
Atherosclerosis O
may O
induce O
VTE O
, O
or O
the O
2 O
conditions O
may O
share O
common O
risk O
factors O
. O
We O
assessed O
the O
effect O
of O
tamoxifen O
on O
VTE O
in O
a O
breast O
cancer O
prevention O
trial O
and O
studied O
its O
association O
with O
risk O
factors O
for O
VTE O
. O
The O
incidence O
of O
VTE O
was O
studied O
in O
5408 B-total-participants
hysterectomized B-eligibility
women I-eligibility
randomly O
assigned O
to O
tamoxifen O
20 O
mg O
/ O
d O
or O
placebo B-control
for O
5 O
years O
. O
There O
were O
28 B-cv-bin-abs
VTEs B-outcome
on O
placebo O
and O
44 B-iv-bin-abs
on O
tamoxifen O
therapy O
( O
hazard O
ratio O
[ O
HR] O
= O
1.63 O
; O
95 O
% O
confidence O
interval O
[ O
CI O
] O
, O
1.02 O
to O
2.63 O
) O
, O
80 O
% O
of O
which O
were O
superficial O
phlebitis O
, O
accounting O
for O
all O
of O
the O
excess O
due O
to O
tamoxifen O
within O
18 O
months O
from O
randomization O
. O
Compared O
with O
placebo O
, O
the O
risk B-outcome
of I-outcome
VTE I-outcome
on O
tamoxifen O
was O
higher O
in O
women O
aged O
55 O
years O
or O
older O
, O
women O
with O
a O
body O
mass O
index O
> O
or O
= O
25 O
kg O
/ O
m2 O
, O
elevated O
blood O
pressure O
, O
total O
cholesterol O
> O
or O
= O
250 O
mg O
/ O
dL O
, O
current O
smoking O
, O
and O
a O
family O
history O
of O
coronary O
heart O
disease O
( O
CHD O
) O
. O
Of O
the O
685 O
women O
with O
a O
CHD O
risk O
score O
> O
or O
= O
5 O
who O
entered O
the O
trial O
, O
1 B-cv-bin-abs
in O
the O
placebo O
arm O
and O
13 B-iv-bin-abs
in O
the O
tamoxifen O
arm O
developed B-outcome
VTE I-outcome
( O
log O
- O
rank O
P O
= O
0.0013 O
) O
. O
In O
multivariate O
regression O
analysis O
, O
age O
> O
or O
= O
60 O
years O
, O
height O
> O
or O
= O
165 O
cm O
, O
and O
diastolic O
blood O
pressure O
> O
or O
= O
90 O
mm O
Hg O
had O
independent O
detrimental O
effects O
on O
VTE O
risk O
during O
tamoxifen O
therapy O
, O
whereas O
transdermal O
estrogen O
therapy O
concomitant O
with O
tamoxifen O
was O
not O
associated O
with O
any O
excess O
of O
VTE O
( O
HR O
= O
0.64 O
; O
95 O
% O
CI O
, O
0.23 O
to O
1.82 O
) O
. O
Women O
with O
conventional O
risk O
factors O
for O
atherosclerosis O
have O
a O
higher O
risk O
of O
VTE O
during O
tamoxifen O
therapy O
. O
This O
information O
should O
be O
incorporated O
into O
counseling O
women O
on O
its O
risk O
- O
benefit O
ratio O
, O
particularly O
in O
the O
prevention O
setting O
. O

Neutron B-intervention
versus O
photon B-control
radiotherapy I-control
for O
local O
control O
in O
inoperable O
breast O
cancer O
. O
By O
virtue O
of O
their O
high O
linear O
energy O
transfer O
( O
LET O
) O
characteristics O
the O
biologic O
effectiveness O
of O
neutrons O
is O
less O
dependent O
on O
tissue O
oxygenation O
tension O
and O
cell O
cycle O
phase O
as O
compared O
to O
that O
with O
photons O
. O
Hence O
, O
an O
improved O
clinical O
benefit O
is O
to O
be O
expected O
predominantly O
in O
large O
, O
hypoxic O
and O
slowly O
growing O
tumors O
. O
Since O
a O
short O
course O
of O
radiotherapy O
is O
required O
for O
clinical O
reasons O
, O
it O
prompted O
the O
authors O
to O
initiate O
a O
randomly O
controlled O
trial O
on O
locally O
advanced O
breast O
cancer O
. O
Between O
1996 O
and O
1999 O
, O
27 B-total-participants
patients B-eligibility
with I-eligibility
locally I-eligibility
advanced I-eligibility
breast I-eligibility
cancer I-eligibility
were O
irradiated O
with O
photons O
( O
60 O
Gy O
, O
30 O
fractions O
; O
8 O
MV O
, O
( O
60 O
) O
Co O
) O
or O
neutrons O
( O
18 O
Gy O
, O
twelve O
fractions O
; O
66 O
MeV O
( O
p O
-- O
>Be O
) O
) O
. O
The O
mean O
tumor O
diameters O
were O
699 O
+ O
/- O
399 O
ml O
for O
the O
photon O
group O
and O
1,097 O
+ O
/- O
831 O
ml O
in O
the O
neutron O
group O
. O
After O
a O
mean O
follow O
- O
up O
period O
of O
21.5 O
months O
tumor O
involution O
was O
evaluated O
in O
22 B-total-participants
patients O
. O
Partial B-outcome
and I-outcome
complete I-outcome
remissions I-outcome
were O
registered O
in O
6 B-iv-bin-abs
/ O
10 B-intervention-participants
patients O
of O
the O
photon O
group O
and O
5 B-cv-bin-abs
/ O
12 B-control-participants
patients O
of O
the O
neutron O
group O
. O
Late O
grade B-outcome
3 I-outcome
- I-outcome
4 I-outcome
morbidity I-outcome
according O
to O
RTOG O
definition O
was O
scored O
in O
5 B-iv-bin-abs
/ O
10 B-intervention-participants
patients O
in O
the O
photon O
group O
and O
in O
6 B-cv-bin-abs
/ O
12 B-control-participants
patients O
in O
the O
neutron O
group O
. O
With O
regard O
to O
tumor B-outcome
control I-outcome
and O
late B-outcome
radiation I-outcome
morbidity I-outcome
no O
differences O
between O
the O
two O
treatment O
arms O
were O
observed O
. O
The O
underlying O
data O
indicate O
that O
no O
benefit O
is O
to O
be O
expected O
from O
neutron O
therapy O
in O
breast O
cancer O
. O

First O
and O
subsequent O
cycle O
use O
of O
pegfilgrastim B-intervention
prevents O
febrile B-condition
neutropenia I-condition
in O
patients O
with O
breast O
cancer O
: O
a O
multicenter O
, O
double O
- O
blind O
, O
placebo O
- O
controlled O
phase O
III O
study O
. O
We O
evaluated O
the O
efficacy O
of O
pegfilgrastim O
to O
reduce O
the O
incidence O
of O
febrile O
neutropenia O
associated O
with O
docetaxel O
in O
breast O
cancer O
patients O
. O
Patients O
were O
randomly O
assigned O
to O
either O
placebo B-control
or O
pegfilgrastim O
6 O
mg O
subcutaneously O
on O
day O
2 O
of O
each O
21 O
- O
day O
chemotherapy O
cycle O
of O
100 O
mg O
/ O
m O
( O
2 O
) O
docetaxel O
. O
The O
primary O
end O
point O
was O
the O
percentage B-outcome-measure
of I-outcome-measure
patients I-outcome-measure
developing I-outcome-measure
febrile I-outcome-measure
neutropenia I-outcome-measure
( O
defined O
as O
body O
temperature O
> O
/ O
= O
38.2 O
degrees O
C O
and O
neutrophil O
count O
< O
0.5 O
x O
10 O
( O
9 O
) O
/L O
on O
the O
same O
day O
of O
the O
fever O
or O
the O
day O
after O
) O
. O
Secondary O
end O
points O
were O
incidence B-outcome-measure
of I-outcome-measure
hospitalizations I-outcome-measure
associated I-outcome-measure
with I-outcome-measure
a I-outcome-measure
diagnosis I-outcome-measure
of I-outcome-measure
febrile I-outcome-measure
neutropenia I-outcome-measure
, O
intravenous B-outcome-measure
( I-outcome-measure
IV I-outcome-measure
) I-outcome-measure
anti I-outcome-measure
- I-outcome-measure
infectives I-outcome-measure
required I-outcome-measure
for I-outcome-measure
febrile I-outcome-measure
neutropenia I-outcome-measure
, O
and O
the O
ability B-outcome-measure
to I-outcome-measure
maintain I-outcome-measure
planned I-outcome-measure
chemotherapy I-outcome-measure
dose I-outcome-measure
on I-outcome-measure
time I-outcome-measure
. O
Patients O
with O
febrile O
neutropenia O
were O
converted O
to O
open O
- O
label O
pegfilgrastim O
in O
subsequent O
cycles O
. O
Nine B-total-participants
hundred I-total-participants
twenty I-total-participants
- I-total-participants
eight I-total-participants
patients O
received O
placebo O
( O
n O
= O
465 B-control-participants
) O
or O
pegfilgrastim O
( O
n O
= O
463 B-intervention-participants
) O
. O
Patients O
receiving O
pegfilgrastim O
, O
compared O
with O
patients O
receiving O
placebo O
, O
had O
a O
lower O
incidence B-outcome
of I-outcome
febrile I-outcome
neutropenia I-outcome
( O
1 B-iv-bin-percent
% I-iv-bin-percent
v O
17 B-cv-bin-percent
% I-cv-bin-percent
, O
respectively O
; O
P O
< O
.001 O
) O
, O
febrile B-outcome
neutropenia I-outcome
- I-outcome
related I-outcome
hospitalization I-outcome
( O
1 B-iv-bin-percent
% I-iv-bin-percent
v O
14 B-cv-bin-percent
% I-cv-bin-percent
, O
respectively O
; O
P O
< O
.001 O
) O
, O
and O
use B-outcome
of I-outcome
IV I-outcome
anti I-outcome
- I-outcome
infectives I-outcome
( O
2 B-iv-bin-percent
% I-iv-bin-percent
v O
10 B-cv-bin-percent
% I-cv-bin-percent
, O
respectively O
; O
P O
< O
.001 O
) O
. O
The O
percentage B-outcome
of I-outcome
patients I-outcome
receiving I-outcome
the I-outcome
planned I-outcome
dose I-outcome
on I-outcome
time I-outcome
was O
similar O
between O
patients O
receiving O
pegfilgrastim O
and O
patients O
who O
initially O
received O
placebo O
( O
80 B-iv-bin-percent
% I-iv-bin-percent
and O
78 B-cv-bin-percent
% I-cv-bin-percent
, O
respectively O
) O
, O
as O
would O
be O
expected O
of O
the O
study O
design O
. O
Pegfilgrastim O
was O
generally O
well B-outcome
tolerated I-outcome
and I-outcome
safe I-outcome
, O
and O
the O
adverse B-outcome
events I-outcome
reported O
were O
typical O
of O
this O
patient O
population O
. O
First O
and O
subsequent O
cycle O
use O
of O
pegfilgrastim O
with O
a O
moderately O
myelosuppressive O
chemotherapy O
regimen O
markedly O
reduced O
febrile O
neutropenia O
, O
febrile O
neutropenia O
- O
related O
hospitalizations O
, O
and O
IV O
anti O
- O
infective O
use O
. O

Cisplatin B-intervention
plus I-intervention
oral I-intervention
etoposide I-intervention
( O
EoP O
) O
combination O
is O
more O
effective O
than O
paclitaxel B-control
in O
patients B-eligibility
with I-eligibility
advanced I-eligibility
breast I-eligibility
cancer I-eligibility
pretreated I-eligibility
with I-eligibility
anthracyclines I-eligibility
: O
a O
randomised O
phase O
III O
trial O
of O
Turkish B-ethinicity
Oncology O
Group O
. O
Our O
objective O
was O
to O
determine O
whether O
oral O
etoposide O
and O
cisplatin O
combination O
( O
EoP O
) O
is O
superior O
to O
paclitaxel O
in O
the O
treatment O
of O
advanced O
breast O
cancer O
( O
ABC O
) O
patients O
pretreated O
with O
anthracyclines O
. O
From O
December O
1997 O
to O
August O
2003 O
, O
201 B-total-participants
patients O
were O
randomised O
, O
100 B-intervention-participants
to O
EoP O
and O
101 B-control-participants
to O
paclitaxel O
arms O
. O
Four O
patients O
in O
each O
arm O
were O
ineligible O
. O
The O
doses O
of O
etoposide O
and O
cisplatin O
were O
50 O
mg O
p.o O
. O
twice O
a O
day O
for O
7 O
days O
and O
70 O
mg O
m O
( O
-2 O
) O
intravenously O
( O
i. O
v. O
) O
on O
day O
1 O
, O
respectively O
, O
and O
it O
was O
175 O
mg O
m O
( O
-2 O
) O
on O
day O
1 O
for O
paclitaxel O
. O
Both O
treatments O
were O
repeated O
every O
3 O
weeks O
. O
A O
median O
of O
four O
cycles O
of O
study O
treatment O
was O
given O
in O
both O
arms O
. O
The O
response B-outcome
rate I-outcome
obtained O
in O
the O
EoP O
arm O
was O
significantly O
higher O
( O
36.3 B-iv-bin-percent
vs O
22.2 B-cv-bin-percent
% I-cv-bin-percent
; O
P O
= O
0.038 O
) O
. O
Median B-outcome
response I-outcome
duration I-outcome
was O
longer O
for O
the O
EoP O
arm O
( O
7 B-iv-cont-median
vs O
4 B-cv-cont-median
months I-cv-cont-median
) O
( O
P O
= O
0.132 O
) O
. O
Also O
, O
time B-outcome
to I-outcome
progression I-outcome
was O
significantly O
in O
favour O
of O
the O
EoP O
arm O
( O
5.5 B-iv-cont-median
vs O
3.9 B-cv-cont-median
months I-cv-cont-median
; O
P O
= O
0.003 O
) O
. O
Median B-outcome
overall I-outcome
survival I-outcome
was O
again O
significantly O
longer O
in O
the O
EoP O
arm O
( O
14 B-iv-cont-median
vs O
9.5 B-cv-cont-median
months I-cv-cont-median
; O
P O
= O
0.039 O
) O
. O
Toxicity B-outcome
profile I-outcome
of O
both O
groups O
was O
similar O
. O
Two B-iv-bin-abs
patients O
in O
each O
arm O
were O
lost B-outcome
due I-outcome
to I-outcome
febrile I-outcome
neutropenia I-outcome
. O
The O
observed O
activity O
and O
acceptable O
toxicity O
of O
EoP O
endorses O
the O
employment O
of O
this O
combination O
in O
the O
treatment O
of O
ABC O
following O
anthracyclines O
. O

Site B-intervention
of I-intervention
primary I-intervention
tumor I-intervention
has O
a O
prognostic O
role O
in O
operable O
breast O
cancer O
: O
the O
international O
breast O
cancer O
study O
group O
experience O
. O
Cancer O
presenting O
at O
the O
medial O
site O
of O
the O
breast O
may O
have O
a O
worse O
prognosis O
compared O
with O
tumors O
located O
in O
external O
quadrants O
. O
For O
medial O
tumors O
, O
axillary O
lymph O
node O
staging O
may O
not O
accurately O
reflect O
the O
metastatic O
potential O
of O
the O
disease O
. O
Eight B-total-participants
- I-total-participants
thousand I-total-participants
four I-total-participants
- I-total-participants
hundred I-total-participants
twenty I-total-participants
- I-total-participants
two I-total-participants
patients O
randomly O
assigned O
to O
International O
Breast O
Cancer O
Study O
Group O
clinical O
trials O
between O
1978 O
and O
1999 O
were O
classified O
as O
medial B-intervention
site I-intervention
( O
1,622 B-intervention-participants
; O
19 O
% O
) O
or O
lateral B-control
, I-control
central I-control
, I-control
and I-control
other I-control
sites I-control
( O
6,800 B-control-participants
; O
81 O
% O
) O
. O
Median O
follow O
- O
up O
was O
11 O
years O
. O
A O
statistically O
significant O
difference O
was O
observed O
for O
patients O
with O
medial O
tumors O
versus O
those O
with O
nonmedial O
tumors O
in O
disease B-outcome
- I-outcome
free I-outcome
survival I-outcome
( O
DFS B-outcome
; I-outcome
10 I-outcome
- I-outcome
year I-outcome
DFS I-outcome
, O
46 B-iv-bin-percent
% I-iv-bin-percent
v O
48 B-cv-bin-percent
% I-cv-bin-percent
; O
HR O
, O
1.10 O
; O
95 O
% O
CI O
, O
1.02 O
to O
1.18 O
; O
P O
= O
.01 O
) O
and O
overall B-outcome
survival I-outcome
( O
10 B-outcome
- I-outcome
year I-outcome
OS I-outcome
59 B-iv-bin-percent
% I-iv-bin-percent
v O
61 B-cv-bin-percent
% I-cv-bin-percent
; O
HR O
, O
1.09 O
; O
1.01 O
to O
1.19 O
; O
P O
= O
.04 O
) O
. O
This O
difference O
increased O
after O
adjustment O
for O
other O
prognostic O
factors O
( O
HR O
, O
1.22 O
; O
95 O
% O
CI O
, O
1.13 O
to O
1.32 O
for O
DFS B-outcome
; O
and O
HR O
, O
1.24 O
; O
95 O
% O
CI O
, O
1.14 O
to O
1.35 O
for O
OS B-outcome
; O
both O
P O
= O
.0001 O
) O
. O
The O
risk B-outcome
of I-outcome
relapse I-outcome
for O
patients O
with O
medial O
presentation O
was O
largest O
for O
the O
node O
- O
negative O
cohort O
and O
for O
patients O
with O
tumors O
larger O
than O
2 O
cm O
. O
In O
the O
subgroup O
of O
2,931 O
patients O
with O
negative O
axillary O
lymph O
nodes O
, O
10 B-outcome
- I-outcome
year I-outcome
DFS I-outcome
was O
61 B-iv-bin-percent
% I-iv-bin-percent
v O
67 B-cv-bin-percent
% I-cv-bin-percent
, O
and O
OS B-outcome
was O
73 B-iv-bin-percent
% I-iv-bin-percent
v O
80 B-cv-bin-percent
% I-cv-bin-percent
for O
medial O
versus O
nonmedial O
sites O
, O
respectively O
( O
HR O
1.33 O
; O
95 O
% O
CI O
, O
1.15 O
to O
1.54 O
; O
P O
= O
.0001 O
for O
DFS B-outcome
; O
and O
HR O
1.40 O
; O
95 O
% O
CI O
, O
1.17 O
to O
1.67 O
; O
P O
= O
.0003 O
for O
OS B-outcome
) O
. O
Tumor O
site O
has O
a O
significant O
prognostic O
utility O
, O
especially O
for O
axillary O
lymph O
node O
- O
negative O
disease O
, O
that O
should O
be O
considered O
in O
therapeutic O
algorithms O
. O
New O
staging O
procedures O
such O
as O
biopsy O
of O
the O
sentinel O
internal O
mammary O
nodes O
or O
novel O
imaging O
methods O
should O
be O
further O
studied O
in O
patients O
with O
medial O
tumors O
. O

Gemcitabine B-intervention
, I-intervention
epirubicin I-intervention
, I-intervention
and I-intervention
paclitaxel I-intervention
versus O
fluorouracil B-control
, I-control
epirubicin I-control
, I-control
and I-control
cyclophosphamide I-control
as O
first O
- O
line O
chemotherapy O
in O
metastatic O
breast O
cancer O
: O
a O
Central O
European O
Cooperative O
Oncology O
Group O
International O
, O
multicenter O
, O
prospective O
, O
randomized O
phase O
III O
trial O
. O
The O
objectives O
of O
this O
phase O
III O
trial O
were O
to O
compare O
the O
time O
to O
progressive O
disease O
( O
TtPD O
) O
, O
overall O
response O
rate O
( O
ORR O
) O
, O
overall O
survival O
, O
and O
toxicity O
of O
gemcitabine O
, O
epirubicin O
, O
and O
paclitaxel O
( O
GET O
) O
versus O
fluorouracil O
( O
FU O
) O
, O
epirubicin O
, O
and O
cyclophosphamide O
( O
FEC O
) O
as O
first O
- O
line O
therapy O
in O
patients O
with O
metastatic O
breast O
cancer O
( O
MBC O
) O
. O
Female O
patients O
aged O
18 B-age
to I-age
75 I-age
years I-age
with B-eligibility
stage I-eligibility
IV I-eligibility
and I-eligibility
measurable I-eligibility
MBC I-eligibility
were O
enrolled O
and O
randomly O
assigned O
to O
either O
gemcitabine O
( O
1,000 O
mg O
/ O
m O
( O
2 O
) O
, O
days O
1 O
and O
4 O
) O
, O
epirubicin O
( O
90 O
mg O
/ O
m O
( O
2 O
) O
, O
day O
1 O
) O
, O
and O
paclitaxel O
( O
175 O
mg O
/ O
m O
( O
2 O
) O
, O
day O
1 O
) O
or O
FU O
( O
500 O
mg O
/ O
m O
( O
2 O
) O
, O
day O
1 O
) O
, O
epirubicin O
( O
90 O
mg O
/ O
m O
( O
2 O
) O
, O
day O
1 O
) O
, O
and O
cyclophosphamide O
( O
500 O
mg O
/ O
m O
( O
2 O
) O
, O
day O
1 O
) O
. O
Both O
regimens O
were O
administered O
every O
21 O
days O
for O
a O
maximum O
of O
eight O
cycles O
. O
Between O
October O
1999 O
and O
November O
2002 O
, O
259 B-total-participants
patients O
( O
GET O
, O
n O
= O
124 B-intervention-participants
; O
FEC O
, O
n O
= O
135 B-control-participants
) O
were O
enrolled O
. O
Baseline O
characteristics O
were O
well O
balanced O
across O
treatment O
arms O
. O
After O
a O
median O
of O
20.4 O
months O
of O
follow O
- O
up O
, O
median B-outcome
TtPD I-outcome
was O
9.1 B-iv-cont-median
months I-iv-cont-median
and O
9.0 B-cv-cont-median
months I-cv-cont-median
in O
the O
GET O
and O
FEC O
arms O
, O
respectively O
( O
P O
= O
.557 O
) O
. O
The O
ORR B-outcome
was O
62.3 B-iv-bin-percent
% I-iv-bin-percent
in O
the O
GET O
arm O
( O
n O
= O
114 B-intervention-participants
) O
and O
51.2 B-cv-bin-percent
% I-cv-bin-percent
in O
the O
FEC O
arm O
( O
n O
= O
129 B-control-participants
; O
P O
= O
.093 O
) O
. O
Grade B-outcome
3 I-outcome
and I-outcome
4 I-outcome
toxicities I-outcome
, O
including O
neutropenia B-outcome
, O
thrombocytopenia B-outcome
, O
anemia B-outcome
, O
stomatitis B-outcome
, O
neurosensory B-outcome
toxicity I-outcome
, O
and O
allergy B-outcome
, O
occurred O
significantly O
more O
often O
in O
the O
GET O
arm O
. O
No O
significant O
differences O
in O
terms O
of O
TtPD B-outcome
and O
ORR B-outcome
were O
observed O
between O
the O
two O
treatment O
arms O
. O
Treatment O
- O
related O
toxicity O
was O
higher O
in O
the O
GET O
arm O
. O

Zoledronic B-intervention
acid I-intervention
significantly O
reduces O
skeletal B-condition
complications I-condition
compared O
with O
placebo O
in O
Japanese B-ethinicity
women B-eligibility
with I-eligibility
bone I-eligibility
metastases I-eligibility
from I-eligibility
breast I-eligibility
cancer I-eligibility
: O
a O
randomized O
, O
placebo O
- O
controlled O
trial O
. O
To O
investigate O
the O
efficacy O
and O
safety O
of O
zoledronic O
acid O
for O
the O
treatment O
of O
bone O
metastases O
from O
breast O
cancer O
. O
Women O
with O
bone O
metastases O
( O
N O
= O
228 B-total-participants
) O
were O
randomly O
assigned O
to O
receive O
4 O
mg O
zoledronic O
acid O
( O
n O
= O
114 B-intervention-participants
) O
or O
placebo B-control
( O
n O
= O
114 B-control-participants
) O
via O
15 O
- O
minute O
infusions O
every O
4 O
weeks O
for O
1 O
year O
. O
The O
primary O
efficacy O
end O
point O
was O
the O
skeletal B-outcome-measure
- I-outcome-measure
related I-outcome-measure
event I-outcome-measure
( I-outcome-measure
SRE I-outcome-measure
) I-outcome-measure
rate I-outcome-measure
ratio I-outcome-measure
between O
treatment O
groups O
. O
An O
SRE O
was O
defined O
as O
pathologic O
fracture O
, O
spinal O
cord O
compression O
, O
and O
radiation O
or O
surgery O
to O
bone O
. O
Secondary O
end O
points O
included O
percentage B-outcome-measure
of I-outcome-measure
patients I-outcome-measure
with I-outcome-measure
at I-outcome-measure
least I-outcome-measure
one I-outcome-measure
SRE I-outcome-measure
, O
time B-outcome-measure
- I-outcome-measure
to I-outcome-measure
- I-outcome-measure
first I-outcome-measure
SRE I-outcome-measure
, O
and O
Andersen B-outcome-measure
- I-outcome-measure
Gill I-outcome-measure
multiple I-outcome-measure
- I-outcome-measure
event I-outcome-measure
analysis I-outcome-measure
. O
The O
SRE O
rate O
ratio O
at O
1 O
year O
( O
excluding O
HCM O
and O
adjusted O
for O
prior O
fracture O
) O
was O
0.61 O
( O
permutation O
test O
; O
P O
= O
.027 O
) O
, O
indicating O
that O
zoledronic O
acid O
reduced O
the O
rate B-outcome
of I-outcome
SRE I-outcome
by O
39 O
% O
compared O
with O
placebo O
. O
The O
percentage O
of O
patients B-outcome
with I-outcome
at I-outcome
least I-outcome
one I-outcome
SRE I-outcome
( O
excluding O
HCM O
) O
was O
significantly O
reduced O
by O
20 O
% O
by O
zoledronic O
acid O
( O
29.8 B-iv-bin-percent
% I-iv-bin-percent
v O
49.6 B-cv-bin-percent
% I-cv-bin-percent
for O
placebo O
; O
P O
= O
.003 O
) O
. O
Zoledronic O
acid O
significantly O
delayed O
time B-outcome
- I-outcome
to I-outcome
- I-outcome
first I-outcome
SRE I-outcome
( O
median O
not B-iv-cont-median
reached I-iv-cont-median
v O
364 B-cv-cont-median
days I-cv-cont-median
; O
Cox O
regression O
; O
P O
= O
.007 O
) O
and O
reduced O
the O
risk B-outcome
of I-outcome
SREs I-outcome
by O
41 O
% O
in O
multiple O
event O
analysis O
( O
risk O
ratio O
= O
0.59 O
; O
P O
= O
.019 O
) O
compared O
with O
placebo O
. O
Zoledronic O
acid O
was O
well O
tolerated O
with O
a O
safety B-outcome
profile I-outcome
similar O
to O
placebo O
. O
No O
patient O
treated O
with O
zoledronic O
acid O
had O
grade B-outcome
3 I-outcome
or I-outcome
4 I-outcome
serum I-outcome
creatinine I-outcome
increase I-outcome
. O
Zoledronic O
acid O
significantly O
reduced O
skeletal O
complications O
compared O
with O
placebo O
across O
multiple O
end O
points O
in O
Japanese O
women O
with O
bone O
metastases O
from O
breast O
cancer O
. O

Pamidronate B-intervention
in O
the O
prevention O
of O
chemotherapy B-condition
- I-condition
induced I-condition
bone I-condition
loss I-condition
in O
premenopausal O
women O
with O
breast O
cancer O
: O
a O
randomized O
controlled O
trial O
. O
Mortality O
from O
breast O
cancer O
has O
decreased O
in O
large O
part O
because O
of O
adjuvant O
chemotherapy O
. O
Sequelae O
of O
therapy O
include O
ovarian O
failure O
and O
bone O
loss O
, O
loss O
that O
would O
increase O
these O
patients O
' O
risk O
of O
fracture O
with O
aging O
. O
In O
this O
study O
, O
we O
assessed O
the O
efficacy O
of O
pamidronate O
in O
preventing O
such O
loss O
. O
The O
study O
was O
a O
1 O
- O
yr O
randomized O
, O
double O
- O
blind O
, O
placebo O
- O
controlled O
trial O
comparing O
pamidronate O
60 O
mg O
iv O
every O
3 O
months O
with O
placebo B-control
in O
40 B-total-participants
premenopausal B-eligibility
women I-eligibility
with I-eligibility
newly I-eligibility
diagnosed I-eligibility
breast I-eligibility
cancer I-eligibility
. O
Bone O
mineral O
density O
( O
BMD O
) O
of O
the O
spine O
and O
hip O
and O
remodeling O
markers O
were O
monitored O
over O
1 O
yr O
. O
Over O
half O
of O
the O
subjects O
became O
amenorrheic O
, O
and O
those O
who O
did O
were O
4 O
yr O
older O
than O
those O
who O
did O
not O
( O
P O
= O
0.02 O
) O
. O
The O
mean O
difference O
in O
percent B-outcome
change I-outcome
in I-outcome
BMD I-outcome
at I-outcome
12 I-outcome
months I-outcome
between O
the O
two O
treatment O
groups O
was O
5.1 O
% O
at B-outcome
the I-outcome
lumbar I-outcome
spine I-outcome
( O
P O
= O
0.002 O
) O
in O
the O
overall O
study O
group O
and O
5 O
% O
at B-outcome
the I-outcome
lumbar I-outcome
spine I-outcome
and O
5.2 O
% O
at B-outcome
the I-outcome
total I-outcome
hip I-outcome
in O
the O
amenorrheic O
subgroup O
( O
P O
< O
0.03 O
) O
. O
Biochemical B-outcome
markers I-outcome
of I-outcome
bone I-outcome
remodeling I-outcome
did O
not O
differ O
between O
the O
two O
treatment O
groups O
, O
and O
treatment O
was O
well O
tolerated O
. O
Chemotherapy O
- O
induced O
amenorrhea O
is O
common O
with O
ensuing O
bone O
loss O
at O
the O
spine O
and O
hip O
. O
Pamidronate O
prevented O
bone O
loss O
at O
the O
spine O
and O
hip O
and O
was O
well O
tolerated O
. O

[ O
Survival O
of O
breast O
cancer O
patients O
treated O
with O
inhibitors B-intervention
of I-intervention
the I-intervention
aromatase I-intervention
vs O
tamoxifen B-control
] O
. O
In O
Mexico B-location
the O
breast O
cancer O
occupies O
the O
second O
place O
as O
cause O
of O
death O
by O
oncological O
illness O
and O
the O
etiology O
is O
considered O
multifactorial O
. O
The O
systemic O
treatment O
of O
this O
cancer O
is O
necessarily O
after O
the O
surgery O
and O
simultaneously O
when O
radiotherapy O
is O
used O
; O
therefore O
the O
recent O
introduction O
of O
newly O
non O
toxics O
and O
efficient O
antiestrogens O
which O
block O
the O
effect O
of O
estrogens O
from O
circulation O
have O
become O
drugs O
of O
first O
line O
in O
the O
metastasis O
illness O
. O
To O
compare O
the O
clinical O
evolution O
and O
the O
survival O
of O
patients O
with O
locally O
advanced O
breast O
cancer O
and O
metastasis O
with O
the O
use O
of O
two O
therapeutic O
modalities O
. O
Under O
informed O
consent O
20 B-total-participants
patients B-eligibility
with I-eligibility
diagnosis I-eligibility
of I-eligibility
breast I-eligibility
cancer I-eligibility
and I-eligibility
out I-eligibility
of I-eligibility
oncological I-eligibility
therapeutic I-eligibility
processing I-eligibility
were O
included O
. O
Randomly O
an O
inhibitor O
of O
the O
aromatase O
( O
anastrozole O
, O
1 O
mg O
for O
day O
) O
was O
used O
in O
10 B-intervention-participants
patients O
and O
in O
the O
other O
10 B-control-participants
patients O
tamoxifen O
( O
20 O
mg O
for O
day O
) O
both O
for O
2 O
years O
, O
subject O
to O
verification O
of O
positive O
estrogens O
- O
progesterone O
receptors O
. O
Half O
of O
the O
patients O
of O
each O
group O
had O
a O
clinical O
stage O
III O
. O
The O
most O
frequent O
histological O
diagnosis O
was O
the O
ductal B-outcome
carcinoma I-outcome
in O
70 B-cv-bin-percent
% I-cv-bin-percent
of O
the O
group O
with O
tamoxifen O
use O
, O
while O
in O
anastrozole O
group O
was O
90 B-iv-bin-percent
% I-iv-bin-percent
; O
the O
mastectomy B-outcome
prior I-outcome
to I-outcome
the I-outcome
tamoxifen I-outcome
was O
carried O
out O
in O
60 B-iv-bin-percent
% I-iv-bin-percent
of O
the O
patients O
and O
in O
50 B-cv-bin-percent
% I-cv-bin-percent
of O
the O
group O
with O
anastrozole O
. O
The O
acceptable O
response O
to O
the O
processing O
in O
the O
patients O
with O
tamoxifen O
was O
complete B-outcome
in O
the O
60 B-cv-bin-percent
% I-cv-bin-percent
of O
the O
cases O
, O
but O
with O
the O
use O
of O
anastrozole O
was O
80 B-iv-bin-percent
% I-iv-bin-percent
; O
survival B-outcome
in O
the O
group O
with O
anastrozole O
was O
of O
100 B-iv-bin-percent
% I-iv-bin-percent
in O
two O
years O
of O
follow O
up O
, O
while O
in O
women O
that O
received O
tamoxifen O
the O
survival O
was O
90 B-cv-bin-percent
% I-cv-bin-percent
( O
p<0.001 O
) O
. O
The O
use O
of O
anastrozole O
improved O
the O
survival B-outcome
as O
well O
as O
the O
quality B-outcome
of I-outcome
life I-outcome
, O
showing O
no O
side O
effects O
in O
this O
group O
of O
patients O
. O

First O
- O
line O
gemcitabine B-intervention
versus O
epirubicin B-control
in O
postmenopausal O
women O
aged O
60 O
or O
older O
with O
metastatic O
breast O
cancer O
: O
a O
multicenter O
, O
randomized O
, O
phase O
III O
study O
. O
This O
randomized O
, O
phase O
III O
study O
compared O
the O
efficacy O
and O
safety O
of O
first O
- O
line O
gemcitabine O
versus O
epirubicin O
in O
the O
treatment O
of O
postmenopausal O
women O
with O
metastatic O
breast O
cancer O
( O
MBC O
) O
. O
Patients O
aged O
> B-age
or I-age
= I-age
60 I-age
years I-age
( O
median O
68 O
years O
) O
with B-eligibility
clinically I-eligibility
measurable I-eligibility
MBC I-eligibility
received O
either O
gemcitabine O
1200 O
mg O
/ O
m O
( O
2 O
) O
or O
epirubicin O
35 O
mg O
/ O
m O
( O
2 O
) O
on O
days O
1 O
, O
8 O
, O
and O
15 O
of O
a O
28 O
- O
day O
cycle O
. O
Of O
410 B-total-participants
patients O
entered O
, O
397 B-total-participants
( O
198 B-intervention-participants
gemcitabine O
and O
199 B-control-participants
epirubicin O
) O
were O
randomized O
and O
qualified O
for O
the O
time O
to O
progressive O
disease O
( O
TTP O
) O
and O
survival O
analyses O
. O
Total O
cycles O
administered O
in O
185 O
gemcitabine O
and O
192 O
epirubicin O
patients O
, O
respectively O
, O
were O
699 O
( O
mean O
3.5 O
, O
range O
0 O
- O
12 O
) O
and O
917 O
( O
mean O
4.6 O
, O
range O
0 O
- O
10 O
) O
. O
Epirubicin O
demonstrated O
statistically O
significant O
superiority O
in O
TTP B-outcome
( O
6.1 B-cv-cont-median
and O
3.4 B-iv-cont-median
months I-iv-cont-median
, O
P O
= O
0.0001 O
) O
, O
overall B-outcome
survival I-outcome
( O
19.1 B-cv-cont-median
and O
11.8 B-iv-cont-median
months I-iv-cont-median
, O
P O
= O
0.0004 O
) O
, O
and O
independently O
assessed O
response B-outcome
rate I-outcome
( O
40.3 B-cv-bin-percent
% I-cv-bin-percent
and O
16.4 B-iv-bin-percent
% I-iv-bin-percent
in O
186 B-control-participants
and O
183 B-intervention-participants
evaluable O
patients O
, O
P O
< O
0.001 O
) O
. O
For O
gemcitabine O
( O
n O
= O
190 B-intervention-participants
) O
and O
epirubicin O
( O
n O
= O
192 B-control-participants
) O
, O
respectively O
, O
common O
WHO O
grade B-outcome
3 I-outcome
/ I-outcome
4 I-outcome
toxicities I-outcome
were O
neutropenia B-outcome
( O
25.3 B-iv-bin-percent
% I-iv-bin-percent
and O
17.9 B-cv-bin-percent
% I-cv-bin-percent
) O
and O
leukopenia B-outcome
( O
14.3 B-iv-bin-percent
% I-iv-bin-percent
and O
19.3 B-cv-bin-percent
% I-cv-bin-percent
) O
. O
Of O
the O
28 O
on O
- O
study O
deaths B-outcome
( O
17 B-iv-bin-abs
gemcitabine O
, O
11 B-cv-bin-abs
epirubicin O
) O
, O
three O
were O
considered O
possibly O
or O
probably O
related O
to O
treatment O
( O
gemcitabine O
) O
. O
Postmenopausal O
women O
> O
or O
= O
60 O
years O
of O
age O
with O
MBC O
tolerate O
chemotherapy O
well O
. O
In O
this O
study O
, O
epirubicin O
was O
superior O
to O
gemcitabine O
in O
the O
treatment O
of O
MBC O
in O
women O
age O
> O
or O
= O
60 O
, O
confirming O
that O
anthracyclines O
remain O
important O
drugs O
for O
first O
- O
line O
treatment O
of O
MBC O
. O

Efficacy O
and O
tolerability O
of O
aprepitant B-intervention
for O
the O
prevention O
of O
chemotherapy B-condition
- I-condition
induced I-condition
nausea I-condition
and I-condition
vomiting I-condition
in O
patients O
with O
breast O
cancer O
after O
moderately O
emetogenic O
chemotherapy O
. O
This O
is O
the O
first O
study O
in O
which O
the O
NK O
( O
1 O
) O
-receptor O
antagonist O
, O
aprepitant O
( O
APR O
) O
, O
was O
evaluated O
for O
the O
prevention O
of O
chemotherapy O
- O
induced O
nausea O
and O
vomiting O
( O
CINV O
) O
with O
moderately O
emetogenic O
chemotherapy O
. O
Eligible O
breast B-eligibility
cancer I-eligibility
patients I-eligibility
were I-eligibility
naive I-eligibility
to I-eligibility
emetogenic I-eligibility
chemotherapy I-eligibility
and I-eligibility
treated I-eligibility
with I-eligibility
cyclophosphamide I-eligibility
+ I-eligibility
/- I-eligibility
doxorubicin I-eligibility
or I-eligibility
epirubicin I-eligibility
. O
Patients O
were O
randomly O
assigned O
to O
either O
an O
aprepitant O
regimen O
( O
day O
1 O
, O
APR O
125 O
mg O
, O
ondansetron O
( O
OND O
) O
8 O
mg O
, O
and O
dexamethasone O
12 O
mg O
before O
chemotherapy O
and O
OND O
8 O
mg O
8 O
hours O
later O
; O
days O
2 O
through O
3 O
, O
APR O
80 O
qd O
) O
[ O
DOSAGE O
ERROR O
CORRECTED O
] O
or O
a O
control B-control
regimen I-control
( O
day O
1 O
, O
OND O
8 O
mg O
and O
dexamethasone O
20 O
mg O
before O
chemotherapy O
and O
OND O
8 O
mg O
8 O
hours O
later O
; O
days O
2 O
through O
3 O
, O
OND O
8 O
mg O
bid O
) O
. O
Data O
on O
nausea O
, O
vomiting O
, O
and O
use O
of O
rescue O
medication O
were O
collected O
with O
a O
self O
- O
report O
diary O
. O
The O
primary O
efficacy O
end O
point O
was O
the O
proportion B-outcome-measure
of I-outcome-measure
patients I-outcome-measure
with I-outcome-measure
complete I-outcome-measure
response I-outcome-measure
, O
defined O
as O
no O
vomiting O
and O
no O
use O
of O
rescue O
therapy O
, O
during O
120 O
hours O
after O
initiation O
of O
chemotherapy O
in O
cycle O
1 O
. O
The O
secondary O
end O
point O
was O
the O
proportion B-outcome-measure
of I-outcome-measure
patients I-outcome-measure
with I-outcome-measure
an I-outcome-measure
average I-outcome-measure
item I-outcome-measure
score I-outcome-measure
higher I-outcome-measure
than I-outcome-measure
6 I-outcome-measure
of I-outcome-measure
7 I-outcome-measure
on I-outcome-measure
the I-outcome-measure
Functional I-outcome-measure
Living I-outcome-measure
Index I-outcome-measure
- I-outcome-measure
Emesis I-outcome-measure
questionnaire I-outcome-measure
. O
Of O
866 B-total-participants
patients O
randomized O
, O
857 B-total-participants
patients O
( O
99 O
% O
) O
were O
assessable O
. O
Overall O
complete B-outcome
response I-outcome
was O
greater O
with O
the O
aprepitant O
regimen O
than O
with O
the O
control O
regimen O
( O
50.8 B-iv-bin-percent
% I-iv-bin-percent
v O
42.5 B-cv-bin-percent
% I-cv-bin-percent
; O
P O
= O
.015 O
) O
. O
More O
patients O
in O
the O
aprepitant O
group O
reported O
minimal O
or O
no O
impact B-outcome
of I-outcome
CINV I-outcome
on I-outcome
daily I-outcome
life I-outcome
( O
63.5 B-iv-bin-percent
% I-iv-bin-percent
v O
55.6 B-cv-bin-percent
% I-cv-bin-percent
; O
P O
= O
.019 O
) O
. O
Both O
treatments O
were O
generally O
well B-outcome
tolerated I-outcome
. O
The O
aprepitant O
regimen O
was O
more O
effective O
than O
the O
control O
regimen O
for O
prevention O
of O
CINV O
in O
patients O
receiving O
both O
an O
anthracycline O
and O
cyclophosphamide O
. O

Phase O
III O
randomized O
trial O
of O
doxorubicin B-intervention
and I-intervention
docetaxel I-intervention
versus O
doxorubicin B-control
and I-control
cyclophosphamide I-control
as O
primary O
medical O
therapy O
in O
women O
with O
breast O
cancer O
: O
an O
anglo O
- O
celtic O
cooperative O
oncology O
group O
study O
. O
PURPOSE O
To O
compare O
the O
clinical O
and O
pathologic O
response O
rates O
of O
doxorubicin O
and O
cyclophosphamide O
( O
AC O
) O
with O
doxorubicin O
and O
docetaxel O
( O
AD O
) O
as O
primary O
chemotherapy O
in O
women B-eligibility
with I-eligibility
primary I-eligibility
or I-eligibility
locally I-eligibility
advanced I-eligibility
breast I-eligibility
cancer I-eligibility
. O
PATIENTS O
AND O
METHODS O
Eligible O
patients O
with O
histologically O
proven O
breast O
cancer O
with O
primary O
tumors O
> O
/ O
= O
3 O
cm O
, O
inflammatory O
or O
locally O
advanced O
disease O
, O
and O
no O
evidence O
of O
metastases O
were O
randomly O
assigned O
to O
receive O
a O
maximum O
of O
six O
cycles O
of O
either O
doxorubicin O
( O
60 O
mg O
/ O
m O
( O
2 O
) O
) O
plus O
cyclophosphamide O
( O
600 O
mg O
/ O
m O
( O
2 O
) O
) O
administered O
intravenously O
( O
IV O
) O
every O
3 O
weeks O
or O
doxorubicin O
( O
60 O
mg O
/ O
m O
( O
2 O
) O
) O
plus O
docetaxel O
( O
75 O
mg O
/ O
m O
( O
2 O
) O
) O
IV O
every O
3 O
weeks O
, O
followed O
by O
surgery O
on O
completion O
of O
chemotherapy O
. O
Results O
A O
total O
of O
363 B-total-participants
patients O
were O
randomly O
assigned O
to O
AC O
( O
n O
= O
180 B-intervention-participants
) O
or O
AD O
( O
n O
= O
183 B-control-participants
) O
. O
A O
complete B-outcome
clinical I-outcome
response I-outcome
was O
observed O
in O
17 B-iv-bin-percent
% I-iv-bin-percent
and O
20 B-cv-bin-percent
% I-cv-bin-percent
of O
patients O
treated O
with O
AC O
and O
AD O
, O
respectively O
( O
P O
= O
.42 O
) O
. O
Overall B-outcome
( I-outcome
complete I-outcome
and I-outcome
partial I-outcome
) I-outcome
clinical I-outcome
response I-outcome
rates I-outcome
for O
AC O
and O
AD O
were O
61 B-iv-bin-percent
% I-iv-bin-percent
and O
70 B-cv-bin-percent
% I-cv-bin-percent
, O
respectively O
( O
P O
= O
.06 O
) O
. O
There O
was O
no O
significant O
difference O
in O
either O
the O
pathologic O
complete B-outcome
response I-outcome
rates I-outcome
in O
the O
breast O
with O
AC O
( O
24 B-iv-bin-percent
% I-iv-bin-percent
) O
and O
AD O
( O
21 B-cv-bin-percent
% I-cv-bin-percent
; O
P O
= O
.61 O
) O
or O
in O
the O
number B-outcome
of I-outcome
patients I-outcome
with I-outcome
positive I-outcome
axillary I-outcome
nodes I-outcome
at I-outcome
surgery I-outcome
with O
AC O
( O
61 B-iv-bin-percent
% I-iv-bin-percent
) O
and O
AD O
( O
66 B-cv-bin-percent
% I-cv-bin-percent
; O
P O
= O
.28 O
) O
. O
At O
a O
median O
follow O
- O
up O
of O
32 O
months O
, O
there O
is O
no O
significant O
difference O
between O
the O
two O
groups O
for O
the O
number B-outcome
of I-outcome
relapses I-outcome
. O
CONCLUSION O
In O
contrast O
to O
the O
positive O
results O
reported O
for O
sequential O
docetaxel O
after O
AC O
as O
primary O
chemotherapy O
of O
breast O
cancer O
, O
our O
data O
do O
not O
suggest O
a O
benefit O
for O
simultaneous O
AD O
over O
AC O
. O

Mitotic O
index O
and O
benefit O
of O
adjuvant B-intervention
anthracycline I-intervention
- I-intervention
based I-intervention
chemotherapy I-intervention
in O
patients O
with O
early O
breast O
cancer O
. O
We O
have O
evaluated O
whether O
the O
mitotic O
index O
could O
predict O
the O
benefit O
of O
adjuvant O
anthracycline O
- O
based O
chemotherapy O
in O
patients B-eligibility
with I-eligibility
early I-eligibility
breast I-eligibility
cancer I-eligibility
who I-eligibility
are I-eligibility
eligible I-eligibility
for I-eligibility
adjuvant I-eligibility
chemotherapy I-eligibility
according I-eligibility
to I-eligibility
Saint I-eligibility
Gallen I-eligibility
guidelines I-eligibility
. O
A O
total O
of O
937 B-total-participants
patients O
from O
a O
single O
institution O
were O
included O
in O
two O
randomized O
trials O
that O
compared O
adjuvant O
anthracycline O
- O
based O
chemotherapy O
with O
no B-control
chemotherapy I-control
. O
These O
patients O
account O
for O
83 O
% O
of O
the O
overall O
population O
included O
in O
these O
trials O
. O
The O
first O
trial O
included O
premenopausal O
patients O
with O
node O
- O
negative O
disease O
, O
and O
the O
second O
one O
included O
postmenopausal O
patients O
, O
regardless O
of O
lymph O
node O
status O
. O
The O
treatment O
benefit O
was O
assessed O
according O
to O
the O
number O
of O
mitoses O
per O
field O
( O
x400 O
) O
. O
The O
mitotic O
index O
was O
assessable O
in O
888 B-total-participants
patients O
( O
94 O
% O
) O
. O
All O
the O
patients O
presented O
as O
either O
node O
- O
positive O
or O
an O
average O
- O
risk O
breast O
cancer O
according O
to O
2003 O
Saint O
Gallen O
consensus O
conference O
guidelines O
. O
The O
5 B-outcome
- I-outcome
year I-outcome
overall I-outcome
survival I-outcome
rates I-outcome
were O
91 B-iv-bin-percent
% I-iv-bin-percent
and O
87 B-cv-bin-percent
% I-cv-bin-percent
for O
patients O
treated O
or O
not O
with O
adjuvant O
chemotherapy O
( O
P O
= O
.09 O
) O
. O
In O
patients O
with O
low O
/ O
medium O
mitotic O
index O
( O
< O
three O
mitoses O
/ O
field O
; O
n O
= O
450 O
) O
, O
the O
5 B-outcome
- I-outcome
year I-outcome
overall I-outcome
survival I-outcome
rate I-outcome
was O
95 B-iv-bin-percent
% I-iv-bin-percent
for O
patients O
treated O
or O
not O
with O
adjuvant O
chemotherapy O
( O
P O
= O
.56 O
) O
. O
In O
patients O
with O
high O
mitotic O
index O
( O
> O
/ O
= O
three O
mitoses O
/ O
field O
; O
n O
= O
438 O
) O
, O
the O
5 B-outcome
- I-outcome
year I-outcome
overall I-outcome
survival I-outcome
rates I-outcome
were O
86 B-iv-bin-percent
% I-iv-bin-percent
and O
79 B-cv-bin-percent
% I-cv-bin-percent
for O
patients O
treated O
or O
not O
treated O
with O
adjuvant O
chemotherapy O
, O
respectively O
( O
P O
= O
.02 O
) O
. O
A O
high O
mitotic O
index O
is O
associated O
with O
the O
efficacy O
of O
adjuvant O
anthracycline O
- O
based O
chemotherapy O
in O
patients O
eligible O
for O
adjuvant O
chemotherapy O
in O
daily O
practice O
. O

Dietary B-intervention
flaxseed I-intervention
alters O
tumor O
biological O
markers O
in O
postmenopausal O
breast O
cancer O
. O
Flaxseed O
, O
the O
richest O
source O
of O
mammalian O
lignan O
precursors O
, O
has O
previously O
been O
shown O
to O
reduce O
the O
growth O
of O
tumors O
in O
rats O
. O
This O
study O
examined O
, O
in O
a O
randomized O
double O
- O
blind O
placebo O
- O
controlled O
clinical O
trial O
, O
the O
effects O
of O
dietary O
flaxseed O
on O
tumor O
biological O
markers O
and O
urinary O
lignan O
excretion O
in O
postmenopausal B-eligibility
patients I-eligibility
with I-eligibility
newly I-eligibility
diagnosed I-eligibility
breast I-eligibility
cancer I-eligibility
. O
Patients O
were O
randomized O
to O
daily O
intake O
of O
either O
a O
25 O
g O
flaxseed O
- O
containing O
muffin O
( O
n O
= O
19 B-intervention-participants
) O
or O
a O
control B-control
( I-control
placebo I-control
) I-control
muffin O
( O
n O
= O
13 B-control-participants
) O
. O
At O
the O
time O
of O
diagnosis O
and O
again O
at O
definitive O
surgery O
, O
tumor O
tissue O
was O
analyzed O
for O
the O
rate O
of O
tumor O
cell O
proliferation O
( O
Ki-67 B-outcome-measure
labeling I-outcome-measure
index I-outcome-measure
, O
primary O
end O
point O
) O
, O
apoptosis B-outcome-measure
, O
c B-outcome-measure
- I-outcome-measure
erbB2 I-outcome-measure
expression I-outcome-measure
, O
and O
estrogen B-outcome-measure
and I-outcome-measure
progesterone I-outcome-measure
receptor I-outcome-measure
levels I-outcome-measure
. O
Twenty O
- O
four O
- O
hour O
urine O
samples O
were O
analyzed O
for O
lignans O
, O
and O
3 O
- O
day O
diet O
records O
were O
evaluated O
for O
macronutrient O
and O
caloric O
intake O
. O
Mean B-outcome
treatment I-outcome
times I-outcome
were O
39 B-cv-cont-mean
and O
32 B-iv-cont-mean
days I-iv-cont-mean
in O
the O
placebo O
and O
flaxseed O
groups O
, O
respectively O
. O
Reductions B-outcome
in I-outcome
Ki-67 I-outcome
labeling I-outcome
index I-outcome
( O
34.2 O
% O
; O
P O
= O
0.001 O
) O
and O
in O
c B-outcome
- I-outcome
erbB2 I-outcome
expression I-outcome
( O
71.0 O
% O
; O
P O
= O
0.003 O
) O
and O
an O
increase O
in O
apoptosis B-outcome
( O
30.7 O
% O
; O
P O
= O
0.007 O
) O
were O
observed O
in O
the O
flaxseed O
, O
but O
not O
in O
the O
placebo O
group O
. O
No O
significant O
differences O
in O
caloric B-outcome
and I-outcome
macronutrient I-outcome
intake I-outcome
were O
seen O
between O
groups O
and O
between O
pre- O
and O
posttreatment O
periods O
. O
A O
significant O
increase O
in O
mean B-outcome
urinary I-outcome
lignan I-outcome
excretion I-outcome
was O
observed O
in O
the O
flaxseed O
group O
( O
1,300 O
% O
; O
P O
< O
0.01 O
) O
compared O
with O
placebo O
controls O
. O
The O
total O
intake O
of O
flaxseed O
was O
correlated O
with O
changes O
in O
c O
- O
erbB2 O
score O
( O
r O
= O
-0.373 O
; O
P O
= O
0.036 O
) O
and O
apoptotic O
index O
( O
r O
= O
0.495 O
; O
P O
< O
0.004 O
) O
. O
Dietary O
flaxseed O
has O
the O
potential O
to O
reduce O
tumor O
growth O
in O
patients O
with O
breast O
cancer O
. O

Secondary B-condition
leukemia I-condition
after O
epirubicin B-intervention
- I-intervention
based I-intervention
adjuvant I-intervention
chemotherapy I-intervention
in O
operable B-eligibility
breast I-eligibility
cancer I-eligibility
patients I-eligibility
: O
16 O
years O
experience O
of O
the O
French B-location
Adjuvant O
Study O
Group O
. O
The O
purpose O
of O
this O
study O
was O
to O
evaluate O
incidence O
and O
risk O
factors O
of O
secondary O
leukemia O
after O
adjuvant O
epirubicin O
- O
based O
chemotherapy O
in O
breast O
cancer O
patients O
. O
Among O
eight O
French O
Adjuvant O
Study O
Group O
trials O
, O
3653 B-total-participants
patients O
were O
assessable O
: O
2603 B-intervention-participants
received O
epirubicin O
; O
682 B-intervention-participants
received O
hormonotherapy B-intervention
; O
and O
368 B-control-participants
had O
no B-control
systemic I-control
treatment I-control
. O
Chemotherapy O
was O
FEC O
regimen O
in O
85 O
% O
of O
cases O
( O
fluorouracil O
500 O
mg O
/ O
m2 O
, O
epirubicin O
50 O
, O
75 O
or O
100 O
mg O
/ O
m2 O
, O
cyclophosphamide O
500 O
mg O
/ O
m2 O
, O
three O
or O
six O
cycles O
) O
. O
Epirubicin O
cumulative O
dose O
was O
< O
300 O
mg O
/ O
m2 O
in O
1045 O
patients O
; O
300 O
- O
600 O
mg O
/ O
m2 O
in O
1187 O
; O
and O
> O
or O
= O
600 O
mg O
/ O
m2 O
in O
286 O
, O
followed O
by O
radiotherapy O
in O
96 O
% O
of O
cases O
. O
The O
median O
follow O
- O
up O
was O
104 O
months O
. O
Eight B-iv-bin-abs
cases B-outcome
of I-outcome
leukemia I-outcome
occurred O
in O
epirubicin O
- O
exposed O
patients O
and O
one B-cv-bin-abs
in O
non O
- O
exposed O
patients O
. O
After O
9 O
years O
, O
the O
risk B-outcome
of I-outcome
developing I-outcome
a I-outcome
leukemia I-outcome
was O
0.34 B-iv-bin-percent
% I-iv-bin-percent
( O
95 O
% O
confidence O
interval O
0.11 O
- O
0.57 O
) O
in O
epirubicin O
- O
exposed O
patients O
. O
In O
patients O
receiving O
chemotherapy O
, O
leukemia B-outcome
subtypes I-outcome
were O
: O
AML2 B-outcome
( O
two B-iv-bin-percent
) O
, O
AML3 B-outcome
( O
one B-iv-bin-abs
) O
, O
AML4 B-outcome
( O
three B-iv-bin-abs
) O
and O
ALL B-outcome
( O
two B-iv-bin-abs
) O
. O
None O
of O
the O
classically O
recognized O
risk O
factors O
was O
significantly O
correlated O
with O
the O
occurrence O
of O
a O
leukemia O
. O
Irrespective O
of O
the O
dose O
, O
the O
incidence B-outcome
of I-outcome
secondary I-outcome
leukemia I-outcome
after O
adjuvant O
epirubicin O
- O
based O
chemotherapy O
was O
low O
. O
After O
a O
long O
follow O
- O
up O
, O
the O
benefit O
/ O
risk O
ratio O
for O
early O
breast O
cancer O
patients O
remained O
in O
favor O
of O
epirubicin O
- O
based O
adjuvant O
chemotherapy O
: O
eight O
cases O
( O
0.31 O
% O
) O
occurred O
, O
and O
in O
some O
of O
them O
, O
treatment O
causality O
could O
be O
debatable O
. O

Adjuvant O
docetaxel O
for O
node O
- O
positive O
breast O
cancer O
. O
We O
compared O
docetaxel B-intervention
plus I-intervention
doxorubicin I-intervention
and I-intervention
cyclophosphamide I-intervention
( I-intervention
TAC I-intervention
) I-intervention
with O
fluorouracil B-control
plus I-control
doxorubicin I-control
and I-control
cyclophosphamide I-control
( I-control
FAC I-control
) I-control
as O
adjuvant O
chemotherapy O
for O
operable O
node O
- O
positive O
breast O
cancer O
. O
We O
randomly O
assigned O
1491 B-total-participants
women B-eligibility
with I-eligibility
axillary I-eligibility
node I-eligibility
- I-eligibility
positive I-eligibility
breast I-eligibility
cancer I-eligibility
to O
six O
cycles O
of O
treatment O
with O
either O
TAC O
or O
FAC O
as O
adjuvant O
chemotherapy O
after O
surgery O
. O
The O
primary O
end O
point O
was O
disease B-outcome-measure
- I-outcome-measure
free I-outcome-measure
survival I-outcome-measure
. O
At O
a O
median O
follow O
- O
up O
of O
55 O
months O
, O
the O
estimated O
rates O
of O
disease B-outcome
- I-outcome
free I-outcome
survival I-outcome
at I-outcome
five I-outcome
years I-outcome
were O
75 B-iv-bin-percent
percent I-iv-bin-percent
among O
the O
745 B-intervention-participants
patients O
randomly O
assigned O
to O
receive O
TAC O
and O
68 B-cv-bin-percent
percent I-cv-bin-percent
among O
the O
746 B-control-participants
randomly O
assigned O
to O
receive O
FAC O
, O
representing O
a O
28 O
percent O
reduction O
in O
the O
risk O
of O
relapse O
( O
P O
= O
0.001 O
) O
in O
the O
TAC O
group O
. O
The O
estimated O
rates O
of O
overall B-outcome
survival I-outcome
at I-outcome
five I-outcome
years I-outcome
were O
87 B-iv-bin-percent
percent I-iv-bin-percent
and O
81 B-cv-bin-percent
percent I-cv-bin-percent
, O
respectively O
. O
Treatment O
with O
TAC O
resulted O
in O
a O
30 B-iv-bin-percent
percent I-iv-bin-percent
reduction B-outcome
in I-outcome
the I-outcome
risk I-outcome
of I-outcome
death I-outcome
( O
P O
= O
0.008 O
) O
. O
The O
incidence O
of O
grade B-outcome
3 I-outcome
or I-outcome
4 I-outcome
neutropenia I-outcome
was O
65.5 B-iv-bin-percent
percent I-iv-bin-percent
in O
the O
TAC O
group O
and O
49.3 B-cv-bin-percent
percent I-cv-bin-percent
in O
the O
FAC O
group O
( O
P<0.001 O
) O
; O
rates O
of O
febrile B-outcome
neutropenia I-outcome
were O
24.7 B-iv-bin-percent
percent I-iv-bin-percent
and O
2.5 B-cv-bin-percent
percent I-cv-bin-percent
, O
respectively O
( O
P<0.001 O
) O
. O
Grade B-outcome
3 I-outcome
or I-outcome
4 I-outcome
infections I-outcome
occurred O
in O
3.9 B-iv-bin-percent
percent I-iv-bin-percent
of O
the O
patients O
who O
received O
TAC O
and O
2.2 B-cv-bin-percent
percent I-cv-bin-percent
of O
those O
who O
received O
FAC O
( O
P O
= O
0.05 O
) O
; O
no B-outcome
deaths I-outcome
occurred O
as O
a O
result O
of O
infection O
. O
Two B-iv-bin-abs
patients O
in O
each O
group O
died B-outcome
during O
treatment O
. O
Congestive B-outcome
heart I-outcome
failure I-outcome
and I-outcome
acute I-outcome
myeloid I-outcome
leukemia I-outcome
occurred O
in O
less O
than O
2 B-iv-bin-percent
percent I-iv-bin-percent
of O
the O
patients O
in O
each O
group O
. O
Quality B-outcome
- I-outcome
of I-outcome
- I-outcome
life I-outcome
scores I-outcome
decreased O
during O
chemotherapy O
but O
returned O
to O
baseline O
levels O
after O
treatment O
. O
Adjuvant O
chemotherapy O
with O
TAC O
, O
as O
compared O
with O
FAC O
, O
significantly O
improves O
the O
rates O
of O
disease O
- O
free O
and O
overall O
survival O
among O
women O
with O
operable O
node O
- O
positive O
breast O
cancer O
. O

[ O
Clinical O
value O
of O
combined O
therapy O
with O
188Re B-intervention
- I-intervention
HEDP I-intervention
and I-intervention
pamidronate I-intervention
in O
breast O
cancer O
with O
bone O
metastasis O
] O
. O
To O
evaluate O
the O
clinical O
therapeutic O
value O
of O
( O
188 O
) O
Re O
- O
HEDP O
combined O
with O
pamidronate O
in O
breast O
cancer O
with O
bone O
metastasis O
. O
Forty B-total-participants
- I-total-participants
eight I-total-participants
patients B-eligibility
with I-eligibility
breast I-eligibility
cancer I-eligibility
with I-eligibility
multi I-eligibility
- I-eligibility
bone I-eligibility
metastases I-eligibility
were O
randomly O
divided O
into O
three O
groups O
: O
15 B-control-participants
patients O
received O
( B-control
188 I-control
) I-control
Re I-control
- I-control
HEDP I-control
( O
group O
A O
) O
, O
15 B-control-participants
patients O
received O
pamidronate B-control
( O
group O
B O
) O
and O
18 B-intervention-participants
patients O
were O
treated O
by O
( O
188 O
) O
Re O
- O
HEDP O
plus O
pamidronate O
( O
group O
C O
) O
. O
The O
overall B-outcome
pain I-outcome
relief I-outcome
rate I-outcome
was O
73.3 B-cv-bin-percent
% I-cv-bin-percent
, O
80.0 B-cv-bin-percent
% I-cv-bin-percent
, O
100.0 B-iv-bin-percent
% I-iv-bin-percent
in O
groups O
A O
, O
B O
and O
C. O
The O
response B-outcome
rate I-outcome
of I-outcome
bone I-outcome
metastasis I-outcome
was O
40.0 B-cv-bin-percent
% I-cv-bin-percent
, O
33.3 B-cv-bin-percent
% I-cv-bin-percent
, O
66.7 B-iv-bin-percent
% I-iv-bin-percent
in O
groups O
A O
, O
B O
and O
C O
respectively O
. O
The O
therapeutic B-outcome
effect I-outcome
of O
group O
C O
was O
better O
than O
those O
of O
groups O
A O
and O
B O
( O
P O
< O
0.05 O
) O
, O
without O
any O
significance O
in O
the O
difference O
( O
P O
> O
0.05 O
) O
. O
The O
therapeutic O
effect O
of O
( O
188 O
) O
Re O
- O
HEDP O
combined O
with O
pamidronate O
for O
breast O
cancer O
with O
bone O
metastasis O
is O
remarkable O
in O
bone O
pain O
relief O
and O
bone O
metastasis O
control O
, O
which O
is O
better O
than O
either O
( O
188 O
) O
Re O
- O
HEDP O
or O
pamidronate O
alone O
. O

Decreased O
use O
of O
adjuvant O
breast O
cancer O
therapy O
in O
a O
randomized O
controlled O
trial O
of O
a O
decision B-intervention
aid I-intervention
with O
individualized O
risk O
information O
. O
Oncology O
patients O
often O
seek O
involvement O
in O
their O
medical O
consultations O
. O
Such O
involvement O
is O
endorsed O
by O
most O
health O
care O
providers O
and O
mirrored O
in O
practice O
guidelines O
. O
However O
, O
oncologists O
exhibit O
great O
variation O
in O
how O
they O
provide O
patients O
with O
disease O
- O
relevant O
information O
, O
and O
many O
remain O
reluctant O
to O
do O
so O
at O
all O
. O
The O
authors O
examined O
the O
impact O
of O
a O
patient O
- O
specific O
decision O
aid O
on O
women O
's O
decisions O
about O
adjuvant O
therapy O
for O
breast O
cancer O
. O
386 B-total-participants
women B-eligibility
with I-eligibility
breast I-eligibility
cancer I-eligibility
were O
randomized O
to O
receive O
either O
an O
informational O
pamphlet O
about O
adjuvant O
therapy O
( O
usual B-control
care I-control
) O
or O
a O
patient O
- O
specific O
, O
evidence O
- O
based O
decision O
aid O
about O
adjuvant O
therapy O
. O
The O
authors O
compared O
rates O
of O
adjuvant O
therapy O
between O
the O
groups O
controlling O
for O
age O
, O
education O
, O
marital O
status O
, O
race O
, O
tumor O
severity O
, O
and O
practice O
type O
of O
their O
physician O
( O
university O
- O
based O
or O
community O
- O
based O
) O
. O
Among O
women O
with O
low O
tumor O
severity O
, O
only O
58 B-iv-bin-percent
% I-iv-bin-percent
( O
35 B-iv-bin-abs
/ O
60 B-intervention-participants
) O
of O
women O
in O
the O
decision O
aid O
group O
chose B-outcome
adjuvant I-outcome
therapy I-outcome
, O
compared O
to O
87 B-cv-bin-percent
% I-cv-bin-percent
( O
33 B-cv-bin-abs
/ O
38 B-control-participants
) O
of O
their O
counterparts O
in O
usual O
care O
( O
P<0.01 O
) O
. O
This O
study O
illustrates O
the O
important O
impact O
of O
medical O
decision O
aids O
on O
treatment O
choices O
, O
particularly O
for O
patients O
for O
whom O
treatment O
has O
little O
benefit O
. O
In O
the O
case O
of O
adjuvant O
therapy O
for O
breast O
cancer O
, O
providing O
individualized O
, O
evidence O
- O
based O
risk O
information O
for O
shared O
decision O
making O
resulted O
in O
fewer O
women O
with O
low O
tumor O
severity O
choosing O
adjuvant O
treatment O
. O

Switching O
of O
postmenopausal O
women O
with O
endocrine O
- O
responsive O
early O
breast O
cancer O
to O
anastrozole O
after O
2 O
years O
' O
adjuvant O
tamoxifen O
: O
combined O
results O
of O
ABCSG O
trial O
8 O
and O
ARNO O
95 O
trial O
. O
Tamoxifen O
has O
been O
the O
standard O
adjuvant O
treatment O
for O
postmenopausal O
women O
with O
hormone O
- O
responsive O
early O
breast O
cancer O
for O
more O
than O
20 O
years O
. O
However O
, O
the O
third O
- O
generation O
aromatase O
inhibitor O
anastrozole O
has O
proven O
efficacy O
and O
tolerability O
benefits O
compared O
with O
tamoxifen O
when O
used O
as O
initial O
adjuvant O
therapy O
. O
We O
investigate O
whether O
women O
who O
have O
received O
a O
period O
of O
adjuvant O
tamoxifen O
would O
benefit O
from O
being O
switched O
to O
anastrozole O
. O
We O
present O
a O
combined O
analysis O
of O
data O
from O
two O
prospective O
, O
multicentre O
, O
randomised O
, O
open O
- O
label O
trials O
with O
nearly O
identical O
inclusion O
criteria O
. O
Postmenopausal B-eligibility
women I-eligibility
with I-eligibility
hormone I-eligibility
- I-eligibility
sensitive I-eligibility
early I-eligibility
breast I-eligibility
cancer I-eligibility
who I-eligibility
had I-eligibility
completed I-eligibility
2 I-eligibility
years I-eligibility
' I-eligibility
adjuvant I-eligibility
oral I-eligibility
tamoxifen I-eligibility
( O
20 O
or O
30 O
mg O
daily O
) O
were O
randomised O
to O
receive O
1 O
mg O
oral O
anastrozole B-intervention
( O
n O
= O
1618 B-intervention-participants
) O
or O
20 O
or O
30 O
mg O
tamoxifen B-control
( O
n O
= O
1606 B-control-participants
) O
daily O
for O
the O
remainder O
of O
their O
adjuvant O
therapy O
. O
The O
primary O
endpoint O
was O
event B-outcome-measure
- I-outcome-measure
free I-outcome-measure
survival I-outcome-measure
, O
with O
an O
event O
defined O
as O
local O
or O
distant O
metastasis O
, O
or O
contralateral O
breast O
cancer O
. O
Analysis O
was O
by O
intention O
to O
treat O
. O
3224 B-total-participants
patients O
were O
included O
in O
analyses O
. O
At O
a O
median O
follow O
- O
up O
of O
28 O
months O
, O
we O
noted O
a O
40 O
% O
decrease O
in O
the O
risk B-outcome
for I-outcome
an I-outcome
event I-outcome
in O
the O
anastrozole O
group O
as O
compared O
with O
the O
tamoxifen O
group O
( O
67 B-iv-bin-abs
events O
with O
anastrozole O
vs O
110 B-cv-bin-abs
with O
tamoxifen O
, O
hazard O
ratio O
0.60 O
, O
95 O
% O
CI O
0.44 O
- O
0.81 O
, O
p O
= O
0.0009 O
) O
. O
Both O
study O
treatments O
were O
well B-outcome
tolerated I-outcome
. O
There O
were O
significantly O
more O
fractures B-outcome
( O
p O
= O
0.015 O
) O
and O
significantly O
fewer O
thromboses B-outcome
( O
p O
= O
0.034 O
) O
in O
patients O
treated O
with O
anastrozole O
than O
in O
those O
on O
tamoxifen O
. O
These O
data O
lend O
support O
to O
a O
switch O
from O
tamoxifen O
to O
anastrozole O
in O
patients O
who O
have O
completed O
2 O
years O
' O
adjuvant O
tamoxifen O
. O

Weekly O
paclitaxel B-intervention
improves O
pathologic O
complete O
remission O
in O
operable O
breast O
cancer O
when O
compared O
with O
paclitaxel O
once O
every O
3 O
weeks O
. O
To O
determine O
the O
impact O
a O
change O
in O
schedule O
of O
paclitaxel O
administration O
from O
once O
every O
3 O
weeks O
to O
frequent O
administration O
would O
have O
on O
the O
pathologic O
complete O
response O
( O
pCR O
) O
rate O
in O
the O
breast O
and O
lymph O
nodes O
for O
patients O
with O
invasive O
breast O
cancer O
treated O
with O
primary O
systemic O
chemotherapy O
( O
PST O
) O
. O
Patients B-eligibility
with I-eligibility
clinical I-eligibility
stage I-eligibility
I I-eligibility
- I-eligibility
IIIA I-eligibility
breast I-eligibility
cancer I-eligibility
were O
randomly O
assigned O
to O
receive O
PST O
of O
paclitaxel O
doses O
administered O
either O
weekly O
( O
for O
a O
total O
of O
12 O
doses O
of O
paclitaxel O
) O
or O
once O
every O
3 O
weeks O
( O
four O
cycles O
) O
, O
followed O
by O
four O
cycles O
of O
fluorouracil O
/ O
doxorubicin O
/ O
cyclophosphamide O
( O
FAC O
) O
in O
standard B-control
doses I-control
every O
3 O
weeks O
. O
Two O
different O
doses O
of O
paclitaxel O
were O
used O
based O
on O
lymph O
node O
status O
defined O
by O
ultrasound O
and O
fine O
needle O
aspiration O
. O
Clinical O
response O
and O
extent O
of O
residual O
disease O
in O
the O
breast O
and O
lymph O
nodes O
was O
assessed O
after O
completion O
of O
all O
chemotherapy O
. O
A O
total O
of O
258 B-total-participants
patients O
were O
randomly O
assigned O
to O
receive O
doses O
of O
paclitaxel O
administered O
either O
weekly O
or O
once O
every O
3 O
weeks O
, O
followed O
by O
FAC O
. O
Of O
these O
258 B-total-participants
patients O
, O
110 B-total-participants
patients O
had O
histologic O
lymph O
node O
involvement O
and O
148 B-total-participants
patients O
had O
clinical O
N0 O
disease O
. O
Weekly O
paclitaxel O
followed O
by O
FAC O
was O
administered O
to O
127 B-intervention-participants
patients O
and O
once O
- O
every-3 O
- O
weeks O
paclitaxel O
followed O
by O
FAC O
was O
administered O
to O
131 B-control-participants
patients O
. O
Clinical B-outcome
response I-outcome
to O
treatment O
was O
similar O
between O
groups O
( O
P O
= O
.25 O
) O
. O
Patients O
receiving O
weekly O
paclitaxel O
had O
a O
higher O
pCR B-outcome
rate I-outcome
( O
28.2 B-iv-bin-percent
% I-iv-bin-percent
) O
than O
patients O
treated O
with O
once O
- O
every-3 O
- O
weeks O
paclitaxel O
( O
15.7 B-cv-bin-percent
% I-cv-bin-percent
; O
P O
= O
.02 O
) O
, O
with O
improved O
breast B-outcome
conservation I-outcome
rates I-outcome
( O
P O
= O
.05 O
) O
. O
The O
change O
in O
schedule O
of O
paclitaxel O
from O
once O
every O
3 O
weeks O
to O
a O
more O
frequent O
administration O
significantly O
improved O
the O
ability O
to O
eradicate O
invasive O
cancer O
in O
the O
breast O
and O
lymph O
nodes O
. O

Maintaining O
normal O
hemoglobin O
levels O
with O
epoetin B-intervention
alfa I-intervention
in O
mainly O
nonanemic B-eligibility
patients I-eligibility
with I-eligibility
metastatic I-eligibility
breast I-eligibility
cancer I-eligibility
receiving I-eligibility
first I-eligibility
- I-eligibility
line I-eligibility
chemotherapy I-eligibility
: O
a O
survival O
study O
. O
To O
evaluate O
the O
effect O
on O
survival O
and O
quality O
of O
life O
of O
maintaining O
hemoglobin O
( O
Hb O
) O
in O
the O
range O
of O
12 O
to O
14 O
g O
/ O
dL O
with O
epoetin O
alfa O
versus O
placebo O
in O
women O
with O
metastatic O
breast O
cancer O
( O
MBC O
) O
receiving O
first O
- O
line O
chemotherapy O
. O
Eligible O
patients O
were O
randomly O
assigned O
to O
receive O
epoetin O
alfa O
40,000 O
U O
once O
weekly O
or O
placebo B-control
for O
12 O
months O
. O
Study O
drug O
was O
initiated O
if O
baseline O
Hb O
was O
< O
or O
= O
13 O
g O
/ O
dL O
or O
when O
Hb O
decreased O
to O
< O
or O
= O
13g O
/ O
dL O
during O
the O
study O
. O
The O
primary O
end O
point O
was O
12 B-outcome-measure
- I-outcome-measure
month I-outcome-measure
overall I-outcome-measure
survival I-outcome-measure
( I-outcome-measure
OS I-outcome-measure
) I-outcome-measure
. O
The O
study O
drug O
administration O
was O
stopped O
early O
in O
accordance O
with O
a O
recommendation O
from O
the O
Independent O
Data O
Monitoring O
Committee O
because O
of O
higher O
mortality O
in O
the O
group O
treated O
with O
epoetin O
alfa O
. O
Enrollment O
had O
been O
completed O
, O
with O
939 B-total-participants
patients O
enrolled O
( O
epoetin O
alfa O
, O
n O
= O
469 B-intervention-participants
; O
placebo O
, O
n O
= O
470 B-control-participants
) O
. O
Most O
patients O
had O
Hb O
more O
than O
12 O
g O
/ O
dL O
at O
baseline O
( O
median O
Hb O
, O
12.8 O
g O
/ O
dL O
) O
or O
during O
the O
study O
. O
From O
the O
final O
analysis O
, O
12 B-outcome
- I-outcome
month I-outcome
OS I-outcome
was O
70 B-iv-bin-percent
% I-iv-bin-percent
for O
epoetin O
alfa O
recipients O
and O
76 B-cv-bin-percent
% I-cv-bin-percent
for O
placebo O
recipients O
( O
P O
= O
.01 O
) O
. O
Optimal B-outcome
tumor I-outcome
response I-outcome
and O
time B-outcome
to I-outcome
disease I-outcome
progression I-outcome
were O
similar O
between O
groups O
. O
The O
reason O
for O
the O
difference O
in O
mortality O
between O
groups O
could O
not O
be O
determined O
from O
additional O
subsequent O
analyses O
involving O
both O
study O
data O
and O
chart O
review O
. O
In O
this O
trial O
, O
the O
use O
of O
epoetin O
alfa O
to O
maintain O
high O
Hb O
targets O
in O
women O
with O
MBC O
, O
most O
of O
whom O
did O
not O
have O
anemia O
at O
the O
start O
of O
treatment O
, O
was O
associated O
with O
decreased O
survival O
. O
Additional O
research O
is O
required O
to O
clarify O
the O
potential O
impact O
of O
erythropoietic O
agents O
on O
survival O
when O
the O
Hb O
target O
range O
is O
10 O
to O
12 O
g O
/ O
dL. O

Pathological O
complete O
response O
rates O
comparing O
3 O
versus O
6 O
cycles O
of O
epidoxorubicin B-intervention
and I-intervention
docetaxel I-intervention
in O
the O
neoadjuvant O
setting O
of O
patients O
with O
stage O
II O
and O
III O
breast O
cancer O
. O
We O
conducted O
a O
prospective O
randomized O
study O
to O
compare O
the O
results O
of O
3 O
cycles O
of O
epidoxorubicin O
/ O
docetaxel O
to O
6 B-control
cycles I-control
of I-control
epidoxorubicin I-control
/ I-control
docetaxel I-control
prior O
to O
surgery O
in O
breast O
cancer O
patients O
with O
clinical O
stages O
II O
and O
III O
. O
Forty B-total-participants
- I-total-participants
five I-total-participants
patients B-eligibility
eligible I-eligibility
for I-eligibility
neoadjuvant I-eligibility
chemotherapy I-eligibility
were O
randomly O
assigned O
to O
receive O
either O
3 O
( O
group O
1 O
) O
or O
6 O
( O
group O
2 O
) O
cycles O
of O
epidoxorubicin O
/ O
docetaxel O
prior O
to O
surgery O
. O
Chemotherapy O
consisted O
of O
epidoxorubicin O
75 O
mg O
/ O
m O
and O
docetaxel O
75 O
mg O
/ O
m O
on O
day O
1 O
in O
3 O
- O
week O
cycles O
. O
The O
primary O
endpoint O
was O
the O
pathological B-outcome-measure
complete I-outcome-measure
response I-outcome-measure
( I-outcome-measure
pCR I-outcome-measure
) I-outcome-measure
rate I-outcome-measure
; O
secondary O
endpoints O
were O
the O
rates B-outcome-measure
of I-outcome-measure
breast I-outcome-measure
- I-outcome-measure
conserving I-outcome-measure
surgery I-outcome-measure
and O
the O
axillary B-outcome-measure
lymph I-outcome-measure
node I-outcome-measure
status I-outcome-measure
in O
both O
groups O
. O
A O
pCR B-outcome
occurred O
in O
10 B-iv-bin-percent
% I-iv-bin-percent
( O
two B-iv-bin-abs
of O
20 B-intervention-participants
) O
in O
Group O
1 O
and O
in O
36 B-cv-bin-percent
% I-cv-bin-percent
( O
nine B-cv-bin-abs
of O
25 B-control-participants
) O
in O
Group O
2 O
, O
which O
was O
statistically O
significant O
( O
p O
= O
0.045 O
) O
. O
Breast B-outcome
- I-outcome
conserving I-outcome
surgery I-outcome
could I-outcome
be I-outcome
performed I-outcome
in O
70 B-iv-bin-percent
% I-iv-bin-percent
( O
14 B-iv-bin-abs
of O
20 B-intervention-participants
) O
in O
Group O
1 O
and O
in O
76 B-cv-bin-percent
% I-cv-bin-percent
( O
19 B-cv-bin-abs
of O
25 B-control-participants
) O
in O
Group O
2 O
( O
p O
= O
0.065 O
) O
. O
Axillary B-outcome
lymph I-outcome
node I-outcome
status I-outcome
was I-outcome
negative I-outcome
in O
45 B-iv-bin-percent
% I-iv-bin-percent
( O
nine B-iv-bin-abs
of O
20 B-intervention-participants
) O
in O
Group O
1 O
and O
52 B-cv-bin-percent
% I-cv-bin-percent
( O
13 B-cv-bin-abs
of O
25 B-control-participants
) O
in O
Group O
2 O
( O
p O
= O
0.86 O
) O
. O
We O
conclude O
that O
6 O
cycles O
of O
pre O
- O
operative O
epidoxorubicin O
/ O
docetaxel O
versus O
3 O
cycles O
of O
pre O
- O
operative O
epidoxorubicin O
/ O
docetaxel O
significantly O
increases O
the O
pCR O
rates O
for O
breast O
cancer O
patients O
. O

Role O
of O
detection O
method O
in O
predicting O
breast O
cancer O
survival O
: O
analysis O
of O
randomized O
screening O
trials O
. O
Screening O
mammography O
detects O
breast O
cancers O
earlier O
than O
those O
detected O
symptomatically O
, O
and O
so O
mammographically O
detected O
breast O
cancers O
tend O
to O
have O
better O
prognoses O
. O
The O
so O
- O
called O
stage O
shift O
that O
results O
from O
screen O
detection O
is O
subject O
to O
lead O
- O
time O
and O
length O
biases O
, O
and O
so O
earlier O
detection O
may O
not O
translate O
into O
longer O
survival O
. O
We O
used O
data O
from O
three O
large O
breast O
cancer O
screening O
trials O
-- O
Health O
Insurance O
Plan O
( O
HIP O
) O
of O
New B-location
York I-location
and O
two O
Canadian B-location
National O
Breast O
Cancer O
Screening O
Studies O
( O
CNBSS O
) O
-- O
to O
investigate O
survival O
benefits O
of O
breast O
cancer O
screening O
beyond O
stage O
shift O
. O
We O
also O
address O
whether O
method O
of O
detection O
is O
an O
independent O
prognostic O
factor O
in O
breast O
cancer O
. O
The O
HIP O
trial O
randomly O
assigned O
approximately O
62,000 B-total-participants
women O
to O
screening B-intervention
and O
control B-control
groups O
. O
The O
two O
CNBSS O
trial O
cohorts O
CNBSS-1 O
and O
CNBSS-2 O
included O
a O
total O
of O
44,970 B-intervention-participants
women O
in O
the O
screening O
group O
and O
44,961 B-control-participants
in O
the O
control O
group O
. O
After O
adjusting O
for O
stage O
and O
other O
tumor O
characteristics O
in O
a O
Cox O
proportional O
hazards O
model O
, O
survival O
distributions O
were O
compared O
by O
method O
of O
breast O
cancer O
detection O
with O
both O
univariate O
and O
multivariable O
analyses O
. O
All O
P O
values O
are O
two O
- O
sided O
. O
Breast B-outcome
cancers I-outcome
detected I-outcome
by I-outcome
screening I-outcome
mammography I-outcome
had O
a O
shift O
in O
stage O
distribution O
to O
earlier O
stages O
( O
for O
HIP O
, O
P O
< O
.001 O
; O
for O
CNBSS-1 O
, O
P O
= O
.03 O
; O
and O
for O
CNBSS-2 O
, O
P O
< O
.001 O
) O
. O
After O
adjusting O
for O
tumor O
size O
, O
lymph O
node O
status O
, O
and O
disease O
stage O
in O
a O
Cox O
proportional O
hazards O
model O
, O
method O
of O
detection O
was O
a O
statistically O
significant O
independent O
predictor O
of O
disease O
- O
specific O
survival O
. O
Patients O
with O
interval O
cancers O
had O
a O
53 B-iv-bin-percent
% I-iv-bin-percent
( O
95 O
% O
confidence O
interval O
[ O
CI O
] O
= O
17 O
% O
to O
100 O
% O
) O
greater O
hazard O
of O
death B-outcome
from I-outcome
breast I-outcome
cancer I-outcome
than O
patients O
with O
screen O
- O
detected O
cancers O
, O
and O
patients O
with O
cancer O
in O
the O
control O
groups O
had O
a O
36 B-cv-bin-percent
% I-cv-bin-percent
( O
95 O
% O
CI O
= O
10 O
% O
to O
68 O
% O
) O
greater O
hazard O
of O
death O
than O
patients O
with O
screen O
- O
detected O
cancer O
. O
There O
was O
an O
apparent O
survival B-outcome
benefit I-outcome
beyond O
stage O
shift O
for O
patients O
with O
screen O
- O
detected O
breast O
cancers O
compared O
with O
patients O
with O
breast O
cancers O
detected O
otherwise O
. O
Method O
of O
detection O
appears O
to O
be O
an O
important O
prognostic O
factor O
, O
even O
after O
adjusting O
for O
known O
tumor O
characteristics O
. O
This O
finding O
suggests O
that O
clinical O
trialists O
should O
routinely O
collect O
information O
about O
method O
of O
detection O
. O

[ O
Effect O
of O
preoperative B-intervention
lymphatic I-intervention
chemotherapy I-intervention
on O
Bcl-2 O
and O
Bax O
expression O
in O
axillary O
metastasis O
of O
breast O
cancer O
] O
. O
To O
observe O
the O
expression O
of O
Bcl-2 O
and O
Bax O
proteins O
and O
cell O
apoptosis O
induced O
by O
preoperative O
lymphatic O
chemotherapy O
with O
epirubicin O
- O
activated O
carbon O
suspension O
( O
Epi O
- O
CH O
) O
in O
the O
cells O
of O
axillary O
metastatic O
lymph O
node O
of O
breast O
cancer O
and O
investigate O
the O
mechanism O
. O
Sixty B-total-participants
patients O
with O
breast B-eligibility
cancer I-eligibility
of I-eligibility
stages I-eligibility
II I-eligibility
- I-eligibility
III I-eligibility
were O
randomly O
divided O
into O
two O
groups O
. O
Forty B-intervention-participants
patients O
in O
Epi O
- O
CH O
group O
were O
injected O
with O
10 O
mg O
Epi O
- O
CH O
in O
the O
tissue O
around O
the O
primary O
tumor O
or O
biopsy O
excision O
72 O
h O
before O
operation O
. O
Twenty B-control-participants
patients O
in O
the O
control B-control
group O
were O
injected O
with O
10 O
mg O
epirubicin O
solution O
in O
the O
same O
region O
. O
The O
stained O
lymph O
nodes O
full O
of O
tumor O
cells O
in O
Epi O
- O
CH O
group O
and O
the O
non O
- O
stained O
nodes O
in O
the O
control O
group O
were O
selected O
for O
apoptotic O
detection O
by O
TUNEL O
method O
. O
The O
expression O
of O
Bcl-2 O
and O
Bax O
proteins O
were O
examined O
by O
SP O
immunohistochemistry O
. O
The O
apoptotic B-outcome
index I-outcome
of O
the O
metastatic O
cancer O
cells O
in O
Epi O
- O
CH O
group O
was O
increased O
remarkably O
in O
comparison O
with O
that O
in O
the O
control O
group O
[ O
( O
9.5 B-iv-cont-mean
+/- O
2.7 B-iv-cont-sd
) O
% O
vs O
( O
3.8 B-cv-cont-mean
+/- O
1.4 B-cv-cont-sd
) O
% O
, O
P<0.01 O
) O
. O
Compared O
with O
the O
control O
group O
, O
the O
expression B-outcome
of I-outcome
Bcl-2 I-outcome
and I-outcome
Bax I-outcome
proteins I-outcome
were O
up O
- O
regulated O
significantly O
in O
Epi O
- O
CH O
group O
( O
P<0.05 O
and O
P<0.01 O
, O
respectively O
) O
, O
resulting O
in O
decreased O
ratio B-outcome
of I-outcome
Bcl-2 I-outcome
/ I-outcome
Bax I-outcome
. O
Lymphatic O
chemotherapy O
can O
promote O
cell O
apotosis O
in O
axillary O
metastasis O
of O
breast O
cancer O
, O
which O
may O
result O
from O
decreased O
ratio O
of O
Bcl-2 O
/ O
Bax O
. O

Randomized O
phase O
III O
study O
of O
docetaxel B-intervention
compared O
with O
paclitaxel B-control
in O
metastatic O
breast O
cancer O
. O
This O
randomized O
, O
controlled O
, O
multicenter O
, O
open O
- O
label O
, O
phase O
III O
study O
compared O
docetaxel O
versus O
paclitaxel O
in O
patients B-eligibility
with I-eligibility
advanced I-eligibility
breast I-eligibility
cancer I-eligibility
that I-eligibility
had I-eligibility
progressed I-eligibility
after I-eligibility
an I-eligibility
anthracycline I-eligibility
- I-eligibility
containing I-eligibility
chemotherapy I-eligibility
regimen I-eligibility
. O
Patients O
( O
n O
= O
449 B-total-participants
) O
were O
randomly O
assigned O
to O
receive O
either O
docetaxel O
100 O
mg O
/ O
m2 O
( O
n O
= O
225 B-intervention-participants
) O
or O
paclitaxel O
175 O
mg O
/ O
m2 O
( O
n O
= O
224 B-control-participants
) O
on O
day O
1 O
, O
every O
21 O
days O
until O
tumor O
progression O
, O
unacceptable O
toxicity O
, O
or O
withdrawal O
of O
consent O
. O
In O
the O
intent O
- O
to O
- O
treat O
population O
, O
both O
the O
median B-outcome
overall I-outcome
survival I-outcome
( O
OS O
, O
15.4 B-iv-cont-median
v O
12.7 B-cv-cont-median
months I-cv-cont-median
; O
hazard O
ratio O
[ O
HR O
] O
, O
1.41 O
; O
95 O
% O
CI O
, O
1.15 O
to O
1.73 O
; O
P O
= O
.03 O
) O
and O
the O
median B-outcome
time I-outcome
to I-outcome
progression I-outcome
( O
TTP O
, O
5.7 B-iv-cont-median
months I-iv-cont-median
v O
3.6 B-cv-cont-median
months I-cv-cont-median
; O
HR O
, O
1.64 O
; O
95 O
% O
CI O
, O
1.33 O
to O
2.02 O
; O
P O
< O
.0001 O
) O
for O
docetaxel O
were O
significantly O
longer O
than O
for O
paclitaxel O
, O
and O
the O
overall B-outcome
response I-outcome
rate I-outcome
( O
ORR B-outcome
, O
32 B-iv-bin-percent
% I-iv-bin-percent
v O
25 B-cv-bin-percent
% I-cv-bin-percent
; O
P O
= O
.10 O
) O
was O
higher O
for O
docetaxel O
. O
These O
results O
were O
confirmed O
by O
multivariate O
analyses O
. O
The O
incidence O
of O
treatment O
- O
related O
hematologic B-outcome
and I-outcome
nonhematologic I-outcome
toxicities I-outcome
was O
greater O
for O
docetaxel O
than O
for O
paclitaxel O
; O
however O
, O
quality O
- O
of O
- O
life O
scores O
were O
not O
statistically O
different O
between O
treatment O
groups O
over O
time O
. O
Docetaxel O
was O
superior O
to O
paclitaxel O
in O
terms O
of O
OS B-outcome
and O
TTP B-outcome
. O
ORR B-outcome
was O
higher O
for O
docetaxel O
. O
Hematologic B-outcome
and I-outcome
nonhematologic I-outcome
toxicities I-outcome
occurred O
more O
frequently O
in O
the O
docetaxel O
group O
. O
The O
global O
quality O
- O
of O
- O
life O
scores O
were O
similar O
for O
both O
agents O
over O
time O
. O

Gabapentin B-intervention
for O
hot B-condition
flashes I-condition
in O
420 B-total-participants
women O
with O
breast O
cancer O
: O
a O
randomised O
double O
- O
blind O
placebo O
- O
controlled O
trial O
. O
Most O
women O
receiving O
systemic O
therapy O
for O
breast O
cancer O
experience O
hot O
flashes O
. O
We O
undertook O
a O
randomised O
, O
double O
- O
blind O
, O
placebo O
- O
controlled O
, O
multi O
- O
institutional O
trial O
to O
assess O
the O
efficacy O
of O
gabapentin O
in O
controlling O
hot O
flashes O
in O
women O
with O
breast O
cancer O
. O
420 B-total-participants
women B-eligibility
with I-eligibility
breast I-eligibility
cancer I-eligibility
who I-eligibility
were I-eligibility
having I-eligibility
two I-eligibility
or I-eligibility
more I-eligibility
hot I-eligibility
flashes I-eligibility
per I-eligibility
day I-eligibility
were O
randomly O
assigned O
placebo B-control
, O
gabapentin O
300 O
mg O
/ O
day O
, O
or O
gabapentin O
900 O
mg O
/ O
day O
by O
mouth O
in O
three O
divided O
doses O
for O
8 O
weeks O
. O
Each O
patient O
kept O
a O
1 O
- O
week O
, O
self O
- O
report O
diary O
on O
the O
frequency O
, O
severity O
, O
and O
duration O
of O
hot O
flashes O
before O
the O
start O
of O
the O
study O
and O
during O
weeks O
4 O
and O
8 O
of O
treatment O
. O
Analyses O
were O
by O
intention O
to O
treat O
. O
Evaluable O
data O
were O
available O
on O
371 B-total-participants
participants O
at O
4 O
weeks O
( O
119 B-control-participants
placebo O
, O
123 B-intervention-participants
gabapentin O
300 O
mg O
, O
and O
129 B-intervention-participants
gabapentin O
900 O
mg O
) O
and O
347 B-total-participants
at O
8 O
weeks O
( O
113 B-control-participants
placebo O
, O
114 B-intervention-participants
gabapentin O
300 O
mg O
, O
and O
120 B-intervention-participants
gabapentin O
900 O
mg O
) O
. O
The O
percentage O
decreases O
in O
hot B-outcome
- I-outcome
flash I-outcome
severity I-outcome
score I-outcome
between O
baseline O
and O
weeks B-outcome
4 I-outcome
and I-outcome
8 I-outcome
, O
respectively O
were O
: O
21 B-cv-bin-percent
% I-cv-bin-percent
( O
95 O
% O
CI O
12 O
to O
30 O
) O
and O
15 B-cv-bin-percent
% I-cv-bin-percent
( O
1 O
to O
29 O
) O
in O
the O
placebo O
group O
; O
33 B-iv-bin-percent
% I-iv-bin-percent
( O
23 O
to O
43 O
) O
and O
31 B-iv-bin-percent
% I-iv-bin-percent
( O
16 O
to O
46 O
) O
in O
the O
group O
assigned O
gabapentin O
300 O
mg O
; O
and O
49 B-iv-bin-percent
% I-iv-bin-percent
( O
42 O
to O
56 O
) O
and O
46 B-iv-bin-percent
% I-iv-bin-percent
( O
34 O
to O
58 O
) O
in O
the O
group O
assigned O
gabapentin O
900 O
mg O
. O
The O
differences O
between O
the O
groups O
were O
significant O
( O
p O
= O
0.0001 O
at O
4 O
weeks O
and O
p O
= O
0.007 O
at O
8 O
weeks O
by O
ANCOVA O
for O
overall O
treatment O
effect O
, O
adjusted O
for O
baseline O
values O
) O
; O
only O
the O
higher O
dose O
of O
gabapentin O
was O
associated O
with O
significant O
decreases O
in O
hot B-outcome
- I-outcome
flash I-outcome
frequency I-outcome
and I-outcome
severity I-outcome
. O
Gabapentin O
is O
effective O
in O
the O
control O
of O
hot O
flashes O
at O
a O
dose O
of O
900 O
mg O
/ O
day O
, O
but O
not O
at O
a O
dose O
of O
300 O
mg O
/ O
day O
. O
This O
drug O
should O
be O
considered O
for O
treatment O
of O
hot O
flashes O
in O
women O
with O
breast O
cancer O
. O

Phase O
III O
trial O
of O
nanoparticle B-intervention
albumin I-intervention
- I-intervention
bound I-intervention
paclitaxel I-intervention
compared O
with O
polyethylated B-control
castor I-control
oil I-control
- I-control
based I-control
paclitaxel I-control
in O
women O
with O
breast O
cancer O
. O
ABI-007 O
, O
the O
first O
biologically O
interactive O
albumin O
- O
bound O
paclitaxel O
in O
a O
nanameter O
particle O
, O
free O
of O
solvents O
, O
was O
compared O
with O
polyethylated O
castor O
oil O
- O
based O
standard O
paclitaxel O
in O
patients B-eligibility
with I-eligibility
metastatic I-eligibility
breast I-eligibility
cancer I-eligibility
( I-eligibility
MBC I-eligibility
) I-eligibility
. O
This O
phase O
III O
study O
was O
performed O
to O
confirm O
preclinical O
studies O
demonstrating O
superior O
efficacy O
and O
reduced O
toxicity O
of O
ABI-007 O
compared O
with O
standard O
paclitaxel O
. O
Patients O
were O
randomly O
assigned O
to O
3 O
- O
week O
cycles O
of O
either O
ABI-007 O
260 O
mg O
/ O
m O
( O
2 O
) O
intravenously O
without O
premedication O
( O
n O
= O
229 B-intervention-participants
) O
or O
standard O
paclitaxel O
175 O
mg O
/ O
m O
( O
2 O
) O
intravenously O
with O
premedication O
( O
n O
= O
225 B-control-participants
) O
. O
ABI-007 O
demonstrated O
significantly O
higher O
response B-outcome
rates I-outcome
compared O
with O
standard O
paclitaxel O
( O
33 B-iv-bin-percent
% I-iv-bin-percent
v O
19 B-cv-bin-percent
% I-cv-bin-percent
, O
respectively O
; O
P O
= O
.001 O
) O
and O
significantly O
longer O
time B-outcome
to I-outcome
tumor I-outcome
progression I-outcome
( O
23.0 B-iv-cont-median
v O
16.9 B-cv-cont-median
weeks I-cv-cont-median
, O
respectively O
; O
hazard O
ratio O
= O
0.75 O
; O
P O
= O
.006 O
) O
. O
The O
incidence B-outcome
of I-outcome
grade I-outcome
4 I-outcome
neutropenia I-outcome
was O
significantly O
lower O
for O
ABI-007 O
compared O
with O
standard O
paclitaxel O
( O
9 B-iv-bin-percent
% I-iv-bin-percent
v O
22 B-cv-bin-percent
% I-cv-bin-percent
, O
respectively O
; O
P O
< O
.001 O
) O
despite O
a O
49 O
% O
higher O
paclitaxel O
dose O
. O
Febrile B-outcome
neutropenia I-outcome
was O
uncommon O
( O
< O
2 O
% O
) O
, O
and O
the O
incidence O
did O
not O
differ O
between O
the O
two O
study O
arms O
. O
Grade B-outcome
3 I-outcome
sensory I-outcome
neuropathy I-outcome
was O
more O
common O
in O
the O
ABI-007 O
arm O
than O
in O
the O
standard O
paclitaxel O
arm O
( O
10 B-iv-bin-percent
% I-iv-bin-percent
v O
2 B-cv-bin-percent
% I-cv-bin-percent
, O
respectively O
; O
P O
< O
.001 O
) O
but O
was O
easily O
managed O
and O
improved O
rapidly O
( O
median O
, O
22 O
days O
) O
. O
No O
hypersensitivity B-outcome
reactions I-outcome
occurred O
with O
ABI-007 O
despite O
the O
absence O
of O
premedication O
and O
shorter O
administration O
time O
. O
ABI-007 O
demonstrated O
greater O
efficacy O
and O
a O
favorable O
safety O
profile O
compared O
with O
standard O
paclitaxel O
in O
this O
patient O
population O
. O
The O
improved O
therapeutic O
index O
and O
elimination O
of O
corticosteroid O
premedication O
required O
for O
solvent O
- O
based O
taxanes O
make O
the O
novel O
albumin O
- O
bound O
paclitaxel O
ABI-007 O
an O
important O
advance O
in O
the O
treatment O
of O
MBC O
. O

Trastuzumab B-intervention
after O
adjuvant O
chemotherapy O
in O
HER2 B-eligibility
- I-eligibility
positive I-eligibility
breast I-eligibility
cancer I-eligibility
. O
Trastuzumab O
, O
a O
recombinant O
monoclonal O
antibody O
against O
HER2 O
, O
has O
clinical O
activity O
in O
advanced O
breast O
cancer O
that O
overexpresses O
HER2 O
. O
We O
investigated O
its O
efficacy O
and O
safety O
after O
excision O
of O
early O
- O
stage O
breast O
cancer O
and O
completion O
of O
chemotherapy O
. O
This O
international O
, O
multicenter O
, O
randomized O
trial O
compared O
one O
or O
two O
years O
of O
trastuzumab O
given O
every O
three O
weeks O
with O
observation O
in O
patients O
with O
HER2 O
- O
positive O
and O
either O
node O
- O
negative O
or O
node O
- O
positive O
breast O
cancer O
who O
had O
completed O
locoregional O
therapy O
and O
at O
least O
four O
cycles O
of O
neoadjuvant O
or O
adjuvant O
chemotherapy O
. O
Data O
were O
available O
for O
1694 B-total-participants
women O
randomly O
assigned O
to O
two O
years O
of O
treatment O
with O
trastuzumab O
, O
1694 B-intervention-participants
women O
assigned O
to O
one O
year O
of O
trastuzumab O
, O
and O
1693 B-control-participants
women O
assigned O
to O
observation B-control
. O
We O
report O
here O
the O
results O
only O
of O
treatment O
with O
trastuzumab O
for O
one O
year O
or O
observation O
. O
At O
the O
first O
planned O
interim O
analysis O
( O
median O
follow O
- O
up O
of O
one O
year O
) O
, O
347 O
events B-outcome
( O
recurrence B-outcome
of I-outcome
breast I-outcome
cancer I-outcome
, I-outcome
contralateral I-outcome
breast I-outcome
cancer I-outcome
, I-outcome
second I-outcome
nonbreast I-outcome
malignant I-outcome
disease I-outcome
, I-outcome
or I-outcome
death I-outcome
) O
were O
observed O
: O
127 B-iv-bin-abs
events O
in O
the O
trastuzumab O
group O
and O
220 B-cv-bin-abs
in O
the O
observation O
group O
. O
The O
unadjusted O
hazard O
ratio O
for O
an O
event O
in O
the O
trastuzumab O
group O
, O
as O
compared O
with O
the O
observation O
group O
, O
was O
0.54 O
( O
95 O
percent O
confidence O
interval O
, O
0.43 O
to O
0.67 O
; O
P<0.0001 O
by O
the O
log O
- O
rank O
test O
, O
crossing O
the O
interim O
analysis O
boundary O
) O
, O
representing O
an O
absolute O
benefit O
in O
terms O
of O
disease B-outcome
- I-outcome
free I-outcome
survival I-outcome
at I-outcome
two I-outcome
years I-outcome
of O
8.4 O
percentage O
points O
. O
Overall B-outcome
survival I-outcome
in O
the O
two O
groups O
was O
not O
significantly O
different O
( O
29 B-iv-bin-abs
deaths B-outcome
with O
trastuzumab O
vs. O
37 B-cv-bin-abs
with O
observation O
) O
. O
Severe B-outcome
cardiotoxicity I-outcome
developed O
in O
0.5 B-iv-bin-percent
percent I-iv-bin-percent
of O
the O
women O
who O
were O
treated O
with O
trastuzumab O
. O
One O
year O
of O
treatment O
with O
trastuzumab O
after O
adjuvant O
chemotherapy O
significantly O
improves O
disease O
- O
free O
survival O
among O
women O
with O
HER2 O
- O
positive O
breast O
cancer O
. O
( O
ClinicalTrials O
. O
gov O
number O
, O
NCT00045032 O
. O
) O

Tamoxifen B-intervention
versus O
control B-control
after O
adjuvant O
, O
risk O
- O
adapted O
chemotherapy O
in O
postmenopausal B-eligibility
, I-eligibility
receptor I-eligibility
- I-eligibility
negative I-eligibility
patients I-eligibility
with I-eligibility
breast I-eligibility
cancer I-eligibility
: O
a O
randomized O
trial O
( O
GABG O
- O
IV O
D-93 O
) O
-- O
the O
German B-location
Adjuvant O
Breast O
Cancer O
Group O
. O
To O
investigate O
the O
effect O
of O
adjuvant O
sequential O
tamoxifen O
after O
chemotherapy O
in O
postmenopausal O
patients O
with O
hormone O
receptor O
- O
negative O
breast O
cancer O
. O
Patients O
were O
randomly O
assigned O
to O
oral O
tamoxifen O
( O
30 O
mg O
daily O
for O
5 O
years O
; O
n O
= O
421 B-intervention-participants
) O
or O
no O
additional O
treatment O
( O
n O
= O
408 B-control-participants
) O
after O
risk O
- O
adapted O
polychemotherapy O
consisting O
of O
three O
28 O
- O
day O
cycles O
of O
CMF O
( O
cyclophosphamide O
, O
500 O
mg O
/ O
m O
( O
2 O
) O
, O
methotrexate O
, O
40 O
mg O
/ O
m O
( O
2 O
) O
, O
and O
fluorouracil O
, O
600 O
mg O
/ O
m O
( O
2 O
) O
) O
in O
patients O
with O
negative O
or O
one O
to O
three O
positive O
lymph O
nodes O
and O
four O
21 O
- O
day O
cycles O
of O
epirubicin O
90 O
mg O
/ O
m O
( O
2 O
) O
, O
cyclophosphamide O
600 O
mg O
/ O
m O
( O
2 O
) O
followed O
by O
three O
cycles O
of O
CMF O
in O
patients O
with O
four O
to O
nine O
positive O
lymph O
nodes O
. O
Thirty O
- O
six O
percent O
of O
the O
patients O
included O
were O
older O
than O
60 B-age
years I-age
, O
63 O
% O
were O
node O
negative O
, O
13 O
% O
had O
four O
to O
nine O
positive O
nodes O
, O
55 O
% O
had O
tumor O
grade O
3 O
, O
and O
41 O
% O
received O
breast O
- O
preserving O
surgery O
. O
At O
5.3 O
years O
' O
median O
follow O
- O
up O
, O
the O
first B-outcome
event I-outcome
of I-outcome
failure I-outcome
( I-outcome
recurrence I-outcome
, I-outcome
secondary I-outcome
tumor I-outcome
, I-outcome
or I-outcome
death I-outcome
) I-outcome
had O
occurred O
in O
123 B-iv-bin-abs
patients O
in O
the O
tamoxifen O
group O
and O
107 B-cv-bin-abs
patients O
of O
the O
control O
group O
. O
Event B-outcome
- I-outcome
free I-outcome
survival I-outcome
rates I-outcome
after I-outcome
5 I-outcome
years I-outcome
were O
70.3 B-iv-bin-percent
% I-iv-bin-percent
( O
95 O
% O
CI O
, O
65.5 O
% O
to O
75.0 O
% O
) O
and O
72.8 B-cv-bin-percent
% I-cv-bin-percent
( O
95 O
% O
CI O
, O
68.2 O
% O
to O
77.5 O
% O
) O
for O
the O
tamoxifen O
and O
control O
groups O
, O
respectively O
. O
The O
estimated B-outcome
hazard I-outcome
ratio I-outcome
of O
tamoxifen O
versus O
control O
was O
1.13 O
( O
95 O
% O
CI O
, O
0.87 O
to O
1.48 O
; O
P O
= O
.34 O
) O
, O
which O
gives O
no O
indication O
of O
an O
additional O
benefit O
of O
tamoxifen O
in O
these O
patients O
. O
This O
study O
contributes O
substantially O
to O
finalization O
of O
the O
presently O
emerging O
evidence O
that O
tamoxifen O
does O
not O
benefit O
women O
with O
receptor O
- O
negative O
breast O
cancer O
after O
chemotherapy O
. O

Tamoxifen B-intervention
for O
the O
prevention O
of O
breast O
cancer O
: O
current O
status O
of O
the O
National O
Surgical O
Adjuvant O
Breast O
and O
Bowel O
Project O
P-1 O
study O
. O
Initial O
findings O
from O
the O
National O
Surgical O
Adjuvant O
Breast O
and O
Bowel O
Project O
Breast O
Cancer O
Prevention O
Trial O
( O
P-1 O
) O
demonstrated O
that O
tamoxifen O
reduced O
the O
risk O
of O
estrogen O
receptor O
- O
positive O
tumors O
and O
osteoporotic O
fractures O
in O
women B-eligibility
at I-eligibility
increased I-eligibility
risk I-eligibility
for I-eligibility
breast I-eligibility
cancer I-eligibility
. O
Side O
effects O
of O
varying O
clinical O
significance O
were O
observed O
. O
The O
trial O
was O
unblinded O
because O
of O
the O
positive O
results O
, O
and O
follow O
- O
up O
continued O
. O
This O
report O
updates O
our O
initial O
findings O
. O
Women O
( O
n O
= O
13,388 B-total-participants
) O
were O
randomly O
assigned O
to O
receive O
placebo B-control
or O
tamoxifen O
for O
5 O
years O
. O
Rates O
of O
breast O
cancer O
and O
other O
events O
were O
compared O
by O
the O
use O
of O
risk O
ratios O
( O
RRs O
) O
and O
95 O
% O
confidence O
intervals O
( O
CIs O
) O
. O
Estimates O
of O
the O
net O
benefit O
from O
5 O
years O
of O
tamoxifen O
therapy O
were O
compared O
by O
age O
, O
race O
, O
and O
categories O
of O
predicted O
breast O
cancer O
risk O
. O
Statistical O
tests O
were O
two O
- O
sided O
. O
After O
7 O
years O
of O
follow O
- O
up O
, O
the O
cumulative B-outcome
rate I-outcome
of I-outcome
invasive I-outcome
breast I-outcome
cancer I-outcome
was O
reduced O
from O
42.5 B-cv-bin-abs
per O
1000 B-control-participants
women O
in O
the O
placebo O
group O
to O
24.8 B-iv-bin-abs
per O
1000 B-intervention-participants
women O
in O
the O
tamoxifen O
group O
( O
RR O
= O
0.57 O
, O
95 O
% O
CI O
= O
0.46 O
to O
0.70 O
) O
and O
the O
cumulative B-outcome
rate I-outcome
of I-outcome
noninvasive I-outcome
breast I-outcome
cancer I-outcome
was O
reduced O
from O
15.8 B-cv-bin-abs
per O
1000 B-control-participants
women O
in O
the O
placebo O
group O
to O
10.2 B-iv-bin-abs
per O
1000 B-intervention-participants
women O
in O
the O
tamoxifen O
group O
( O
RR O
= O
0.63 O
, O
95 O
% O
CI O
= O
0.45 O
to O
0.89 O
) O
. O
These O
reductions O
were O
similar O
to O
those O
seen O
in O
the O
initial O
report O
. O
Tamoxifen O
led O
to O
a O
32 B-iv-bin-percent
% I-iv-bin-percent
reduction B-outcome
in I-outcome
osteoporotic I-outcome
fractures I-outcome
( O
RR O
= O
0.68 O
, O
95 O
% O
CI O
= O
0.51 O
to O
0.92 O
) O
. O
Relative O
risks O
of O
stroke B-outcome
, O
deep B-outcome
- I-outcome
vein I-outcome
thrombosis I-outcome
, O
and O
cataracts B-outcome
( O
which O
increased O
with O
tamoxifen O
) O
and O
of O
ischemic B-outcome
heart I-outcome
disease I-outcome
and O
death B-outcome
( O
which O
were O
not O
changed O
with O
tamoxifen O
) O
were O
also O
similar O
to O
those O
initially O
reported O
. O
Risks B-outcome
of I-outcome
pulmonary I-outcome
embolism I-outcome
were O
approximately O
11 O
% O
lower O
than O
in O
the O
original O
report O
, O
and O
risks O
of O
endometrial O
cancer O
were O
about O
29 O
% O
higher O
, O
but O
these O
differences O
were O
not O
statistically O
significant O
. O
The O
net O
benefit O
achieved O
with O
tamoxifen O
varied O
according O
to O
age O
, O
race O
, O
and O
level O
of O
breast O
cancer O
risk O
. O
Despite O
the O
potential O
bias O
caused O
by O
the O
unblinding O
of O
the O
P-1 O
trial O
, O
the O
magnitudes O
of O
all O
beneficial O
and O
undesirable O
treatment O
effects O
of O
tamoxifen O
were O
similar O
to O
those O
initially O
reported O
, O
with O
notable O
reductions O
in O
breast O
cancer O
and O
increased O
risks O
of O
thromboembolic O
events O
and O
endometrial O
cancer O
. O
Readily O
identifiable O
subsets O
of O
individuals O
comprising O
2.5 O
million O
women O
could O
derive O
a O
net O
benefit O
from O
the O
drug O
. O

Phase O
III O
trial O
of O
epirubicin B-intervention
plus I-intervention
paclitaxel I-intervention
compared O
with O
epirubicin B-control
plus I-control
cyclophosphamide I-control
as O
first O
- O
line O
chemotherapy O
for O
metastatic O
breast O
cancer O
: O
United B-location
Kingdom I-location
National O
Cancer O
Research O
Institute O
trial O
AB01 O
. O
To O
compare O
the O
effectiveness O
and O
tolerability O
of O
epirubicin O
and O
paclitaxel O
( O
EP O
) O
with O
epirubicin O
and O
cyclophosphamide O
( O
EC O
) O
as O
first O
- O
line O
chemotherapy O
for O
metastatic O
breast O
cancer O
( O
MBC O
) O
. O
Patients B-eligibility
previously I-eligibility
untreated I-eligibility
with I-eligibility
chemotherapy I-eligibility
( I-eligibility
except I-eligibility
for I-eligibility
adjuvant I-eligibility
therapy I-eligibility
) I-eligibility
were O
randomly O
assigned O
to O
receive O
either O
EP O
( O
epirubicin O
75 O
mg O
/ O
m2 O
and O
paclitaxel O
200 O
mg O
/ O
m2 O
) O
or O
EC O
( O
epirubicin O
75 O
mg O
/ O
m2 O
and O
cyclophosphamide O
600 O
mg O
/ O
m2 O
) O
administered O
intravenously O
every O
3 O
weeks O
for O
a O
maximum O
of O
six O
cycles O
. O
The O
primary O
outcome O
was O
progression B-outcome-measure
- I-outcome-measure
free I-outcome-measure
survival I-outcome-measure
; O
secondary O
outcome O
measures O
were O
overall B-outcome-measure
survival I-outcome-measure
, O
response B-outcome-measure
rates I-outcome-measure
, O
and O
toxicity B-outcome-measure
. O
Between O
1996 O
and O
1999 O
, O
705 B-total-participants
patients O
( O
353 B-intervention-participants
EP O
patients O
and O
352 B-control-participants
EC O
patients O
) O
underwent O
random O
assignment O
. O
Patient O
characteristics O
were O
well O
matched O
between O
the O
two O
groups O
, O
and O
71 O
% O
of O
patients O
received O
six O
cycles O
of O
treatment O
. O
Objective B-outcome
response I-outcome
rates I-outcome
were O
65 B-iv-bin-percent
% I-iv-bin-percent
for O
the O
EP O
group O
and O
55 B-cv-bin-percent
% I-cv-bin-percent
for O
the O
EC O
group O
( O
P O
= O
.015 O
) O
. O
At O
the O
time O
of O
analysis O
, O
641 O
patients O
( O
91 O
% O
) O
had O
died B-outcome
. O
Median B-outcome
progression I-outcome
- I-outcome
free I-outcome
survival I-outcome
time I-outcome
was O
7.0 B-iv-cont-median
months I-iv-cont-median
for O
the O
EP O
group O
and O
7.1 B-cv-cont-median
months I-cv-cont-median
for O
the O
EC O
group O
( O
hazard O
ratio O
= O
1.07 O
; O
95 O
% O
CI O
, O
0.92 O
to O
1.24 O
; O
P O
= O
.41 O
) O
, O
and O
median B-outcome
overall I-outcome
survival I-outcome
time I-outcome
was O
13 B-iv-cont-median
months I-iv-cont-median
for O
the O
EP O
group O
and O
14 B-cv-cont-median
months I-cv-cont-median
for O
the O
EC O
group O
( O
hazard O
ratio O
= O
1.02 O
; O
95 O
% O
CI O
, O
0.87 O
to O
1.19 O
; O
P O
= O
.8 O
) O
. O
EP O
patients O
, O
compared O
with O
EC O
patients O
, O
had O
more O
grade B-outcome
3 I-outcome
and I-outcome
4 I-outcome
mucositis I-outcome
( O
6 B-iv-bin-percent
% I-iv-bin-percent
v O
2 B-cv-bin-percent
% I-cv-bin-percent
, O
respectively O
; O
P O
= O
.0006 O
) O
and O
grade B-outcome
3 I-outcome
and I-outcome
4 I-outcome
neurotoxicity I-outcome
( O
5 B-iv-bin-percent
% I-iv-bin-percent
v O
1 B-cv-bin-percent
% I-cv-bin-percent
, O
respectively O
; O
P O
< O
.0001 O
) O
. O
In O
terms O
of O
progression B-outcome
- I-outcome
free I-outcome
survival I-outcome
and I-outcome
overall I-outcome
survival I-outcome
, O
there O
was O
no O
evidence O
of O
a O
difference O
between O
EP O
and O
EC O
. O
The O
data O
demonstrate O
no O
additional O
advantage O
to O
using O
EP O
instead O
of O
EC O
as O
first O
- O
line O
chemotherapy O
for O
MBC O
in O
taxane O
- O
nave O
patients O
. O

Randomized O
clinical O
trial O
comparing O
blue B-intervention
dye I-intervention
with O
combined B-control
dye I-control
and I-control
isotope I-control
for O
sentinel O
lymph O
node O
biopsy O
in O
breast O
cancer O
. O
Use O
of O
blue O
dye O
alone O
as O
a O
marker O
for O
sentinel O
lymph O
node O
( O
SLN O
) O
biopsy O
is O
effective O
, O
but O
combining O
it O
with O
isotope O
marking O
can O
improve O
the O
success O
rate O
. O
Use O
of O
the O
isotope O
adds O
extra O
cost O
and O
there O
are O
potential O
radiation O
hazards O
. O
The O
two O
techniques O
were O
compared O
in O
a O
randomized O
trial O
. O
Women B-eligibility
with I-eligibility
early I-eligibility
breast I-eligibility
cancer I-eligibility
( I-eligibility
less I-eligibility
than I-eligibility
3 I-eligibility
cm I-eligibility
) I-eligibility
and I-eligibility
no I-eligibility
palpable I-eligibility
axillary I-eligibility
nodes I-eligibility
were O
recruited O
. O
Women O
older B-age
than I-age
70 I-age
years I-age
with O
multicentric O
cancers O
or O
previous O
surgery O
to O
the O
breast O
or O
axilla O
were O
excluded O
. O
Patients O
were O
randomized O
to O
either O
blue O
dye O
alone O
or O
combined O
mapping O
for O
SLN O
biopsy O
. O
All O
women O
had O
a O
level O
I O
and O
II O
axillary O
dissection O
after O
the O
SLN O
biopsy O
. O
A O
total O
of O
123 B-total-participants
patients O
were O
recruited O
, O
of O
whom O
five O
were O
excluded O
from O
analysis O
. O
Blue O
dye O
alone O
was O
used O
in O
57 B-intervention-participants
women O
and O
61 B-control-participants
had O
combined O
mapping O
. O
Baseline O
demographic O
data O
were O
similar O
in O
the O
two O
cohorts O
. O
The O
success B-outcome
rate I-outcome
of I-outcome
SLN I-outcome
biopsy I-outcome
was O
higher O
with O
combined O
mapping O
than O
with O
blue O
dye O
alone O
( O
100 B-cv-bin-percent
versus O
86 B-iv-bin-percent
per I-iv-bin-percent
cent I-iv-bin-percent
; O
P O
= O
0.002 O
) O
. O
The O
accuracy B-outcome
and I-outcome
false I-outcome
- I-outcome
negative I-outcome
rate I-outcome
were O
similar O
( O
accuracy B-outcome
100 B-cv-bin-percent
per I-cv-bin-percent
cent I-cv-bin-percent
for O
combined O
mapping O
versus O
98 B-iv-bin-percent
per I-iv-bin-percent
cent I-iv-bin-percent
for O
blue O
dye O
; O
false B-outcome
- I-outcome
negative I-outcome
rate I-outcome
0 B-cv-bin-percent
versus O
5 B-iv-bin-percent
per I-iv-bin-percent
cent I-iv-bin-percent
) O
. O
Combined O
mapping O
was O
superior O
to O
blue O
dye O
alone O
in O
identification O
of O
the O
SLN O
, O
but O
accuracy O
and O
false O
- O
negative O
rates O
were O
similar O
. O

Comparison O
of O
rapidly O
cycled O
tandem O
high B-intervention
- I-intervention
dose I-intervention
chemotherapy I-intervention
plus I-intervention
peripheral I-intervention
- I-intervention
blood I-intervention
stem I-intervention
- I-intervention
cell I-intervention
support I-intervention
versus O
dose B-control
- I-control
dense I-control
conventional I-control
chemotherapy I-control
for O
adjuvant O
treatment O
of O
high O
- O
risk O
breast O
cancer O
: O
results O
of O
a O
multicentre O
phase O
III O
trial O
. O
Breast O
cancer O
with O
extensive O
axillary O
- O
lymph O
- O
node O
involvement O
has O
a O
poor O
prognosis O
after O
conventional O
treatment O
. O
In O
trials O
with O
historical O
controls O
, O
high O
- O
dose O
chemotherapy O
produced O
improved O
outcomes O
. O
We O
compared O
an O
intensive O
double O
- O
cycle O
high O
- O
dose O
chemotherapy O
regimen O
with O
an O
accelerated O
conventionally O
dosed O
regimen O
in O
high O
- O
risk O
breast O
cancer O
in O
a O
multicentre O
trial O
. O
Patients B-eligibility
with I-eligibility
at I-eligibility
least I-eligibility
nine I-eligibility
positive I-eligibility
nodes I-eligibility
were O
randomly O
assigned O
either O
two O
courses O
of O
accelerated O
( O
2 O
- O
week O
intervals O
, O
with O
filgrastim O
support O
) O
, O
conventionally O
dosed O
epirubicin O
and O
cyclophosphamide O
followed O
by O
two O
courses O
of O
high O
- O
dose O
chemotherapy O
( O
epirubicin O
, O
cyclophosphamide O
, O
and O
thiotepa O
supported O
by O
peripheral O
- O
blood O
progenitors O
) O
or O
four O
identical O
cycles O
of O
epirubicin O
and O
cyclophosphamide O
followed O
by O
three O
cycles O
of O
accelerated O
cyclophosphamide O
, O
methotrexate O
, O
and O
fluorouracil O
. O
The O
primary O
endpoint O
was O
event B-outcome-measure
- I-outcome-measure
free I-outcome-measure
survival I-outcome-measure
. O
Analyses O
were O
done O
both O
by O
intention O
to O
treat O
and O
per O
protocol O
. O
403 B-total-participants
patients O
were O
enrolled O
; O
201 B-intervention-participants
were O
assigned O
high O
- O
dose O
chemotherapy O
and O
202 B-control-participants
conventional O
treatment O
. O
The O
mean O
number O
of O
positive O
nodes O
was O
17.6 O
, O
and O
median O
follow O
- O
up O
was O
48.6 O
months O
. O
4 B-outcome
- I-outcome
year I-outcome
event I-outcome
- I-outcome
free I-outcome
survival I-outcome
( O
intention O
- O
to O
- O
treat O
analysis O
) O
was O
60 B-iv-bin-percent
% I-iv-bin-percent
( O
95 O
% O
CI O
53 O
- O
67 O
) O
in O
the O
high O
- O
dose O
chemotherapy O
group O
and O
44 B-cv-bin-percent
% I-cv-bin-percent
( O
37 O
- O
52 O
) O
in O
the O
control O
group O
( O
p O
= O
0.00069 O
) O
. O
The O
corresponding O
overall B-outcome
survival I-outcome
was O
75 B-iv-bin-percent
% I-iv-bin-percent
( O
69 O
- O
82 O
) O
versus O
70 B-cv-bin-percent
% I-cv-bin-percent
( O
64 O
- O
77 O
; O
p O
= O
0.02 O
) O
. O
There O
were O
no B-outcome
treatment I-outcome
- I-outcome
related I-outcome
deaths I-outcome
. O
Our O
finding O
of O
significant O
improvements O
in O
both O
event O
- O
free O
and O
overall O
survival O
for O
high O
- O
dose O
chemotherapy O
compared O
with O
a O
dose O
- O
dense O
conventional O
regimen O
contrasts O
with O
the O
results O
of O
other O
studies O
. O
The O
discrepancy O
might O
be O
due O
partly O
to O
design O
differences O
( O
tandem O
, O
brief O
induction O
) O
between O
our O
regimen O
and O
those O
studied O
in O
other O
trials O
. O
This O
approach O
merits O
further O
study O
. O

Long O
- O
term O
follow O
- O
up O
of O
a O
randomised O
trial O
designed O
to O
determine O
the O
need O
for O
irradiation B-intervention
following I-intervention
conservative I-intervention
surgery I-intervention
for O
the O
treatment O
of O
invasive O
breast O
cancer O
. O
Four B-total-participants
hundred I-total-participants
consecutive O
patients O
aged O
under B-age
70 I-age
years I-age
diagnosed B-eligibility
with I-eligibility
a I-eligibility
clinical I-eligibility
T1 I-eligibility
or I-eligibility
T2 I-eligibility
breast I-eligibility
cancer I-eligibility
were O
randomised O
to O
receive O
post B-intervention
- I-intervention
operative I-intervention
radiotherapy I-intervention
( O
n O
= O
208 B-intervention
) O
or O
not B-control
( O
n O
= O
192 B-control-participants
) O
, O
and O
monitored O
to O
record O
all O
local O
recurrences O
, O
distant O
recurrences O
and O
deaths O
for O
up O
to O
20 O
years O
( O
median O
13.7 O
years O
) O
. O
All O
patients O
were O
treated O
by O
wide O
local O
excision O
and O
adjuvant O
therapy O
[ O
estrogen O
receptor O
( O
ER O
) O
positive O
: O
tamoxifen O
; O
ER O
negative O
: O
CMF O
chemotherapy O
] O
. O
Kaplan O
- O
Meier O
and O
log O
- O
rank O
test O
methods O
were O
used O
to O
estimate O
and O
compare O
survival O
and O
recurrence O
. O
The O
20 O
- O
year O
Kaplan O
- O
Meier O
rates O
for O
local B-outcome
breast I-outcome
recurrence I-outcome
were O
28.6 B-iv-bin-percent
% I-iv-bin-percent
[ O
95 O
% O
confidence O
interval O
( O
CI O
) O
19.6 O
% O
to O
37.6 O
% O
] O
for O
radiotherapy O
and O
49.8 B-cv-bin-percent
% I-cv-bin-percent
( O
95 O
% O
CI O
40.8 O
% O
to O
58.9 O
% O
) O
. O
There O
was O
no O
significant O
difference O
between O
the O
two O
groups O
with O
regard O
to O
disease B-outcome
- I-outcome
free I-outcome
or I-outcome
overall I-outcome
survival I-outcome
. O
The O
hazard B-outcome
ratio I-outcome
for I-outcome
death I-outcome
among O
women O
who O
received O
radiation O
, O
as O
compared O
with O
those O
that O
did O
not O
, O
was O
0.91 O
( O
95 O
% O
CI O
0.64 O
- O
1.28 O
; O
P O
= O
0.59 O
) O
. O
Therefore O
, O
post O
- O
operative O
radiotherapy O
produced O
a O
clear O
- O
cut O
reduction O
in O
locoregional B-outcome
recurrence I-outcome
0.45 O
( O
0.31 O
- O
0.64 O
; O
P O
= O
0.0001 O
) O
, O
but O
did O
not O
influence O
the O
incidence B-outcome
of I-outcome
distant I-outcome
metastases I-outcome
or O
time B-outcome
of I-outcome
death I-outcome
. O
However O
, O
of O
the O
119 O
patients O
who O
had O
a O
local O
recurrence O
, O
51 O
( O
42.8 O
% O
) O
had O
a O
distant B-outcome
recurrence I-outcome
, O
whereas O
of O
the O
281 O
without O
local O
recurrence O
only O
59 O
( O
21 O
% O
) O
ever O
had O
a O
distant B-outcome
recurrence I-outcome
. O
A O
Cox O
's O
regression O
analysis O
with O
local O
recurrence O
as O
a O
time O
- O
dependent O
variable O
showed O
a O
risk O
ratio O
of O
5.28 O
( O
P O
< O
0.0001 O
) O
. O
This O
strong O
relationship O
is O
dependent O
on O
the O
intensity O
of O
post O
- O
treatment O
follow O
- O
up O
and O
investigation O
. O

Randomized O
trial O
comparing O
axillary B-intervention
clearance I-intervention
versus O
no B-control
axillary I-control
clearance I-control
in O
older O
patients O
with O
breast O
cancer O
: O
first O
results O
of O
International O
Breast O
Cancer O
Study O
Group O
Trial O
10 O
- O
93 O
. O
Axillary O
clearance O
in O
early O
breast O
cancer O
aims O
to O
improve O
locoregional O
control O
and O
provide O
staging O
information O
but O
is O
associated O
with O
undesirable O
morbidity O
. O
We O
therefore O
investigated O
whether O
avoiding O
axillary O
surgery O
in O
older O
women O
would O
result O
in O
improved O
quality O
of O
life O
( O
QL O
) O
with O
similar O
disease O
- O
free O
survival O
( O
DFS O
) O
and O
overall O
survival O
( O
OS O
) O
. O
Between O
1993 O
and O
2002 O
, O
women O
> O
or O
= O
60 O
years O
old O
with B-eligibility
clinically I-eligibility
node I-eligibility
- I-eligibility
negative I-eligibility
operable I-eligibility
breast I-eligibility
cancer I-eligibility
in I-eligibility
whom I-eligibility
adjuvant I-eligibility
tamoxifen I-eligibility
was I-eligibility
considered I-eligibility
indicated I-eligibility
regardless I-eligibility
of I-eligibility
pathologic I-eligibility
nodal I-eligibility
status I-eligibility
were O
randomly O
assigned O
to O
primary O
surgery O
plus O
axillary O
clearance O
( O
Sx O
+ O
Ax O
) O
followed O
by O
tamoxifen O
( O
Tam O
) O
versus O
Sx O
without O
Ax O
followed O
by O
Tam O
for O
5 O
consecutive O
years O
. O
The O
primary O
end O
point O
was O
QL B-outcome-measure
reported O
by O
the O
patient O
and O
by O
physician O
assessment O
. O
A O
total O
of O
473 B-total-participants
patients O
( O
234 B-intervention-participants
to O
Sx O
+ O
Ax O
, O
239 B-control-participants
to O
Sx O
) O
were O
randomly O
assigned O
. O
The O
median O
age O
was O
74 B-age
years I-age
; O
80 O
% O
had O
estrogen O
receptor O
- O
positive O
disease O
. O
In O
both O
the O
patients O
' O
subjective O
assessment O
of O
their O
QL O
and O
the O
physicians O
' O
perception O
of O
the O
patients O
' O
QL O
, O
the O
largest O
adverse O
QL O
effects O
of O
Ax O
were O
observed O
from O
baseline O
to O
the O
first O
postoperative O
assessment O
, O
but O
the O
differences O
tended O
to O
disappear O
in O
6 O
to O
12 O
months O
. O
At O
a O
median O
follow O
- O
up O
of O
6.6 O
years O
, O
results O
for O
Sx O
+ O
Ax O
and O
Sx O
yielded O
similar O
DFS B-outcome
( O
6 B-outcome
- I-outcome
year I-outcome
DFS I-outcome
, O
67 B-iv-bin-percent
% I-iv-bin-percent
v O
66 B-cv-bin-percent
% I-cv-bin-percent
; O
hazard O
ratio O
[ O
HR O
] O
Sx O
+ O
Ax O
/ O
Sx O
, O
1.06 O
; O
95 O
% O
CI O
, O
0.79 O
to O
1.42 O
; O
P O
= O
.69 O
) O
and O
OS B-outcome
( O
6 B-outcome
- I-outcome
year I-outcome
OS I-outcome
, O
75 B-iv-bin-percent
% I-iv-bin-percent
v O
73 B-cv-bin-percent
% I-cv-bin-percent
; O
HR O
Sx O
+ O
Ax O
/ O
Sx O
, O
1.05 O
; O
95 O
% O
CI O
, O
0.76 O
to O
1.46 O
; O
P O
= O
.77 O
) O
. O
Avoiding O
axillary O
clearance O
for O
women O
> O
or O
= O
60 O
years O
old O
who O
have O
clinically O
node O
- O
negative O
disease O
and O
receive O
Tam O
for O
endocrine O
- O
responsive O
disease O
yields O
similar O
efficacy O
with O
better O
early O
QL O
. O

In O
a O
randomized O
controlled O
trial O
, O
patients O
preferred O
electronic B-intervention
data I-intervention
collection I-intervention
of O
breast O
cancer O
risk O
- O
factor O
information O
in O
a O
mammography O
setting O
. O
We O
evaluated O
patient O
acceptance O
of O
an O
electronic O
questionnaire O
to O
collect O
breast O
cancer O
risk O
- O
factor O
data O
in O
a O
mammography O
setting O
. O
We O
developed O
an O
electronic O
questionnaire O
on O
a O
tablet O
computer O
incorporating O
prefilled O
answers O
and O
skip O
patterns O
. O
Using O
a O
randomized O
controlled O
study O
design O
, O
we O
tested O
the O
survey O
in O
a O
mammography O
clinic O
that O
administers O
a O
paper O
risk O
- O
factor O
questionnaire O
to O
every O
woman O
at O
her O
screening O
mammogram O
. O
We O
randomized O
160 B-total-participants
women O
to O
use O
the O
electronic O
survey O
( O
experimental O
group O
, O
n O
= O
86 B-intervention-participants
) O
or O
paper B-control
survey I-control
( O
control O
group O
, O
n O
= O
74 B-control-participants
) O
. O
We O
evaluated O
patient O
acceptance O
and O
data O
completeness O
. O
Overall O
, O
70.4 B-iv-bin-percent
% I-iv-bin-percent
of O
the O
experimental O
group O
women O
thought O
the O
survey B-outcome
was I-outcome
very I-outcome
easy I-outcome
to I-outcome
use I-outcome
, O
compared O
to O
55.6 B-cv-bin-percent
% I-cv-bin-percent
of O
women O
in O
the O
control O
group O
. O
Ninety B-iv-bin-percent
percent I-iv-bin-percent
of O
experimental O
group O
women O
preferred B-outcome
using I-outcome
the I-outcome
tablet I-outcome
, O
compared O
to O
the O
paper O
questionnaire O
. O
Preference O
for O
the O
tablet O
did O
not O
differ O
by O
age O
; O
however O
, O
women O
> O
or O
= O
60 O
years O
did O
not O
find O
the O
tablet O
as O
easy O
to O
use O
as O
did O
women O
< O
60 O
years O
. O
The O
proportion B-outcome
of I-outcome
missing I-outcome
data I-outcome
was O
significantly O
lower O
on O
the O
tablet O
compared O
to O
the O
paper O
questionnaire O
( O
4.6 B-iv-bin-percent
% I-iv-bin-percent
vs. O
6.2 B-cv-bin-percent
% I-cv-bin-percent
, O
P O
= O
.04 O
) O
. O
Electronic O
questionnaires O
are O
feasible O
to O
use O
in O
a O
mammography O
setting O
, O
can O
improve O
data O
quality O
, O
and O
are O
preferred O
by O
women O
regardless O
of O
age O
. O

Menopausal B-intervention
hormone I-intervention
therapy I-intervention
( I-intervention
HT I-intervention
) I-intervention
in O
patients O
with O
breast O
cancer O
. O
To O
assess O
the O
effect O
of O
menopausal O
hormone O
therapy O
( O
HT O
) O
on O
reoccurrence O
, O
cancer O
- O
related O
mortality O
, O
and O
overall O
mortality O
after O
a O
diagnosis O
of O
breast O
cancer O
. O
We O
performed O
a O
quantitative O
review O
of O
all O
studies O
reporting O
experience O
with O
menopausal O
HT O
for O
symptomatic O
use O
after O
a O
diagnosis O
of O
breast O
cancer O
. O
Rates O
of O
reoccurrence O
, O
cancer O
- O
related O
mortality O
, O
and O
overall O
mortality O
were O
calculated O
in O
this O
entire O
group O
. O
A O
subgroup O
analysis O
was O
performed O
in O
studies O
using O
a O
control O
population O
to O
assess O
the O
odds O
ratio O
of O
cancer O
reoccurrence O
and O
mortality O
in O
hormone O
users O
versus O
non O
- O
users O
. O
Fifteen O
studies O
encompassing O
1416 B-intervention-participants
breast O
cancer O
survivors O
using O
HT O
were O
identified O
. O
Seven O
studies O
included O
a O
control B-control
group I-control
comprised O
of O
1998 B-control-participants
patients O
. O
Among O
the O
1416 O
HT O
users O
, O
reoccurrence B-outcome
was O
noted O
in O
10.0 B-iv-bin-percent
% I-iv-bin-percent
( O
95 O
% O
CI O
: O
8.4 O
- O
11.6 O
% O
) O
. O
Cancer B-outcome
- I-outcome
related I-outcome
mortality I-outcome
occurred O
at O
a O
rate O
of O
2.6 B-iv-bin-percent
% I-iv-bin-percent
( O
95 O
% O
CI O
: O
1.8 O
- O
3.7 O
% O
) O
, O
while O
overall B-outcome
mortality I-outcome
was O
4.5 B-iv-bin-percent
% I-iv-bin-percent
( O
95 O
% O
CI O
: O
3.4 O
- O
5.8 O
% O
) O
. O
Compared O
to O
non O
- O
users O
, O
patients O
using O
HT O
had O
a O
decreased O
chance B-outcome
of I-outcome
reoccurrence I-outcome
and I-outcome
cancer I-outcome
- I-outcome
related I-outcome
mortality I-outcome
with O
combined O
odds O
ratio O
of O
0.5 O
( O
95 O
% O
CI O
: O
0.2 O
- O
0.7 O
) O
and O
0.3 O
( O
95 O
% O
CI O
: O
0.0 O
- O
0.6 O
) O
, O
respectively O
. O
In O
our O
review O
, O
menopausal O
HT O
use O
in O
breast O
cancer O
survivors O
was O
not O
associated O
with O
increased O
cancer B-outcome
reoccurrence I-outcome
, O
cancer B-outcome
- I-outcome
related I-outcome
mortality I-outcome
or I-outcome
total I-outcome
mortality I-outcome
. O
Despite O
conflicting O
opinions O
on O
this O
issue O
, O
it O
is O
important O
for O
primary O
care O
physicians O
to O
feel O
comfortable O
medically O
managing O
the O
increasing O
number O
of O
breast O
cancer O
survivors O
. O
In O
the O
subset O
of O
women O
with O
severe O
menopausal O
symptoms O
, O
HT O
options O
should O
be O
reviewed O
if O
non O
- O
hormonal O
methods O
are O
ineffective O
. O
Future O
trials O
should O
focus O
on O
better O
ways O
to O
identify O
breast O
cancer O
survivors O
who O
may O
safely O
benefit O
from O
HT O
versus O
those O
who O
have O
a O
substantial O
risk O
of O
reoccurrence O
with O
HT O
use O
. O

Treatment O
of O
chemotherapy B-condition
- I-condition
induced I-condition
anemia I-condition
in O
breast O
cancer O
: O
results O
of O
a O
randomized O
controlled O
trial O
of O
darbepoetin B-intervention
alfa I-intervention
200 O
microg O
every O
2 O
weeks O
versus O
epoetin B-control
alfa I-control
40,000 O
U O
weekly O
. O
Current O
chemotherapy O
regimens O
for O
breast O
cancer O
result O
in O
high O
incidences O
of O
anemia O
, O
which O
can O
be O
treated O
with O
erythropoietic O
agents O
. O
The O
relative O
efficacy O
of O
darbepoetin O
alfa O
and O
epoetin O
alfa O
was O
explored O
in O
this O
phase O
II O
, O
open O
- O
label O
, O
randomized O
, O
multicenter O
trial O
in O
anemic B-eligibility
patients I-eligibility
with I-eligibility
breast I-eligibility
cancer I-eligibility
receiving I-eligibility
chemotherapy I-eligibility
. O
Patients O
were O
randomized O
at O
a O
1 O
:1 O
ratio O
to O
receive O
darbepoetin O
alfa O
200 O
microg O
every O
2 O
weeks O
( O
n O
= O
72 B-intervention-participants
) O
or O
epoetin O
alfa O
40,000 O
U O
weekly O
( O
n O
= O
69 B-control-participants
) O
for O
< O
or O
= O
16 O
weeks O
. O
Clinical B-outcome-measure
and I-outcome-measure
hematologic I-outcome-measure
endpoints O
and O
validation O
of O
a O
novel O
patient O
satisfaction O
questionnaire O
for O
anemia O
treatment O
were O
evaluated O
for O
all O
patients O
randomized O
to O
receive O
> O
or O
= O
1 O
dose O
of O
study O
drug O
. O
Baseline O
characteristics O
were O
generally O
similar O
between O
treatment O
groups O
. O
Mean B-outcome
changes I-outcome
in I-outcome
hemoglobin I-outcome
( I-outcome
Hb I-outcome
) I-outcome
level I-outcome
from O
baseline O
were O
similar O
at O
1.9 B-iv-cont-mean
g I-iv-cont-mean
/ I-iv-cont-mean
dL I-iv-cont-mean
for O
darbepoetin O
alfa O
and O
1.7 B-cv-cont-mean
g I-cv-cont-mean
/ I-cv-cont-mean
dL I-cv-cont-mean
for O
epoetin O
alfa O
. O
Hematopoietic B-outcome
responses I-outcome
( O
> O
or O
= O
2 O
g O
/ O
dL O
increase O
in O
Hb O
level O
from O
baseline O
or O
Hb O
level O
> O
or O
= O
12 O
g O
/ O
dL O
) O
were O
also O
similar O
between O
groups O
( O
88 B-iv-bin-percent
% I-iv-bin-percent
for O
darbepoetin O
alfa O
and O
81 B-cv-bin-percent
% I-cv-bin-percent
for O
epoetin O
alfa O
) O
. O
The O
proportions O
of O
patients B-outcome
who I-outcome
received I-outcome
a I-outcome
transfusion I-outcome
during I-outcome
treatment I-outcome
were O
6 B-iv-bin-percent
% I-iv-bin-percent
( O
95 O
% O
CI O
, O
0 O
- O
11 O
% O
) O
for O
darbepoetin O
alfa O
and O
16 B-cv-bin-percent
% I-cv-bin-percent
( O
95 O
% O
CI O
, O
7%-25 O
% O
) O
for O
epoetin O
alfa O
. O
Most O
patients O
( O
67 B-iv-bin-abs
patients O
receiving O
darbepoetin O
alfa O
[ O
93 B-iv-bin-percent
% I-iv-bin-percent
] O
; O
61 B-cv-bin-abs
patients O
receiving O
epoetin O
alfa O
[ O
90 B-cv-bin-percent
% I-cv-bin-percent
] O
) O
exhibited B-outcome
a I-outcome
clinically I-outcome
meaningful I-outcome
target I-outcome
Hb I-outcome
level I-outcome
> O
or O
= O
11 O
g O
/ O
dL. O
No O
differences O
in O
safety B-outcome
were O
observed O
. O
These O
results O
suggest O
that O
, O
in O
patients O
with O
breast O
cancer O
, O
darbepoetin O
alfa O
200 O
microg O
every O
2 O
weeks O
and O
epoetin O
alfa O
40,000 O
U O
weekly O
result O
in O
comparable O
clinical O
outcomes O
for O
the O
treatment O
of O
chemotherapy O
- O
induced O
anemia O
. O

Preliminary O
results O
on O
safety O
and O
activity O
of O
a O
randomized O
, O
double O
- O
blind O
, O
2 O
x O
2 O
trial O
of O
low B-intervention
- I-intervention
dose I-intervention
tamoxifen I-intervention
and I-intervention
fenretinide I-intervention
for O
breast O
cancer O
prevention O
in O
premenopausal O
women O
. O
To O
determine O
whether O
low O
- O
dose O
tamoxifen O
and O
fenretinide O
have O
a O
synergistic O
effect O
on O
surrogate O
biomarkers O
, O
including O
circulating O
insulin O
- O
like O
growth O
factor O
I O
( O
IGF O
- O
I O
) O
and O
mammographic O
density O
, O
in O
premenopausal B-eligibility
women I-eligibility
at I-eligibility
risk I-eligibility
for I-eligibility
breast I-eligibility
cancer I-eligibility
and O
to O
study O
drug O
safety O
. O
Premenopausal O
women O
( O
n O
= O
235 B-total-participants
) O
were O
randomly O
assigned O
in O
a O
double O
- O
blind O
four O
- O
arm O
trial O
to O
receive O
tamoxifen O
5 O
mg O
/ O
d O
, O
fenretinide O
200 O
mg O
/ O
d O
, O
both O
agents O
, O
or O
placebo B-control
for O
2 O
years O
. O
The O
present O
analysis O
refers O
to O
preliminary O
data O
on O
safety O
, O
IGF O
- O
I O
, O
and O
breast O
cancer O
events O
. O
Patients O
were O
included O
if O
they O
had O
an O
excised O
ductal O
carcinoma O
- O
in O
- O
situ O
( O
57 O
% O
) O
, O
lobular O
carcinoma O
- O
in O
- O
situ O
( O
13 O
% O
) O
, O
minimal O
invasive O
breast O
cancer O
( O
7 O
% O
) O
, O
or O
a O
5 O
- O
year O
Gail O
risk O
> O
or O
= O
1.3 O
% O
( O
23 O
% O
) O
. O
After O
a O
median O
follow O
- O
up O
of O
40 O
months O
, O
there O
was O
a O
reduction O
of O
13 O
% O
, O
2 O
% O
, O
20 O
% O
, O
and O
1 O
% O
in O
IGF B-outcome
- I-outcome
I I-outcome
levels I-outcome
for O
patients O
on O
tamoxifen O
, O
fenretinide O
, O
tamoxifen O
plus O
fenretinide O
, O
and O
placebo O
, O
respectively O
. O
Recruitment O
was O
stopped O
based O
on O
the O
lack O
of O
an O
interaction O
on O
IGF B-outcome-measure
- I-outcome-measure
I I-outcome-measure
levels I-outcome-measure
, O
which O
was O
a O
primary O
end O
point O
for O
the O
study O
. O
Thirty O
- O
six O
patients O
have O
dropped B-outcome
out I-outcome
of O
the O
study O
, O
17 O
because O
of O
adverse B-outcome
events I-outcome
and O
19 O
for O
various O
other B-outcome
reasons I-outcome
. O
One B-iv-bin-abs
stage O
I O
endometrial O
cancer O
occurred O
in O
a O
patient O
on O
fenretinide O
, O
and O
one B-iv-bin-abs
optic B-outcome
nerve I-outcome
ischemia I-outcome
and O
one B-iv-bin-abs
deep B-outcome
venous I-outcome
thrombosis I-outcome
occurred O
on O
tamoxifen O
. O
There O
was O
no O
difference O
in O
menopausal B-outcome
symptoms I-outcome
, O
endometrial B-outcome
thickness I-outcome
, O
polyps B-outcome
, O
or O
ovarian B-outcome
cysts I-outcome
among O
treatment O
arms O
. O
To O
date O
, O
24 O
breast B-outcome
cancers I-outcome
have O
been O
observed O
, O
without O
differences O
among O
arms O
. O
The O
combination O
of O
low O
- O
dose O
tamoxifen O
and O
fenretinide O
is O
safe O
but O
not O
synergistic O
in O
lowering O
IGF O
- O
I O
levels O
in O
premenopausal O
women O
. O
The O
clinical O
implications O
require O
further O
follow O
- O
up O
. O

Dose B-intervention
- I-intervention
dense I-intervention
adjuvant I-intervention
chemotherapy I-intervention
for O
node B-eligibility
- I-eligibility
positive I-eligibility
breast I-eligibility
cancer I-eligibility
in I-eligibility
women I-eligibility
60 I-eligibility
years I-eligibility
and I-eligibility
older I-eligibility
: O
feasibility O
and O
tolerability O
in O
a O
subset O
of O
patients O
in O
a O
randomized O
trial O
. O
To O
evaluate O
the O
feasibility O
and O
tolerability O
of O
dose O
- O
dense O
adjuvant O
chemotherapy O
for O
older B-eligibility
patients I-eligibility
with I-eligibility
node I-eligibility
- I-eligibility
positive I-eligibility
breast I-eligibility
cancer I-eligibility
, O
a O
retrospective O
subset O
analysis O
compared O
dose O
delays O
and O
dose O
reductions O
for O
women O
aged O
> B-age
or I-age
= I-age
60 I-age
years I-age
with O
those O
of O
younger O
women O
. O
Patients O
were O
randomized O
to O
a O
dose O
- O
dense O
( O
DD O
, O
14 O
- O
day O
cycle O
) O
or O
conventional B-control
- I-control
schedule I-control
( O
CS O
, O
21 O
- O
day O
cycle O
) O
regimen O
. O
DD O
patients O
( O
n O
= O
104 B-intervention-participants
; O
25 O
aged O
> O
or O
= O
60 O
years O
) O
received O
epirubicin O
90 O
mg O
/ O
m2 O
plus O
paclitaxel O
175 O
mg O
/ O
m2 O
( O
four O
cycles O
) O
, O
then O
cyclophosphamide O
600 O
mg O
/ O
m2 O
, O
methotrexate O
40 O
mg O
/ O
m2 O
and O
fluorouracil O
600 O
mg O
/ O
m2 O
( O
CMF O
600 O
/ O
40 O
/ O
600 O
) O
( O
three O
cycles O
) O
, O
plus O
filgrastim O
5 O
microg O
/ O
kg O
per O
day O
in O
every O
cycle O
. O
CS O
patients O
( O
n O
= O
107 B-control-participants
; O
27 O
aged O
> O
or O
= O
60 O
years O
) O
received O
epirubicin O
90 O
mg O
/ O
m2 O
plus O
cyclophosphamide O
600 O
mg O
/ O
m2 O
( O
four O
cycles O
) O
, O
then O
CMF O
600 O
/ O
40 O
/ O
600 O
( O
three O
cycles O
) O
, O
plus O
filgrastim O
if O
required O
. O
Delays B-outcome
were O
more O
common O
in O
older O
patients O
in O
both O
the O
DD O
and O
CS O
groups O
( O
DD O
, O
17 B-iv-bin-percent
% I-iv-bin-percent
versus O
6 B-iv-bin-percent
% I-iv-bin-percent
; O
CS O
, O
11 B-cv-bin-percent
% I-cv-bin-percent
versus O
6 B-cv-bin-percent
% I-cv-bin-percent
) O
, O
as O
were O
Grades B-outcome
3 I-outcome
- I-outcome
4 I-outcome
leukopenia I-outcome
( O
26 B-iv-bin-percent
% I-iv-bin-percent
versus O
12 B-cv-bin-percent
% I-cv-bin-percent
) O
and O
neutropenia B-outcome
( O
33 B-iv-bin-percent
% I-iv-bin-percent
versus O
25 B-cv-bin-percent
% I-cv-bin-percent
) O
. O
All O
older O
DD O
and O
89 O
% O
of O
older O
CS O
patients O
received O
all O
seven O
chemotherapy O
cycles O
, O
with O
99 O
% O
of O
cycles O
at O
full O
dose O
. O
This O
study O
demonstrates O
that O
a O
dose O
- O
dense O
regimen O
combining O
epirubicin O
and O
paclitaxel O
can O
be O
administered O
to O
patients O
> O
or O
= O
60 O
years O
of O
age O
with O
a O
tolerable O
safety O
profile O
. O

Effect O
of O
preoperative O
short O
course O
famotidine B-intervention
on O
TILs O
and O
survival O
in O
breast O
cancer O
. O
Histamine O
receptor O
antagonists O
have O
been O
shown O
to O
induce O
tumor O
- O
infiltrating O
lymphocytes O
( O
TILs O
) O
in O
colonic O
cancers O
and O
improve O
survival O
. O
The O
role O
of O
histamine O
receptor O
anatagonists O
in O
breast O
cancer O
is O
unclarified O
. O
To O
evaluate O
the O
role O
of O
histamine O
receptor O
antagonists O
in O
inducing O
( O
TILs O
) O
in O
breast O
cancer O
. O
Forty B-total-participants
- I-total-participants
five I-total-participants
patients B-eligibility
with I-eligibility
operable I-eligibility
breast I-eligibility
cancers I-eligibility
( O
25 B-intervention-participants
cases O
who O
received O
preoperative O
famotidine O
and O
20 B-control-participants
controls B-control
) O
were O
studied O
for O
the O
effect O
of O
famotidine O
in O
inducing O
TILs O
and O
survival O
in O
breast O
cancer O
. O
Significant B-outcome
TILs I-outcome
were O
seen O
in O
75 B-iv-bin-percent
% I-iv-bin-percent
( O
18 B-iv-bin-abs
/ O
24 B-intervention-participants
) O
of O
cases O
as O
opposed O
to O
35 B-cv-bin-percent
% I-cv-bin-percent
( O
7 B-cv-bin-abs
/ O
20 B-control-participants
) O
controls O
. O
In O
logistic O
regression O
analysis O
the O
only O
variable O
found O
to O
be O
predictive O
of O
TILs O
was O
famotidine O
, O
odds O
ratio O
7.324 O
( O
1.693 O
- O
31.686 O
) O
P O
= O
0.008 O
. O
In O
Cox O
's O
regression O
presence O
of O
TILs O
was O
favorably O
associated O
with O
improved O
disease O
free O
survival O
at O
a O
median O
follow O
up O
of O
35.56 O
months O
. O
The O
hazard O
ratio O
for O
disease B-outcome
relapse I-outcome
was O
3.327 O
( O
1.174 O
- O
9.426 O
) O
P O
= O
0.024 O
in O
TIL O
negative O
as O
compared O
to O
TIL O
positive O
patients O
. O
Famotidine O
use O
alone O
was O
not O
significant O
in O
the O
original O
model O
, O
however O
, O
on O
incorporation O
of O
quadrant O
of O
involvement O
in O
addition O
to O
other O
established O
prognostic O
factors O
in O
the O
above O
multivariate O
model O
, O
it O
assumed O
borderline O
significance O
with O
a O
hazard O
ratio O
for O
disease B-outcome
free I-outcome
survival I-outcome
3.404 O
( O
1.005 O
- O
11.531 O
, O
P O
= O
0.049 O
) O
. O
Preoperative O
short O
course O
famotidine O
induces O
TILs O
in O
breast O
cancer O
. O
Patients O
with O
TILs O
demonstrable O
in O
tumor O
specimens O
had O
an O
improved O
disease B-outcome
free I-outcome
survival I-outcome
. O
Famotidine O
may O
improve O
disease O
free O
survival O
in O
breast O
cancer O
and O
these O
findings O
need O
validation O
in O
larger O
population O
subsets O
. O

Multicenter O
randomized O
phase O
III O
study O
of O
the O
cardioprotective O
effect O
of O
dexrazoxane B-intervention
( I-intervention
Cardioxane I-intervention
) I-intervention
in O
advanced O
/ O
metastatic O
breast O
cancer O
patients O
treated O
with O
anthracycline O
- O
based O
chemotherapy O
. O
Anthracycline B-condition
- I-condition
induced I-condition
cardiotoxicity I-condition
has O
led O
to O
the O
adoption O
of O
empirical O
dose O
limits O
that O
may O
restrict O
continued O
use O
of O
anthracyclines O
among O
patients O
who O
might O
benefit O
. O
Dexrazoxane O
, O
a O
cardioprotective O
agent O
, O
has O
been O
shown O
to O
reduce O
the O
risk O
of O
anthracycline O
- O
associated O
cardiotoxicity O
when O
given O
from O
first O
dose O
of O
anthracycline O
. O
This O
study O
sought O
to O
confirm O
the O
benefit O
of O
dexrazoxane O
in O
patients O
at O
high O
risk O
of O
cardiotoxicity O
due O
to O
prior O
anthracycline O
use O
. O
A O
total O
of O
164 B-total-participants
female B-eligibility
breast I-eligibility
cancer I-eligibility
patients I-eligibility
, I-eligibility
previously I-eligibility
treated I-eligibility
with I-eligibility
anthracyclines I-eligibility
, O
received O
anthracycline O
- O
based O
chemotherapy O
either O
with O
( O
n O
= O
85 B-intervention-participants
) O
or O
without B-control
( O
n O
= O
79 B-control-participants
) O
dexrazoxane O
for O
a O
maximum O
of O
six O
cycles O
. O
Compared O
with O
those O
receiving O
anthracycline O
alone O
, O
patients O
treated O
with O
dexrazoxane O
experienced O
significantly O
fewer O
cardiac B-outcome
events I-outcome
( O
39 B-cv-bin-percent
% I-cv-bin-percent
versus O
13 B-iv-bin-percent
% I-iv-bin-percent
, O
P O
< O
0.001 O
) O
and O
a O
lower O
and O
less O
severe B-outcome
incidence I-outcome
of I-outcome
congestive I-outcome
heart I-outcome
failure I-outcome
( O
11 B-cv-bin-percent
% I-cv-bin-percent
versus O
1 B-iv-bin-percent
% I-iv-bin-percent
, O
P O
< O
0.05 O
) O
. O
Tumor B-outcome
response I-outcome
rate I-outcome
was O
unaffected O
by O
dexrazoxane O
therapy O
. O
The O
frequency B-outcome
of I-outcome
adverse I-outcome
events I-outcome
was O
similar O
between O
groups O
and O
there O
were O
no O
significant O
between O
- O
group O
differences O
in O
the O
number B-outcome
of I-outcome
dose I-outcome
modifications I-outcome
/ I-outcome
interruptions I-outcome
. O
Dexrazoxane O
significantly O
reduced O
the O
occurrence O
and O
severity O
of O
anthracycline O
- O
induced O
cardiotoxicity O
in O
patients O
at O
increased O
risk O
of O
cardiac O
dysfunction O
due O
to O
previous O
anthracycline O
treatment O
without O
compromising O
the O
antitumor O
efficacy O
of O
the O
chemotherapeutic O
regimen O
. O

Consolidation O
with O
high B-intervention
- I-intervention
dose I-intervention
combination I-intervention
alkylating I-intervention
agents I-intervention
with O
bone O
marrow O
transplantation O
significantly O
improves O
disease O
- O
free O
survival O
in O
hormone O
- O
insensitive O
metastatic O
breast O
cancer O
in O
complete O
remission O
compared O
with O
intensive O
standard O
- O
dose O
chemotherapy O
alone O
. O
We O
conducted O
this O
study O
to O
determine O
event O
- O
free O
and O
overall O
survival O
among O
women B-eligibility
with I-eligibility
hormone I-eligibility
- I-eligibility
insensitive I-eligibility
or I-eligibility
hormone I-eligibility
- I-eligibility
resistant I-eligibility
metastatic I-eligibility
breast I-eligibility
cancer I-eligibility
receiving O
consolidation O
with O
high O
- O
dose O
chemotherapy O
( O
HDC O
) O
and O
hematopoietic O
support O
versus O
no O
further O
chemotherapy O
after O
intensive O
induction O
chemotherapy O
. O
Eligible O
patients O
received O
induction O
doxorubicin O
, O
5 O
- O
fluorouracil O
, O
and O
methotrexate O
( O
AFM O
) O
for O
2 O
to O
4 O
cycles O
. O
Women O
in O
complete O
remission O
were O
randomized O
to O
immediate O
HDC O
with O
cyclophosphamide O
, O
cisplatin O
, O
and O
carmustine O
followed O
by O
autologous O
hematopoietic O
support O
or O
to O
no O
further O
therapy O
. O
Patients O
on O
the O
observation B-control
arm I-control
of O
therapy O
were O
offered O
salvage O
HDC O
at O
the O
time O
of O
relapse O
. O
Partial O
responders O
to O
AFM O
were O
offered O
immediate O
HDC O
. O
A O
total O
of O
425 B-total-participants
patients O
were O
enrolled O
onto O
the O
study O
. O
The O
median B-outcome
event I-outcome
- I-outcome
free I-outcome
survival I-outcome
for O
women O
randomized O
to O
induction O
therapy O
alone O
was O
3.8 B-cv-cont-median
months I-cv-cont-median
, O
compared O
with O
9.7 B-iv-cont-median
months I-iv-cont-median
for O
women O
who O
completed O
HDC O
( O
P O
< O
.006 O
) O
. O
Of O
the O
patients O
randomized O
to O
observation O
, O
5 B-cv-bin-abs
( O
10 B-cv-bin-percent
% I-cv-bin-percent
) O
of O
51 B-control-participants
remain O
event B-outcome
free I-outcome
, O
compared O
with O
13 B-iv-bin-abs
( O
26 B-iv-bin-percent
% I-iv-bin-percent
) O
of O
49 B-intervention-participants
patients O
who O
underwent O
immediate O
HDC O
( O
P O
= O
.03 O
) O
. O
Of O
women O
converted O
to O
a O
complete O
response O
by O
salvage O
HDC O
after O
a O
partial O
response O
to O
AFM O
, O
overall B-outcome
survival I-outcome
was O
similar O
to O
that O
in O
women O
randomized O
to O
immediate O
HDC O
. O
Follow O
- O
up O
is O
now O
in O
excess O
of O
5 O
years O
. O
The O
5 B-outcome
- I-outcome
year I-outcome
event I-outcome
- I-outcome
free I-outcome
survival I-outcome
is O
15 O
% O
( O
95 O
% O
confidence O
interval O
, O
12%-18 O
% O
) O
, O
and O
the O
5 B-outcome
- I-outcome
year I-outcome
overall I-outcome
survival I-outcome
is O
20 O
% O
( O
95 O
% O
confidence O
interval O
, O
17%-25 O
% O
) O
. O
Immediate O
HDC O
after O
a O
complete O
response O
to O
AFM O
produced O
some O
durable O
long O
- O
term O
responses O
in O
hormone O
- O
insensitive/-resistant O
metastatic O
breast O
cancer O
. O
Salvage O
HDC O
converted O
30 O
% O
of O
partial O
responders O
to O
complete O
responders O
with O
similar O
survivals O
. O
The O
addition O
of O
novel O
targeted O
therapies O
to O
intensive O
- O
dose O
chemotherapy O
regimens O
may O
further O
improve O
survival O
in O
metastatic O
breast O
cancer O
. O

A O
double O
- O
blind O
, O
multicenter O
, O
parallel O
- O
group O
study O
of O
paroxetine B-intervention
, I-intervention
desipramine I-intervention
, O
or O
placebo B-control
in O
breast O
cancer O
patients O
( O
stages O
I O
, O
II O
, O
III O
, O
and O
IV O
) O
with O
major O
depression O
. O
This O
study O
compared O
the O
efficacy O
and O
safety O
of O
paroxetine O
and O
desipramine O
with O
those O
of O
placebo O
in O
the O
treatment O
of O
depressive B-condition
disorders I-condition
in O
adult O
women O
with O
breast O
cancer O
, O
stages O
I O
- O
IV O
. O
In O
a O
double O
- O
blind O
, O
placebo O
- O
controlled O
study O
, O
35 B-total-participants
female B-eligibility
outpatients I-eligibility
with I-eligibility
breast I-eligibility
cancer I-eligibility
and I-eligibility
DSM I-eligibility
- I-eligibility
III I-eligibility
- I-eligibility
R I-eligibility
major I-eligibility
depression I-eligibility
or I-eligibility
adjustment I-eligibility
disorder I-eligibility
with I-eligibility
depressed I-eligibility
mood I-eligibility
were O
randomly O
assigned O
to O
treatment O
with O
paroxetine O
( O
N O
= O
13 B-intervention-participants
) O
, O
desipramine O
( O
N O
= O
11 B-intervention-participants
) O
, O
or O
placebo O
( O
N O
= O
11 B-control-participants
) O
for O
6 O
weeks O
. O
Primary O
efficacy O
was O
assessed O
by O
change B-outcome-measure
from I-outcome-measure
baseline I-outcome-measure
in I-outcome-measure
score I-outcome-measure
on I-outcome-measure
the I-outcome-measure
21 I-outcome-measure
- I-outcome-measure
item I-outcome-measure
Hamilton I-outcome-measure
Rating I-outcome-measure
Scale I-outcome-measure
for I-outcome-measure
Depression I-outcome-measure
( I-outcome-measure
HAM I-outcome-measure
- I-outcome-measure
D I-outcome-measure
) I-outcome-measure
, O
and O
the O
secondary O
outcome O
measure O
was O
change B-outcome-measure
from I-outcome-measure
baseline I-outcome-measure
in I-outcome-measure
the I-outcome-measure
Clinical I-outcome-measure
Global I-outcome-measure
Impressions I-outcome-measure
- I-outcome-measure
Severity I-outcome-measure
of I-outcome-measure
Illness I-outcome-measure
scale I-outcome-measure
( I-outcome-measure
CGI I-outcome-measure
- I-outcome-measure
S I-outcome-measure
) I-outcome-measure
score I-outcome-measure
. O
Mean O
changes O
in O
the O
total O
HAM O
- O
D O
and O
CGI O
- O
S O
scores O
from O
baseline O
to O
6 O
- O
week O
endpoint O
for O
the O
paroxetine O
and O
desipramine O
groups O
were O
not O
significantly O
different O
than O
those O
for O
the O
placebo O
- O
treated O
group O
. O
An O
unusually O
high O
rate B-outcome
of I-outcome
response I-outcome
( O
defined O
as O
> O
or O
= O
50 O
% O
improvement O
in O
the O
HAM O
- O
D O
score O
) O
in O
the O
placebo O
group O
was O
observed O
( O
55 B-cv-bin-percent
% I-cv-bin-percent
[ O
N O
= O
6 B-cv-bin-abs
] O
) O
; O
adverse O
events O
precipitated O
patient O
discontinuation B-outcome
in O
the O
active O
treatment O
groups O
( O
9 B-iv-bin-percent
% I-iv-bin-percent
[ O
N O
= O
1 B-iv-bin-abs
] O
for O
desipramine O
, O
15 B-iv-bin-percent
% I-iv-bin-percent
[ O
N O
= O
2 B-iv-bin-abs
] O
for O
paroxetine O
) O
similar O
to O
that O
in O
the O
placebo O
- O
treated O
patients O
( O
18 B-cv-bin-percent
% I-cv-bin-percent
[ O
N O
= O
2 B-cv-bin-abs
] O
) O
. O
Improvement O
on O
symptom O
dimensions O
within O
the O
HAM O
- O
D O
and O
Hamilton O
Rating O
Scale O
for O
Anxiety O
( O
depressive B-outcome
, I-outcome
anxiety I-outcome
, I-outcome
cognitive I-outcome
, I-outcome
neurovegetative I-outcome
, I-outcome
or I-outcome
somatic I-outcome
) O
was O
also O
similar O
between O
groups O
. O
The O
small O
number O
of O
women O
in O
this O
study O
most O
likely O
contributed O
to O
the O
lack O
of O
observed O
differences O
in O
efficacy O
observed O
during O
the O
6 O
weeks O
of O
treatment O
. O
Randomized O
, O
placebo O
- O
controlled O
trials O
of O
adequate O
power O
seeking O
to O
determine O
efficacy O
of O
antidepressants O
in O
the O
United O
States O
for O
the O
treatment O
of O
women O
with O
breast O
cancer O
and O
comorbid O
depression O
remain O
of O
paramount O
importance O
. O

Comparison O
of O
anastrozole B-intervention
versus O
tamoxifen B-control
as O
preoperative O
therapy O
in O
postmenopausal O
women O
with O
hormone O
receptor O
- O
positive O
breast O
cancer O
: O
the O
Pre O
- O
Operative O
" O
Arimidex O
" O
Compared O
to O
Tamoxifen O
( O
PROACT O
) O
trial O
. O
The O
Pre O
- O
Operative O
" O
Arimidex O
" O
Compared O
to O
Tamoxifen O
( O
PROACT O
) O
study O
was O
a O
randomized O
, O
multicenter O
study O
comparing O
anastrozole O
with O
tamoxifen O
as O
a O
preoperative O
treatment O
of O
postmenopausal O
women O
with O
large O
, O
operable O
( O
T2 O
/ O
3 O
, O
N0 O
- O
2 O
, O
M0 O
) O
, O
or O
potentially O
operable O
( O
T4b O
, O
N0 O
- O
2 O
, O
M0 O
) O
breast O
cancer O
. O
The O
effect O
of O
preoperative O
endocrine O
therapy O
in O
patients O
scheduled O
for O
mastectomy O
or O
with O
inoperable O
tumors O
at O
baseline O
was O
also O
investigated O
. O
Patients B-eligibility
with I-eligibility
hormone I-eligibility
receptor I-eligibility
- I-eligibility
positive I-eligibility
breast I-eligibility
cancer I-eligibility
received O
anastrozole O
( O
n O
= O
228 B-intervention-participants
) O
or O
tamoxifen O
( O
n O
= O
223 B-control-participants
) O
with O
or O
without O
chemotherapy O
for O
12 O
weeks O
before O
primary O
surgery O
. O
Objective B-outcome
responses I-outcome
for O
anastrozole O
and O
tamoxifen O
occurred O
in O
39.5 B-iv-bin-percent
% I-iv-bin-percent
and O
35.4 B-cv-bin-percent
% I-cv-bin-percent
of O
patients O
, O
respectively O
( O
ultrasound B-outcome
measurements I-outcome
) O
, O
and O
50.0 B-iv-bin-percent
% I-iv-bin-percent
and O
46.2 B-cv-bin-percent
% I-cv-bin-percent
of O
patients O
, O
respectively O
( O
caliper B-outcome
measurements I-outcome
) O
. O
In O
hormonal O
therapy O
- O
only O
patients O
( O
n O
= O
314 O
) O
, O
feasible B-outcome
surgery I-outcome
at O
baseline O
improved O
after B-outcome
3 I-outcome
months I-outcome
in O
43.0 B-iv-bin-percent
% I-iv-bin-percent
of O
patients O
receiving O
anastrozole O
and O
30.8 B-cv-bin-percent
% I-cv-bin-percent
receiving O
tamoxifen O
( O
P O
= O
.04 O
) O
. O
In O
the O
intent O
- O
to O
- O
treat O
population O
, O
improvement O
in O
feasible B-outcome
surgery I-outcome
at O
baseline O
to O
actual O
surgery O
at B-outcome
3 I-outcome
months I-outcome
was O
found O
to O
be O
numerically O
higher O
in O
the O
anastrozole O
group O
compared O
with O
the O
tamoxifen O
group O
, O
although O
this O
difference O
did O
not O
reach O
significance O
. O
Drug O
- O
related O
adverse B-outcome
events I-outcome
were O
reported O
in O
20.2 B-iv-bin-percent
% I-iv-bin-percent
and O
18.1 B-cv-bin-percent
% I-cv-bin-percent
of O
patients O
, O
respectively O
, O
in O
the O
anastrozole O
and O
tamoxifen O
groups O
. O
Anastrozole O
is O
an O
effective B-outcome
and I-outcome
well I-outcome
- I-outcome
tolerated I-outcome
preoperative O
therapy O
, O
producing O
clinically O
beneficial O
tumor O
downstaging O
and O
reductions O
in O
tumor O
volume O
. O
These O
effects O
enable O
more O
minimal O
surgical O
interventions O
in O
patients O
scheduled O
for O
mastectomy O
, O
and O
mastectomy O
in O
patients O
with O
previously O
inoperable O
tumors O
. O
Anastrozole O
appears O
to O
be O
at O
least O
as O
effective O
as O
tamoxifen O
in O
this O
setting O
, O
and O
more O
effective O
than O
tamoxifen O
in O
certain O
clinically O
relevant O
subgroups O
. O
Cancer O
2006 O
. O
( O
c O
) O
2006 O
American O
Cancer O
Society O
. O

Randomised O
trial O
: O
survival O
benefit O
and O
safety O
of O
adjuvant B-intervention
dose I-intervention
- I-intervention
dense I-intervention
chemotherapy I-intervention
for O
node O
- O
positive O
breast O
cancer O
. O
We O
evaluated O
the O
survival O
benefit O
, O
safety O
, O
feasibility O
, O
and O
tolerability O
of O
dose O
- O
dense O
( O
DD O
) O
adjuvant O
chemotherapy O
with O
epirubicin O
and O
paclitaxel O
for O
women B-eligibility
with I-eligibility
node I-eligibility
- I-eligibility
positive I-eligibility
primary I-eligibility
breast I-eligibility
cancer I-eligibility
. O
Randomised O
patients O
( O
n O
= O
216 B-total-participants
) O
received O
DD O
or O
conventional B-control
- I-control
schedule I-control
( I-control
CS I-control
) I-control
chemotherapy I-control
. O
Dose O
- O
dense O
regimen O
patients O
( O
n O
= O
108 B-intervention-participants
) O
received O
epirubicin O
90 O
mg O
m-2 O
plus O
paclitaxel O
175 O
mg O
m-2 O
in O
four O
14 O
- O
day O
cycles O
, O
then O
cyclophosphamide O
600 O
mg O
m-2 O
, O
methotrexate O
40 O
mg O
m-2 O
, O
and O
fluorouracil O
600 O
mg O
m-2 O
( O
CMF O
600 O
/ O
40 O
/ O
600 O
) O
in O
three O
14 O
- O
day O
cycles O
, O
plus O
filgrastim O
5 O
microg O
kg O
day-1 O
as O
growth O
support O
in O
every O
cycle O
. O
Conventional O
- O
schedule O
regimen O
patients O
( O
n O
= O
108 B-control-participants
) O
received O
epirubicin O
90 O
mg O
m-2 O
plus O
cyclophosphamide O
600 O
mg O
m-2 O
in O
four O
21 O
- O
day O
cycles O
, O
then O
CMF O
600 O
/ O
40 O
/ O
600 O
in O
three O
21 O
- O
day O
cycles O
, O
plus O
filgrastim O
if O
required O
. O
After O
a O
median O
follow O
- O
up O
of O
38.4 O
months O
, O
71 O
patients O
( O
33 O
% O
) O
relapsed B-outcome
or I-outcome
died I-outcome
: O
DD O
, O
33 B-iv-bin-abs
patients O
( O
15 B-iv-bin-abs
deaths O
) O
; O
CS O
, O
38 B-cv-bin-abs
patients O
( O
22 B-cv-bin-abs
deaths O
) O
. O
Dose O
dense O
showed O
a O
trend O
for O
improved O
disease B-outcome
- I-outcome
free I-outcome
survival I-outcome
( I-outcome
DFS I-outcome
) I-outcome
and O
overall B-outcome
survival I-outcome
( I-outcome
OS I-outcome
) I-outcome
. O
Four B-outcome
- I-outcome
year I-outcome
rates I-outcome
of I-outcome
DFS I-outcome
and O
OS B-outcome
were O
64 B-iv-bin-percent
and O
85 B-cv-bin-percent
% I-cv-bin-percent
for O
DD O
, O
and O
58 B-iv-bin-percent
and O
75 B-cv-bin-percent
% I-cv-bin-percent
for O
CS O
. O
All O
seven O
cycles O
were O
administered O
to O
208 O
patients O
( O
96 O
% O
) O
. O
Rates B-outcome
of I-outcome
cycle I-outcome
delay I-outcome
, O
discontinuation B-outcome
, O
dose B-outcome
reduction I-outcome
, O
and O
adverse B-outcome
events I-outcome
were O
similar O
in O
both O
groups O
. O
Dose O
- O
dense O
sequential O
chemotherapy O
with O
epirubicin O
/ O
paclitaxel O
then O
CMF O
, O
supported O
by O
filgrastim O
, O
is O
safe O
and O
improves O
survival O
for O
patients O
with O
node O
- O
positive O
breast O
cancer O
. O

Randomized O
multicenter O
trial O
of O
sentinel B-intervention
node I-intervention
biopsy I-intervention
versus O
standard B-control
axillary I-control
treatment I-control
in O
operable O
breast O
cancer O
: O
the O
ALMANAC O
Trial O
. O
Sentinel O
lymph O
node O
biopsy O
in O
women O
with O
operable O
breast O
cancer O
is O
routinely O
used O
in O
some O
countries O
for O
staging O
the O
axilla O
despite O
limited O
data O
from O
randomized O
trials O
on O
morbidity O
and O
mortality O
outcomes O
. O
We O
conducted O
a O
multicenter O
randomized O
trial O
to O
compare O
quality O
- O
of O
- O
life O
outcomes O
between O
patients B-eligibility
with I-eligibility
clinically I-eligibility
node I-eligibility
- I-eligibility
negative I-eligibility
invasive I-eligibility
breast I-eligibility
cancer I-eligibility
who O
received O
sentinel O
lymph O
node O
biopsy O
and O
patients O
who O
received O
standard O
axillary O
treatment O
. O
The O
primary O
outcome O
measures O
were O
arm B-outcome-measure
and I-outcome-measure
shoulder I-outcome-measure
morbidity I-outcome-measure
and O
quality B-outcome-measure
of I-outcome-measure
life I-outcome-measure
. O
From O
November O
1999 O
to O
October O
2003 O
, O
1031 B-total-participants
patients O
were O
randomly O
assigned O
to O
undergo O
sentinel O
lymph O
node O
biopsy O
( O
n O
= O
515 B-intervention-participants
) O
or O
standard O
axillary O
surgery O
( O
n O
= O
516 B-control-participants
) O
. O
Patients O
with O
sentinel O
lymph O
node O
metastases O
proceeded O
to O
delayed O
axillary O
clearance O
or O
received O
axillary O
radiotherapy O
( O
depending O
on O
the O
protocol O
at O
the O
treating O
institution O
) O
. O
Intention O
- O
to O
- O
treat O
analyses O
of O
data O
at O
1 O
, O
3 O
, O
6 O
, O
and O
12 O
months O
after O
surgery O
are O
presented O
. O
All O
statistical O
tests O
were O
two O
- O
sided O
. O
The O
relative O
risks O
of O
any B-outcome
lymphedema I-outcome
and O
sensory B-outcome
loss I-outcome
for O
the O
sentinel O
lymph O
node O
biopsy O
group O
compared O
with O
the O
standard O
axillary O
treatment O
group O
at B-outcome
12 I-outcome
months I-outcome
were O
0.37 O
( O
95 O
% O
confidence O
interval O
[ O
CI O
] O
= O
0.23 O
to O
0.60 O
; O
absolute O
rates O
: O
5 B-iv-bin-percent
% I-iv-bin-percent
versus O
13 B-cv-bin-percent
% I-cv-bin-percent
) O
and O
0.37 O
( O
95 O
% O
CI O
= O
0.27 O
to O
0.50 O
; O
absolute O
rates O
: O
11 B-iv-bin-percent
% I-iv-bin-percent
versus O
31 B-cv-bin-percent
% I-cv-bin-percent
) O
, O
respectively O
. O
Drain B-outcome
usage I-outcome
, O
length B-outcome
of I-outcome
hospital I-outcome
stay I-outcome
, O
and O
time B-outcome
to I-outcome
resumption I-outcome
of I-outcome
normal I-outcome
day I-outcome
- I-outcome
to I-outcome
- I-outcome
day I-outcome
activities I-outcome
after O
surgery O
were O
statistically O
significantly O
lower O
in O
the O
sentinel O
lymph O
node O
biopsy O
group O
( O
all O
P O
< O
.001 O
) O
, O
and O
axillary O
operative O
time O
was O
reduced O
( O
P O
= O
.055 O
) O
. O
Overall O
patient O
- O
recorded O
quality B-outcome
of I-outcome
life I-outcome
and I-outcome
arm I-outcome
functioning I-outcome
scores I-outcome
were O
statistically O
significantly O
better O
in O
the O
sentinel O
lymph O
node O
biopsy O
group O
throughout O
( O
all O
P O
< O
or O
= O
.003 O
) O
. O
These O
benefits O
were O
seen O
with O
no O
increase O
in O
anxiety B-outcome
levels I-outcome
in O
the O
sentinel O
lymph O
node O
biopsy O
group O
( O
P O
> O
.05 O
) O
. O
Sentinel O
lymph O
node O
biopsy O
is O
associated O
with O
reduced O
arm O
morbidity O
and O
better O
quality O
of O
life O
than O
standard O
axillary O
treatment O
and O
should O
be O
the O
treatment O
of O
choice O
for O
patients O
who O
have O
early O
- O
stage O
breast O
cancer O
with O
clinically O
negative O
nodes O
. O

Fifteen O
- O
year O
results O
of O
a O
randomized O
phase O
III O
trial O
of O
fenretinide B-intervention
to O
prevent O
second O
breast O
cancer O
. O
The O
synthetic O
retinoid O
fenretinide O
administered O
for O
5 O
years O
for O
prevention O
of O
second O
breast O
cancer O
showed O
no O
difference O
after O
a O
median O
of O
8 O
years O
, O
but O
a O
possible O
reduction O
in O
premenopausal O
women O
. O
We O
conducted O
a O
long O
- O
term O
analysis O
in O
a O
subgroup O
of O
women O
who O
were O
regularly O
followed O
up O
in O
a O
single O
center O
. O
We O
analyzed O
data O
after O
a O
median O
follow O
- O
up O
of O
14.6 O
years O
( O
IQ O
range O
, O
12.3 O
- O
16.3 O
years O
) O
from O
1739 B-total-participants
women O
aged B-age
30 I-age
- I-age
70 I-age
( O
872 B-intervention-participants
in O
the O
fenretinide O
arm O
and O
867 B-control-participants
in O
the O
observation B-control
arm O
) O
, O
representing O
60 O
% O
of O
the O
initial O
cohort O
of O
2867 O
women O
. O
The O
main O
efficacy O
endpoint O
was O
second B-outcome-measure
primary I-outcome-measure
breast I-outcome-measure
cancer I-outcome-measure
( I-outcome-measure
contralateral I-outcome-measure
or I-outcome-measure
ipsilateral I-outcome-measure
) I-outcome-measure
. O
The O
number B-outcome
of I-outcome
second I-outcome
breast I-outcome
cancers I-outcome
was O
168 B-iv-bin-abs
in O
the O
fenretinide O
arm O
and O
190 B-cv-bin-abs
in O
the O
control O
arm O
( O
hazard O
ratio O
= O
0.83 O
, O
95 O
% O
CI O
, O
0.67 O
- O
1.03 O
) O
. O
There O
were O
83 B-iv-bin-abs
events B-outcome
in O
the O
fenretinide O
arm O
and O
126 B-cv-bin-abs
in O
the O
observation O
arm O
in O
premenopausal O
women O
( O
HR O
= O
0.62 O
, O
95 O
% O
CI O
, O
0.46 O
- O
0.83 O
) O
, O
and O
85 B-iv-bin-abs
and O
64 B-cv-bin-abs
events O
in O
postmenopausal O
women O
( O
HR O
= O
1.23 O
, O
95 O
% O
CI O
, O
0.63 O
- O
2.40 O
) O
. O
The O
younger O
were O
the O
women O
, O
the O
greater O
was O
the O
risk O
reduction O
associated O
with O
fenretinide O
, O
which O
attained O
50 O
% O
in O
women O
aged O
40 O
years O
or O
younger O
and O
disappeared O
after O
age O
55 O
( O
P O
- O
age*treatment O
interaction O
= O
0.023 O
) O
. O
There O
was O
no O
difference O
in O
cancers B-outcome
in I-outcome
other I-outcome
organs I-outcome
, O
distant B-outcome
metastases I-outcome
or O
survival B-outcome
. O
Fenretinide O
induces O
a O
significant O
risk O
reduction O
of O
second O
breast O
cancer O
in O
premenopausal O
women O
, O
which O
is O
remarkable O
at O
younger O
ages O
, O
and O
persists O
several O
years O
after O
treatment O
cessation O
. O
Since O
adverse O
events O
are O
limited O
, O
a O
trial O
in O
young O
women O
at O
high O
- O
risk O
is O
warranted O
. O

Complete B-intervention
hormonal I-intervention
blockade I-intervention
versus O
epirubicin B-control
- I-control
based I-control
chemotherapy I-control
in O
premenopausal O
, O
one O
to O
three O
node O
- O
positive O
, O
and O
hormone O
- O
receptor O
positive O
, O
early O
breast O
cancer O
patients O
: O
7 O
- O
year O
follow O
- O
up O
results O
of O
French B-location
Adjuvant O
Study O
Group O
06 O
randomised O
trial O
. O
The O
purpose O
of O
this O
study O
was O
to O
determine O
optimal O
adjuvant O
therapy O
between O
complete O
hormonal O
blockade O
in O
premenopausal B-eligibility
patients I-eligibility
with I-eligibility
hormone I-eligibility
receptor I-eligibility
positive I-eligibility
breast I-eligibility
cancer I-eligibility
and I-eligibility
one I-eligibility
to I-eligibility
three I-eligibility
positive I-eligibility
nodes I-eligibility
. O
We O
randomised O
333 B-total-participants
patients O
to O
receive O
either O
LHRH O
agonist O
( O
triptorelin O
3.75 O
mg O
i. O
m. O
, O
monthly O
) O
plus O
tamoxifen O
30 O
mg O
/ O
day O
for O
3 O
years O
( O
TAM O
- O
LHRHa O
, O
n O
= O
164 B-intervention-participants
) O
, O
or O
fluorouracil O
500 O
mg O
/ O
m2 O
, O
epirubicin O
50 O
mg O
/ O
m2 O
and O
cyclophosphamide O
500 O
mg O
/ O
m2 O
every O
21 O
days O
for O
six O
cycles O
, O
without O
any O
hormonal O
treatment O
( O
FEC50 O
, O
n O
= O
169 B-control-participants
) O
. O
The O
7 B-outcome
- I-outcome
year I-outcome
disease I-outcome
- I-outcome
free I-outcome
survival I-outcome
( I-outcome
DFS I-outcome
) I-outcome
was O
76 B-iv-bin-percent
% I-iv-bin-percent
with O
TAM O
- O
LHRHa O
, O
and O
72 B-cv-bin-percent
% I-cv-bin-percent
with O
FEC50 O
( O
P O
= O
0.13 O
) O
. O
The O
7 B-outcome
- I-outcome
year I-outcome
overall I-outcome
survival I-outcome
( I-outcome
OS I-outcome
) I-outcome
was O
91 B-iv-bin-percent
% I-iv-bin-percent
and O
88 B-cv-bin-percent
% I-cv-bin-percent
, O
respectively O
( O
P O
= O
0.20 O
) O
. O
The O
multivariate O
analysis O
confirmed O
that O
both O
treatments O
were O
not O
different O
for O
DFS O
and O
OS O
( O
P O
= O
0.83 O
and O
P O
= O
0.41 O
, O
respectively O
) O
. O
Amenorrhoea B-outcome
occurred O
in O
64 B-cv-bin-percent
% I-cv-bin-percent
of O
patients O
treated O
with O
FEC50 O
; O
it O
was O
temporary O
in O
58 B-iv-bin-percent
% I-iv-bin-percent
of O
cases O
after O
hormonotherapy O
and O
in O
31 B-cv-bin-percent
% I-cv-bin-percent
after O
chemotherapy O
. O
In O
intermediate O
- O
risk O
breast O
cancer O
, O
complete O
hormonal O
blockade O
and O
chemotherapy O
provided O
similar O
outcomes O
. O
Hormonal O
treatment O
is O
an O
alternative O
to O
chemotherapy O
in O
hormone O
- O
sensitive O
patients O
, O
considering O
the O
preference O
of O
patients O
in O
terms O
of O
quality O
of O
life O
. O

Patient O
- O
reported O
symptoms O
and O
quality O
of O
life O
during O
treatment O
with O
tamoxifen B-intervention
or O
raloxifene B-control
for O
breast O
cancer O
prevention O
: O
the O
NSABP O
Study O
of O
Tamoxifen O
and O
Raloxifene O
( O
STAR O
) O
P-2 O
trial O
. O
Tamoxifen O
has O
been O
approved O
for O
breast O
cancer O
risk O
reduction O
in O
high O
- O
risk O
women O
, O
but O
how O
raloxifene O
compares O
with O
tamoxifen O
is O
unknown O
. O
To O
compare O
the O
differences O
in O
patient O
- O
reported O
outcomes O
, O
quality O
of O
life O
[ O
QOL O
] O
, O
and O
symptoms O
in O
Study O
of O
Tamoxifen O
and O
Raloxifene O
( O
STAR O
) O
participants O
by O
treatment O
assignment O
. O
STAR O
was O
a O
double O
- O
blind O
, O
randomized O
phase O
3 O
prevention O
trial O
designed O
to O
evaluate O
the O
relative O
efficacy O
of O
raloxifene O
vs O
tamoxifen O
in O
reducing O
the O
incidence O
of O
invasive O
breast O
cancer O
in O
high B-eligibility
- I-eligibility
risk I-eligibility
postmenopausal I-eligibility
women I-eligibility
. O
Between O
July O
1 O
, O
1999 O
, O
and O
November O
4 O
, O
2004 O
, O
19,747 B-total-participants
participants O
were O
enrolled O
at O
centers O
throughout O
North B-location
America I-location
, O
with O
a O
median O
potential O
follow O
- O
up O
time O
of O
4.6 O
years O
( O
range O
, O
1.2 O
- O
6.5 O
years O
) O
. O
Patient O
- O
reported O
symptoms O
were O
collected O
from O
all O
participants O
using O
a O
36 O
- O
item O
symptom O
checklist O
. O
Quality O
of O
life O
was O
measured O
with O
the O
Medical O
Outcomes O
Study O
Short O
- O
Form O
Health O
Survey O
( O
SF-36 O
) O
, O
the O
Center O
for O
Epidemiologic O
Studies O
- O
Depression O
( O
CES O
- O
D O
) O
, O
and O
the O
Medical O
Outcomes O
Study O
Sexual O
Activity O
Questionnaire O
in O
a O
substudy O
of O
1983 B-total-participants
participants O
, O
median O
potential O
follow O
- O
up O
5.4 O
years O
( O
range O
, O
4.6 O
- O
6.0 O
years O
) O
. O
Questionnaires O
were O
administered O
before O
treatment O
, O
every O
6 O
months O
for O
60 O
months O
and O
at O
72 O
months O
. O
Primary O
QOL O
end O
points O
were O
the O
SF-36 B-outcome-measure
physical I-outcome-measure
( I-outcome-measure
PCS I-outcome-measure
) I-outcome-measure
and O
mental B-outcome-measure
( I-outcome-measure
MCS I-outcome-measure
) I-outcome-measure
component I-outcome-measure
summaries I-outcome-measure
. O
Among O
women O
in O
the O
QOL O
analysis O
, O
mean O
PCS O
, O
MCS O
, O
and O
CES O
- O
D O
scores O
worsened O
modestly O
over O
the O
study O
's O
60 O
months O
, O
with O
no O
significant O
difference O
between O
the O
tamoxifen O
( O
n O
= O
973 B-intervention-participants
) O
and O
raloxifene O
( O
n O
= O
1010 B-control-participants
) O
groups O
( O
P>.2 O
) O
. O
Sexual B-outcome
function I-outcome
was O
slightly O
better O
for O
participants O
assigned O
to O
tamoxifen O
( O
age O
- O
adjusted O
repeated O
measure O
odds O
ratio O
, O
1.22 O
% O
; O
95 O
% O
CI O
, O
1.01 O
- O
1.46 O
) O
. O
Of O
the O
women O
in O
the O
symptom O
assessment O
analyses O
, O
the O
9769 B-control-participants
in O
the O
raloxifene O
group O
reported O
greater O
mean B-outcome
symptom I-outcome
severity I-outcome
over O
60 O
months O
of O
assessments O
than O
the O
9743 B-intervention-participants
in O
the O
tamoxifen O
group O
for O
musculoskeletal B-outcome
problems I-outcome
( O
1.15 B-iv-cont-mean
vs O
1.10 B-cv-cont-mean
, O
P O
= O
.002 O
) O
, O
dyspareunia B-outcome
( O
0.78 B-iv-cont-mean
vs O
0.68 B-cv-cont-mean
, O
P<.001 O
) O
, O
and O
weight B-outcome
gain I-outcome
( O
0.82 B-iv-cont-mean
vs O
0.76 B-cv-cont-mean
, O
P<.001 O
) O
. O
Women O
in O
the O
tamoxifen O
group O
reported O
greater O
mean B-outcome
symptom I-outcome
severity I-outcome
for I-outcome
gynecological I-outcome
problems I-outcome
( O
0.29 B-iv-cont-mean
vs O
0.19 B-cv-cont-mean
, O
P<.001 O
) O
, O
vasomotor B-outcome
symptoms I-outcome
( O
0.96 B-iv-cont-mean
vs O
0.85 B-cv-cont-mean
, O
P<.001 O
) O
, O
leg B-outcome
cramps I-outcome
( O
1.10 B-iv-cont-mean
vs O
0.91 B-cv-cont-mean
, O
P<.001 O
) O
, O
and O
bladder B-outcome
control I-outcome
symptoms I-outcome
( O
0.88 B-iv-cont-mean
vs O
0.73 B-cv-cont-mean
, O
P<.001 O
) O
. O
No O
significant O
differences O
existed O
between O
the O
tamoxifen O
and O
raloxifene O
groups O
in O
patient B-outcome
- I-outcome
reported I-outcome
outcomes I-outcome
for I-outcome
physical I-outcome
health I-outcome
, I-outcome
mental I-outcome
health I-outcome
, I-outcome
and I-outcome
depression I-outcome
, O
although O
the O
tamoxifen O
group O
reported O
better O
sexual B-outcome
function I-outcome
. O
Although O
mean O
symptom O
severity O
was O
low O
among O
these O
postmenopausal O
women O
, O
those O
in O
the O
tamoxifen O
group O
reported O
more O
gynecological O
problems O
, O
vasomotor O
symptoms O
, O
leg O
cramps O
, O
and O
bladder O
control O
problems O
, O
whereas O
women O
in O
the O
raloxifene O
group O
reported O
more O
musculoskeletal O
problems O
, O
dyspareunia O
, O
and O
weight O
gain O
. O
clinicaltrials.gov O
Identifier O
: O
NCT00003906 O
. O

Pilot O
phase O
III O
immunotherapy O
study O
in O
early O
- O
stage O
breast O
cancer O
patients O
using O
oxidized B-intervention
mannan I-intervention
- I-intervention
MUC1 I-intervention
[ O
ISRCTN71711835 O
] O
. O
Mucin O
1 O
( O
MUC1 O
) O
is O
a O
high O
molecular O
weight O
glycoprotein O
overexpressed O
on O
adenocarcinoma O
cells O
and O
is O
a O
target O
for O
immunotherapy O
protocols O
. O
To O
date O
, O
clinical O
trials O
against O
MUC1 O
have O
included O
advanced O
cancer O
patients O
. O
Herein O
, O
we O
report O
a O
trial O
using O
early O
stage O
breast O
cancer O
patients O
and O
injection O
of O
oxidized O
mannan O
- O
MUC1 O
. O
In O
a O
randomized O
, O
double O
- O
blind O
study O
, O
31 B-total-participants
patients B-eligibility
with I-eligibility
stage I-eligibility
II I-eligibility
breast I-eligibility
cancer I-eligibility
and I-eligibility
with I-eligibility
no I-eligibility
evidence I-eligibility
of I-eligibility
disease I-eligibility
received O
subcutaneous O
injections O
of O
either O
placebo B-control
or O
oxidized O
mannan O
- O
MUC1 O
, O
to O
immunize O
against O
MUC1 O
and O
prevent O
cancer O
reoccurrence O
/ O
metastases O
. O
Twenty B-total-participants
- I-total-participants
eight I-total-participants
patients O
received O
the O
full O
course O
of O
injections O
of O
either O
oxidized O
mannan O
- O
MUC1 O
or O
placebo O
. O
Survival O
and O
immunological O
assays O
were O
assessed O
. O
After O
more O
than O
5.5 O
years O
had O
elapsed O
since O
the O
last O
patient O
began O
treatment O
( O
8.5 O
years O
from O
the O
start O
of O
treatment O
of O
the O
first O
patient O
) O
, O
the O
recurrence B-outcome
rate I-outcome
in O
patients O
receiving O
the O
placebo O
was O
27 B-cv-bin-percent
% I-cv-bin-percent
( O
4 B-cv-bin-abs
/ O
15 B-control-participants
; O
the O
expected O
rate O
of O
recurrence O
in O
stage O
II O
breast O
cancer O
) O
; O
those O
receiving O
immunotherapy O
had O
no O
recurrences O
( O
0 B-iv-bin-abs
/ O
16 B-intervention-participants
) O
, O
and O
this O
finding O
was O
statistically O
significant O
( O
P O
= O
0.0292 O
) O
. O
Of O
the O
patients O
receiving O
oxidized O
mannan O
- O
MUC1 O
, O
nine B-iv-bin-abs
out O
of O
13 B-intervention-participants
had O
measurable B-outcome
antibodies I-outcome
to I-outcome
MUC1 I-outcome
and O
four B-iv-bin-abs
out O
of O
10 B-intervention-participants
had O
MUC1 B-outcome
- I-outcome
specific I-outcome
T I-outcome
cell I-outcome
responses I-outcome
; O
none B-cv-bin-abs
of O
the O
placebo O
- O
treated O
patients O
exhibited O
an O
immune O
response O
to O
MUC1 O
. O
The O
results O
suggest O
that O
, O
in O
early O
breast O
cancer O
, O
MUC1 O
immunotherapy O
is O
beneficial O
, O
and O
that O
a O
larger O
phase O
III O
study O
should O
be O
undertaken O
. O

Effect O
of O
letrozole B-intervention
versus O
placebo B-control
on O
bone O
mineral O
density O
in O
women O
with B-eligibility
primary I-eligibility
breast I-eligibility
cancer I-eligibility
completing I-eligibility
5 I-eligibility
or I-eligibility
more I-eligibility
years I-eligibility
of I-eligibility
adjuvant I-eligibility
tamoxifen I-eligibility
: O
a O
companion O
study O
to O
NCIC O
CTG O
MA.17 O
. O
Aromatase O
inhibition O
depletes O
estrogen O
levels O
and O
may O
be O
associated O
with O
accelerated O
bone O
resorption O
. O
The O
National O
Cancer O
Institute O
of O
Canada B-location
Clinical O
Trials O
Group O
( O
NCIC O
CTG O
) O
study O
MA.17B O
evaluated O
bone O
turnover O
markers O
and O
bone O
mineral O
density O
( O
BMD O
) O
in O
postmenopausal O
women O
randomly O
assigned O
to O
MA.17 O
, O
a O
placebo O
- O
controlled O
trial O
of O
letrozole O
after O
standard O
adjuvant O
tamoxifen O
. O
Eligible O
women O
had O
a O
baseline O
BMD O
T O
score O
of O
at O
least O
2.0 O
in O
either O
the O
hip O
or O
L2 O
- O
4 O
spine O
; O
all O
received O
calcium O
500 O
mg O
and O
vitamin O
D O
400 O
U O
daily O
. O
Percentage O
change O
in O
BMD O
( O
L2 O
- O
L4 O
spine O
and O
hip O
) O
at O
12 O
and O
24 O
months O
, O
rate O
of O
osteoporosis O
, O
and O
change O
in O
markers O
of O
bone O
formation O
( O
serum O
bone O
alkaline O
phosphatase O
) O
and O
resorption O
( O
serum O
C O
- O
telopeptide O
and O
urine O
N O
- O
telopeptide O
) O
at O
6 O
, O
12 O
, O
and O
24 O
months O
were O
compared O
. O
Two B-total-participants
hundred I-total-participants
twenty I-total-participants
- I-total-participants
six I-total-participants
patients O
( O
122 B-intervention-participants
letrozole O
, O
104 B-control-participants
placebo O
) O
were O
enrolled O
. O
Baseline O
characteristics O
were O
similar O
in O
the O
two O
groups O
, O
including O
BMD O
, O
median O
age O
of O
60.7 B-age
years I-age
( O
81 O
% O
< O
70 O
years O
) O
, O
and O
median O
follow O
- O
up O
of O
1.6 O
years O
. O
At O
24 O
months O
, O
patients O
receiving O
letrozole O
had O
a O
significant O
decrease O
in O
total B-outcome
hip I-outcome
BMD I-outcome
( O
-3.6 B-iv-cont-mean
% I-iv-cont-mean
v O
-0.71 B-cv-cont-mean
% I-cv-cont-mean
; O
P O
= O
.044 O
) O
and O
lumbar B-outcome
spine I-outcome
BMD I-outcome
( O
-5.35 B-iv-cont-mean
% I-iv-cont-mean
v O
-0.70 B-cv-cont-mean
% I-cv-cont-mean
; O
P O
= O
.008 O
) O
. O
Letrozole O
increased O
urine B-outcome
N I-outcome
- I-outcome
telopeptide I-outcome
at I-outcome
6 I-outcome
, I-outcome
12 I-outcome
, I-outcome
and I-outcome
24 I-outcome
months I-outcome
( O
P O
= O
.054 O
, O
< O
.001 O
, O
and O
.016 O
, O
respectively O
) O
. O
No O
patient O
went O
below O
the O
threshold O
for O
osteoporosis O
in O
total B-outcome
hip I-outcome
BMD I-outcome
, O
whereas O
at O
the O
L2 O
- O
L4 O
( O
posteroanterior O
view O
) O
, O
more O
women O
became O
osteoporotic B-outcome
by I-outcome
BMD I-outcome
while O
receiving O
letrozole O
( O
4.1 B-iv-bin-percent
% I-iv-bin-percent
v O
0 B-cv-bin-percent
% I-cv-bin-percent
; O
P O
= O
.064 O
) O
. O
After O
5 O
years O
of O
adjuvant O
tamoxifen O
, O
subsequent O
letrozole O
causes O
a O
modest O
increase O
in O
bone O
resorption O
and O
reduction O
in O
bone O
mineral O
density O
in O
the O
spine O
and O
hip O
compared O
to O
placebo O
. O
Further O
follow O
- O
up O
is O
necessary O
to O
evaluate O
the O
long O
- O
term O
clinical O
implications O
of O
this O
difference O
. O

Omission O
of O
fentanyl O
during O
sevoflurane B-intervention
anesthesia I-intervention
decreases O
the O
incidences O
of O
postoperative B-condition
nausea I-condition
and I-condition
vomiting I-condition
and O
accelerates O
postanesthesia O
recovery O
in O
major O
breast O
cancer O
surgery O
. O
Our O
purpose O
was O
to O
investigate O
the O
effect O
of O
omission O
of O
fentanyl O
during O
sevoflurane O
anesthesia O
on O
the O
incidences O
of O
postoperative O
nausea O
and O
vomiting O
and O
on O
postanesthesia O
recovery O
in O
female O
patients O
undergoing O
major O
breast O
cancer O
surgery O
. O
Female O
patients O
( O
American O
Society O
of O
Anesthesiologists O
[ O
ASA O
] O
physical O
status O
[ O
PS O
] O
class O
I O
- O
II O
; O
age O
, O
28 B-age
- I-age
84 I-age
years I-age
) O
undergoing B-eligibility
major I-eligibility
breast I-eligibility
cancer I-eligibility
surgery I-eligibility
were O
randomized O
to O
one O
of O
two O
anesthesia O
maintenance O
groups O
: O
sevoflurane O
- O
fentanyl O
anesthesia O
( O
SF O
; O
n O
= O
25 B-intervention-participants
) O
or O
fentanyl B-control
- I-control
free I-control
sevoflurane I-control
anesthesia I-control
( O
S O
; O
n O
= O
26 B-control-participants
) O
. O
All O
patients O
were O
administered O
with O
propofol O
2 O
mg O
x O
kg O
( O
-1 O
) O
intravenously O
for O
anesthesia O
induction O
, O
a O
laryngeal O
mask O
airway O
was O
placed O
, O
and O
they O
received O
rectal O
diclofenac O
and O
local O
infiltration O
anesthesia O
. O
Anesthesia O
was O
maintained O
with O
sevoflurane O
in O
oxygen O
- O
air O
and O
they O
breathed O
spontaneously O
. O
The O
patients O
in O
group O
SF O
received O
fentanyl O
0.1 O
mg O
intravenously O
and O
those O
in O
group O
S O
received O
normal O
saline O
during O
anesthesia O
. O
Group O
SF O
revealed O
higher O
incidences O
of O
postoperative B-outcome
nausea I-outcome
( O
68 B-iv-bin-percent
% I-iv-bin-percent
vs O
27 B-cv-bin-percent
% I-cv-bin-percent
) O
and O
vomiting B-outcome
( O
32 B-iv-bin-percent
% I-iv-bin-percent
vs O
8 B-cv-bin-percent
% I-cv-bin-percent
) O
in O
the O
first O
24 O
postoperative O
hours O
than O
group O
S. O
The O
median O
( O
25th-75th O
percentile O
) O
length B-outcome
of I-outcome
time I-outcome
from I-outcome
postanesthesia I-outcome
care I-outcome
unit I-outcome
( I-outcome
PACU I-outcome
) I-outcome
admission I-outcome
to I-outcome
ambulation I-outcome
was O
significantly O
longer O
in O
group O
SF O
( O
n O
= O
23 B-intervention-participants
) O
at O
195 B-iv-cont-median
min I-iv-cont-median
( O
158 B-iv-cont-q1
- O
219 B-iv-cont-q3
min I-iv-cont-q3
) O
, O
than O
in O
group O
S O
, O
at O
141 B-cv-cont-mean
min I-cv-cont-mean
( O
101 B-cv-cont-q1
- O
175 B-cv-cont-q3
min I-cv-cont-q3
) O
. O
Two B-iv-bin-abs
patients O
in O
group O
SF O
could B-outcome
not I-outcome
walk I-outcome
during I-outcome
the I-outcome
PACU I-outcome
stay I-outcome
. O
Omission O
of O
fentanyl O
during O
sevoflurane O
anesthesia O
, O
combined O
with O
diclofenac O
and O
local O
infiltration O
anesthesia O
, O
decreases O
the O
incidences O
of O
postoperative O
nausea O
and O
vomiting O
and O
accelerates O
postanesthesia O
recovery O
in O
patients O
undergoing O
major O
breast O
cancer O
surgery O
. O

Clinical O
outcomes O
of O
ethnic O
minority O
women O
in O
MA.17 O
: O
a O
trial O
of O
letrozole B-intervention
after O
5 O
years O
of O
tamoxifen O
in O
postmenopausal O
women O
with O
early O
stage O
breast O
cancer O
. O
Aromatase O
inhibitors O
are O
widely O
employed O
in O
the O
adjuvant O
treatment O
of O
early O
stage O
breast O
cancer O
. O
The O
impact O
of O
aromatase O
inhibitors O
has O
not O
been O
established O
in O
ethnic O
minority O
women O
. O
The O
purpose O
of O
this O
study O
was O
to O
evaluate O
the O
impact O
of O
letrozole O
on O
minority O
women O
in O
MA.17 O
, O
a O
placebo O
- O
controlled O
trial O
of O
letrozole O
following O
5 O
years O
of O
tamoxifen O
in O
postmenopausal B-eligibility
women I-eligibility
with I-eligibility
early I-eligibility
stage I-eligibility
breast I-eligibility
cancer I-eligibility
. O
Retrospective O
comparison O
of O
disease O
- O
free O
survival O
( O
DFS O
) O
, O
side O
effects O
, O
and O
mean O
changes O
in O
quality O
of O
life O
( O
QOL O
) O
scores O
from O
baseline O
between O
Caucasian B-ethinicity
and O
minority O
women O
was O
performed O
. O
Minority B-intervention
( O
n O
= O
352 B-intervention-participants
) O
and O
Caucasian B-control
( O
n O
= O
4708 B-control-participants
) O
women O
were O
analyzed O
. O
There O
was O
no O
difference O
between O
these O
groups O
in O
DFS B-outcome
( O
91.6 B-iv-bin-percent
% I-iv-bin-percent
versus O
92.4 B-cv-bin-percent
% I-cv-bin-percent
respectively O
for O
4 O
year O
DFS O
) O
. O
Letrozole O
, O
compared O
with O
placebo O
, O
significantly O
improved O
DFS B-outcome
for O
Caucasians O
( O
HR O
= O
0.55 O
; O
P O
< O
0.0001 O
) O
but O
not O
for O
minorities O
( O
HR O
= O
1.39 O
; O
P O
= O
0.53 O
) O
. O
Among O
women O
who O
received O
letrozole O
, O
minorities O
had O
a O
significantly O
lower O
incidence B-outcome
of I-outcome
hot I-outcome
flashes I-outcome
( O
49 B-iv-bin-percent
% I-iv-bin-percent
versus O
58 B-cv-bin-percent
% I-cv-bin-percent
; O
P O
= O
0.02 O
) O
, O
fatigue B-outcome
( O
29 B-iv-bin-percent
% I-iv-bin-percent
versus O
39 B-cv-bin-percent
% I-cv-bin-percent
; O
P O
= O
0.005 O
) O
, O
and O
arthritis B-outcome
( O
2 B-iv-bin-percent
% I-iv-bin-percent
versus O
7 B-cv-bin-percent
% I-cv-bin-percent
; O
P O
= O
0.006 O
) O
compared O
with O
Caucasians O
. O
Mean O
change O
in O
QOL B-outcome
scores I-outcome
for O
minority O
women O
who O
received O
letrozole O
demonstrated O
improved O
mental B-outcome
health I-outcome
at O
the O
6 O
- O
month O
assessment O
( O
P O
= O
0.02 O
) O
and O
less O
bodily B-outcome
pain I-outcome
at O
the O
12 O
- O
month O
assessment O
( O
P O
= O
0.046 O
) O
. O
Letrozole O
improved O
DFS B-outcome
in O
Caucasians O
but O
a O
definite O
benefit O
in O
minority O
women O
has O
not O
yet O
been O
demonstrated O
. O
Minority O
women O
tolerated O
letrozole O
better O
than O
Caucasians O
in O
terms O
of O
toxicity O
. O
These O
results O
need O
confirmation O
in O
other O
trials O
of O
aromatase O
inhibitors O
. O

Quality O
of O
life O
of O
postmenopausal O
women O
in O
the O
ATAC O
( O
" B-intervention
Arimidex I-intervention
" I-intervention
, I-intervention
tamoxifen I-intervention
, I-intervention
alone I-intervention
or I-intervention
in I-intervention
combination I-intervention
) O
trial O
after O
completion O
of O
5 O
years O
' O
adjuvant O
treatment O
for O
early O
breast O
cancer O
. O
The O
impact O
of O
treatment O
on O
health O
- O
related O
quality O
of O
life O
( O
HRQoL O
) O
is O
an O
important O
consideration O
in O
the O
adjuvant O
treatment O
of O
operable O
breast O
cancer O
. O
Here O
we O
report O
mature O
HRQoL O
outcomes O
from O
the O
ATAC O
trial O
, O
comparing O
anastrozole O
with O
tamoxifen B-control
as O
primary O
adjuvant O
therapy O
for O
postmenopausal B-eligibility
women I-eligibility
with I-eligibility
localized I-eligibility
breast I-eligibility
cancer I-eligibility
. O
Patients O
completed O
the O
Functional O
Assessment O
of O
Cancer O
Therapy O
- O
Breast O
( O
FACT O
- O
B O
) O
questionnaire O
plus O
endocrine O
subscale O
( O
ES O
) O
at O
baseline O
, O
3 O
and O
6 O
months O
, O
and O
every O
6 O
months O
thereafter O
. O
Baseline O
characteristics O
in O
the O
HRQoL O
sub O
- O
protocol O
were O
well O
balanced O
between O
the O
anastrozole O
( O
n O
= O
335 B-intervention-participants
) O
and O
tamoxifen O
( O
n O
= O
347 B-control-participants
) O
groups O
in O
the O
primary O
analysis O
population O
. O
As O
with O
previously O
published O
results O
at O
2 O
years O
, O
there O
was O
no O
statistically O
significant O
difference O
in O
the O
Trial B-outcome-measure
Outcome I-outcome-measure
Index I-outcome-measure
of I-outcome-measure
the I-outcome-measure
FACT I-outcome-measure
- I-outcome-measure
B I-outcome-measure
, O
the O
primary O
endpoint O
of O
the O
study O
, O
between O
treatments O
at O
5 O
years O
. O
There O
were O
no O
statistically O
significant O
differences O
between O
treatment O
groups O
in O
ES B-outcome
total I-outcome
scores I-outcome
. O
Consistent O
with O
the O
2 O
- O
year O
analysis O
, O
there O
were O
differences O
between O
treatment O
groups O
in O
patient O
- O
reported O
side O
effects O
: O
diarrhea B-outcome
( O
anastrozole O
3.1 B-iv-bin-percent
% I-iv-bin-percent
vs. O
tamoxifen O
1.3 B-cv-bin-percent
% I-cv-bin-percent
) O
, O
vaginal B-outcome
dryness I-outcome
( O
18.5 B-iv-bin-percent
% I-iv-bin-percent
vs. O
9.1 B-cv-bin-percent
% I-cv-bin-percent
) O
, O
diminished B-outcome
libido I-outcome
( O
34.0 B-iv-bin-percent
% I-iv-bin-percent
vs. O
26.1 B-cv-bin-percent
% I-cv-bin-percent
) O
, O
and O
dyspareunia B-outcome
( O
17.3 B-iv-bin-percent
% I-iv-bin-percent
vs. O
8.1 B-cv-bin-percent
% I-cv-bin-percent
) O
were O
significantly O
more O
frequent O
with O
anastrozole O
compared O
to O
tamoxifen O
. O
Dizziness B-outcome
( O
3.1 B-iv-bin-percent
% I-iv-bin-percent
vs. O
5.4 B-cv-bin-percent
% I-cv-bin-percent
) O
and O
vaginal B-outcome
discharge I-outcome
( O
1.2 B-iv-bin-percent
% I-iv-bin-percent
vs. O
5.2 B-cv-bin-percent
% I-cv-bin-percent
) O
were O
significantly O
less O
frequent O
with O
anastrozole O
compared O
to O
tamoxifen O
. O
In O
this O
, O
the O
first O
report O
of O
HRQoL O
over O
5 O
years O
of O
initial O
adjuvant O
therapy O
with O
an O
aromatase O
inhibitor O
, O
we O
conclude O
that O
anastrozole O
and O
tamoxifen O
had O
similar O
impacts O
on O
HRQoL O
, O
which O
was O
maintained O
or O
slightly O
improved O
during O
the O
treatment O
period O
for O
both O
groups O
. O

Ten O
- O
year O
follow O
- O
up O
results O
of O
a O
randomised O
controlled O
study O
comparing O
level B-control
- I-control
I I-control
vs O
level B-intervention
- I-intervention
III I-intervention
axillary I-intervention
lymph I-intervention
node I-intervention
dissection I-intervention
for O
primary O
breast O
cancer O
. O
The O
most O
appropriate O
level O
of O
axillary O
dissection O
for O
breast O
cancer O
remains O
unclear O
. O
The O
present O
randomised O
study O
compared O
the O
treatment O
results O
of O
level O
- O
I O
vs O
level O
- O
III O
dissection O
in O
T1 O
/ O
2 O
/ O
3 O
and O
N0 O
/ O
1a O
/ O
1b O
( O
1987 O
UICC O
classification O
) O
breast B-eligibility
cancer I-eligibility
without I-eligibility
distant I-eligibility
metastasis I-eligibility
. O
Between O
1995 O
and O
1997 O
, O
522 B-total-participants
patients O
were O
enrolled O
, O
and O
514 B-total-participants
were O
eligible O
. O
They O
were O
stratified O
into O
breast O
- O
conserving O
surgery O
or O
mastectomy O
, O
and O
then O
further O
stratified O
into O
level O
- O
III O
dissection O
( O
group O
- O
A O
, O
n O
= O
258 B-intervention-participants
) O
or O
level O
- O
I O
dissection O
( O
group O
- O
B O
, O
n O
= O
256 B-control-participants
) O
. O
All O
patients O
were O
given O
oral O
5 O
- O
fluorouracil O
at O
200 O
mg O
day-1 O
and O
tamoxifen O
at O
20 O
mg O
day-1 O
, O
daily O
for O
2 O
years O
. O
Group O
- O
A O
resulted O
in O
a O
significantly O
longer O
operation B-outcome
time I-outcome
( O
77.0 B-iv-cont-mean
vs O
60.5 B-cv-cont-mean
min I-cv-cont-mean
, O
P<0.0001 O
) O
and O
significantly O
larger O
blood B-outcome
loss I-outcome
( O
62.1 B-iv-cont-mean
vs O
48.1 B-cv-cont-mean
ml I-cv-cont-mean
, O
P<0.0001 O
) O
than O
group O
- O
B O
, O
but O
in O
no O
significant O
differences O
in O
the O
frequencies O
of O
arm B-outcome
oedema I-outcome
and I-outcome
shoulder I-outcome
disturbance I-outcome
. O
Group O
- O
A O
resulted O
in O
a O
significantly O
larger O
number B-outcome
of I-outcome
dissected I-outcome
nodes I-outcome
than O
group O
- O
B O
( O
18.7 B-iv-cont-mean
vs O
14.8 B-cv-cont-mean
, O
P<0.0001 O
) O
, O
but O
in O
no O
differences O
in O
the O
number B-outcome
of I-outcome
involved I-outcome
nodes I-outcome
( O
1.54 B-iv-cont-mean
vs O
1.44 B-cv-cont-mean
) O
. O
There O
were O
no O
significant O
differences O
in O
the O
10 B-outcome
- I-outcome
year I-outcome
overall I-outcome
and O
disease B-outcome
- I-outcome
free I-outcome
survival I-outcome
rates I-outcome
: O
89.6 B-iv-bin-percent
and O
76.6 B-iv-bin-percent
% I-iv-bin-percent
for O
group O
- O
A O
vs O
87.8 B-cv-bin-percent
and O
74.1 B-cv-bin-percent
% I-cv-bin-percent
for O
group O
- O
B O
, O
respectively O
. O
In O
conclusion O
, O
level O
- O
III O
dissection O
resulted O
in O
a O
longer O
operation B-outcome
time I-outcome
and O
greater O
blood B-outcome
loss I-outcome
than O
level O
- O
I O
, O
but O
did O
not O
improve O
the O
survival B-outcome
rate I-outcome
. O
Level O
- O
III O
dissection O
is O
not O
a O
recommended O
surgery O
for O
T1 O
- O
3 O
/ O
N0 O
- O
1b O
breast O
cancer O
. O

Impact O
of O
on B-intervention
- I-intervention
site I-intervention
initiation I-intervention
visits I-intervention
on O
patient O
recruitment O
and O
data O
quality O
in O
a O
randomized O
trial O
of O
adjuvant O
chemotherapy O
for O
breast O
cancer O
. O
To O
provide O
empirical O
evidence O
on O
the O
impact O
of O
on O
- O
site O
initiation O
visits O
on O
the O
following O
outcomes O
: O
patient O
recruitment O
, O
quantity O
and O
quality O
of O
data O
submitted O
to O
the O
trial O
coordinating O
office O
, O
and O
patients O
' O
follow O
- O
up O
time O
. O
This O
methodological O
study O
was O
performed O
as O
part O
of O
a O
randomized O
trial O
comparing O
two O
combination O
chemotherapies O
for O
adjuvant O
treatment O
of O
breast O
cancer O
. O
Centers O
participating O
to O
the O
trial O
were O
randomized O
to O
either O
receive O
systematic O
on O
- O
site O
visits O
( O
Visited O
group O
) O
, O
or O
not B-control
( I-control
Non I-control
- I-control
visited I-control
group I-control
) I-control
. O
The O
study O
was O
terminated O
after O
two O
years O
, O
while O
the O
main O
randomized O
trial O
continued O
. O
Of O
the O
135 B-total-participants
centers O
that O
had O
expressed O
an O
interest O
in O
the O
trial O
, O
only O
69 B-total-participants
randomized O
at O
least O
one O
patient O
( O
35 O
/ O
68 O
in O
the O
Visited O
group O
, O
34 O
/ O
67 O
in O
the O
Non O
- O
visited O
group O
) O
. O
Almost O
two O
- O
thirds O
of O
the O
patients O
were O
entered O
by O
17 B-total-participants
centers O
( O
10 B-intervention-participants
in O
the O
Visited O
group O
, O
seven B-control-participants
in O
the O
Non O
- O
visited O
group O
) O
that O
accrued O
more O
than O
10 O
patients O
each O
. O
None O
of O
the O
prespecified O
outcomes O
favored O
the O
group O
of O
centers O
submitted O
to O
on O
- O
site O
initiation O
visits O
( O
ie O
, O
mean O
number B-outcome
of I-outcome
queries I-outcome
par I-outcome
patient I-outcome
: O
6.1 B-iv-cont-mean
+ O
/- O
9.7 B-iv-cont-sd
versus O
5.4 B-cv-cont-mean
+ O
/- O
6.4 B-cv-cont-sd
, O
respectively O
for O
the O
Visited O
and O
Non O
- O
visited O
groups O
) O
. O
Spontaneous B-outcome
transmittal I-outcome
of I-outcome
case I-outcome
report I-outcome
forms I-outcome
, O
although O
required O
by O
protocol O
, O
was O
low O
in O
both O
randomized O
groups O
( O
mean O
number O
of O
pages O
per O
patient O
: O
1.5 B-iv-cont-mean
+ O
/- O
2.0 B-iv-cont-sd
versus O
2.1 B-cv-cont-mean
+ O
/- O
2.3 B-cv-cont-sd
, O
respectively O
) O
, O
with O
investigators O
submitting B-outcome
about I-outcome
one I-outcome
- I-outcome
third I-outcome
of I-outcome
the I-outcome
expected I-outcome
forms I-outcome
on I-outcome
time I-outcome
( O
29 B-iv-bin-percent
% I-iv-bin-percent
and O
39 B-cv-bin-percent
% I-cv-bin-percent
, O
respectively O
) O
. O
This O
study O
could O
not O
evaluate O
the O
impact O
of O
repeated O
on O
- O
site O
visits O
on O
clinical O
outcomes O
. O
Systematic O
on O
- O
site O
initiation O
visits O
did O
not O
contribute O
significantly O
to O
this O
clinical O
trial O
. O

Epirubicin B-intervention
- I-intervention
based I-intervention
chemotherapy I-intervention
as O
adjuvant O
treatment O
for O
poor O
prognosis O
, O
node O
- O
negative O
breast O
cancer O
: O
10 O
- O
year O
follow O
- O
up O
results O
of O
the O
French O
Adjuvant O
Study O
Group O
03 O
trial O
. O
We O
evaluated O
the O
contribution O
of O
an O
epirubicin O
- O
based O
adjuvant O
chemotherapy O
on O
disease O
- O
free O
survival O
( O
DFS O
) O
in O
poor O
prognosis O
, O
node B-eligibility
- I-eligibility
negative I-eligibility
breast I-eligibility
cancer I-eligibility
( I-eligibility
BC I-eligibility
) I-eligibility
patients I-eligibility
. O
Poor O
prognostic O
factors O
were O
defined O
as O
: O
pathologic O
tumor O
size O
> O
or O
= O
4 O
cm O
, O
estrogen O
- O
receptor O
negative O
, O
and O
progesterone O
- O
receptor O
negative O
. O
Scarff O
- O
Bloom O
Richardson O
grade O
2 O
tumors O
must O
have O
two O
of O
these O
factors O
, O
and O
only O
one O
in O
case O
of O
grade O
3 O
. O
Between O
1988 O
and O
1994 O
, O
328 B-total-participants
patients O
were O
randomized O
to O
receive O
either O
no B-control
systemic I-control
treatment I-control
( I-control
control I-control
, O
n O
= O
161 B-control-participants
) O
, O
or O
fluorouracil O
500 O
mg O
/ O
m O
( O
2 O
) O
, O
epirubicin O
50 O
mg O
/ O
m O
( O
2 O
) O
, O
cyclophosphamide O
500 O
mg O
/ O
m O
( O
2 O
) O
, O
6 O
cycles O
every O
21 O
days O
( O
FEC50 O
, O
n O
= O
167 B-intervention-participants
) O
, O
without O
any O
hormonal O
treatment O
. O
The O
median O
follow O
up O
was O
114 O
months O
. O
The O
10 B-outcome
- I-outcome
year I-outcome
DFS I-outcome
rates I-outcome
were O
64 B-cv-bin-percent
and O
71 B-iv-bin-percent
% I-iv-bin-percent
, O
respectively O
( O
p O
= O
0.23 O
) O
. O
In O
the O
Cox O
regression O
model O
, O
independent O
prognostic O
factors O
of O
relapse O
were O
the O
number O
of O
nodes O
examined O
< O
10 O
( O
p O
= O
0.002 O
) O
, O
BCS O
( O
p O
= O
0.01 O
) O
, O
and O
premenopausal O
status O
( O
p O
= O
0.04 O
) O
. O
In O
this O
model O
, O
the O
relative O
risk B-outcome
of I-outcome
relapse I-outcome
was O
1.46 O
( O
CI95 O
% O
: O
1.05 O
- O
1.87 O
) O
in O
favor O
of O
FEC50 O
. O
In O
patients O
who O
underwent O
BCS O
, O
21 O
% O
developed O
a O
local B-outcome
relapse I-outcome
( O
24 B-cv-bin-percent
versus O
18 B-iv-bin-percent
% I-iv-bin-percent
, O
respectively O
) O
. O
The O
10 B-outcome
- I-outcome
year I-outcome
local I-outcome
DFS I-outcome
was O
70.5 B-cv-bin-percent
and O
79.3 B-iv-bin-percent
% I-iv-bin-percent
, O
respectively O
( O
p O
= O
0.27 O
) O
. O
The O
10 B-outcome
- I-outcome
year I-outcome
overall I-outcome
survival I-outcome
was O
not O
different O
( O
74.1 B-cv-bin-percent
versus O
70.7 B-iv-bin-percent
% I-iv-bin-percent
, O
p O
= O
0.82 O
) O
. O
After O
10 O
years O
of O
follow O
- O
up O
, O
the O
FEC50 O
regimen O
reduced O
the O
risk B-outcome
of I-outcome
relapse I-outcome
in O
poor O
- O
prognosis O
node O
- O
negative O
BC O
patients O
. O
The O
incidence B-outcome
of I-outcome
local I-outcome
relapse I-outcome
was O
high O
, O
and O
probably O
related O
to O
inclusion O
criteria O
. O
Epirubicin O
was O
probably O
underdosed O
in O
such O
patients O
, O
and O
ongoing O
studies O
using O
100 O
mg O
/ O
m O
( O
2 O
) O
of O
epirubicin O
will O
give O
us O
the O
answer O
in O
a O
near O
future O
. O

A O
randomized O
phase O
II O
trial O
comparing O
preoperative B-intervention
plus I-intervention
perioperative I-intervention
chemotherapy I-intervention
with O
preoperative O
chemotherapy O
in O
patients O
with O
locally O
advanced O
breast O
cancer O
. O
The O
aim O
of O
this O
study O
was O
to O
investigate O
in O
a O
randomized O
trial O
the O
activity O
of O
perioperative O
chemotherapy O
in O
patients B-eligibility
treated I-eligibility
with I-eligibility
preoperative I-eligibility
chemotherapy I-eligibility
for I-eligibility
locally I-eligibility
advanced I-eligibility
breast I-eligibility
cancer I-eligibility
and O
to O
compare O
it O
with O
the O
preoperative O
chemotherapy O
alone O
. O
Patients O
with O
cT2 O
- O
3 O
N0 O
- O
2 O
M0 O
histologically O
proven O
breast O
cancer O
, O
with O
estrogen O
receptors O
and O
progesterone O
receptors O
in O
less O
than O
20 O
% O
of O
cells O
, O
or O
with O
absence O
of O
progesterone O
receptors O
, O
received O
epirubicin O
25 O
mg O
/ O
m O
days O
1 O
and O
2 O
, O
cisplatin O
60 O
mg O
/ O
m O
day O
1 O
, O
and O
fluorouracil O
200 O
mg O
/ O
m O
daily O
as O
continuous O
infusion O
. O
Responding O
patients O
were O
randomized O
to O
continue O
fluorouracil O
until O
2 O
weeks O
after O
surgery O
( O
perioperative O
chemotherapy O
) O
or O
to O
stop O
fluorouracil O
1 O
week O
before O
surgery O
. O
Fifty B-total-participants
- I-total-participants
eight I-total-participants
patients O
completed O
six O
courses O
of O
epirubicin O
, O
cisplatin O
and O
fluorouracil O
, O
and O
were O
randomized O
to O
perioperative O
chemotherapy O
( O
29 B-intervention-participants
patients O
) O
or O
to O
control B-control
( O
29 B-control-participants
patients O
) O
. O
The O
median B-outcome
Ki-67 I-outcome
index I-outcome
remained O
stable O
( O
32 O
- O
27.5 O
% O
) O
in O
the O
perioperative O
chemotherapy O
arm O
( O
P O
= O
0.3 O
) O
and O
decreased O
from O
55 O
to O
22.5 O
% O
in O
the O
control O
arm O
( O
P O
= O
0.01 O
) O
. O
The O
rate B-outcome
of I-outcome
pathological I-outcome
complete I-outcome
remission I-outcome
was O
41 B-iv-bin-percent
% I-iv-bin-percent
in O
both O
arms O
( O
P O
= O
1.0 O
) O
. O
No O
significant O
difference O
in O
terms O
of O
disease B-outcome
- I-outcome
free I-outcome
survival I-outcome
and I-outcome
overall I-outcome
survival I-outcome
was O
observed O
between O
the O
two O
arms O
. O
Perioperative O
chemotherapy O
failed O
to O
show O
an O
increase O
in O
the O
pathological O
complete O
remission O
rate O
. O
A O
biological O
effect O
on O
Ki-67 O
expression O
was O
demonstrated O
. O

Phase O
III O
trial O
comparing O
doxorubicin B-intervention
plus I-intervention
cyclophosphamide I-intervention
with O
docetaxel B-control
plus I-control
cyclophosphamide I-control
as O
adjuvant O
therapy O
for O
operable O
breast O
cancer O
. O
The O
combination O
of O
doxorubicin O
and O
cyclophosphamide O
( O
AC O
) O
is O
a O
standard O
adjuvant O
chemotherapy O
regimen O
. O
Studies O
of O
docetaxel O
and O
cyclophosphamide O
( O
TC O
) O
in O
metastatic O
breast O
cancer O
( O
MBC O
) O
showed O
promise O
in O
MBC O
. O
In O
1997 O
, O
we O
initiated O
a O
randomized O
adjuvant O
trial O
of O
TC O
compared O
with O
standard O
- O
dose O
AC O
with O
a O
primary O
end O
point O
of O
disease B-outcome-measure
- I-outcome-measure
free I-outcome-measure
survival I-outcome-measure
( I-outcome-measure
DFS I-outcome-measure
) I-outcome-measure
. O
Patients O
were O
eligible O
if O
they O
had O
stage B-eligibility
I I-eligibility
to I-eligibility
III I-eligibility
operable I-eligibility
invasive I-eligibility
breast I-eligibility
cancer I-eligibility
with I-eligibility
complete I-eligibility
surgical I-eligibility
excision I-eligibility
of I-eligibility
the I-eligibility
primary I-eligibility
tumor I-eligibility
. O
Between O
June O
1997 O
and O
December O
1999 O
, O
1,016 B-total-participants
patients O
were O
randomly O
assigned O
to O
four O
cycles O
of O
either O
standard O
- O
dose O
AC O
( O
60 O
and O
600 O
mg O
/ O
m2 O
, O
respectively O
; O
n O
= O
510 B-intervention-participants
) O
or O
TC O
( O
75 O
and O
600 O
mg O
/ O
m2 O
, O
respectively O
; O
n O
= O
506 B-control-participants
) O
, O
administered O
intravenously O
every O
3 O
weeks O
as O
adjuvant O
chemotherapy O
. O
Radiation O
therapy O
( O
as O
indicated O
) O
and O
tamoxifen O
, O
for O
patients O
with O
hormone O
receptor O
- O
positive O
disease O
, O
were O
administered O
after O
completion O
of O
chemotherapy O
. O
Both O
treatment O
groups O
( O
TC O
and O
AC O
) O
were O
well O
balanced O
with O
respect O
to O
major O
prognostic O
factors O
. O
Patients O
were O
observed O
through O
2005 O
for O
a O
median O
of O
5.5 O
years O
. O
At O
5 O
years O
, O
DFS B-outcome
rate I-outcome
was O
significantly O
superior O
for O
TC O
compared O
with O
AC O
( O
86 B-iv-bin-percent
% I-iv-bin-percent
v O
80 B-cv-bin-percent
% I-cv-bin-percent
, O
respectively O
; O
hazard O
ratio O
[ O
HR O
] O
= O
0.67 O
; O
95 O
% O
CI O
, O
0.50 O
to O
0.94 O
; O
P O
= O
.015 O
) O
. O
Overall B-outcome
survival I-outcome
rates I-outcome
for O
TC O
and O
AC O
were O
90 B-iv-bin-percent
% I-iv-bin-percent
and O
87 B-cv-bin-percent
% I-cv-bin-percent
, O
respectively O
( O
HR O
= O
0.76 O
; O
95 O
% O
CI O
, O
0.52 O
to O
1.1 O
; O
P O
= O
.13 O
) O
. O
More O
myalgia B-outcome
, I-outcome
arthralgia I-outcome
, I-outcome
edema I-outcome
, I-outcome
and I-outcome
febrile I-outcome
neutropenia I-outcome
occurred O
on O
the O
TC O
arm O
; O
more O
nausea B-outcome
and I-outcome
vomiting I-outcome
occurred O
on O
the O
AC O
arm O
as O
well O
as O
one O
incident O
of O
congestive B-outcome
heart I-outcome
failure I-outcome
. O
At O
5 O
years O
, O
TC O
was O
associated O
with O
a O
superior O
DFS O
and O
a O
different O
toxicity O
profile O
compared O
with O
AC O
. O

Randomized O
, O
placebo O
- O
controlled O
trial O
of O
Saforis B-intervention
for O
prevention O
and O
treatment O
of O
oral O
mucositis O
in O
breast B-eligibility
cancer I-eligibility
patients I-eligibility
receiving I-eligibility
anthracycline I-eligibility
- I-eligibility
based I-eligibility
chemotherapy I-eligibility
. O
Oral O
mucositis O
( O
OM O
) O
is O
a O
frequent O
complication O
of O
mucotoxic O
cancer O
therapy O
, O
causing O
significant O
oral O
pain O
, O
increased O
infection O
risk O
, O
and O
impaired O
functioning O
. O
The O
efficacy O
and O
safety O
of O
Saforis O
( O
glutamine O
) O
powder O
in O
UpTec O
for O
oral O
suspension O
was O
evaluated O
for O
the O
prevention O
and O
treatment O
of O
OM O
. O
Three B-total-participants
hundred I-total-participants
twenty I-total-participants
- I-total-participants
six I-total-participants
patients O
developing O
World O
Health O
Organization O
( O
WHO O
) O
grade O
> O
or O
= O
2 O
OM O
during O
a O
chemotherapy O
screening O
cycle O
were O
randomized O
to O
Saforis O
( O
n O
= O
163 B-intervention-participants
) O
or O
placebo B-control
( O
n O
= O
163 B-control-participants
) O
3 O
times O
/ O
day O
during O
their O
next O
chemotherapy O
cycle O
( O
Treatment O
Cycle O
1 O
) O
. O
Patients O
were O
crossed O
over O
to O
the O
alternate O
treatment O
during O
Treatment O
Cycle O
2 O
. O
As O
prespecified O
in O
the O
statistical O
plan O
, O
because O
of O
a O
carryover O
effect O
in O
Treatment O
Cycle O
2 O
the O
primary O
efficacy O
analysis O
was O
based O
on O
Treatment O
Cycle O
1 O
only O
. O
Compared O
with O
placebo O
, O
Saforis O
significantly O
reduced O
the O
incidence O
of O
clinically O
significant O
WHO B-outcome
grade I-outcome
> I-outcome
or I-outcome
= I-outcome
2 I-outcome
OM I-outcome
( O
38.7 B-iv-bin-percent
% I-iv-bin-percent
vs. O
49.7 B-cv-bin-percent
% I-cv-bin-percent
; O
P O
= O
.026 O
) O
and O
severe B-outcome
WHO I-outcome
grade I-outcome
> I-outcome
or I-outcome
=3 I-outcome
OM I-outcome
( O
1.2 B-iv-bin-percent
% I-iv-bin-percent
vs. O
6.7 B-cv-bin-percent
% I-cv-bin-percent
; O
P O
= O
.005 O
) O
in O
Treatment O
Cycle O
1 O
. O
Saforis O
also O
significantly O
reduced O
the O
worst B-outcome
Oral I-outcome
Mucositis I-outcome
Assessment I-outcome
Scale I-outcome
ulceration I-outcome
score I-outcome
in O
Treatment O
Cycle O
1 O
compared O
with O
placebo O
( O
mean O
, O
0.23 B-iv-cont-mean
+ O
/- O
0.39 B-iv-cont-sd
vs. O
0.32 B-cv-cont-mean
+ O
/- O
0.45 B-cv-cont-sd
; O
P O
= O
.013 O
) O
. O
Patients O
receiving O
Saforis O
in O
Treatment O
Cycle O
1 O
had O
a O
lower O
- O
than O
- O
expected O
OM O
incidence O
when O
crossed O
over O
to O
placebo O
in O
Treatment O
Cycle O
2 O
, O
indicating O
a O
significant O
carryover O
effect O
( O
P O
= O
.027 O
) O
. O
The O
incidence O
of O
treatment O
- O
emergent O
adverse B-outcome
events I-outcome
was O
similar O
between O
groups O
. O
Saforis O
is O
safe O
and O
effective O
for O
preventing O
and O
treating O
OM O
in O
patients O
receiving O
mucotoxic O
cancer O
chemotherapy O
. O

Zoledronic B-intervention
acid I-intervention
prevents O
cancer O
treatment O
- O
induced O
bone B-condition
loss I-condition
in O
premenopausal B-eligibility
women I-eligibility
receiving I-eligibility
adjuvant I-eligibility
endocrine I-eligibility
therapy I-eligibility
for I-eligibility
hormone I-eligibility
- I-eligibility
responsive I-eligibility
breast I-eligibility
cancer I-eligibility
: O
a O
report O
from O
the O
Austrian B-location
Breast O
and O
Colorectal O
Cancer O
Study O
Group O
. O
Adjuvant O
therapy O
for O
breast O
cancer O
can O
be O
associated O
with O
decreased O
bone O
mineral O
density O
( O
BMD O
) O
that O
may O
lead O
to O
skeletal O
morbidity O
. O
This O
study O
examined O
whether O
zoledronic O
acid O
can O
prevent O
bone O
loss O
associated O
with O
adjuvant O
endocrine O
therapy O
in O
premenopausal O
patients O
. O
This O
study O
is O
a O
randomized O
, O
open O
- O
label O
, O
phase O
III O
, O
four O
- O
arm O
trial O
comparing O
tamoxifen B-intervention
( O
20 O
mg O
/ O
d O
orally O
) O
and O
goserelin B-intervention
( O
3.6 O
mg O
every O
28 O
days O
subcutaneously O
) O
+ O
/- O
zoledronic O
acid O
( O
4 O
mg O
intravenously O
every O
6 O
months O
) O
versus O
anastrozole B-intervention
( O
1 O
mg O
/ O
d O
orally O
) O
and O
goserelin O
+ O
/- O
zoledronic O
acid O
for O
3 O
years O
in O
premenopausal O
women O
with O
hormone O
- O
responsive O
breast O
cancer O
. O
In O
a O
BMD O
subprotocol O
at O
three O
trial O
centers O
, O
patients O
underwent O
serial O
BMD O
measurements O
at O
0 O
, O
6 O
, O
12 O
, O
24 O
, O
and O
36 O
months O
. O
Four B-total-participants
hundred I-total-participants
one I-total-participants
patients O
were O
included O
in O
the O
BMD O
subprotocol O
. O
Endocrine O
treatment O
without O
zoledronic O
acid O
led O
to O
significant O
( O
P O
< O
.001 O
) O
overall B-outcome
bone I-outcome
loss I-outcome
after O
3 O
years O
of O
treatment O
( O
BMD O
, O
-14.4 O
% O
after O
36 O
months O
; O
mean O
T O
score O
reduction O
, O
-1.4 O
) O
. O
Overall B-outcome
bone I-outcome
loss I-outcome
was O
significantly O
more O
severe O
in O
patients O
receiving O
anastrozole O
/ O
goserelin O
( O
BMD O
, O
-17.3 O
% O
; O
mean O
T O
score O
reduction O
, O
-2.6 O
) O
compared O
with O
patients O
receiving O
tamoxifen O
/ O
goserelin O
( O
BMD O
, O
-11.6 O
% O
; O
mean O
T O
score O
reduction O
, O
-1.1 O
) O
. O
In O
contrast O
, O
BMD B-outcome
remained O
stable O
in O
zoledronic O
acid O
- O
treated O
patients O
( O
P O
< O
.0001 O
compared O
with O
endocrine O
therapy O
alone O
) O
. O
No O
interactions O
with O
age O
or O
other O
risk O
factors O
were O
noted O
. O
Endocrine O
therapy O
caused O
significant O
bone O
loss O
that O
increased O
with O
treatment O
duration O
in O
premenopausal O
women O
with O
breast O
cancer O
. O
Zoledronic O
acid O
4 O
mg O
every O
6 O
months O
effectively O
inhibited O
bone O
loss O
. O
Regular O
BMD O
measurements O
and O
initiation O
of O
concomitant O
bisphosphonate O
therapy O
on O
evidence O
of O
bone O
loss O
should O
be O
considered O
for O
patients O
undergoing O
endocrine O
therapy O
. O

Long O
- O
term O
safety O
of O
intravenous O
ibandronic B-intervention
acid I-intervention
for O
up O
to O
4 O
years O
in O
metastatic O
breast O
cancer O
: O
an O
open O
- O
label O
trial O
. O
Despite O
their O
widespread O
use O
in O
metastatic O
bone O
disease O
, O
some O
bisphosphonate O
drugs O
are O
associated O
with O
adverse O
events O
( O
AEs O
) O
, O
particularly O
renal O
toxicity O
, O
adding O
to O
treatment O
burdens O
and O
increasing O
healthcare O
costs O
. O
Ibandronic O
acid O
is O
a O
single O
- O
nitrogen O
bisphosphonate O
with O
high O
efficacy O
against O
bone O
events O
and O
metastatic O
bone O
pain O
, O
and O
a O
renal O
safety O
profile O
compar- O
able O
to O
that O
of O
placebo O
. O
In O
this O
study O
, O
the O
safety O
of O
ibandronic O
acid O
was O
examined O
over O
a O
period O
of O
4 O
years O
. O
During O
an O
initial O
96 O
- O
week O
period O
, O
breast B-eligibility
cancer I-eligibility
patients I-eligibility
with I-eligibility
bone I-eligibility
metastases I-eligibility
were O
randomised O
in O
double O
- O
blind O
fashion O
to O
placebo B-control
or O
ibandronic O
acid O
6 O
mg O
administered O
by O
intravenous O
infusion O
over O
1 O
- O
2 O
hours O
every O
3 O
- O
4 O
weeks O
as O
part O
of O
a O
previously O
reported O
phase O
III O
trial O
( O
MF O
4265 O
study O
) O
. O
All O
patients O
completing O
the O
phase O
III O
trial O
were O
offered O
open O
- O
label O
active O
treatment O
for O
a O
further O
96 O
weeks O
( O
extension O
phase O
) O
. O
A O
total O
of O
62 B-total-participants
patients O
received O
ibandronic O
acid O
6 O
mg O
in O
this O
extension O
phase O
and O
were O
classified O
according O
to O
their O
initial O
treatment O
( O
placebo O
/ O
ibandronic O
acid O
6 O
mg O
[ O
placebo O
/ O
6 O
mg O
] O
and O
ibandronic O
acid O
6mg O
/ O
ibandronic O
acid O
6 O
mg O
[ O
6mg O
/ O
6 O
mg O
] O
groups O
) O
. O
Safety O
was O
assessed O
by O
AE O
reports O
and O
clinical O
laboratory O
evaluations O
. O
During O
the O
4 O
- O
year O
study O
, O
most O
patients O
experienced O
at O
least O
one O
AE O
, O
with O
malignancy O
progression O
being O
most O
commonly O
reported O
. O
However O
, O
fewer O
treatment B-outcome
- I-outcome
related I-outcome
AEs I-outcome
were O
reported O
in B-outcome
the I-outcome
extension I-outcome
phase I-outcome
( O
placebo O
/ O
6 O
mg O
: O
6.3 B-cv-bin-percent
% I-cv-bin-percent
[ O
1 B-cv-bin-abs
/ O
16 B-control-participants
] O
; O
6mg O
/ O
6 O
mg O
: O
13.0 B-iv-bin-percent
% I-iv-bin-percent
[ O
6 B-iv-bin-abs
/ O
46 B-intervention-participants
] O
) O
than O
in B-outcome
the I-outcome
initial I-outcome
phase I-outcome
of O
the O
study O
( O
placebo O
: O
56.3 B-cv-bin-percent
% I-cv-bin-percent
[ O
9 B-cv-bin-abs
/ O
16 B-control-participants
] O
; O
6 O
mg O
: O
67.4 B-iv-bin-percent
% I-iv-bin-percent
[ O
31 B-iv-bin-abs
/ O
46 B-intervention-participants
] O
) O
. O
Serious O
AEs B-outcome
were O
mainly O
due O
to O
malignancy O
progression O
. O
There O
were O
no O
clinically O
relevant O
renal B-outcome
AEs I-outcome
, O
and O
in O
both O
groups O
, O
serum B-outcome
creatinine I-outcome
levels I-outcome
were O
similar O
for O
up O
to O
4 O
years O
. O
This O
96 O
- O
week O
open O
- O
label O
safety O
extension O
of O
a O
phase O
III O
, O
placebo O
- O
controlled O
trial O
demonstrates O
that O
long O
- O
term O
use O
of O
intravenous O
ibandronic O
acid O
is O
well O
tolerated O
. O

[ O
Randomized O
controlled O
trial O
of O
two O
kinds O
of O
home B-intervention
- I-intervention
produced I-intervention
docetaxel I-intervention
in O
China B-location
for O
advanced B-eligibility
breast I-eligibility
cancer I-eligibility
] O
. O
Two O
kinds O
of O
home O
- O
produced O
docetaxel O
in O
China O
, O
injection O
Yiyoutasai O
and O
injection O
Aisu O
, O
have O
the O
same O
structure O
. O
Data O
from O
preclinical O
study O
had O
shown O
that O
injection O
Yiyoutasai O
has O
the O
same O
pharmacokinetics O
and O
toxicity O
as O
injection O
Aisu O
. O
This O
study O
was O
to O
evaluate O
the O
efficacy O
and O
toxicity O
of O
injection O
Yiyoutasai O
in O
treating O
advanced O
breast O
cancer O
. O
Eligible O
breast O
cancer O
patients O
were O
enrolled O
and O
randomly O
assigned O
to O
study O
group O
and O
control B-control
group I-control
, O
and O
received O
injection O
of O
75 O
mg O
/ O
m O
( O
2 O
) O
Yiyoutasai B-intervention
or O
Aisu B-control
, O
respectively O
. O
The O
injections O
were O
repeated O
every O
3 O
weeks O
. O
All O
patients O
received O
at O
least O
2 O
cycles O
. O
The O
efficacy O
of O
Yiyoutasai O
and O
Aisu O
were O
evaluated O
after O
treatment O
. O
A O
total O
of O
67 B-total-participants
patients O
were O
enrolled O
: O
33 B-intervention-participants
in O
study O
group O
, O
and O
34 B-control-participants
in O
control O
group O
. O
Of O
the O
31 B-intervention-participants
evaluable O
cases O
in O
study O
group O
, O
1 B-iv-bin-abs
achieved O
complete B-outcome
remission I-outcome
( I-outcome
CR I-outcome
) I-outcome
, O
9 B-iv-bin-abs
achieved O
partial B-outcome
remission I-outcome
( I-outcome
PR I-outcome
) I-outcome
, O
11 B-iv-bin-abs
had O
stable B-outcome
disease I-outcome
( I-outcome
SD I-outcome
) I-outcome
, O
and O
10 B-iv-bin-abs
had O
progressive B-outcome
disease I-outcome
( I-outcome
PD I-outcome
) I-outcome
; O
the O
total B-outcome
response I-outcome
rate I-outcome
was O
22.22 B-iv-bin-percent
% I-iv-bin-percent
. O
There O
were O
1 B-cv-bin-abs
CR B-outcome
, O
5 B-cv-bin-abs
PR B-outcome
, O
19 B-cv-bin-abs
SD B-outcome
, O
and O
9 B-cv-bin-abs
PD B-outcome
in O
control O
group O
; O
the O
total B-outcome
response I-outcome
rate I-outcome
was O
15.15 B-cv-bin-percent
% I-cv-bin-percent
. O
There O
was O
no O
significant O
difference O
between O
the O
2 O
groups O
( O
P O
= O
0.662 O
) O
. O
The O
median O
follow O
- O
up O
was O
16.5 O
months O
( O
8 O
- O
28 O
months O
) O
. O
In O
study O
group O
, O
the O
median B-outcome
progression I-outcome
- I-outcome
free I-outcome
survival I-outcome
time I-outcome
was O
6.2 B-iv-cont-median
months I-iv-cont-median
( O
2 O
- O
12 O
months O
) O
, O
the O
1 B-outcome
- I-outcome
year I-outcome
survival I-outcome
rate I-outcome
was O
68.51 B-iv-bin-percent
% I-iv-bin-percent
, O
and O
the O
2 B-outcome
- I-outcome
year I-outcome
survival I-outcome
rate I-outcome
was O
40.12 B-iv-bin-percent
% I-iv-bin-percent
; O
in O
control O
group O
, O
the O
median B-outcome
progression I-outcome
- I-outcome
free I-outcome
survival I-outcome
time I-outcome
was O
7.1 B-cv-cont-median
months I-cv-cont-median
( O
2.3 O
- O
11 O
months O
) O
, O
the O
1 B-outcome
- I-outcome
year I-outcome
survival I-outcome
rate I-outcome
was O
65.23 B-cv-bin-percent
% I-cv-bin-percent
, O
and O
the O
2 B-outcome
- I-outcome
year I-outcome
survival I-outcome
rate I-outcome
was O
39.71 B-cv-bin-percent
% I-cv-bin-percent
. O
There O
was O
no O
significant O
difference O
between O
the O
2 O
groups O
( O
P O
= O
0.102 O
, O
0.098 O
, O
0.089 O
, O
respectively O
) O
. O
Common O
adverse B-outcome
events I-outcome
were O
myelosuppression B-outcome
, I-outcome
transient I-outcome
transaminase I-outcome
elevation I-outcome
, I-outcome
and I-outcome
alopecia I-outcome
. O
One B-iv-bin-abs
patient O
in O
study O
group O
suffered O
from O
severe B-outcome
allergic I-outcome
reaction I-outcome
after O
infusion O
, O
1 B-cv-bin-abs
in O
control O
group O
suffered O
from O
whole B-outcome
body I-outcome
edema I-outcome
. O
Yiyoutasai O
and O
Aisu O
have O
similar O
efficacy O
on O
and O
toxicity O
to O
advanced O
breast O
cancer O
patients O
. O

A O
phase O
II O
randomized O
study O
of O
two O
taxanes B-intervention
and I-intervention
cisplatin I-intervention
for O
metastatic O
breast O
cancer O
after O
anthracycline O
: O
a O
final O
analysis O
. O
The O
purpose O
of O
the O
study O
is O
to O
compare O
two O
taxanes O
/ O
cisplatin O
combinations O
for O
metastatic O
breast O
cancer O
in O
terms O
of O
time O
to O
disease O
progression O
, O
response O
rates O
and O
toxicity O
. O
Between O
April O
2000 O
and O
December O
2002 O
, O
101 B-total-participants
patients B-eligibility
with I-eligibility
advanced I-eligibility
breast I-eligibility
carcinoma I-eligibility
, I-eligibility
previously I-eligibility
treated I-eligibility
with I-eligibility
an I-eligibility
anthracycline I-eligibility
but I-eligibility
not I-eligibility
with I-eligibility
a I-eligibility
taxane I-eligibility
, O
were O
enrolled O
. O
Fifty B-intervention-participants
patients O
were O
treated O
with O
docetaxel O
60 O
mg O
/ O
m2 O
and O
cisplatin O
50 O
mg O
/ O
m2 O
, O
and O
51 B-control-participants
patients O
were O
treated O
with O
paclitaxel B-control
175 I-control
mg I-control
/ I-control
m2 I-control
and I-control
cisplatin I-control
50 I-control
mg I-control
/ I-control
m2 I-control
. O
Each O
cycle O
repeated O
every O
3 O
weeks O
. O
The O
overall B-outcome
response I-outcome
rate I-outcome
was O
62.5 B-iv-bin-percent
and O
42.6 B-cv-bin-percent
% I-cv-bin-percent
in O
the O
docetaxel O
and O
palcitaxel O
groups O
respectively O
( O
P O
= O
0.06 O
) O
. O
Median B-outcome
time I-outcome
to I-outcome
disease I-outcome
progression I-outcome
was O
9.8 B-iv-cont-median
and O
6.5 B-cv-cont-median
months I-cv-cont-median
in O
docetaxel O
and O
paclitaxel O
groups O
respectively O
( O
P O
= O
0.15 O
) O
. O
The O
median B-outcome
overall I-outcome
survival I-outcome
time I-outcome
was O
22.7 B-iv-cont-median
months I-iv-cont-median
in O
the O
docetaxel O
arm O
and O
22.4 B-cv-cont-median
months I-cv-cont-median
in O
the O
paclitaxel O
arm O
. O
Grade B-outcome
3 I-outcome
/ I-outcome
4 I-outcome
arthralgia I-outcome
/ I-outcome
myalgia I-outcome
, O
sensory B-outcome
neuropathy I-outcome
and O
anemia B-outcome
occurred O
more O
frequently O
in O
the O
paclitaxel O
arm O
, O
while O
more O
mucositis B-outcome
, O
fatigue B-outcome
and O
neutropenia B-outcome
occurred O
in O
the O
docetaxel O
arm O
. O
Taxane O
/ O
cisplatin O
combinations O
were O
active O
for O
advanced O
breast O
cancer O
, O
while O
there O
appeared O
to O
be O
evidence O
in O
favor O
of O
a O
docetaxel O
/ O
cisplatin O
combination O
. O
The O
toxicity O
in O
favor O
of O
docetaxel O
/ O
cisplatin O
warrants O
future O
first O
- O
line O
clinical O
trials O
. O

Five O
years O
of O
letrozole B-intervention
compared O
with O
tamoxifen B-control
as O
initial O
adjuvant O
therapy O
for O
postmenopausal O
women O
with O
endocrine O
- O
responsive O
early O
breast O
cancer O
: O
update O
of O
study O
BIG O
1 O
- O
98 O
. O
Previous O
analyses O
of O
the O
Breast O
International O
Group O
( O
BIG O
) O
1 O
- O
98 O
four O
- O
arm O
study O
compared O
initial O
therapy O
with O
letrozole O
or O
tamoxifen O
including O
patients O
randomly O
assigned O
to O
sequential O
treatment O
whose O
information O
was O
censored O
at O
the O
time O
of O
therapy O
change O
. O
Because O
this O
presentation O
may O
unduly O
reflect O
early O
events O
, O
the O
present O
analysis O
is O
limited O
to O
patients O
randomly O
assigned O
to O
the O
continuous O
therapy O
arms O
and O
includes O
protocol O
- O
defined O
updated O
results O
. O
Four B-total-participants
thousand I-total-participants
nine I-total-participants
hundred I-total-participants
twenty I-total-participants
- I-total-participants
two I-total-participants
of O
the O
8,028 O
postmenopausal B-eligibility
women I-eligibility
with I-eligibility
receptor I-eligibility
- I-eligibility
positive I-eligibility
early I-eligibility
breast I-eligibility
cancer I-eligibility
randomly O
assigned O
( O
double O
- O
blind O
) O
to O
the O
BIG O
1 O
- O
98 O
trial O
were O
assigned O
to O
5 O
years O
of O
continuous O
adjuvant O
therapy O
with O
either O
letrozole O
or O
tamoxifen O
; O
the O
remainder O
of O
women O
were O
assigned O
to O
receive O
the O
agents O
in O
sequence O
. O
Disease B-outcome-measure
- I-outcome-measure
free I-outcome-measure
survival I-outcome-measure
( I-outcome-measure
DFS I-outcome-measure
) I-outcome-measure
was O
the O
primary O
end O
point O
. O
At O
a O
median O
follow O
- O
up O
time O
of O
51 O
months O
, O
we O
observed O
352 B-iv-bin-abs
DFS B-outcome
events I-outcome
among O
2,463 B-intervention-participants
women O
receiving O
letrozole O
and O
418 B-cv-bin-abs
events O
among O
2,459 B-control-participants
women O
receiving O
tamoxifen O
. O
This O
reflected O
an O
18 O
% O
reduction O
in O
the O
risk B-outcome
of I-outcome
an I-outcome
event I-outcome
( O
hazard O
ratio O
, O
0.82 O
; O
95 O
% O
CI O
, O
0.71 O
to O
0.95 O
; O
P O
= O
.007 O
) O
. O
No O
predefined O
subsets O
showed O
differential O
benefit O
. O
Adverse B-outcome
events I-outcome
were O
similar O
to O
previous O
reports O
. O
Patients O
on O
tamoxifen O
experienced O
more O
thromboembolic B-outcome
events I-outcome
, O
endometrial B-outcome
pathology I-outcome
, O
hot B-outcome
flashes I-outcome
, O
night B-outcome
sweats I-outcome
, O
and O
vaginal B-outcome
bleeding I-outcome
. O
Patients O
on O
letrozole O
experienced O
more O
bone B-outcome
fractures I-outcome
, O
arthralgia B-outcome
, O
low B-outcome
- I-outcome
grade I-outcome
hypercholesterolemia I-outcome
, O
and O
cardiovascular B-outcome
events I-outcome
other O
than O
ischemia O
and O
cardiac O
failure O
. O
The O
present O
updated O
analysis O
, O
which O
was O
limited O
to O
patients O
on O
monotherapy O
arms O
in O
BIG O
1 O
- O
98 O
, O
yields O
results O
similar O
to O
those O
from O
the O
previous O
primary O
analysis O
but O
more O
directly O
comparable O
with O
results O
from O
other O
trials O
of O
continuous O
therapy O
using O
a O
single O
endocrine O
agent O
. O

Venlafaxine B-intervention
is O
superior O
to O
clonidine B-control
as O
treatment O
of O
hot B-condition
flashes I-condition
in O
breast O
cancer O
patients O
-- O
a O
double O
- O
blind O
, O
randomized O
study O
. O
Classical O
hormone O
replacement O
therapy O
for O
hot O
flashes O
is O
contraindicated O
in O
breast O
cancer O
especially O
in O
endocrine O
responsive O
disease O
. O
In O
a O
double O
- O
blind O
, O
randomized O
phase O
III O
study O
, O
breast B-eligibility
cancer I-eligibility
patients I-eligibility
suffering I-eligibility
from I-eligibility
hot I-eligibility
flashes I-eligibility
at I-eligibility
least I-eligibility
twice I-eligibility
a I-eligibility
day I-eligibility
, I-eligibility
who I-eligibility
were I-eligibility
not I-eligibility
taking I-eligibility
any I-eligibility
medication I-eligibility
against I-eligibility
hypertension I-eligibility
and I-eligibility
depression I-eligibility
received O
either O
clonidine O
0.075 O
mg O
twice O
a O
day O
or O
venlafaxine O
37.5 O
mg O
twice O
a O
day O
for O
4 O
weeks O
. O
The O
primary O
end O
point O
was O
defined O
as O
the O
frequency B-outcome-measure
of I-outcome-measure
hot I-outcome-measure
flashes I-outcome-measure
after O
4 O
weeks O
of O
treatment O
. O
A O
self O
- O
reported O
1 O
- O
week O
hot O
flash O
and O
other O
symptom O
questionnaire O
were O
kept O
before O
the O
start O
of O
treatment O
until O
the O
end O
of O
treatment O
course O
. O
From O
April O
2002 O
to O
October O
2004 O
, O
80 B-total-participants
patients O
were O
recruited O
of O
whom O
64 B-total-participants
were O
assessable O
for O
efficacy O
analyses O
. O
Thirty B-control-participants
- I-control-participants
three I-control-participants
received O
clonidine O
and O
31 B-intervention-participants
venlafaxine O
, O
nine O
patients O
stopped O
early O
because O
of O
side O
- O
effects O
and O
seven O
withdrew O
consent O
. O
At O
the O
end O
of O
treatment O
week O
4 O
, O
the O
median B-outcome
hot I-outcome
flash I-outcome
frequency I-outcome
dropped O
by O
7.6 B-iv-cont-median
hot O
flashes O
per O
day O
for O
patients O
receiving O
venlafaxine O
and O
4.85 B-cv-cont-median
hot O
flashes O
per O
day O
for O
those O
receiving O
clonidine O
( O
P O
= O
0.025 O
) O
. O
Venlafaxine O
is O
significantly O
more O
effective O
in O
reducing O
the O
frequency O
of O
hot O
flashes O
in O
breast O
cancer O
patients O
than O
clonidine O
. O

[ O
Efficacy O
of O
activated B-intervention
charcoal I-intervention
- I-intervention
epirubicin I-intervention
suspension O
for O
treatment O
of O
breast O
cancer O
with O
axillary O
metastasis O
] O
. O
To O
investigate O
the O
effect O
of O
activated O
charcoal O
- O
epirubicin O
suspension O
( O
Epi O
- O
CH O
) O
for O
treatment O
of O
breast O
cancer O
and O
clearance O
of O
axillary O
lymph O
node O
metastasis O
. O
Sixty B-total-participants
patients B-eligibility
with I-eligibility
breast I-eligibility
cancer I-eligibility
of I-eligibility
stages I-eligibility
II I-eligibility
- I-eligibility
III I-eligibility
were O
randomized O
into O
Epi O
- O
CH O
group O
( O
n O
= O
40 B-intervention-participants
) O
receiving O
injection O
with O
10 O
mg O
Epi O
- O
CH O
in O
the O
tissue O
around O
the O
primary O
tumor O
72 O
h O
before O
modified O
radical O
resection O
and O
control O
group O
( O
n O
= O
20 B-control-participants
) O
with O
10 O
mg O
of O
aqueous B-control
epirubicin I-control
injection O
in O
the O
same O
region O
. O
The O
dissected O
axillary O
lymph O
nodes O
and O
the O
staining O
lymph O
nodes O
were O
counted O
. O
The O
concentration O
of O
epirubicin O
in O
the O
lymph O
nodes O
was O
detected O
by O
high O
- O
performance O
liquid O
chorography O
, O
and O
the O
specimens O
of O
lymph O
nodes O
were O
observed O
microscopically O
. O
In O
comparison O
with O
the O
control O
group O
, O
Epi O
- O
CH O
injection O
allowed O
dissection O
of O
4.04 O
more O
lymph O
nodes O
( O
P<0.01 O
) O
and O
resulted O
in O
the O
staining B-outcome
rate I-outcome
of I-outcome
the I-outcome
axillary I-outcome
lymph I-outcome
nodes O
of O
86.9 B-iv-bin-percent
% I-iv-bin-percent
( O
565 B-iv-bin-abs
/ O
650 B-intervention-participants
) O
. O
The O
proportion B-outcome
of I-outcome
the I-outcome
staining I-outcome
lymph I-outcome
nodes I-outcome
with I-outcome
diameter>1.0 I-outcome
cm I-outcome
was O
significantly O
lower O
than O
that O
with O
diameter O
< O
or O
= O
1.0 O
cm O
( O
96 B-iv-bin-abs
/ O
131 B-intervention-participants
vs O
469 B-cv-bin-abs
/ O
519 B-control-participants
, O
P<0.01 O
) O
. O
The O
metastatic B-outcome
rate I-outcome
of I-outcome
stained I-outcome
lymph I-outcome
nodes I-outcome
was O
similar O
with O
that O
in O
non O
- O
stained O
lymph O
nodes O
( O
214 B-iv-bin-abs
/ O
565 B-intervention-participants
vs O
23 B-cv-bin-abs
/ O
85 B-control-participants
, O
P>0.05 O
) O
. O
In O
Epi O
- O
CH O
group O
, O
the O
concentration B-outcome
of I-outcome
epirubicin I-outcome
in I-outcome
the I-outcome
stained I-outcome
lymph I-outcome
nodes I-outcome
was O
significantly O
higher O
than O
that O
in O
non O
- O
stained O
ones O
( O
443.0 B-iv-cont-mean
-/+ O
123.1 B-iv-cont-sd
vs O
31.8 B-cv-cont-mean
-/+ O
11.9 B-cv-cont-sd
ng I-cv-cont-sd
/ I-cv-cont-sd
g I-cv-cont-sd
, O
P<0.01 O
) O
. O
Remarkable O
degeneration B-outcome
and O
necrosis B-outcome
could O
be O
observed O
microscopically O
in O
the O
stained O
lymph O
nodes O
. O
Epi O
- O
CH O
allows O
more O
effective O
treatment O
of O
breast O
cancer O
and O
clearance O
of O
axiliary O
metastasis O
by O
increasing O
the O
dissected O
lymph O
nodes O
and O
raising O
the O
concentration O
of O
epirubicin O
in O
the O
axillary O
lymph O
nodes O
. O

Twenty O
- O
year O
follow O
- O
up O
of O
the O
Royal O
Marsden O
randomized O
, O
double O
- O
blinded O
tamoxifen B-intervention
breast O
cancer O
prevention O
trial O
. O
Several O
clinical O
trials O
have O
reported O
an O
early O
reduction O
in O
breast O
cancer O
incidence O
in O
healthy O
women O
using O
tamoxifen O
to O
reduce O
their O
risk O
of O
breast O
cancer O
but O
have O
not O
reported O
longer O
follow O
- O
up O
data O
for O
the O
evaluation O
of O
breast O
cancer O
prevention O
. O
We O
report O
the O
blinded O
20 O
- O
year O
follow O
- O
up O
( O
median O
follow O
- O
up O
= O
13 O
years O
) O
of O
the O
Royal O
Marsden O
trial O
to O
identify O
any O
long O
- O
term O
prevention O
of O
breast O
cancer O
associated O
with O
tamoxifen O
treatment O
. O
We O
randomly O
assigned O
2494 B-total-participants
healthy B-eligibility
women I-eligibility
to O
oral O
tamoxifen O
( O
20 O
mg O
/ O
day O
) O
or O
placebo B-control
for O
8 O
years O
. O
The O
primary O
outcome O
was O
occurrence B-outcome-measure
of I-outcome-measure
invasive I-outcome-measure
breast I-outcome-measure
cancer I-outcome-measure
. O
A O
secondary O
planned O
analysis O
of O
estrogen B-outcome-measure
receptor I-outcome-measure
( I-outcome-measure
ER I-outcome-measure
) I-outcome-measure
-positive I-outcome-measure
invasive I-outcome-measure
breast I-outcome-measure
cancer I-outcome-measure
was O
also O
done O
. O
Survival O
was O
assessed O
by O
use O
of O
a O
Cox O
proportional O
hazards O
model O
in O
both O
univariate O
and O
multivariable O
analyses O
. O
The O
durability O
of O
the O
treatment O
effect O
was O
assessed O
by O
use O
of O
a O
Cox O
regression O
analysis O
. O
All O
statistical O
tests O
were O
two O
- O
sided O
. O
Among O
the O
2471 B-total-participants
eligible O
participants O
( O
1238 B-intervention-participants
participants O
in O
the O
tamoxifen O
arm O
and O
1233 B-control-participants
participants O
in O
the O
placebo O
arm O
) O
, O
186 O
developed O
invasive B-outcome
breast I-outcome
cancer I-outcome
( O
82 B-iv-bin-abs
on O
tamoxifen O
and O
104 B-cv-bin-abs
on O
placebo O
; O
hazard O
ratio O
[ O
HR O
] O
= O
0.78 O
, O
95 O
% O
confidence O
interval O
[ O
CI O
] O
= O
0.58 O
to O
1.04 O
; O
P O
= O
.1 O
) O
. O
Of O
these O
186 O
cancers O
, O
139 O
were O
ER B-outcome
positive I-outcome
( O
53 B-iv-bin-abs
on O
tamoxifen O
and O
86 B-cv-bin-abs
on O
placebo O
; O
HR O
= O
0.61 O
, O
95 O
% O
CI O
= O
0.43 O
to O
0.86 O
; O
P O
= O
.005 O
) O
. O
The O
risk B-outcome
of I-outcome
ER I-outcome
- I-outcome
positive I-outcome
breast I-outcome
cancer I-outcome
was O
not O
statistically O
significantly O
lower O
in O
the O
tamoxifen O
arm O
than O
in O
the O
placebo O
arm O
during O
the O
8 O
- O
year O
treatment O
period O
( O
30 B-iv-bin-abs
cancers O
in O
the O
tamoxifen O
arm O
and O
39 B-cv-bin-abs
in O
the O
placebo O
arm O
; O
HR O
= O
0.77 O
, O
95 O
% O
CI O
= O
0.48 O
to O
1.23 O
; O
P O
= O
.3 O
) O
but O
was O
statistically O
significantly O
lower O
in O
the O
posttreatment B-outcome
period I-outcome
( O
23 B-iv-bin-abs
in O
the O
tamoxifen O
arm O
and O
47 B-cv-bin-abs
in O
the O
placebo O
arm O
; O
HR O
= O
0.48 O
, O
95 O
% O
CI O
= O
0.29 O
to O
0.79 O
; O
P O
= O
.004 O
) O
. O
Fifty B-iv-bin-abs
- I-iv-bin-abs
four I-iv-bin-abs
participants O
in O
each O
arm O
have O
died B-outcome
from O
any O
cause O
( O
HR O
= O
0.99 O
, O
95 O
% O
CI O
= O
0.68 O
to O
1.44 O
; O
P O
= O
.95 O
) O
. O
The O
adverse B-outcome
event I-outcome
profiles I-outcome
for O
both O
arms O
were O
similar O
to O
those O
previously O
reported O
and O
occurred O
predominantly O
during O
the O
treatment O
period O
. O
A O
statistically O
significant O
reduction O
in O
the O
incidence O
of O
ER O
- O
positive O
breast O
cancer O
was O
observed O
in O
the O
tamoxifen O
arm O
that O
occurred O
predominantly O
during O
the O
post O
treatment O
follow O
- O
up O
, O
indicating O
long O
- O
term O
prevention O
of O
estrogen O
- O
dependent O
breast O
cancer O
by O
tamoxifen O
. O

The O
ratio O
of O
positive O
to O
excised O
nodes O
identifies O
high O
- O
risk O
subsets O
and O
reduces O
inter O
- O
institutional O
differences O
in O
locoregional O
recurrence O
risk O
estimates O
in O
breast O
cancer O
patients O
with O
1 O
- O
3 O
positive O
nodes O
: O
an O
analysis O
of O
prospective O
data O
from O
British B-location
Columbia I-location
and O
the O
M.D. O
Anderson O
Cancer O
Center O
. O
To O
examine O
the O
power B-intervention
of I-intervention
the I-intervention
nodal I-intervention
ratio I-intervention
( I-intervention
NR I-intervention
) I-intervention
of O
positive O
/ O
excised O
nodes O
in O
predicting O
postmastectomy O
locoregional O
recurrence O
( O
LRR O
) O
in O
patients O
with O
1 O
- O
3 O
positive O
nodes O
( O
N+ O
) O
and O
in O
identifying O
cohorts O
at O
similar O
risk O
across O
independent O
data O
sets O
. O
Data O
from O
82 B-intervention-participants
patients B-eligibility
with I-eligibility
1 I-eligibility
- I-eligibility
3 I-eligibility
N+ I-eligibility
treated I-eligibility
without I-eligibility
postmastectomy I-eligibility
radiotherapy I-eligibility
( I-eligibility
PMRT I-eligibility
) I-eligibility
in I-eligibility
the I-eligibility
British I-eligibility
Columbia I-eligibility
( I-eligibility
BC I-eligibility
) I-eligibility
randomized O
trial O
were O
compared O
with O
data O
from O
462 B-control-participants
patients O
treated B-control
without I-control
PMRT I-control
in O
prospective O
chemotherapy O
trials O
at O
the O
M.D. O
Anderson O
Cancer O
Center O
( O
MDACC O
) O
. O
Kaplan O
- O
Meier O
LRR O
curves O
were O
compared O
between O
centers O
using O
the O
absolute O
number O
of O
N+ O
and O
nodal O
ratios O
. O
The O
median B-outcome
number I-outcome
of I-outcome
excised I-outcome
nodes I-outcome
was O
10 B-iv-cont-median
in O
BC O
and O
16 B-cv-cont-median
in O
MDACC O
( O
p O
< O
0.001 O
) O
. O
Examining O
LRR O
by O
number O
of O
N+ O
, O
the O
10 B-outcome
- I-outcome
year I-outcome
LRR I-outcome
rate I-outcome
for O
patients O
with O
1 O
- O
3 O
N+ O
was O
higher O
in O
BC O
compared O
with O
MDACC O
( O
21.5 B-iv-bin-percent
% I-iv-bin-percent
vs. O
12.6 B-cv-bin-percent
% I-cv-bin-percent
; O
p O
= O
0.02 O
) O
. O
However O
, O
when O
examining O
LRR O
using O
NR O
, O
no O
differences O
were O
found O
between O
institutions O
. O
In O
patients B-outcome
with I-outcome
NR I-outcome
< I-outcome
or I-outcome
= I-outcome
0.20 I-outcome
, O
the O
10 B-outcome
- I-outcome
year I-outcome
LRR I-outcome
rate I-outcome
was O
17.7 B-iv-bin-percent
% I-iv-bin-percent
BC O
vs. O
10.9 B-cv-bin-percent
% I-cv-bin-percent
MDACC O
( O
p O
= O
0.27 O
) O
. O
In O
patients B-outcome
with I-outcome
NR I-outcome
> I-outcome
or I-outcome
= I-outcome
0.20 I-outcome
, O
the O
10 B-outcome
- I-outcome
year I-outcome
LRR I-outcome
rate I-outcome
was O
28.7 B-iv-bin-percent
% I-iv-bin-percent
BC O
vs. O
22.7 B-cv-bin-percent
% I-cv-bin-percent
MDACC O
( O
p O
= O
0.32 O
) O
. O
On O
Cox O
regression O
analysis O
, O
NR O
was O
a O
stronger O
prognostic O
factor O
compared O
with O
number O
of O
N O
+ O
. O
In O
patients O
with O
1 O
- O
3 O
N+ O
, O
evaluating O
nodal O
positivity O
using O
NR O
reduced O
inter O
- O
institutional O
differences O
in O
LRR O
estimates O
that O
may O
exist O
due O
to O
variations O
in O
numbers O
of O
nodes O
excised O
. O
Nodal O
ratio O
> O
0.20 O
was O
associated O
with O
LRR O
> O
20 O
% O
, O
warranting O
PMRT O
consideration O
. O
Nodal O
ratio O
may O
be O
useful O
for O
extrapolating O
data O
from O
prospective O
trials O
to O
clinical O
practices O
in O
which O
axillary O
staging O
extent O
vary O
. O

Letrozole B-intervention
in O
advanced O
breast O
cancer O
: O
the O
PO25 O
trial O
. O
Tamoxifen O
has O
been O
a O
standard O
first O
- O
line O
endocrine O
therapy O
for O
post O
- O
menopausal O
women O
with O
hormone O
- O
responsive O
advanced O
breast O
cancer O
, O
but O
more O
than O
half O
of O
patients O
fail O
to O
respond O
and O
time O
to O
progression O
is O
less O
than O
12 O
months O
in O
responders O
. O
The O
third O
- O
generation O
aromatase O
inhibitors O
were O
developed O
to O
provide O
more O
effective O
alternatives O
to O
tamoxifen O
. O
In O
the O
Femara O
Study O
PO25 O
, O
post B-eligibility
- I-eligibility
menopausal I-eligibility
women I-eligibility
with I-eligibility
advanced I-eligibility
breast I-eligibility
cancer I-eligibility
were O
randomized O
to O
receive O
letrozole O
2.5 O
mg O
( O
n O
= O
453 B-intervention-participants
) O
or O
tamoxifen B-control
20 O
mg O
( O
n O
= O
454 B-control-participants
) O
given O
orally O
daily O
until O
progressive O
disease O
occurred O
. O
Patients O
were O
permitted O
to O
cross O
over O
to O
the O
other O
treatment O
at O
progression O
. O
In O
the O
primary O
efficacy O
analysis O
, O
median B-outcome
time I-outcome
to I-outcome
progression I-outcome
( I-outcome
TTP I-outcome
) I-outcome
was O
significantly O
longer O
with O
letrozole O
than O
with O
tamoxifen O
( O
9.4 B-iv-cont-median
months I-iv-cont-median
vs. O
6.0 B-cv-cont-median
months I-cv-cont-median
, O
respectively O
; O
P<0.0001 O
) O
. O
The O
objective B-outcome
response I-outcome
rate I-outcome
( I-outcome
ORR I-outcome
) I-outcome
was O
significantly O
higher O
for O
letrozole O
than O
for O
tamoxifen O
( O
32 B-iv-bin-percent
% I-iv-bin-percent
vs. O
21 B-cv-bin-percent
% I-cv-bin-percent
; O
P O
= O
0.0002 O
) O
. O
Prospectively O
planned O
analyses O
of O
the O
intent O
- O
to O
- O
treat O
population O
showed O
that O
letrozole O
significantly O
improved O
overall B-outcome
survival I-outcome
( I-outcome
OS I-outcome
) I-outcome
compared O
with O
tamoxifen O
over O
the O
first O
24 O
months O
of O
the O
trial O
. O
An O
exploratory O
analysis O
of O
patients O
, O
who O
did O
not O
cross O
over O
, O
indicated O
a O
median B-outcome
OS I-outcome
benefit O
of O
14 O
months O
for O
letrozole O
compared O
with O
tamoxifen O
. O
Letrozole O
is O
the O
only O
third O
- O
generation O
aromatase O
inhibitor O
that O
has O
demonstrated O
significant O
improvements O
in O
ORR O
, O
TTP O
, O
and O
early O
OS O
. O

Lumpectomy B-intervention
plus I-intervention
tamoxifen I-intervention
or I-intervention
anastrozole I-intervention
with I-intervention
or I-intervention
without I-intervention
whole I-intervention
breast I-intervention
irradiation I-intervention
in O
women B-eligibility
with I-eligibility
favorable I-eligibility
early I-eligibility
breast I-eligibility
cancer I-eligibility
. O
In O
women O
with O
favorable O
early O
breast O
cancer O
treated O
by O
lumpectomy O
plus O
tamoxifen O
or O
anastrazole O
, O
it O
remains O
unclear O
whether O
whole O
breast O
radiotherapy O
is O
beneficial O
. O
Between O
January O
1996 O
and O
June O
2004 O
, O
the O
Austrian B-location
Breast O
and O
Colorectal O
Cancer O
Study O
Group O
( O
ABCSG O
) O
randomly O
assigned O
869 B-total-participants
women O
to O
receive O
breast O
radiotherapy O
+ O
/- O
boost O
( O
n O
= O
414 B-intervention-participants
) O
or O
not B-control
( O
n O
= O
417 B-control-participants
) O
after O
breast O
- O
conserving O
surgery O
( O
ABCSG O
Study O
8A O
) O
. O
Favorable O
early O
breast O
cancer O
was O
specified O
as O
tumor O
size O
<3 O
cm O
, O
Grading O
1 O
or O
2 O
, O
negative O
lymph O
nodes O
, O
positive O
estrogen O
and/or O
progesterone O
receptor O
status O
, O
and O
manageable O
by O
breast O
- O
conserving O
surgery O
. O
Breast O
radiotherapy O
was O
performed O
after O
lumpectomy O
with O
2 O
tangential O
opposed O
breast O
fields O
with O
mean O
50 O
Gy O
, O
plus O
boost O
in O
71 O
% O
of O
patients O
with O
mean O
10 O
Gy O
, O
in O
a O
median O
of O
6 O
weeks O
. O
The O
primary O
endpoint O
was O
local B-outcome-measure
relapse I-outcome-measure
- I-outcome-measure
free I-outcome-measure
survival I-outcome-measure
; O
further O
endpoints O
were O
contralateral B-outcome-measure
breast I-outcome-measure
cancer I-outcome-measure
, O
distant B-outcome-measure
metastases I-outcome-measure
, O
and O
disease B-outcome-measure
- I-outcome-measure
free I-outcome-measure
and I-outcome-measure
overall I-outcome-measure
survival I-outcome-measure
. O
The O
median O
follow O
- O
up O
was O
53.8 O
months O
. O
The O
mean O
age O
was O
66 B-age
years I-age
. O
Overall O
, O
there O
were O
21 O
local B-outcome
relapses I-outcome
, O
with O
2 B-iv-bin-abs
relapses O
in O
the O
radiotherapy O
group O
( O
5 B-outcome
- I-outcome
y I-outcome
rate I-outcome
0.4 B-iv-bin-percent
% I-iv-bin-percent
) O
vs. O
19 B-control-participants
in O
the O
no O
- O
radiotherapy O
group O
( O
5.1 B-cv-bin-percent
% I-cv-bin-percent
) O
, O
respectively O
( O
p O
= O
0.0001 O
, O
hazard O
ratio O
10.2 O
) O
. O
Overall B-outcome
relapses I-outcome
occurred O
in O
30 O
patients O
, O
with O
7 B-iv-bin-abs
events O
in O
the O
radiotherapy O
group O
( O
5 B-outcome
- I-outcome
y I-outcome
rate I-outcome
2.1 B-iv-bin-percent
% I-iv-bin-percent
) O
vs. O
23 B-cv-bin-abs
events O
in O
the O
no O
- O
radiotherapy O
group O
( O
6.1 B-cv-bin-percent
% I-cv-bin-percent
) O
( O
p O
= O
0.002 O
, O
hazard O
ratio O
3.5 O
) O
. O
No O
significant O
differences O
were O
found O
for O
distant B-outcome
metastases I-outcome
and O
overall B-outcome
survival I-outcome
. O
Breast O
radiotherapy O
+ O
/- O
boost O
in O
women O
with O
favorable O
early O
breast O
cancer O
after O
lumpectomy O
combined O
with O
tamoxifen O
/ O
anastrazole O
leads O
to O
a O
significant O
reduction O
in O
local O
and O
overall O
relapse O
. O

Web B-intervention
- I-intervention
based I-intervention
proactive I-intervention
system I-intervention
to O
improve O
breast O
cancer O
screening O
: O
a O
randomized O
controlled O
trial O
. O
Screening O
mammography O
is O
recommended O
for O
early O
detection O
of O
breast O
cancer O
but O
screening O
rates O
remain O
suboptimal O
. O
A O
primary O
care O
portal O
for O
a O
large O
academic O
primary O
practice O
was O
developed O
for O
all O
preventive O
services O
. O
Another O
Web O
- O
based O
system O
( O
PRECARES O
[ O
PREventive O
CAre O
REminder O
System O
] O
) O
was O
developed O
for O
appointment O
secretaries O
to O
manage O
proactive O
breast O
cancer O
screening O
. O
Female O
patients O
aged O
40 B-age
to I-age
75 I-age
years I-age
were O
randomly O
assigned O
to O
a O
control B-control
group I-control
( I-control
usual I-control
care I-control
) I-control
and O
an O
intervention O
group O
. O
For O
the O
intervention O
group O
, O
2 O
monthly O
letters O
inviting O
patients O
to O
undergo O
mammography O
were O
sent O
starting O
3 O
months O
before O
they O
were O
due O
for O
annual O
screening O
, O
followed O
by O
a O
telephone O
call O
to O
nonresponding O
patients O
. O
A O
subgroup O
of O
women O
employees O
was O
further O
randomized O
to O
receive O
a O
reminder O
by O
either O
US O
mail O
or O
e O
- O
mail O
. O
Of O
the O
total O
eligible O
population O
of O
6665 B-total-participants
women O
identified O
as O
having O
consented O
to O
participate O
in O
research O
, O
3339 B-intervention-participants
were O
randomly O
assigned O
to O
the O
control O
group O
and O
3326 B-control-participants
to O
the O
intervention O
group O
. O
The O
screening B-outcome
rate I-outcome
for I-outcome
annual I-outcome
mammography I-outcome
was O
64.3 B-iv-bin-percent
% I-iv-bin-percent
for O
the O
intervention O
group O
and O
55.3 B-cv-bin-percent
% I-cv-bin-percent
for O
the O
control O
group O
( O
P O
< O
.001 O
) O
. O
There O
were O
no O
significant O
differences O
between O
the O
2 O
groups O
for O
any O
of O
the O
other O
adult O
preventive O
services O
. O
For O
the O
employee O
subgroup O
, O
the O
screening B-outcome
rate I-outcome
was O
57.5 B-cv-bin-percent
% I-cv-bin-percent
for O
the O
control O
group O
, O
68.1 B-iv-bin-percent
% I-iv-bin-percent
for O
the O
US O
mail O
group O
, O
and O
72.2 B-iv-bin-percent
% I-iv-bin-percent
for O
the O
e O
- O
mail O
group O
( O
intervention O
vs O
control O
, O
P O
< O
.001 O
; O
e O
- O
mail O
vs O
US O
mail O
; O
P O
= O
.24 O
) O
. O
The O
breast O
cancer O
screening O
rate O
improved O
significantly O
with O
the O
practice O
redesign O
of O
having O
appointment O
secretaries O
proactively O
manage O
breast O
cancer O
screening O
needs O
. O

[ O
Evaluation O
on O
the O
effect O
of O
intervention O
regarding O
breast B-intervention
self I-intervention
- I-intervention
examination I-intervention
for O
decreasing O
breast O
cancer O
mortality O
] O
. O
A O
randomized O
trial O
of O
breast O
self O
- O
examination O
( O
BSE O
) O
Program O
was O
carried O
out O
to O
evaluate O
whether O
the O
intensive O
BSE O
could O
reduce O
the O
number O
of O
deaths O
among O
women O
from O
breast O
cancer O
. O
This O
study O
was O
a O
randomized O
controlled O
trial O
( O
RCT O
) O
. O
A O
total O
of O
266 B-total-participants
064 I-total-participants
women O
( O
age O
of O
30 B-age
to I-age
64 I-age
years I-age
) O
associated O
with O
519 O
textile O
factories O
in O
Shanghai B-location
had O
been O
randomly O
assigned O
to O
a O
BSE O
group O
( O
132 B-intervention-participants
979 I-intervention-participants
women O
) O
or O
a O
control B-control
group I-control
( O
133 B-control-participants
085 I-control-participants
women O
) O
since O
1989 O
. O
Initial O
instruction O
in O
BSE O
group O
would O
include O
demonstration O
of O
proper O
palpation O
techniques O
and O
was O
followed O
by O
2 O
reinforcement O
sessions O
during O
the O
subsequent O
4 O
years O
including O
video O
shows O
, O
BSE O
instruction O
sessions O
and O
BSE O
practice O
under O
medical O
supervision O
. O
These O
activities O
were O
continued O
for O
5 O
years O
. O
Attendance O
at O
all O
events O
was O
recorded O
. O
The O
cohort O
was O
followed O
through O
July O
2000 O
for O
development O
of O
breast O
diseases O
, O
and O
the O
breast O
cancer O
cases O
were O
followed O
through O
2001 O
for O
vital O
status O
. O
Data O
analysis O
methods O
used O
would O
include O
Kaplan O
- O
Meier O
plots O
, O
log O
- O
rank O
test O
and O
Cox O
modeling O
. O
Among O
women O
under O
instruction O
, O
864 B-iv-bin-abs
breast B-outcome
cancers I-outcome
detected O
and O
133 B-iv-bin-abs
breast B-outcome
cancer I-outcome
deaths I-outcome
occurred O
while O
896 B-cv-bin-abs
breast B-outcome
cancers I-outcome
were O
detected O
and O
130 B-cv-bin-abs
deaths B-outcome
recorded O
in O
the O
control O
group O
. O
The O
tumor B-outcome
size I-outcome
( O
P O
= O
0.07 O
) O
, O
TNM O
stage O
( O
P O
= O
0.39 O
) O
and O
cumulative B-outcome
breast I-outcome
cancer I-outcome
mortality I-outcome
rate I-outcome
( O
P O
= O
0.72 O
) O
were O
not O
significantly O
different O
between O
the O
2 O
groups O
. O
However O
, O
more O
and O
smaller O
fibroadenomas B-outcome
were O
detected O
in O
the O
instruction O
group O
than O
in O
the O
control O
group O
( O
P O
< O
0.01 O
) O
. O
Intensive O
instruction O
in O
BSE O
did O
not O
seem O
to O
have O
reduced O
the O
mortality O
rate O
of O
breast O
cancer O
, O
but O
more O
and O
smaller O
benign O
breast O
lumps O
could O
be O
detected O
. O

Polychemotherapy B-intervention
for O
early O
breast O
cancer O
: O
results O
from O
the O
international O
adjuvant O
breast O
cancer O
chemotherapy O
randomized O
trial O
. O
Survival O
of O
patients O
with O
early O
- O
stage O
breast O
cancer O
is O
improved O
following O
treatment O
with O
single O
- O
modality O
tamoxifen O
, O
ovarian O
ablation O
or O
suppression O
, O
or O
chemotherapy O
. O
The O
Adjuvant O
Breast O
Cancer O
Trials O
were O
designed O
to O
ascertain O
any O
additional O
benefits O
of O
combined O
treatment O
. O
The O
Adjuvant O
Breast O
Cancer O
Chemotherapy O
Trial O
was O
a O
randomized O
phase O
III O
trial O
in O
which O
patients B-eligibility
with I-eligibility
early I-eligibility
- I-eligibility
stage I-eligibility
breast I-eligibility
cancer I-eligibility
who I-eligibility
were I-eligibility
receiving I-eligibility
prolonged I-eligibility
( I-eligibility
5 I-eligibility
years I-eligibility
) I-eligibility
tamoxifen I-eligibility
treatment I-eligibility
, I-eligibility
with I-eligibility
or I-eligibility
without I-eligibility
ovarian I-eligibility
ablation I-eligibility
or I-eligibility
suppression I-eligibility
, O
were O
randomly O
assigned O
to O
standard O
chemotherapy O
versus O
none B-control
. O
Trial O
endpoints O
included O
relapse B-outcome-measure
- I-outcome-measure
free I-outcome-measure
and O
overall B-outcome-measure
survival I-outcome-measure
. O
Hazard O
ratios O
( O
HRs O
) O
were O
derived O
from O
Cox O
models O
, O
and O
all O
statistical O
tests O
were O
two O
- O
sided O
. O
Between O
1992 O
and O
2000 O
, O
1991 B-total-participants
patients O
between B-age
the I-age
ages I-age
of I-age
26 I-age
and I-age
81 I-age
years I-age
were O
randomly O
assigned O
( O
987 B-intervention-participants
to O
chemotherapy O
, O
1004 B-control-participants
to O
no O
chemotherapy O
) O
from O
106 O
UK B-location
and O
16 O
non B-location
- I-location
UK I-location
centers O
. O
Nine B-intervention-participants
hundred I-intervention-participants
seven I-intervention-participants
( O
92 O
% O
) O
patients O
received O
chemotherapy O
as O
allocated O
( O
87 O
% O
received O
cyclophosphamide O
, O
methotrexate O
, O
and O
5 O
- O
fluorouracil O
; O
11 O
% O
received O
anthracycline O
- O
containing O
regimens O
) O
. O
A O
total O
of O
244 O
of O
the O
619 O
premenopausal O
patients O
received O
elective O
ovarian O
ablation O
or O
suppression O
. O
Chemotherapy O
improved O
relapse B-outcome
- I-outcome
free I-outcome
survival I-outcome
( O
relapse O
in O
the O
chemotherapy O
group O
versus O
no O
- O
chemotherapy O
group O
, O
298 B-iv-bin-abs
events O
versus O
332 B-cv-bin-abs
events O
, O
HR O
= O
0.86 O
, O
95 O
% O
confidence O
interval O
[ O
CI O
] O
= O
0.73 O
to O
1.01 O
; O
P O
= O
.06 O
) O
and O
overall B-outcome
survival I-outcome
( O
death O
from O
any O
cause O
in O
the O
chemotherapy O
group O
versus O
no O
- O
chemotherapy O
group O
, O
243 B-iv-bin-abs
events O
versus O
282 B-cv-bin-abs
events O
, O
HR O
= O
0.83 O
, O
95 O
% O
CI O
= O
0.70 O
to O
0.99 O
; O
P O
= O
.03 O
) O
after O
adjustment O
for O
nodal O
status O
, O
estrogen O
receptor O
status O
, O
and O
age O
. O
Subgroup O
analyses O
showed O
that O
the O
benefit O
of O
chemotherapy O
was O
greatest O
in O
younger O
women O
( O
< O
50 O
years O
) O
and O
in O
particular O
for O
premenopausal O
women O
not O
receiving O
ovarian O
ablation O
or O
suppression O
. O
Modest O
yet O
sustainable O
benefits O
for O
chemoendocrine O
therapy O
occur O
in O
women O
with O
breast O
cancer O
. O
However O
, O
the O
full O
impact O
on O
overall O
survival O
may O
not O
emerge O
for O
several O
years O
. O

Ovarian B-intervention
ablation I-intervention
or I-intervention
suppression I-intervention
in O
premenopausal O
early O
breast O
cancer O
: O
results O
from O
the O
international O
adjuvant O
breast O
cancer O
ovarian O
ablation O
or O
suppression O
randomized O
trial O
. O
Substantial O
survival O
benefits O
exist O
for O
patients O
with O
early O
- O
stage O
breast O
cancer O
who O
undergo O
treatment O
with O
single O
- O
modality O
tamoxifen O
, O
ovarian O
ablation O
or O
suppression O
, O
or O
chemotherapy O
. O
To O
determine O
whether O
additional O
benefits O
exist O
with O
combined O
treatment O
, O
the O
Adjuvant O
Breast O
Cancer O
( O
ABC O
) O
Trials O
were O
undertaken O
. O
The O
ABC O
Ovarian O
Ablation O
or O
Suppression O
Trial O
randomly O
assigned O
pre- B-eligibility
and I-eligibility
perimenopausal I-eligibility
patients I-eligibility
with I-eligibility
early I-eligibility
- I-eligibility
stage I-eligibility
breast I-eligibility
cancer I-eligibility
who I-eligibility
were I-eligibility
receiving I-eligibility
prolonged I-eligibility
( I-eligibility
5 I-eligibility
years I-eligibility
) I-eligibility
tamoxifen I-eligibility
treatment I-eligibility
with I-eligibility
or I-eligibility
without I-eligibility
chemotherapy I-eligibility
to O
ovarian O
ablation O
or O
suppression O
( O
by O
oophorectomy O
, O
ovarian O
irradiation O
, O
or O
treatment O
with O
luteinizing O
hormone O
- O
releasing O
hormone O
agonist O
) O
versus O
no B-control
ovarian I-control
ablation I-control
or I-control
suppression I-control
. O
Trial O
endpoints O
included O
relapse B-outcome-measure
- I-outcome-measure
free I-outcome-measure
and O
overall B-outcome-measure
survival I-outcome-measure
. O
Hazard O
ratios O
( O
HRs O
) O
were O
derived O
from O
Cox O
models O
, O
and O
all O
statistical O
tests O
were O
two O
- O
sided O
. O
Between O
1993 O
and O
2000 O
, O
2144 B-total-participants
( O
1063 B-intervention-participants
ovarian O
ablation O
or O
suppression O
, O
1081 B-control-participants
no O
ovarian O
ablation O
or O
suppression O
) O
patients O
were O
randomly O
assigned O
. O
A O
total O
of O
942 B-intervention-participants
( O
89 O
% O
) O
received O
ovarian O
ablation O
or O
suppression O
as O
allocated O
. O
Overall O
, O
no O
evidence O
of O
a O
benefit O
for O
ovarian O
ablation O
or O
suppression O
was O
observed O
for O
relapse B-outcome
- I-outcome
free I-outcome
survival I-outcome
( O
relapse O
in O
the O
ovarian O
ablation O
/ O
suppression O
versus O
no O
ovarian O
ablation O
/ O
suppression O
group O
, O
290 B-iv-bin-abs
events O
versus O
306 B-cv-bin-abs
events O
, O
HR O
= O
0.95 O
, O
95 O
% O
confidence O
interval O
[ O
CI O
] O
= O
0.81 O
to O
1.12 O
; O
P O
= O
.56 O
) O
or O
overall B-outcome
survival I-outcome
( O
death O
from O
any O
cause O
in O
the O
ovarian O
ablation O
or O
suppression O
versus O
no O
ovarian O
ablation O
/ O
suppression O
group O
, O
215 B-iv-bin-abs
events O
versus O
230 B-cv-bin-abs
events O
, O
HR O
= O
0.94 O
, O
95 O
% O
CI O
= O
0.78 O
to O
1.13 O
; O
P O
= O
.44 O
) O
, O
nor O
were O
differences O
seen O
after O
adjustment O
for O
age O
, O
nodal O
status O
, O
or O
estrogen O
receptor O
( O
ER O
) O
status O
. O
Overall O
, O
no O
added O
effect O
of O
ovarian O
ablation O
or O
suppression O
was O
seen O
on O
relapse B-outcome
- I-outcome
free I-outcome
survival I-outcome
or O
overall B-outcome
survival I-outcome
of O
premenopausal O
women O
who O
were O
treated O
for O
early O
- O
stage O
breast O
cancer O
. O
However O
, O
the O
role O
of O
ovarian O
ablation O
or O
suppression O
in O
young O
( O
< O
40 O
years O
) O
women O
with O
ER O
- O
positive O
tumors O
, O
especially O
those O
not O
receiving O
chemotherapy O
, O
requires O
further O
study O
. O

Elevated B-intervention
plasma I-intervention
tissue I-intervention
inhibitor I-intervention
of I-intervention
metalloproteinase-1 I-intervention
level O
predicts O
decreased O
response O
and O
survival O
in O
metastatic O
breast O
cancer O
. O
Tissue O
inhibitors O
of O
metalloproteinase O
( O
TIMPs O
) O
have O
at O
least O
2 O
different O
functions O
. O
They O
inhibit O
the O
catalytic O
activity O
of O
matrix O
metalloproteinases O
, O
and O
they O
act O
as O
growth O
factors O
. O
Pretreatment O
ethylenediamine O
tetracetic O
acid O
plasma O
TIMP-1 O
was O
assayed O
from O
251 B-intervention-participants
patients O
who O
were O
enrolled O
in O
a O
Phase O
III O
, O
second O
- O
line O
, O
hormone O
therapy O
trial O
, O
and O
from O
a O
control B-control
group I-control
of O
50 B-control-participants
healthy O
, O
postmenopausal O
women O
by O
using O
the O
TIMP-1 O
enzyme O
- O
linked O
immunosorbent O
assay O
. O
The O
plasma O
TIMP-1 O
levels O
from O
the O
postmenopausal O
control O
group O
( O
n O
= O
50 O
women O
) O
were O
201 O
+ O
/- O
86 O
ng O
/ O
mL O
mean O
+ O
/- O
standard O
deviation O
( O
range O
, O
49 O
- O
455 O
ng O
/ O
mL O
) O
. O
The O
upper O
limit O
of O
normal O
was O
defined O
as O
the O
mean O
+ O
/- O
2 O
standard O
deviations O
of O
the O
control O
group O
( O
373 O
ng O
/ O
mL O
) O
. O
Patient O
pretreatment O
plasma O
TIMP-1 O
levels O
ranged O
from O
70 O
ng O
/ O
mL O
to O
982 O
ng O
/ O
mL. O
Plasma B-outcome
TIMP-1 I-outcome
was O
elevated O
above O
the O
mean O
+ O
2 O
standard O
deviations O
of O
the O
control O
group O
( O
373 B-iv-cont-mean
ng I-iv-cont-mean
/ I-iv-cont-mean
mL I-iv-cont-mean
) O
in O
19 B-cv-bin-abs
patients O
( O
7.6 B-cv-bin-percent
% I-cv-bin-percent
) O
. O
In O
univariate O
analysis O
, O
patients O
who O
had O
elevated O
versus O
normal O
plasma O
TIMP-1 O
levels O
had O
a O
reduced O
clinical B-outcome
benefit I-outcome
rate I-outcome
( O
CBR O
) O
( O
16 B-iv-bin-percent
% I-iv-bin-percent
vs O
42 B-cv-bin-percent
% I-cv-bin-percent
; O
P O
= O
.03 O
) O
. O
The O
time B-outcome
to I-outcome
progression I-outcome
( I-outcome
TTP I-outcome
) I-outcome
( O
84 B-iv-cont-median
days I-iv-cont-median
vs O
174 B-cv-cont-median
days I-cv-cont-median
; O
P O
< O
.0001 O
) O
and O
overall B-outcome
survival I-outcome
( O
141 B-iv-cont-median
days I-iv-cont-median
vs O
860 B-cv-cont-median
days I-cv-cont-median
; O
P O
= O
.0001 O
) O
also O
were O
significantly O
shorter O
in O
patients O
who O
had O
elevated O
TIMP-1 O
levels O
. O
TTP B-outcome
and I-outcome
overall I-outcome
survival I-outcome
also O
were O
significantly O
shorter O
in O
patients O
who O
had O
higher O
TIMP-1 O
plasma O
levels O
when O
it O
was O
analyzed O
as O
a O
continuous O
variable O
. O
In O
multivariate O
analysis O
, O
elevated O
plasma O
TIMP-1 O
level O
remained O
a O
prognostic O
factor O
for O
reduced O
overall O
survival O
( O
P O
< O
.0001 O
) O
along O
with O
elevated O
serum O
HER-2 O
/ O
neu O
( O
P O
< O
.0001 O
) O
and O
the O
presence O
of O
visceral O
metastases O
( O
P O
= O
.008 O
) O
. O
Elevated O
pretreatment O
plasma O
levels O
of O
TIMP-1 O
predicted O
a O
decreased O
response O
to O
second O
- O
line O
hormone O
therapy O
and O
reduced O
survival O
in O
women O
with O
metastatic O
breast O
cancer O
. O

Oral B-intervention
ibandronate I-intervention
is O
as O
active O
as O
intravenous B-control
zoledronic I-control
acid I-control
for O
reducing O
bone O
turnover O
markers O
in O
women O
with O
breast O
cancer O
and O
bone O
metastases O
. O
Phase O
III O
study O
comparing O
the O
effect O
of O
oral O
ibandronate O
and O
intravenous O
zoledronic O
acid O
on O
bone O
markers O
. O
Breast B-eligibility
cancer I-eligibility
patients I-eligibility
with I-eligibility
bone I-eligibility
metastases I-eligibility
received O
ibandronate O
50 O
mg O
/ O
day O
( O
n O
= O
137 B-intervention-participants
) O
or O
zoledronic O
acid O
4 O
mg O
every O
4 O
weeks O
( O
n O
= O
138 B-control-participants
) O
for O
12 O
weeks O
. O
The O
primary O
end O
point O
was O
mean B-outcome-measure
percentage I-outcome-measure
change I-outcome-measure
in I-outcome-measure
serum I-outcome-measure
levels I-outcome-measure
of I-outcome-measure
cross I-outcome-measure
- I-outcome-measure
linked I-outcome-measure
C I-outcome-measure
- I-outcome-measure
terminal I-outcome-measure
telopeptide I-outcome-measure
of I-outcome-measure
type I-outcome-measure
I I-outcome-measure
collagen I-outcome-measure
( I-outcome-measure
S I-outcome-measure
- I-outcome-measure
CTX I-outcome-measure
) I-outcome-measure
at I-outcome-measure
week I-outcome-measure
12 I-outcome-measure
. O
Urinary B-outcome-measure
CTX I-outcome-measure
( I-outcome-measure
U I-outcome-measure
- I-outcome-measure
CTX I-outcome-measure
) I-outcome-measure
, O
bone B-outcome-measure
alkaline I-outcome-measure
phosphatase I-outcome-measure
( I-outcome-measure
ALP I-outcome-measure
) I-outcome-measure
, O
amino B-outcome-measure
- I-outcome-measure
terminal I-outcome-measure
procollagen I-outcome-measure
propeptide I-outcome-measure
of I-outcome-measure
type I-outcome-measure
I I-outcome-measure
collagen I-outcome-measure
( I-outcome-measure
PINP I-outcome-measure
) I-outcome-measure
and I-outcome-measure
osteocalcin I-outcome-measure
( I-outcome-measure
OC I-outcome-measure
) I-outcome-measure
were O
also O
measured O
and O
bone O
pain O
and O
safety O
assessed O
. O
Both O
bisphosphonates O
significantly O
reduced O
S B-outcome
- I-outcome
CTX I-outcome
( O
mean O
ibandronate O
76 B-iv-cont-mean
% I-iv-cont-mean
+ O
/- O
29 B-iv-cont-sd
( O
SD O
) O
versus O
mean O
zoledronic O
acid O
73 B-cv-cont-mean
% I-cv-cont-mean
+ O
/- O
47 B-cv-cont-sd
; O
P O
< O
0.001 O
for O
both O
versus O
baseline O
) O
and O
U B-outcome
- I-outcome
CTX I-outcome
( O
ibandronate O
78 B-iv-cont-mean
% I-iv-cont-mean
+ O
/- O
50 B-iv-cont-sd
versus O
zoledronic O
acid O
86 B-cv-cont-mean
% I-cv-cont-mean
+ O
/- O
17 B-cv-cont-sd
; O
P O
< O
0.001 O
) O
. O
The O
difference B-outcome
in I-outcome
S I-outcome
- I-outcome
CTX I-outcome
between O
treatments O
was O
0.6 O
% O
( O
confidence O
interval O
-1.7 O
% O
to O
3.0 O
% O
) O
, O
which O
was O
within O
the O
prespecified O
noninferiority O
margin O
. O
Bone B-outcome
ALP I-outcome
, I-outcome
PINP I-outcome
and I-outcome
OC I-outcome
decreased O
by O
26%-47 O
% O
compared O
with O
baseline O
with O
both O
bisphosphonates O
. O
Compared O
with O
zoledronic O
acid O
, O
ibandronate O
patients O
reported O
fewer O
adverse B-outcome
events I-outcome
overall I-outcome
( O
65.0 B-iv-bin-percent
% I-iv-bin-percent
versus O
75.9 B-cv-bin-percent
% I-cv-bin-percent
) O
, O
and O
on O
days B-outcome
1 I-outcome
- I-outcome
3 I-outcome
( O
8.0 B-iv-bin-percent
% I-iv-bin-percent
versus O
47.5 B-cv-bin-percent
% I-cv-bin-percent
) O
, O
including O
less O
pyrexia B-outcome
( O
overall O
incidence O
0 B-iv-bin-percent
% I-iv-bin-percent
versus O
16.8 B-cv-bin-percent
% I-cv-bin-percent
) O
and O
bone B-outcome
pain I-outcome
( O
5.8 B-iv-bin-percent
% I-iv-bin-percent
versus O
12.4 B-cv-bin-percent
% I-cv-bin-percent
) O
. O
Oral O
ibandronate O
was O
well O
tolerated O
and O
statistically O
noninferior O
to O
zoledronic O
acid O
for O
percentage O
change O
in O
the O
bone O
resorption O
marker O
, O
S O
- O
CTX O
. O

Tamoxifen B-intervention
for O
the O
prevention O
of O
breast O
cancer O
: O
late O
results O
of O
the O
Italian B-location
Randomized O
Tamoxifen O
Prevention O
Trial O
among O
women O
with O
hysterectomy O
. O
Initial O
findings O
of O
the O
Italian O
Randomized O
Tamoxifen O
Prevention O
Trial O
found O
no O
reduction O
in O
risk O
of O
breast O
cancer O
with O
tamoxifen O
use O
, O
whereas O
the O
National O
Surgical O
Adjuvant O
Breast O
and O
Bowel O
Project O
Breast O
Cancer O
Prevention O
Trial O
showed O
that O
tamoxifen O
treatment O
reduces O
risk O
of O
estrogen O
receptor O
- O
positive O
breast O
cancer O
. O
Here O
we O
present O
an O
extended O
follow O
- O
up O
of O
the O
Italian O
trial O
. O
From O
October O
1 O
, O
1992 O
, O
to O
December O
31 O
, O
1997 O
, O
5408 B-total-participants
otherwise O
healthy B-eligibility
women I-eligibility
who I-eligibility
had I-eligibility
undergone I-eligibility
hysterectomy I-eligibility
were O
randomly O
assigned O
in O
a O
double O
- O
blind O
manner O
to O
tamoxifen O
( O
20 O
mg O
daily O
) O
or O
placebo B-control
for O
5 O
years O
. O
Rates O
of O
breast O
cancer O
and O
other O
events O
in O
the O
two O
groups O
were O
compared O
by O
the O
use O
of O
risk O
ratios O
( O
RRs O
) O
and O
95 O
% O
confidence O
intervals O
( O
CIs O
) O
. O
After O
11 O
years O
of O
follow O
- O
up O
, O
136 O
women O
( O
74 B-cv-bin-abs
placebo O
, O
62 B-iv-bin-abs
tamoxifen O
) O
developed O
breast B-outcome
cancer I-outcome
( O
RR O
= O
0.84 O
, O
95 O
% O
CI O
= O
0.60 O
to O
1.17 O
; O
annual O
rates O
were O
2.48 O
and O
2.07 O
per O
1000 O
women O
- O
years O
, O
respectively O
) O
. O
The O
rates B-outcome
of I-outcome
breast I-outcome
cancer I-outcome
in O
the O
two O
study O
groups O
were O
similar O
among O
women O
who O
had O
had O
bilateral O
oophorectomy O
and O
among O
women O
at O
low O
risk O
for O
hormone O
receptor O
- O
positive O
( O
HR+ O
) O
disease O
but O
were O
much O
lower O
in O
the O
tamoxifen O
group O
among O
women O
at O
high O
risk O
( O
placebo O
, O
6.26 B-cv-bin-abs
per O
1000 B-control-participants
women O
- O
years O
, O
tamoxifen O
, O
1.50 B-iv-bin-abs
per O
1000 B-intervention-participants
women O
- O
years O
; O
RR O
= O
0.24 O
, O
95 O
% O
CI O
= O
0.10 O
to O
0.59 O
) O
. O
During O
the O
treatment O
period O
, O
women O
in O
the O
tamoxifen O
group O
reported O
more O
hot B-outcome
flashes I-outcome
( O
RR O
= O
1.78 O
, O
95 O
% O
CI O
= O
1.57 O
to O
2.00 O
) O
, O
vaginal B-outcome
discharge I-outcome
( O
RR O
= O
3.44 O
, O
95 O
% O
CI O
= O
2.90 O
to O
4.09 O
) O
, O
and O
urinary B-outcome
disturbances I-outcome
( O
RR O
= O
1.52 O
, O
95 O
% O
CI O
= O
1.23 O
to O
1.89 O
) O
but O
fewer O
headaches B-outcome
( O
RR O
= O
0.68 O
, O
95 O
% O
CI O
= O
0.50 O
to O
0.94 O
) O
than O
women O
in O
the O
placebo O
group O
. O
Hypertriglyceridemia B-outcome
( O
RR O
= O
4.33 O
, O
95 O
% O
CI O
= O
1.96 O
to O
9.53 O
) O
, O
thromboembolic B-outcome
events I-outcome
( O
RR O
= O
1.63 O
, O
95 O
% O
CI O
= O
1.02 O
to O
2.62 O
) O
, O
and O
cardiac B-outcome
arrhythmia I-outcome
or I-outcome
atrial I-outcome
fibrillation I-outcome
( O
RR O
= O
1.73 O
, O
95 O
% O
CI O
= O
1.01 O
to O
2.98 O
) O
were O
also O
more O
frequent O
in O
the O
tamoxifen O
group O
than O
in O
the O
placebo O
group O
. O
Appropriate O
selection O
of O
women O
at O
high O
risk O
for O
HR+ O
disease O
may O
improve O
the O
risk O
- O
benefit O
ratio O
of O
tamoxifen O
intervention O
. O

Cardiovascular O
risk O
profile O
of O
patients O
with O
HER2 O
/ O
neu O
- O
positive O
breast O
cancer O
treated O
with O
anthracycline B-intervention
- I-intervention
taxane I-intervention
- I-intervention
containing I-intervention
adjuvant I-intervention
chemotherapy I-intervention
and/or I-intervention
trastuzumab I-intervention
. O
To O
evaluate O
the O
cardiovascular O
risk O
profile O
of O
a O
subset O
of O
patients O
with O
early O
- O
stage O
breast O
cancer O
treated O
with O
adjuvant O
taxane O
- O
anthracycline O
- O
containing O
chemotherapy O
and/or O
trastuzumab O
( O
Herceptin O
) O
. O
Twenty B-intervention-participants
- I-intervention-participants
six I-intervention-participants
patients B-eligibility
with I-eligibility
breast I-eligibility
cancer I-eligibility
( O
mean O
, O
20 O
months O
postchemotherapy O
) O
and O
10 B-control-participants
healthy B-control
age O
- O
matched O
women O
were O
studied O
. O
We O
measured O
14 O
metabolic O
and O
vascular O
established O
cardiovascular O
disease O
( O
CVD O
) O
risk O
factors O
, O
body O
mass O
index O
, O
cardiorespiratory O
fitness O
, O
and O
left O
ventricular O
systolic O
function O
. O
All O
assessments O
were O
done O
within O
a O
14 O
- O
day O
period O
. O
Cardiac O
abnormalities O
were O
suggested O
by O
left O
ventricular O
ejection O
fraction O
( O
LVEF O
) O
< O
50 O
% O
in O
8 O
% O
of O
patients O
, O
LVEF O
remained O
> O
10 O
% O
below O
pretreatment O
values O
in O
38 O
% O
, O
whereas O
50 O
% O
presented O
with O
resting O
sinus O
tachycardia O
. O
Brain B-outcome
natriuretic I-outcome
peptide I-outcome
was O
significantly O
elevated O
in O
40 O
% O
of O
patients O
and O
was O
correlated O
with O
LVEF O
( O
r O
= O
-0.72 O
, O
P O
= O
or O
< O
0.001 O
) O
. O
For O
the O
majority O
of O
CVD O
risk O
factors O
, O
similar O
proportions O
of O
patients O
and O
controls O
( O
35 O
- O
60 O
% O
) O
were O
classified O
as O
" O
undesirable O
. O
" O
A O
significantly O
higher O
proportion O
of O
patients O
were O
classified O
with O
low B-outcome
cardiorespiratory I-outcome
fitness I-outcome
( O
46 B-iv-bin-percent
% I-iv-bin-percent
versus O
0 B-cv-bin-percent
% I-cv-bin-percent
, O
P O
< O
0.01 O
) O
, O
being O
overweight B-outcome
/ I-outcome
obese I-outcome
( O
72 B-iv-bin-percent
% I-iv-bin-percent
versus O
50 B-cv-bin-percent
% I-cv-bin-percent
, O
P O
< O
0.05 O
) O
, O
and O
having O
resting B-outcome
sinus I-outcome
tachycardia I-outcome
( O
50 B-iv-bin-percent
% I-iv-bin-percent
versus O
0 B-cv-bin-percent
% I-cv-bin-percent
, O
P O
< O
0.01 O
) O
compared O
with O
controls O
. O
Cardiorespiratory B-outcome
fitness I-outcome
and O
body B-outcome
mass I-outcome
index I-outcome
were O
correlated O
with O
CVD O
risk O
factors O
( O
r O
= O
-0.64 O
to O
0.63 O
, O
P O
< O
0.05 O
; O
r O
= O
-0.63 O
to O
0.67 O
, O
P O
< O
0.05 O
, O
respectively O
) O
. O
Exploratory O
analyses O
revealed O
several O
differences O
between O
CVD O
risk O
factors O
based O
on O
chemotherapy O
regimen O
. O
Breast O
cancer O
survivors O
treated O
with O
adjuvant O
chemotherapy O
are O
at O
a O
higher O
risk O
of O
developing O
late O
- O
occurring O
CVD O
than O
age O
- O
matched O
controls O
due O
to O
direct O
and O
indirect O
treatment O
- O
related O
toxicity O
. O

Phase O
2 O
randomized O
trial O
of O
primary O
endocrine B-intervention
therapy I-intervention
versus O
chemotherapy B-control
in O
postmenopausal O
patients O
with O
estrogen O
receptor O
- O
positive O
breast O
cancer O
. O
Few O
studies O
have O
compared O
primary O
neoadjuvant O
endocrine O
therapy O
with O
neoadjuvant O
chemotherapy O
in O
breast O
cancer O
patients O
. O
The O
need O
for O
preoperative O
chemotherapy O
with O
doxorubicin O
or O
taxanes O
may O
be O
reduced O
in O
postmenopausal O
patients O
with O
estrogen O
receptor O
( O
ER O
) O
-positive O
and/or O
progesterone O
receptor O
( O
PgR O
) O
-positive O
tumors O
. O
This O
randomized O
, O
controlled O
, O
phase O
2 O
study O
evaluated O
the O
efficacy O
of O
neoadjuvant O
chemotherapy O
compared O
with O
endocrine O
treatment O
with O
aromatase O
inhibitors O
in O
postmenopausal B-eligibility
women I-eligibility
with I-eligibility
ER I-eligibility
- I-eligibility
positive I-eligibility
and/or I-eligibility
PgR I-eligibility
- I-eligibility
positive I-eligibility
breast I-eligibility
cancer I-eligibility
. O
Eligible O
patients O
were O
randomly O
assigned O
to O
receive O
neoadjuvant O
anastrozole O
1 O
mg O
/ O
day O
( O
n O
= O
61 B-intervention-participants
) O
or O
exemestane O
25 O
mg O
/ O
day O
( O
n O
= O
60 B-control-participants
) I-control-participants
for O
3 O
months O
or O
doxorubicin O
60 O
mg O
/ O
m O
( O
2 O
) O
with O
paclitaxel O
200 O
mg O
/ O
m O
( O
2 O
) O
( O
four O
3 O
- O
week O
cycles O
) O
. O
Study O
end O
points O
included O
overall B-outcome-measure
objective I-outcome-measure
response I-outcome-measure
determined O
by O
palpation O
, O
mammography O
, O
and O
ultrasound O
, O
and O
the O
number O
of O
patients O
who O
qualified O
for O
breast O
- O
conserving O
surgery O
and O
radiotherapy O
. O
Clinical B-outcome
objective I-outcome
response I-outcome
was O
64 B-iv-bin-percent
% I-iv-bin-percent
in O
the O
endocrine O
therapy O
and O
chemotherapy O
treatment O
groups O
. O
Median B-outcome
time I-outcome
to I-outcome
clinical I-outcome
response I-outcome
was O
57 B-iv-cont-median
and O
51 B-cv-cont-median
days I-cv-cont-median
with O
aromatase O
inhibitors O
and O
chemotherapy O
, O
respectively O
( O
P O
> O
.05 O
) O
. O
Rates O
of O
pathological O
complete B-outcome
response I-outcome
( O
3 B-iv-bin-percent
% I-iv-bin-percent
vs O
6 B-cv-bin-percent
% I-cv-bin-percent
) O
and O
disease B-outcome
progression I-outcome
( O
9 B-iv-bin-percent
% I-iv-bin-percent
vs O
9 B-cv-bin-percent
% I-cv-bin-percent
) O
did O
not O
differ O
significantly O
in O
the O
endocrine O
therapy O
or O
chemotherapy O
group O
, O
respectively O
( O
P O
> O
.05 O
) O
. O
Rates B-outcome
of I-outcome
breast I-outcome
- I-outcome
conserving I-outcome
surgery I-outcome
were O
slightly O
higher O
in O
the O
endocrine O
group O
( O
33 B-iv-bin-percent
% I-iv-bin-percent
vs O
24 B-cv-bin-percent
% I-cv-bin-percent
; O
P O
= O
.058 O
) O
. O
The O
most O
frequent O
toxicities O
from O
chemotherapy O
were O
alopecia B-outcome
( O
79 B-cv-bin-percent
% I-cv-bin-percent
) O
, O
grade B-outcome
3 I-outcome
/ I-outcome
4 I-outcome
neutropenia I-outcome
( O
33 B-cv-bin-percent
% I-cv-bin-percent
) O
, O
and O
grade B-outcome
2 I-outcome
neuropathy I-outcome
( O
30 B-cv-bin-percent
% I-cv-bin-percent
) O
. O
Endocrine O
treatment O
was O
well B-outcome
tolerated I-outcome
. O
No O
deaths B-outcome
occurred O
during O
the O
preoperative O
treatment O
. O
Preoperative O
neoadjuvant O
endocrine O
therapy O
with O
aromatase O
inhibitors O
was O
well O
tolerated O
and O
resulted O
in O
rates O
similar O
to O
chemotherapy O
in O
overall O
objective O
response O
and O
breast O
- O
conserving O
surgery O
in O
postmenopausal O
women O
with O
ER O
- O
positive O
and/or O
PgR O
- O
positive O
tumors O
. O

Impact O
of O
a O
higher B-intervention
radiation I-intervention
dose I-intervention
on O
local O
control O
and O
survival O
in O
breast O
- O
conserving O
therapy O
of O
early O
breast O
cancer O
: O
10 O
- O
year O
results O
of O
the O
randomized O
boost O
versus O
no O
boost O
EORTC O
22881 O
- O
10882 O
trial O
. O
To O
investigate O
the O
long O
- O
term O
impact O
of O
a O
boost O
radiation O
dose O
of O
16 O
Gy O
on O
local O
control O
, O
fibrosis O
, O
and O
overall O
survival O
for O
patients O
with O
stage O
I O
and O
II O
breast O
cancer O
who O
underwent O
breast O
- O
conserving O
therapy O
. O
A O
total O
of O
5,318 B-total-participants
patients B-eligibility
with I-eligibility
microscopically I-eligibility
complete I-eligibility
excision I-eligibility
followed I-eligibility
by I-eligibility
whole I-eligibility
- I-eligibility
breast I-eligibility
irradiation I-eligibility
of I-eligibility
50 I-eligibility
Gy I-eligibility
were O
randomly O
assigned O
to O
receive O
either O
a O
boost O
dose O
of O
16 O
Gy O
( O
2,661 B-intervention-participants
patients O
) O
or O
no B-control
boost I-control
dose I-control
( O
2,657 B-control-participants
patients O
) O
, O
with O
a O
median O
follow O
- O
up O
of O
10.8 O
years O
. O
The O
median O
age O
was O
55 B-age
years I-age
. O
Local B-outcome
recurrence I-outcome
was O
reported O
as O
the O
first O
treatment O
failure O
in O
278 B-cv-bin-abs
patients O
with O
no O
boost O
versus O
165 B-iv-bin-abs
patients O
with O
boost O
; O
at O
10 B-outcome
years I-outcome
, O
the O
cumulative B-outcome
incidence I-outcome
of I-outcome
local I-outcome
recurrence I-outcome
was O
10.2 B-cv-bin-percent
% I-cv-bin-percent
versus O
6.2 B-iv-bin-percent
% I-iv-bin-percent
for O
the O
no O
boost O
and O
the O
boost O
group O
, O
respectively O
( O
P O
< O
.0001 O
) O
. O
The O
hazard O
ratio O
of O
local B-outcome
recurrence I-outcome
was O
0.59 O
( O
0.46 O
to O
0.76 O
) O
in O
favor O
of O
the O
boost O
, O
with O
no O
statistically O
significant O
interaction O
per O
age O
group O
. O
The O
absolute B-outcome
risk I-outcome
reduction I-outcome
at I-outcome
10 I-outcome
years I-outcome
per O
age O
group O
was O
the O
largest O
in O
patients O
< O
or O
= O
40 O
years O
of O
age O
: O
23.9 O
% O
to O
13.5 O
% O
( O
P O
= O
.0014 O
) O
. O
As O
a O
result O
, O
the O
number B-outcome
of I-outcome
salvage I-outcome
mastectomies I-outcome
has O
been O
reduced O
by O
41 O
% O
. O
Severe B-outcome
fibrosis I-outcome
was O
statistically O
significantly O
increased O
( O
P O
< O
.0001 O
) O
in O
the O
boost O
group O
, O
with O
a O
10 B-outcome
- I-outcome
year I-outcome
rate I-outcome
of O
4.4 B-iv-bin-percent
% I-iv-bin-percent
versus O
1.6 B-cv-bin-percent
% I-cv-bin-percent
in O
the O
no O
boost O
group O
( O
P O
< O
.0001 O
) O
. O
Survival B-outcome
at I-outcome
10 I-outcome
years I-outcome
was O
82 B-iv-bin-percent
% I-iv-bin-percent
in O
both O
arms O
. O
After O
a O
median O
follow O
- O
up O
period O
of O
10.8 O
years O
, O
a O
boost O
dose O
of O
16 O
Gy O
led O
to O
improved O
local O
control O
in O
all O
age O
groups O
, O
but O
no O
difference O
in O
survival O
. O

Trastuzumab O
plus O
vinorelbine B-intervention
or O
taxane B-control
chemotherapy I-control
for O
HER2 O
- O
overexpressing O
metastatic O
breast O
cancer O
: O
the O
trastuzumab O
and O
vinorelbine O
or O
taxane O
study O
. O
The O
optimal O
trastuzumab O
- O
based O
chemotherapy O
regimen O
for O
HER2 O
- O
overexpressing O
, O
metastatic O
breast O
cancer O
is O
not O
known O
. O
The O
trastuzumab O
and O
vinorelbine O
or O
taxane O
( O
TRAVIOTA O
) O
study O
was O
a O
prospective O
, O
multicenter O
, O
randomized O
trial O
that O
was O
designed O
to O
compare O
these O
regimens O
. O
Eligible O
patients B-eligibility
had I-eligibility
HER2 I-eligibility
- I-eligibility
overexpressing I-eligibility
, I-eligibility
metastatic I-eligibility
breast I-eligibility
cancer I-eligibility
and I-eligibility
had I-eligibility
received I-eligibility
no I-eligibility
prior I-eligibility
chemotherapy I-eligibility
for I-eligibility
advanced I-eligibility
disease I-eligibility
. O
Patients O
were O
randomized O
1 O
:1 O
to O
receive O
either O
trastuzumab O
with O
weekly O
vinorelbine O
therapy O
or O
weekly O
taxane O
therapy O
( O
paclitaxel O
or O
docetaxel O
at O
the O
investigator O
's O
choice O
) O
. O
Originally O
planned O
for O
250 O
patients O
, O
the O
study O
was O
closed O
because O
of O
poor O
accrual O
with O
81 B-total-participants
evaluable O
patients O
, O
including O
41 B-intervention-participants
patients O
who O
received O
vinorelbine O
and O
40 B-control-participants
patients O
who O
received O
taxane O
. O
Response B-outcome
rates I-outcome
were O
51 B-iv-bin-percent
% I-iv-bin-percent
and O
40 B-cv-bin-percent
% I-cv-bin-percent
for O
the O
vinorelbine O
/ O
trastuzumab O
arm O
and O
the O
taxane O
/ O
trastuzumab O
arm O
, O
respectively O
( O
Fisher O
exact O
test O
; O
P O
= O
.37 O
) O
. O
The O
median B-outcome
time I-outcome
to I-outcome
disease I-outcome
progression I-outcome
was O
8.5 B-iv-cont-median
months I-iv-cont-median
and O
6.0 B-cv-cont-median
months I-cv-cont-median
for O
the O
vinorelbine- O
and O
taxane O
- O
based O
arms O
, O
respectively O
( O
log O
- O
rank O
test O
; O
P O
= O
.09 O
) O
. O
Treatment O
with O
either O
regimen O
generally O
was O
well B-outcome
tolerated I-outcome
, O
yielding O
comparable O
rates O
of O
neurologic O
and O
gastrointestinal O
toxicity O
. O
Vinorelbine O
- O
based O
treatment O
was O
associated O
with O
more O
anemia B-outcome
and I-outcome
neutropenia I-outcome
and O
with O
2 B-iv-bin-abs
episodes O
of O
cardiotoxicity B-outcome
. O
Taxane O
- O
based O
therapy O
was O
associated O
with O
more O
dermatologic B-outcome
toxicity I-outcome
, O
myalgias B-outcome
, O
and O
fluid B-outcome
retention I-outcome
. O
Both O
vinorelbine O
/ O
trastuzumab O
and O
taxane O
/ O
trastuzumab O
treatments O
were O
active O
as O
first O
- O
line O
therapy O
for O
HER2 O
- O
positive O
, O
metastatic O
breast O
cancer O
and O
had O
comparable O
rates B-outcome
of I-outcome
efficacy I-outcome
and I-outcome
tolerability I-outcome
. O
The O
toxicities O
observed O
were O
the O
result O
of O
recognized O
side O
effects O
associated O
with O
each O
of O
the O
chemotherapy O
agents O
and O
schedules O
. O
These O
data O
can O
inform O
treatment O
decision O
making O
in O
this O
clinical O
setting O
. O

Comparison O
of O
ductal B-intervention
lavage I-intervention
and O
random B-control
periareolar I-control
fine I-control
needle I-control
aspiration I-control
as O
tissue O
acquisition O
methods O
in O
early O
breast O
cancer O
prevention O
trials O
. O
Short O
- O
term O
phase O
I O
and O
phase O
II O
breast O
cancer O
prevention O
trials O
require O
tissue O
acquisition O
at O
baseline O
and O
after O
intervention O
to O
evaluate O
modulation O
of O
potential O
biomarkers O
. O
Currently O
used O
tissue O
acquisition O
methods O
include O
ductal O
lavage O
( O
DL O
) O
, O
random O
periareolar O
fine O
needle O
aspiration O
( O
RPFNA O
) O
, O
and O
core O
needle O
biopsy O
. O
The O
optimum O
method O
to O
retrieve O
adequate O
samples O
and O
the O
most O
accepted O
method O
by O
study O
participants O
is O
not O
known O
. O
We O
compared O
RPFNA O
and O
DL O
as O
breast O
tissue O
acquisition O
methods O
for O
short O
- O
term O
breast O
cancer O
prevention O
trials O
by O
evaluating O
sample O
adequacy O
and O
tolerability O
in O
subjects O
who O
participated O
in O
two O
prospective O
phase O
II O
breast O
cancer O
prevention O
trials O
. O
Eighty B-total-participants
- I-total-participants
six I-total-participants
women B-eligibility
at I-eligibility
increased I-eligibility
risk I-eligibility
for I-eligibility
breast I-eligibility
cancer I-eligibility
were O
included O
in O
this O
study O
and O
underwent O
baseline O
DL O
and O
RPFNA O
. O
High O
risk O
was O
defined O
as O
having O
a O
5 O
- O
year O
Gail O
score O
of O
> O
1.67 O
% O
or O
a O
history O
of O
atypical O
hyperplasia O
( O
AH O
) O
, O
lobular O
carcinoma O
, O
or O
breast O
cancer O
. O
Median O
age O
was O
54.5 B-age
years I-age
( O
range O
, O
39 O
- O
75 O
years O
) O
; O
75 O
% O
of O
the O
women O
were O
postmenopausal O
. O
About O
51 O
% O
of O
the O
women O
yielded O
nipple O
aspiration O
fluid O
, O
and O
breast O
fluid O
samples O
via O
DL O
were O
retrieved O
in O
73 O
% O
of O
these O
subjects O
. O
Of O
these O
samples O
, O
71 O
% O
were O
adequate O
samples O
( O
greater O
than O
10 O
epithelial O
cells O
) O
. O
However O
, O
when O
the O
entire O
cohort O
was O
considered O
, O
only O
31 O
% O
of O
the O
subjects O
had O
adequate O
samples O
. O
RPFNA O
was O
also O
attempted O
in O
all O
subjects O
, O
and O
sample O
retrieval O
rate O
was O
100 O
% O
. O
Out O
of O
these O
, O
96 O
% O
of O
the O
subjects O
had O
adequate O
samples O
. O
In O
DL O
samples O
, O
AH B-outcome
rate I-outcome
was O
3.7 B-iv-bin-percent
% I-iv-bin-percent
was O
and O
hyperplasia B-outcome
( I-outcome
H I-outcome
) I-outcome
rate I-outcome
was O
11.1 B-iv-bin-percent
% I-iv-bin-percent
. O
In O
RPFNA O
samples O
, O
AH B-outcome
rate I-outcome
was O
12.9 B-cv-bin-percent
% I-cv-bin-percent
, O
and O
H B-outcome
rate I-outcome
was O
24.7 B-cv-bin-percent
% I-cv-bin-percent
. O
Cytology O
findings O
in O
RPFNA O
samples O
correlated O
with O
age O
, O
menopausal O
status O
, O
and O
breast O
cancer O
risk O
category O
( O
previous O
history O
of O
lobular O
carcinoma O
in O
situ O
) O
. O
Both O
procedures O
were O
well B-outcome
tolerated I-outcome
, O
and O
no B-outcome
complications I-outcome
occurred O
among O
participants O
. O
Considering O
that O
the O
main O
end O
point O
for O
short O
- O
term O
prevention O
trials O
is O
the O
modulation O
of O
biomarkers O
, O
it O
is O
important O
to O
optimize O
adequate O
sample O
acquisition O
; O
therefore O
, O
RPFNA O
is O
a O
more O
practical O
option O
for O
future O
phase O
I O
and O
II O
breast O
cancer O
prevention O
trials O
compared O
with O
DL O
. O

A O
phase O
II O
, O
randomized O
, O
blinded O
study O
of O
the O
farnesyltransferase O
inhibitor O
tipifarnib B-intervention
combined I-intervention
with I-intervention
letrozole I-intervention
in O
the O
treatment O
of O
advanced O
breast O
cancer O
after O
antiestrogen O
therapy O
. O
This O
study O
assessed O
the O
clinical O
efficacy O
of O
the O
farnesyltransferase O
inhibitor O
, O
tipifarnib O
, O
combined O
with O
letrozole O
in O
patients O
with O
advanced O
breast O
cancer O
and O
disease O
progression O
following O
antiestrogen O
therapy O
. O
Postmenopausal B-eligibility
women I-eligibility
with I-eligibility
estrogen I-eligibility
- I-eligibility
receptor I-eligibility
- I-eligibility
positive I-eligibility
advanced I-eligibility
breast I-eligibility
cancer I-eligibility
that I-eligibility
had I-eligibility
progressed I-eligibility
after I-eligibility
tamoxifen I-eligibility
were O
given O
2.5 O
mg O
letrozole O
once O
daily O
and O
were O
randomly O
assigned O
( O
2 O
:1 O
) O
to O
tipifarnib O
300 O
mg O
( O
TL O
) O
or O
placebo B-control
( O
L O
) O
twice O
daily O
for O
21 O
consecutive O
days O
in O
28 O
- O
day O
cycles O
. O
The O
primary O
endpoint O
was O
objective B-outcome-measure
response I-outcome-measure
rate I-outcome-measure
. O
Of O
120 B-total-participants
patients O
treated O
with O
TL O
( O
n O
= O
80 B-intervention-participants
) O
or O
L O
( O
n O
= O
40 B-control-participants
) O
, O
113 B-total-participants
were O
evaluable O
for O
response O
. O
Objective B-outcome
response I-outcome
rate I-outcome
was O
30 B-iv-bin-percent
% I-iv-bin-percent
( O
95 O
% O
CI O
; O
20 O
- O
41 O
% O
) O
for O
TL O
and O
38 B-cv-bin-percent
% I-cv-bin-percent
( O
95 O
% O
CI O
; O
23 O
- O
55 O
% O
) O
for O
L. O
There O
was O
no O
significant O
difference O
in O
response B-outcome
duration I-outcome
, O
time B-outcome
to I-outcome
disease I-outcome
progression I-outcome
or O
survival B-outcome
. O
Clinical B-outcome
benefit I-outcome
rates I-outcome
were I-outcome
49 B-iv-bin-percent
% I-iv-bin-percent
( O
TL O
) O
and O
62 B-cv-bin-percent
% I-cv-bin-percent
( O
L O
) O
. O
Tipifarnib O
was O
generally O
well O
tolerated O
; O
a O
higher O
incidence O
of O
drug B-outcome
- I-outcome
related I-outcome
asymptomatic I-outcome
grade I-outcome
3 I-outcome
/ I-outcome
4 I-outcome
neutropenia I-outcome
was O
observed O
for O
TL O
( O
18 B-iv-bin-percent
% I-iv-bin-percent
) O
than O
for O
L O
( O
0 B-cv-bin-percent
% I-cv-bin-percent
) O
. O
Tipifarnib O
population O
pharmacokinetics O
were O
similar O
to O
previous O
studies O
, O
with O
no O
significant O
difference O
in O
trough O
letrozole O
concentrations O
between O
the O
TL O
and O
L O
groups O
. O
Adding O
tipifarnib O
to O
letrozole O
did O
not O
improve O
objective O
response O
rate O
in O
this O
population O
of O
patients O
with O
advanced O
breast O
cancer O
. O

Phase O
III O
study O
to O
evaluate O
the O
use O
of O
high B-intervention
- I-intervention
dose I-intervention
chemotherapy I-intervention
as O
consolidation O
of O
treatment O
for O
high O
- O
risk O
postoperative O
breast O
cancer O
: O
Japan O
Clinical O
Oncology O
Group O
study O
, O
JCOG O
9208 O
. O
A O
randomized O
controlled O
trial O
was O
conducted O
to O
evaluate O
the O
efficacy O
of O
high O
- O
dose O
chemotherapy O
( O
HDC O
) O
as O
consolidation O
of O
the O
treatment O
of O
high O
- O
risk O
postoperative O
breast O
cancer O
. O
Patients O
under B-age
56 I-age
years I-age
of O
age O
with B-eligibility
stage I-eligibility
I I-eligibility
to I-eligibility
IIIB I-eligibility
breast I-eligibility
cancer I-eligibility
involving I-eligibility
10 I-eligibility
or I-eligibility
more I-eligibility
axillary I-eligibility
lymph I-eligibility
nodes I-eligibility
were O
eligible O
. O
The O
primary O
endpoint O
was O
relapse B-outcome-measure
- I-outcome-measure
free I-outcome-measure
survival I-outcome-measure
( I-outcome-measure
RFS I-outcome-measure
) I-outcome-measure
. O
Between O
May O
1993 O
and O
March O
1999 O
, O
97 B-total-participants
patients O
were O
enrolled O
, O
and O
two O
patients O
became O
ineligible O
. O
The O
median O
age O
of O
the O
97 O
patients O
was O
46 O
years O
( O
range O
27 O
- O
55 O
years O
) O
, O
and O
72 O
( O
74 O
% O
) O
were O
premenopausal O
. O
The O
median O
number O
of O
involved O
axillary O
nodes O
was O
16 O
( O
range O
10 O
- O
49 O
) O
. O
All O
patients O
had O
undergone O
a O
radical O
mastectomy O
. O
Major O
characteristics O
were O
well O
balanced O
between O
the O
treatment O
arms O
. O
Forty B-control-participants
- I-control-participants
eight I-control-participants
patients O
in O
the O
standard B-control
- I-control
dose I-control
( I-control
STD I-control
) I-control
arm O
received O
six O
courses O
of O
cyclophosphamide O
, O
doxorubicin O
, O
and O
5 O
- O
fluorouracil O
followed O
by O
tamoxifen O
. O
Forty B-intervention-participants
- I-intervention-participants
nine I-intervention-participants
patients O
were O
assigned O
to O
undergo O
HDC O
with O
cyclophosphamide O
and O
thiotepa O
after O
six O
courses O
of O
cyclophosphamide O
, O
doxorubicin O
, O
and O
5 O
- O
fluorouracil O
followed O
by O
tamoxifen O
; O
however O
, O
15 O
of O
these O
patients O
( O
31 O
% O
) O
did O
not O
undergo O
HDC O
. O
HDC O
was O
well B-outcome
tolerated I-outcome
without O
any O
treatment O
- O
related O
mortality O
. O
At O
a O
median O
follow O
- O
up O
of O
63 O
months O
, O
the O
5 B-outcome
- I-outcome
year I-outcome
RFS I-outcome
of O
47 B-control-participants
eligible O
patients O
in O
the O
STD O
arm O
and O
48 B-intervention-participants
eligible O
patients O
in O
the O
HDC O
arm O
was O
37 B-cv-bin-percent
% I-cv-bin-percent
and O
52 B-iv-bin-percent
% I-iv-bin-percent
on O
an O
intent O
- O
to O
- O
treat O
basis O
, O
respectively O
( O
P O
= O
0.17 O
) O
. O
Five B-outcome
- I-outcome
year I-outcome
overall I-outcome
survival I-outcome
of O
all O
randomized O
patients O
was O
62 B-cv-bin-percent
% I-cv-bin-percent
for O
the O
STD O
arm O
and O
63 B-iv-bin-percent
% I-iv-bin-percent
for O
the O
HDC O
arm O
( O
P O
= O
0.78 O
) O
. O
Although O
the O
prespecified O
values O
of O
the O
two O
arms O
were O
not O
so O
accurate O
as O
to O
allow O
detection O
of O
the O
observed O
difference O
, O
no O
advantage O
of O
HDC O
was O
observed O
in O
terms O
of O
RFS O
or O
overall O
survival O
. O

Anti O
- O
tumor O
activity O
of O
capecitabine B-intervention
and O
vinorelbine B-control
in O
patients O
with O
anthracycline- O
and O
taxane O
- O
pretreated O
metastatic O
breast O
cancer O
: O
findings O
from O
the O
EORTC O
10001 O
randomized O
phase O
II O
trial O
. O
The O
aim O
of O
this O
randomized O
phase O
II O
study O
was O
to O
evaluate O
the O
anti O
- O
tumor O
activity O
and O
safety O
of O
capecitabine O
and O
vinorelbine O
in O
patients B-eligibility
with I-eligibility
metastatic I-eligibility
breast I-eligibility
cancer I-eligibility
pretreated I-eligibility
with I-eligibility
taxanes I-eligibility
and I-eligibility
anthracyclines I-eligibility
. O
We O
planned O
to O
randomize O
72 B-total-participants
patients O
to O
capecitabine O
1250 O
mg O
/ O
m O
( O
2 O
) O
orally O
bid O
days O
1 O
- O
14 O
or O
vinorelbine O
30 O
mg O
/ O
m O
( O
2 O
) O
i. O
v. O
days O
1 O
and O
8 O
, O
both O
given O
every O
3 O
weeks O
. O
The O
study O
was O
stopped O
due O
to O
poor O
accrual O
with O
47 O
patients O
enrolled O
. O
Responses B-outcome
were O
seen O
in O
2 B-iv-bin-abs
/ O
23 B-intervention-participants
patients O
treated O
with O
capecitabine O
( O
8.7 B-iv-bin-percent
% I-iv-bin-percent
; O
95 O
% O
CI O
1.1 O
- O
29.0 O
) O
and O
3 B-cv-bin-abs
/ O
24 B-control-participants
patients O
treated O
with O
vinorelbine O
( O
12.5 B-cv-bin-percent
% I-cv-bin-percent
; O
95 O
% O
CI O
2.7 O
- O
32.4 O
) O
. O
Median B-outcome
progression I-outcome
- I-outcome
free I-outcome
survival I-outcome
was O
2.8 B-iv-cont-median
and O
2.6 B-cv-cont-median
months I-cv-cont-median
, O
and O
median B-outcome
overall I-outcome
survival I-outcome
was O
9.3 B-iv-cont-median
and O
11.0 B-cv-cont-median
months I-cv-cont-median
, O
in O
the O
capecitabine O
and O
vinorelbine O
arms O
, O
respectively O
. O
There O
was O
more O
hematologic B-outcome
toxicity I-outcome
, O
neurotoxicity B-outcome
, O
and O
nausea B-outcome
/ I-outcome
vomiting I-outcome
with O
vinorelbine O
and O
more O
diarrhea B-outcome
and O
hand B-outcome
- I-outcome
foot I-outcome
syndrome I-outcome
with O
capecitabine O
. O
The O
anti O
- O
tumor O
activity O
of O
capecitabine O
and O
vinorelbine O
seems O
to O
be O
comparable O
, O
but O
the O
toxicity O
profiles O
are O
different O
. O

Cost O
- O
benefit O
analysis O
of O
a O
follow B-intervention
- I-intervention
up I-intervention
program I-intervention
in O
patients B-eligibility
with I-eligibility
breast I-eligibility
cancer I-eligibility
: O
a O
randomized O
prospective O
study O
. O
Increasing O
the O
number O
of O
breast O
cancer O
patients O
in O
follow O
- O
up O
involves O
increased O
costs O
and O
, O
with O
limited O
health O
care O
resources O
, O
there O
is O
a O
need O
to O
evaluate O
the O
cost O
- O
benefit O
to O
the O
patient O
of O
follow O
- O
up O
regimens O
. O
We O
present O
a O
randomized O
prospective O
study O
to O
evaluate O
the O
cost O
- O
benefit O
of O
intensive O
follow O
- O
up O
in O
the O
early O
detection O
of O
relapses O
in O
patients O
with O
breast O
cancer O
. O
One B-total-participants
hundred I-total-participants
and I-total-participants
twenty I-total-participants
- I-total-participants
one I-total-participants
patients O
were O
randomized O
to O
standard B-control
clinical I-control
follow I-control
- I-control
up I-control
( O
n O
= O
63 B-control-participants
) O
or O
to O
an O
intensive O
follow O
- O
up O
( O
n O
= O
58 B-intervention-participants
) O
that O
included O
diagnostic O
laboratory O
tests O
and O
imaging O
designed O
to O
detect O
early O
relapse O
following O
curative O
treatment O
. O
All O
patients O
had O
annual O
mammography O
. O
The O
number O
of O
scheduled O
outpatient O
appointments O
kept O
were O
359 O
in O
the O
standard O
clinical O
follow O
- O
up O
and O
355 O
in O
the O
intensive O
follow O
- O
up O
group O
. O
After O
a O
median O
of O
3 O
years O
of O
follow O
- O
up O
, O
there O
were O
28 O
relapses B-outcome
, O
11 B-cv-bin-abs
in O
standard O
clinical O
follow O
- O
up O
, O
and O
13 B-iv-bin-abs
in O
the O
intensive O
follow O
- O
up O
group O
. O
The O
overall B-outcome
cost I-outcome
of I-outcome
follow I-outcome
- I-outcome
up I-outcome
was O
24,567 B-cv-cont-mean
euros I-cv-cont-mean
in O
the O
standard O
clinical O
follow O
- O
up O
group O
and O
74,171 B-iv-cont-mean
euros I-iv-cont-mean
in O
the O
intensive O
follow O
- O
up O
group O
. O
Performing O
complimentary O
investigations O
in O
breast O
cancer O
follow O
- O
up O
is O
associated O
with O
higher O
costs O
without O
difference O
in O
early O
detection O
of O
relapses O
. O

Randomized O
trial O
of O
high B-intervention
- I-intervention
dose I-intervention
chemotherapy I-intervention
with O
autologous O
peripheral O
- O
blood O
stem O
- O
cell O
support O
compared O
with O
standard O
- O
dose O
chemotherapy O
in O
women O
with O
metastatic O
breast O
cancer O
: O
NCIC O
MA.16 O
. O
We O
conducted O
a O
multicenter O
, O
randomized O
trial O
to O
compare O
progression O
- O
free O
survival O
( O
PFS O
) O
, O
overall O
survival O
( O
OS O
) O
, O
and O
quality O
of O
life O
in O
women O
with O
metastatic O
breast O
cancer O
( O
MBC O
) O
receiving O
high O
- O
dose O
chemotherapy O
plus O
autologous O
stem O
- O
cell O
transplantation O
( O
ASCT O
; O
HDCT O
) O
compared O
with O
standard O
- O
dose O
therapy O
. O
Between O
April O
1997 O
and O
December O
2000 O
, O
386 B-total-participants
women B-eligibility
with I-eligibility
MBC I-eligibility
and I-eligibility
no I-eligibility
prior I-eligibility
chemotherapy I-eligibility
for I-eligibility
metastatic I-eligibility
disease I-eligibility
were O
registered O
. O
After O
initial O
response O
to O
anthracycline- O
or O
taxane O
- O
based O
induction O
chemotherapy O
, O
224 B-total-participants
patients O
were O
randomly O
assigned O
: O
112 B-intervention-participants
to O
high O
- O
dose O
cyclophosphamide O
, O
mitoxantrone O
, O
and O
carboplatin O
chemotherapy O
and O
ASCT O
( O
HDCT O
) O
, O
and O
112 B-control-participants
to O
standard B-control
therapy I-control
( I-control
ST I-control
) I-control
. O
Median O
age O
was O
47 B-age
years I-age
( O
range O
, O
25 O
to O
67 O
years O
) O
. O
Thirty O
two O
percent O
of O
women O
randomly O
assigned O
had O
estrogen O
and O
progesterone O
receptor O
- O
negative O
breast O
cancer O
, O
42 O
% O
had O
visceral O
metastases O
, O
and O
58 O
% O
had O
bone O
metastases O
. O
Complete B-outcome
remission I-outcome
rates I-outcome
before O
random O
assignment O
were O
11 B-iv-bin-percent
% I-iv-bin-percent
for O
those O
receiving O
HDCT O
and O
12 B-cv-bin-percent
% I-cv-bin-percent
for O
those O
receiving O
ST O
. O
After O
a O
median O
follow O
- O
up O
of O
48 O
months O
, O
79 B-iv-bin-abs
deaths B-outcome
were O
observed O
in O
the O
HDCT O
arm O
and O
77 B-cv-bin-abs
deaths O
were O
observed O
in O
the O
ST O
arm O
; O
seven B-iv-bin-abs
patients O
( O
6 B-iv-bin-percent
% I-iv-bin-percent
) O
in O
the O
HDCT O
arm O
died B-outcome
as I-outcome
a I-outcome
result I-outcome
of I-outcome
toxicity I-outcome
. O
The O
median B-outcome
OS I-outcome
was O
24 B-iv-cont-median
months I-iv-cont-median
for O
the O
HDCT O
arm O
( O
95 O
% O
CI O
, O
21 O
to O
35 O
months O
) O
and O
28 B-cv-cont-median
months I-cv-cont-median
for O
ST O
( O
95 O
% O
CI O
, O
22 O
to O
33 O
months O
; O
hazard O
ratio O
[ O
HR O
] O
, O
0.9 O
; O
95 O
% O
CI O
, O
0.6 O
to O
1.2 O
; O
P O
= O
.43 O
) O
. O
PFS B-outcome
was O
11 B-iv-cont-median
months I-iv-cont-median
for O
HDCT O
and O
9 B-cv-cont-median
months I-cv-cont-median
for O
ST O
( O
HR O
, O
0.6 O
in O
favor O
of O
HDCT O
; O
95 O
% O
CI O
, O
0.5 O
to O
0.9 O
; O
P O
= O
.006 O
) O
. O
HDCT O
did O
not O
improve O
OS O
in O
women O
with O
MBC O
when O
used O
as O
consolidation O
after O
response O
to O
induction O
chemotherapy O
. O

Pegase O
03 O
: O
a O
prospective O
randomized O
phase O
III O
trial O
of O
FEC O
with O
or O
without O
high B-intervention
- I-intervention
dose I-intervention
thiotepa I-intervention
, I-intervention
cyclophosphamide I-intervention
and O
autologous O
stem O
cell O
transplantation O
in O
first O
- O
line O
treatment O
of O
metastatic O
breast O
cancer O
. O
Pegase O
03 O
is O
a O
multicenter O
prospective O
randomized O
phase O
III O
trial O
evaluating O
the O
impact O
of O
first O
- O
line O
high O
- O
dose O
chemotherapy O
( O
HDC O
) O
with O
stem O
cell O
support O
on O
overall O
survival O
( O
OS O
) O
, O
disease O
- O
free O
survival O
( O
DFS O
) O
and O
response O
rate O
in O
308 B-total-participants
patients B-eligibility
with I-eligibility
histologically I-eligibility
proven I-eligibility
metastatic I-eligibility
breast I-eligibility
cancer I-eligibility
responding I-eligibility
to I-eligibility
induction I-eligibility
therapy I-eligibility
. O
Eligible O
patients O
received O
four O
induction O
cycles O
with O
FEC O
100 O
( O
5 O
- O
fluorouracil O
500 O
mg O
/ O
m O
( O
2 O
) O
, O
epirubicin O
100 O
mg O
/ O
m O
( O
2 O
) O
, O
cyclophosphamide O
500 O
mg O
/ O
m O
( O
2 O
) O
) O
. O
Patients O
with O
objective O
response O
( O
N O
= O
179 B-total-participants
) O
were O
randomized O
to O
one O
cycle O
of O
HDC O
( O
cyclophosphamide O
6000 O
mg O
/ O
m O
( O
2 O
) O
and O
thiotepa O
800 O
mg O
/ O
m O
( O
2 O
) O
( O
CHUT O
) O
) O
and O
stem O
cell O
support O
( O
N O
= O
88 B-intervention-participants
) O
, O
or O
no B-control
further I-control
treatment I-control
( O
N O
= O
91 B-control-participants
) O
. O
All O
patients O
were O
observed O
until O
disease O
progression O
or O
death O
. O
One B-iv-bin-abs
toxic B-outcome
death I-outcome
occurred O
after O
CHUT O
. O
Other O
toxicities O
were O
manageable O
. O
The O
response B-outcome
rate I-outcome
at I-outcome
3 I-outcome
months I-outcome
was O
higher O
in O
the O
intensification O
arm O
: O
82.7 B-iv-bin-percent
% I-iv-bin-percent
( O
25.3 B-iv-bin-percent
% I-iv-bin-percent
complete B-outcome
response I-outcome
( I-outcome
CR I-outcome
) I-outcome
) O
versus O
59.2 B-cv-bin-percent
% I-cv-bin-percent
( O
14.1 B-cv-bin-percent
% I-cv-bin-percent
CR O
) O
( O
P O
= O
0.0002 O
) O
. O
Median O
follow O
- O
up O
was O
48 O
months O
. O
Median B-outcome
DFS I-outcome
was O
11 B-iv-cont-median
and O
6.6 B-cv-cont-median
months I-cv-cont-median
in O
the O
intensification O
and O
the O
observation O
arms O
, O
respectively O
( O
P O
= O
0.0001 O
) O
. O
There O
was O
no O
survival B-outcome
difference O
: O
33.6 B-iv-bin-percent
versus O
27.3 B-cv-bin-percent
% I-cv-bin-percent
OS B-outcome
at I-outcome
3 I-outcome
years I-outcome
( O
P O
= O
0.8 O
) O
and O
22.9 B-iv-cont-median
versus O
22.3 B-cv-cont-median
months I-cv-cont-median
median B-outcome
time I-outcome
to I-outcome
relapse I-outcome
in O
the O
intensification O
and O
observation O
arms O
, O
respectively O
. O
In O
this O
randomized O
trial O
, O
HDC O
with O
CHUT O
improved O
DFS O
but O
not O
OS O
, O
corroborating O
findings O
from O
earlier O
trials O
. O

Thoracic B-intervention
paravertebral I-intervention
block I-intervention
for O
breast O
cancer O
surgery O
: O
a O
randomized O
double O
- O
blind O
study O
. O
We O
examined O
in O
this O
randomized O
, O
double O
- O
blind O
study O
whether O
a O
multilevel O
paravertebral O
block O
performed O
before O
general O
anesthesia O
with O
propofol O
and O
a O
laryngeal O
mask O
enhances O
postoperative O
analgesia O
after O
breast O
cancer O
surgery O
. O
Eighty B-total-participants
- I-total-participants
eight I-total-participants
patients O
were O
randomized O
to O
receive O
paravertebral O
injections O
with O
either O
ropivacaine O
0.5 O
% O
( O
30 O
mL O
) O
or O
an O
equivalent O
amount O
of O
isotonic B-control
saline I-control
. O
Nine O
patients O
were O
excluded O
after O
randomization O
, O
thus O
79 B-total-participants
patients O
remained O
for O
evaluation O
( O
ropivacaine O
, O
n O
= O
38 B-intervention-participants
; O
placebo O
, O
n O
= O
41 B-control-participants
) O
. O
Variables O
of O
efficacy O
were O
the O
amount O
of O
fentanyl O
delivered O
by O
the O
patient O
- O
controlled O
analgesia O
device O
in O
the O
postanesthesia O
care O
unit O
( O
PACU O
) O
, O
postoperative O
pain O
measured O
on O
a O
numeric O
rating O
scale O
at O
regular O
intervals O
from O
the O
day O
of O
surgery O
and O
until O
the O
second O
postoperative O
day O
. O
The O
median B-outcome
consumption I-outcome
of I-outcome
fentanyl I-outcome
in I-outcome
the I-outcome
PACU I-outcome
was O
less O
in O
the O
ropivacaine O
group O
compared O
with O
the O
placebo O
group O
( O
0 B-iv-cont-median
microg I-iv-cont-median
[ O
range O
: O
0 O
- O
250 O
microg O
] O
versus O
100 B-cv-cont-median
microg I-cv-cont-median
[ O
range O
: O
0 O
- O
800 O
microg O
] O
, O
P O
= O
0.001 O
) O
. O
Also O
, O
fewer O
patients O
in O
the O
ropivacaine O
group O
reported O
pain B-outcome
> I-outcome
or I-outcome
=3 I-outcome
on O
the O
numbers O
rating O
scale O
in O
the O
PACU O
( O
13 B-iv-bin-abs
vs O
31 B-cv-bin-abs
, O
P O
< O
0.0001 O
) O
. O
No O
statistical O
difference O
in O
pain B-outcome
scores I-outcome
or O
consumption B-outcome
of I-outcome
analgesics I-outcome
could O
be O
demonstrated O
after O
discharge O
from O
the O
PACU O
. O
A O
multilevel O
paravertebral O
block O
provides O
good O
analgesia O
for O
breast O
surgery O
, O
but O
the O
duration O
of O
analgesia O
is O
briefer O
than O
described O
in O
previous O
studies O
. O

Histopathological O
assessment O
of O
anastrozole B-intervention
and O
tamoxifen B-control
as O
preoperative O
( O
neoadjuvant O
) O
treatment O
in O
postmenopausal O
Japanese B-ethinicity
women O
with O
hormone O
receptor O
- O
positive O
breast O
cancer O
in O
the O
PROACT O
trial O
. O
The O
PReOperative O
' O
Arimidex O
' O
Compared O
with O
Tamoxifen O
( O
PROACT O
) O
trial O
compared O
neoadjuvant O
anastrozole O
and O
tamoxifen O
in O
postmenopausal B-eligibility
women I-eligibility
with I-eligibility
large I-eligibility
, I-eligibility
operable I-eligibility
or I-eligibility
potentially I-eligibility
operable I-eligibility
, I-eligibility
locally I-eligibility
advanced I-eligibility
hormone I-eligibility
receptor I-eligibility
- I-eligibility
positive I-eligibility
breast I-eligibility
cancer I-eligibility
. O
Here O
, O
we O
compare O
objective O
clinical O
responses O
with O
histopathological O
tumor O
responses O
to O
therapy O
in O
a O
cohort O
of O
97 B-total-participants
Japanese O
patients O
, O
in O
order O
to O
investigate O
the O
consistency O
of O
assessment O
methods O
and O
the O
change O
in O
estrogen O
- O
receptor O
( O
ER O
) O
and O
progesterone O
- O
receptor O
( O
PgR O
) O
status O
. O
Histopathological O
response O
and O
the O
change O
in O
ER O
and O
PgR O
status O
were O
assessed O
by O
comparing O
pathological O
specimens O
collected O
at O
baseline O
( O
via O
needle O
biopsy O
) O
with O
those O
collected O
at O
3 O
months O
( O
from O
excised O
tumors O
) O
. O
The O
response O
was O
evaluated O
using O
Pathological O
Response O
Criteria O
for O
Breast O
Cancer O
as O
defined O
by O
the O
Japanese O
Breast O
Cancer O
Society O
. O
The O
patients O
were O
randomized O
to O
receive O
anastrozole O
( O
n O
= O
48 B-intervention-participants
) O
or O
tamoxifen O
( O
n O
= O
49 B-control-participants
) O
. O
A O
numerically O
greater O
histopathological B-outcome
response I-outcome
rate I-outcome
was O
observed O
when O
neoadjuvant O
anastrozole O
compared O
with O
neoadjuvant O
tamoxifen O
( O
35.4 B-iv-bin-percent
and O
12.2 B-cv-bin-percent
% I-cv-bin-percent
, O
respectively O
) O
. O
The O
histopathological B-outcome
and I-outcome
clinical I-outcome
objective I-outcome
response I-outcome
rates I-outcome
agreed O
in O
63 O
/ O
97 O
patients O
. O
The O
ER B-outcome
status I-outcome
of O
5 B-iv-bin-abs
/ O
40 B-intervention-participants
patients O
changed B-outcome
from I-outcome
positive I-outcome
at I-outcome
baseline I-outcome
to I-outcome
negative I-outcome
at I-outcome
3 I-outcome
months I-outcome
in O
the O
anastrozole O
group O
compared O
with O
20 B-cv-bin-abs
/ O
37 B-control-participants
patients O
in O
the O
tamoxifen O
group O
. O
The O
PgR B-outcome
status I-outcome
of O
16 B-iv-bin-abs
/ O
17 B-intervention-participants
patients O
in O
the O
anastrozole O
group O
and O
of O
1 B-cv-bin-abs
/ O
11 B-control-participants
patients O
in O
the O
tamoxifen O
group O
changed B-outcome
from I-outcome
positive I-outcome
to I-outcome
negative I-outcome
. O
These O
data O
support O
the O
findings O
of O
the O
main O
PROACT O
trial O
, O
which O
confirmed O
that O
anastrozole O
, O
as O
compared O
with O
tamoxifen O
, O
is O
an O
effective O
neoadjuvant O
endocrine O
treatment O
in O
objective O
response O
rates O
for O
postmenopausal O
women O
with O
large O
operable O
hormone O
- O
receptor O
positive O
breast O
cancer O
. O
Further O
follow O
- O
up O
is O
required O
to O
confirm O
whether O
histopathological O
responses O
to O
therapy O
correlate O
with O
an O
overall O
improvement O
in O
survival O
. O

Weekly O
docetaxel B-intervention
versus O
CMF B-control
as O
adjuvant O
chemotherapy O
for O
elderly O
breast O
cancer O
patients O
: O
safety O
data O
from O
the O
multicentre O
phase O
3 O
randomised O
ELDA O
trial O
. O
Within O
an O
ongoing O
multicentre O
phase O
3 O
randomised O
trial O
( O
ELDA O
, O
cancertrials O
. O
gov O
ID O
: O
NCT00331097 O
) O
, O
early B-eligibility
breast I-eligibility
cancer I-eligibility
patients I-eligibility
, I-eligibility
65 I-eligibility
- I-eligibility
79 I-eligibility
years I-eligibility
old I-eligibility
, I-eligibility
with I-eligibility
average I-eligibility
to I-eligibility
high I-eligibility
risk I-eligibility
of I-eligibility
recurrence I-eligibility
, O
are O
randomly O
assigned O
to O
receive O
CMF O
( O
cyclophosphamide O
600 O
mg O
/ O
m2 O
, O
methotrexate O
40 O
mg O
/ O
m2 O
, O
fluorouracil O
600 O
mg O
/ O
m2 O
, O
days O
1 O
- O
8) O
or O
docetaxel O
( O
35 O
mg O
/ O
m2 O
days O
1 O
- O
8 O
- O
15 O
) O
, O
every O
4 O
weeks O
. O
Here O
we O
report O
an O
unplanned O
safety O
analysis O
prompted O
by O
an O
amendment O
introducing O
creatinine O
clearance O
as O
a O
tool O
to O
adjust O
methotrexate O
dose O
. O
Before O
such O
change O
, O
101 B-total-participants
patients O
with O
a O
median O
age O
of O
70 B-age
were O
randomly O
assigned O
CMF O
( O
53 B-control-participants
patients O
) O
or O
docetaxel O
( O
48 B-intervention-participants
patients O
) O
. O
At O
least O
one O
grades B-outcome
3 I-outcome
- I-outcome
4 I-outcome
toxic I-outcome
event I-outcome
of I-outcome
any I-outcome
type I-outcome
was O
reported O
in O
40 B-cv-bin-abs
( O
75.5 B-cv-bin-percent
% I-cv-bin-percent
) O
and O
19 B-iv-bin-abs
( O
39.6 B-iv-bin-percent
% I-iv-bin-percent
) O
patients O
with O
CMF O
and O
docetaxel O
, O
respectively O
( O
p O
= O
0.0002 O
) O
. O
Grades B-outcome
3 I-outcome
- I-outcome
4 I-outcome
hematological I-outcome
events I-outcome
were O
observed O
in O
37 B-cv-bin-abs
( O
69.8 B-cv-bin-percent
% I-cv-bin-percent
) O
vs. O
4 B-iv-bin-abs
( O
8.3 B-iv-bin-percent
% I-iv-bin-percent
) O
cases O
( O
p<0.0001 O
) O
and O
grades B-outcome
3 I-outcome
- I-outcome
4 I-outcome
non I-outcome
- I-outcome
hematological I-outcome
toxicity I-outcome
in O
12 B-cv-bin-abs
( O
22.6 B-cv-bin-percent
% I-cv-bin-percent
) O
vs. O
15 B-iv-bin-abs
( O
31.2 B-iv-bin-percent
% I-iv-bin-percent
) O
patients O
( O
p O
= O
0.11 O
) O
, O
with O
CMF O
and O
docetaxel O
, O
respectively O
. O
A O
higher O
incidence O
of O
anemia B-outcome
, O
neutropenia B-outcome
, O
thrombocytopenia B-outcome
and O
febrile B-outcome
neutropenia I-outcome
was O
reported O
with O
CMF O
. O
Constipation B-outcome
, O
mucositis B-outcome
, O
nausea B-outcome
and O
vomiting B-outcome
were O
more O
common O
with O
CMF O
; O
diarrhoea B-outcome
, O
abdominal B-outcome
pain I-outcome
, O
dysgeusia B-outcome
, O
neuropathy B-outcome
and O
liver B-outcome
toxicity I-outcome
were O
more O
frequent O
with O
docetaxel O
. O
No O
significant O
interaction O
was O
found O
between O
the O
occurrence O
of O
severe O
toxicity B-outcome
and O
baseline O
variables O
, O
including O
creatinine O
clearance O
and O
geriatric O
activity O
scales O
. O
In O
conclusion O
, O
weekly O
docetaxel O
appears O
to O
be O
less O
toxic O
than O
CMF O
in O
terms O
of O
hematological O
toxicity O
. O

Feasibility O
of O
two O
dose B-intervention
- I-intervention
dense I-intervention
FEC I-intervention
regimens I-intervention
with O
growth O
factor O
support O
for O
adjuvant O
therapy O
in O
patients B-eligibility
with I-eligibility
early I-eligibility
breast I-eligibility
cancer I-eligibility
: O
results O
from O
a O
randomised O
study O
of O
the O
Central O
European O
Cooperative O
Oncology O
Group O
( O
CECOG O
) O
. O
Addition O
of O
epirubicin O
to O
adjuvant O
chemotherapy O
can O
provide O
important O
benefits O
for O
patients O
with O
early O
breast O
cancer O
, O
but O
the O
optimal O
dose O
remains O
unclear O
. O
Further O
improvements O
can O
be O
achieved O
with O
dose O
- O
dense O
regimens O
, O
but O
densification O
of O
fluorouracil O
/ O
epirubicin O
/ O
cyclophosphamide O
( O
FEC O
) O
has O
proved O
difficult O
, O
with O
FEC O
( O
60 O
) O
providing O
little O
benefit O
over O
standard O
chemotherapy O
and O
FEC O
( O
100 O
) O
associated O
with O
toxicity O
. O
We O
investigated O
the O
feasibility O
of O
two O
intermediate O
dose O
- O
dense O
FEC O
regimens O
. O
Patients O
were O
randomised O
to O
six O
cycles O
of O
FEC O
( O
75 O
) O
or O
FEC B-control
( I-control
90 I-control
) I-control
, O
with O
all O
three O
drugs O
given O
on O
day O
1 O
of O
each O
14 O
- O
day O
cycle O
. O
Patients O
also O
received O
pegfilgrastim O
6 O
mg O
as O
a O
single O
subcutaneous O
injection O
on O
day O
2 O
of O
each O
cycle O
. O
The O
primary O
efficacy O
endpoint O
was O
the O
proportion B-outcome
of I-outcome
subjects I-outcome
receiving I-outcome
> I-outcome
or I-outcome
= I-outcome
85 I-outcome
% I-outcome
relative I-outcome
dose I-outcome
intensity I-outcome
and O
was O
achieved O
by O
96 B-iv-bin-percent
% I-iv-bin-percent
and O
88 B-cv-bin-abs
% I-cv-bin-abs
of O
patients O
in O
the O
FEC O
( O
75 O
) O
and O
FEC O
( O
90 O
) O
arms O
, O
respectively O
. O
Of O
147 B-intervention-participants
FEC O
( O
75 O
) O
infusions O
, O
4.1 B-iv-bin-percent
% I-iv-bin-percent
were O
delayed O
, O
while O
9.8 B-cv-bin-percent
% I-cv-bin-percent
of O
143 B-control-participants
FEC O
( O
90 O
) O
infusions B-outcome
were I-outcome
delayed I-outcome
. O
The O
most O
common O
reasons O
for O
delay O
were O
adverse O
events O
and O
personal O
/ O
logistical O
reasons O
. O
One B-cv-bin-abs
dose O
reduction O
occurred O
during O
the O
study O
( O
FEC O
( O
90 O
) O
) O
, O
related O
to O
diarrhoea B-outcome
. O
Grade B-outcome
3 I-outcome
- I-outcome
4 I-outcome
haematological I-outcome
toxicities I-outcome
were O
reported O
in O
two B-cv-bin-abs
patients O
in O
the O
FEC O
( O
90 O
) O
arm O
. O
There O
were O
no O
incidences B-outcome
of I-outcome
febrile I-outcome
neutropenia I-outcome
during O
the O
study O
. O
The O
most O
common O
adverse O
events O
were O
increases B-outcome
in I-outcome
liver I-outcome
enzymes I-outcome
and I-outcome
gastrointestinal I-outcome
events I-outcome
; O
no O
event O
resulted O
in O
discontinuation O
. O
Only O
one B-cv-bin-abs
patient O
( O
FEC O
( O
90 O
) O
) O
experienced O
serious B-outcome
adverse I-outcome
events I-outcome
( I-outcome
vomiting I-outcome
and I-outcome
throat I-outcome
oedema I-outcome
) I-outcome
. O
In O
conclusion O
, O
dose O
- O
dense O
FEC O
( O
75 O
) O
and O
FEC O
( O
90 O
) O
are O
feasible O
with O
pegfilgrastim O
support O
. O
These O
regimens O
are O
associated O
with O
a O
very O
low O
risk O
of O
Grade O
3 O
- O
4 O
toxicity O
. O

Late O
cardiac O
effects O
of O
adjuvant B-intervention
chemotherapy I-intervention
in O
breast O
cancer O
survivors O
treated O
on O
Southwest O
Oncology O
Group O
protocol O
s8897 O
. O
The O
late O
cardiac O
effects O
of O
adjuvant O
anthracycline O
therapy O
in O
survivors O
of O
early O
- O
stage O
breast O
cancer O
have O
had O
limited O
study O
. O
Subclinical O
and O
clinical O
cardiac O
late O
effects O
may O
contribute O
to O
added O
comorbidity O
over O
time O
. O
We O
recruited O
patients O
treated O
on O
Southwest O
Oncology O
Group O
( O
SWOG O
) O
protocol O
S8897 O
who O
had O
been O
randomly O
assigned O
to O
adjuvant O
chemotherapy O
with O
or O
without B-control
doxorubicin I-control
. O
Left O
ventricular O
ejection O
fraction O
( O
LVEF O
) O
was O
evaluated O
at O
5 O
to O
8 O
years O
and O
10 O
to O
13 O
years O
after O
treatment O
randomization O
. O
Cardiac O
risk O
factors O
and O
events O
were O
reported O
by O
clinicians O
annually O
between O
the O
two O
assessments O
. O
A O
total O
of O
180 B-total-participants
breast B-eligibility
cancer I-eligibility
survivors I-eligibility
from O
a O
potential O
sample O
of O
1,176 O
patients O
were O
entered O
, O
163 O
patients O
at O
5 O
to O
8 O
years O
and O
17 O
additional O
patients O
at O
10 O
to O
13 O
years O
, O
with O
93 O
longitudinal O
assessments O
of O
LVEF O
. O
There O
was O
no O
significant O
difference O
in O
the O
proportion O
of O
women O
with O
an O
LVEF B-outcome
less I-outcome
than I-outcome
50 I-outcome
% I-outcome
at B-outcome
5 I-outcome
to I-outcome
8 I-outcome
( O
cyclophosphamide O
, O
doxorubicin O
, O
and O
fluorouracil O
[ O
CAF O
] O
v O
cyclophosphamide O
, O
methotrexate O
, O
and O
fluorouracil O
[ O
CMF O
] O
: O
5 B-iv-bin-percent
% I-iv-bin-percent
v O
7 B-cv-bin-percent
% I-cv-bin-percent
; O
P O
= O
.68 O
) O
or O
10 B-outcome
to I-outcome
13 I-outcome
years I-outcome
( O
CAF O
v O
CMF O
: O
3 B-iv-bin-percent
% I-iv-bin-percent
v O
0 B-cv-bin-percent
% I-cv-bin-percent
; O
P O
= O
.16 O
) O
; O
however O
, O
in O
an O
exploratory O
analysis O
, O
the O
mean B-outcome
LVEF I-outcome
in O
the O
doxorubicin O
group O
was O
statistically O
significantly O
lower O
in O
the O
5- O
to O
8 O
- O
year O
sample O
( O
64.8 B-iv-bin-percent
% I-iv-bin-percent
v O
61.4 B-cv-bin-percent
% I-cv-bin-percent
; O
P O
= O
.01 O
) O
but O
not O
in O
the O
10- O
to O
13 O
- O
year O
sample O
. O
In O
the O
longitudinal O
analysis O
, O
there O
was O
no O
significant O
deterioration O
in O
LVEF B-outcome
. O
Women O
enrolled O
onto O
an O
adjuvant O
chemotherapy O
treatment O
clinical O
trial O
for O
breast O
cancer O
were O
successfully O
recruited O
to O
participate O
in O
a O
research O
study O
of O
the O
late O
effects O
of O
treatment O
, O
although O
many O
SWOG O
institutions O
and O
potentially O
eligible O
patients O
chose O
not O
to O
participate O
. O
In O
this O
selected O
sample O
, O
with O
up O
to O
13 O
years O
of O
follow O
- O
up O
, O
exposure O
to O
doxorubicin O
did O
not O
increase O
the O
likelihood O
of O
adverse O
cardiac O
effects O
. O

Effect O
of O
once O
- O
weekly O
epoetin B-intervention
beta I-intervention
on O
survival O
in O
patients B-eligibility
with I-eligibility
metastatic I-eligibility
breast I-eligibility
cancer I-eligibility
receiving I-eligibility
anthracycline- I-eligibility
and/or I-eligibility
taxane I-eligibility
- I-eligibility
based I-eligibility
chemotherapy I-eligibility
: O
results O
of O
the O
Breast O
Cancer O
- O
Anemia O
and O
the O
Value O
of O
Erythropoietin O
( O
BRAVE O
) O
study O
. O
The O
Breast O
Cancer O
- O
Anemia O
and O
the O
Value O
of O
Erythropoietin O
( O
BRAVE O
) O
study O
evaluated O
whether O
epoetin O
beta O
would O
improve O
survival O
in O
patients O
with O
metastatic O
breast O
cancer O
( O
MBC O
) O
. O
BRAVE O
was O
an O
open O
- O
label O
, O
randomized O
, O
multicenter O
study O
in O
patients O
with O
MBC O
treated O
with O
anthracycline- O
and/or O
taxane O
- O
based O
chemotherapy O
. O
Patients O
( O
hemoglobin O
[ O
Hb O
] O
< O
12.9 O
g O
/ O
dL O
) O
were O
randomly O
assigned O
( O
1 O
:1 O
) O
to O
epoetin O
beta O
30,000 O
U O
subcutaneously O
once O
weekly O
or O
control B-control
for O
24 O
weeks O
. O
The O
primary O
efficacy O
variable O
was O
overall B-outcome-measure
survival I-outcome-measure
. O
Secondary O
efficacy O
outcomes O
included O
progression B-outcome-measure
- I-outcome-measure
free I-outcome-measure
survival I-outcome-measure
, O
transfusion- B-outcome-measure
and I-outcome-measure
severe I-outcome-measure
anemia I-outcome-measure
- I-outcome-measure
free I-outcome-measure
survival I-outcome-measure
, O
Hb B-outcome-measure
response I-outcome-measure
, O
safety B-outcome-measure
, O
and O
quality B-outcome-measure
of I-outcome-measure
life I-outcome-measure
( I-outcome-measure
QoL I-outcome-measure
) I-outcome-measure
. O
After O
18 O
months O
of O
follow O
- O
up O
, O
62 B-iv-bin-abs
( O
27 B-iv-bin-percent
% I-iv-bin-percent
) O
of O
231 B-intervention-participants
patients O
survived B-outcome
with O
epoetin O
beta O
therapy O
and O
63 B-cv-bin-abs
( O
27 B-cv-bin-percent
% I-cv-bin-percent
) O
of O
232 B-control-participants
with O
control O
. O
No O
difference O
was O
detected O
in O
overall B-outcome
survival I-outcome
( O
hazard O
ratio O
[ O
HR O
] O
= O
1.07 O
; O
95 O
% O
CI O
, O
0.87 O
to O
1.33 O
, O
P O
= O
.522 O
) O
or O
progression B-outcome
- I-outcome
free I-outcome
survival I-outcome
( O
HR O
= O
1.07 O
; O
95 O
% O
CI O
, O
0.89 O
to O
1.30 O
, O
P O
= O
.448 O
) O
. O
There O
was O
a O
statistically O
significant O
benefit O
on O
transfusion- B-outcome
and I-outcome
severe I-outcome
anemia I-outcome
- I-outcome
free I-outcome
survival I-outcome
compared O
with O
control O
( O
HR O
= O
0.59 O
; O
P O
= O
.0097 O
) O
. O
Median B-outcome
Hb I-outcome
level I-outcome
increased O
with O
epoetin O
beta O
( O
11.7 B-iv-cont-median
g I-iv-cont-median
/ I-iv-cont-median
dL I-iv-cont-median
at B-outcome
baseline I-outcome
to O
13.3 B-iv-cont-median
g I-iv-cont-median
/ I-iv-cont-median
dL I-iv-cont-median
at B-outcome
24 I-outcome
weeks I-outcome
) O
but O
did O
not O
change O
with O
control O
( O
11.5 B-cv-cont-median
v O
11.4 B-cv-cont-median
g I-cv-cont-median
/ I-cv-cont-median
dL I-cv-cont-median
) O
. O
Patients O
receiving O
epoetin O
beta O
experienced O
more O
thromboembolic B-outcome
events I-outcome
( I-outcome
TEEs I-outcome
) I-outcome
compared O
with O
controls O
( O
13 B-iv-bin-percent
% I-iv-bin-percent
v O
6 B-cv-bin-abs
% I-cv-bin-abs
; O
P O
= O
.012 O
) O
with O
no O
difference O
in O
serious B-outcome
TEEs I-outcome
( O
4 B-iv-bin-percent
% I-iv-bin-percent
v O
3 B-cv-bin-percent
% I-cv-bin-percent
) O
. O
Epoetin O
beta O
did O
not O
significantly O
improve O
QoL B-outcome
in O
this O
study O
where O
patients O
had O
a O
high O
baseline O
Hb O
value O
. O
In O
patients O
with O
MBC O
receiving O
chemotherapy O
and O
initial O
Hb O
less O
than O
12.9 O
g O
/ O
dL O
, O
epoetin O
beta O
increased O
Hb O
. O
No O
difference O
was O
detected O
in O
overall B-outcome
survival I-outcome
. O
Because O
of O
its O
superiority O
design O
, O
this O
study O
can O
not O
, O
however O
, O
exclude O
clinically O
important O
differences O
in O
survival O
with O
absolute O
certainty O
. O

Combined O
clinical O
trial O
results O
of O
a O
HER2 B-intervention
/ I-intervention
neu I-intervention
( I-intervention
E75 I-intervention
) I-intervention
vaccine I-intervention
for O
the O
prevention O
of O
recurrence O
in O
high O
- O
risk O
breast O
cancer O
patients O
: O
U.S. B-location
Military O
Cancer O
Institute O
Clinical O
Trials O
Group O
Study O
I-01 O
and O
I-02 O
. O
E75 O
is O
an O
immunogenic O
peptide O
from O
the O
HER2 O
/ O
neu O
protein O
, O
which O
is O
overexpressed O
in O
many O
breast O
cancer O
patients O
. O
We O
have O
conducted O
two O
overlapping O
E75 O
vaccine O
trials O
to O
prevent O
recurrence O
in O
node B-eligibility
- I-eligibility
positive I-eligibility
( I-eligibility
NP I-eligibility
) I-eligibility
and I-eligibility
node I-eligibility
- I-eligibility
negative I-eligibility
( I-eligibility
NN I-eligibility
) I-eligibility
breast I-eligibility
cancer I-eligibility
patients I-eligibility
. O
E75 O
( O
HER2 O
/ O
neu O
369 O
- O
377 O
) O
+ O
granulocyte O
macrophage O
colony O
- O
stimulating O
factor O
was O
given O
intradermally O
to O
previously O
treated O
, O
disease O
- O
free O
NP O
breast O
cancer O
patients O
in O
a O
dose O
escalation O
safety O
trial O
and O
to O
NN O
breast O
cancer O
patients O
in O
a O
dose O
optimization O
study O
. O
Local O
and O
systemic O
toxicity O
was O
monitored O
. O
Immunologic O
responses O
were O
assessed O
using O
in O
vitro O
assays O
and O
in O
vivo O
delayed O
- O
type O
hypersensitivity O
responses O
. O
Clinical O
recurrences O
were O
documented O
. O
One B-total-participants
hundred I-total-participants
and I-total-participants
eighty I-total-participants
- I-total-participants
six I-total-participants
patients O
were O
enrolled O
in O
the O
two O
studies O
( O
NP O
, O
95 O
; O
NN O
, O
91 O
) O
. O
Human O
leucocyte O
antigen O
A2 O
( O
HLA O
- O
A2 O
) O
and O
HLA O
- O
A3 O
patients O
were O
vaccinated O
( O
n O
= O
101 B-intervention-participants
) O
, O
whereas O
all O
others O
( O
n O
= O
85 B-control-participants
) O
were O
followed O
prospectively O
as O
controls B-control
. O
Toxicities O
were O
minimal O
, O
and O
a O
dose O
- O
dependent O
immunologic O
response O
to O
the O
vaccine O
was O
shown O
. O
Planned O
primary O
analysis O
revealed O
a O
recurrence B-outcome
rate I-outcome
of O
5.6 B-iv-bin-percent
% I-iv-bin-percent
in O
vaccinated O
patients O
compared O
with O
14.2 B-cv-bin-percent
% I-cv-bin-percent
in O
the O
controls O
( O
P O
= O
0.04 O
) O
at O
a O
median O
of O
20 O
months O
follow O
- O
up O
. O
As O
vaccine O
- O
specific O
immunity O
waned O
over O
time O
, O
the O
difference B-outcome
in I-outcome
recurrence I-outcome
lost O
significance O
at O
26 O
months O
median O
follow O
- O
up O
( O
8.3 B-iv-bin-percent
% I-iv-bin-percent
versus O
14.8 B-cv-bin-percent
% I-cv-bin-percent
) O
; O
however O
, O
a O
significant O
difference O
in O
the O
pattern O
of O
recurrence O
persisted O
. O
E75 O
is O
safe B-outcome
and I-outcome
effective I-outcome
in O
raising O
a O
dose O
- O
dependent O
HER2 O
/ O
neu O
immunity O
in O
HLA O
- O
A2 O
and O
HLA O
- O
A3 O
NP O
and O
NN O
breast O
cancer O
patients O
. O
More O
importantly O
, O
E75 O
may O
reduce O
recurrences B-outcome
in I-outcome
disease I-outcome
- I-outcome
free I-outcome
, O
conventionally O
treated O
, O
high O
- O
risk O
breast O
cancer O
patients O
. O
These O
findings O
warrant O
a O
prospective O
, O
randomized O
phase O
III O
trial O
of O
the O
E75 O
vaccine O
with O
periodic O
booster O
to O
prevent O
breast O
cancer O
recurrences O
. O

Hair B-intervention
salon I-intervention
stylists I-intervention
as O
breast O
cancer O
prevention O
lay O
health O
advisors O
for O
African B-ethinicity
American I-ethinicity
and O
Afro B-ethinicity
- I-ethinicity
Caribbean I-ethinicity
women O
. O
To O
assess O
the O
effectiveness O
of O
breast O
health O
promoting O
messages O
administered O
by O
salon O
stylists O
to O
clients O
in O
the O
salon O
setting O
. O
Forty O
salons O
in O
an O
urban O
, O
minority O
area O
were O
randomly O
assigned O
to O
provide O
messages O
to O
clients O
or O
to O
serve O
as O
controls B-control
. O
Pre O
- O
intervention O
surveys O
were O
completed O
by O
1,185 B-total-participants
salon O
clients O
. O
Following O
program O
initiation O
, O
assessments O
of O
1,210 B-total-participants
clients O
were O
conducted O
. O
Among O
women O
completing O
surveys O
at O
control O
salons O
, O
10 B-cv-bin-percent
% I-cv-bin-percent
reported O
exposure B-outcome
to I-outcome
breast I-outcome
health I-outcome
messages I-outcome
, O
as O
opposed O
to O
37 B-iv-bin-percent
% I-iv-bin-percent
at O
experimental O
salons O
( O
OR O
5.4 O
, O
95 O
% O
CI O
3.7 O
- O
7.9 O
) O
. O
Self O
- O
reported O
exposure O
to O
stylist O
- O
delivered O
messages O
was O
associated O
with O
improved B-outcome
breast I-outcome
self I-outcome
- I-outcome
examination I-outcome
rates I-outcome
( O
OR O
1.6 O
, O
95 O
% O
CI O
1.2 O
- O
2.1 O
) O
and O
with O
greater B-outcome
intentions I-outcome
to I-outcome
have I-outcome
a I-outcome
clinical I-outcome
breast I-outcome
examination I-outcome
( O
OR O
1.9 O
, O
95 O
% O
CI O
1.1 O
- O
3.3 O
) O
. O
Hair O
salons O
are O
a O
potentially O
important O
venue O
for O
promotion O
of O
health O
behaviors O
related O
to O
breast O
cancer O
detection O
. O

Competing O
causes O
of O
death O
from O
a O
randomized O
trial O
of O
extended O
adjuvant B-intervention
endocrine I-intervention
therapy I-intervention
for O
breast O
cancer O
. O
Older O
women O
with O
early O
- O
stage O
breast O
cancer O
experience O
higher O
rates O
of O
non O
- O
breast O
cancer O
- O
related O
death O
. O
We O
examined O
factors O
associated O
with O
cause O
- O
specific O
death O
in O
a O
large O
cohort O
of O
breast O
cancer O
patients O
treated O
with O
extended O
adjuvant O
endocrine O
therapy O
. O
In O
the O
MA.17 O
trial O
, O
conducted O
by O
the O
National O
Cancer O
Institute O
of O
Canada B-location
Clinical O
Trials O
Group O
, O
5170 B-total-participants
breast O
cancer O
patients O
( O
median O
age O
= O
62 B-age
years O
; O
range O
= O
32 O
- O
94 O
years O
) O
who B-eligibility
were I-eligibility
disease I-eligibility
free I-eligibility
after I-eligibility
approximately I-eligibility
5 I-eligibility
years I-eligibility
of I-eligibility
adjuvant I-eligibility
tamoxifen I-eligibility
treatment I-eligibility
were O
randomly O
assigned O
to O
treatment O
with O
letrozole O
( O
2583 B-intervention-participants
women O
) O
or O
placebo B-control
( O
2587 B-control-participants
women O
) O
. O
The O
median O
follow O
- O
up O
was O
3.9 O
years O
( O
range O
0 O
- O
7 O
years O
) O
. O
We O
investigated O
the O
association O
of O
11 O
baseline O
factors O
with O
the O
competing O
risks O
of O
death O
from O
breast O
cancer O
, O
other O
malignancies O
, O
and O
other O
causes O
. O
All O
statistical O
tests O
were O
two O
- O
sided O
likelihood O
ratio O
criterion O
tests O
. O
During O
follow O
- O
up O
, O
256 O
deaths B-outcome
were O
reported O
( O
102 O
from O
breast O
cancer O
, O
50 O
from O
other O
malignancies O
, O
100 O
from O
other O
causes O
, O
and O
four O
from O
an O
unknown O
cause O
) O
. O
Non B-outcome
- I-outcome
breast I-outcome
cancer I-outcome
deaths I-outcome
accounted O
for O
60 O
% O
of O
the O
252 O
known O
deaths O
( O
72 O
% O
for O
those O
> O
or O
= O
70 O
years O
and O
48 O
% O
for O
those O
< O
70 O
years O
) O
. O
Two O
baseline O
factors O
were O
differentially O
associated O
with O
type O
of O
death O
: O
cardiovascular B-outcome
disease I-outcome
was O
associated O
with O
a O
statistically O
significant O
increased O
risk O
of O
death O
from O
other O
causes O
( O
P.002 O
) O
, O
and O
osteoporosis B-outcome
was O
associated O
with O
a O
statistically O
significant O
increased O
risk O
of O
death O
from O
other O
malignancies O
( O
P.05 O
) O
. O
An O
increased O
risk B-outcome
of I-outcome
breast I-outcome
cancer I-outcome
- I-outcome
specific I-outcome
death I-outcome
was O
associated O
with O
lymph O
node O
involvement O
( O
P O
< O
.001 O
) O
. O
Increased O
risk O
of O
death O
from O
all O
three O
causes O
was O
associated O
with O
older O
age O
( O
P O
< O
.001 O
) O
. O
Non O
- O
breast O
cancer O
- O
related O
deaths O
were O
more O
common O
than O
breast O
cancer O
- O
specific O
deaths O
in O
this O
cohort O
of O
5 O
- O
year O
breast O
cancer O
survivors O
, O
especially O
among O
older O
women O
. O

Phase O
3 O
study O
comparing O
the O
use O
of O
docetaxel B-intervention
on I-intervention
an I-intervention
every-3 I-intervention
- I-intervention
week I-intervention
versus O
weekly B-control
schedule I-control
in O
the O
treatment O
of O
metastatic O
breast O
cancer O
. O
Previous O
studies O
have O
evaluated O
3 O
- O
week O
and O
weekly O
docetaxel O
schedules O
in O
patients O
with O
metastatic O
breast O
cancer O
( O
MBC O
) O
. O
The O
varying O
efficacy O
results O
and O
toxicity O
profiles O
noted O
in O
these O
earlier O
studies O
led O
to O
a O
comparison O
of O
the O
schedules O
to O
determine O
which O
was O
safer O
and O
more O
efficacious O
. O
A O
phase O
3 O
clinical O
trial O
was O
conducted O
in O
patients B-eligibility
with I-eligibility
MBC I-eligibility
who O
were O
treated O
with O
docetaxel O
either O
every O
3 O
weeks O
or O
once O
weekly O
to O
determine O
and O
compare O
response O
rate O
and O
duration O
, O
time O
to O
disease O
progression O
, O
progression O
- O
free O
survival O
( O
PFS O
) O
, O
overall O
survival O
( O
OS O
) O
, O
and O
toxicity O
. O
Patients O
were O
randomized O
to O
receive O
docetaxel O
at O
a O
starting O
dose O
of O
either O
75 O
mg O
/ O
m O
( O
2 O
) O
every O
3 O
weeks O
or O
35 O
mg O
/ O
m O
( O
2 O
) O
weekly O
for O
3 O
consecutive O
weeks O
followed O
by O
1 O
week O
of O
rest O
. O
A O
total O
of O
118 B-total-participants
patients O
underwent O
efficacy O
analysis O
; O
59 B-intervention-participants
patients O
were O
randomized O
to O
the O
every-3 O
- O
week O
treatment O
arm O
and O
59 B-control-participants
to O
the O
weekly O
arm O
. O
The O
response B-outcome
rate I-outcome
was O
35.6 B-iv-bin-percent
% I-iv-bin-percent
( O
95 O
% O
confidence O
interval O
[ O
95 O
% O
CI O
] O
, O
23.6 O
- O
49.1 O
% O
) O
for O
the O
every-3 O
- O
week O
arm O
versus O
20.3 B-cv-bin-percent
% I-cv-bin-percent
( O
95 O
% O
CI O
, O
11.0 O
- O
32.8 O
% O
) O
for O
the O
weekly O
arm O
. O
There O
was O
no O
statistical O
difference O
between O
the O
every O
3 O
- O
week O
and O
the O
weekly O
treatment O
arms O
with O
regard O
to O
median B-outcome
PFS I-outcome
( O
5.7 B-iv-cont-median
months I-iv-cont-median
vs O
5.5 B-cv-cont-median
months I-cv-cont-median
; O
P O
= O
.46 O
) O
or O
OS B-outcome
( O
18.3 B-iv-cont-median
months I-iv-cont-median
vs O
18.6 B-cv-cont-median
months I-cv-cont-median
, O
respectively O
; O
P O
= O
.34 O
) O
. O
There O
was O
a O
higher O
overall B-outcome
toxicity I-outcome
rate I-outcome
( O
grades O
3 O
and O
4 O
, O
according O
to O
the O
National O
Cancer O
Institute O
Common O
Toxicity O
Criteria O
[ O
version O
2.0 O
] O
) O
in O
the O
every-3 O
- O
week O
treatment O
arm O
versus O
the O
weekly O
treatment O
arm O
( O
88.1 B-iv-bin-percent
% I-iv-bin-percent
vs O
55.9 B-cv-bin-percent
% I-cv-bin-percent
, O
respectively O
; O
P O
= O
.0001 O
) O
. O
Compared O
with O
patients O
who O
received O
weekly O
docetaxel O
, O
those O
who O
received O
docetaxel O
every O
3 O
weeks O
had O
a O
higher O
response O
rate O
but O
experienced O
similar O
PFS O
and O
OS O
and O
a O
more O
pronounced O
toxicity O
. O

Double O
- O
blind O
, O
randomized O
placebo O
controlled O
trial O
of O
fulvestrant B-intervention
compared O
with O
exemestane B-control
after O
prior O
nonsteroidal O
aromatase O
inhibitor O
therapy O
in O
postmenopausal O
women O
with O
hormone O
receptor O
- O
positive O
, O
advanced O
breast O
cancer O
: O
results O
from O
EFECT O
. O
The O
third O
- O
generation O
nonsteroidal O
aromatase O
inhibitors O
( O
AIs O
) O
are O
increasingly O
used O
as O
adjuvant O
and O
first O
- O
line O
advanced O
therapy O
for O
postmenopausal O
, O
hormone O
receptor O
- O
positive O
( O
HR+ O
) O
breast O
cancer O
. O
Because O
many O
patients O
subsequently O
experience O
progression O
or O
relapse O
, O
it O
is O
important O
to O
identify O
agents O
with O
efficacy O
after O
AI O
failure O
. O
Evaluation O
of O
Faslodex O
versus O
Exemestane O
Clinical O
Trial O
( O
EFECT O
) O
is O
a O
randomized O
, O
double O
- O
blind O
, O
placebo O
controlled O
, O
multicenter O
phase O
III O
trial O
of O
fulvestrant O
versus O
exemestane O
in O
postmenopausal O
women O
with O
HR+ O
advanced O
breast O
cancer O
( O
ABC O
) O
progressing O
or O
recurring O
after O
nonsteroidal O
AI O
. O
The O
primary O
end O
point O
was O
time B-outcome-measure
to I-outcome-measure
progression I-outcome-measure
( I-outcome-measure
TTP I-outcome-measure
) I-outcome-measure
. O
A O
fulvestrant O
loading O
- O
dose O
( O
LD O
) O
regimen O
was O
used O
: O
500 O
mg O
intramuscularly O
on O
day O
0 O
, O
250 O
mg O
on O
days O
14 O
, O
28 O
, O
and O
250 O
mg O
every O
28 O
days O
thereafter O
. O
Exemestane O
25 O
mg O
orally O
was O
administered O
once O
daily O
. O
A O
total O
of O
693 B-total-participants
women O
were O
randomly O
assigned O
to O
fulvestrant O
( O
n O
= O
351 B-intervention-participants
) O
or O
exemestane O
( O
n O
= O
342 B-control-participants
) O
. O
Approximately O
60 O
% O
of O
patients O
had O
received O
at O
least O
two O
prior O
endocrine O
therapies O
. O
Median B-outcome
TTP I-outcome
was O
3.7 B-iv-cont-median
months I-iv-cont-median
in O
both O
groups O
( O
hazard O
ratio O
= O
0.963 O
; O
95 O
% O
CI O
, O
0.819 O
to O
1.133 O
; O
P O
= O
.6531 O
) O
. O
The O
overall B-outcome
response I-outcome
rate I-outcome
( O
7.4 B-iv-bin-percent
% I-iv-bin-percent
v O
6.7 B-cv-bin-percent
% I-cv-bin-percent
; O
P O
= O
.736 O
) O
and O
clinical B-outcome
benefit I-outcome
rate I-outcome
( O
32.2 B-iv-bin-percent
% I-iv-bin-percent
v O
31.5 B-cv-bin-percent
% I-cv-bin-percent
; O
P O
= O
.853 O
) O
were O
similar O
between O
fulvestrant O
and O
exemestane O
respectively O
. O
Median B-outcome
duration I-outcome
of I-outcome
clinical I-outcome
benefit I-outcome
was O
9.3 B-iv-cont-median
and O
8.3 B-cv-cont-median
months I-cv-cont-median
, O
respectively O
. O
Both O
treatments O
were O
well B-outcome
tolerated I-outcome
, O
with O
no O
significant O
differences O
in O
the O
incidence B-outcome
of I-outcome
adverse I-outcome
events I-outcome
or I-outcome
quality I-outcome
of I-outcome
life I-outcome
. O
Pharmacokinetic O
data O
confirm O
that O
steady O
- O
state O
was O
reached O
within O
1 O
month O
with O
the O
LD O
schedule O
of O
fulvestrant O
. O
Fulvestrant O
LD O
and O
exemestane O
are O
equally O
active O
and O
well O
- O
tolerated O
in O
a O
meaningful O
proportion O
of O
postmenopausal O
women O
with O
ABC O
who O
have O
experienced O
progression O
or O
recurrence O
during O
treatment O
with O
a O
nonsteroidal O
AI O
. O

Intent O
- O
to O
- O
treat O
analysis O
of O
the O
placebo O
- O
controlled O
trial O
of O
letrozole B-intervention
for O
extended O
adjuvant O
therapy O
in O
early B-eligibility
breast I-eligibility
cancer I-eligibility
: O
NCIC O
CTG O
MA.17 O
. O
MA.17 O
evaluated O
letrozole O
or O
placebo B-control
after O
5 O
years O
of O
tamoxifen O
and O
showed O
significant O
improvement O
in O
disease O
- O
free O
survival O
( O
DFS O
) O
for O
letrozole O
[ O
hazard O
ratio O
( O
HR O
) O
0.57 O
, O
P O
= O
0.00008 O
] O
. O
The O
trial O
was O
unblinded O
and O
placebo O
patients O
were O
offered O
letrozole O
. O
An O
intent O
- O
to O
- O
treat O
analysis O
of O
all O
outcomes O
, O
before O
and O
after O
unblinding O
, O
on O
the O
basis O
of O
the O
original O
randomization O
was O
carried O
out O
. O
In O
all O
, O
5187 B-total-participants
patients O
were O
randomly O
allocated O
to O
the O
study O
at O
baseline O
and O
, O
at O
unblinding O
, O
1579 B-control-participants
( O
66 O
% O
) O
of O
2383 O
placebo O
patients O
accepted O
letrozole O
. O
At O
median O
follow O
- O
up O
of O
64 O
months O
( O
range O
16 O
- O
95 O
) O
, O
399 O
recurrences B-outcome
or I-outcome
contralateral I-outcome
breast I-outcome
cancers I-outcome
( O
CLBCs O
) O
( O
164 B-iv-bin-abs
letrozole O
and O
235 B-cv-bin-abs
placebo O
) O
occurred O
. O
Four B-outcome
- I-outcome
year I-outcome
DFS I-outcome
was O
94.3 B-iv-bin-percent
% I-iv-bin-percent
( O
letrozole O
) O
and O
91.4 B-cv-bin-percent
% I-cv-bin-percent
( O
placebo O
) O
[ O
HR O
0.68 O
, O
95 O
% O
confidence O
interval O
( O
CI O
) O
0.55 O
- O
0.83 O
, O
P O
= O
0.0001 O
] O
and O
showed O
superiority O
for O
letrozole O
in O
both O
node O
- O
positive O
and O
-negative O
patients O
. O
Corresponding O
4 B-outcome
- I-outcome
year I-outcome
distant I-outcome
DFS I-outcome
was O
96.3 B-iv-bin-percent
% I-iv-bin-percent
and O
94.9 B-cv-bin-percent
% I-cv-bin-percent
( O
HR O
0.80 O
, O
95 O
% O
CI O
0.62 O
- O
1.03 O
, O
P O
= O
0.082 O
) O
. O
Four B-outcome
- I-outcome
year I-outcome
overall I-outcome
survival I-outcome
was O
95.1 B-iv-bin-percent
% I-iv-bin-percent
for O
both O
groups O
. O
The O
annual B-outcome
rate I-outcome
of I-outcome
CLBC I-outcome
was O
0.28 B-iv-bin-percent
% I-iv-bin-percent
for O
letrozole O
and O
0.46 B-cv-bin-percent
% I-cv-bin-percent
for O
placebo O
patients O
( O
HR O
0.61 O
, O
95 O
% O
CI O
0.39 O
- O
0.97 O
, O
P O
= O
0.033 O
) O
. O
Patients O
originally O
randomly O
assigned O
to O
receive O
letrozole O
within O
3 O
months O
of O
stopping O
tamoxifen O
did O
better O
than O
placebo O
patients O
in O
DFS O
and O
CLBC O
, O
despite O
66 O
% O
of O
placebo O
patients O
taking O
letrozole O
after O
unblinding O
. O

Late O
extended O
adjuvant O
treatment O
with O
letrozole B-intervention
improves O
outcome O
in O
women B-eligibility
with I-eligibility
early I-eligibility
- I-eligibility
stage I-eligibility
breast I-eligibility
cancer I-eligibility
who I-eligibility
complete I-eligibility
5 I-eligibility
years I-eligibility
of I-eligibility
tamoxifen I-eligibility
. O
The O
National O
Cancer O
Institute O
of O
Canada B-location
Clinical O
Trials O
Group O
MA.17 O
trial O
examined O
the O
efficacy O
of O
letrozole O
( O
LET O
) O
started O
within O
3 O
months O
of O
5 O
years O
of O
adjuvant O
tamoxifen O
in O
postmenopausal O
hormone O
receptor O
- O
positive O
early O
- O
stage O
breast O
cancer O
. O
When O
the O
trial O
was O
unblinded O
, O
patients O
who O
received O
placebo B-control
( I-control
PLAC I-control
) I-control
were O
offered O
LET O
. O
This O
cohort O
analysis O
describes O
the O
outcomes O
of O
women O
assigned O
PLAC O
at O
the O
initial O
random O
assignment O
after O
unblinding O
. O
Efficacy O
outcomes O
of O
women O
who O
chose O
LET O
( O
PLAC O
- O
LET O
group O
) O
were O
compared O
with O
those O
who O
did O
not O
( O
PLAC O
- O
PLAC O
group O
) O
by O
the O
hazard O
ratios O
and O
by O
P O
values O
calculated O
from O
Cox O
models O
that O
adjusted O
for O
imbalances O
between O
the O
groups O
. O
Toxicity O
analyses O
included O
only O
events O
that O
occurred O
after O
unblinding O
. O
There O
were O
1,579 B-intervention-participants
women O
in O
the O
PLAC O
- O
LET O
group O
( O
median O
time O
from O
tamoxifen O
, O
2.8 O
years O
) O
and O
804 B-control-participants
in O
the O
PLAC O
- O
PLAC O
group O
. O
Patients O
in O
the O
PLAC O
- O
LET O
group O
were O
younger O
; O
had O
a O
better O
performance O
status O
; O
and O
were O
more B-outcome
likely I-outcome
to I-outcome
have I-outcome
had I-outcome
node I-outcome
- I-outcome
positive I-outcome
disease I-outcome
, O
axillary B-outcome
dissection I-outcome
, O
and O
adjuvant B-outcome
chemotherapy I-outcome
than O
those O
in O
the O
PLAC O
- O
PLAC O
group O
. O
At O
a O
median O
follow O
- O
up O
of O
5.3 O
years O
, O
disease B-outcome
- I-outcome
free I-outcome
survival I-outcome
( O
DFS O
; O
adjusted O
hazard O
ratio O
[ O
HR O
] O
, O
0.37 O
; O
95 O
% O
CI O
, O
0.23 O
to O
0.61 O
; O
P O
< O
.0001 O
) O
and O
distant B-outcome
DFS I-outcome
( O
HR O
, O
0.39 O
; O
95 O
% O
CI O
, O
0.20 O
to O
0.74 O
; O
P O
= O
.004 O
) O
were O
superior O
in O
the O
PLAC O
- O
LET O
group O
. O
More O
self O
- O
reported O
new O
diagnoses O
of O
osteoporosis B-outcome
and I-outcome
significantly I-outcome
more I-outcome
clinical I-outcome
fractures I-outcome
occurred O
in O
the O
women O
who O
took O
LET O
( O
5.2 B-iv-bin-percent
% I-iv-bin-percent
v O
3.1 B-cv-bin-percent
% I-cv-bin-percent
, O
P O
= O
.02 O
) O
. O
Interpretation O
of O
this O
cohort O
analysis O
suggests O
that O
LET O
improves O
DFS O
and O
distant O
DFS O
even O
when O
there O
has O
been O
a O
substantial O
period O
of O
time O
since O
the O
discontinuation O
of O
prior O
adjuvant O
tamoxifen O
. O

Increased O
risk O
of O
recurrence O
after O
hormone B-intervention
replacement I-intervention
therapy I-intervention
in O
breast O
cancer O
survivors O
. O
Hormone O
replacement O
therapy O
( O
HT O
) O
is O
known O
to O
increase O
the O
risk O
of O
breast O
cancer O
in O
healthy O
women O
, O
but O
its O
effect O
on O
breast O
cancer O
risk O
in O
breast O
cancer O
survivors O
is O
less O
clear O
. O
The O
randomized O
HABITS O
study O
, O
which O
compared O
HT O
for O
menopausal O
symptoms O
with O
best O
management O
without O
hormones O
among O
women B-eligibility
with I-eligibility
previously I-eligibility
treated I-eligibility
breast I-eligibility
cancer I-eligibility
, O
was O
stopped O
early O
due O
to O
suspicions O
of O
an O
increased O
risk O
of O
new O
breast O
cancer O
events O
following O
HT O
. O
We O
present O
results O
after O
extended O
follow O
- O
up O
. O
HABITS O
was O
a O
randomized O
, O
non O
- O
placebo O
- O
controlled O
noninferiority O
trial O
that O
aimed O
to O
be O
at O
a O
power O
of O
80 O
% O
to O
detect O
a O
36 O
% O
increase O
in O
the O
hazard O
ratio O
( O
HR O
) O
for O
a O
new O
breast O
cancer O
event O
following O
HT O
. O
Cox O
models O
were O
used O
to O
estimate O
relative O
risks O
of O
a O
breast O
cancer O
event O
, O
the O
maximum O
likelihood O
method O
was O
used O
to O
calculate O
95 O
% O
confidence O
intervals O
( O
CIs O
) O
, O
and O
chi O
( O
2 O
) O
tests O
were O
used O
to O
assess O
statistical O
significance O
, O
with O
all O
P O
values O
based O
on O
two O
- O
sided O
tests O
. O
The O
absolute O
risk O
of O
a O
new O
breast O
cancer O
event O
was O
estimated O
with O
the O
cumulative O
incidence O
function O
. O
Most O
patients O
who O
received O
HT O
were O
prescribed O
continuous O
combined O
or O
sequential O
estradiol O
hemihydrate O
and O
norethisterone O
. O
Of O
the O
447 B-total-participants
women O
randomly O
assigned O
, O
442 B-total-participants
could O
be O
followed O
for O
a O
median O
of O
4 O
years O
. O
Thirty B-iv-bin-abs
- I-iv-bin-abs
nine I-iv-bin-abs
of O
the O
221 B-intervention-participants
women O
in O
the O
HT O
arm O
and O
17 B-cv-bin-abs
of O
the O
221 B-control-participants
women O
in O
the O
control B-control
arm I-control
experienced O
a O
new B-outcome
breast I-outcome
cancer I-outcome
event I-outcome
( O
HR O
= O
2.4 O
, O
95 O
% O
CI O
= O
1.3 O
to O
4.2 O
) O
. O
Cumulative B-outcome
incidences I-outcome
at I-outcome
5 I-outcome
years I-outcome
were O
22.2 B-iv-bin-percent
% I-iv-bin-percent
in O
the O
HT O
arm O
and O
8.0 B-cv-bin-percent
% I-cv-bin-percent
in O
the O
control O
arm O
. O
By O
the O
end O
of O
follow O
- O
up O
, O
six B-iv-bin-abs
women O
in O
the O
HT O
arm O
had O
died B-outcome
of I-outcome
breast I-outcome
cancer I-outcome
and O
six B-iv-bin-abs
were O
alive O
with O
distant B-outcome
metastases I-outcome
. O
In O
the O
control O
arm O
, O
five B-cv-bin-abs
women O
had O
died B-outcome
of I-outcome
breast I-outcome
cancer I-outcome
and O
four B-cv-bin-abs
had O
metastatic B-outcome
breast I-outcome
cancer I-outcome
( O
P O
= O
.51 O
, O
log O
- O
rank O
test O
) O
. O
After O
extended O
follow O
- O
up O
, O
there O
was O
a O
clinically O
and O
statistically O
significant O
increased O
risk O
of O
a O
new O
breast O
cancer O
event O
in O
survivors O
who O
took O
HT O
. O

Predictors O
of O
follow O
- O
up O
exercise B-intervention
behavior I-intervention
6 O
months O
after O
a O
randomized O
trial O
of O
exercise O
training O
during O
breast O
cancer O
chemotherapy O
. O
Exercise O
during O
breast O
cancer O
chemotherapy O
is O
beneficial O
but O
it O
needs O
to O
be O
maintained O
into O
survivorship O
to O
optimize O
long O
- O
term O
benefits O
. O
Here O
, O
we O
report O
the O
predictors O
of O
follow O
- O
up O
exercise O
behavior O
6 O
months O
after O
a O
randomized O
exercise O
trial O
in O
breast O
cancer O
patients O
. O
Breast O
cancer O
patients O
( O
N O
= O
242 B-total-participants
) O
initiating O
adjuvant O
chemotherapy O
were O
randomly O
assigned O
to O
usual B-control
care I-control
( O
n O
= O
82 B-control-participants
) O
, O
supervised O
resistance O
exercise O
( O
n O
= O
82 B-intervention-participants
) O
, O
or O
supervised O
aerobic O
exercise O
( O
n O
= O
78 B-intervention-participants
) O
for O
the O
duration O
of O
their O
chemotherapy O
. O
At O
baseline O
and O
postintervention O
, O
data O
were O
collected O
on O
demographic O
, O
medical O
, O
behavioral O
, O
fitness O
, O
psychosocial O
, O
and O
motivational O
variables O
. O
At O
6 O
- O
month O
follow O
- O
up O
, O
participants O
were O
mailed O
a O
questionnaire O
that O
assessed O
exercise O
behavior O
over O
the O
past O
6 O
months O
and O
were O
categorized O
as O
either O
meeting O
both O
aerobic O
and O
resistance O
exercise O
guidelines O
, O
either O
exercise O
guideline O
, O
or O
neither O
exercise O
guideline O
. O
Two B-total-participants
hundred I-total-participants
one I-total-participants
( O
83.1 O
% O
) O
participants O
provided O
6 O
- O
month O
follow O
- O
up O
data O
with O
85 B-control-participants
( O
42.3 O
% O
) O
meeting O
neither O
exercise O
guideline O
, O
74 B-intervention-participants
( O
36.8 O
% O
) O
meeting O
either O
exercise O
guideline O
, O
and O
42 B-intervention-participants
( O
20.9 O
% O
) O
meeting O
both O
exercise O
guidelines O
. O
In O
multivariate O
regression O
analysis O
, O
seven O
variables O
independently O
predicted O
the O
likelihood O
of O
meeting O
exercise O
guidelines O
at O
follow O
- O
up O
including O
higher O
pretrial B-outcome
exercise I-outcome
( O
beta O
= O
0.23 O
; O
P O
= O
0.002 O
) O
, O
younger O
age O
( O
beta O
= O
-0.15 O
; O
P O
= O
0.028 O
) O
, O
breast B-outcome
conserving I-outcome
surgery I-outcome
( O
beta O
= O
0.15 O
; O
P O
= O
0.033 O
) O
, O
strength B-outcome
improvements I-outcome
( O
beta O
= O
0.15 O
; O
P O
= O
0.028 O
) O
, O
lower O
postintervention B-outcome
fatigue I-outcome
( O
beta O
= O
0.13 O
; O
P O
= O
0.067 O
) O
, O
a O
more O
positive B-outcome
attitude I-outcome
( O
beta O
= O
0.12 O
; O
P O
= O
0.086 O
) O
, O
and O
lower O
postintervention B-outcome
body I-outcome
mass I-outcome
index I-outcome
( O
beta O
= O
-0.11 O
; O
P O
= O
0.105 O
) O
. O
Exercise O
behavior O
6 O
months O
after O
a O
randomized O
trial O
was O
predicted O
by O
a O
wide O
range O
of O
demographic O
, O
medical O
, O
behavioral O
, O
fitness O
, O
psychosocial O
, O
and O
motivational O
variables O
. O
These O
findings O
may O
help O
facilitate O
the O
uptake O
of O
exercise O
behavior O
during O
the O
transition O
from O
breast O
cancer O
patient O
to O
survivor O
. O

Clinical O
effects O
of O
shenqi B-intervention
fuzheng I-intervention
injection I-intervention
in O
the O
neoadjuvant O
chemotherapy O
for O
local O
advanced O
breast O
cancer O
and O
the O
effects O
on O
T O
- O
lymphocyte O
subsets O
. O
To O
evaluate O
clinical O
effects O
of O
shenqi O
fuzheng O
Injection O
( O
[ O
Chinese O
characters O
: O
see O
text O
] O
) O
in O
the O
neoadjuvant O
chemotherapy O
for O
local O
advanced O
breast O
cancer O
and O
the O
effects O
on O
T O
- O
lymphocyte O
subsets O
. O
During O
the O
period O
from O
2000 O
to O
2005 O
, O
126 B-total-participants
patients B-eligibility
with I-eligibility
local I-eligibility
advanced I-eligibility
breast I-eligibility
cancer I-eligibility
were O
treated O
with O
the O
neoadjuvant O
chemotherapy O
. O
They O
were O
randomly O
divided O
into O
the O
following O
two O
groups O
: O
a O
control B-control
group I-control
of O
61 B-control-participants
cases O
treated O
by O
chemotherapy O
alone O
and O
a O
study O
group O
of O
65 B-intervention-participants
cases O
treated O
by O
chemotherapy O
plus O
shenqi O
fuzheng O
injection O
. O
All O
the O
cases O
of O
both O
groups O
were O
given O
the O
CEF O
( O
CTX O
500 O
mg O
/ O
m2 O
, O
d1,8 O
; O
EPI O
40 O
mg O
/ O
m2 O
, O
d1 O
, O
8 O
; O
and O
5 O
- O
Fu O
500 O
mg O
/ O
m2 O
d1,8 O
) O
regimen O
. O
The O
clinical O
effects O
, O
the O
effects O
on O
T O
- O
lymphocyte O
subgroup O
and O
NK O
cells O
, O
and O
the O
toxic O
side O
effects O
were O
observed O
. O
All O
the O
patients O
completed O
two O
cycles O
of O
the O
chemotherapy O
, O
and O
the O
efficacy O
and O
the O
toxic O
side O
effects O
were O
evaluated O
. O
For O
the O
primary O
tumor O
in O
the O
breast O
, O
the O
total B-outcome
effective I-outcome
rate I-outcome
was O
69.2 B-iv-bin-percent
% I-iv-bin-percent
( O
45 B-iv-bin-abs
/ O
65 B-intervention-participants
) O
in O
the O
study O
group O
and O
49.2 B-cv-bin-percent
% I-cv-bin-percent
( O
30 B-cv-bin-abs
/ O
61 B-control-participants
) O
in O
the O
control O
group O
with O
a O
statistically O
significant O
difference O
in O
the O
intergroup O
comparison O
( O
chi2 O
= O
5.251 O
, O
P O
= O
0.022 O
, O
< O
0.05 O
) O
. O
There O
was O
no O
progression B-outcome
of I-outcome
the I-outcome
disease I-outcome
in O
both O
the O
groups O
, O
and O
there O
were O
no O
grade B-outcome
IV I-outcome
toxic I-outcome
side I-outcome
effects I-outcome
in O
the O
two O
groups O
. O
The O
major O
toxic O
responses O
were O
myelosuppression B-outcome
and I-outcome
gastrointestinal I-outcome
reaction I-outcome
, O
which O
were O
milder O
in O
the O
study O
group O
than O
the O
control O
group O
, O
and O
with O
a O
shorter O
recovery O
course O
in O
the O
former O
than O
the O
latter O
. O
Besides O
, O
an O
obvious O
rise O
of O
the O
T O
- O
lymphocyte O
subgroup O
and O
NK O
cells O
was O
found O
in O
the O
study O
group O
after O
the O
neoadjuvant O
chemotherapy O
, O
with O
a O
very O
significant O
difference O
from O
the O
controls O
( O
P O
< O
0.01 O
) O
. O
Shenqi O
fuzheng O
Injection O
can O
improve O
and O
regulate O
immune O
function O
of O
the O
patients O
with O
local O
advanced O
breast O
cancer O
given O
the O
neoadjuvant O
chemotherapy O
, O
and O
therefore O
it O
can O
enhance O
the O
curative O
effect O
and O
reduce O
the O
side O
effect O
as O
well O
. O

Recruiting O
and O
retaining O
breast O
cancer O
survivors O
into O
a O
randomized O
controlled O
exercise B-intervention
trial O
: O
the O
Yale O
Exercise O
and O
Survivorship O
Study O
. O
Given O
observational O
findings O
that O
physical O
activity O
reduces O
breast O
cancer O
risk O
, O
improves O
survival O
, O
and O
improves O
quality O
of O
life O
in O
breast O
cancer O
survivors O
, O
a O
need O
has O
been O
identified O
for O
randomized O
controlled O
trials O
that O
test O
the O
efficacy O
of O
exercise O
on O
biological O
mechanisms O
associated O
with O
breast O
cancer O
survival O
. O
The O
primary O
aims O
of O
the O
Yale O
Exercise O
and O
Survivorship O
Study O
were O
to O
1 O
) O
determine O
the O
feasibility O
of O
recruiting O
breast O
cancer O
survivors O
into O
a O
randomized O
controlled O
trial O
of O
the O
effects O
of O
exercise O
on O
biological O
markers O
and/or O
mechanisms O
associated O
with O
survival O
, O
2 O
) O
compare O
the O
effectiveness O
of O
various O
recruitment O
strategies O
on O
accrual O
rates O
and O
baseline O
characteristics O
, O
and O
3 O
) O
report O
adherence O
to O
the O
exercise O
trial O
. O
Seventy B-total-participants
- I-total-participants
five I-total-participants
postmenopausal B-eligibility
breast I-eligibility
cancer I-eligibility
survivors I-eligibility
self O
- O
referred O
into O
the O
trial O
or O
were O
recruited O
through O
the O
New O
Haven O
Tumor O
[ O
corrected O
] O
Registry O
and O
randomly O
assigned O
to O
an O
exercise O
( O
n O
= O
37 B-intervention-participants
) O
or O
usual B-control
- I-control
care I-control
( O
n O
= O
38 B-control-participants
) O
group O
. O
The O
exercise O
group O
participated O
in O
150 O
min O
/ O
wk O
of O
supervised O
gym O
- O
based O
and O
home O
- O
based O
aerobic O
exercise O
for O
6 O
months O
. O
The O
usual O
- O
care O
group O
was O
instructed O
to O
maintain O
current O
physical O
activity O
level O
. O
A O
total O
of O
75 B-total-participants
women O
( O
an O
accrual O
rate O
of O
9.5 O
% O
) O
were O
randomized O
to O
the O
trial O
. O
Rates O
of O
accrual O
were O
higher O
for O
women O
who O
self O
- O
referred O
into O
the O
study O
( O
19.8 O
% O
) O
compared O
with O
women O
recruited O
via O
the O
cancer O
registry O
( O
7.6 O
% O
) O
; O
however O
, O
demographic O
, O
physiologic O
, O
and O
prognostic O
characteristics O
did O
not O
differ O
between O
the O
2 O
recruitment O
strategies O
. O
On O
average O
, O
exercisers O
increased O
moderate- B-outcome
intensity I-outcome
to I-outcome
vigorous I-outcome
- I-outcome
intensity I-outcome
aerobic I-outcome
exercise I-outcome
by O
129 B-iv-cont-mean
minutes I-iv-cont-mean
per O
week O
compared O
with O
44 B-cv-cont-mean
minutes I-cv-cont-mean
per O
week O
among O
usual O
- O
care O
participants O
( O
P O
< O
.001 O
) O
. O
Women O
in O
the O
exercise O
- O
intervention O
group O
increased O
their O
average B-outcome
pedometer I-outcome
steps I-outcome
by O
1621 B-iv-cont-mean
steps I-iv-cont-mean
per O
day O
compared O
with O
a O
decrease O
of O
60 B-cv-cont-mean
steps I-cv-cont-mean
per O
day O
among O
women O
in O
the O
usual O
- O
care O
group O
( O
P O
< O
.01 O
) O
. O
Findings O
from O
this O
study O
will O
provide O
useful O
information O
for O
investigators O
who O
are O
conducting O
exercise O
trials O
in O
cancer O
populations O
, O
clinicians O
who O
are O
treating O
women O
diagnosed O
with O
breast O
cancer O
, O
and O
exercise O
professionals O
who O
are O
developing O
community O
- O
based O
exercise O
programs O
for O
cancer O
survivors O
. O

Bisphosphonate B-intervention
treatment O
in O
primary O
breast O
cancer O
: O
results O
from O
a O
randomised O
comparison O
of O
oral O
pamidronate O
versus O
no O
pamidronate O
in O
patients O
with O
primary O
breast O
cancer O
. O
During O
the O
period O
from O
January O
1990 O
to O
January O
1996 O
a O
total O
of O
953 B-total-participants
patients B-eligibility
with I-eligibility
lymph I-eligibility
node I-eligibility
negative I-eligibility
primary I-eligibility
breast I-eligibility
cancer I-eligibility
were O
randomised O
to O
oral O
pamidronate O
( O
n O
= O
460 B-intervention
) O
150 O
mg O
twice O
daily O
for O
4 O
years O
or O
no B-control
adjuvant I-control
pamidronate I-control
( O
n O
= O
493 B-control-participants
) O
in O
order O
to O
investigate O
whether O
oral O
pamidronate O
can O
prevent O
the O
occurrence O
of O
bone O
metastases O
and O
fractures O
. O
The O
patients O
received O
adjuvant O
chemotherapy O
, O
loco O
- O
regional O
radiation O
therapy O
, O
but O
no O
endocrine O
treatment O
. O
During O
the O
follow O
- O
up O
period O
the O
number B-outcome
of I-outcome
patients I-outcome
with I-outcome
pure I-outcome
bone I-outcome
metastases I-outcome
was O
35 B-cv-bin-abs
in O
the O
control O
group O
and O
31 B-iv-bin-abs
in O
the O
pamidronate O
group O
. O
The O
number B-outcome
of I-outcome
patients I-outcome
with I-outcome
a I-outcome
combination I-outcome
of I-outcome
bone I-outcome
and I-outcome
other I-outcome
distant I-outcome
metastases I-outcome
were O
22 B-cv-bin-abs
in O
the O
control O
group O
and O
20 B-iv-bin-abs
in O
the O
pamidronate O
group O
. O
The O
hazard O
rate O
ratio O
for O
recurrence B-outcome
in I-outcome
bone I-outcome
in O
the O
pamidronate O
group O
compared O
to O
the O
control O
group O
was O
1.03 O
( O
95 O
% O
confidence O
interval O
0.75 O
- O
1.40 O
) O
and O
p O
= O
0.86 O
. O
No O
effect O
was O
observed O
on O
overall B-outcome
survival I-outcome
. O
In O
a O
small O
subgroup O
of O
27 O
patients O
from O
the O
study O
, O
12 O
of O
whom O
were O
treated O
with O
pamidronate O
a O
significant O
bone O
preserving O
effect O
was O
observed O
on O
bone B-outcome
mineral I-outcome
density I-outcome
in I-outcome
the I-outcome
lumbar I-outcome
spine I-outcome
, O
but O
not O
in O
the O
proximal O
femur O
. O
The O
results O
from O
the O
trial O
do O
not O
support O
a O
beneficial O
effect O
of O
oral O
pamidronate O
on O
the O
occurrence O
of O
bone O
metastases O
or O
fractures O
in O
patients O
with O
primary O
breast O
cancer O
receiving O
adjuvant O
chemotherapy O
. O

[ O
Neoadjuvant O
treatment O
for O
locally O
advanced O
breast O
cancer O
. O
Comparison O
of O
two O
schemes O
based O
on O
docetaxel B-intervention
- I-intervention
epirubicin I-intervention
vs. O
5 B-control
- I-control
fluorouracil I-control
- I-control
epirubicin I-control
- I-control
cyclophosphamide I-control
] O
. O
Breast O
cancer O
is O
the O
most O
common O
type O
of O
cancer O
in O
women O
worldwide O
. O
In O
Mexico B-location
, O
> O
34 O
% O
of O
patients O
are O
in O
locally O
advanced O
stages O
at O
the O
time O
of O
diagnosis O
. O
Neoadjuvant O
chemotherapy O
is O
administered O
to O
control O
local O
disease O
, O
make O
surgical O
resection O
possible O
and O
increase O
the O
possibility O
of O
breast O
tissue O
conservation O
. O
We O
performed O
a O
double O
- O
blind O
, O
randomized O
clinical O
trial O
in O
patients B-eligibility
with I-eligibility
locally I-eligibility
advanced I-eligibility
breast I-eligibility
cancer I-eligibility
( I-eligibility
stages I-eligibility
IIB I-eligibility
and I-eligibility
IIIA I-eligibility
) I-eligibility
with O
two O
therapy O
schemes O
; O
5 B-control
- I-control
fluorouracil I-control
- I-control
epirubicin I-control
- I-control
cyclophosphamide I-control
( I-control
control I-control
group I-control
) I-control
vs. O
docetaxel O
- O
epirubicin O
( O
study O
group O
) O
. O
Both O
were O
indicated O
in O
three O
preoperative O
cycles O
, O
and O
patients O
were O
submitted O
afterwards O
to O
surgery O
. O
Pathological O
response O
was O
measured O
. O
Forty B-total-participants
one I-total-participants
patients O
were O
included O
in O
our O
study O
. O
They O
were O
distributed O
in O
two O
homogeneous O
groups O
: O
21 B-control-participants
in O
the O
control O
group O
and O
20 B-intervention-participants
in O
the O
study O
group O
. O
Dimensional B-outcome
pathological I-outcome
response I-outcome
was O
higher O
in O
the O
study O
group O
than O
in O
the O
control O
one O
( O
p O
< O
0.05 O
) O
. O
Five B-cv-bin-abs
patients O
in O
the O
control O
group O
and O
ten B-iv-bin-abs
patients O
of O
the O
study O
group O
experienced O
complete B-outcome
pathological I-outcome
response I-outcome
( O
p O
< O
0.05 O
) O
. O
The O
most O
common O
secondary O
events O
were O
leucopenia B-outcome
, O
neutropenia B-outcome
and O
fever B-outcome
. O
Morbidity B-outcome
, O
number B-outcome
of I-outcome
lymph I-outcome
nodes I-outcome
, O
disease B-outcome
- I-outcome
free I-outcome
survival I-outcome
and O
general B-outcome
survival I-outcome
did O
not O
show O
significant O
differences O
between O
groups O
. O
No O
mortality B-outcome
was O
reported O
during O
a O
minimum O
follow O
- O
up O
of O
28 O
months O
. O
Our O
results O
confirm O
the O
effectiveness O
of O
docetaxel O
- O
epirubicin O
to O
obtain O
complete B-outcome
pathological I-outcome
response I-outcome
. O
Neoadjuvant O
therapy O
has O
been O
shown O
to O
increase O
the O
pathological B-outcome
response I-outcome
when O
a O
taxane O
is O
added O
to O
an O
anthracycline O
. O
This O
combination O
presented O
more O
secondary O
events O
, O
but O
they O
can O
be O
effectively O
managed O
medically O
. O
Neoadjuvant O
docetaxel O
- O
epirubicin O
followed O
by O
surgery O
is O
an O
appropriate O
regimen O
for O
patients O
with O
locally O
advanced O
breast O
cancer O
. O

Analysis O
of O
chemotherapy O
- O
induced O
amenorrhea O
rates O
by O
three O
different O
anthracycline B-intervention
and I-intervention
taxane I-intervention
containing O
regimens O
for O
early O
breast O
cancer O
. O
Chemotherapy O
- O
induced O
amenorrhea O
( O
CIA O
) O
by O
newer O
taxane O
- O
containing O
regimens O
was O
evaluated O
in O
early O
breast O
cancer O
( O
EBC O
) O
patients O
. O
A O
prospective O
cohort O
of O
122 B-total-participants
premenopausal B-eligibility
EBC I-eligibility
patients I-eligibility
participated O
in O
a O
phase O
III O
trial O
of O
preoperative O
docetaxel O
/ O
capecitabine O
( O
TX O
) O
versus O
doxorubicin B-control
/ I-control
cyclophosphamide I-control
( I-control
AC I-control
) I-control
; O
34 B-intervention-participants
patients O
received O
adjuvant O
AC O
followed O
by O
paclitaxel O
( O
T O
) O
and O
129 B-control-participants
patients O
received O
5 O
- O
fluorouracil O
/ O
doxorubicin O
/ O
cyclophosphamide O
( O
FAC O
) O
. O
The O
CIA B-outcome
rate I-outcome
was O
90.2 B-iv-bin-percent
% I-iv-bin-percent
with O
TX O
/ O
AC O
, O
73.5 B-iv-bin-percent
% I-iv-bin-percent
with O
AC O
followed O
by O
T O
, O
and O
72.1 B-cv-bin-percent
% I-cv-bin-percent
with O
FAC O
at B-outcome
1 I-outcome
year I-outcome
( O
P O
= O
0.002 O
) O
, O
and O
66.7 B-iv-bin-percent
% I-iv-bin-percent
, O
73.3 B-iv-bin-percent
% I-iv-bin-percent
, O
and O
58.9 B-cv-bin-percent
% I-cv-bin-percent
, O
respectively O
, O
at B-outcome
3 I-outcome
years I-outcome
( O
P O
= O
0.268 O
) O
. O
At O
one O
year O
, O
age O
( O
P O
< O
0.001 O
) O
and O
taxane O
use O
( O
P O
= O
0.002 O
) O
, O
and O
after O
two O
years O
, O
age O
and O
tamoxifen O
use O
were O
significant O
factors O
for O
CIA O
in O
multivariate O
analysis O
. O
Serum B-outcome
estradiol I-outcome
and I-outcome
follicle I-outcome
- I-outcome
stimulating I-outcome
hormone I-outcome
levels I-outcome
were O
significantly O
correlated O
with O
menstrual O
status O
, O
age O
, O
and O
tamoxifen O
use O
. O
Taxanes O
resulted O
in O
higher O
CIA O
rates O
in O
the O
first O
year O
, O
but O
age O
and O
tamoxifen O
use O
were O
significant O
factors O
for O
persistent O
CIA O
. O

Racial B-intervention
differences I-intervention
in O
clinical O
outcomes O
from O
metastatic O
breast O
cancer O
: O
a O
pooled O
analysis O
of O
CALGB O
9342 O
and O
9840 O
- O
-Cancer O
and O
Leukemia O
Group O
B O
. O
African O
American O
women O
are O
more O
likely O
to O
be O
diagnosed O
with O
metastatic O
breast O
cancer O
at O
the O
time O
of O
presentation O
than O
whites O
, O
and O
have O
shorter O
survival O
once O
diagnosed O
. O
This O
study O
examines O
racial O
differences O
in O
clinical O
outcomes O
in O
the O
setting O
of O
two O
large O
cooperative O
group O
randomized O
clinical O
trials O
. O
The O
study O
cohort O
consisted O
of O
787 B-intervention-participants
white B-intervention
( O
80 O
% O
) O
and O
195 B-control-participants
African B-control
American I-control
( O
20 O
% O
) O
patients B-eligibility
with I-eligibility
metastatic I-eligibility
breast I-eligibility
cancer I-eligibility
enrolled O
in O
two O
successive O
Cancer O
and O
Leukemia O
Group O
B O
( O
CALGB O
) O
trials O
using O
taxanes O
in O
the O
metastatic O
setting O
. O
Differences O
in O
overall O
survival O
( O
OS O
) O
, O
response O
incidence O
, O
and O
time O
to O
treatment O
failure O
( O
TTF O
) O
were O
examined O
by O
race O
. O
In O
addition O
, O
differences O
in O
the O
incidence O
of O
baseline O
and O
treatment O
- O
related O
toxicities O
were O
examined O
. O
With O
779 O
deaths B-outcome
( O
166 B-cv-bin-abs
African O
Americans O
and O
613 B-iv-bin-abs
whites O
) O
, O
median B-outcome
OS I-outcome
was O
14.3 B-cv-cont-median
months I-cv-cont-median
for O
African O
Americans O
and O
18.75 B-iv-cont-median
months I-iv-cont-median
for O
whites O
( O
hazard O
ratio O
[ O
HR O
] O
= O
1.37 O
; O
95 O
% O
CI O
, O
1.15 O
to O
1.63 O
) O
. O
When O
adjusted O
for O
prognostic O
factors O
, O
African O
Americans O
had O
a O
24 O
% O
increase O
in O
the O
hazard B-outcome
of I-outcome
death I-outcome
compared O
with O
whites O
( O
HR O
= O
1.24 O
; O
95 O
% O
CI O
, O
1.02 O
to O
1.51 O
) O
. O
No O
significant O
differences O
in O
TTF B-outcome
or I-outcome
overall I-outcome
response I-outcome
to O
therapy O
were O
seen O
. O
No O
clinically O
significant O
toxicity B-outcome
differences O
were O
seen O
. O
African O
Americans O
with O
metastatic O
breast O
cancer O
have O
an O
increased O
hazard B-outcome
of I-outcome
death I-outcome
compared O
with O
whites O
despite O
the O
receipt O
of O
similar O
per O
- O
protocol O
treatment O
, O
but O
experience O
no O
differences O
in O
TTF O
or O
overall O
response O
to O
therapy O
. O
We O
hypothesize O
that O
more O
direct O
and O
robust O
measures O
of O
comorbidities O
, O
and O
perhaps O
other O
factors O
such O
as O
receipt O
of O
subsequent O
therapy O
could O
help O
further O
explain O
the O
observed O
survival O
difference O
. O

Celecoxib O
anti O
- O
aromatase O
neoadjuvant O
( O
CAAN O
) O
trial O
for O
locally O
advanced O
breast O
cancer O
. O
To O
evaluate O
the O
efficacy O
and O
safety O
of O
combing O
aromatase O
inhibitor O
( O
AI O
) O
and O
cyclooxygenase-2 O
( O
COX-2 O
) O
inhibitor O
neoadjuvantly O
in O
postmenopausal O
patients O
with O
invasive O
hormone O
- O
sensitive O
breast O
cancer O
. O
Eighty B-total-participants
- I-total-participants
two I-total-participants
patients O
were O
randomly O
assigned O
to O
receive O
exemestane B-intervention
25 I-intervention
mg I-intervention
daily I-intervention
and I-intervention
celecoxib I-intervention
400 I-intervention
mg I-intervention
twice O
daily O
( O
group O
A O
, O
n O
= O
30 B-intervention-participants
) O
, O
exemestane O
25 O
mg O
daily O
( O
group O
B O
, O
n O
= O
24 B-intervention-participants
) O
and O
letrozole B-control
2.5 O
mg O
daily O
( O
group O
C O
, O
n O
= O
28 B-control-participants
) O
. O
All O
groups O
showed O
clinical B-outcome
responses I-outcome
( O
58.6 B-iv-bin-percent
% I-iv-bin-percent
for O
group O
A O
, O
54.5 B-iv-bin-percent
% I-iv-bin-percent
for O
group O
B O
and O
62.0 B-cv-bin-percent
% I-cv-bin-percent
for O
group O
C O
) O
and O
decrease B-outcome
in I-outcome
tumor I-outcome
area I-outcome
( O
61.8 B-iv-bin-percent
% I-iv-bin-percent
for O
group O
A O
, O
58.1 B-iv-bin-percent
% I-iv-bin-percent
for O
group O
B O
and O
55.7 B-cv-bin-percent
% I-cv-bin-percent
for O
group O
C O
) O
. O
3 B-iv-bin-abs
out O
of O
5 B-intervention-participants
patients O
with O
complete B-outcome
clinical I-outcome
response I-outcome
were O
observed O
from O
group O
A O
and O
2 B-cv-bin-abs
out O
of O
69 B-control-participants
patients O
operated O
with O
pathologic O
complete O
response O
were O
observed O
in O
group O
C. O
The O
mean B-outcome
microscopic I-outcome
tumor I-outcome
size I-outcome
was O
2.53 B-iv-cont-mean
cm I-iv-cont-mean
for O
group O
A O
, O
3.05 B-iv-cont-mean
cm I-iv-cont-mean
for O
group O
B O
and O
2.10 B-cv-cont-mean
cm I-cv-cont-mean
for O
group O
C. O
The O
differences O
were O
only O
statistically O
significant O
when O
group O
C O
was O
compared O
with O
group O
B O
( O
P O
= O
0.025 O
) O
. O
The O
toxicity B-outcome
profiles I-outcome
among O
groups O
were O
satisfactory O
. O
AI O
is O
effective O
in O
treating O
breast O
cancer O
and O
may O
be O
safely O
used O
preoperatively O
. O
The O
addition O
of O
COX-2 O
inhibitor O
may O
provide O
additional O
benefit O
. O

Venlafaxine B-intervention
versus O
clonidine B-control
for O
the O
treatment O
of O
hot B-condition
flashes I-condition
in O
breast O
cancer O
patients O
: O
a O
double O
- O
blind O
, O
randomized O
cross O
- O
over O
study O
. O
Breast O
cancer O
patients O
with O
treatment O
- O
induced O
menopause O
experience O
frequent O
and O
severe O
hot O
flashes O
( O
HF O
) O
. O
We O
compared O
venlafaxine O
and O
clonidine O
for O
the O
treatment O
of O
HF O
with O
regard O
to O
side O
effects O
, O
efficacy O
, O
quality O
of O
life O
and O
sexual O
functioning O
. O
In O
a O
double O
- O
blind O
, O
cross O
- O
over O
study O
, O
60 B-total-participants
breast B-eligibility
cancer I-eligibility
patients I-eligibility
experiencing I-eligibility
HF I-eligibility
were O
randomized O
to O
8 O
weeks O
venlafaxine O
followed O
by O
2 O
weeks O
wash O
- O
out O
, O
and O
8 O
weeks O
clonidine O
or O
vice O
versa O
. O
HF O
frequency O
and O
severity O
, O
side O
effects O
, O
quality O
of O
life O
and O
sexuality O
were O
assessed O
. O
Thirty B-intervention-participants
patients O
started O
with O
venlafaxine O
and O
30 B-control-participants
with O
clonidine O
. O
Premature B-outcome
discontinuation I-outcome
for I-outcome
toxicity I-outcome
occurred O
in O
14 B-iv-bin-abs
/ O
59 B-intervention-participants
during O
venlafaxine O
and O
5 B-cv-bin-abs
/ O
53 B-control-participants
during O
clonidine O
( O
P O
= O
.038 O
) O
. O
Venlafaxine O
induced O
more O
side O
effects O
. O
Median O
reduction B-outcome
in I-outcome
HF I-outcome
score I-outcome
was O
49 B-iv-bin-abs
% I-iv-bin-abs
for O
venlafaxine O
and O
55 B-cv-bin-abs
% I-cv-bin-abs
for O
clonidine O
( O
ns O
) O
. O
Venlafaxine O
and O
clonidine O
are O
equally O
, O
but O
moderately O
effective O
in O
HF B-outcome
reduction I-outcome
. O
Side O
effects O
are O
the O
main O
reason O
for O
drug O
discontinuation O
, O
occurring O
more O
often O
with O
venlafaxine O
. O

Gemcitabine B-intervention
plus I-intervention
Paclitaxel I-intervention
versus O
Paclitaxel B-control
monotherapy O
in O
patients B-eligibility
with I-eligibility
metastatic I-eligibility
breast I-eligibility
cancer I-eligibility
and I-eligibility
prior I-eligibility
anthracycline I-eligibility
treatment I-eligibility
. O
The O
objective O
of O
this O
phase O
III O
global O
study O
was O
to O
compare O
the O
efficacy O
of O
gemcitabine O
plus O
paclitaxel O
( O
GT O
) O
versus O
paclitaxel O
in O
patients O
with O
advanced O
breast O
cancer O
. O
It O
was O
designed O
as O
a O
pivotal O
study O
for O
the O
approval O
of O
G O
for O
a O
breast O
cancer O
treatment O
indication O
. O
Patients O
who O
relapsed O
after O
adjuvant O
anthracyclines O
were O
randomly O
assigned O
to O
gemcitabine,1,250 O
mg O
/ O
m O
( O
2 O
) O
days O
1 O
and O
8 O
plus O
paclitaxel O
, O
175 O
mg O
/ O
m O
( O
2 O
) O
on O
day O
1 O
; O
or O
, O
to O
paclitaxel O
at O
same O
dose O
on O
day O
1 O
( O
both O
arms O
administered O
every O
21 O
days O
, O
unblinded O
) O
. O
The O
primary O
end O
point O
was O
overall B-outcome-measure
survival I-outcome-measure
( I-outcome-measure
OS I-outcome-measure
) I-outcome-measure
and O
secondary O
end O
points O
were O
time B-outcome-measure
to I-outcome-measure
progression I-outcome-measure
( I-outcome-measure
TTP I-outcome-measure
) I-outcome-measure
, O
response B-outcome-measure
rate I-outcome-measure
( I-outcome-measure
RR I-outcome-measure
) I-outcome-measure
, O
progression B-outcome-measure
- I-outcome-measure
free I-outcome-measure
survival I-outcome-measure
, O
response B-outcome-measure
duration I-outcome-measure
, O
and O
toxicity B-outcome-measure
. O
This O
final O
OS O
analysis O
was O
planned O
at O
380 O
deaths O
. O
A O
total O
of O
266 B-intervention-participants
patients O
were O
randomly O
assigned O
to O
GT O
and O
263 B-control-participants
to O
paclitaxel O
. O
Median B-outcome
survival I-outcome
on O
GT O
was O
18.6 B-iv-cont-median
months I-iv-cont-median
versus O
15.8 B-cv-cont-median
months I-cv-cont-median
on O
paclitaxel O
( O
log O
- O
rank O
P O
= O
. O
0489 O
) O
, O
with O
an O
adjusted O
Cox O
hazard O
ratio O
of O
0.78 O
( O
95 O
% O
CI O
, O
0.64 O
to O
0.96 O
; O
P O
= O
.0187 O
) O
. O
The O
TTP B-outcome
was O
longer O
( O
6.14 B-iv-cont-median
v O
3.98 B-cv-cont-median
months I-cv-cont-median
; O
log O
- O
rank O
P O
= O
.0002 O
) O
and O
the O
RR B-outcome
was O
better O
( O
41.4 B-iv-bin-percent
% I-iv-bin-percent
v O
26.2 B-cv-bin-percent
% I-cv-bin-percent
; O
P O
= O
.0002 O
) O
on O
GT O
. O
There O
was O
more O
grade B-outcome
3 I-outcome
to I-outcome
4 I-outcome
neutropenia I-outcome
on O
GT O
and O
grade B-outcome
2 I-outcome
to I-outcome
4 I-outcome
fatigue I-outcome
and I-outcome
neuropathy I-outcome
were O
slightly O
more O
prevalent O
on O
GT O
. O
This O
phase O
III O
study O
documents O
a O
role O
for O
gemcitabine O
in O
advanced O
breast O
cancer O
after O
anthracycline O
- O
based O
adjuvant O
therapy O
. O
The O
results O
establish O
GT O
as O
a O
reasonable O
choice O
for O
women O
who O
require O
cytoreduction O
with O
manageable O
toxicities O
and O
validate O
ongoing O
testing O
of O
GT O
in O
the O
adjuvant O
setting O
. O

Randomized O
trial O
of O
denosumab B-intervention
in O
patients O
receiving O
adjuvant O
aromatase O
inhibitors O
for O
nonmetastatic O
breast O
cancer O
. O
Adjuvant O
aromatase O
inhibitor O
therapy O
is O
well O
established O
in O
postmenopausal O
women O
with O
hormone O
receptor O
- O
positive O
breast O
cancer O
, O
but O
such O
therapy O
is O
complicated O
by O
accelerated O
bone O
loss O
and O
increased O
fracture O
risk O
. O
We O
investigated O
the O
ability O
of O
denosumab O
, O
a O
fully O
human O
monoclonal O
antibody O
against O
receptor O
activator O
of O
nuclear O
factor O
- O
kappaB O
ligand O
, O
to O
protect O
against O
aromatase O
inhibitor O
- O
induced O
bone O
loss O
. O
Eligible O
women B-eligibility
with I-eligibility
hormone I-eligibility
receptor I-eligibility
- I-eligibility
positive I-eligibility
nonmetastatic I-eligibility
breast I-eligibility
cancer I-eligibility
treated I-eligibility
with I-eligibility
adjuvant I-eligibility
aromatase I-eligibility
inhibitor I-eligibility
therapy I-eligibility
were O
stratified O
by O
duration O
of O
aromatase O
inhibitor O
therapy O
( O
< O
or O
= O
6 O
v O
> O
6 O
months O
) O
, O
received O
supplemental O
calcium O
and O
vitamin O
D O
, O
and O
were O
randomly O
assigned O
to O
receive O
placebo B-control
( O
n O
= O
125 B-control-participants
) O
or O
subcutaneous O
denosumab O
60 O
mg O
( O
n O
= O
127 B-intervention-participants
) O
every O
6 O
months O
. O
At O
enrollment O
, O
all O
patients O
were O
required O
to O
have O
evidence O
of O
low O
bone O
mass O
, O
excluding O
osteoporosis O
. O
The O
primary O
end O
point O
was O
percentage B-outcome-measure
change I-outcome-measure
from I-outcome-measure
baseline I-outcome-measure
at I-outcome-measure
month I-outcome-measure
12 I-outcome-measure
in I-outcome-measure
lumbar I-outcome-measure
spine I-outcome-measure
bone I-outcome-measure
mineral I-outcome-measure
density I-outcome-measure
( I-outcome-measure
BMD I-outcome-measure
) I-outcome-measure
. O
At B-outcome
12 I-outcome
and I-outcome
24 I-outcome
months I-outcome
, O
lumbar B-outcome
spine I-outcome
BMD I-outcome
increased O
by O
5.5 O
% O
and O
7.6 O
% O
, O
respectively O
, O
in O
the O
denosumab O
group O
versus O
placebo O
( O
P O
< O
.0001 O
at O
both O
time O
points O
) O
. O
Increases O
were O
observed O
as O
early O
as O
1 O
month O
and O
were O
not O
influenced O
by O
duration O
of O
aromatase O
inhibitor O
therapy O
. O
Increases O
in O
BMD B-outcome
were O
also O
observed O
at B-outcome
the I-outcome
total I-outcome
hip I-outcome
, I-outcome
total I-outcome
body I-outcome
, I-outcome
femoral I-outcome
neck I-outcome
, I-outcome
and I-outcome
the I-outcome
predominantly I-outcome
cortical I-outcome
one I-outcome
- I-outcome
third I-outcome
radius I-outcome
. O
Bone B-outcome
turnover I-outcome
markers I-outcome
decreased O
with O
denosumab O
treatment O
. O
Overall O
incidence B-outcome
of I-outcome
treatment I-outcome
- I-outcome
emergent I-outcome
adverse I-outcome
events I-outcome
( I-outcome
AEs I-outcome
) I-outcome
was O
similar O
between O
treatment O
groups O
. O
In O
women O
with O
nonmetastatic O
breast O
cancer O
and O
low O
bone O
mass O
who O
were O
receiving O
adjuvant O
aromatase O
inhibitor O
therapy O
, O
twice O
- O
yearly O
administration O
of O
denosumab O
led O
to O
significant O
increases O
in O
BMD O
over O
24 O
months O
at O
trabecular O
and O
cortical O
bone O
, O
with O
overall O
AE O
rates O
similar O
to O
those O
of O
placebo O
. O

The O
addition O
of O
a O
boost B-intervention
dose I-intervention
on O
the O
primary O
tumour O
bed O
after O
lumpectomy O
in O
breast O
conserving O
treatment O
for O
breast O
cancer O
. O
A O
summary O
of O
the O
results O
of O
EORTC O
22881 O
- O
10882 O
" O
boost O
versus O
no O
boost O
" O
trial O
. O
To O
investigate O
the O
impact O
of O
the O
boost O
dose O
to O
the O
primary O
tumour O
bed O
in O
the O
framework O
of O
breast O
conserving O
therapy O
on O
local O
control O
, O
cosmetic O
results O
, O
fibrosis O
and O
overall O
survival O
for O
patients B-eligibility
with I-eligibility
early I-eligibility
stage I-eligibility
breast I-eligibility
cancer I-eligibility
. O
Five B-control-participants
thousand I-control-participants
five I-control-participants
hundred I-control-participants
and I-control-participants
sixty I-control-participants
- I-control-participants
nine I-control-participants
patients O
after O
lumpectomy O
followed O
by O
whole O
breast O
irradiation O
of O
50 O
Gy O
were O
randomised O
. O
After O
a O
microscopically O
complete O
lumpectomy O
( O
5318 B-intervention-participants
patients O
) O
, O
the O
boost O
doses O
were O
either O
0 O
or O
16 O
Gy O
, O
while O
after O
a O
microscopically O
incomplete O
( O
251 O
patients O
) O
lumpectomy O
randomisation O
was O
between O
10 O
and O
26 O
Gy O
. O
The O
results O
at O
a O
median O
follow O
- O
up O
of O
10 O
years O
are O
presented O
. O
At O
10 O
years O
, O
the O
cumulative B-outcome
incidence I-outcome
of I-outcome
local I-outcome
recurrence I-outcome
was O
10.2 B-cv-bin-percent
% I-cv-bin-percent
versus O
6.2 B-iv-bin-percent
% I-iv-bin-percent
for O
the O
0 O
Gy O
and O
the O
16 O
Gy O
boost O
groups O
( O
p O
< O
0.0001 O
) O
and O
17.5 B-iv-bin-percent
% I-iv-bin-percent
versus O
10.8 B-iv-bin-percent
% I-iv-bin-percent
for O
the O
10 O
and O
26 O
Gy O
boost O
groups O
, O
respectively O
( O
p O
> O
0.1 O
) O
. O
There O
was O
no O
statistically O
significant O
interaction O
per O
age O
group O
but O
recurrences B-outcome
tended O
to O
occur O
earlier O
in O
younger O
patients O
. O
As O
younger O
patients O
had O
a O
higher O
cumulative B-outcome
risk I-outcome
of I-outcome
local I-outcome
relapse I-outcome
by O
year O
10 O
, O
the O
magnitude O
of O
the O
absolute O
10 O
- O
year O
risk O
reduction O
achieved O
with O
the O
boost O
decreased O
with O
increasing O
age O
. O
Development O
of O
fibrosis O
was O
significantly O
dependent O
on O
the O
boost O
dose O
with O
a O
10 B-outcome
- I-outcome
year I-outcome
rate I-outcome
for I-outcome
severe I-outcome
fibrosis I-outcome
of O
1.6 B-cv-bin-percent
% I-cv-bin-percent
after O
0 O
Gy O
, O
3.3 B-iv-bin-percent
% I-iv-bin-percent
after O
10 O
Gy O
, O
4.4 B-iv-bin-percent
% I-iv-bin-percent
after O
16 O
Gy O
and O
14.4 B-iv-bin-percent
% I-iv-bin-percent
after O
26 O
Gy O
, O
respectively O
. O
An O
increase O
of O
the O
dose O
with O
16 O
Gy O
improved O
local O
control O
for O
patients O
after O
a O
complete O
lumpectomy O
only O
. O
The O
development O
of O
fibrosis O
was O
clearly O
dose O
dependent O
. O
With O
10 O
years O
median O
follow O
- O
up O
, O
no O
impact O
of O
survival O
was O
observed O
. O

Autologous B-intervention
bone I-intervention
marrow I-intervention
stromal I-intervention
cells I-intervention
transplantation I-intervention
for O
the O
treatment O
of O
secondary O
arm O
lymphedema O
: O
a O
prospective O
controlled O
study O
in O
patients O
with O
breast O
cancer O
related O
lymphedema O
. O
To O
determine O
the O
short- O
and O
long O
- O
term O
effect O
of O
bone O
marrow O
stromal O
cells O
( O
BMSCs O
) O
transplantation O
as O
a O
treatment O
for O
breast O
cancer O
- O
related O
lymphedema O
. O
To O
contrast O
it O
with O
complex O
decongestive O
physiotherapy O
( O
CDT O
) O
. O
Fifteen B-intervention-participants
women B-eligibility
with I-eligibility
lymphedema I-eligibility
, I-eligibility
who I-eligibility
had I-eligibility
undergone I-eligibility
breast I-eligibility
cancer I-eligibility
surgery I-eligibility
and I-eligibility
/ I-eligibility
no I-eligibility
radiotherapy I-eligibility
5 I-eligibility
years I-eligibility
before I-eligibility
, O
served O
as O
the O
experimental O
group O
and O
received O
BMSC O
transplantation O
; O
35 B-control-participants
patients O
were O
measured O
as O
the O
control O
group O
treated O
with O
CDT B-control
. O
They O
were O
kept O
on O
follow O
- O
up O
for O
1 O
year O
. O
Two O
patients O
in O
the O
CDT O
Group O
failed O
to O
keep O
follow O
- O
up O
. O
Before B-outcome
treatment I-outcome
, O
patients O
had O
average B-outcome
volume I-outcome
of I-outcome
edema I-outcome
in O
the O
affected O
arm O
of O
1166.2 B-iv-cont-mean
ml I-iv-cont-mean
in O
BMSC O
Group O
and O
1091.0 B-cv-cont-mean
ml I-cv-cont-mean
in O
the O
CDT O
Group O
. O
With O
therapy O
, O
there O
was O
an O
average B-outcome
decrease I-outcome
in I-outcome
lymphedema I-outcome
volume I-outcome
of O
730.7 B-iv-cont-mean
, O
887.9 B-iv-cont-mean
and O
958.6 B-iv-cont-mean
ml I-iv-cont-mean
in O
the O
BMSC O
Group O
and O
714.8 B-cv-cont-mean
, O
657.9 B-cv-cont-mean
and O
571.3 B-cv-cont-mean
ml I-cv-cont-mean
in O
the O
CDT O
Group O
after B-outcome
1 I-outcome
, I-outcome
3 I-outcome
and I-outcome
12 I-outcome
months I-outcome
, O
respectively O
. O
Before B-outcome
treatment I-outcome
, O
the O
percentage B-outcome
of I-outcome
lymphedema I-outcome
was O
28.6 B-iv-cont-mean
% I-iv-cont-mean
in O
the O
BMSC O
Group O
and O
26.8 B-cv-cont-mean
% I-cv-cont-mean
in O
the O
CDT O
Group O
. O
After B-outcome
treatment I-outcome
, O
there O
was O
a O
decrease O
of O
64.6 B-iv-cont-mean
, O
78.5 B-iv-cont-mean
and O
81.0 B-iv-cont-mean
% I-iv-cont-mean
in O
the O
BMSC O
Group O
and O
67.2 B-cv-cont-mean
, O
60.4 B-cv-cont-mean
and O
54.5 B-cv-cont-mean
% I-cv-cont-mean
in O
the O
CDT O
Group O
after B-outcome
1 I-outcome
, I-outcome
3 I-outcome
and I-outcome
12 I-outcome
months I-outcome
, O
respectively O
. O
When O
asked O
to O
quantify O
subjectively O
their O
pain B-outcome
on O
a O
numeric O
scale O
from O
0 O
to O
5 O
, O
the O
average O
score O
of O
these O
patients O
was O
3.4 B-iv-cont-mean
in O
the O
BMSC O
group O
and O
4.0 B-cv-cont-mean
in O
the O
CDT O
Group O
. O
The O
average B-outcome
score I-outcome
was O
reduced O
to O
1.6 B-iv-cont-mean
, O
0.8 B-iv-cont-mean
and O
0.6 B-iv-cont-mean
in O
the O
BMSC O
Group O
and O
to O
1.2 B-cv-cont-mean
, O
1.7 B-cv-cont-mean
and O
1.6 B-cv-cont-mean
in O
CDT O
Group O
after B-outcome
1 I-outcome
, I-outcome
3 I-outcome
and I-outcome
12 I-outcome
months I-outcome
, O
respectively O
. O
Autologous O
BMSCs O
transplantation O
for O
the O
treatment O
of O
breast O
cancer O
related O
lymphedema O
is O
effective O
and O
feasible O
. O

Neuropsychological B-condition
functioning I-condition
in O
postmenopausal O
breast O
cancer O
patients O
treated O
with O
tamoxifen B-intervention
or I-intervention
exemestane I-intervention
after O
AC O
- O
chemotherapy O
: O
cross O
- O
sectional O
findings O
from O
the O
neuropsychological O
TEAM O
- O
side O
study O
. O
Previous O
studies O
have O
indicated O
that O
a O
subset O
of O
cancer O
patients O
treated O
with O
chemotherapy O
show O
cognitive O
deficits O
and/or O
experience O
cognitive O
complaints O
, O
whereas O
literature O
about O
the O
influence O
of O
hormonal O
therapies O
on O
cognition O
is O
sparse O
. O
Because O
of O
the O
accumulating O
knowledge O
about O
the O
importance O
of O
estrogen O
for O
cognitive O
functioning O
, O
there O
is O
growing O
concern O
about O
adjuvant O
hormonal O
therapy O
for O
breast O
cancer O
( O
BC O
) O
affecting O
cognition O
. O
We O
examined O
the O
cognitive O
functioning O
of O
postmenopausal B-eligibility
BC I-eligibility
patients I-eligibility
who I-eligibility
were I-eligibility
, I-eligibility
following I-eligibility
doxorubicin I-eligibility
/ I-eligibility
cyclophosphamide I-eligibility
( I-eligibility
AC I-eligibility
) I-eligibility
chemotherapy I-eligibility
, O
randomized O
to O
tamoxifen O
or O
exemestane O
, O
and O
compared O
their O
performance O
with O
that O
of O
non O
- O
cancer O
controls O
. O
Thirty B-intervention-participants
BC O
patients O
using O
tamoxifen O
and O
50 B-intervention-participants
patients O
using O
exemestane O
underwent O
interviews O
, O
questionnaires O
and O
cognitive O
tests O
, O
on O
average O
two O
years O
after O
completion O
of O
AC O
chemotherapy O
. O
Forty B-control-participants
eight I-control-participants
healthy B-control
controls I-control
were O
tested O
with O
similar O
measures O
. O
Memory B-outcome
complaints I-outcome
were O
reported O
by O
28 B-iv-bin-percent
% I-iv-bin-percent
of O
AC O
/ O
tamoxifen O
users O
, O
24 B-iv-bin-percent
% I-iv-bin-percent
of O
AC O
/ O
exemestane O
users O
and O
6 B-cv-bin-percent
% I-cv-bin-percent
of O
healthy O
controls O
( O
p O
= O
0.02 O
) O
. O
Cognitive O
testing O
revealed O
no O
statistically O
significant O
differences O
between O
tamoxifen O
and O
exemestane O
users O
, O
but O
suggested O
that O
tamoxifen O
use O
is O
possibly O
related O
to O
worse O
verbal B-outcome
functioning I-outcome
, O
while O
exemestane O
use O
is O
possibly O
related O
to O
slower O
manual O
motor B-outcome
speed I-outcome
. O
Both O
patient O
groups O
performed O
significantly O
worse O
than O
healthy O
controls O
on O
verbal B-outcome
fluency I-outcome
and O
information B-outcome
processing I-outcome
speed I-outcome
. O
Our O
findings O
show O
that O
sequential O
treatment O
of O
AC O
- O
chemotherapy O
and O
hormonal O
therapy O
in O
postmenopausal O
, O
primary O
BC O
is O
associated O
with O
lower O
test O
scores O
for O
certain O
cognitive O
functions O
, O
and O
provide O
indications O
for O
possibly O
distinctive O
associations O
for O
different O
types O
of O
hormonal O
treatment O
. O
Future O
research O
with O
larger O
groups O
is O
recommended O
to O
obtain O
a O
more O
definite O
picture O
. O

Ten O
- O
year O
follow O
- O
up O
of O
3 O
years O
of O
oral B-intervention
adjuvant I-intervention
clodronate I-intervention
therapy I-intervention
shows O
significant O
prevention O
of O
osteoporosis B-condition
in O
early O
- O
stage O
breast O
cancer O
. O
We O
have O
previously O
reported O
that O
3 O
- O
year O
adjuvant O
clodronate O
treatment O
prevents O
bone O
loss O
in O
breast O
cancer O
patients O
. O
Here O
we O
report O
the O
10 O
- O
year O
follow O
- O
up O
data O
of O
clodronate O
in O
the O
prevention O
of O
treatment O
- O
related O
osteoporosis O
in O
women O
with O
early O
- O
stage O
breast O
cancer O
. O
Two B-total-participants
hundred I-total-participants
sixty I-total-participants
- I-total-participants
eight I-total-participants
pre- B-eligibility
and I-eligibility
postmenopausal I-eligibility
, I-eligibility
node I-eligibility
- I-eligibility
positive I-eligibility
breast I-eligibility
cancer I-eligibility
patients I-eligibility
were O
randomly O
assigned O
to O
clodronate O
, O
1.6 O
g O
orally O
administered O
daily O
, O
or O
to O
control B-control
groups I-control
for O
3 O
years O
. O
Premenopausal O
women O
were O
treated O
with O
adjuvant O
CMF O
chemotherapy O
; O
and O
postmenopausal O
women O
were O
treated O
with O
antiestrogens O
, O
either O
20 O
mg O
tamoxifen O
or O
60 O
mg O
toremifene O
, O
for O
3 O
years O
. O
The O
bone O
mineral O
density O
( O
BMD O
) O
of O
the O
lumbar O
spine O
and O
hip O
was O
measured O
before O
treatment O
and O
at O
1 O
, O
2 O
, O
3 O
, O
5 O
, O
and O
10 O
years O
after O
therapy O
. O
Eighty B-total-participants
- I-total-participants
nine I-total-participants
disease O
- O
free O
patients O
were O
included O
in O
the O
analyses O
of O
osteoporosis O
- O
free O
survival O
. O
During O
the O
10 O
- O
year O
period O
, O
24 O
of O
89 O
patients O
were O
diagnosed O
with O
osteoporosis O
. O
Fourteen O
patients O
developed O
spinal B-outcome
osteoporosis I-outcome
( O
three B-iv-bin-abs
of O
41 B-intervention-participants
in O
the O
clodronate O
group O
, O
and O
11 B-cv-bin-abs
of O
48 B-control-participants
in O
the O
control O
group O
) O
, O
and O
14 O
of O
89 O
patients O
were O
diagnosed O
with O
hip B-outcome
osteoporosis I-outcome
( O
seven B-iv-bin-abs
of O
41 B-intervention-participants
in O
the O
clodronate O
group O
, O
and O
seven B-cv-bin-abs
of O
48 B-control-participants
in O
the O
control O
group O
) O
. O
The O
10 O
- O
year O
spinal O
, O
osteoporosis B-outcome
- I-outcome
free I-outcome
survival I-outcome
rate I-outcome
was O
92.7 B-iv-bin-percent
% I-iv-bin-percent
in O
the O
clodronate O
group O
, O
and O
77.0 B-cv-bin-percent
% I-cv-bin-percent
in O
the O
control O
group O
( O
P O
= O
.035 O
) O
. O
No O
difference O
was O
seen O
in O
the O
frequency B-outcome
of I-outcome
hip I-outcome
osteoporosis I-outcome
( O
85.4 B-iv-bin-percent
% I-iv-bin-percent
v O
82.9 B-cv-bin-percent
% I-cv-bin-percent
; O
P O
= O
.92 O
) O
. O
Baseline O
BMD B-outcome
measurement O
had O
a O
predictive O
value O
of O
18 O
of O
24 O
patients O
( O
75 O
% O
) O
who O
developed O
osteoporosis O
had O
osteopenia O
of O
the O
lumbar O
spine O
at O
baseline O
. O
Three O
years O
of O
clodronate O
therapy O
significantly O
reduces O
the O
incidence B-outcome
of I-outcome
lumbar I-outcome
spine I-outcome
osteoporosis I-outcome
. O
Patients O
at O
risk O
of O
developing O
osteoporosis O
are O
among O
those O
who O
have O
pretreatment O
osteopenia O
, O
that O
is O
, O
baseline O
BMD O
measurement O
has O
predictive O
value O
. O

[ O
Comparison O
between O
intratumoral B-intervention
and O
peritumoral B-control
injection I-control
of I-control
radiotracer I-control
for O
locating O
and O
biopsying O
the O
sentinel O
lymph O
node O
in O
nonpalpable O
breast O
cancer O
] O
. O
To O
determine O
whether O
there O
are O
differences O
in O
the O
technical O
efficacy O
in O
detecting O
and O
biopsying O
the O
sentinel O
node O
after O
intratumoral O
or O
peritumoral O
administration O
of O
the O
radiotracer O
in O
patients O
with O
nonpalpable O
early O
- O
stage O
breast O
cancer O
. O
This O
prospective O
, O
randomized O
study O
included O
80 B-total-participants
patients B-eligibility
with I-eligibility
nonpalpable I-eligibility
breast I-eligibility
cancer I-eligibility
without I-eligibility
axillary I-eligibility
adenopathies I-eligibility
who I-eligibility
were I-eligibility
scheduled I-eligibility
for I-eligibility
primary I-eligibility
surgical I-eligibility
treatment I-eligibility
. O
Patients O
were O
randomized O
to O
one O
of O
two O
groups O
: O
the O
INTRA O
group O
( O
intratumoral O
radiotracer O
administration O
, O
n O
= O
35 B-intervention-participants
) O
or O
the O
PERI O
group O
( O
peritumoral O
radiotracer O
administration O
, O
n O
= O
45 B-control-participants
) O
. O
Patients O
with O
suspicious O
axillary O
lymph O
nodes O
at O
clinical O
or O
ultrasonographic O
examination O
that O
had O
positive O
results O
after O
fine O
- O
needle O
aspiration O
cytology O
were O
excluded O
. O
The O
rates B-outcome
of I-outcome
sentinel I-outcome
node I-outcome
detection I-outcome
were O
97.1 B-iv-bin-percent
% I-iv-bin-percent
( O
34 B-iv-bin-abs
/ O
35 B-intervention-participants
) O
for O
intratumoral O
injection O
and O
84.4 B-cv-bin-percent
% I-cv-bin-percent
( O
38 B-cv-bin-abs
/ O
45 B-control-participants
) O
for O
peritumoral O
injection O
. O
Radiotracer B-outcome
migration I-outcome
failure I-outcome
occurred O
in O
8 O
cases O
( O
one B-iv-bin-abs
in O
the O
INTRA O
group O
and O
7 B-cv-bin-abs
in O
the O
PERI O
group O
) O
. O
The O
sentinel B-outcome
node I-outcome
was I-outcome
detected I-outcome
in I-outcome
an I-outcome
extra I-outcome
- I-outcome
axillary I-outcome
location I-outcome
in O
21.9 O
% O
of O
cases O
( O
11 B-iv-bin-abs
/ O
59 B-intervention-participants
in O
the O
INTRA O
group O
and O
16 B-cv-bin-abs
/ O
64 B-control-participants
in O
the O
PERI O
group O
) O
. O
Our O
study O
found O
no O
statistically O
significant O
differences O
in O
the O
detection O
rates O
of O
axillary O
or O
extra O
- O
axillary O
sentinel O
lymph O
nodes O
between O
the O
two O
groups O
; O
however O
, O
we O
observed O
greater O
technical O
efficacy O
with O
intratumoral O
radiotracer O
administration O
. O

Phase O
III O
study O
comparing O
exemestane B-intervention
with O
tamoxifen B-control
as O
first O
- O
line O
hormonal O
treatment O
of O
metastatic O
breast O
cancer O
in O
postmenopausal O
women O
: O
the O
European O
Organisation O
for O
Research O
and O
Treatment O
of O
Cancer O
Breast O
Cancer O
Cooperative O
Group O
. O
This O
phase O
III O
randomized O
open O
- O
label O
clinical O
trial O
was O
designed O
to O
evaluate O
the O
efficacy O
and O
safety O
of O
the O
steroidal O
aromatase O
inactivator O
exemestane O
versus O
the O
antiestrogen O
tamoxifen O
as O
first O
- O
line O
treatment O
for O
metastatic O
breast O
cancer O
( O
MBC O
) O
in O
postmenopausal O
women O
. O
The O
study O
was O
conducted O
at O
81 O
centers O
and O
enrolled O
postmenopausal B-eligibility
patients I-eligibility
with I-eligibility
measurable I-eligibility
hormone I-eligibility
- I-eligibility
sensitive I-eligibility
metastatic I-eligibility
or I-eligibility
locally I-eligibility
advanced I-eligibility
breast I-eligibility
cancer I-eligibility
. O
Prior O
adjuvant O
chemotherapy O
and/or O
tamoxifen O
were O
allowed O
. O
One O
previous O
chemotherapy O
regimen O
and O
no O
prior O
hormone O
therapy O
for O
advanced O
disease O
were O
permitted O
. O
Patients O
were O
randomly O
assigned O
to O
receive O
exemestane O
25 O
mg O
or O
tamoxifen O
20 O
mg O
orally O
once O
daily O
until O
disease O
progression O
or O
unacceptable O
toxicity O
occurred O
. O
A O
total O
of O
371 B-total-participants
patients O
enrolled O
at O
79 O
sites O
( O
182 B-intervention-participants
exemestane O
, O
189 B-control-participants
tamoxifen O
) O
were O
included O
in O
the O
analysis O
. O
Both O
treatments O
were O
generally O
well O
tolerated O
without O
major O
toxicity O
. O
Overall B-outcome
response I-outcome
rate I-outcome
was O
greater O
for O
exemestane O
than O
for O
tamoxifen O
treatment O
( O
46 B-iv-bin-percent
% I-iv-bin-percent
v O
31 B-cv-bin-percent
% I-cv-bin-percent
; O
odds O
ratio O
= O
1.85 O
; O
95 O
% O
CI O
, O
1.21 O
to O
2.82 O
; O
P O
= O
.005 O
) O
. O
Median B-outcome
progression I-outcome
- I-outcome
free I-outcome
survival I-outcome
( I-outcome
PFS I-outcome
) I-outcome
was O
longer O
with O
exemestane O
( O
9.9 B-cv-cont-median
months I-cv-cont-median
; O
95 O
% O
CI O
, O
8.7 O
to O
11.8 O
months O
) O
than O
with O
tamoxifen O
( O
5.8 B-iv-cont-median
months I-iv-cont-median
; O
95 O
% O
CI O
, O
5.3 O
to O
8.1 O
months O
) O
. O
However O
, O
these O
early O
differences O
( O
Wilcoxon O
P O
= O
.028 O
) O
did O
not O
translate O
to O
a O
longer O
- O
term O
benefit O
in O
PFS B-outcome-measure
, O
the O
primary O
study O
end O
point O
( O
log O
- O
rank O
P O
= O
.121 O
) O
. O
There O
was O
also O
no O
difference O
in O
survival B-outcome
between O
both O
study O
arms O
. O
Exemestane O
is O
an O
effective O
and O
well O
- O
tolerated O
first O
- O
line O
hormonal O
treatment O
for O
postmenopausal O
women O
with O
MBC O
and O
offers O
significant O
early O
improvement O
in O
time O
to O
tumor O
progression O
when O
compared O
with O
tamoxifen O
. O

Extended O
efficacy O
and O
safety O
of O
denosumab B-intervention
in O
breast B-eligibility
cancer I-eligibility
patients I-eligibility
with I-eligibility
bone I-eligibility
metastases I-eligibility
not I-eligibility
receiving I-eligibility
prior I-eligibility
bisphosphonate I-eligibility
therapy I-eligibility
. O
Denosumab O
, O
a O
fully O
human O
monoclonal O
antibody O
to O
RANKL O
, O
suppresses O
bone O
resorption O
. O
This O
study O
evaluated O
the O
effects O
of O
denosumab O
in O
i. O
v. O
bisphosphonate O
( O
IV O
BP O
) O
-nave O
patients O
with O
breast O
cancer O
- O
related O
bone O
metastases O
. O
Eligible O
women O
( O
n O
= O
255 B-total-participants
) O
, O
stratified O
by O
type O
of O
antineoplastic O
therapy O
, O
were O
randomized O
to O
1 O
of O
5 O
blinded O
denosumab O
cohorts O
or O
an O
open B-control
- I-control
label I-control
IV I-control
BP I-control
cohort O
. O
Denosumab O
was O
administered O
s.c O
. O
every O
4 O
weeks O
( O
30 O
, O
120 O
, O
or O
180 O
mg O
) O
or O
every O
12 O
weeks O
( O
60 O
or O
180 O
mg O
) O
through O
21 O
weeks O
. O
Final O
efficacy O
results O
for O
up O
to O
25 O
weeks O
are O
reported O
, O
including O
percentage O
change O
from O
baseline O
in O
urine O
N O
- O
telopeptide O
corrected O
for O
creatinine O
( O
uNTx O
/ O
Cr O
) O
and O
incidence O
of O
skeletal O
- O
related O
events O
( O
SRE O
) O
. O
Safety O
results O
are O
reported O
through O
the O
end O
of O
follow O
- O
up O
( O
up O
to O
57 O
weeks O
) O
. O
At O
week B-outcome
13 I-outcome
and I-outcome
25 I-outcome
, I-outcome
the I-outcome
median I-outcome
percent I-outcome
changes I-outcome
in I-outcome
uNTx I-outcome
/ I-outcome
creatinine I-outcome
( I-outcome
Cr I-outcome
) I-outcome
among O
patients O
with O
measurable O
uNTx O
were O
-73 B-iv-cont-median
% I-iv-cont-median
and O
-75 B-iv-cont-median
% I-iv-cont-median
for O
the O
pooled O
denosumab O
groups O
and O
-79 B-cv-cont-median
% I-cv-cont-median
and O
-71 B-cv-cont-median
% I-cv-cont-median
for O
the O
IV O
BP O
group O
. O
Among O
patients O
with O
> O
or O
= O
1 O
postbaseline O
measurement O
of O
uNTx O
at O
week O
25 O
, O
52 B-iv-bin-percent
% I-iv-bin-percent
( O
109 B-iv-bin-abs
of O
208 B-intervention-participants
) O
of O
denosumab O
- O
treated O
patients O
and O
46 B-cv-bin-percent
% I-cv-bin-percent
( O
19 B-cv-bin-abs
of O
41 B-control-participants
) O
of O
IV O
BP O
- O
treated O
patients O
achieved B-outcome
> I-outcome
65 I-outcome
% I-outcome
uNTx I-outcome
/ I-outcome
Cr I-outcome
reduction I-outcome
. O
On O
- O
study O
SREs B-outcome
occurred O
in O
12 B-iv-bin-percent
% I-iv-bin-percent
( O
26 B-iv-bin-abs
of O
211 B-intervention-participants
) O
of O
denosumab O
- O
treated O
patients O
and O
16 B-cv-bin-percent
% I-cv-bin-percent
( O
7 B-cv-bin-abs
of O
43 B-control-participants
) O
of O
IV O
BP O
- O
treated O
patients O
. O
Overall B-outcome
rates I-outcome
of I-outcome
adverse I-outcome
events I-outcome
were O
95 B-iv-bin-percent
% I-iv-bin-percent
in O
denosumab O
and O
IV O
BP O
groups O
. O
No O
denosumab O
- O
related O
serious O
or O
fatal O
adverse B-outcome
events I-outcome
occurred O
. O
In O
IV O
BP O
- O
nave O
breast O
cancer O
patients O
with O
bone O
metastases O
, O
denosumab O
suppresses O
bone O
turnover O
and O
seems O
to O
reduce O
SRE O
risk O
similarly O
to O
IV O
BPs O
, O
with O
a O
safety O
profile O
consistent O
with O
an O
advanced O
cancer O
population O
receiving O
systemic O
therapy O
. O

Elevated B-intervention
plasma I-intervention
endoglin I-intervention
( I-intervention
CD105 I-intervention
) I-intervention
predicts O
decreased O
response O
and O
survival O
in O
a O
metastatic O
breast O
cancer O
trial O
of O
hormone O
therapy O
. O
Background O
Endoglin O
( O
CD105 O
) O
is O
a O
co O
- O
receptor O
for O
TGF O
- O
beta O
, O
is O
expressed O
by O
human O
vascular O
endothelial O
cells O
, O
and O
plays O
a O
major O
role O
in O
angiogenesis O
. O
Materials O
and O
methods O
Pretreatment O
EDTA O
plasma O
from O
224 B-intervention-participants
metastatic B-eligibility
breast I-eligibility
cancer I-eligibility
patients I-eligibility
enrolled O
in O
a O
phase O
III O
2nd O
- O
line O
hormone O
therapy O
trial O
and O
50 B-control-participants
control B-control
subjects I-control
were O
assayed O
for O
endoglin O
using O
an O
ELISA O
. O
Results O
The O
female O
control O
group O
( O
n O
= O
50 B-control-participants
) O
plasma O
endoglin O
upper O
limit O
of O
normal O
was O
defined O
as O
the O
mean O
+ O
2 O
SD O
( O
8.7 O
ng O
/ O
ml O
) O
. O
The O
breast O
cancer O
patient O
plasma B-outcome
endoglin I-outcome
was O
6.40 O
+ O
/- O
2.23 O
ng O
/ O
ml O
( O
range O
3.00 O
- O
19.79 O
ng O
/ O
ml O
) O
. O
Elevated B-outcome
plasma I-outcome
endoglin I-outcome
levels I-outcome
were I-outcome
detected I-outcome
in O
26 B-iv-bin-abs
of O
224 B-intervention-participants
patients O
( O
11.6 B-iv-bin-percent
% I-iv-bin-percent
) O
. O
Patients O
with O
elevated O
plasma O
endoglin O
had O
a O
reduced O
clinical B-outcome
benefit I-outcome
rate I-outcome
( O
CR O
+ O
PR O
+ O
Stable O
) O
( O
15 B-iv-bin-percent
vs. O
42 B-cv-bin-percent
% I-cv-bin-percent
) O
( O
P O
= O
0.01 O
) O
to O
hormone O
therapy O
. O
TTP B-outcome
was O
shorter O
for O
patients O
with O
elevated O
plasma O
endoglin O
, O
but O
did O
not O
reach O
statistical O
significance O
( O
P O
= O
0.2 O
) O
. O
Patients O
with O
elevated O
plasma O
endoglin O
had O
decreased O
overall B-outcome
survival I-outcome
( O
median O
645 B-iv-cont-median
vs. O
947 B-cv-cont-median
days I-cv-cont-median
) O
( O
P O
= O
0.005 O
) O
. O
Conclusion O
Elevated O
pretreatment O
plasma O
endoglin O
levels O
predicted O
for O
decreased O
clinical O
benefit O
and O
a O
shorter O
overall O
survival O
in O
metastatic O
breast O
cancer O
patients O
treated O
with O
2nd O
- O
line O
hormone O
therapy O
. O

Randomized O
controlled O
trial O
of O
aerobic B-intervention
exercise I-intervention
on O
insulin O
and O
insulin O
- O
like O
growth O
factors O
in O
breast O
cancer O
survivors O
: O
the O
Yale O
Exercise O
and O
Survivorship O
study O
. O
High O
insulin O
and O
insulin O
- O
like O
growth O
factor O
- O
I O
( O
IGF O
- O
I O
) O
levels O
may O
be O
associated O
with O
an O
increased O
breast O
cancer O
risk O
and/or O
death O
. O
Given O
the O
need O
to O
identify O
modifiable O
factors O
that O
decrease O
insulin O
, O
IGF O
- O
I O
, O
and O
breast O
cancer O
risk O
and O
death O
, O
we O
investigated O
the O
effects O
of O
a O
6 O
- O
month O
randomized O
controlled O
aerobic O
exercise O
intervention O
versus O
usual O
care O
on O
fasting O
insulin O
, O
IGF O
- O
I O
, O
and O
its O
binding O
protein O
( O
IGFBP-3 O
) O
in O
postmenopausal O
breast O
cancer O
survivors O
. O
Seventy B-total-participants
- I-total-participants
five I-total-participants
postmenopausal B-eligibility
breast I-eligibility
cancer I-eligibility
survivors I-eligibility
were O
identified O
from O
the O
Yale O
- O
New B-location
Haven I-location
Hospital O
Tumor O
Registry O
and O
randomly O
assigned O
to O
an O
exercise O
( O
n O
= O
37 B-intervention
) O
or O
usual B-control
care I-control
( O
n O
= O
38 B-control-participants
) O
group O
. O
The O
exercise O
group O
participated O
in O
150 O
minutes O
per O
week O
of O
moderate O
- O
intensity O
aerobic O
exercise O
. O
The O
usual O
care O
group O
was O
instructed O
to O
maintain O
their O
current O
physical O
activity O
level O
. O
A O
fasting O
blood O
sample O
was O
collected O
on O
each O
study O
participant O
at O
baseline O
and O
6 O
months O
. O
Blood O
levels O
of O
insulin O
and O
IGF O
were O
measured O
with O
ELISA O
. O
On O
average O
, O
exercisers O
increased B-outcome
aerobic I-outcome
exercise I-outcome
by O
129 B-iv-cont-mean
minutes I-iv-cont-mean
per O
week O
compared O
with O
45 B-cv-cont-mean
minutes I-cv-cont-mean
per O
week O
among O
usual O
care O
participants O
( O
P O
< O
0.001 O
) O
. O
Women O
randomized O
to O
exercise O
experienced O
decreases O
in O
insulin B-outcome
, O
IGF B-outcome
- I-outcome
I I-outcome
, O
and O
IGFBP-3 B-outcome
, O
whereas O
women O
randomized O
to O
usual O
care O
had O
increases O
in O
these O
hormones O
. O
Between O
- O
group O
differences O
in O
insulin B-outcome
, I-outcome
IGF I-outcome
- I-outcome
I I-outcome
, I-outcome
and I-outcome
IGFBP-3 I-outcome
were O
20.7 O
% O
( O
P O
= O
0.089 O
) O
, O
8.9 O
% O
( O
P O
= O
0.026 O
) O
, O
and O
7.9 O
% O
( O
P O
= O
0.006 O
) O
, O
respectively O
. O
Moderate O
- O
intensity O
aerobic O
exercise O
, O
such O
as O
brisk O
walking O
, O
decreases O
IGF B-outcome
- I-outcome
I I-outcome
and I-outcome
IGFBP-3 I-outcome
. O
The O
exercise O
- O
induced O
decreases O
in O
IGF O
may O
mediate O
the O
observed O
association O
between O
higher O
levels O
of O
physical O
activity O
and O
improved O
survival O
in O
women O
diagnosed O
with O
breast O
cancer O
. O

A O
randomised O
pilot O
Phase O
II O
study O
of O
doxorubicin B-intervention
and I-intervention
cyclophosphamide I-intervention
( I-intervention
AC I-intervention
) I-intervention
or I-intervention
epirubicin I-intervention
and I-intervention
cyclophosphamide I-intervention
( I-intervention
EC I-intervention
) I-intervention
given I-intervention
2 I-intervention
weekly I-intervention
with I-intervention
pegfilgrastim I-intervention
( I-intervention
accelerated I-intervention
) I-intervention
vs O
3 O
weekly O
( O
standard B-control
) O
for O
women B-eligibility
with I-eligibility
early I-eligibility
breast I-eligibility
cancer I-eligibility
. O
Accelerated O
( O
dose O
- O
dense O
) O
chemotherapy O
, O
in O
which O
the O
frequency O
of O
administration O
is O
increased O
without O
changing O
total O
dose O
or O
duration O
, O
may O
increase O
the O
efficacy O
of O
cancer O
chemotherapy O
. O
We O
performed O
a O
randomised O
Phase O
II O
study O
to O
assess O
the O
safety O
and O
relative O
toxicity O
of O
AC O
( O
doxorubicin O
; O
cyclophosphamide O
) O
vs O
E O
( O
epirubicin O
) O
C O
given O
by O
conventional O
or O
accelerated O
schedules O
as O
neoadjuvant O
or O
adjuvant O
chemotherapy O
for O
early O
breast O
cancer O
. O
Furthermore O
, O
the O
relative O
toxicity O
of O
doxorubicin O
and O
epirubicin O
remains O
uncertain O
. O
Patients O
were O
randomised O
to O
one O
of O
four O
arms O
; O
four O
courses O
of O
standard O
3 O
weekly O
cyclophosphamide O
600 O
mg O
m O
( O
-2 O
) O
in O
combination O
with O
doxorubicin O
60 O
mg O
m O
( O
-2 O
) O
( O
AC O
) O
vs O
epirubicin O
90 O
mg O
m O
( O
-2 O
) O
( O
EC O
) O
3 O
weekly O
vs O
the O
same O
regimens O
administered O
every O
2 O
weeks O
with O
pegfilgrastim O
( O
G O
- O
CSF O
) O
. O
A O
total O
of O
126 B-total-participants
patients O
were O
treated O
, O
42 B-control-participants
with O
standard O
AC O
, O
42 B-intervention-participants
with O
accelerated O
AC O
, O
19 B-intervention-participants
with O
standard O
EC O
and O
23 B-intervention-participants
with O
accelerated O
EC O
. O
Significantly O
more O
grade B-outcome
3 I-outcome
/ I-outcome
4 I-outcome
day I-outcome
one I-outcome
neutropenia I-outcome
was O
seen O
with O
standard O
( O
6 B-cv-bin-abs
/ O
61 B-control-participants
, O
10 B-cv-bin-percent
% I-cv-bin-percent
) O
compared O
to O
accelerated O
( O
0 B-iv-bin-abs
/ O
65 B-intervention-participants
, O
) O
regimens O
( O
P O
= O
0.01 O
) O
. O
A O
trend O
towards O
more O
neutropenic B-outcome
sepsis I-outcome
was O
seen O
in O
the O
combined O
standard O
and O
accelerated O
AC O
arms O
( O
12 B-iv-bin-abs
/ O
84 B-intervention-participants
, O
14 B-iv-bin-percent
% I-iv-bin-percent
) O
compared O
to O
the O
combined O
EC O
arms O
( O
1 B-iv-bin-abs
/ O
42 B-intervention-participants
, O
2 B-iv-bin-percent
% I-iv-bin-percent
) O
, O
P O
= O
0.06 O
. O
Falls O
in O
left B-outcome
ventricular I-outcome
ejection I-outcome
fraction I-outcome
were O
not O
increased O
with O
accelerated O
treatment O
. O
Accelerated O
AC O
and O
EC O
with O
pegfilgrastim O
are O
safe O
and O
feasible O
regimens O
in O
the O
treatment O
of O
early O
breast O
cancer O
with O
less O
neutropenia O
than O
conventional O
3 O
weekly O
schedules O
. O

Sentinel B-intervention
node I-intervention
biopsy I-intervention
compared O
with O
complete B-control
axillary I-control
dissection I-control
for O
staging O
early B-eligibility
breast I-eligibility
cancer I-eligibility
with I-eligibility
clinically I-eligibility
negative I-eligibility
lymph I-eligibility
nodes I-eligibility
: O
results O
of O
randomized O
trial O
. O
Sentinel O
lymph O
node O
( O
SLN O
) O
staging O
is O
currently O
used O
to O
avoid O
complete O
axillary O
dissection O
in O
breast O
cancer O
patients O
with O
negative O
SLNs O
. O
Evidence O
of O
a O
similar O
efficacy O
, O
in O
terms O
of O
survival O
and O
regional O
control O
, O
of O
this O
strategy O
as O
compared O
with O
axillary O
resection O
is O
based O
on O
few O
clinical O
trials O
. O
In O
1998 O
, O
we O
started O
a O
randomized O
study O
comparing O
the O
two O
strategies O
, O
and O
we O
present O
here O
its O
results O
. O
Patients O
were O
randomly O
assigned O
to O
sentinel O
lymph O
node O
biopsy O
( O
SLNB O
) O
and O
axillary O
dissection O
[ O
axillary O
lymph O
node O
dissection O
( O
ALND O
arm O
) O
] O
or O
to O
SLNB O
plus O
axillary O
resection O
if O
SLNs O
contained O
metastases O
( O
SLNB O
arm O
) O
. O
Main O
end O
points O
were O
overall B-outcome-measure
survival I-outcome-measure
( I-outcome-measure
OS I-outcome-measure
) I-outcome-measure
and O
axillary B-outcome-measure
recurrence I-outcome-measure
. O
One B-control-participants
hundred I-control-participants
and I-control-participants
fifteen I-control-participants
patients O
were O
assigned O
to O
the O
ALND O
arm O
and O
110 B-intervention-participants
to O
the O
SLNB O
arm O
. O
A O
positive B-outcome
SLN I-outcome
was O
found O
in O
27 B-cv-bin-abs
patients O
in O
the O
ALND O
arm O
and O
in O
31 B-iv-bin-abs
in O
the O
SLNB O
arm O
. O
Overall B-outcome
accuracy I-outcome
of O
SLNB O
was O
93.0 B-iv-bin-percent
% I-iv-bin-percent
. O
Sensitivity B-outcome
and O
negative B-outcome
predictive I-outcome
values I-outcome
were O
77.1 B-iv-bin-percent
% I-iv-bin-percent
and O
91.1 B-iv-bin-percent
% I-iv-bin-percent
, O
respectively O
. O
At O
a O
median O
follow O
- O
up O
of O
5.5 O
years O
, O
no B-iv-bin-abs
axillary B-outcome
recurrence I-outcome
was O
observed O
in O
the O
SLNB O
arm O
. O
OS B-outcome
and O
event B-outcome
- I-outcome
free I-outcome
survival I-outcome
were O
not O
statistically O
different O
between O
the O
two O
arms O
. O
The O
SLNB O
procedure O
does O
not O
appear O
inferior O
to O
conventional O
ALND O
for O
the O
subset O
of O
patients O
here O
considered O
. O

Randomized O
controlled O
trial O
of O
mindfulness B-intervention
- I-intervention
based I-intervention
stress I-intervention
reduction I-intervention
( O
MBSR O
) O
for O
survivors O
of O
breast O
cancer O
. O
Considerable O
morbidity O
persists O
among O
survivors O
of O
breast O
cancer O
( O
BC O
) O
including O
high O
levels O
of O
psychological O
stress O
, O
anxiety O
, O
depression O
, O
fear O
of O
recurrence O
, O
and O
physical O
symptoms O
including O
pain O
, O
fatigue O
, O
and O
sleep O
disturbances O
, O
and O
impaired O
quality O
of O
life O
. O
Effective O
interventions O
are O
needed O
during O
this O
difficult O
transitional O
period O
. O
We O
conducted O
a O
randomized O
controlled O
trial O
of O
84 B-total-participants
female B-eligibility
BC I-eligibility
survivors I-eligibility
( I-eligibility
Stages I-eligibility
0 I-eligibility
- I-eligibility
III I-eligibility
) I-eligibility
recruited O
from O
the O
H. O
Lee O
Moffitt O
Cancer O
and O
Research O
Institute O
. O
All O
subjects O
were O
within O
18 O
months O
of O
treatment O
completion O
with O
surgery O
and O
adjuvant O
radiation O
and/or O
chemotherapy O
. O
Subjects O
were O
randomly O
assigned O
to O
a O
6 O
- O
week O
Mindfulness O
- O
Based O
Stress O
Reduction O
( O
MBSR O
) O
program O
designed O
to O
self O
- O
regulate O
arousal O
to O
stressful O
circumstances O
or O
symptoms O
( O
n O
= O
41 B-intervention-participants
) O
or O
to O
usual B-control
care I-control
( O
n O
= O
43 B-control-participants
) O
. O
Outcome O
measures O
compared O
at O
6 O
weeks O
by O
random O
assignment O
included O
validated B-outcome-measure
measures I-outcome-measure
of I-outcome-measure
psychological I-outcome-measure
status I-outcome-measure
( I-outcome-measure
depression I-outcome-measure
, I-outcome-measure
anxiety I-outcome-measure
, I-outcome-measure
perceived I-outcome-measure
stress I-outcome-measure
, I-outcome-measure
fear I-outcome-measure
of I-outcome-measure
recurrence I-outcome-measure
, I-outcome-measure
optimism I-outcome-measure
, I-outcome-measure
social I-outcome-measure
support I-outcome-measure
) I-outcome-measure
and O
psychological B-outcome-measure
and I-outcome-measure
physical I-outcome-measure
subscales I-outcome-measure
of I-outcome-measure
quality I-outcome-measure
of I-outcome-measure
life I-outcome-measure
( O
SF-36 O
) O
. O
Compared O
with O
usual O
care O
, O
subjects O
assigned O
to O
MBSR O
( O
BC O
) O
had O
significantly O
lower O
( O
two O
- O
sided O
p<0.05 O
) O
adjusted O
mean B-outcome
levels I-outcome
of I-outcome
depression I-outcome
( O
6.3 B-iv-cont-mean
vs O
9.6 B-cv-cont-mean
) O
, O
anxiety B-outcome
( O
28.3 B-iv-cont-mean
vs O
33.0 B-cv-cont-mean
) O
, O
and O
fear B-outcome
of I-outcome
recurrence I-outcome
( O
9.3 B-iv-cont-mean
vs O
11.6 B-cv-cont-mean
) O
at O
6 O
weeks O
, O
along O
with O
higher B-outcome
energy I-outcome
( O
53.5 B-iv-cont-mean
vs O
49.2 B-cv-cont-mean
) O
, O
physical B-outcome
functioning I-outcome
( O
50.1 B-iv-cont-mean
vs O
47.0 B-cv-cont-mean
) O
, O
and O
physical B-outcome
role I-outcome
functioning I-outcome
( O
49.1 B-iv-cont-mean
vs O
42.8 B-cv-cont-mean
) O
. O
In O
stratified O
analyses O
, O
subjects O
more O
compliant O
with O
MBSR O
tended O
to O
experience O
greater O
improvements O
in O
measures O
of O
energy B-outcome
and I-outcome
physical I-outcome
functioning I-outcome
. O
Among O
BC O
survivors O
within O
18 O
months O
of O
treatment O
completion O
, O
a O
6 O
- O
week O
MBSR O
( O
BC O
) O
program O
resulted O
in O
significant O
improvements O
in O
psychological O
status O
and O
quality O
of O
life O
compared O
with O
usual O
care O
. O

Managing O
the O
risk O
of O
invasive O
breast O
cancer O
in O
women O
at O
risk O
for O
breast O
cancer O
and O
osteoporosis O
: O
the O
role O
of O
raloxifene B-intervention
. O
Raloxifene O
hydrochloride O
is O
a O
selective O
estrogen O
receptor O
modulator O
( O
SERM O
) O
that O
has O
antiestrogenic O
effects O
on O
breast O
and O
endometrial O
tissue O
and O
estrogenic O
effects O
on O
bone O
, O
lipid O
metabolism O
, O
and O
blood O
clotting O
. O
Raloxifene O
significantly O
improves O
serum O
lipids O
and O
serum O
markers O
of O
cardiovascular O
disease O
risk O
, O
but O
it O
has O
no O
significant O
effect O
on O
the O
risk O
of O
primary O
coronary O
events O
. O
A O
meta O
- O
analysis O
of O
randomized O
, O
double O
- O
blind O
, O
placebo O
- O
controlled O
trials O
of O
raloxifene O
for O
osteoporosis O
showed O
the O
odds O
of O
fracture B-outcome
risk I-outcome
were O
0.60 O
( O
95 O
% O
confidence O
interval O
[ O
CI O
] O
= O
0.49 O
- O
0.74 O
) O
for O
raloxifene O
60 O
mg O
/ O
day O
compared O
with O
placebo B-control
. O
During O
8 O
years O
of O
follow O
- O
up O
in O
an O
osteoporosis O
trial O
, O
the O
raloxifene O
group O
had O
a O
76 B-iv-bin-percent
% I-iv-bin-percent
reduction O
in O
the O
incidence B-outcome
of I-outcome
invasive I-outcome
ER I-outcome
- I-outcome
positive I-outcome
breast I-outcome
cancer I-outcome
compared O
with O
the O
placebo O
group O
. O
In O
the O
STAR O
trial O
, O
the O
incidence B-outcome
of I-outcome
invasive I-outcome
breast I-outcome
cancer I-outcome
was O
4.30 B-iv-bin-abs
per O
1000 B-intervention-participants
women O
- O
years O
with O
raloxifene O
and O
4.41 B-cv-bin-abs
per O
1000 B-control-participants
with O
tamoxifen O
; O
RR O
= O
1.02 O
; O
95 O
% O
CI O
, O
0.82 O
- O
1.28 O
. O
The O
effect O
of O
raloxifene O
on O
invasive O
breast O
cancer O
was O
, O
therefore O
, O
equivalent O
to O
that O
of O
tamoxifen O
with O
more O
favorable O
rates O
of O
adverse O
effects O
including O
uterine B-outcome
malignancy I-outcome
and O
clotting B-outcome
events I-outcome
. O
Millions O
of O
postmenopausal O
women O
could O
derive O
net O
benefit O
from O
raloxifene O
through O
reduced O
rates O
of O
fracture O
and O
invasive O
breast O
cancer O
. O

Trastuzumab B-intervention
beyond O
progression O
in O
human O
epidermal O
growth O
factor O
receptor O
2 O
- O
positive O
advanced O
breast O
cancer O
: O
a O
german B-location
breast O
group O
26 O
/ O
breast O
international O
group O
03 O
- O
05 O
study O
. O
Trastuzumab O
shows O
clinical O
activity O
in O
human O
epidermal O
growth O
factor O
receptor O
2 O
( O
HER-2 O
) O
-positive O
early O
and O
advanced O
breast O
cancer O
. O
In O
the O
German O
Breast O
Group O
26 O
/ O
Breast O
International O
Group O
03 O
- O
05 O
trial O
, O
we O
investigated O
if O
trastuzumab O
treatment O
should O
be O
continued O
beyond O
progression O
. O
Patients B-eligibility
with I-eligibility
HER-2 I-eligibility
- I-eligibility
positive I-eligibility
breast I-eligibility
cancer I-eligibility
that I-eligibility
progresses I-eligibility
during I-eligibility
treatment I-eligibility
with I-eligibility
trastuzumab I-eligibility
were O
randomly O
assigned O
to O
receive O
capecitabine O
( O
2,500 O
mg O
/ O
m O
( O
2 O
) O
body O
- O
surface O
area O
on O
days O
1 O
through O
14 O
[ O
1,250 O
mg O
/ O
m O
( O
2 O
) O
semi O
- O
daily O
] O
) O
alone O
or O
with O
continuation O
of O
trastuzumab O
( O
6 O
mg O
/ O
kg O
body O
weight O
) O
in O
3 O
- O
week O
cycles O
. O
The O
primary O
end O
point O
was O
time B-outcome-measure
to I-outcome-measure
progression I-outcome-measure
. O
We O
randomly O
assigned O
78 B-control-participants
patients O
to O
capecitabine B-control
and O
78 B-intervention-participants
patients O
to O
capecitabine B-intervention
plus I-intervention
trastuzumab I-intervention
. O
Sixty B-cv-bin-abs
- I-cv-bin-abs
five I-cv-bin-abs
events B-outcome
and O
38 B-cv-bin-abs
deaths B-outcome
in O
the O
capecitabine O
group O
and O
62 B-iv-bin-abs
events O
and O
33 B-iv-bin-abs
deaths B-outcome
in O
the O
capecitabine O
- O
plus O
- O
trastuzumab O
group O
occurred O
during O
15.6 O
months O
of O
follow O
- O
up O
. O
Median B-outcome
times I-outcome
to I-outcome
progression I-outcome
were O
5.6 B-iv-cont-median
months I-iv-cont-median
in O
the O
capecitabine O
group O
and O
8.2 B-cv-cont-median
months I-cv-cont-median
in O
the O
capecitabine O
- O
plus O
- O
trastuzumab O
group O
with O
an O
unadjusted O
hazard O
ratio O
of O
0.69 O
( O
95 O
% O
CI O
, O
0.48 O
to O
0.97 O
; O
two O
- O
sided O
log O
- O
rank O
P O
= O
.0338 O
) O
. O
Overall B-outcome
survival I-outcome
rates I-outcome
were O
20.4 B-iv-cont-median
months I-iv-cont-median
( O
95 O
% O
CI O
, O
17.8 O
to O
24.7 O
) O
in O
the O
capecitabine O
group O
and O
25.5 B-cv-cont-median
months I-cv-cont-median
( O
95 O
% O
CI O
, O
19.0 O
to O
30.7 O
) O
in O
the O
capecitabine O
- O
plus O
- O
trastuzumab O
group O
( O
P O
= O
.257 O
) O
. O
Overall B-outcome
response I-outcome
rates I-outcome
were O
27.0 B-cv-bin-percent
% I-cv-bin-percent
with O
capecitabine O
and O
48.1 B-iv-bin-percent
% I-iv-bin-percent
with O
capecitabine O
plus O
trastuzumab O
( O
odds O
ratio O
, O
2.50 O
; O
P O
= O
.0115 O
) O
. O
Continuation O
of O
trastuzumab O
beyond O
progression O
was O
not O
associated O
with O
increased O
toxicity B-outcome
. O
Continuation O
of O
trastuzumab O
plus O
capecitabine O
showed O
a O
significant O
improvement O
in O
overall O
response O
and O
time O
to O
progression O
compared O
with O
capecitabine O
alone O
in O
women O
with O
HER-2 O
- O
positive O
breast O
cancer O
who O
experienced O
progression O
during O
trastuzumab O
treatment O
. O

A O
comparative O
study O
of O
exemestane B-intervention
versus O
anastrozole B-control
in O
patients O
with O
postmenopausal O
breast O
cancer O
with O
visceral O
metastases O
. O
Patients O
developing O
visceral O
breast O
cancer O
metastases O
generally O
receive O
chemotherapy O
rather O
than O
endocrine O
therapy O
. O
Recent O
aromatase O
inhibitor O
studies O
have O
reported O
activity O
in O
such O
patients O
; O
therefore O
, O
this O
study O
formally O
evaluated O
anastrozole O
and O
exemestane O
in O
postmenopausal O
patients O
in O
this O
setting O
. O
Postmenopausal B-eligibility
women I-eligibility
with I-eligibility
advanced I-eligibility
breast I-eligibility
cancer I-eligibility
and I-eligibility
> I-eligibility
or I-eligibility
= I-eligibility
1 I-eligibility
visceral I-eligibility
( I-eligibility
liver I-eligibility
or I-eligibility
lung I-eligibility
) I-eligibility
lesion I-eligibility
were O
randomized O
to O
anastrozole O
( O
1 O
mg O
/ O
day O
orally O
) O
or O
exemestane O
( O
25 O
mg O
/ O
day O
orally O
) O
for O
> O
or O
= O
8 O
weeks O
. O
The O
primary O
endpoint O
was O
objective B-outcome-measure
response I-outcome-measure
in I-outcome-measure
visceral I-outcome-measure
lesions I-outcome-measure
based O
on O
modified O
Response O
Evaluation O
Criteria O
in O
Solid O
Tumors O
. O
Secondary O
endpoints O
included O
clinical B-outcome-measure
benefit I-outcome-measure
( O
objective O
response O
plus O
stable O
disease O
> O
or O
= O
180 O
days O
) O
, O
overall B-outcome-measure
survival I-outcome-measure
, O
and O
adverse B-outcome-measure
events I-outcome-measure
. O
A O
total O
of O
130 B-total-participants
patients O
were O
enrolled O
, O
and O
128 B-total-participants
patients O
( O
64 B-control-participants
anastrozole O
, O
64 B-intervention-participants
exemestane O
) O
were O
included O
in O
the O
intent O
- O
to O
- O
treat O
analysis O
. O
Accrual O
delays O
caused O
study O
closure O
before O
the O
target O
enrollment O
( O
N O
= O
200 O
) O
was O
reached O
, O
limiting O
the O
statistical O
power O
of O
the O
study O
. O
Objective B-outcome
response I-outcome
in I-outcome
visceral I-outcome
sites I-outcome
was O
approximately O
15 B-iv-bin-percent
% I-iv-bin-percent
in O
both O
groups O
. O
Clinical B-outcome
benefit I-outcome
in I-outcome
visceral I-outcome
sites I-outcome
was O
32 B-cv-bin-percent
% I-cv-bin-percent
of O
the O
patients O
treated O
with O
anastrozole O
and O
38 B-iv-bin-percent
% I-iv-bin-percent
of O
the O
patients O
treated O
with O
exemestane O
. O
Median B-outcome
survival I-outcome
was O
33.3 B-cv-cont-median
months I-cv-cont-median
and O
30.5 B-iv-cont-median
months I-iv-cont-median
in O
the O
anastrozole O
and O
exemestane O
groups O
, O
respectively O
. O
Toxicities O
were O
similar O
to O
those O
previously O
reported O
; O
however O
, O
treatment B-outcome
- I-outcome
related I-outcome
adverse I-outcome
events I-outcome
were O
more O
frequent O
with O
anastrozole O
( O
41 B-cv-bin-percent
% I-cv-bin-percent
) O
than O
with O
exemestane O
( O
31 B-iv-bin-percent
% I-iv-bin-percent
) O
. O
Both O
treatments O
were O
generally O
well B-outcome
tolerated I-outcome
in O
patients O
with O
postmenopausal O
breast O
cancer O
with O
visceral O
metastases O
. O
Efficacy B-outcome
was O
similar O
in O
both O
treatment O
groups O
for O
all O
endpoints O
. O
Aromatase O
inhibitors O
can O
be O
considered O
as O
a O
treatment O
option O
in O
postmenopausal O
patients O
with O
hormone O
receptor O
- O
positive O
visceral O
breast O
cancer O
metastases O
. O

Incidence O
of O
invasive O
breast O
cancer O
in O
postmenopausal O
women O
after O
discontinuation O
of O
long O
- O
term O
raloxifene B-intervention
administration O
. O
Postmenopausal B-eligibility
women I-eligibility
with I-eligibility
osteoporosis I-eligibility
had O
a O
66 O
% O
relative O
risk O
reduction O
for O
invasive O
breast O
cancer O
over O
8 O
years O
of O
raloxifene O
therapy O
in O
the O
randomized O
, O
placebo O
- O
controlled O
4 O
- O
year O
MORE O
( O
Multiple O
Outcomes O
of O
Raloxifene O
Evaluation O
) O
trial O
and O
the O
CORE O
( O
Continuing O
Outcomes O
Relevant O
to O
Evista O
) O
trial O
, O
a O
4 O
- O
year O
follow O
- O
up O
to O
MORE O
. O
The O
first O
post O
hoc O
analysis O
examined O
the O
effects O
of O
raloxifene O
on O
the O
cumulative O
incidence O
of O
invasive O
breast O
cancer O
on O
a O
yearly O
basis O
. O
Another O
analysis O
compared O
the O
incidence O
of O
invasive O
breast O
cancer O
in O
3967 B-total-participants
patients O
who O
continued O
raloxifene O
for O
8 O
years O
( O
RLX O
- O
C O
, O
n O
= O
2280 B-intervention-participants
) O
, O
discontinued O
raloxifene O
after O
4 O
years O
in O
MORE O
( O
RLX O
- O
D O
, O
n O
= O
401 B-intervention-participants
) O
, O
or O
took O
placebo B-control
( O
n O
= O
1286 B-control-participants
) O
for O
a O
mean O
2.9 O
years O
' O
treatment O
duration O
( O
57,338 O
patient O
- O
years O
) O
. O
The O
unadjusted O
breast B-outcome
cancer I-outcome
incidence I-outcome
rate I-outcome
was O
5.39 B-cv-bin-abs
per O
1000 B-control-participants
patient O
- O
years O
in O
the O
placebo O
group O
compared O
with O
2.26 B-iv-bin-abs
in O
the O
RLX O
- O
C O
group O
( O
hazard O
ratio O
[ O
HR O
] O
, O
0.41 O
[ O
95 O
% O
CI O
0.21 O
- O
0.81 O
] O
) O
and O
3.59 B-iv-bin-abs
in O
the O
RLX O
- O
D O
group O
( O
HR O
, O
0.69 O
[ O
95 O
% O
CI O
0.23 O
- O
2.01 O
] O
) O
. O
Because O
the O
choice O
of O
taking O
the O
study O
drug O
was O
not O
randomized O
in O
CORE O
, O
propensity O
scores O
were O
used O
to O
adjust O
for O
potential O
imbalances O
in O
baseline O
characteristics O
before O
CORE O
. O
Results O
after O
adjustment O
by O
the O
propensity O
score O
method O
were O
similar O
to O
the O
unadjusted O
results O
. O
This O
analysis O
suggests O
a O
persistent O
effect O
for O
breast O
cancer O
risk O
reduction O
in O
patients O
who O
discontinued O
raloxifene O
, O
although O
this O
conclusion O
is O
limited O
by O
the O
small O
sample O
size O
. O

Use O
of O
axillary B-intervention
deodorant I-intervention
and O
effect O
on O
acute O
skin O
toxicity O
during O
radiotherapy O
for O
breast O
cancer O
: O
a O
prospective O
randomized O
noninferiority O
trial O
. O
To O
prospectively O
determine O
the O
effect O
of O
deodorant O
use O
on O
acute O
skin O
toxicity O
and O
quality O
of O
life O
during O
breast O
radiotherapy O
( O
RT O
) O
. O
Before O
breast O
RT O
, O
84 B-total-participants
patients O
were O
randomly O
assigned O
to O
the O
deodorant O
group O
( O
n O
= O
40 B-intervention-participants
) O
or O
the O
no B-control
- I-control
deodorant I-control
group O
( O
n O
= O
44 B-control-participants
) O
. O
The O
patients O
were O
stratified O
by O
axillary O
RT O
and O
previous O
chemotherapy O
. O
Toxicity O
evaluations O
were O
always O
performed O
by O
the O
principal O
investigator O
, O
who O
was O
unaware O
of O
the O
group O
assignment O
, O
at O
the O
end O
of O
RT O
and O
2 O
weeks O
after O
completion O
using O
the O
Radiation O
Therapy O
Oncology O
Group O
acute O
skin O
toxicity O
criteria O
. O
Symptoms O
of O
acute O
skin O
toxicity O
( O
i. O
e. O
, O
discomfort O
, O
pain O
, O
pruritus O
, O
sweating O
) O
and O
quality O
of O
life O
were O
self O
- O
evaluated O
. O
For O
each O
criterion O
, O
the O
point O
estimate O
of O
rate O
difference O
with O
the O
95 O
% O
one O
- O
sided O
upper O
confidence O
limit O
was O
computed O
. O
To O
claim O
noninferiority O
owing O
to O
deodorant O
use O
, O
the O
95 O
% O
one O
- O
sided O
upper O
confidence O
limit O
had O
to O
be O
lower O
than O
the O
noninferiority O
margin O
, O
fixed O
to O
12.8 O
% O
. O
In O
the O
deodorant O
vs. O
no O
- O
deodorant O
groups O
, O
Grade B-outcome
2 I-outcome
axillary I-outcome
radiodermatitis I-outcome
occurred O
in O
23 B-iv-bin-percent
% I-iv-bin-percent
vs. O
30 B-cv-bin-percent
% I-cv-bin-percent
, O
respectively O
, O
satisfying O
the O
statistical O
criteria O
for O
noninferiority O
( O
p O
= O
.019 O
) O
. O
Grade B-outcome
2 I-outcome
breast I-outcome
radiodermatitis I-outcome
occurred O
in O
30 B-iv-bin-percent
% I-iv-bin-percent
vs. O
34 B-cv-bin-percent
% I-cv-bin-percent
of O
the O
deodorant O
vs. O
no O
- O
deodorant O
groups O
, O
respectively O
, O
also O
satisfying O
the O
statistical O
criteria O
for O
noninferiority O
( O
p O
= O
.049 O
) O
. O
Similar O
results O
were O
observed O
for O
the O
self O
- O
reported O
evaluations O
. O
The O
deodorant O
group O
reported O
less O
sweating B-outcome
( O
18 B-iv-bin-percent
% I-iv-bin-percent
vs. O
39 B-cv-bin-percent
% I-cv-bin-percent
, O
p O
= O
.032 O
) O
. O
No O
Grade B-outcome
3 I-outcome
or I-outcome
4 I-outcome
radiodermatitis I-outcome
was O
observed O
. O
According O
to O
our O
noninferiority O
margin O
definition O
, O
the O
occurrence O
of O
skin O
toxicity O
and O
its O
related O
symptoms O
were O
statistically O
equivalent O
in O
both O
groups O
. O
No O
evidence O
was O
found O
to O
prohibit O
deodorant O
use O
( O
notwithstanding O
the O
use O
of O
an O
antiperspirant O
with O
aluminum O
) O
during O
RT O
for O
breast O
cancer O
. O

[ O
Effect O
of O
shugan B-intervention
liangxue I-intervention
compound O
for O
relieving O
hot B-condition
flashes I-condition
in O
breast O
cancer O
patients O
] O
. O
To O
observe O
the O
effect O
of O
Shugan O
Liangxue O
Compound O
( O
SLC O
) O
for O
relieving O
hot O
flashes O
in O
breast O
cancer O
patients O
medicated O
with O
tamoxifen O
. O
A O
randomized O
, O
double O
blind O
clinical O
trial O
for O
observing O
the O
therapeutic O
effects O
of O
SLC O
was O
carried O
out O
on O
73 B-total-participants
breast B-eligibility
cancer I-eligibility
patients I-eligibility
hospitalized O
from O
October O
2004 O
to O
November O
2006 O
, O
who B-eligibility
were I-eligibility
treated I-eligibility
with I-eligibility
tamoxifen I-eligibility
, I-eligibility
and I-eligibility
revealed I-eligibility
hot I-eligibility
flashes I-eligibility
. O
They O
were O
randomly O
assigned O
to O
two O
groups O
, O
the O
37 B-intervention-participants
in O
the O
treated O
group O
treated O
by O
SLC O
, O
and O
the O
36 B-control-participants
in O
the O
control O
group O
treated O
with O
placebo B-control
. O
Taking O
the O
improvement O
of O
hot O
flashes O
as O
an O
end O
point O
index O
and O
that O
of O
sleep O
as O
a O
secondary O
index O
, O
the O
effects O
of O
treatment O
were O
compared O
by O
Kupperman O
scoring O
with O
the O
average O
times O
of O
hot O
flashes O
per O
day O
and O
condition O
of O
sleep O
within O
1 O
week O
before O
treatment O
as O
baseline O
. O
The O
effects O
on O
66 B-total-participants
patients O
( O
33 B-intervention-participants
in O
the O
treated O
group O
and O
33 B-control-participants
in O
the O
control O
group O
) O
were O
evaluable O
. O
In O
the O
treated O
group O
hot B-outcome
flashes I-outcome
disappeared I-outcome
in O
5 B-iv-bin-abs
patients O
( O
15.2 B-iv-bin-abs
% I-iv-bin-abs
) O
, O
relieved B-outcome
in O
14 B-iv-bin-abs
( O
42.4 B-iv-bin-percent
% I-iv-bin-percent
) O
and O
unchanged B-outcome
in O
14 B-iv-bin-abs
( O
42.4 B-iv-bin-percent
% I-iv-bin-percent
) O
; O
while O
in O
the O
control O
group O
, O
it O
disappeared B-outcome
in O
none B-cv-bin-abs
, O
relieved B-outcome
in O
10 B-cv-bin-abs
( O
30.3 B-cv-bin-percent
% I-cv-bin-percent
) O
and O
unchanged B-outcome
in O
23 B-cv-bin-abs
( O
69.7 B-cv-bin-percent
% I-cv-bin-percent
) O
, O
comparison O
between O
groups O
showed O
significant O
difference O
( O
P O
= O
0.012 O
) O
. O
As O
for O
the O
condition B-outcome
of I-outcome
sleep I-outcome
, O
it O
was O
improved B-outcome
in O
21 B-iv-bin-abs
( O
63.6 B-iv-bin-percent
% I-iv-bin-percent
) O
and O
unchanged B-outcome
in O
12 B-iv-bin-abs
( O
36.4 B-iv-bin-percent
% I-iv-bin-percent
) O
in O
the O
treated O
group O
; O
while O
the O
condition B-outcome
of I-outcome
sleep I-outcome
in O
the O
control O
group O
was O
improved B-outcome
in O
13 B-cv-bin-abs
( O
39.4 B-cv-bin-percent
% I-cv-bin-percent
) O
and O
unchanged B-outcome
in O
20 B-cv-bin-abs
( O
60.6 B-cv-bin-percent
% I-cv-bin-percent
) O
, O
also O
with O
significant O
difference O
between O
the O
two O
groups O
( O
P O
= O
0.002 O
) O
. O
SLC O
is O
effective O
in O
alleviating O
tamoxifen O
- O
induced O
hot O
flashes O
and O
improving O
the O
condition O
of O
sleep O
. O

Analysis O
of O
cardiac O
and O
pulmonary O
complication O
probabilities O
after O
radiation B-intervention
therapy I-intervention
for O
patients O
with O
early O
- O
stage O
breast O
cancer O
. O
The O
purpose O
of O
this O
study O
was O
to O
evaluate O
the O
radiobiological O
implications O
of O
clinical O
use O
of O
respiratory O
- O
gated O
techniques O
for O
postoperative O
radiation O
therapy O
of O
early O
- O
stage O
left O
- O
sided O
breast O
cancer O
after O
breast O
- O
conserving O
surgery O
. O
Radiation O
therapy O
treatment O
plans O
of O
80 B-total-participants
patients B-eligibility
with I-eligibility
early I-eligibility
- I-eligibility
stage I-eligibility
breast I-eligibility
cancer I-eligibility
( I-eligibility
stage I-eligibility
I I-eligibility
- I-eligibility
II I-eligibility
) I-eligibility
, I-eligibility
receiving I-eligibility
whole I-eligibility
breast I-eligibility
irradiation I-eligibility
after I-eligibility
breast I-eligibility
- I-eligibility
conserving I-eligibility
therapy I-eligibility
, O
were O
analyzed O
. O
The O
control O
group O
consisting O
of O
47 B-control-participants
patients O
received O
standard B-control
radiation I-control
therapy I-control
, O
and O
the O
respiratory O
- O
gated O
group O
consisting O
of O
33 B-intervention-participants
patients O
received O
deep B-intervention
inspiration I-intervention
- I-intervention
gated I-intervention
radiation I-intervention
therapy I-intervention
. O
Normal O
tissue O
complication O
probabilities O
( O
NTCP O
) O
for O
cardiac O
mortality O
and O
for O
clinical O
radiation O
- O
induced O
pneumonitis O
were O
calculated O
for O
all O
patients O
included O
in O
present O
study O
, O
using O
relative O
seriality O
model O
. O
NTCP O
data O
were O
analyzed O
for O
113 O
radiation O
therapy O
plans O
, O
which O
included O
free O
breathing O
plans O
for O
the O
respiratory O
- O
gated O
groups O
. O
Pneumonitis B-outcome
probability I-outcome
was O
0.6 B-cv-bin-percent
% I-cv-bin-percent
( O
range O
0.0 O
- O
2.8 O
% O
) O
and O
0.3 B-iv-bin-percent
% I-iv-bin-percent
( O
0.0 O
- O
1.2 O
% O
) O
for O
control O
and O
respiratory O
- O
gated O
group O
, O
respectively O
. O
Cardiac B-outcome
mortality I-outcome
was O
1.3 B-cv-bin-percent
% I-cv-bin-percent
( O
0.0 O
- O
5.0 O
% O
) O
and O
0.2 B-iv-bin-percent
% I-iv-bin-percent
( O
0.0 O
- O
2.8 O
% O
) O
for O
control O
and O
respiratory O
- O
gated O
group O
, O
respectively O
. O
Using O
respiratory O
- O
gated O
radiation O
therapy O
, O
NTCP B-outcome
was O
reduced O
in O
comparison O
with O
the O
control O
group O
by O
83 B-cv-bin-percent
% I-cv-bin-percent
( O
P<0.00001 O
) O
and O
by O
55 B-iv-bin-percent
% I-iv-bin-percent
( O
P O
= O
0.01270 O
) O
for O
cardiac O
mortality O
and O
for O
clinical O
radiation O
- O
induced O
pneumonitis O
, O
respectively O
. O
Use O
of O
respiratory O
- O
gated O
radiation O
therapy O
, O
for O
postoperative O
treatment O
of O
early O
- O
stage O
breast O
cancer O
, O
significantly O
reduces O
excessive O
cardiac B-outcome
mortality I-outcome
probability O
and O
pulmonary B-outcome
complication I-outcome
probability O
, O
as O
compared O
to O
standard O
radiation O
therapy O
techniques O
. O
This O
is O
especially O
important O
from O
heart O
complication O
probability O
point O
of O
view O
, O
as O
cardiac O
mortality O
remains O
one O
of O
the O
important O
issues O
of O
postoperative O
breast O
irradiation O
in O
patients O
with O
early O
stage O
breast O
cancer O
. O

Prospective O
randomized O
trial O
of O
paravertebral B-intervention
block I-intervention
for O
patients O
undergoing O
breast O
cancer O
surgery O
. O
The O
goal O
of O
the O
current O
study O
was O
to O
evaluate O
the O
effect O
of O
regional O
anesthesia O
using O
paravertebral O
block O
( O
PVB O
) O
on O
postoperative O
pain O
after O
breast O
surgery O
. O
Patients B-eligibility
undergoing I-eligibility
unilateral I-eligibility
breast I-eligibility
surgery I-eligibility
without I-eligibility
reconstruction I-eligibility
were O
randomized O
to O
general B-control
anesthesia I-control
( I-control
GA I-control
) I-control
only I-control
or O
PVB O
with O
GA O
and O
pain O
scores O
assessed O
. O
Eighty B-total-participants
patients O
were O
randomized O
( O
41 B-intervention-participants
to O
GA O
and O
39 B-control-participants
to O
PVB O
with O
GA O
) O
. O
Operative O
times O
were O
not O
significantly O
different O
between O
groups O
. O
Pain B-outcome
scores I-outcome
were O
lower O
after O
PVB O
compared O
to O
GA O
at B-outcome
1 I-outcome
hour I-outcome
( O
1 B-iv-cont-mean
vs O
3 B-cv-cont-mean
, O
P O
= O
.006 O
) O
and O
3 B-outcome
hours I-outcome
( O
0 B-iv-cont-mean
vs O
2 B-cv-cont-mean
, O
P O
= O
.001 O
) O
but O
not O
at O
later O
time O
points O
. O
The O
overall B-outcome
worst I-outcome
pain I-outcome
experienced I-outcome
was O
lower O
with O
PVB O
( O
3 B-iv-cont-mean
vs O
5 B-cv-cont-mean
, O
P O
= O
.02 O
) O
. O
More O
patients O
were O
pain B-outcome
- I-outcome
free I-outcome
in O
the O
PVB O
group O
at B-outcome
1 I-outcome
hour I-outcome
( O
44 B-iv-bin-percent
% I-iv-bin-percent
vs O
17 B-cv-bin-percent
% I-cv-bin-percent
, O
P O
= O
.014 O
) O
and O
3 B-outcome
hours I-outcome
( O
54 B-iv-bin-percent
% I-iv-bin-percent
vs O
17 B-cv-bin-percent
% I-cv-bin-percent
, O
P O
= O
.005 O
) O
postoperatively O
. O
PVB O
significantly O
decreases O
postoperative O
pain O
up O
to O
3 O
hours O
after O
breast O
cancer O
surgery O
. O

Bone B-condition
fractures I-condition
among O
postmenopausal O
patients O
with O
endocrine O
- O
responsive O
early O
breast O
cancer O
treated O
with O
5 O
years O
of O
letrozole B-intervention
or O
tamoxifen B-control
in O
the O
BIG O
1 O
- O
98 O
trial O
. O
To O
compare O
the O
incidence O
and O
timing O
of O
bone O
fractures O
in O
postmenopausal B-eligibility
women I-eligibility
treated I-eligibility
with I-eligibility
5 I-eligibility
years I-eligibility
of I-eligibility
adjuvant I-eligibility
tamoxifen I-eligibility
or I-eligibility
letrozole I-eligibility
for I-eligibility
endocrine I-eligibility
- I-eligibility
responsive I-eligibility
early I-eligibility
breast I-eligibility
cancer I-eligibility
in O
the O
Breast O
International O
Group O
( O
BIG O
) O
1 O
- O
98 O
trial O
. O
We O
evaluated O
4895 B-total-participants
patients O
allocated O
to O
5 O
years O
of O
letrozole O
or O
tamoxifen O
in O
the O
BIG O
1 O
- O
98 O
trial O
who O
received O
at O
least O
some O
study O
medication O
( O
median O
follow O
- O
up O
60.3 O
months O
) O
. O
Bone O
fracture O
information O
( O
grade O
, O
cause O
, O
site O
) O
was O
collected O
every O
6 O
months O
during O
trial O
treatment O
. O
The O
incidence B-outcome
of I-outcome
bone I-outcome
fractures I-outcome
was O
higher O
among O
patients O
treated O
with O
letrozole O
[ O
228 B-iv-bin-abs
of O
2448 B-intervention-participants
women O
( O
9.3 B-iv-bin-percent
% I-iv-bin-percent
) O
] O
versus O
tamoxifen O
[ O
160 B-cv-bin-abs
of O
2447 B-control-participants
women O
( O
6.5 B-cv-bin-percent
% I-cv-bin-percent
) O
] O
. O
The O
wrist O
was O
the O
most O
common O
site O
of O
fracture B-outcome
in O
both O
treatment O
groups O
. O
Statistically O
significant O
risk O
factors O
for O
bone O
fractures O
during O
treatment O
included O
age O
, O
smoking O
history O
, O
osteoporosis O
at O
baseline O
, O
previous O
bone O
fracture O
, O
and O
previous O
hormone O
replacement O
therapy O
. O
Consistent O
with O
other O
trials O
comparing O
aromatase O
inhibitors O
to O
tamoxifen O
, O
letrozole O
was O
associated O
with O
an O
increase O
in O
bone O
fractures O
. O
Benefits O
of O
superior O
disease O
control O
associated O
with O
letrozole O
and O
lower O
incidence O
of O
fracture O
with O
tamoxifen O
should O
be O
considered O
with O
the O
risk O
profile O
for O
individual O
patients O
. O

Pentoxifylline B-intervention
and I-intervention
vitamin I-intervention
E I-intervention
treatment O
for O
prevention O
of O
radiation B-condition
- I-condition
induced I-condition
side I-condition
- I-condition
effects I-condition
in O
women B-eligibility
with I-eligibility
breast I-eligibility
cancer I-eligibility
: O
a O
phase O
two O
, O
double O
- O
blind O
, O
placebo O
- O
controlled O
randomised O
clinical O
trial O
( O
Ptx-5 O
) O
. O
A O
previous O
study O
has O
shown O
that O
pentoxifylline O
in O
combination O
with O
vitamin O
E O
can O
reverse O
radiation O
- O
induced O
fibrosis O
. O
The O
aim O
of O
the O
present O
study O
is O
to O
investigate O
if O
the O
same O
drugs O
could O
prevent O
radiation O
- O
induced O
side O
- O
effects O
in O
women O
with O
breast O
cancer O
. O
A O
randomised O
, O
placebo O
- O
controlled O
, O
double O
- O
blind O
, O
parallel O
group O
trial O
was O
performed O
. O
Women O
with O
breast O
cancer O
were O
treated O
for O
12 O
months O
with O
400 O
mg O
pentoxifylline O
t.i.d O
. O
or O
placebo B-control
, O
in O
combination O
with O
100 O
mg O
vitamin O
E O
t.i.d O
. O
, O
starting O
1 O
- O
3 O
months O
after O
the O
completion O
of O
radiotherapy O
. O
The O
primary O
end O
- O
point O
was O
passive B-outcome-measure
abduction I-outcome-measure
of I-outcome-measure
the I-outcome-measure
shoulder I-outcome-measure
, O
and O
the O
secondary O
end O
- O
point O
was O
difference B-outcome-measure
in I-outcome-measure
arm I-outcome-measure
volumes I-outcome-measure
. O
The O
trial O
is O
registered O
on O
the O
ISRCTN O
. O
org O
website O
, O
number O
ISRCTN39143623 O
. O
83 B-total-participants
patients O
were O
included O
in O
the O
study O
; O
42 B-intervention-participants
in O
the O
pentoxifylline+vitamin O
E O
group O
and O
41 B-control-participants
in O
the O
placebo+vitamin O
E O
group O
. O
Both O
treatments O
were O
generally O
well O
tolerated O
. O
Seven O
patients O
were O
withdrawn B-outcome
from I-outcome
the I-outcome
treatment I-outcome
due I-outcome
to I-outcome
disease I-outcome
progression I-outcome
; O
four B-iv-bin-abs
in O
the O
pentoxifylline O
group O
and O
three B-cv-bin-abs
in O
the O
placebo O
group O
. O
At O
inclusion O
, O
patients O
had O
impaired B-outcome
passive I-outcome
abduction I-outcome
of I-outcome
the I-outcome
shoulder I-outcome
. O
During O
treatment O
, O
both O
the O
groups O
improved O
significantly O
. O
Median B-outcome
improvement I-outcome
from O
baseline O
was O
3.7 B-iv-cont-median
degrees I-iv-cont-median
( O
p O
= O
0.0035 O
) O
on O
pentoxifylline O
and O
was O
9.4 B-cv-cont-median
degrees I-cv-cont-median
( O
p O
= O
0.0041 O
) O
in O
the O
placebo O
group O
, O
but O
no O
difference O
between O
the O
groups O
was O
detected O
( O
p O
= O
0.20 O
) O
. O
Arm B-outcome
volumes I-outcome
increased O
over O
time O
in O
the O
placebo O
group O
( O
1.04 B-iv-cont-median
% I-iv-cont-median
) O
, O
but O
not O
on O
pentoxifylline O
( O
0.50 B-cv-cont-median
% I-cv-cont-median
) O
, O
and O
differed O
significantly O
between O
the O
groups O
( O
p O
= O
0.0172 O
) O
. O
The O
combination O
of O
pentoxifylline O
and O
vitamin O
E O
was O
safe O
and O
may O
be O
used O
for O
the O
prevention O
of O
some O
radiation O
- O
induced O
side O
- O
effects O
. O

Phase O
II O
study O
of O
gemcitabine B-intervention
in I-intervention
combination I-intervention
with I-intervention
vinorelbine I-intervention
versus O
gemcitabine B-control
followed I-control
by I-control
vinorelbine I-control
for O
metastatic B-eligibility
breast I-eligibility
cancer I-eligibility
. O
No O
clear O
data O
are O
available O
concerning O
the O
superiority O
of O
combination O
chemotherapy O
to O
sequential O
therapy O
using O
agents O
beyond O
1st O
or O
2nd O
line O
chemotherapy O
for O
treating O
patients O
with O
metastatic O
breast O
cancer O
. O
Patients O
were O
randomized O
to O
receive O
a O
combination O
of O
gemcitabine O
and O
vinorelbine O
or O
gemcitabine O
until O
disease O
progression O
followed O
by O
vinorelbine O
monotherapy O
. O
Quality O
of O
life O
was O
assessed O
using O
EORTC O
QLQ O
- O
C30 O
questionnaires O
. O
Forty B-intervention-participants
- I-intervention-participants
two I-intervention-participants
patients O
were O
randomized O
to O
the O
combination O
arm O
and O
40 B-control-participants
were O
randomized O
to O
the O
sequential O
arm O
. O
Baseline O
characteristics O
were O
well O
balanced O
between O
the O
arms O
. O
The O
median B-outcome
number I-outcome
of I-outcome
chemotherapy I-outcome
cycles I-outcome
was O
4 B-iv-cont-median
( O
range O
, O
1 O
- O
23 O
) O
for O
the O
combination O
arm O
and O
6 B-cv-cont-median
( O
range O
, O
1 O
- O
25 O
) O
for O
the O
sequential O
arm O
. O
Patients O
receiving O
combination O
therapy O
had O
a O
higher O
composite B-outcome
response I-outcome
rate I-outcome
( O
26.8 B-iv-bin-percent
% I-iv-bin-percent
vs. O
12.5 B-cv-bin-percent
% I-cv-bin-percent
; O
P O
= O
0.106 O
) O
but O
a O
shorter O
median B-outcome
time I-outcome
to I-outcome
treatment I-outcome
failure I-outcome
( O
3.6 B-iv-cont-median
vs. O
4.4 B-cv-cont-median
months I-cv-cont-median
, O
P O
= O
0.252 O
) O
as O
compared O
to O
patients O
receiving O
sequential O
monotherapy O
. O
Median B-outcome
overall I-outcome
survival I-outcome
for O
the O
combination O
and O
sequential O
arms O
was O
10.6 B-iv-cont-median
months I-iv-cont-median
and O
8.9 B-cv-cont-median
months I-cv-cont-median
, O
respectively O
( O
P O
= O
0.436 O
) O
. O
Toxicities B-outcome
were O
manageable O
and O
similar O
in O
both O
arms O
. O
Quality B-outcome
of I-outcome
life I-outcome
measurements O
in O
global O
health O
, O
role O
, O
and O
social O
function O
were O
superior O
in O
the O
combination O
arm O
( O
P O
< O
0.05 O
) O
. O
Combined O
gemcitabine O
and O
vinorelbine O
therapy O
appears O
comparable O
to O
sequential O
monotherapy O
for O
heavily O
pretreated O
patients O
with O
metastatic O
breast O
cancer O
as O
demonstrated O
by O
improved O
quality O
of O
life O
outcomes O
with O
similar O
therapeutic O
efficacies O
and O
incidences O
of O
adverse O
events O
. O

An O
open O
- O
label O
, O
randomized O
phase O
II O
study O
of O
adecatumumab B-intervention
, O
a O
fully O
human O
anti O
- O
EpCAM O
antibody O
, O
as O
monotherapy O
in O
patients B-eligibility
with I-eligibility
metastatic I-eligibility
breast I-eligibility
cancer I-eligibility
. O
High O
- O
level O
expression O
of O
epithelial O
cell O
adhesion O
molecule O
( O
EpCAM O
) O
is O
associated O
with O
unfavorable O
prognosis O
in O
breast O
cancer O
. O
This O
study O
was O
designed O
to O
investigate O
two O
doses O
of O
the O
fully O
human O
IgG1 O
anti O
- O
EpCAM O
antibody O
adecatumumab O
( O
MT201 O
) O
in O
patients O
with O
metastatic O
breast O
cancer O
( O
MBC O
) O
. O
A O
total O
of O
109 B-total-participants
patients O
were O
stratified O
into O
high- O
and O
low O
- O
level O
EpCAM O
expression O
by O
immunohistochemical O
staining O
of O
primary O
tumors O
and O
subsequently O
randomly O
assigned O
to O
receive O
monotherapy O
with O
either O
high- O
( O
6 O
mg O
/ O
kg O
every O
two O
weeks O
( O
q2w O
) O
) O
or O
low O
- O
dose O
adecatumumab O
( O
2 O
mg O
/ O
kg/ O
q2w O
) O
until O
disease O
progression O
. O
No O
complete O
or O
partial O
tumor O
responses O
could O
be O
confirmed O
by O
central O
RECIST O
assessment O
. O
The O
probability O
for O
tumor B-outcome
progression I-outcome
was O
significantly O
lower O
in O
patients O
receiving O
high O
- O
dose O
adecatumumab O
and O
expressing O
high O
levels O
of O
EpCAM O
( O
hazard O
ratio O
0.43 O
; O
P O
= O
0.0057 O
versus O
low O
dose O
and O
low O
EpCAM O
) O
. O
Three B-iv-bin-abs
of O
18 B-intervention-participants
patients O
with O
highest O
EpCAM O
expression O
treated O
with O
adecatumumab O
developed O
new B-outcome
metastases I-outcome
up I-outcome
to I-outcome
week I-outcome
6 I-outcome
, O
compared O
with O
14 B-cv-bin-abs
of O
29 B-control-participants
patients O
with O
low O
EpCAM O
. O
Most O
frequent O
treatment O
- O
related O
adverse B-outcome
events I-outcome
( O
high O
dose O
/ O
low O
dose O
) O
were O
chills B-outcome
( O
59% B-iv-bin-percent
/ O
20 B-cv-bin-percent
% I-cv-bin-percent
) O
, O
nausea B-outcome
( O
55% B-iv-bin-percent
/ O
18 B-cv-bin-percent
% I-cv-bin-percent
) O
, O
fatigue B-outcome
( O
39% B-iv-bin-percent
/ O
23 B-cv-bin-percent
% I-cv-bin-percent
) O
and O
diarrhea B-outcome
( O
43% B-iv-bin-percent
/ O
7 B-cv-bin-percent
% I-cv-bin-percent
) O
. O
Single O
- O
agent O
adecatumumab O
shows O
dose- O
and O
target O
- O
dependent O
clinical O
activity O
in O
EpCAM O
- O
positive O
MBC O
, O
albeit O
no O
objective O
tumor O
regression O
. O
Further O
investigation O
of O
adecatumumab O
in O
patients O
with O
EpCAM O
- O
overexpressing O
tumors O
and O
lower O
tumor O
burden O
is O
warranted O
. O

Does O
preoperative B-intervention
core I-intervention
needle I-intervention
biopsy I-intervention
increase O
surgical O
site O
infections O
in O
breast O
cancer O
surgery O
? O
Randomized O
study O
of O
antibiotic O
prophylaxis O
. O
Preoperative O
core O
needle O
biopsies O
may O
increase O
the O
risk O
of O
surgical O
site O
infection O
( O
SSI O
) O
in O
breast O
cancer O
surgery O
. O
The O
purpose O
of O
this O
randomized O
trial O
was O
to O
determine O
whether O
a O
prophylactic O
antibiotic O
would O
prevent O
SSI O
under O
these O
conditions O
. O
Imaging O
- O
guided O
multiple O
core O
needle O
biopsies O
were O
performed O
one O
to O
two O
weeks O
prior O
to O
surgery O
to O
obtain O
confirmation O
of O
the O
presence O
of O
breast O
cancer O
. O
Then O
the O
patients O
were O
randomized O
to O
receive O
either O
a O
single O
intravenous O
dose O
of O
1.0 O
g O
of O
dicloxacillin O
( O
n O
= O
144 B-intervention-participants
) O
or O
placebo B-control
infusion I-control
of I-control
saline I-control
( O
n O
= O
148 B-control-participants
) O
30 O
min O
prior O
to O
operation O
. O
After O
breast O
surgery O
, O
incisional O
morbidity O
was O
monitored O
for O
30 O
days O
. O
The O
number O
of O
SSIs O
was O
compared O
with O
that O
in O
672 O
patients O
treated O
before O
the O
implementation O
of O
core O
needle O
biopsies O
. O
The O
patient O
characteristics O
and O
risk O
factors O
for O
SSI O
were O
similar O
in O
the O
antibiotic O
prophylaxis O
and O
placebo O
groups O
. O
The O
incidence B-outcome
of I-outcome
SSI I-outcome
was O
7.2 O
% O
( O
21 O
/ O
292 O
) O
in O
the O
prospective O
trial O
compared O
with O
6.8 O
% O
( O
46 O
/ O
672 O
) O
in O
the O
retrospective O
cohort O
( O
p O
= O
0.890 O
) O
. O
The O
incidence B-outcome
of I-outcome
postoperative I-outcome
SSIs I-outcome
was O
5.6 B-iv-bin-percent
% I-iv-bin-percent
( O
8 B-iv-bin-abs
/ O
144 B-intervention-participants
) O
in O
the O
dicloxacillin O
group O
and O
8.8 B-cv-bin-percent
% I-cv-bin-percent
( O
13 B-cv-bin-abs
/ O
148 B-control-participants
) O
in O
the O
placebo O
group O
( O
p O
= O
0.371 O
) O
. O
For O
the O
first O
two O
weeks O
, O
there O
was O
a O
non O
- O
significant O
trend O
to O
fewer O
SSIs B-outcome
in O
the O
antibiotic O
group O
( O
n O
= O
1 B-iv-bin-abs
) O
than O
the O
placebo O
group O
( O
n O
= O
4 B-cv-bin-abs
) O
. O
Body B-outcome
mass I-outcome
index I-outcome
, I-outcome
smoking I-outcome
, I-outcome
or I-outcome
previous I-outcome
illness I-outcome
did O
not O
affect O
the O
likelihood O
of O
SSI O
. O
Core O
needle O
biopsy O
did O
not O
increase O
the O
incidence B-outcome
of I-outcome
SSI I-outcome
. O
Antibiotic O
prophylaxis O
did O
not O
prevent O
SSI O
, O
probably O
because O
so O
few O
infections O
occurred O
. O

Patterns O
of O
HER2 B-intervention
testing I-intervention
in O
the O
management O
of O
primary O
breast O
cancer O
. O
Women O
with O
invasive O
breast O
cancer O
should O
be O
tested O
for O
human O
epidermal O
growth O
factor O
receptor-2 O
( O
HER2 O
) O
status O
at O
the O
time O
of O
diagnosis O
. O
To O
date O
, O
no O
population O
- O
based O
patterns O
of O
use O
studies O
have O
examined O
demographic O
and O
clinicopathologic O
factors O
associated O
with O
decisions O
by O
clinicians O
to O
test O
patients O
. O
We O
reviewed O
summary O
pathology O
reports O
submitted O
to O
the O
Connecticut B-location
Tumor O
Registry O
for O
all O
Black B-intervention
/ I-intervention
African I-intervention
American I-intervention
( O
B O
/ O
AA O
) O
women O
( O
n O
= O
644 B-intervention-participants
) O
and O
a O
7 O
% O
random O
sample O
( O
n O
= O
720 B-control-participants
) O
of O
White B-control
women B-eligibility
diagnosed I-eligibility
in I-eligibility
2000 I-eligibility
- I-eligibility
2003 I-eligibility
with I-eligibility
primary I-eligibility
invasive I-eligibility
breast I-eligibility
carcinoma I-eligibility
. O
Receipt O
of O
a O
HER2 O
test O
( O
yes O
vs. O
no O
) O
was O
examined O
in O
relation O
to O
patient O
race O
, O
age O
, O
socioeconomic O
status O
, O
year O
of O
diagnosis O
, O
estrogen O
receptor O
( O
ER O
) O
status O
, O
tumor O
grade O
, O
lymph O
node O
status O
, O
size O
and O
stage O
at O
diagnosis O
. O
A O
greater O
proportion O
of O
tumors O
from O
B O
/ O
AA O
patients O
were O
tested B-outcome
compared O
to O
those O
of O
White O
women O
( O
69.5 B-iv-bin-percent
% I-iv-bin-percent
vs. O
61.9 B-cv-bin-percent
% I-cv-bin-percent
, O
p<0.05 O
) O
. O
Tumors O
of O
patients O
under O
the O
age O
of O
60 O
were O
1.50 O
- O
times O
more O
likely O
than O
older O
women O
to O
have O
been O
tested O
, O
and O
B O
/ O
AA O
women O
were O
1.40 O
- O
times O
more O
likely O
than O
White O
patients O
to O
be O
tested O
. O
HER2 O
testing O
was O
more O
likely O
to O
be O
observed O
when O
information O
also O
was O
reported O
about O
ER B-outcome
status I-outcome
( O
OR O
= O
15.9 O
, O
p<0.001 O
) O
, O
tumor B-outcome
grade I-outcome
( O
OR O
= O
2.28 O
, O
p<0.05 O
) O
, O
tumor B-outcome
size I-outcome
( O
OR O
= O
2.16 O
, O
p<0.05 O
) O
, O
and O
lymph B-outcome
node I-outcome
status I-outcome
( O
OR O
= O
2.06 O
, O
p<0.05 O
) O
. O
Variation O
in O
which O
breast O
cancer O
patients O
received O
HER2 O
testing O
appears O
to O
reflect O
expectations O
about O
a O
woman O
's O
prognosis O
. O
Discrepancies O
in O
receipt O
of O
testing O
deserve O
further O
study O
as O
current O
guidelines O
call O
for O
all O
tumors O
to O
be O
assessed O
in O
order O
to O
adequately O
characterize O
prognosis O
and O
determine O
eligibility O
for O
HER2 O
- O
targeted O
therapy O
. O

Pegylated B-intervention
liposomal I-intervention
doxorubicin I-intervention
plus I-intervention
docetaxel I-intervention
significantly O
improves O
time O
to O
progression O
without O
additive O
cardiotoxicity O
compared O
with O
docetaxel O
monotherapy O
in O
patients O
with O
advanced O
breast O
cancer O
previously O
treated O
with O
neoadjuvant O
- O
adjuvant O
anthracycline O
therapy O
: O
results O
from O
a O
randomized O
phase O
III O
study O
. O
To O
determine O
whether O
the O
combination O
of O
pegylated O
liposomal O
doxorubicin O
( O
PLD O
) O
and O
docetaxel O
significantly O
prolongs O
time O
to O
disease O
progression O
compared O
with O
docetaxel O
alone O
without O
an O
increase O
in O
cardiac O
toxicity O
in O
women O
with O
advanced O
breast O
cancer O
who O
had O
experienced O
relapse O
at O
least O
1 O
year O
after O
prior O
adjuvant O
or O
neoadjuvant O
anthracycline O
therapy O
. O
This O
international O
, O
phase O
III O
study O
randomly O
assigned O
751 B-total-participants
patients O
to O
receive O
either O
docetaxel B-control
75 O
mg O
/ O
m O
( O
2 O
) O
( O
n O
= O
373 B-control-participants
) O
or O
PLD O
30 O
mg O
/ O
m O
( O
2 O
) O
followed O
by O
docetaxel O
60 O
mg O
/ O
m O
( O
2 O
) O
every O
21 O
days O
( O
n O
= O
378 B-intervention-participants
) O
and O
continued O
until O
disease O
progression O
or O
prohibitive O
toxicity O
. O
The O
primary O
end O
point O
was O
time B-outcome-measure
to I-outcome-measure
progression I-outcome-measure
( I-outcome-measure
TTP I-outcome-measure
) I-outcome-measure
. O
Secondary O
end O
points O
were O
overall B-outcome-measure
survival I-outcome-measure
( I-outcome-measure
OS I-outcome-measure
) I-outcome-measure
, O
objective B-outcome-measure
response I-outcome-measure
rate I-outcome-measure
( I-outcome-measure
ORR I-outcome-measure
) I-outcome-measure
, O
cardiac B-outcome-measure
toxicity I-outcome-measure
, O
and O
safety B-outcome-measure
. O
Treatment O
with O
PLD O
- O
docetaxel O
significantly O
improved O
median B-outcome
TTP I-outcome
from O
7.0 B-cv-cont-median
to O
9.8 B-iv-cont-median
months I-iv-cont-median
( O
hazard O
ratio O
[ O
HR O
] O
= O
0.65 O
; O
95 O
% O
CI O
, O
0.55 O
to O
0.77 O
; O
P O
= O
.000001 O
) O
and O
the O
ORR B-outcome
from O
26 B-cv-bin-percent
% I-cv-bin-percent
to O
35 B-iv-bin-percent
% I-iv-bin-percent
( O
P O
= O
.0085 O
) O
. O
OS B-outcome
was O
similar O
between O
the O
two O
groups O
( O
HR O
= O
1.02 O
; O
95 O
% O
CI O
, O
0.86 O
to O
1.22 O
) O
. O
The O
incidence O
of O
grade B-outcome
3 I-outcome
or I-outcome
4 I-outcome
adverse I-outcome
events I-outcome
were O
similar O
( O
78 B-iv-bin-percent
% I-iv-bin-percent
v O
72 B-cv-bin-percent
% I-cv-bin-percent
) O
, O
although O
a O
higher O
incidence O
of O
hand B-outcome
- I-outcome
foot I-outcome
syndrome I-outcome
( O
24 B-iv-bin-percent
% I-iv-bin-percent
v O
0 B-cv-bin-percent
% I-cv-bin-percent
) O
and O
mucositis B-outcome
/ I-outcome
stomatitis I-outcome
( O
12 B-iv-bin-percent
% I-iv-bin-percent
v O
1 B-cv-bin-percent
% I-cv-bin-percent
) O
were O
observed O
in O
the O
PLD O
- O
docetaxel O
combination O
. O
Protocol O
- O
defined O
left B-outcome
ventricular I-outcome
ejection I-outcome
fraction I-outcome
decreases I-outcome
and I-outcome
congestive I-outcome
heart I-outcome
failure I-outcome
were O
reported O
in O
5 B-iv-bin-percent
% I-iv-bin-percent
and O
1 B-cv-bin-percent
% I-cv-bin-percent
in O
both O
treatment O
arms O
, O
respectively O
. O
The O
PLD O
- O
docetaxel O
combination O
was O
more O
effective O
than O
docetaxel O
alone O
in O
women O
with O
metastatic O
breast O
cancer O
who O
had O
experienced O
relapse O
at O
least O
1 O
year O
after O
prior O
adjuvant O
anthracycline O
therapy O
without O
an O
increase O
in O
cardiac O
toxicity O
, O
although O
mucocutaneous O
toxicity O
was O
more O
common O
. O

Vasomotor O
symptoms O
, O
adoption O
of O
a O
low B-intervention
- I-intervention
fat I-intervention
dietary I-intervention
pattern I-intervention
, O
and O
risk O
of O
invasive O
breast O
cancer O
: O
a O
secondary O
analysis O
of O
the O
Women O
's O
Health O
Initiative O
randomized O
controlled O
dietary O
modification O
trial O
. O
To O
assess O
whether O
the O
effect O
of O
a O
low O
- O
fat O
dietary O
pattern O
on O
breast O
cancer O
incidence O
varied O
by O
report O
of O
baseline O
vasomotor O
symptoms O
. O
Postmenopausal O
women O
age O
50 B-age
to I-age
79 I-age
years I-age
enrolled O
onto O
the O
Women O
's O
Health O
Initiative O
( O
WHI O
) O
Dietary O
Modification O
trial O
from O
1993 O
to O
1998 O
were O
randomly O
assigned O
to O
a O
low O
- O
fat O
dietary O
intervention O
( O
n O
= O
19,541 B-intervention-participants
) O
or O
comparison B-control
( O
n O
= O
29,294 B-control-participants
) O
. O
Presence O
of O
vasomotor O
symptoms O
at O
baseline O
was O
ascertained O
from O
a O
34 O
- O
item O
self O
- O
report O
symptom O
inventory O
. O
Women O
were O
queried O
semi O
- O
annually O
for O
a O
new O
diagnosis O
of O
breast O
cancer O
. O
Each O
case O
report O
was O
verified O
by O
medical O
record O
and O
pathology O
report O
review O
by O
centrally O
trained O
WHI O
physician O
adjudicators O
. O
Among O
participants O
who O
reported O
hot O
flashes O
( O
HFs O
) O
at O
baseline O
( O
n O
= O
3,375 O
) O
, O
those O
assigned O
to O
the O
low O
- O
fat O
diet O
had O
a O
breast B-outcome
cancer I-outcome
rate I-outcome
of O
0.27 B-iv-bin-percent
compared O
with O
their O
counterparts O
in O
the O
control O
group O
who O
had O
a O
rate O
of O
0.41 B-cv-bin-percent
( O
hazard O
ratio O
[ O
HR O
] O
= O
0.65 O
; O
95 O
% O
CI O
, O
0.42 O
to O
1.01 O
) O
. O
Among O
women O
reporting O
no O
HFs O
( O
n O
= O
45,160 O
) O
, O
the O
breast B-outcome
cancer I-outcome
rate I-outcome
was O
0.42 B-iv-bin-percent
in O
those O
assigned O
to O
the O
low O
- O
fat O
diet O
compared O
with O
0.46 B-cv-bin-percent
in O
the O
control O
group O
( O
HR O
= O
0.93 O
; O
95 O
% O
CI O
, O
0.84 O
to O
1.03 O
; O
P O
for O
interaction O
= O
.12 O
by O
HF O
status O
) O
. O
Furthermore O
, O
the O
dietary O
benefits O
observed O
seemed O
to O
be O
specific O
to O
estrogen O
receptor O
( O
ER O
) O
-positive O
/ O
progesterone O
receptor O
( O
PR O
) O
-positive O
tumors O
( O
ER O
positive O
/ O
PR O
positive O
v O
other O
, O
P O
for O
risk O
= O
.03 O
) O
. O
Although O
women O
with O
and O
without O
HFs O
differed O
with O
regard O
to O
breast O
cancer O
risk O
factors O
, O
the O
effect O
of O
the O
diet O
intervention O
on O
breast B-outcome
cancer I-outcome
incidence I-outcome
by O
HF O
status O
was O
consistent O
across O
risk O
factor O
strata O
. O
The O
results O
of O
this O
trial O
, O
which O
are O
hypothesis O
generating O
, O
suggest O
that O
HFs O
may O
identify O
a O
subgroup O
of O
postmenopausal O
women O
whose O
risk O
of O
invasive O
breast O
cancer O
might O
be O
reduced O
with O
the O
adoption O
of O
a O
low O
- O
fat O
eating O
pattern O
. O

Activity O
of O
fulvestrant B-intervention
500 O
mg O
versus O
anastrozole B-control
1 O
mg O
as O
first O
- O
line O
treatment O
for O
advanced O
breast O
cancer O
: O
results O
from O
the O
FIRST O
study O
. O
To O
compare O
the O
clinical O
activity O
of O
the O
pure O
antiestrogen O
fulvestrant O
at O
500 O
mg O
/ O
mo O
( O
double O
the O
approved O
dose O
) O
with O
the O
aromatase O
inhibitor O
anastrozole O
as O
first O
- O
line O
endocrine O
therapy O
for O
advanced B-eligibility
hormone I-eligibility
receptor I-eligibility
- I-eligibility
positive I-eligibility
breast I-eligibility
cancer I-eligibility
in I-eligibility
postmenopausal I-eligibility
women I-eligibility
. O
FIRST O
( O
Fulvestrant O
First O
- O
Line O
Study O
Comparing O
Endocrine O
Treatments O
) O
is O
a O
phase O
II O
, O
randomized O
, O
open O
- O
label O
, O
multicenter O
study O
of O
a O
fulvestrant O
high O
- O
dose O
( O
HD O
) O
regimen O
( O
500 O
mg O
/ O
mo O
plus O
500 O
mg O
on O
day O
14 O
of O
month O
1 O
) O
versus O
anastrozole O
( O
1 O
mg O
/ O
d O
) O
. O
The O
primary O
efficacy O
end O
point O
was O
clinical B-outcome-measure
benefit I-outcome-measure
rate I-outcome-measure
( I-outcome-measure
CBR I-outcome-measure
) I-outcome-measure
, O
defined O
as O
the O
proportion O
of O
patients O
experiencing O
an O
objective O
response O
( O
OR O
) O
or O
stable O
disease O
for O
> O
or O
= O
24 O
weeks O
. O
The O
primary O
analysis O
was O
performed O
6 O
months O
after O
the O
last O
patient O
was O
randomly O
assigned O
. O
CBR B-outcome
was O
similar O
for O
fulvestrant O
HD O
( O
n O
= O
102 B-iv-bin-abs
) O
and O
anastrozole O
( O
n O
= O
103 B-cv-bin-abs
) O
, O
72.5 B-iv-bin-percent
% I-iv-bin-percent
v O
67.0 B-cv-bin-percent
% I-cv-bin-percent
, O
respectively O
( O
odds O
ratio O
, O
1.30 O
; O
95 O
% O
CI O
, O
0.72 O
to O
2.38 O
; O
P O
= O
.386 O
) O
. O
Objective B-outcome
response I-outcome
rate I-outcome
( I-outcome
ORR I-outcome
) I-outcome
was O
also O
similar O
between O
treatments O
: O
fulvestrant O
HD O
, O
36.0 B-iv-bin-percent
% I-iv-bin-percent
; O
anastrozole O
, O
35.5 B-cv-bin-percent
% I-cv-bin-percent
. O
Time B-outcome
to I-outcome
progression I-outcome
( I-outcome
TTP I-outcome
) I-outcome
was O
significantly O
longer O
for O
fulvestrant O
versus O
anastrozole O
( O
median O
TTP O
not B-iv-cont-median
reached I-iv-cont-median
for O
fulvestrant O
HD O
v O
12.5 B-cv-cont-median
months I-cv-cont-median
for O
anastrozole O
; O
hazard O
ratio O
, O
0.63 O
; O
95 O
% O
CI O
, O
0.39 O
to O
1.00 O
; O
P O
= O
.0496 O
) O
. O
Duration B-outcome
of I-outcome
OR I-outcome
and I-outcome
CB I-outcome
also O
numerically O
favored O
fulvestrant O
HD O
. O
Both O
treatments O
were O
well B-outcome
tolerated I-outcome
, O
with O
no O
significant O
differences O
in O
the O
incidence O
of O
prespecified O
adverse B-outcome
events I-outcome
. O
First O
- O
line O
fulvestrant O
HD O
was O
at O
least O
as O
effective O
as O
anastrozole O
for O
CBR O
and O
ORR O
and O
was O
associated O
with O
significantly O
longer O
TTP O
. O
Fulvestrant O
HD O
was O
generally O
well O
tolerated O
, O
with O
a O
safety O
profile O
similar O
to O
that O
of O
anastrozole O
. O

The O
effect O
of O
body O
mass O
index O
on O
overall O
and O
disease O
- O
free O
survival O
  O
in O
node B-eligibility
- I-eligibility
positive I-eligibility
breast I-eligibility
cancer I-eligibility
patients I-eligibility
treated I-eligibility
with I-eligibility
docetaxel I-eligibility
  I-eligibility
and I-eligibility
doxorubicin I-eligibility
- I-eligibility
containing I-eligibility
adjuvant I-eligibility
chemotherapy I-eligibility
: O
  O
the O
experience O
of O
the O
BIG O
02 O
- O
98 O
trial O
. O
Obesity O
has O
been O
shown O
to O
be O
an O
indicator O
of O
poor O
prognosis O
for O
patients O
with O
primary O
breast O
cancer O
( O
BC O
) O
regardless O
of O
the O
use O
of O
adjuvant O
systemic O
therapy O
. O
This O
is O
a O
retrospective O
analysis O
of O
2,887 B-total-participants
node O
- O
positive O
BC O
patients O
enrolled O
in O
the O
BIG O
02 O
- O
98 O
adjuvant O
study O
, O
a O
randomised O
phase O
III O
trial O
whose O
primary O
objective O
was O
to O
evaluate O
disease O
- O
free O
survival O
( O
DFS O
) O
by O
adding O
docetaxel O
to O
doxorubicin O
- O
based O
chemotherapy O
. O
In O
the O
current O
analysis O
, O
the O
effect O
of O
body O
mass O
index O
( O
BMI O
) O
on O
DFS O
and O
overall O
survival O
( O
OS O
) O
was O
assessed O
. O
BMI O
was O
obtained O
before O
the O
first O
cycle O
of O
chemotherapy O
. O
Obesity O
was O
defined O
as O
a O
BMI O
> O
or O
= O
30 O
kg O
/ O
m2 O
. O
In O
total O
, O
547 B-intervention-participants
( O
19 O
% O
) O
patients O
were O
obese B-intervention
at O
baseline O
, O
while O
2,340 B-control-participants
( O
81 O
% O
) O
patients O
were O
non B-control
- I-control
obese I-control
. O
Estimated O
5 B-outcome
- I-outcome
year I-outcome
OS I-outcome
was O
87.5 B-cv-bin-percent
% I-cv-bin-percent
for O
non O
- O
obese O
and O
82.9 B-iv-bin-percent
% I-iv-bin-percent
for O
obese O
patients O
( O
HR O
1.34 O
; O
P O
= O
0.013 O
) O
. O
Estimated O
5 B-outcome
- I-outcome
years I-outcome
DFS I-outcome
was O
75.9 B-cv-bin-percent
% I-cv-bin-percent
for O
nonobese O
and O
70.0 B-iv-bin-percent
% I-iv-bin-percent
for O
obese O
patients O
( O
HR O
1.20 O
; O
P O
= O
0.041 O
) O
. O
Ina O
multivariate O
model O
, O
obesity O
remained O
an O
independent O
prognostic O
factor O
for O
OS O
and O
DFS O
. O
In O
this O
study O
, O
obesity O
was O
associated O
with O
poorer O
outcome O
in O
node O
- O
positive O
BC O
patients O
. O
Given O
the O
increasing O
prevalence O
of O
obesity O
worldwide O
, O
more O
research O
on O
improving O
the O
treatment O
of O
obese O
BC O
patients O
is O
needed O
. O

Radioguided B-intervention
localization I-intervention
of O
nonpalpable O
breast O
cancer O
lesions O
: O
randomized O
comparison O
with O
wire O
localization O
in O
patients B-eligibility
undergoing I-eligibility
conservative I-eligibility
surgery I-eligibility
and I-eligibility
sentinel I-eligibility
node I-eligibility
biopsy I-eligibility
. O
The O
aim O
of O
this O
investigation O
was O
to O
determine O
whether O
radioguided O
occult O
lesion O
localization O
and O
routine O
wire O
localization O
differ O
in O
respect O
to O
the O
effectiveness O
of O
complete O
excision O
of O
nonpalpable O
breast O
cancer O
lesions O
. O
This O
prospective O
randomized O
study O
included O
patients O
with O
breast O
cancer O
scheduled O
for O
conservative O
tumor O
excision O
and O
sentinel O
node O
biopsy O
. O
Patients O
were O
randomized O
to O
either O
radioguided O
localization O
or O
wire B-control
localization I-control
. O
Comparative O
radiologic O
, O
surgical O
, O
and O
pathologic O
data O
were O
collected O
and O
analyzed O
to O
establish O
the O
duration O
, O
ease O
of O
use O
, O
and O
accuracy O
of O
the O
two O
techniques O
for O
occult O
lesion O
localization O
. O
The O
effectiveness O
of O
sentinel O
node O
biopsy O
also O
was O
assessed O
. O
One O
radiologist O
and O
two O
surgeons O
participated O
in O
the O
study O
. O
Among O
134 B-total-participants
patients O
, O
68 B-control-participants
were O
treated O
with O
wire O
localization O
and O
66 B-intervention-participants
with O
radioguided O
localization O
. O
The O
mean O
duration O
of O
radiologic O
localization O
was O
significantly O
shorter O
for O
radioguided O
localization O
( O
p O
< O
0.001 O
) O
. O
No O
statistical O
differences O
were O
found O
for O
the O
other O
parameters O
studied O
. O
Radiography O
of O
the O
surgical O
specimen O
showed O
100 O
% O
lesion O
excision O
with O
both O
techniques O
. O
Complete B-outcome
tumor I-outcome
excision I-outcome
with O
tumor O
- O
free O
margins O
was O
achieved O
in O
89.4 B-iv-bin-percent
% I-iv-bin-percent
of O
patients O
who O
underwent O
radioguided O
localization O
group O
and O
82.4 B-cv-bin-percent
% I-cv-bin-percent
of O
patients O
who O
underwent O
wire O
localization O
. O
Pathologic O
examination O
showed O
the O
excised B-outcome
tissue I-outcome
volume I-outcome
was O
slightly O
larger O
( O
p O
= O
0.371 O
) O
and O
lesion B-outcome
concentricity I-outcome
slightly O
less O
( O
p O
= O
0.730 O
) O
with O
radioguided O
localization O
. O
The O
sentinel B-outcome
node I-outcome
detection I-outcome
rate I-outcome
was O
91 B-iv-bin-percent
% I-iv-bin-percent
with O
radioguided O
localization O
and O
84 B-cv-bin-percent
% I-cv-bin-percent
with O
wire O
localization O
. O
The O
radioguided O
technique O
is O
as O
effective O
as O
the O
standard O
wire O
technique O
for O
localization O
and O
excision O
of O
nonpalpable O
breast O
cancer O
lesions O
and O
is O
somewhat O
faster O
and O
simpler O
to O
perform O
than O
wire O
localization O
. O

Effect O
of O
anaesthetic B-intervention
technique I-intervention
on O
oestrogen B-eligibility
receptor I-eligibility
- I-eligibility
negative I-eligibility
breast I-eligibility
cancer I-eligibility
cell I-eligibility
function I-eligibility
in I-eligibility
vitro I-eligibility
. O
Metastatic O
recurrence O
is O
the O
main O
cause O
of O
breast O
cancer O
- O
related O
deaths O
. O
Tumour O
cell O
proliferation O
and O
migration O
are O
crucial O
steps O
in O
the O
metastatic O
process O
. O
Several O
perioperative O
factors O
, O
including O
general O
anaesthesia O
and O
opioid O
analgesia O
, O
adversely O
affect O
immune O
function O
, O
potentially O
increasing O
metastatic O
recurrence O
. O
Regional O
anaesthesia O
- O
analgesia O
has O
been O
consistently O
shown O
to O
attenuate O
the O
stress O
response O
to O
surgery O
, O
and O
also O
reduce O
opioid O
and O
general O
anaesthesia O
requirements O
, O
thereby O
attenuating O
this O
perioperative O
immunosuppression O
. O
We O
investigated O
the O
effect O
of O
serum O
from O
breast O
cancer O
surgery O
patients O
who O
received O
different O
anaesthetic O
techniques O
on O
breast O
cancer O
cell O
function O
in O
vitro O
. O
Patients O
were O
randomized O
to O
receive O
propofol B-intervention
/ I-intervention
paravertebral I-intervention
anaesthesia I-intervention
- I-intervention
analgesia I-intervention
( O
propofol O
/ O
paravertebral O
, O
n O
= O
11 B-intervention-participants
) O
or O
sevoflurane B-control
general I-control
anaesthesia I-control
with O
opioid O
analgesia O
( O
sevoflurane O
/ O
opioid O
, O
n O
= O
11 B-control-participants
) O
. O
The O
ER O
- O
negative O
MDA O
- O
MB-231 O
cell O
line O
was O
treated O
with O
patient O
serum O
from O
both O
groups O
. O
The O
effects O
on O
proliferation O
and O
migration O
were O
measured O
. O
Treatment O
groups O
were O
well O
balanced O
for O
age O
, O
weight O
, O
surgical O
procedure O
, O
and O
cancer O
pathology O
. O
Pain B-outcome
scores I-outcome
were O
lower O
at B-outcome
1 I-outcome
and I-outcome
2 I-outcome
h I-outcome
in O
the O
propofol O
/ O
paravertebral O
analgesia O
group O
. O
Compared O
with O
preoperative O
values O
, O
proliferation B-outcome
of I-outcome
MDA I-outcome
- I-outcome
MB-231 I-outcome
cells I-outcome
treated I-outcome
with O
postoperative O
patient O
serum O
at O
10 O
% O
concentration O
from O
the O
propofol O
/ O
paravertebral O
group O
was O
significantly O
reduced O
compared O
with O
the O
sevoflurane O
/ O
opioid O
group O
( O
-24 O
% O
vs O
73 O
% O
, O
P O
= O
0.01 O
) O
. O
There O
was O
no O
significant O
change B-outcome
in I-outcome
MDA I-outcome
- I-outcome
MB-231 I-outcome
cell I-outcome
migration I-outcome
after I-outcome
treatment I-outcome
with O
patient O
serum O
between O
the O
two O
groups O
. O
Serum O
from O
patients O
receiving O
propofol O
/ O
paravertebral O
anaesthesia O
for O
breast O
cancer O
surgery O
inhibited O
proliferation O
, O
but O
not O
migration O
, O
of O
ER O
- O
MDA O
- O
MB-231 O
cells O
in O
vitro O
, O
to O
a O
greater O
extent O
than O
that O
from O
patients O
receiving O
sevoflurane O
/ O
opioid O
anaesthesia O
- O
analgesia O
. O
This O
implies O
that O
anaesthetic O
technique O
alters O
the O
serum O
molecular O
milieu O
in O
ways O
that O
may O
affect O
breast O
cancer O
cell O
function O
, O
possibly O
by O
altering O
anaesthetic O
and O
opioid O
drug O
administration O
and O
resultant O
pain O
scores O
. O

Trastuzumab B-intervention
plus I-intervention
anastrozole I-intervention
versus O
anastrozole B-control
alone I-control
for O
the O
treatment O
of O
postmenopausal O
women O
with O
human O
epidermal O
growth O
factor O
receptor O
2 O
- O
positive O
, O
hormone O
receptor O
- O
positive O
metastatic O
breast O
cancer O
: O
results O
from O
the O
randomized O
phase O
III O
TAnDEM O
study O
. O
TAnDEM O
is O
the O
first O
randomized O
phase O
III O
study O
to O
combine O
a O
hormonal O
agent O
and O
trastuzumab O
without O
chemotherapy O
as O
treatment O
for O
human O
epidermal O
growth O
factor O
receptor O
2 O
( O
HER2 O
) O
/hormone O
receptor O
- O
copositive O
metastatic O
breast O
cancer O
( O
MBC O
) O
. O
Postmenopausal B-eligibility
women I-eligibility
with I-eligibility
HER2 I-eligibility
/ I-eligibility
hormone I-eligibility
receptor I-eligibility
- I-eligibility
copositive I-eligibility
MBC I-eligibility
were O
randomly O
assigned O
to O
anastrozole O
( O
1 O
mg O
/ O
d O
orally O
) O
with O
or O
without O
trastuzumab O
( O
4 O
mg O
/ O
kg O
intravenous O
infusion O
on O
day O
1 O
, O
then O
2 O
mg O
/ O
kg O
every O
week O
) O
until O
progression O
. O
The O
primary O
end O
point O
was O
progression B-outcome-measure
- I-outcome-measure
free I-outcome-measure
survival I-outcome-measure
( I-outcome-measure
PFS I-outcome-measure
) I-outcome-measure
in O
the O
intent O
- O
to O
- O
treat O
population O
. O
Results O
Overall O
, O
103 B-intervention-participants
patients O
received O
trastuzumab O
plus O
anastrozole O
; O
104 B-control-participants
received O
anastrozole O
alone O
. O
Patients O
in O
the O
trastuzumab O
plus O
anastrozole O
arm O
experienced O
significant O
improvements O
in O
PFS B-outcome
compared O
with O
patients O
receiving O
anastrozole O
alone O
( O
hazard O
ratio O
= O
0.63 O
; O
95 O
% O
CI O
, O
0.47 O
to O
0.84 O
; O
median B-outcome
PFS I-outcome
, O
4.8 B-iv-cont-median
v O
2.4 B-cv-cont-median
months I-cv-cont-median
; O
log O
- O
rank O
P O
= O
.0016 O
) O
. O
In O
patients B-outcome
with I-outcome
centrally I-outcome
confirmed I-outcome
hormone I-outcome
receptor I-outcome
positivity I-outcome
( O
n O
= O
150 O
) O
, O
median B-outcome
PFS I-outcome
was O
5.6 B-iv-cont-median
and O
3.8 B-cv-cont-median
months I-cv-cont-median
in O
the O
trastuzumab O
plus O
anastrozole O
and O
anastrozole O
alone O
arms O
, O
respectively O
( O
log O
- O
rank O
P O
= O
.006 O
) O
. O
Overall B-outcome
survival I-outcome
in O
the O
overall O
and O
centrally O
confirmed O
hormone O
receptor O
- O
positive O
populations O
showed O
no O
statistically O
significant O
treatment O
difference O
; O
however O
, O
70 O
% O
of O
patients O
in O
the O
anastrozole O
alone O
arm O
crossed O
over O
to O
receive O
trastuzumab O
after O
progression O
on O
anastrozole O
alone O
. O
Incidence B-outcome
of I-outcome
grade I-outcome
3 I-outcome
and I-outcome
4 I-outcome
adverse I-outcome
events I-outcome
was O
23 B-iv-bin-percent
% I-iv-bin-percent
and O
5 B-iv-bin-percent
% I-iv-bin-percent
, O
respectively O
, O
in O
the O
trastuzumab O
plus O
anastrozole O
arm O
, O
and O
15 B-cv-bin-percent
% I-cv-bin-percent
and O
1 B-cv-bin-percent
% I-cv-bin-percent
, O
respectively O
, O
in O
the O
anastrozole O
alone O
arm O
; O
one B-iv-bin-abs
patient O
in O
the O
combination O
arm O
experienced O
New O
York O
Heart O
Association O
class O
II O
congestive B-outcome
heart I-outcome
failure I-outcome
. O
Trastuzumab O
plus O
anastrozole O
improves O
outcomes O
for O
patients O
with O
HER2 O
/ O
hormone O
receptor O
- O
copositive O
MBC O
compared O
with O
anastrozole O
alone O
, O
although O
adverse O
events O
and O
serious O
adverse O
events O
were O
more O
frequent O
with O
the O
combination O
. O

New O
- O
onset O
breast O
tenderness O
after O
initiation O
of O
estrogen B-intervention
plus I-intervention
progestin I-intervention
therapy I-intervention
and O
breast O
cancer O
risk O
. O
Estrogen O
plus O
progestin O
therapy O
increases O
breast O
cancer O
incidence O
and O
breast O
tenderness O
. O
Whether O
breast O
tenderness O
during O
estrogen O
plus O
progestin O
therapy O
is O
associated O
with O
breast O
cancer O
risk O
is O
uncertain O
. O
We O
analyzed O
data O
from O
the O
Women O
's O
Health O
Initiative O
Estrogen O
+ O
Progestin O
Trial O
, O
which O
randomized O
postmenopausal B-eligibility
women I-eligibility
with I-eligibility
an I-eligibility
intact I-eligibility
uterus I-eligibility
to O
receive O
daily O
conjugated O
equine O
estrogens O
, O
0.625 O
mg O
, O
plus O
medroxyprogesterone O
acetate O
, O
2.5 O
mg O
( O
n O
= O
8506 B-intervention-participants
) O
, O
or O
placebo B-control
( O
n O
= O
8102 B-control-participants
) O
. O
At O
baseline O
and O
annually O
, O
participants O
underwent O
mammography O
and O
clinical O
breast O
examination O
. O
Self O
- O
reported O
breast O
tenderness O
was O
assessed O
at O
baseline O
and O
at O
12 O
months O
. O
The O
incidence B-outcome
of I-outcome
invasive I-outcome
breast I-outcome
cancer I-outcome
was O
confirmed O
by O
medical O
record O
review O
( O
mean O
follow O
- O
up O
of O
5.6 O
years O
) O
. O
Of O
women O
without O
baseline O
breast O
tenderness O
( O
n O
= O
14,538 O
) O
, O
significantly O
more O
assigned O
to O
receive O
conjugated O
equine O
estrogens O
plus O
medroxyprogesterone O
vs O
placebo O
experienced O
new B-outcome
- I-outcome
onset I-outcome
breast I-outcome
tenderness I-outcome
after I-outcome
12 I-outcome
months I-outcome
( O
36.1 B-iv-bin-percent
% I-iv-bin-percent
vs O
11.8 B-cv-bin-percent
% I-cv-bin-percent
, O
P O
< O
.001 O
) O
. O
Of O
women O
in O
the O
conjugated O
equine O
estrogens O
plus O
medroxyprogesterone O
group O
, O
breast B-outcome
cancer I-outcome
risk I-outcome
was O
significantly O
higher O
in O
those O
with O
new O
- O
onset O
breast O
tenderness O
compared O
with O
those O
without O
( O
hazard O
ratio O
, O
1.48 O
; O
95 O
% O
confidence O
interval O
, O
1.08 O
- O
2.03 O
; O
P O
= O
.02 O
) O
. O
In O
the O
placebo O
group O
, O
breast O
cancer O
risk O
was O
not O
significantly O
associated O
with O
new B-outcome
- I-outcome
onset I-outcome
breast I-outcome
tenderness I-outcome
( O
P O
= O
.97 O
) O
. O
New O
- O
onset O
breast O
tenderness O
during O
conjugated O
equine O
estrogens O
plus O
medroxyprogesterone O
therapy O
was O
associated O
with O
increased O
breast O
cancer O
risk O
. O
The O
sensitivity O
and O
specificity O
of O
the O
association O
between O
breast O
tenderness O
and O
breast O
cancer O
were O
similar O
in O
magnitude O
to O
those O
of O
the O
Gail O
model O
. O
Trial O
Registration O
clinicaltrials O
. O
gov O
Identifier O
: O
NCT00000611 O
. O

Dose B-intervention
- I-intervention
intensified I-intervention
epirubicin I-intervention
versus O
standard B-control
- I-control
dose I-control
epirubicin I-control
/ I-control
cyclophosphamide I-control
followed O
by O
CMF O
in O
breast B-eligibility
cancer I-eligibility
patients I-eligibility
with I-eligibility
10 I-eligibility
or I-eligibility
more I-eligibility
positive I-eligibility
lymph I-eligibility
nodes I-eligibility
: O
results O
of O
a O
randomised O
trial O
( O
GABG O
- O
IV O
E-93 O
) O
- O
the O
German O
Adjuvant O
Breast O
Cancer O
Group O
. O
To O
compare O
dose O
- O
intensified O
epirubicin O
monotherapy O
with O
a O
standard O
sequential O
regimen O
, O
patients O
with O
primary O
breast O
cancer O
and O
> O
or O
= O
10 O
involved O
axillary O
nodes O
were O
randomised O
to O
either O
four O
21 O
- O
day O
cycles O
of O
epirubicin O
120 O
mg O
/ O
m O
( O
2 O
) O
( O
E120 O
; O
n O
= O
202 B-intervention-participants
) O
or O
four O
21 O
- O
day O
cycles O
of O
epirubicin O
90 O
mg O
/ O
m O
( O
2 O
) O
plus O
cyclophosphamide O
600 O
mg O
/ O
m O
( O
2 O
) O
( O
EC O
) O
followed O
by O
three O
28 O
- O
day O
cycles O
of O
cyclophosphamide O
, O
methotrexate O
and O
5 O
- O
fluorouracil O
( O
CMF O
; O
n O
= O
209 B-control-participants
) O
. O
Simultaneous O
hormonal O
treatment O
was O
applied O
in O
both O
arms O
. O
At O
5 O
years O
' O
median O
follow O
- O
up O
, O
the O
5 B-outcome
- I-outcome
year I-outcome
event I-outcome
- I-outcome
free I-outcome
survival I-outcome
( I-outcome
EFS I-outcome
) I-outcome
rates I-outcome
were O
47.7 B-iv-bin-percent
% I-iv-bin-percent
( O
95 O
% O
confidence O
interval O
[ O
CI O
] O
, O
40.2 O
- O
55.2 O
% O
) O
for O
E120 O
and O
45.9 B-cv-bin-percent
% I-cv-bin-percent
( O
38.5 O
- O
53.3 O
% O
) O
for O
EC O
- O
CMF O
. O
E120 O
was O
as O
effective O
as O
EC O
- O
CMF O
with O
regard O
to O
EFS B-outcome
( O
hazard O
ratio O
[ O
HR O
] O
for O
E120 O
versus O
EC O
- O
CMF O
1.04 O
; O
95 O
% O
CI O
, O
0.79 O
- O
1.36 O
; O
p O
= O
0.79 O
) O
and O
overall B-outcome
survival I-outcome
( O
HR O
1.06 O
; O
95 O
% O
CI O
0.77 O
- O
1.46 O
; O
p O
= O
0.72 O
) O
. O
The O
data O
demonstrate O
that O
4 O
cycles O
of O
dose O
- O
intensified O
epirubicin O
monotherapy O
can O
be O
as O
effective O
as O
7 O
cycles O
of O
standard O
sequential O
polychemotherapy O
in O
high O
- O
risk O
breast O
cancer O
patients O
with O
> O
or O
= O
10 O
positive O
lymph O
nodes O
, O
despite O
treatment O
with O
a O
single O
agent O
and O
a O
shorter O
treatment O
duration O
. O

Trastuzumab B-intervention
for O
patients O
with O
axillary O
- O
node O
- O
positive O
breast O
cancer O
: O
results O
of O
the O
FNCLCC O
- O
PACS O
04 O
trial O
. O
To O
evaluate O
the O
efficacy O
of O
trastuzumab O
in O
patients O
with O
node O
- O
positive O
breast O
cancer O
treated O
with O
surgery O
, O
adjuvant O
chemotherapy O
, O
radiotherapy O
, O
and O
hormone O
therapy O
if O
applicable O
. O
Three O
thousand O
ten O
patients O
with O
operable O
node O
- O
positive O
breast O
cancer O
were O
randomly O
assigned O
to O
receive O
adjuvant O
anthracycline O
- O
based O
chemotherapy O
with O
or O
without O
docetaxel O
. O
Patients B-eligibility
who I-eligibility
presented I-eligibility
human I-eligibility
epidermal I-eligibility
growth I-eligibility
factor I-eligibility
receptor I-eligibility
2 I-eligibility
( I-eligibility
HER2 I-eligibility
) I-eligibility
-overexpressing I-eligibility
tumors I-eligibility
were O
secondary O
randomly O
assigned O
to O
either O
a O
sequential O
regimen O
of O
trastuzumab O
( O
6 O
mg O
/ O
kg O
every O
3 O
weeks O
) O
for O
1 O
year O
or O
observation B-control
. O
The O
primary O
end O
point O
was O
disease B-outcome-measure
- I-outcome-measure
free I-outcome-measure
survival I-outcome-measure
( I-outcome-measure
DFS I-outcome-measure
) I-outcome-measure
. O
Overall O
528 B-total-participants
patients O
were O
randomly O
assigned O
between O
trastuzumab O
( O
n O
= O
260 B-intervention-participants
) O
and O
observation O
( O
n O
= O
268 B-control-participants
) O
arm O
. O
Of O
the O
234 O
patients O
( O
90 O
% O
) O
who O
received O
at O
least O
one O
administration O
of O
trastuzumab O
, O
196 B-iv-bin-abs
( O
84 B-iv-bin-percent
% I-iv-bin-percent
) O
received B-outcome
at I-outcome
least I-outcome
6 I-outcome
months I-outcome
of I-outcome
treatment I-outcome
, O
and O
41 B-iv-bin-abs
( O
18 B-iv-bin-percent
% I-iv-bin-percent
) O
discontinued B-outcome
treatment I-outcome
due O
to O
cardiac O
events O
( O
any O
grade O
) O
. O
At O
the O
date O
of O
analysis O
( O
October O
2007 O
) O
, O
129 O
DFS B-outcome
events I-outcome
were O
recorded O
. O
Random O
assignment O
to O
the O
trastuzumab O
arm O
was O
associated O
with O
a O
nonsignificant O
14 B-iv-bin-percent
% I-iv-bin-percent
reduction B-outcome
in I-outcome
the I-outcome
risk I-outcome
of I-outcome
relapse I-outcome
( O
hazard O
ratio O
, O
0.86 O
; O
95 O
% O
CI O
, O
0.61 O
to O
1.22 O
; O
P O
= O
.41 O
, O
log O
- O
rank O
stratified O
on O
pathologic O
node O
involvement O
) O
. O
Three B-outcome
- I-outcome
year I-outcome
DFS I-outcome
rates O
were O
78 B-cv-bin-percent
% I-cv-bin-percent
( O
95 O
% O
CI O
, O
72.3 O
to O
82.5 O
) O
and O
81 B-iv-bin-percent
% I-iv-bin-percent
( O
95 O
% O
CI O
, O
75.3 O
to O
85.4 O
) O
in O
the O
observation O
and O
trastuzumab O
arms O
, O
respectively O
. O
After O
a O
47 O
- O
month O
median O
follow O
- O
up O
, O
1 O
year O
of O
trastuzumab O
given O
sequentially O
after O
adjuvant O
chemotherapy O
was O
not O
associated O
with O
a O
statistically O
significant O
decrease O
in O
the O
risk O
of O
relapse O
. O

Effect O
of O
oral B-intervention
clodronate I-intervention
on O
bone B-condition
mass I-condition
, I-condition
bone I-condition
turnover I-condition
and I-condition
subsequent I-condition
metastases I-condition
in O
women O
with O
primary O
breast O
cancer O
. O
Breast O
cancer O
treatments O
have O
been O
associated O
with O
accelerated O
bone O
loss O
and O
increased O
osteoporosis O
risk O
. O
In O
a O
subgroup O
analysis O
of O
a O
randomised O
, O
double O
- O
blind O
, O
placebo O
- O
controlled O
study O
, O
we O
compared O
the O
changes O
in O
spine O
and O
total O
hip O
bone O
mineral O
density O
( O
BMD O
) O
and O
biochemical O
markers O
of O
bone O
turnover O
in O
women B-eligibility
with I-eligibility
primary I-eligibility
breast I-eligibility
cancer I-eligibility
who O
had O
received O
standard O
therapy O
plus O
either O
oral O
clodronate O
1600 O
mg O
/ O
d O
( O
n O
= O
419 B-intervention-participants
) O
or O
placebo B-control
( O
n O
= O
432 B-control-participants
) O
for O
2 O
years O
. O
After O
2 O
years O
, O
spine B-outcome
BMD I-outcome
was O
1.92 O
% O
higher O
in O
patients O
who O
received O
clodronate O
instead O
of O
placebo O
( O
P<0.0001 O
) O
and O
total B-outcome
hip I-outcome
BMD I-outcome
was O
1.29 O
% O
higher O
( O
P O
= O
0.002 O
versus O
placebo O
) O
. O
Patients O
who O
received O
clodronate O
had O
a O
median O
26 O
% O
reduction O
in O
levels B-outcome
of I-outcome
serum I-outcome
N I-outcome
- I-outcome
terminal I-outcome
pro I-outcome
- I-outcome
peptide I-outcome
of I-outcome
type I-outcome
I I-outcome
procollagen I-outcome
( I-outcome
PINP I-outcome
) I-outcome
-- O
a O
marker O
of O
bone O
turnover O
-- O
after O
2 O
years O
of O
therapy O
. O
This O
compares O
with O
a O
median O
5 O
% O
increase O
in O
patients O
who O
received O
placebo O
( O
P<0.0001 O
) O
. O
Effects O
on O
BMD O
, O
but O
not O
biochemical O
markers O
, O
persisted O
for O
up O
to O
3 O
years O
post O
- O
treatment O
. O
Early O
changes O
in O
PINP O
were O
associated O
with O
changes O
in O
BMD O
and O
the O
likelihood O
of O
developing O
bone O
metastases O
. O
This O
study O
shows O
the O
use O
of O
oral O
clodronate O
during O
primary O
breast O
cancer O
treatment O
is O
associated O
with O
reduced O
bone O
turnover O
and O
protection O
against O
bone O
metastases O
. O

Focused B-intervention
microwave I-intervention
thermotherapy I-intervention
for O
preoperative O
treatment O
of O
invasive O
breast O
cancer O
: O
a O
review O
of O
clinical O
studies O
. O
Preoperative O
focused O
microwave O
thermotherapy O
( O
FMT O
) O
is O
a O
promising O
method O
for O
targeted O
treatment O
of O
breast O
cancer O
cells O
. O
Results O
of O
four O
multi O
- O
institutional O
clinical O
studies O
of O
preoperative O
FMT O
for O
treating O
invasive O
carcinomas O
in O
the O
intact O
breast O
are O
reviewed O
. O
Externally O
applied O
wide O
- O
field O
adaptive O
phased O
- O
array O
FMT O
has O
been O
investigated O
both O
as O
a O
preoperative O
heat O
- O
alone O
ablation O
treatment O
and O
as O
a O
combination O
treatment O
with O
preoperative O
anthracycline O
- O
based O
chemotherapy O
for O
breast O
tumors O
ranging O
in O
ultrasound O
- O
measured O
size O
from O
0.8 O
to O
7.8 O
cm O
. O
In O
phase O
I O
, O
eight B-iv-bin-abs
of O
ten B-intervention-participants
( O
80 O
% O
) O
patients O
receiving O
a O
single O
low O
dose O
of O
FMT O
prior O
to O
receiving O
mastectomy O
had O
a O
partial B-outcome
tumor I-outcome
response I-outcome
quantified O
by O
either O
ultrasound O
measurements O
of O
tumor O
volume O
reduction O
or O
by O
pathologic O
cell O
kill O
. O
In O
phase O
II O
, O
the O
FMT O
thermal O
dose O
was O
increased O
to O
establish O
a O
threshold O
dose O
to O
induce O
100 O
% O
pathologic O
tumor O
cell O
kill O
for O
invasive O
carcinomas O
prior O
to O
breast B-control
- I-control
conserving I-control
surgery I-control
( I-control
BCS I-control
) I-control
. O
In O
a O
randomized O
study O
for O
patients B-eligibility
with I-eligibility
early I-eligibility
- I-eligibility
stage I-eligibility
invasive I-eligibility
breast I-eligibility
cancer I-eligibility
, O
of O
those O
patients O
receiving O
preoperative O
FMT O
at O
ablative O
temperatures O
, O
0 B-iv-bin-abs
of O
34 B-intervention-participants
( O
0 B-iv-bin-percent
% I-iv-bin-percent
) O
patients O
had O
positive B-outcome
tumor I-outcome
margins I-outcome
, O
whereas O
positive B-outcome
margins I-outcome
occurred O
in O
4 B-cv-bin-abs
of O
41 B-control-participants
( O
9.8 B-cv-bin-percent
% I-cv-bin-percent
) O
of O
patients O
receiving O
BCS O
alone O
( O
P O
= O
0.13 O
) O
. O
In O
a O
randomized O
study O
for O
patients O
with O
large O
tumors O
, O
based O
on O
ultrasound O
measurements O
the O
median B-outcome
tumor I-outcome
volume I-outcome
reduction I-outcome
was O
88.4 B-iv-bin-percent
% I-iv-bin-percent
( O
n O
= O
14 B-iv-bin-percent
) O
for O
patients O
receiving O
FMT O
and O
neoadjuvant O
chemotherapy O
, O
compared O
with O
58.8 B-cv-bin-percent
% I-cv-bin-percent
( O
n O
= O
10 B-cv-bin-abs
) O
reduction O
in O
the O
neoadjuvant O
chemotherapy O
- O
alone O
arm O
( O
P O
= O
0.048 O
) O
. O
Wide O
- O
field O
adaptive O
phased O
- O
array O
FMT O
can O
be O
safely O
administered O
in O
a O
preoperative O
setting O
, O
and O
data O
from O
randomized O
studies O
suggest O
both O
a O
reduction O
in O
positive O
tumor O
margins O
as O
a O
heat O
- O
alone O
treatment O
for O
early O
- O
stage O
breast O
cancer O
and O
a O
reduction O
in O
tumor O
volume O
when O
used O
in O
combination O
with O
anthracycline O
- O
based O
chemotherapy O
for O
patients O
with O
large O
breast O
cancer O
tumors O
. O
Larger O
randomized O
studies O
are O
required O
to O
verify O
these O
conclusions O
. O

Role O
of O
axillary O
clearance O
after O
a O
tumor O
- O
positive O
sentinel O
node O
in O
the O
administration O
of O
adjuvant O
therapy O
in O
early O
breast O
cancer O
. O
PURPOSE O
The O
After O
Mapping O
of O
the O
Axilla O
: O
Radiotherapy O
or O
Surgery O
? O
( O
AMAROS O
) O
phase O
III O
study O
compares O
axillary B-intervention
lymph I-intervention
node I-intervention
dissection I-intervention
( I-intervention
ALND I-intervention
) I-intervention
and O
axillary B-control
radiation I-control
therapy I-control
( I-control
ART I-control
) I-control
in O
early B-eligibility
breast I-eligibility
cancer I-eligibility
patients I-eligibility
with I-eligibility
tumor I-eligibility
- I-eligibility
positive I-eligibility
sentinel I-eligibility
nodes I-eligibility
. O
In O
the O
ART O
arm O
, O
the O
extent O
of O
nodal O
involvement O
remains O
unknown O
, O
which O
could O
have O
implications O
on O
the O
administration O
of O
adjuvant O
therapy O
. O
In O
this O
preliminary O
analysis O
, O
we O
studied O
the O
influence O
of O
random O
assignment O
to O
ALND O
or O
ART O
on O
the O
choice O
for O
adjuvant O
treatment O
. O
PATIENTS O
AND O
METHODS O
In O
the O
first O
2,000 B-total-participants
patients O
enrolled O
in O
the O
AMAROS O
trial O
, O
we O
analyzed O
the O
administration O
of O
adjuvant O
systemic O
therapy O
. O
Multivariate O
analysis O
was O
used O
to O
assess O
variables O
affecting O
the O
administration O
of O
adjuvant O
chemotherapy O
. O
Adjuvant O
therapy O
was O
applied O
according O
to O
institutional O
guidelines O
. O
Results O
Of O
2,000 B-total-participants
patients O
, O
566 O
patients O
had O
a O
positive O
sentinel O
node O
and O
were O
treated O
per O
random O
assignment O
. O
There O
was O
no O
significant O
difference O
in O
the O
administration O
of O
adjuvant O
systemic O
therapy O
. O
In O
the O
ALND O
and O
ART O
arms O
, O
58 B-iv-bin-percent
% I-iv-bin-percent
( O
175 B-iv-bin-abs
of O
300 B-intervention-participants
) O
and O
61 B-cv-bin-percent
% I-cv-bin-percent
( O
162 B-cv-bin-abs
of O
266 B-control-participants
) O
of O
the O
patients O
, O
respectively O
, O
received B-outcome
chemotherapy I-outcome
. O
Endocrine B-outcome
therapy I-outcome
was O
administered O
in O
78 B-iv-bin-percent
% I-iv-bin-percent
( O
235 B-iv-bin-abs
of O
300 B-intervention-participants
) O
of O
the O
patients O
in O
the O
ALND O
arm O
and O
in O
76 B-cv-bin-percent
% I-cv-bin-percent
( O
203 B-cv-bin-abs
of O
266 B-control-participants
) O
of O
the O
patients O
in O
the O
ART O
arm O
. O
Treatment O
arm O
was O
not O
a O
significant O
factor O
in O
the O
decision O
, O
and O
no O
interactions O
between O
treatment O
arm O
and O
other O
factors O
were O
observed O
. O
Multivariate O
analysis O
showed O
that O
age O
, O
tumor O
grade O
, O
multifocality O
, O
and O
size O
of O
the O
sentinel O
node O
metastasis O
significantly O
affected O
the O
administration O
of O
chemotherapy O
. O
Within O
the O
ALND O
arm O
, O
the O
extent O
of O
nodal O
involvement O
remained O
not O
significant O
in O
a O
sensitivity O
multivariate O
analysis O
. O
CONCLUSION O
Absence O
of O
knowledge O
regarding O
the O
extent O
of O
nodal O
involvement O
in O
the O
ART O
arm O
appears O
to O
have O
no O
major O
impact O
on O
the O
administration O
of O
adjuvant O
therapy O
. O

Randomized O
trial O
of O
a O
lay B-intervention
health I-intervention
advisor I-intervention
and I-intervention
computer I-intervention
intervention I-intervention
to O
increase O
mammography O
screening O
in O
African B-ethinicity
American I-ethinicity
women O
. O
Low O
- O
income O
African O
American O
women O
face O
numerous O
barriers O
to O
mammography O
screening O
. O
We O
tested O
the O
efficacy O
of O
a O
combined O
interactive O
computer O
program O
and O
lay O
health O
advisor O
intervention O
to O
increase O
mammography O
screening O
. O
In O
this O
randomized O
, O
single O
blind O
study O
, O
participants O
were O
181 B-total-participants
African O
American O
female O
health O
center O
patients O
of O
ages O
41 B-age
to I-age
75 I-age
years I-age
, O
at O
< O
or O
= O
250 O
% O
of O
poverty O
level O
, O
with B-eligibility
no I-eligibility
breast I-eligibility
cancer I-eligibility
history I-eligibility
, I-eligibility
and I-eligibility
with I-eligibility
no I-eligibility
screening I-eligibility
mammogram I-eligibility
in I-eligibility
the I-eligibility
past I-eligibility
15 I-eligibility
months I-eligibility
. O
They O
were O
assigned O
to O
either O
( O
a O
) O
a O
low O
- O
dose O
comparison B-control
group I-control
consisting O
of O
a O
culturally O
appropriate O
mammography O
screening O
pamphlet O
or O
( O
b O
) O
interactive O
, O
tailored O
computer O
instruction O
at O
baseline O
and O
four O
monthly O
lay O
health O
advisor O
counseling O
sessions O
. O
Self B-outcome-measure
- I-outcome-measure
reported I-outcome-measure
screening I-outcome-measure
data I-outcome-measure
were O
collected O
at O
baseline O
and O
6 O
months O
and O
verified O
by O
medical O
record O
. O
For O
intent O
- O
to O
- O
treat O
analysis O
of O
primary O
outcome O
( O
medical O
record O
- O
verified O
mammography O
screening O
, O
available O
on O
all O
but O
two O
participants O
) O
, O
the O
intervention O
group O
had O
increased B-outcome
screening I-outcome
to O
51 B-iv-bin-percent
% I-iv-bin-percent
( O
45 B-iv-bin-abs
of O
89 B-intervention-participants
) O
compared O
with O
18 B-cv-bin-percent
% I-cv-bin-percent
( O
16 B-cv-bin-abs
of O
90 B-control-participants
) O
for O
the O
comparison O
group O
at B-outcome
6 I-outcome
months I-outcome
. O
When O
adjusted O
for O
employment O
status O
, O
disability O
, O
first O
- O
degree O
relatives O
with O
breast O
cancer O
, O
health O
insurance O
, O
and O
previous O
breast O
biopsies O
, O
the O
intervention O
group O
was O
three O
times O
more O
likely O
( O
adjusted O
relative O
risk O
, O
2.7 O
; O
95 O
% O
confidence O
interval O
, O
1.8 O
- O
3.7 O
; O
P O
< O
0.0001 O
) O
to O
get O
screened O
than O
the O
low O
- O
dose O
comparison O
group O
. O
Similar O
results O
were O
found O
for O
self O
- O
reported O
mammography O
stage O
of O
screening O
adoption O
. O
The O
combined O
intervention O
was O
efficacious O
in O
improving O
mammography O
screening O
in O
low O
- O
income O
African O
American O
women O
, O
with O
an O
unadjusted O
effect O
size O
( O
relative O
risk O
, O
2.84 O
) O
significantly O
higher O
( O
P O
< O
0.05 O
) O
than O
that O
in O
previous O
studies O
of O
each O
intervention O
alone O
. O

Effectiveness O
of O
early O
physiotherapy B-intervention
to O
prevent O
lymphoedema B-condition
after O
surgery O
for O
breast O
cancer O
: O
randomised O
, O
single O
blinded O
, O
clinical O
trial O
. O
To O
determine O
the O
effectiveness O
of O
early O
physiotherapy O
in O
reducing O
the O
risk O
of O
secondary O
lymphoedema O
after O
surgery O
for O
breast O
cancer O
. O
Randomised O
, O
single O
blinded O
, O
clinical O
trial O
. O
University O
hospital O
in O
Alcal O
de O
Henares O
, O
Madrid B-location
, I-location
Spain I-location
. O
120 B-total-participants
women B-eligibility
who I-eligibility
had I-eligibility
breast I-eligibility
surgery I-eligibility
involving I-eligibility
dissection I-eligibility
of I-eligibility
axillary I-eligibility
lymph I-eligibility
nodes O
between O
May O
2005 O
and O
June O
2007 O
. O
The O
early O
physiotherapy O
group O
was O
treated O
by O
a O
physiotherapist O
with O
a O
physiotherapy O
programme O
including O
manual O
lymph O
drainage O
, O
massage O
of O
scar O
tissue O
, O
and O
progressive O
active O
and O
action O
assisted O
shoulder O
exercises O
. O
This O
group O
also O
received O
an O
educational O
strategy O
. O
The O
control B-control
group I-control
received O
the O
educational O
strategy O
only O
. O
Incidence O
of O
clinically O
significant O
secondary O
lymphoedema O
( O
> O
2 O
cm O
increase O
in O
arm O
circumference O
measured O
at O
two O
adjacent O
points O
compared O
with O
the O
non O
- O
affected O
arm O
) O
. O
116 B-total-participants
women O
completed O
the O
one O
year O
follow O
- O
up O
. O
Of O
these O
, O
18 O
developed O
secondary B-outcome
lymphoedema I-outcome
( O
16 O
% O
): O
14 B-cv-bin-abs
in O
the O
control O
group O
( O
25 B-cv-bin-percent
% I-cv-bin-percent
) O
and O
four B-iv-bin-abs
in O
the O
intervention O
group O
( O
7 B-iv-bin-percent
% I-iv-bin-percent
) O
. O
The O
difference B-outcome
was O
significant O
( O
P O
= O
0.01 O
) O
; O
risk O
ratio O
0.28 O
( O
95 O
% O
confidence O
interval O
0.10 O
to O
0.79 O
) O
. O
A O
survival O
analysis O
showed O
a O
significant O
difference O
, O
with O
secondary B-outcome
lymphoedema I-outcome
being I-outcome
diagnosed I-outcome
four I-outcome
times I-outcome
earlier I-outcome
in O
the O
control O
group O
than O
in O
the O
intervention O
group O
( O
intervention O
/ O
control O
, O
hazard O
ratio O
0.26 O
, O
95 O
% O
confidence O
interval O
0.09 O
to O
0.79 O
) O
. O
Early O
physiotherapy O
could O
be O
an O
effective O
intervention O
in O
the O
prevention O
of O
secondary O
lymphoedema O
in O
women O
for O
at O
least O
one O
year O
after O
surgery O
for O
breast O
cancer O
involving O
dissection O
of O
axillary O
lymph O
nodes O
. O
Current O
controlled O
trials O
ISRCTN95870846 O
. O

DNA B-intervention
repair I-intervention
gene I-intervention
expression I-intervention
and O
risk O
of O
locoregional O
relapse O
in O
breast O
cancer O
patients O
. O
Radiation O
therapy O
appears O
to O
kill O
cells O
mainly O
by O
inducing O
DNA O
double O
- O
strand O
breaks O
. O
We O
investigated O
whether O
the O
DNA O
repair O
gene O
expression O
status O
might O
influence O
the O
risk O
of O
locoregional O
recurrence O
( O
LRR O
) O
in O
breast O
cancer O
patients O
. O
We O
used O
a O
quantitative O
reverse O
transcriptase O
PCR O
- O
based O
approach O
to O
measure O
messenger O
RNA O
levels O
of O
20 O
selected O
DNA O
repair O
genes O
in O
tumor O
samples O
from O
97 B-total-participants
breast O
cancer O
patients O
enrolled O
in O
a O
phase O
III O
trial O
( O
Centre O
Ren O
Huguenin O
cohort O
) O
. O
Normalized O
mRNA O
levels O
were O
tested O
for O
an O
association O
with O
LRR O
- O
free O
survival O
( O
LRR O
- O
FS O
) O
and O
overall O
survival O
( O
OS O
) O
. O
The O
findings O
were O
validated O
in O
comparison O
with O
those O
of O
an O
independent O
cohort O
( O
Netherlands O
Cancer O
Institute O
( O
NKI O
) O
cohort O
) O
. O
Multivariate O
analysis O
encompassing O
known O
prognostic O
factors O
was O
used O
to O
assess O
the O
association O
between O
DNA O
repair O
gene O
expression O
and O
patient O
outcome O
. O
RAD51 O
was O
the O
only O
gene O
associated O
with O
LRR O
in O
both O
cohorts O
. O
With O
a O
median O
follow O
- O
up O
of O
126 O
months O
in O
the O
CRH O
cohort O
, O
the O
5 O
- O
year O
LRR O
- O
FS O
and O
OS B-outcome
rates O
were O
100 B-iv-bin-percent
% I-iv-bin-percent
and O
95 B-iv-bin-percent
% I-iv-bin-percent
in O
the O
61 B-intervention-participants
patients O
with O
low B-intervention
RAD51 I-intervention
expression I-intervention
, O
compared O
with O
70 B-cv-bin-percent
% I-cv-bin-percent
and O
69 B-cv-bin-percent
% I-cv-bin-percent
in O
the O
36 B-control-participants
patients O
with O
high B-control
RAD51 I-control
expression I-control
, O
respectively O
( O
p O
< O
0.001 O
) O
. O
RAD51 O
overexpression O
was O
associated O
with O
a O
higher O
risk B-outcome
of I-outcome
LRR I-outcome
( O
hazard O
ratio O
[ O
HR O
] O
, O
12.83 O
; O
95 O
% O
confidence O
interval O
[ O
CI O
] O
, O
3.6 O
- O
45.6 O
) O
and O
death B-outcome
( O
HR O
, O
4.10 O
; O
95 O
% O
CI O
, O
1.7 O
- O
9.7 O
) O
. O
RAD51 O
overexpression O
was O
also O
significantly O
associated O
with O
shorter O
LRR B-outcome
- I-outcome
FS I-outcome
and I-outcome
OS I-outcome
in O
the O
NKI O
cohort O
. O
Overexpression O
of O
RAD51 O
, O
a O
key O
component O
of O
the O
homologous O
DNA O
repair O
pathway O
, O
is O
associated O
with O
poor O
breast O
cancer O
outcome O
. O
This O
finding O
warrants O
prospective O
studies O
of O
RAD51 O
as O
a O
prognosticator O
and O
therapeutic O
target O
. O

Neoadjuvant B-intervention
chemotherapy I-intervention
with I-intervention
trastuzumab I-intervention
followed O
by O
adjuvant O
trastuzumab O
versus O
neoadjuvant B-control
chemotherapy I-control
alone I-control
, O
in O
patients O
with O
HER2 O
- O
positive O
locally O
advanced O
breast O
cancer O
( O
the O
NOAH O
trial O
): O
a O
randomised O
controlled O
superiority O
trial O
with O
a O
parallel O
HER2 O
- O
negative O
cohort O
. O
The O
monoclonal O
antibody O
trastuzumab O
has O
survival O
benefit O
when O
given O
with O
chemotherapy O
to O
patients O
with O
early O
, O
operable O
, O
and O
metastatic O
breast O
cancer O
that O
has O
HER2 O
( O
also O
known O
as O
ERBB2 O
) O
overexpression O
or O
amplification O
. O
We O
aimed O
to O
assess O
event O
- O
free O
survival O
in O
patients B-eligibility
with I-eligibility
HER2 I-eligibility
- I-eligibility
positive I-eligibility
locally I-eligibility
advanced I-eligibility
or I-eligibility
inflammatory I-eligibility
breast I-eligibility
cancer I-eligibility
receiving I-eligibility
neoadjuvant I-eligibility
chemotherapy I-eligibility
with O
or O
without O
1 O
year O
of O
trastuzumab O
. O
We O
compared O
1 O
year O
of O
treatment O
with O
trastuzumab O
( O
given O
as O
neoadjuvant O
and O
adjuvant O
treatment O
; O
n O
= O
117 B-intervention-participants
) O
with O
no O
trastuzumab O
( O
118 B-control-participants
) O
, O
in O
women O
with O
HER2 O
- O
positive O
locally O
advanced O
or O
inflammatory O
breast O
cancer O
treated O
with O
a O
neoadjuvant O
chemotherapy O
regimen O
consisting O
of O
doxorubicin O
, O
paclitaxel O
, O
cyclophosphamide O
, O
methotrexate O
, O
and O
fluorouracil O
. O
Randomisation O
was O
done O
with O
a O
computer O
program O
and O
minimisation O
technique O
, O
taking O
account O
of O
geographical O
area O
, O
disease O
stage O
, O
and O
hormone O
receptor O
status O
. O
Investigators O
were O
informed O
of O
treatment O
allocation O
. O
A O
parallel O
cohort O
of O
99 O
patients O
with O
HER2 O
- O
negative O
disease O
was O
included O
and O
treated O
with O
the O
same O
chemotherapy O
regimen O
. O
Primary O
endpoint O
was O
event B-outcome-measure
- I-outcome-measure
free I-outcome-measure
survival I-outcome-measure
. O
Analysis O
was O
by O
intention O
to O
treat O
. O
This O
study O
is O
registered O
, O
number O
ISRCTN86043495 O
. O
Trastuzumab O
significantly O
improved O
event B-outcome
- I-outcome
free I-outcome
survival I-outcome
in O
patients O
with O
HER2 O
- O
positive O
breast O
cancer O
( O
3 B-outcome
- I-outcome
year I-outcome
event I-outcome
- I-outcome
free I-outcome
survival I-outcome
, O
71 B-iv-bin-percent
% I-iv-bin-percent
[ O
95 O
% O
CI O
61 O
- O
78 O
; O
n O
= O
36 O
events O
] O
with O
trastuzumab O
, O
vs O
56 B-cv-bin-percent
% I-cv-bin-percent
[ O
46 O
- O
65 O
; O
n O
= O
51 O
events O
] O
without O
; O
hazard O
ratio O
0.59 O
[ O
95 O
% O
CI O
0.38 O
- O
0.90 O
] O
; O
p O
= O
0.013 O
) O
. O
Trastuzumab O
was O
well O
tolerated O
and O
, O
despite O
concurrent O
administration O
with O
doxorubicin O
, O
only O
two B-iv-bin-abs
patients O
( O
2 B-iv-bin-percent
% I-iv-bin-percent
) O
developed O
symptomatic B-outcome
cardiac I-outcome
failure I-outcome
. O
Both O
responded O
to O
cardiac O
drugs O
. O
The O
addition O
of O
neoadjuvant O
and O
adjuvant O
trastuzumab O
to O
neoadjuvant O
chemotherapy O
should O
be O
considered O
for O
women O
with O
HER2 O
- O
positive O
locally O
advanced O
or O
inflammatory O
breast O
cancer O
to O
improve O
event O
- O
free O
survival O
, O
survival O
, O
and O
clinical O
and O
pathological O
tumour O
responses O
. O
F O
Hoffmann O
- O
La O
Roche O
. O

Open O
- O
label O
, O
phase O
II O
, O
multicenter O
, O
randomized O
study O
of O
the O
efficacy O
and O
safety O
of O
two O
dose O
levels O
of O
Pertuzumab B-intervention
, O
a O
human O
epidermal O
growth O
factor O
receptor O
2 O
dimerization O
inhibitor O
, O
in O
patients O
with O
human O
epidermal O
growth O
factor O
receptor O
2 O
- O
negative O
metastatic O
breast O
cancer O
. O
Pertuzumab O
is O
a O
humanized O
monoclonal O
antibody O
inhibiting O
human O
epidermal O
growth O
factor O
receptor O
2 O
( O
HER2 O
) O
dimerization O
. O
The O
aim O
of O
this O
phase O
II O
trial O
was O
to O
assess O
the O
antitumor O
activity O
and O
safety O
profile O
of O
pertuzumab O
monotherapy O
in O
patients O
with O
HER2 O
- O
negative O
metastatic O
breast O
cancer O
. O
The O
utility O
of O
biomarkers O
detected O
in O
paraffin O
- O
embedded O
tissue O
as O
predictors O
of O
response O
was O
also O
explored O
. O
This O
was O
an O
international O
, O
multicenter O
, O
open O
- O
label O
, O
randomized O
phase O
II O
study O
. O
Patients O
( O
n O
= O
79 B-total-participants
) O
with B-eligibility
centrally I-eligibility
confirmed I-eligibility
HER2 I-eligibility
- I-eligibility
negative I-eligibility
metastatic I-eligibility
breast I-eligibility
cancer I-eligibility
were O
randomly O
assigned O
to O
receive O
pertuzumab O
once O
every O
3 O
weeks O
with O
a O
loading O
dose O
of O
840 O
mg O
followed O
thereafter O
by O
either O
420 O
mg O
( O
arm O
A O
) O
or O
1,050 B-control
mg I-control
( I-control
arm I-control
B I-control
) I-control
. O
Patients O
were O
stratified O
by O
country O
and O
prior O
taxane O
therapy O
. O
Of O
79 B-total-participants
patients O
who O
were O
randomly O
assigned O
, O
78 B-total-participants
were O
included O
in O
the O
intent O
- O
to O
- O
treat O
population O
. O
In O
arm O
A O
( O
n O
= O
41 B-intervention-participants
) O
, O
two B-iv-bin-abs
patients O
had O
partial B-outcome
responses I-outcome
, O
and O
18 B-iv-bin-abs
patients O
( O
44 B-iv-bin-percent
% I-iv-bin-percent
) O
experienced O
stable B-outcome
disease I-outcome
( I-outcome
SD I-outcome
) I-outcome
lasting I-outcome
> I-outcome
or I-outcome
= I-outcome
12 I-outcome
weeks I-outcome
. O
In O
arm O
B O
( O
n O
= O
37 B-control-participants
) O
, O
SD B-outcome
was O
observed O
in O
14 B-cv-bin-percent
patients O
( O
38 B-cv-bin-percent
% I-cv-bin-percent
) O
. O
Overall O
, O
six O
of O
78 O
patients O
responded O
or O
had O
SD B-outcome
> I-outcome
or I-outcome
= I-outcome
6 I-outcome
months I-outcome
. O
Pertuzumab O
was O
generally O
well B-outcome
tolerated I-outcome
, O
and O
most O
adverse O
events O
were O
mild O
to O
moderate O
. O
Decline O
in O
left B-outcome
ventricular I-outcome
ejection I-outcome
fraction I-outcome
of O
> O
or O
= O
10 O
% O
and/or O
to O
less O
than O
50 O
% O
was O
observed O
in O
eight B-iv-bin-abs
patients O
, O
with O
one B-iv-bin-abs
case O
of O
congestive B-outcome
heart I-outcome
failure I-outcome
in O
arm O
A. O
Pharmacokinetic O
data O
supported O
a O
fixed O
dose O
of O
pertuzumab O
once O
every O
3 O
weeks O
. O
The O
limited O
efficacy O
observed O
in O
this O
study O
, O
generally O
SD O
of O
relatively O
short O
duration O
, O
suggested O
little O
benefit O
of O
further O
investigation O
of O
single O
- O
agent O
pertuzumab O
in O
unselected O
patients O
with O
HER2 O
- O
negative O
disease O
. O

Long O
- O
term O
results O
of O
hypofractionated B-intervention
radiation I-intervention
therapy I-intervention
for O
breast O
cancer O
. O
The O
optimal O
fractionation O
schedule O
for O
whole O
- O
breast O
irradiation O
after O
breast O
- O
conserving O
surgery O
is O
unknown O
. O
We O
conducted O
a O
study O
to O
determine O
whether O
a O
hypofractionated O
3 O
- O
week O
schedule O
of O
whole O
- O
breast O
irradiation O
is O
as O
effective O
as O
a O
5 O
- O
week O
schedule O
. O
Women B-eligibility
with I-eligibility
invasive I-eligibility
breast I-eligibility
cancer I-eligibility
who I-eligibility
had I-eligibility
undergone I-eligibility
breast I-eligibility
- I-eligibility
conserving I-eligibility
surgery I-eligibility
and I-eligibility
in I-eligibility
whom I-eligibility
resection I-eligibility
margins I-eligibility
were I-eligibility
clear I-eligibility
and I-eligibility
axillary I-eligibility
lymph I-eligibility
nodes I-eligibility
were I-eligibility
negative I-eligibility
were O
randomly O
assigned O
to O
receive O
whole O
- O
breast O
irradiation O
either O
at O
a O
standard B-control
dose I-control
of O
50.0 O
Gy O
in O
25 O
fractions O
over O
a O
period O
of O
35 O
days O
( O
the O
control O
group O
) O
or O
at O
a O
dose O
of O
42.5 O
Gy O
in O
16 O
fractions O
over O
a O
period O
of O
22 O
days O
( O
the O
hypofractionated O
- O
radiation O
group O
) O
. O
The O
risk B-outcome
of I-outcome
local I-outcome
recurrence I-outcome
at I-outcome
10 I-outcome
years I-outcome
was O
6.7 B-cv-bin-percent
% I-cv-bin-percent
among O
the O
612 B-control-participants
women O
assigned O
to O
standard O
irradiation O
as O
compared O
with O
6.2 B-iv-bin-percent
% I-iv-bin-percent
among O
the O
622 B-intervention-participants
women O
assigned O
to O
the O
hypofractionated O
regimen O
( O
absolute O
difference O
, O
0.5 O
percentage O
points O
; O
95 O
% O
confidence O
interval O
[ O
CI O
] O
, O
-2.5 O
to O
3.5 O
) O
. O
At B-outcome
10 I-outcome
years I-outcome
, O
71.3 B-cv-bin-percent
% I-cv-bin-percent
of O
women O
in O
the O
control O
group O
as O
compared O
with O
69.8 B-iv-bin-percent
% I-iv-bin-percent
of O
the O
women O
in O
the O
hypofractionated O
- O
radiation O
group O
had O
a O
good B-outcome
or I-outcome
excellent I-outcome
cosmetic I-outcome
outcome I-outcome
( O
absolute O
difference O
, O
1.5 O
percentage O
points O
; O
95 O
% O
CI O
, O
-6.9 O
to O
9.8 O
) O
. O
Ten O
years O
after O
treatment O
, O
accelerated O
, O
hypofractionated O
whole O
- O
breast O
irradiation O
was O
not O
inferior O
to O
standard O
radiation O
treatment O
in O
women O
who O
had O
undergone O
breast O
- O
conserving O
surgery O
for O
invasive O
breast O
cancer O
with O
clear O
surgical O
margins O
and O
negative O
axillary O
nodes O
. O
( O
ClinicalTrials O
. O
gov O
number O
, O
NCT00156052 O
. O
) O

Comparative O
effectiveness O
of O
MRI B-intervention
in O
breast O
cancer O
( O
COMICE O
) O
trial O
: O
a O
randomised O
controlled O
trial O
. O
MRI O
might O
improve O
diagnosis O
of O
breast O
cancer O
, O
reducing O
rates O
of O
reoperation O
. O
We O
assessed O
the O
clinical O
efficacy O
of O
contrast O
- O
enhanced O
MRI O
in O
women B-eligibility
with I-eligibility
primary I-eligibility
breast I-eligibility
cancer I-eligibility
. O
We O
undertook O
an O
open O
, O
parallel O
group O
trial O
in O
45 O
UK B-location
centres O
, O
with O
1623 B-total-participants
women O
aged O
18 B-age
years I-age
or I-age
older I-age
with O
biopsy O
- O
proven O
primary O
breast O
cancer O
who O
were O
scheduled O
for O
wide O
local O
excision O
after O
triple O
assessment O
. O
Patients O
were O
randomly O
assigned O
to O
receive O
either O
MRI O
( O
n O
= O
816 B-intervention-participants
) O
or O
no B-control
further I-control
imaging I-control
( O
807 B-control-participants
) O
, O
with O
use O
of O
a O
minimisation O
algorithm O
incorporating O
a O
random O
element O
. O
The O
primary O
endpoint O
was O
the O
proportion B-outcome-measure
of I-outcome-measure
patients I-outcome-measure
undergoing I-outcome-measure
a I-outcome-measure
repeat I-outcome-measure
operation I-outcome-measure
or I-outcome-measure
further I-outcome-measure
mastectomy I-outcome-measure
within I-outcome-measure
6 I-outcome-measure
months I-outcome-measure
of I-outcome-measure
random I-outcome-measure
assignment I-outcome-measure
, I-outcome-measure
or I-outcome-measure
a I-outcome-measure
pathologically I-outcome-measure
avoidable I-outcome-measure
mastectomy I-outcome-measure
at I-outcome-measure
initial I-outcome-measure
operation I-outcome-measure
. O
Analysis O
was O
by O
intention O
to O
treat O
. O
This O
study O
is O
registered O
, O
ISRCTN O
number O
57474502 O
. O
816 B-intervention-participants
patients O
were O
randomly O
assigned O
to O
MRI O
and O
807 B-control-participants
to O
no B-control
MRI I-control
. O
Addition O
of O
MRI O
to O
conventional O
triple O
assessment O
was O
not O
significantly O
associated O
with O
reduced O
a O
reoperation B-outcome
rate I-outcome
, O
with O
153 B-iv-bin-abs
( O
19 B-iv-bin-percent
% I-iv-bin-percent
) O
needing O
reoperation O
in O
the O
MRI O
group O
versus O
156 B-cv-bin-abs
( O
19 B-cv-bin-percent
% I-cv-bin-percent
) O
in O
the O
no O
MRI O
group O
, O
( O
odds O
ratio O
0.96 O
, O
95 O
% O
CI O
0.75 O
- O
1.24 O
; O
p O
= O
0.77 O
) O
. O
Our O
findings O
are O
of O
benefit O
to O
the O
NHS O
because O
they O
show O
that O
MRI O
might O
be O
unnecessary O
in O
this O
population O
of O
patients O
to O
reduce O
repeat O
operation O
rates O
, O
and O
could O
assist O
in O
improved O
use O
of O
NHS O
services O
. O
National O
Institute O
for O
Health O
Research O
's O
Health O
Technology O
Assessment O
Programme O
. O

Alberta O
physical B-intervention
activity I-intervention
and O
breast O
cancer O
prevention O
trial O
: O
sex O
hormone O
changes O
in O
a O
year O
- O
long O
exercise O
intervention O
among O
postmenopausal O
women O
. O
We O
examined O
how O
an O
aerobic O
exercise O
intervention O
influenced O
circulating O
estradiol O
, O
estrone O
, O
sex O
hormone O
- O
binding O
globulin O
( O
SHBG O
) O
, O
androstenedione O
, O
and O
testosterone O
levels O
, O
which O
may O
be O
involved O
in O
the O
association O
between O
physical O
activity O
and O
breast O
cancer O
risk O
. O
A O
two O
- O
center O
, O
two O
- O
arm O
randomized O
controlled O
trial O
of O
exercise O
was O
conducted O
in O
320 B-total-participants
postmenopausal B-eligibility
, I-eligibility
sedentary I-eligibility
women I-eligibility
age O
50 B-age
to I-age
74 I-age
years I-age
. O
Participants O
were O
randomly O
assigned O
to O
a O
1 O
- O
year O
aerobic B-intervention
exercise I-intervention
intervention O
of O
225 O
min O
/ O
wk O
( O
n O
= O
160 B-intervention-participants
) O
or O
to O
a O
control O
group O
who O
maintained O
their O
usual B-control
level I-control
of I-control
activity I-control
( O
n O
= O
160 B-control-participants
) O
. O
Baseline O
, O
6 O
- O
month O
, O
and O
12 O
- O
month O
assessments O
of O
estrone O
, O
estradiol O
, O
androstenedione O
, O
and O
testosterone O
were O
quantified O
by O
radioimmunoassay O
after O
extraction O
, O
and O
SHBG O
was O
quantified O
by O
an O
immunometric O
assay O
. O
Intent O
- O
to O
- O
treat O
analyses O
were O
performed O
using O
linear O
mixed O
models O
. O
Blood O
data O
were O
available O
on O
309 B-total-participants
women O
( O
96.6 O
% O
) O
at O
12 O
months O
. O
Women O
in O
the O
intervention O
group O
exercised O
an O
average O
of O
3.6 O
d O
/ O
wk O
for O
178 O
min O
/ O
wk O
. O
At O
12 O
months O
, O
statistically O
significant B-outcome
reductions I-outcome
in I-outcome
estradiol I-outcome
( O
treatment O
effect O
ratio O
[ O
TER O
] O
= O
0.93 O
; O
95 O
% O
CI O
, O
0.88 O
to O
0.98 O
) O
and O
free B-outcome
estradiol I-outcome
( O
TER O
= O
0.91 O
; O
95 O
% O
CI O
, O
0.87 O
to O
0.96 O
) O
and O
increases B-outcome
in I-outcome
SHBG I-outcome
( O
TER O
= O
1.04 O
; O
95 O
% O
CI O
, O
1.02 O
to O
1.07 O
) O
were O
observed O
in O
the O
exercise O
group O
compared O
with O
the O
control O
group O
. O
No B-outcome
significant I-outcome
differences I-outcome
in I-outcome
estrone I-outcome
, I-outcome
androstenedione I-outcome
, I-outcome
and I-outcome
testosterone I-outcome
levels I-outcome
were O
observed O
between O
exercisers O
and O
controls O
at O
12 O
months O
. O
This O
trial O
found O
that O
previously O
sedentary O
postmenopausal O
women O
can O
adhere O
to O
a O
moderate- O
to O
vigorous O
- O
intensity O
exercise O
program O
that O
results O
in O
changes O
in O
estradiol O
and O
SHBG O
concentrations O
that O
are O
consistent O
with O
a O
lower O
risk O
for O
postmenopausal O
breast O
cancer O
. O

Phase O
II O
, O
randomized O
trial O
to O
compare O
anastrozole B-intervention
combined I-intervention
with I-intervention
gefitinib I-intervention
or O
placebo B-control
in O
postmenopausal O
women O
with O
hormone O
receptor O
- O
positive O
metastatic O
breast O
cancer O
. O
This O
phase O
II O
randomized O
trial O
evaluated O
the O
efficacy O
and O
tolerability O
of O
anastrozole O
combined O
with O
gefitinib O
or O
anastrozole O
with O
placebo O
in O
women O
with O
hormone O
receptor O
- O
positive O
metastatic O
breast O
cancer O
( O
MBC O
) O
. O
Postmenopausal B-eligibility
women I-eligibility
with I-eligibility
hormone I-eligibility
receptor I-eligibility
- I-eligibility
positive I-eligibility
measurable I-eligibility
or I-eligibility
evaluable I-eligibility
MBC I-eligibility
who I-eligibility
had I-eligibility
not I-eligibility
received I-eligibility
prior I-eligibility
endocrine I-eligibility
therapy I-eligibility
for I-eligibility
this I-eligibility
disease I-eligibility
stage I-eligibility
or I-eligibility
who I-eligibility
developed I-eligibility
metastatic I-eligibility
disease I-eligibility
during I-eligibility
/ I-eligibility
after I-eligibility
adjuvant I-eligibility
tamoxifen I-eligibility
were O
eligible O
. O
The O
primary O
response O
variable O
was O
progression B-outcome-measure
- I-outcome-measure
free I-outcome-measure
survival I-outcome-measure
( I-outcome-measure
PFS I-outcome-measure
) I-outcome-measure
and O
secondary O
response O
variables O
included O
clinical B-outcome-measure
benefit I-outcome-measure
rate I-outcome-measure
, O
objective B-outcome-measure
response I-outcome-measure
rate I-outcome-measure
, O
overall B-outcome-measure
survival I-outcome-measure
, O
safety B-outcome-measure
and I-outcome-measure
tolerability I-outcome-measure
, O
and O
pharmacokinetics B-outcome-measure
. O
Tumor O
biomarker O
evaluation O
was O
an O
exploratory O
objective O
. O
Forty B-intervention-participants
- I-intervention-participants
three I-intervention-participants
patients O
were O
randomized O
to O
anastrozole O
plus O
gefitinib O
and O
50 B-control-participants
patients O
were O
randomized O
to O
anastrozole O
plus O
placebo O
of O
a O
planned O
total O
of O
174 B-total-participants
patients O
( O
enrollment O
was O
prematurely O
discontinued O
due O
to O
slow O
recruitment O
) O
. O
PFS B-outcome
for O
patients O
receiving O
the O
combination O
of O
anastrozole O
and O
gefitinib O
was O
longer O
than O
for O
patients O
receiving O
anastrozole O
plus O
placebo O
[ O
hazard O
ratio O
( O
gefitinib O
/ O
placebo O
) O
, O
0.55 O
; O
95 O
% O
confidence O
interval O
, O
0.32 O
- O
0.94 O
; O
median B-outcome
PFS I-outcome
, O
14.7 B-iv-cont-median
versus O
8.4 B-cv-cont-median
months I-cv-cont-median
] O
. O
The O
clinical B-outcome
benefit I-outcome
rate I-outcome
was O
49 B-iv-bin-percent
% I-iv-bin-percent
versus O
34 B-cv-bin-percent
% I-cv-bin-percent
, O
and O
the O
objective B-outcome
response I-outcome
rate I-outcome
was O
2 B-iv-bin-percent
% I-iv-bin-percent
versus O
12 B-cv-bin-percent
% I-cv-bin-percent
with O
anastrozole O
plus O
gefitinib O
and O
anastrozole O
plus O
placebo O
, O
respectively O
. O
No O
evidence O
of O
interaction O
between O
baseline O
biomarker O
levels O
and O
relative O
treatment O
effect O
was O
found O
. O
No O
unexpected O
adverse B-outcome
events I-outcome
were O
observed O
. O
This O
small O
randomized O
study O
showed O
that O
anastrozole O
in O
combination O
with O
gefitinib O
is O
associated O
with O
a O
marked O
advantage O
in O
PFS O
compared O
with O
anastrozole O
plus O
placebo O
, O
and O
that O
the O
combination O
was O
tolerated O
in O
postmenopausal O
women O
with O
hormone O
receptor O
- O
positive O
MBC O
. O
Further O
investigation O
of O
epidermal O
growth O
factor O
receptor O
inhibition O
in O
combination O
with O
endocrine O
therapy O
may O
be O
warranted O
. O

Mammographic O
density O
change O
with O
1 O
year O
of O
aerobic B-intervention
exercise I-intervention
among O
postmenopausal O
women O
: O
a O
randomized O
controlled O
trial O
. O
The O
Alberta O
Physical O
Activity O
and O
Breast O
Cancer O
Prevention O
( O
ALPHA O
) O
Trial O
examined O
the O
influence O
of O
aerobic O
exercise O
on O
biological O
factors O
that O
are O
associated O
with O
breast O
cancer O
risk O
. O
Mammographic O
density O
, O
a O
secondary O
outcome O
, O
is O
reported O
here O
. O
The O
ALPHA O
Trial O
was O
a O
parallel O
group O
randomized O
controlled O
trial O
conducted O
between O
May O
2003 O
and O
July O
2007 O
. O
Postmenopausal B-eligibility
, I-eligibility
sedentary I-eligibility
women I-eligibility
ages O
50 B-age
to I-age
74 I-age
years I-age
( O
n O
= O
320 B-total-participants
) O
were O
evenly O
randomized O
to O
aerobic O
exercise O
( O
45 O
minutes O
, O
5 O
days O
per O
week O
) O
or O
control B-control
( I-control
usual I-control
life I-control
- I-control
style I-control
) I-control
for O
1 O
year O
. O
Dense O
fibroglandular O
tissue O
and O
nondense O
fatty O
tissue O
were O
measured O
from O
mammograms O
at O
baseline O
and O
1 O
year O
using O
computer O
- O
assisted O
thresholding O
software O
for O
area O
measurements O
and O
a O
new O
technique O
that O
relies O
on O
the O
calibration O
of O
mammography O
units O
with O
a O
tissue O
- O
equivalent O
phantom O
for O
volumetric O
measurements O
. O
Nondense B-outcome
volume I-outcome
decreased O
in O
the O
exercise O
group O
relative O
to O
the O
control O
group O
( O
difference O
between O
groups O
= O
-38.5 O
cm O
( O
3 O
) O
; O
95 O
% O
confidence O
interval O
, O
-61.6 O
to O
15.4 O
; O
P O
= O
0.001 O
) O
. O
Changes B-outcome
in I-outcome
total I-outcome
body I-outcome
fat I-outcome
accounted O
for O
this O
decrease O
. O
Changes B-outcome
in I-outcome
dense I-outcome
area I-outcome
and I-outcome
dense I-outcome
volume I-outcome
, O
measures O
that O
have O
previously O
been O
associated O
with O
breast O
cancer O
risk O
, O
were O
not O
significantly O
different O
between O
the O
groups O
( O
P O
> O
or O
= O
0.26 O
) O
. O
Achieving O
changes O
in O
mammographic O
measures O
may O
require O
more O
exercise O
or O
a O
study O
population O
with O
higher O
baseline O
levels O
of O
sex O
hormones O
or O
a O
wider O
range O
of O
mammographic O
density O
. O
The O
data O
from O
this O
study O
, O
however O
, O
suggest O
that O
the O
protective O
effect O
of O
exercise O
on O
breast O
cancer O
risk O
may O
operate O
through O
a O
mechanism O
other O
than O
mammographic O
density O
. O

Hormone B-intervention
therapy I-intervention
and O
fatal O
breast O
cancer O
. O
Among O
unanswered O
questions O
is O
whether O
menopausal O
use O
of O
estrogen O
therapy O
( O
ET O
) O
or O
estrogen O
- O
plus O
- O
progestin O
therapy O
( O
CHT O
) O
increases O
risk O
of O
developing O
fatal O
breast O
cancer O
i. O
e. O
, O
developing O
and O
dying O
of O
breast O
cancer O
. O
Using O
a O
population O
- O
based O
case O
- O
control O
design O
, O
we O
estimated O
incidence O
rate O
ratios O
of O
fatal O
breast O
cancer O
in O
postmenopausal B-eligibility
hormone I-eligibility
therapy I-eligibility
( I-eligibility
HT I-eligibility
) I-eligibility
users I-eligibility
compared O
to O
non O
- O
users O
by O
type O
, O
duration O
, O
and O
recency O
of O
HT O
use O
. O
HT O
use O
prior O
to O
breast O
cancer O
diagnosis O
in O
278 B-intervention-participants
women O
who O
died O
of O
breast O
cancer O
within O
6 O
years O
of O
diagnosis O
( O
cases O
) O
was O
compared O
with O
use O
in O
2224 B-control-participants
controls B-control
never O
diagnosed O
with O
breast O
cancer O
using O
conditional O
logistic O
regression O
. O
Measures O
taken O
to O
address O
potential O
bias O
and O
confounding O
inherent O
in O
case O
- O
control O
studies O
included O
collecting O
and O
adjusting O
for O
detailed O
data O
on O
demographic O
and O
other O
factors O
potentially O
associated O
both O
with O
HT O
use O
and O
breast O
cancer O
. O
Fifty B-iv-bin-percent
- I-iv-bin-percent
six I-iv-bin-percent
per I-iv-bin-percent
cent I-iv-bin-percent
of O
cases O
and O
68 B-cv-bin-percent
% I-cv-bin-percent
of O
controls O
reported O
HT B-outcome
use I-outcome
. O
Among O
current O
3 O
+ O
year O
HT O
users O
, O
odds O
ratios O
and O
95 O
% O
confidence O
intervals O
for O
death B-outcome
were O
0.83 O
( O
0.50 O
, O
1.38 O
) O
and O
0.69 O
( O
0.44 O
, O
1.09 O
) O
, O
respectively O
, O
for O
exclusive O
use O
of O
CHT O
or O
of O
ET O
, O
and O
were O
0.94 O
( O
0.59 O
, O
1.48 O
) O
and O
0.70 O
( O
0.45 O
, O
1.07 O
) O
for O
any O
use O
of O
CHT O
or O
of O
ET O
regardless O
of O
other O
hormone O
use O
. O
Point O
estimates O
suggest O
no O
increased O
risk O
of O
fatal O
breast O
cancer O
with O
HT O
use O
, O
although O
50 O
% O
increases O
in O
risk O
in O
longer O
- O
term O
current O
CHT O
users O
can O
not O
be O
ruled O
out O
. O

Phase O
III O
randomized O
trial O
of O
sunitinib B-intervention
versus O
capecitabine B-control
in O
patients O
with O
previously O
treated O
HER2 O
- O
negative O
advanced O
breast O
cancer O
. O
This O
multicenter O
, O
randomized O
, O
open O
- O
label O
phase O
III O
trial O
( O
planned O
enrollment O
: O
700 O
patients O
) O
was O
conducted O
to O
test O
the O
hypothesis O
that O
single O
- O
agent O
sunitinib O
improves O
progression O
- O
free O
survival O
( O
PFS O
) O
compared O
with O
capecitabine O
as O
treatment O
for O
advanced O
breast O
cancer O
( O
ABC O
) O
. O
Patients B-eligibility
with I-eligibility
HER2 I-eligibility
- I-eligibility
negative I-eligibility
ABC I-eligibility
that I-eligibility
recurred I-eligibility
after I-eligibility
anthracycline I-eligibility
and I-eligibility
taxane I-eligibility
therapy I-eligibility
were O
randomized O
( O
1 O
:1 O
) O
to O
sunitinib O
37.5 O
mg O
/ O
day O
or O
capecitabine O
1,250 O
mg O
/ O
m O
( O
2 O
) O
( O
1,000 O
mg O
/ O
m O
( O
2 O
) O
in O
patients O
> B-age
65 I-age
years I-age
) O
BID O
on O
days O
1 O
- O
14 O
q3w O
. O
The O
independent O
data O
- O
monitoring O
committee O
( O
DMC O
) O
determined O
during O
the O
first O
interim O
analysis O
( O
238 B-intervention-participants
patients O
randomized O
to O
sunitinib O
, O
244 B-control-participants
to O
capecitabine O
) O
that O
the O
trial O
be O
terminated O
due O
to O
futility O
in O
reaching O
the O
primary O
endpoint O
. O
No O
statistical O
evidence O
supported O
the O
hypothesis O
that O
sunitinib O
improved O
PFS O
compared O
with O
capecitabine O
( O
one O
- O
sided O
P O
= O
0.999 O
) O
. O
The O
data O
indicated O
that O
PFS B-outcome
was O
shorter O
with O
sunitinib O
than O
capecitabine O
( O
median O
2.8 B-iv-cont-median
vs. O
4.2 B-cv-cont-median
months I-cv-cont-median
, O
respectively O
; O
HR O
, O
1.47 O
; O
95 O
% O
CI O
, O
1.16 O
- O
1.87 O
; O
two O
- O
sided O
P O
= O
0.002 O
) O
. O
Median B-outcome
overall I-outcome
survival I-outcome
( O
15.3 B-iv-cont-median
vs. O
24.6 B-cv-cont-median
months I-cv-cont-median
; O
HR O
, O
1.17 O
; O
two O
- O
sided O
P O
= O
0.350 O
) O
and O
objective B-outcome
response I-outcome
rates I-outcome
( O
11 B-iv-bin-percent
vs. O
16 B-cv-bin-percent
% I-cv-bin-percent
; O
odds O
ratio O
, O
0.65 O
; O
P O
= O
0.109 O
) O
were O
numerically O
inferior O
with O
sunitinib O
versus O
capecitabine O
. O
While O
no O
new O
or O
unexpected O
safety O
findings O
were O
reported O
, O
sunitinib O
treatment O
was O
associated O
with O
higher O
frequencies O
and O
greater O
severities O
of O
many O
common O
adverse O
events O
( O
AEs O
) O
compared O
with O
capecitabine O
, O
resulting O
in O
more O
temporary B-outcome
discontinuations I-outcome
due I-outcome
to I-outcome
AEs I-outcome
with O
sunitinib O
( O
66 B-iv-bin-percent
vs. O
51 B-cv-bin-percent
% I-cv-bin-percent
) O
. O
The O
relative B-outcome
dose I-outcome
intensity I-outcome
was O
lower O
with O
sunitinib O
than O
capecitabine O
( O
73 B-iv-bin-percent
vs. O
95 B-cv-bin-percent
% I-cv-bin-percent
) O
. O
Based O
on O
these O
efficacy O
and O
safety O
results O
, O
sunitinib O
should O
not O
be O
used O
as O
monotherapy O
for O
patients O
with O
ABC O
. O

Does O
the O
use O
of O
fibrin B-intervention
glue I-intervention
prevent O
seroma B-condition
formation I-condition
after O
axillary O
lymphadenectomy O
for O
breast O
cancer O
? O
A O
prospective O
randomized O
trial O
in O
159 B-total-participants
patients O
. O
Seroma O
formation O
frequently O
occurs O
in O
patients O
who O
have O
undergone O
axillary O
lymphadenectomy O
. O
The O
aim O
of O
the O
study O
was O
to O
evaluate O
the O
effect O
of O
fibrin O
glue O
in O
the O
prevention O
of O
seroma O
formation O
after O
axillary O
lymphadenectomy O
. O
Hundred B-total-participants
fifty I-total-participants
- I-total-participants
nine I-total-participants
breast B-eligibility
cancer I-eligibility
patients I-eligibility
about I-eligibility
to I-eligibility
undergo I-eligibility
quadrantectomy I-eligibility
or I-eligibility
mastectomy I-eligibility
plus I-eligibility
axillary I-eligibility
lymphadenectomy I-eligibility
were O
enrolled O
in O
the O
study O
and O
randomized O
into O
two O
groups O
. O
Fibrin O
glue O
spray O
applied O
to O
the O
axillary O
fossa O
plus O
placement O
of O
closed O
suction O
drainage O
were O
used O
in O
80 B-intervention-participants
patients O
( O
group O
A O
) O
; O
placement B-control
of I-control
closed I-control
suction I-control
drainage I-control
was O
only O
used O
in O
79 B-control-participants
patients O
( O
group O
B O
) O
. O
Group O
A O
patients O
showed O
a O
slight O
advantage O
with O
regard O
to O
the O
mean O
duration O
of O
axillary O
drainage O
placement O
( O
4.5 B-iv-cont-mean
+ O
/- O
1.3 B-iv-cont-sd
days I-iv-cont-sd
in O
group O
A O
vs. O
5.1 B-cv-cont-mean
+ O
/- O
1.6 B-cv-cont-sd
days I-cv-cont-sd
in O
group O
B O
) O
and O
number B-outcome
of I-outcome
seroma I-outcome
aspirations I-outcome
( O
6.3 B-iv-cont-mean
+ O
/- O
1.1 B-iv-cont-sd
in O
group O
A O
vs. O
6.7 B-cv-cont-mean
+ O
/- O
1.2 B-cv-cont-sd
in O
group O
B O
) O
. O
No O
statistically O
significant O
differences O
were O
observed O
between O
the O
two O
groups O
of O
patients O
regarding O
the O
mean O
volume B-outcome
of I-outcome
total I-outcome
axillary I-outcome
drainage I-outcome
and O
of O
total B-outcome
seroma I-outcome
volume I-outcome
. O
The O
use O
of O
fibrin O
glue O
does O
not O
prevent O
seroma O
formation O
and O
does O
not O
reduce O
seroma O
magnitude O
and O
duration O
. O
The O
costs O
of O
the O
product O
involved O
do O
not O
justify O
its O
routine O
use O
in O
patients O
undergoing O
axillary O
dissection O
. O

Late O
tamoxifen B-intervention
in O
patients O
previously O
operated O
for O
breast O
cancer O
without O
postoperative O
tamoxifen O
: O
5 O
- O
year O
results O
of O
a O
single O
institution O
randomised O
study O
. O
A O
population O
of O
breast O
cancer O
patients O
exists O
who O
, O
for O
various O
reasons O
, O
never O
received O
adjuvant O
post O
- O
operative O
tamoxifen O
( O
TAM O
) O
. O
This O
study O
was O
aimed O
to O
evaluate O
the O
role O
of O
late O
TAM O
in O
these O
patients O
. O
From O
1997 O
to O
2003 O
, O
patients O
aged O
35 B-age
to I-age
75 I-age
years I-age
, O
operated B-eligibility
more I-eligibility
than I-eligibility
2 I-eligibility
years I-eligibility
previously I-eligibility
for I-eligibility
monolateral I-eligibility
breast I-eligibility
cancer I-eligibility
without I-eligibility
adjuvant I-eligibility
TAM I-eligibility
, I-eligibility
with I-eligibility
no I-eligibility
signs I-eligibility
of I-eligibility
metastases I-eligibility
and I-eligibility
no I-eligibility
contraindication I-eligibility
to I-eligibility
TAM I-eligibility
were O
randomized O
to O
TAM O
20 O
mg O
/ O
day O
orally O
for O
2 O
years O
or O
follow B-control
- I-control
up I-control
alone I-control
. O
Events O
were O
categorized O
as O
locoregional O
relapse O
, O
distant O
metastases O
, O
metachronous O
breast O
cancer O
, O
tumours O
other O
than O
breast O
cancer O
and O
death O
from O
any O
causes O
, O
whichever O
occurred O
first O
. O
The O
sample O
size O
( O
197 O
patients O
per O
arm O
, O
plus O
10 O
% O
allowance O
) O
was O
based O
on O
the O
assumption O
of O
a O
30 O
% O
decrease O
in O
the O
number O
of O
events O
occurring O
at O
a O
rate O
of O
5 O
% O
annually O
in O
the O
10 O
years O
following O
randomization O
. O
Four B-total-participants
hundred I-total-participants
and I-total-participants
thirty I-total-participants
- I-total-participants
three I-total-participants
patients O
were O
randomized O
in O
the O
study O
( O
TAM O
217 B-intervention-participants
, O
follow B-control
- I-control
up I-control
216 B-control-participants
) O
. O
Patients O
characteristics O
( O
TAM O
/ O
follow O
- O
up O
) O
included O
: O
median O
age O
55 O
/ O
55 O
years O
, O
median O
time O
from O
surgery O
25 O
/ O
25 O
months O
( O
range O
, O
25 O
- O
288 O
/ O
25 O
- O
294 O
) O
, O
in O
situ O
carcinoma O
18 O
/ O
24 O
, O
oestrogen O
receptor O
( O
ER O
) O
positive O
in O
75 O
/ O
68 O
, O
negative O
in O
70 O
/ O
57 O
, O
unknown O
in O
72 O
/ O
91 O
patients O
. O
Previous O
adjuvant O
treatment O
included O
chemotherapy O
in O
131 O
/ O
120 O
and O
an O
LHRH O
analogue O
in O
11 O
/ O
13 O
patients O
. O
Thirty B-iv-bin-abs
- I-iv-bin-abs
six I-iv-bin-abs
patients O
prematurely B-outcome
discontinued I-outcome
TAM O
after O
a O
median O
of O
1 O
month O
, O
mostly O
because O
of O
subjective O
intolerance O
. O
Eighty O
- O
three O
events B-outcome
( O
TAM O
39 B-iv-bin-abs
, O
follow O
- O
up O
44 B-cv-bin-abs
) O
occurred O
: O
locoregional B-outcome
relapse I-outcome
in O
10 B-iv-bin-abs
/ O
8 B-cv-bin-abs
, O
distant B-outcome
metastases I-outcome
in O
14 B-iv-bin-abs
/ O
16 B-cv-bin-abs
, O
metachronous B-outcome
breast I-outcome
cancer I-outcome
in O
4 B-iv-bin-abs
/ O
10 B-cv-bin-abs
, O
other B-outcome
tumours I-outcome
in O
11 B-iv-bin-abs
/ O
10 B-cv-bin-abs
patients O
. O
Less O
ER B-outcome
- I-outcome
positive I-outcome
secondary I-outcome
breast I-outcome
cancers I-outcome
occurred O
in O
the O
TAM O
treated O
patients O
than O
in O
follow O
- O
up O
patients O
( O
1 B-iv-bin-abs
vs O
10 B-cv-bin-abs
, O
p O
= O
0.005 O
) O
. O
Event B-outcome
- I-outcome
free I-outcome
survival I-outcome
was O
similar O
in O
both O
groups O
of O
patients O
. O
This O
5 O
- O
year O
analysis O
revealed O
significantly O
less O
metachronous O
ER O
- O
positive O
breast O
cancers O
in O
the O
TAM O
treated O
patients O
. O
No O
other O
statistically O
significant O
differences O
have O
emerged O
thus O
far O
. O

A O
multicenter O
randomized O
phase O
II O
study O
of O
sequential B-intervention
epirubicin I-intervention
/ I-intervention
cyclophosphamide I-intervention
followed I-intervention
by I-intervention
docetaxel I-intervention
with I-intervention
or I-intervention
without I-intervention
celecoxib I-intervention
or I-intervention
trastuzumab I-intervention
according O
to O
HER2 O
status O
, O
as O
primary O
chemotherapy O
for O
localized O
invasive O
breast O
cancer O
patients O
. O
To O
assess O
anti O
- O
tumor O
activity O
of O
sequential O
epirubicin O
/ O
cyclophosphamide O
followed O
by O
docetaxel O
with O
the O
randomized O
addition O
of O
celecoxib O
in O
HER2 O
negative O
patients O
or O
trastuzumab O
in O
HER2 O
positive O
patients O
. O
From O
May O
2004 O
till O
October O
2007 O
, O
340 B-total-participants
patients B-eligibility
with I-eligibility
stage I-eligibility
II I-eligibility
and I-eligibility
III I-eligibility
breast I-eligibility
adenocarcinoma I-eligibility
, I-eligibility
ineligible I-eligibility
for I-eligibility
breast I-eligibility
conserving I-eligibility
surgery I-eligibility
, O
received O
eight O
sequential O
three O
weekly O
cycles O
of O
EC O
- O
D O
[ O
epirubicin O
( O
75 O
mg O
/ O
m O
( O
2 O
) O
) O
-cyclophosphamide O
( O
750 O
mg O
/ O
m O
( O
2 O
) O
) O
for O
four O
cycles O
followed O
by O
docetaxel O
( O
100 O
mg O
/ O
m O
( O
2 O
) O
) O
for O
four O
cycles O
] O
. O
HER2 B-eligibility
- I-eligibility
negative I-eligibility
patients I-eligibility
( O
N O
= O
220 B-total-participants
) O
were O
randomized O
to O
receive O
concomitantly O
with O
docetaxel O
celecoxib O
800 O
mg O
/ O
day O
during O
cycles O
5 O
- O
8 O
or O
no B-control
additional I-control
treatment I-control
, O
while O
HER2 O
- O
positive O
patients O
confirmed O
by O
FISH O
( O
N O
= O
120 B-total-participants
) O
were O
randomized O
to O
trastuzumab O
concomitant O
to O
docetaxel O
( O
8 O
mg O
/ O
kg O
then O
6 O
mg O
/ O
kg O
IV O
every O
3 O
weeks O
) O
or O
no O
additional O
preoperative O
treatment O
. O
In B-outcome
the I-outcome
HER2 I-outcome
negative I-outcome
group I-outcome
, O
pCR B-outcome
( O
grade O
1 O
and O
2 O
of O
Chevallier O
's O
classification O
) O
was O
observed O
in O
11.5 B-iv-bin-percent
and O
13 B-cv-bin-percent
% I-cv-bin-percent
of O
patients O
treated O
without O
and O
with O
neoadjuvant O
Celecoxib O
, O
respectively O
. O
In B-outcome
the I-outcome
HER2 I-outcome
positive I-outcome
group I-outcome
, O
pCR B-outcome
rate I-outcome
reached O
26 B-iv-bin-percent
% I-iv-bin-percent
in O
those O
who O
received O
neoadjuvant O
trastuzumab O
versus O
19 B-cv-bin-percent
% I-cv-bin-percent
in O
the O
others O
. O
There O
was O
no O
unexpected O
toxicity B-outcome
, I-outcome
no I-outcome
cardiac I-outcome
toxicity I-outcome
, I-outcome
and I-outcome
no I-outcome
toxic I-outcome
death I-outcome
. O
Triple O
negative O
breast O
cancers O
experience O
the O
highest O
pCR B-outcome
rate I-outcome
of O
30 O
% O
. O
Celecoxib O
is O
not O
likely O
to O
improve O
pCR B-outcome
rates I-outcome
in O
addition O
to O
EC O
- O
D O
in O
patients O
with O
HER2 O
- O
negative O
tumor O
. O
In O
HER2 O
- O
positive O
tumor O
patients O
, O
trastuzumab O
added O
to O
ECD O
leads O
to O
increased O
pCR O
rates O
. O
It O
was O
the O
only O
combination O
to O
deserve O
further O
study O
according O
to O
the O
two O
- O
stage O
Fleming O
's O
design O
used O
in O
this O
trial O
. O

Three O
dose O
regimens O
of O
fulvestrant B-intervention
in O
postmenopausal O
Japanese B-ethinicity
women B-eligibility
with I-eligibility
advanced I-eligibility
breast I-eligibility
cancer I-eligibility
: O
results O
from O
a O
double O
- O
blind O
, O
phase O
II O
comparative O
study O
( O
FINDER1 O
) O
. O
FINDER1 O
compared O
efficacy O
, O
tolerability O
and O
pharmacokinetics O
( O
PK O
) O
of O
three O
fulvestrant O
dose O
regimens O
in O
postmenopausal O
Japanese O
women O
with O
estrogen O
receptor O
( O
ER O
) O
-positive O
locally O
advanced O
/ O
metastatic O
breast O
cancer O
recurring O
or O
progressing O
after O
prior O
endocrine O
therapy O
. O
The O
primary O
end O
point O
of O
this O
randomised O
, O
multicentre O
, O
phase O
II O
study O
was O
objective B-outcome-measure
response I-outcome-measure
rate I-outcome-measure
( I-outcome-measure
ORR I-outcome-measure
) I-outcome-measure
and O
the O
secondary O
end O
points O
included O
time B-outcome-measure
to I-outcome-measure
progression I-outcome-measure
( I-outcome-measure
TTP I-outcome-measure
) I-outcome-measure
, O
clinical B-outcome-measure
benefit I-outcome-measure
rate I-outcome-measure
( I-outcome-measure
CBR I-outcome-measure
) I-outcome-measure
, O
PK B-outcome-measure
profiles I-outcome-measure
and O
tolerability B-outcome-measure
. O
Postmenopausal O
women O
with O
ER O
- O
positive O
advanced O
breast O
cancer O
were O
randomised O
to O
28 O
- O
day O
cycles O
of O
fulvestrant O
approved O
dose O
( O
AD O
) O
, O
loading O
dose O
( O
LD O
) O
or O
high O
dose O
( O
HD O
) O
until O
disease O
progression O
. O
Hundred B-total-participants
and I-total-participants
forty I-total-participants
- I-total-participants
three I-total-participants
patients O
( O
median O
age O
61 B-age
years I-age
) O
received O
fulvestrant B-intervention
AD I-intervention
( O
n O
= O
45 B-intervention-participants
) O
, O
LD B-intervention
( O
n O
= O
51 B-intervention-participants
) O
or O
HD B-intervention
( O
n O
= O
47 B-intervention-participants
) O
. O
ORR B-outcome
was O
similar O
across O
dose O
regimens O
: O
11.1 B-iv-bin-percent
% I-iv-bin-percent
, O
17.6 B-iv-bin-percent
% I-iv-bin-percent
and O
10.6 B-iv-bin-percent
% I-iv-bin-percent
for O
AD O
, O
LD O
and O
HD O
, O
respectively O
, O
with O
overlapping O
confidence O
intervals O
. O
TTP B-outcome
and I-outcome
CBR I-outcome
were O
also O
similar O
between O
groups O
( O
median B-outcome
TTP I-outcome
: O
6.0 B-iv-cont-median
, O
7.5 B-iv-cont-median
and O
6.0 B-iv-cont-median
months I-iv-cont-median
, O
respectively O
; O
CBR B-outcome
: O
42.2 B-iv-bin-percent
% I-iv-bin-percent
, O
54.9 B-iv-bin-percent
% I-iv-bin-percent
and O
46.8 B-iv-bin-percent
% I-iv-bin-percent
for O
AD O
, O
LD O
and O
HD O
, O
respectively O
) O
. O
C O
( O
max O
) O
and O
area O
under O
the O
plasma O
concentration O
- O
time O
curve O
were O
dose O
proportional O
and O
PK O
steady O
state O
was O
reached O
earlier O
with O
LD O
and O
HD O
than O
with O
AD O
. O
All O
three O
doses O
were O
well O
tolerated O
, O
with O
a O
similar O
adverse O
- O
event O
profile O
and O
no O
emerging O
safety O
concerns O
. O
Fulvestrant O
AD O
, O
LD O
and O
HD O
had O
similar O
efficacy O
and O
tolerability O
profiles O
in O
postmenopausal O
Japanese O
women O
with O
ER O
- O
positive O
advanced O
breast O
cancer O
. O

Comparing O
an O
olive B-intervention
oil I-intervention
- I-intervention
enriched I-intervention
diet I-intervention
to O
a O
standard B-control
lower I-control
- I-control
fat I-control
diet I-control
for O
weight O
loss O
in O
breast O
cancer O
survivors O
: O
a O
pilot O
study O
. O
Traditional O
diets O
that O
include O
moderate O
to O
high O
intakes O
of O
extra O
virgin O
olive O
oil O
have O
been O
related O
to O
a O
decrease O
in O
breast O
cancer O
risk O
. O
We O
hypothesized O
that O
an O
olive O
oil O
- O
enriched O
diet O
would O
lead O
to O
greater O
weight O
loss O
and O
acceptance O
, O
compared O
with O
a O
standard O
diet O
, O
in O
women B-eligibility
previously I-eligibility
diagnosed I-eligibility
with I-eligibility
invasive I-eligibility
breast I-eligibility
cancer I-eligibility
. O
Participants O
consumed O
a O
National O
Cancer O
Institute O
( O
NCI O
) O
diet O
( O
total O
fat O
> O
15 O
% O
and O
< O
30 O
% O
) O
and O
a O
plant O
- O
based O
olive O
oil O
diet O
( O
PBOO O
; O
> O
or O
= O
3 O
tablespoons O
of O
olive O
oil O
/ O
day O
) O
for O
8 O
weeks O
, O
each O
with O
random O
assignment O
to O
the O
order O
. O
We O
established O
a O
weight O
loss O
goal O
of O
at O
least O
5 O
% O
of O
baseline O
weight O
. O
After O
completion O
of O
the O
two O
diet O
trials O
, O
each O
participant O
self O
- O
selected O
one O
of O
the O
diets O
for O
an O
additional O
6 O
months O
of O
follow O
- O
up O
for O
weight O
management O
. O
Body O
measures O
were O
done O
before O
and O
after O
each O
diet O
and O
after O
follow O
- O
up O
; O
fasting O
blood O
samples O
were O
collected O
after O
each O
diet O
and O
after O
follow O
- O
up O
. O
Forty B-total-participants
- I-total-participants
four I-total-participants
overweight O
women O
started O
and O
28 B-total-participants
completed O
the O
44 O
- O
week O
protocol O
. O
Twelve B-iv-bin-abs
( O
80 B-iv-bin-percent
% I-iv-bin-percent
) O
of O
the O
15 B-intervention-participants
women O
who O
started O
with O
the O
PBOO O
diet O
achieved B-outcome
a I-outcome
weight I-outcome
loss I-outcome
of I-outcome
> I-outcome
or I-outcome
= I-outcome
5 I-outcome
% I-outcome
compared O
to O
4 B-cv-bin-abs
( O
31 B-cv-bin-percent
% I-cv-bin-percent
) O
of O
the O
13 B-control-participants
who O
started O
with O
the O
NCI O
diet O
( O
p O
< O
0.01 O
) O
. O
Nineteen O
of O
the O
22 O
women O
eligible O
for O
follow O
- O
up O
chose O
the O
PBOO O
diet O
, O
and O
all O
completed O
the O
study O
. O
Of O
the O
3 O
women O
who O
chose O
the O
NCI O
diet O
for O
follow O
- O
up O
, O
1 O
completed O
the O
study O
. O
The O
PBOO O
diet O
resulted O
in O
lower O
triglycerides B-outcome
( O
NCI O
105 B-cv-cont-mean
+ O
/- O
46 B-cv-cont-sd
mg I-cv-cont-sd
/ I-cv-cont-sd
dL I-cv-cont-sd
, O
PBOO O
96 B-iv-cont-mean
+ O
/- O
37 B-iv-cont-sd
mg I-iv-cont-sd
/ I-iv-cont-sd
dL I-iv-cont-sd
, O
p O
= O
0.06 O
) O
and O
higher B-outcome
high I-outcome
- I-outcome
density I-outcome
lipoprotein I-outcome
cholesterol I-outcome
( O
HDL O
- O
C O
) O
( O
NCI O
64 B-cv-cont-mean
+ O
/- O
13 B-cv-cont-sd
mg I-cv-cont-sd
/ I-cv-cont-sd
dL I-cv-cont-sd
, O
PBOO O
68 B-iv-cont-mean
+ O
/- O
12 B-iv-cont-sd
mg I-iv-cont-sd
/ I-iv-cont-sd
dL I-iv-cont-sd
, O
p O
= O
0.001 O
) O
. O
An O
olive O
oil O
- O
enriched O
diet O
brought O
about O
greater O
weight B-outcome
loss I-outcome
than O
a O
lower O
- O
fat O
diet O
in O
an O
8 O
- O
week O
comparison O
. O
Moreover O
, O
these O
women O
chose O
, O
overwhelmingly O
, O
the O
olive O
oil O
- O
enriched O
diet O
for O
6 O
months O
of O
follow O
- O
up O
. O
An O
olive O
oil O
- O
enriched O
diet O
may O
be O
more O
efficacious O
for O
weight O
loss O
in O
breast O
cancer O
survivors O
than O
a O
standard O
lower O
- O
fat O
diet O
. O

Five O
- O
year O
outcome O
for O
women O
randomised O
in O
a O
phase O
III O
trial O
comparing O
doxorubicin B-intervention
and I-intervention
cyclophosphamide I-intervention
with O
doxorubicin B-control
and I-control
docetaxel I-control
as O
primary O
medical O
therapy O
in O
early O
breast O
cancer O
: O
an O
Anglo O
- O
Celtic O
Cooperative O
Oncology O
Group O
study O
. O
To O
compare O
the O
long O
- O
term O
outcome O
of O
women O
with O
primary O
or O
locally O
advanced O
breast O
cancer O
randomised O
to O
receive O
either O
doxorubicin O
and O
cyclophosphamide O
( O
AC O
) O
or O
doxorubicin O
and O
docetaxel O
( O
AD O
) O
as O
primary O
chemotherapy O
. O
Eligible O
patients B-eligibility
with I-eligibility
histologic I-eligibility
- I-eligibility
proven I-eligibility
breast I-eligibility
cancer I-eligibility
with I-eligibility
primary I-eligibility
tumours I-eligibility
> I-eligibility
or I-eligibility
= I-eligibility
3 I-eligibility
cm I-eligibility
, I-eligibility
inflammatory I-eligibility
or I-eligibility
locally I-eligibility
advanced I-eligibility
disease I-eligibility
, I-eligibility
and I-eligibility
no I-eligibility
evidence I-eligibility
of I-eligibility
distant I-eligibility
metastases I-eligibility
, O
were O
randomised O
to O
receive O
a O
maximum O
of O
6 O
cycles O
of O
either O
doxorubicin O
( O
60 O
mg O
/ O
m O
( O
2 O
) O
) O
plus O
cyclophosphamide O
( O
600 O
mg O
/ O
m O
( O
2 O
) O
) O
i O
/ O
v O
or O
doxorubicin O
( O
50 O
mg O
/ O
m O
( O
2 O
) O
) O
plus O
docetaxel O
( O
75 O
mg O
/ O
m O
( O
2 O
) O
) O
i O
/ O
v O
every O
3 O
weeks O
, O
followed O
by O
surgery O
on O
completion O
of O
chemotherapy O
. O
Clinical O
and O
pathologic O
responses O
have O
previously O
been O
reported O
. O
Time O
to O
relapse O
, O
site O
of O
relapse O
, O
and O
all O
- O
cause O
mortality O
were O
recorded O
. O
This O
updated O
analysis O
compares O
long O
- O
term O
disease O
- O
free O
( O
DFS O
) O
and O
overall O
survival O
( O
OS O
) O
using O
stratified O
log O
rank O
methods O
. O
A O
total O
of O
363 B-total-participants
patients O
were O
randomised O
to O
AC O
( O
n O
= O
181 B-intervention-participants
) O
or O
AD O
( O
n O
= O
182 B-control-participants
) O
. O
A O
complete B-outcome
pathologic I-outcome
response I-outcome
was O
observed O
in O
16 B-iv-bin-percent
% I-iv-bin-percent
for O
AC O
and O
12 B-cv-bin-percent
% I-cv-bin-percent
for O
AD O
( O
P O
= O
0.43 O
) O
. O
The O
number B-outcome
of I-outcome
patients I-outcome
with I-outcome
positive I-outcome
axillary I-outcome
nodes I-outcome
at I-outcome
surgery I-outcome
with O
AC O
was O
61 B-iv-bin-percent
% I-iv-bin-percent
and O
AD O
66 B-cv-bin-percent
% I-cv-bin-percent
( O
P O
= O
0.36 O
) O
. O
At O
a O
median O
follow O
- O
up O
of O
99 O
months O
there O
is O
no O
significant O
difference O
between O
the O
two O
groups O
for O
DFS B-outcome
( O
P O
= O
0.20 O
) O
and O
OS B-outcome
( O
P O
= O
0.24 O
) O
. O
Deaths B-outcome
were O
due O
to O
metastatic O
breast O
cancer O
in O
96 O
% O
of O
patients O
. O
Our O
data O
do O
not O
support O
a O
clinical B-outcome
benefit I-outcome
for O
simultaneous O
administration O
of O
AD O
compared O
with O
AC O
. O
However O
, O
the O
data O
do O
not O
exclude O
a O
smaller O
benefit O
than O
the O
study O
was O
powered O
to O
detect O
and O
are O
consistent O
with O
an O
increase O
in O
both O
disease O
- O
free O
and O
overall O
survival O
of O
about O
5 O
% O
for O
AD O
compared O
with O
AC O
. O
Outcome O
is O
consistent O
with O
the O
pathologic O
complete O
response O
following O
surgery O
. O

Augmentation O
of O
venlafaxine B-intervention
and I-intervention
selective I-intervention
serotonin I-intervention
reuptake I-intervention
inhibitors I-intervention
with I-intervention
zolpidem I-intervention
improves O
sleep B-condition
and I-condition
quality I-condition
of I-condition
life I-condition
in O
breast O
cancer O
patients O
with O
hot O
flashes O
: O
a O
randomized O
, O
double O
- O
blind O
, O
placebo O
- O
controlled O
trial O
. O
Hot O
flashes O
are O
a O
major O
quality O
- O
of O
- O
life O
issue O
for O
breast O
cancer O
survivors O
, O
interrupting O
sleep O
, O
reducing O
quality O
of O
life O
, O
and O
diminishing O
treatment O
adherence O
to O
adjuvant O
endocrine O
therapies O
. O
Serotonin O
- O
norepinephrine O
reuptake O
inhibitors O
( O
SNRIs O
) O
and O
selective O
serotonin O
reuptake O
inhibitors O
( O
SSRIs O
) O
are O
used O
widely O
but O
are O
only O
partially O
effective O
for O
hot O
flashes O
. O
Alternative O
strategies O
are O
needed O
. O
We O
hypothesized O
that O
augmentation O
of O
SSRI O
/ O
SNRI O
therapy O
with O
hypnotic O
agents O
would O
optimize O
hot O
flash O
therapy O
by O
improving O
sleep O
and O
quality O
of O
life O
. O
Women B-eligibility
with I-eligibility
breast I-eligibility
cancer I-eligibility
or I-eligibility
at I-eligibility
high I-eligibility
risk I-eligibility
for I-eligibility
developing I-eligibility
the I-eligibility
disease I-eligibility
who I-eligibility
had I-eligibility
hot I-eligibility
flashes I-eligibility
in I-eligibility
association I-eligibility
with I-eligibility
nocturnal I-eligibility
awakenings I-eligibility
were O
randomized O
to O
double O
- O
blinded O
treatment O
with O
zolpidem B-intervention
10 O
mg O
or O
placebo B-control
for O
5 O
weeks O
. O
SSRI O
/ O
SNRI O
nonusers O
( O
81 O
% O
) O
started O
venlafaxine O
XR O
75 O
mg O
/ O
day O
concurrently O
, O
whereas O
SSRI O
/ O
SNRI O
users O
continued O
that O
therapy O
. O
We O
compared O
the O
proportion O
of O
responders O
, O
defined O
as O
study O
completers O
with O
improved O
subjective O
sleep O
quality O
( O
Pittsburgh O
Sleep O
Quality O
Index O
) O
and/or O
objectively O
assessed O
wake O
time O
after O
sleep O
onset O
on O
actigraphy O
, O
between O
groups O
. O
Of O
53 B-total-participants
women O
( O
aged O
51 B-age
 I-age
8 I-age
y I-age
) O
randomized O
to O
zolpidem O
augmentation O
( O
n O
= O
25 B-intervention-participants
) O
or O
placebo O
augmentation O
( O
n O
= O
28 B-control-participants
) O
, O
38 B-total-participants
completed O
the O
protocol O
( O
57 B-intervention-participants
% I-intervention-participants
on O
placebo O
, O
88 B-control-participants
% I-control-participants
on O
zolpidem O
) O
. O
More O
women O
augmented O
with O
zolpidem O
than O
placebo O
were O
responders O
on O
the O
sleep B-outcome
outcome I-outcome
( O
40 B-iv-bin-percent
% I-iv-bin-percent
vs O
14 B-cv-bin-percent
% I-cv-bin-percent
; O
P O
= O
0.035 O
) O
. O
Quality B-outcome
of I-outcome
life I-outcome
improved O
more O
with O
zolpidem O
than O
with O
placebo O
( O
P O
= O
0.01 O
) O
. O
Treatment O
effects O
on O
hot B-outcome
flashes I-outcome
and O
mood B-outcome
did O
not O
differ O
between O
groups O
. O
Augmentation O
of O
SSRI O
/ O
SNRI O
with O
zolpidem O
improves O
sleep O
and O
quality O
of O
life O
in O
breast O
cancer O
survivors O
with O
hot O
flashes O
and O
associated O
sleep O
disturbance O
. O
Adding O
a O
hypnotic O
agent O
to O
an O
SSRI O
/ O
SNRI O
helps O
women O
to O
sleep O
through O
nighttime O
hot O
flashes O
. O
Treatments O
targeting O
sleep O
may O
be O
an O
important O
supplemental O
strategy O
to O
optimize O
well O
- O
being O
. O

Multicenter O
phase O
II O
randomized O
trial O
evaluating O
antiangiogenic B-intervention
therapy I-intervention
with I-intervention
sunitinib I-intervention
as O
consolidation O
after O
objective O
response O
to O
taxane O
chemotherapy O
in O
women O
with O
HER2 O
- O
negative O
metastatic O
breast O
cancer O
. O
The O
aim O
of O
this O
study O
is O
to O
test O
the O
hypothesis O
that O
antiangiogenic O
treatment O
with O
sunitinib O
consolidation O
can O
prolong O
remissions O
induced O
by O
taxane O
- O
based O
chemotherapy O
in O
women O
with O
metastatic O
breast O
cancer O
. O
The O
method O
involves O
a O
two O
- O
arm O
open O
- O
label O
( O
2 O
:1 O
randomization O
) O
multicenter O
, O
randomized O
phase O
II O
trial O
evaluating O
the O
efficacy O
of O
sunitinib O
( O
arm O
A O
) O
versus O
no B-control
therapy I-control
( O
arm O
B O
) O
in O
patients B-eligibility
with I-eligibility
HER-2 I-eligibility
- I-eligibility
negative I-eligibility
metastatic I-eligibility
breast I-eligibility
cancer I-eligibility
who I-eligibility
achieved I-eligibility
an I-eligibility
objective I-eligibility
response I-eligibility
to I-eligibility
taxane I-eligibility
- I-eligibility
based I-eligibility
chemotherapy I-eligibility
. O
The O
results O
of O
this O
study O
indicates O
that O
the O
primary O
endpoint O
of O
progression B-outcome
- I-outcome
free I-outcome
survival I-outcome
( I-outcome
PFS I-outcome
) I-outcome
> I-outcome
or I-outcome
= I-outcome
5 I-outcome
months I-outcome
was O
achieved O
in O
10 B-iv-bin-abs
of O
36 B-intervention-participants
patients O
( O
28 B-iv-bin-percent
% I-iv-bin-percent
) O
in O
arm O
A O
and O
4 B-cv-bin-abs
of O
19 B-control-participants
patients O
( O
21 B-cv-bin-percent
% I-cv-bin-percent
) O
in O
arm O
B O
. O
The O
median B-outcome
PFS I-outcome
was O
2.8 B-iv-cont-median
and O
3.1 B-cv-cont-median
months I-cv-cont-median
, O
respectively O
. O
A O
protocol O
amendment O
to O
the O
sunitinib O
dosing O
schedule O
was O
made O
because O
53 O
% O
( O
17 O
/ O
32 O
) O
of O
patients O
treated O
at O
a O
starting O
dose O
of O
50 O
mg O
( O
4 O
weeks O
on O
/ O
2 O
weeks O
off O
) O
required B-outcome
dose I-outcome
reduction I-outcome
. O
Changing O
the O
starting O
dose O
to O
sunitinib O
37.5 O
mg O
continuously O
resulted O
in O
dose B-outcome
reductions I-outcome
in O
44 O
% O
( O
7 O
/ O
16 O
) O
of O
patients O
. O
Grades B-outcome
III I-outcome
- I-outcome
IV I-outcome
toxicity I-outcome
occurred O
in O
69 B-iv-bin-percent
% I-iv-bin-percent
of O
patients O
in O
arm O
A O
( O
fatigue B-outcome
31 B-iv-bin-percent
% I-iv-bin-percent
, O
musculoskeletal B-outcome
pain I-outcome
11 B-iv-bin-percent
% I-iv-bin-percent
, O
neutropenia B-outcome
and I-outcome
thrombopenia I-outcome
8 B-outcome
% I-outcome
) O
and O
11 B-cv-bin-percent
% I-cv-bin-percent
in O
arm O
B O
. O
The O
proof O
- O
of O
- O
principle O
study O
does O
not O
confirm O
the O
hypothesis O
that O
sunitinib O
consolidation O
therapy O
can O
lead O
to O
a O
predefined O
clinically O
relevant O
proportion O
of O
patients O
with O
PFS O
of O
> O
or O
= O
5 O
months O
after O
an O
objective O
response O
to O
taxanes O
. O
Furthermore O
, O
toxicity O
was O
significant O
. O

Axillary B-intervention
dissection I-intervention
versus O
no B-control
axillary I-control
dissection I-control
in O
elderly B-eligibility
patients I-eligibility
with I-eligibility
breast I-eligibility
cancer I-eligibility
and I-eligibility
no I-eligibility
palpable I-eligibility
axillary I-eligibility
nodes I-eligibility
: O
results O
after O
15 O
years O
of O
follow O
- O
up O
. O
To O
assess O
the O
long O
- O
term O
safety O
of O
no O
axillary O
clearance O
in O
elderly O
patients O
with O
breast O
cancer O
and O
nonpalpable O
axillary O
nodes O
. O
Lymph O
node O
evaluation O
in O
elderly O
patients O
with O
early O
breast O
cancer O
and O
clinically O
negative O
axillary O
nodes O
is O
controversial O
. O
Our O
randomized O
trial O
with O
5 O
- O
year O
follow O
- O
up O
showed O
no O
breast O
cancer O
mortality O
advantage O
for O
axillary O
clearance O
compared O
with O
observation O
in O
older O
patients O
with O
T1N0 O
disease O
. O
We O
further O
investigated O
axillary O
treatment O
in O
a O
retrospective O
analysis O
of O
671 B-total-participants
consecutive O
patients O
, O
aged O
 B-age
70 I-age
years I-age
, O
with B-eligibility
operable I-eligibility
breast I-eligibility
cancer I-eligibility
and I-eligibility
a I-eligibility
clinically I-eligibility
clear I-eligibility
axilla I-eligibility
, O
treated O
between O
1987 O
and O
1992 O
; O
172 O
received O
and O
499 O
did O
not O
receive O
axillary O
dissection O
; O
20 O
mg O
/ O
day O
tamoxifen O
was O
prescribed O
for O
at O
least O
2 O
years O
. O
We O
used O
multivariable O
analysis O
to O
take O
account O
of O
the O
lack O
of O
randomization O
. O
After O
median O
follow O
- O
up O
of O
15 O
years O
( O
interquartile O
range O
14 O
- O
17 O
years O
) O
there O
was O
no O
significant O
difference O
in O
breast B-outcome
cancer I-outcome
mortality I-outcome
between O
the O
axillary O
and O
no O
axillary O
clearance O
groups O
. O
Crude O
cumulative O
15 B-outcome
- I-outcome
year I-outcome
incidence I-outcome
of I-outcome
axillary I-outcome
disease I-outcome
in O
the O
no O
axillary O
dissection O
group O
was O
low O
: O
5.8 B-iv-bin-percent
% I-iv-bin-percent
overall O
and O
3.7 B-iv-bin-percent
% I-iv-bin-percent
for O
pT1 O
patients O
. O
Elderly O
patients O
with O
early O
breast O
cancer O
and O
clinically O
negative O
nodes O
did O
not O
benefit O
in O
terms O
of O
breast O
cancer O
mortality O
from O
immediate O
axillary O
dissection O
in O
this O
nonrandomized O
study O
. O
Sentinel O
node O
biopsy O
could O
also O
be O
foregone O
due O
to O
the O
very O
low O
cumulative O
incidence O
of O
axillary O
disease O
in O
this O
age O
group O
. O
Axillary O
dissection O
should O
be O
restricted O
to O
the O
small O
number O
of O
patients O
who O
later O
develop O
overt O
axillary O
disease O
. O

A O
randomized O
controlled O
trial O
of O
emotionally B-intervention
expressive I-intervention
writing I-intervention
for O
women O
with O
metastatic O
breast O
cancer O
. O
To O
test O
the O
effects O
of O
emotionally O
expressive O
writing O
in O
a O
randomized O
controlled O
trial O
of O
metastatic B-eligibility
breast I-eligibility
cancer I-eligibility
patients I-eligibility
and O
to O
determine O
whether O
effects O
of O
the O
intervention O
varied O
as O
a O
function O
of O
perceived O
social O
support O
or O
time O
since O
metastatic O
diagnosis O
. O
Women O
( O
N O
= O
62 B-total-participants
) O
living B-eligibility
with I-eligibility
Stage I-eligibility
IV I-eligibility
breast I-eligibility
cancer I-eligibility
were O
randomly O
assigned O
to O
write O
about O
cancer O
- O
related O
emotions O
( O
EMO O
; O
n O
= O
31 B-intervention-participants
) O
or O
the O
facts O
of O
their O
diagnosis O
and O
treatment O
( O
CTL B-control
; O
n O
= O
31 B-control-participants
) O
. O
Participants O
wrote O
at O
home O
for O
four O
20 O
- O
min O
sessions O
within O
a O
3 O
- O
week O
interval O
. O
Depressive O
symptoms O
, O
cancer O
- O
related O
intrusive O
thoughts O
, O
somatic O
symptoms O
, O
and O
sleep O
quality O
at O
3 O
months O
postintervention O
. O
No O
significant O
main O
effects O
of O
experimental O
condition O
were O
observed O
. O
A O
significant B-outcome
condition I-outcome
x I-outcome
social I-outcome
support I-outcome
interaction I-outcome
emerged I-outcome
on I-outcome
intrusive I-outcome
thoughts I-outcome
; O
EMO O
writing O
was O
associated O
with O
reduced O
intrusive O
thoughts O
for O
women O
reporting O
low O
emotional O
support O
( O
eta2 O
= O
.15 O
) O
. O
Significant B-outcome
condition I-outcome
x I-outcome
time I-outcome
since I-outcome
metastatic I-outcome
diagnosis I-outcome
interactions I-outcome
were O
also O
observed O
for O
somatic O
symptoms O
and O
sleep O
disturbances O
. O
Relative O
to O
CTL O
, O
EMO O
participants O
who O
were O
more O
recently O
diagnosed O
had O
fewer O
somatic O
symptoms O
( O
eta2 O
= O
.10 O
) O
, O
whereas O
EMO O
participants O
with O
longer O
diagnosis O
duration O
exhibited O
increases B-outcome
in I-outcome
sleep I-outcome
disturbances I-outcome
( O
eta2 O
= O
.09 O
) O
. O
Although O
there O
was O
no O
main O
effect O
of O
expressive O
writing O
on O
health O
among O
the O
current O
metastatic O
breast O
cancer O
sample O
, O
expressive O
writing O
may O
be O
beneficial O
for O
a O
subset O
of O
metastatic O
patients O
( O
including O
women O
with O
low O
levels O
of O
emotional O
support O
or O
who O
have O
been O
recently O
diagnosed O
) O
and O
contraindicated O
for O
others O
( O
i.e. O
, O
those O
who O
have O
been O
living O
with O
the O
diagnosis O
for O
years O
) O
. O
  O

A O
randomised O
pilot O
of O
a O
self B-intervention
- I-intervention
help I-intervention
workbook I-intervention
intervention O
for O
breast O
cancer O
survivors O
. O
The O
aim O
of O
this O
study O
is O
to O
evaluate O
the O
efficacy O
of O
a O
self O
- O
help O
workbook O
for O
improving O
adjustment O
for O
breast O
cancer O
survivors O
. O
An O
RCT O
compared O
the O
workbook O
( O
n O
= O
20 B-intervention-participants
) O
with O
no B-control
- I-control
workbook I-control
controls I-control
( O
n O
= O
20 B-control-participants
) O
. O
Coping O
, O
traumatic O
stress O
and O
quality O
of O
life O
were O
measured O
at O
baseline O
, O
then O
3 O
and O
6 O
months O
later O
. O
No O
interactions O
were O
found O
. O
A O
significant O
group O
main O
effect O
was O
found O
for O
venting B-outcome
coping I-outcome
; O
controls O
used O
less O
venting O
coping O
than O
workbook O
participants O
( O
p O
= O
0.034 O
) O
. O
A O
significant O
time O
main O
effect O
was O
obtained O
for O
cognitive B-outcome
functioning I-outcome
( O
p O
= O
0.003 O
) O
. O
Reliable O
change O
indices O
showed O
a O
trend O
towards O
a O
protective O
effect O
across O
all O
coping O
measures O
for O
workbook O
participants O
compared O
to O
controls O
. O
Qualitative O
feedback O
suggested O
that O
participants O
felt O
well O
supported O
by O
the O
intervention O
, O
but O
would O
have O
preferred O
receiving O
it O
during O
treatment O
. O
While O
trends O
showed O
some O
promise O
for O
improving O
coping O
, O
endorsement O
for O
the O
workbook O
was O
not O
obtained O
. O
The O
difficulties O
encountered O
in O
recruiting O
survivors O
and O
the O
resulting O
implications O
regarding O
the O
feasibility O
of O
offering O
self O
- O
help O
resources O
to O
this O
population O
are O
discussed O
. O

Eleven O
- O
year O
follow O
- O
up O
of O
a O
randomized O
study O
of O
pectoral B-intervention
fascia I-intervention
preservation I-intervention
after O
mastectomy O
for O
early O
breast O
cancer O
. O
The O
present O
study O
reports O
results O
of O
a O
randomized O
trial O
in O
which O
breast O
cancer O
patients O
operated O
with O
preserved O
pectoral O
fascia O
compared O
to O
removal O
of O
the O
pectoral O
fascia O
showed O
a O
trend O
toward O
an O
increased O
risk O
for O
chest O
wall O
recurrence O
The O
aim O
of O
the O
study O
was O
to O
assess O
whether O
the O
different O
procedural O
modes O
had O
any O
impact O
on O
survival O
or O
local O
control O
in O
breast O
cancer O
patients O
followed O
in O
the O
long O
term O
. O
The O
trial O
included O
247 B-total-participants
patients B-eligibility
with I-eligibility
breast I-eligibility
cancer I-eligibility
who I-eligibility
underwent I-eligibility
modified I-eligibility
radical I-eligibility
mastectomy I-eligibility
in O
five O
Swedish B-location
hospitals O
between O
1993 O
and O
1997 O
. O
The O
median O
follow O
- O
up O
time O
was O
11 O
 O
years O
. O
The O
patients O
were O
randomized O
between O
removal B-control
( O
n O
 O
= O
 O
122 B-control-participants
) O
versus O
preservation O
( O
n O
 O
= O
 O
125 B-intervention-participants
) O
of O
the O
pectoral O
fascia O
. O
The O
breast B-outcome
- I-outcome
cancer I-outcome
- I-outcome
specific I-outcome
survival I-outcome
at B-outcome
10 I-outcome
 I-outcome
years I-outcome
was O
73 O
% O
. O
Removal O
or O
preservation O
of O
the O
pectoral O
fascia O
had O
no O
significant O
impact O
on O
chest B-outcome
- I-outcome
wall I-outcome
recurrence I-outcome
rate I-outcome
or I-outcome
breast I-outcome
- I-outcome
cancer I-outcome
- I-outcome
specific I-outcome
survival I-outcome
. O
A O
total O
of O
18 B-iv-bin-abs
patients O
with O
chest B-outcome
- I-outcome
wall I-outcome
recurrence I-outcome
were O
seen O
in O
the O
group O
allocated O
to O
pectoral O
fascia O
preservation O
versus O
a O
total O
of O
10 B-cv-bin-abs
in O
patients O
allocated O
to O
pectoral O
fascia O
removal O
( O
hazard O
ratio O
 O
= O
 O
1.8 O
, O
95 O
% O
confidence O
interval O
 O
= O
 O
0.8 O
- O
4.0 O
) O
. O
The O
majority O
of O
the O
chest O
- O
wall O
recurrences O
were O
detected O
0 O
- O
5 O
 O
years O
postoperatively O
. O
The O
cumulative B-outcome
chest I-outcome
- I-outcome
wall I-outcome
recurrence I-outcome
rates I-outcome
at B-outcome
5 I-outcome
and O
at B-outcome
10 I-outcome
 I-outcome
years I-outcome
were O
13 B-iv-bin-percent
and O
15 B-iv-bin-percent
% I-iv-bin-percent
, O
respectively O
, O
in O
patients O
allocated O
to O
pectoral O
fascia O
preservation O
and O
8 B-cv-bin-percent
and O
9 B-cv-bin-percent
% I-cv-bin-percent
in O
patients O
allocated O
to O
pectoral O
fascia O
removal O
. O
With O
long O
- O
term O
follow O
- O
up O
neither O
the O
chest B-outcome
wall I-outcome
recurrence I-outcome
rate I-outcome
nor O
the O
breast B-outcome
- I-outcome
cancer I-outcome
- I-outcome
specific I-outcome
survival I-outcome
was O
significantly O
influenced O
by O
the O
preservation O
of O
the O
pectoral O
fascia O
. O
A O
trend O
toward O
an O
increased O
risk O
for O
chest O
wall O
recurrence O
was O
observed O
in O
patients O
with O
preserved O
pectoral O
fascia O
. O
A O
hazard O
ratio O
of O
1.8 O
for O
a O
chest O
- O
wall O
recurrence O
in O
patients O
with O
preserved O
fascia O
indicates O
that O
fascia O
- O
sparing O
mastectomy O
may O
negatively O
affect O
prognosis O
. O

Lapatinib B-intervention
plus I-intervention
capecitabine I-intervention
in O
women O
with O
HER-2 O
- O
positive O
advanced O
breast O
cancer O
: O
final O
survival O
analysis O
of O
a O
phase O
III O
randomized O
trial O
. O
A O
planned O
interim O
analysis O
of O
study O
EGF100151 O
prompted O
early O
termination O
of O
enrollment O
based O
on O
a O
longer O
time O
to O
progression O
with O
lapatinib O
and O
capecitabine O
than O
with O
capecitabine O
alone O
in O
patients O
with O
human O
epidermal O
growth O
factor O
receptor O
( O
HER O
) O
-2 O
( O
+ O
) O
previously O
treated O
advanced O
breast O
cancer O
or O
metastatic O
breast O
cancer O
( O
MBC O
) O
. O
Here O
, O
we O
report O
final O
analyses O
of O
overall O
survival O
. O
Women B-eligibility
with I-eligibility
HER-2 I-eligibility
( I-eligibility
+ I-eligibility
) I-eligibility
MBC I-eligibility
who I-eligibility
progressed I-eligibility
after I-eligibility
regimens I-eligibility
that I-eligibility
included I-eligibility
, I-eligibility
but I-eligibility
were I-eligibility
not I-eligibility
limited I-eligibility
to I-eligibility
, I-eligibility
anthracyclines I-eligibility
, I-eligibility
taxanes I-eligibility
, I-eligibility
and I-eligibility
trastuzumab I-eligibility
, O
were O
randomized O
to O
lapatinib O
( O
1,250 O
mg O
/ O
day O
) O
plus O
capecitabine O
( O
2,000 O
mg O
/ O
m O
( O
2 O
) O
) O
or O
capecitabine B-control
monotherapy I-control
( O
2,500 O
mg O
/ O
m O
( O
2 O
) O
) O
on O
days O
1 O
- O
14 O
of O
a O
21 O
- O
day O
cycle O
. O
At O
enrollment O
termination O
, O
399 B-total-participants
patients O
were O
randomized O
, O
and O
nine O
were O
being O
screened O
and O
were O
offered O
combination O
treatment O
. O
In O
total O
, O
207 B-intervention-participants
and O
201 B-control-participants
patients O
were O
enrolled O
to O
combination O
therapy O
and O
monotherapy O
, O
respectively O
. O
Thirty O
- O
six O
patients O
receiving O
monotherapy O
crossed O
over O
to O
combination O
therapy O
following O
enrollment O
termination O
. O
The O
median B-outcome
overall I-outcome
survival I-outcome
times I-outcome
were O
75.0 B-iv-cont-median
weeks I-iv-cont-median
for O
the O
combination O
arm O
and O
64.7 B-cv-cont-median
weeks I-cv-cont-median
for O
the O
monotherapy O
arm O
( O
hazard O
ratio O
[ O
HR O
] O
, O
0.87 O
; O
95 O
% O
confidence O
interval O
[ O
CI O
] O
, O
0.71 O
- O
1.08 O
; O
p O
= O
.210 O
) O
. O
A O
Cox O
regression O
analysis O
considering O
crossover O
as O
a O
time O
- O
dependent O
covariate O
suggested O
a O
20 B-iv-bin-percent
% I-iv-bin-percent
lower B-outcome
risk I-outcome
for I-outcome
death I-outcome
for O
patients O
treated O
with O
combination O
therapy O
( O
HR O
, O
0.80 O
; O
95 O
% O
CI O
, O
0.64 O
- O
0.99 O
; O
p O
= O
.043 O
) O
. O
The O
low O
incidence O
of O
serious O
adverse B-outcome
events I-outcome
was O
consistent O
with O
previously O
reported O
rates O
. O
Although O
premature O
enrollment O
termination O
and O
subsequent O
crossover O
resulted O
in O
insufficient O
power O
to O
detect O
differences O
in O
overall O
survival O
, O
exploratory O
analyses O
demonstrate O
a O
trend O
toward O
a O
survival O
advantage O
with O
lapatinib O
plus O
capecitabine O
. O
These O
data O
continue O
to O
support O
the O
efficacy O
of O
lapatinib O
in O
patients O
with O
HER-2 O
( O
+ O
) O
MBC O
. O

A O
prospective O
randomized O
, O
placebo O
- O
controlled O
skin O
care O
study O
in O
women O
diagnosed O
with O
breast O
cancer O
undergoing O
radiation O
therapy O
. O
To O
compare O
the O
effectiveness O
of O
three O
different O
skin B-intervention
care I-intervention
products I-intervention
versus O
a O
placebo B-control
in O
reducing O
the O
incidence O
of O
radiation B-condition
therapy I-condition
- I-condition
induced I-condition
skin I-condition
reactions I-condition
prophylactically O
. O
Prospective O
randomized O
, O
double O
- O
blinded O
, O
placebo O
- O
controlled O
study O
. O
A O
radiation O
oncology O
department O
at O
a O
National O
Cancer O
Institute O
- O
designated O
comprehensive O
cancer O
center O
in O
the O
southeastern B-location
United I-location
States I-location
. O
208 B-total-participants
women B-eligibility
with I-eligibility
breast I-eligibility
cancer I-eligibility
who I-eligibility
were I-eligibility
to I-eligibility
receive I-eligibility
whole I-eligibility
breast I-eligibility
radiation I-eligibility
therapy I-eligibility
. O
Patients O
were O
invited O
to O
participate O
after O
radiation O
therapy O
was O
documented O
as O
part O
of O
their O
treatment O
plan O
. O
Patients O
applied O
a O
skin O
care O
product O
starting O
on O
the O
first O
day O
of O
treatment O
and O
were O
assessed O
weekly O
by O
their O
radiation O
oncology O
nurse O
. O
Skin O
reaction O
score O
and O
skin O
product O
. O
None O
of O
the O
products O
were O
statistically O
better O
than O
placebo O
in O
preventing B-outcome
skin I-outcome
reactions I-outcome
. O
Increases B-outcome
in I-outcome
skin I-outcome
reaction I-outcome
over O
time O
did O
not O
vary O
with O
treatment O
group O
for O
the O
linear O
( O
p O
= O
0.16 O
) O
and O
nonlinear O
( O
p O
= O
0.94 O
) O
effects O
of O
time O
and O
for O
both O
time O
components O
tested O
together O
( O
p O
= O
0.41 O
) O
. O
Ninety O
- O
five O
percent O
of O
women O
participating O
in O
this O
study O
experienced O
a O
radiation B-outcome
therapy I-outcome
- I-outcome
induced I-outcome
skin I-outcome
reaction I-outcome
. O
The O
development O
of O
guidelines O
to O
support O
safe O
patient O
care O
is O
encouraged O
because O
patients O
prefer O
to O
take O
action O
rather O
than O
do O
nothing O
. O
However O
, O
the O
findings O
do O
not O
demonstrate O
improved O
clinical O
outcomes O
with O
the O
use O
of O
skin O
care O
products O
. O
Healthcare O
providers O
should O
proactively O
educate O
patients O
about O
acute O
skin O
reactions O
and O
self O
- O
care O
strategies O
to O
minimize O
skin O
breakdown O
. O

Phase O
II O
, O
double O
- O
blind O
, O
randomized O
trial O
of O
capecitabine B-intervention
plus I-intervention
enzastaurin I-intervention
versus O
capecitabine B-control
plus I-control
placebo I-control
in O
patients B-eligibility
with I-eligibility
metastatic I-eligibility
or I-eligibility
recurrent I-eligibility
breast I-eligibility
cancer I-eligibility
after I-eligibility
prior I-eligibility
anthracycline I-eligibility
and I-eligibility
taxane I-eligibility
therapy I-eligibility
. O
Capecitabine O
is O
frequently O
used O
in O
the O
treatment O
of O
recurrent O
/ O
progressive O
metastatic O
breast O
cancer O
( O
MBC O
) O
after O
prior O
anthracycline O
and O
taxane O
therapy O
. O
With O
the O
intention O
of O
improving O
the O
efficacy O
of O
single O
agent O
capecitabine O
, O
we O
initiated O
a O
randomized O
, O
double O
- O
blind O
, O
placebo O
- O
controlled O
Phase O
II O
study O
of O
the O
novel O
serine O
/ O
threonine O
kinase O
inhibitor O
enzastaurin O
in O
combination O
with O
capecitabine O
in O
a O
heavily O
pretreated O
patient O
population O
. O
Patients O
received O
capecitabine O
1,250 O
mg O
/ O
m O
( O
2 O
) O
twice O
daily O
plus O
enzastaurin O
500 O
mg O
/ O
day O
, O
or O
capecitabine O
plus O
placebo O
. O
The O
capecitabine O
was O
administered O
for O
the O
first O
14 O
days O
of O
each O
21 O
day O
cycle O
. O
The O
primary O
outcome O
was O
progression B-outcome-measure
- I-outcome-measure
free I-outcome-measure
survival I-outcome-measure
( I-outcome-measure
PFS I-outcome-measure
) I-outcome-measure
using O
the O
log O
- O
rank O
test O
( O
1 O
- O
sided O
significance O
level O
of O
0.20 O
) O
. O
Of O
109 B-total-participants
patients O
assessed O
for O
eligibility O
, O
85 B-total-participants
were O
enrolled O
, O
randomized O
, O
and O
treated O
( O
42 B-intervention-participants
and O
43 B-control-participants
patients O
in O
each O
respective O
treatment O
group O
) O
. O
The O
study O
was O
terminated O
early O
following O
a O
preplanned O
futility O
analysis O
. O
Median B-outcome
PFS I-outcome
( O
95 O
% O
CI O
) O
was O
2.8 B-iv-cont-median
( O
2.1 O
- O
4.6 O
) O
months O
with O
capecitabine O
plus O
enzastaurin O
versus O
4.3 B-cv-cont-median
( O
2.9 O
- O
6.2 O
) O
months O
with O
capecitabine O
plus O
placebo O
( O
adjusted O
hazard O
ratio O
: O
1.728 O
[ O
1.00 O
- O
2.97 O
] O
; O
P O
= O
0.048 O
) O
. O
Median B-outcome
overall I-outcome
survival I-outcome
( O
95 O
% O
CI O
) O
was O
lower O
with O
capecitabine O
plus O
enzastaurin O
than O
with O
capecitabine O
plus O
placebo O
( O
9.9 B-iv-cont-median
[ O
7.0 O
- O
16.6 O
] O
months O
vs O
14.9 B-cv-cont-median
[ O
9.9 O
- O
19.3 O
] O
months O
, O
P O
= O
0.181 O
) O
. O
Grade B-outcome
3 I-outcome
/ I-outcome
4 I-outcome
adverse I-outcome
events I-outcome
were O
more O
frequent O
with O
capecitabine O
plus O
enzastaurin O
( O
42.9 B-iv-bin-percent
% I-iv-bin-percent
vs O
32.6 B-cv-bin-percent
% I-cv-bin-percent
) O
. O
Given O
the O
lack O
of O
PFS O
benefit O
, O
capecitabine O
plus O
enzastaurin O
is O
unsuitable O
as O
therapy O
for O
patients O
with O
recurrent O
/ O
progressive O
MBC O
after O
prior O
anthracycline O
and O
taxane O
therapy O
. O
This O
trial O
is O
registered O
on O
www O
. O
clinicaltrials O
. O
gov O
( O
identifier O
: O
NCT00437294 O
) O
. O

Evaluation O
of O
a O
30 O
- O
gene O
paclitaxel B-intervention
, I-intervention
fluorouracil I-intervention
, I-intervention
doxorubicin I-intervention
, I-intervention
and I-intervention
cyclophosphamide I-intervention
chemotherapy I-intervention
response O
predictor O
in O
a O
multicenter O
randomized O
trial O
in O
breast O
cancer O
. O
We O
examined O
in O
a O
prospective O
, O
randomized O
, O
international O
clinical O
trial O
the O
performance O
of O
a O
previously O
defined O
30 O
- O
gene O
predictor O
( O
DLDA-30 O
) O
of O
pathologic O
complete O
response O
( O
pCR O
) O
to O
preoperative O
weekly O
paclitaxel O
and O
fluorouracil O
, O
doxorubicin O
, O
and O
cyclophosphamide O
( O
T O
/ O
FAC O
) O
chemotherapy O
, O
and O
assessed O
if O
DLDA-30 O
also O
predicts O
increased O
sensitivity O
to O
FAC O
- O
only O
chemotherapy O
. O
We O
compared O
the O
pCR O
rates O
after O
T O
/ O
FAC O
versus O
FACx6 O
preoperative O
chemotherapy O
. O
We O
also O
did O
an O
exploratory O
analysis O
to O
identify O
novel O
candidate O
genes O
that O
differentially O
predict O
response O
in O
the O
two O
treatment O
arms O
. O
Two B-total-participants
hundred I-total-participants
and I-total-participants
seventy I-total-participants
- I-total-participants
three I-total-participants
patients O
were O
randomly O
assigned O
to O
receive O
either O
weekly O
paclitaxel O
 O
12 O
followed O
by O
FAC O
 O
4 O
( O
T B-intervention
/ I-intervention
FAC I-intervention
, O
n O
= O
138 B-intervention-participants
) O
, O
or O
FAC B-control
 O
6 O
( O
n O
= O
135 B-control-participants
) O
neoadjuvant O
chemotherapy O
. O
All O
patients O
underwent O
a O
pretreatment O
fine O
- O
needle O
aspiration O
biopsy O
of O
the O
tumor O
for O
gene O
expression O
profiling O
and O
treatment O
response O
prediction O
. O
The O
pCR B-outcome
rates I-outcome
were O
19 B-iv-bin-percent
% I-iv-bin-percent
and O
9 B-cv-bin-percent
% I-cv-bin-percent
in O
the O
T O
/ O
FAC O
and O
FAC O
arms O
, O
respectively O
( O
P O
< O
0.05 O
) O
. O
In O
the O
T O
/ O
FAC O
arm O
, O
the O
positive B-outcome
predictive I-outcome
value I-outcome
( I-outcome
PPV I-outcome
) I-outcome
of O
the O
genomic O
predictor O
was O
38 B-iv-bin-percent
% I-iv-bin-percent
[ O
95 O
% O
confidence O
interval O
( O
95 O
% O
CI O
) O
, O
21 O
- O
56 O
% O
] O
, O
the O
negative B-outcome
predictive I-outcome
value I-outcome
was O
88 B-iv-bin-percent
% I-iv-bin-percent
( O
95 O
% O
CI O
, O
77 O
- O
95 O
% O
) O
, O
and O
the O
area B-outcome
under I-outcome
the I-outcome
receiver I-outcome
operating I-outcome
characteristic I-outcome
curve I-outcome
( I-outcome
AUC I-outcome
) I-outcome
was O
0.711 O
. O
In O
the O
FAC O
arm O
, O
the O
PPV B-outcome
was O
9 B-cv-bin-percent
% I-cv-bin-percent
( O
95 O
% O
CI O
, O
1 O
- O
29 O
% O
) O
and O
the O
AUC B-outcome
was O
0.584 O
. O
This O
suggests O
that O
the O
genomic O
predictor O
may O
have O
regimen O
specificity O
. O
Its O
performance O
was O
similar O
to O
a O
clinical O
variable O
- O
based O
predictor O
nomogram O
. O
Gene O
expression O
profiling O
for O
prospective O
response O
prediction O
was O
feasible O
in O
this O
international O
trial O
. O
The O
30 O
- O
gene O
predictor O
can O
identify O
patients O
with O
greater O
than O
average O
sensitivity O
to O
T O
/ O
FAC O
chemotherapy O
. O
However O
, O
it O
captured O
molecular O
equivalents O
of O
clinical O
phenotype O
. O
Next O
- O
generation O
predictive O
markers O
will O
need O
to O
be O
developed O
separately O
for O
different O
molecular O
subsets O
of O
breast O
cancers O
. O

Vandetanib B-intervention
with I-intervention
docetaxel I-intervention
as O
second O
- O
line O
treatment O
for O
advanced O
breast O
cancer O
: O
a O
double O
- O
blind O
, O
placebo O
- O
controlled O
, O
randomized O
Phase O
II O
study O
. O
The O
aim O
of O
this O
Phase O
II O
study O
was O
to O
assess O
the O
efficacy O
and O
safety O
of O
vandetanib O
in O
combination O
with O
docetaxel O
in O
patients B-eligibility
with I-eligibility
pretreated I-eligibility
advanced I-eligibility
breast I-eligibility
cancer I-eligibility
. O
The O
primary O
study O
objective O
was O
to O
compare O
the O
number B-outcome-measure
of I-outcome-measure
progression I-outcome-measure
events I-outcome-measure
in O
patients O
receiving O
once O
- O
daily O
oral O
vandetanib O
( O
100 O
mg O
) O
in O
combination O
with O
docetaxel O
( O
100 O
mg O
/ O
m O
( O
2 O
) O
iv O
every O
21 O
days O
) O
versus O
placebo B-control
plus I-control
docetaxel I-control
. O
Sixty B-total-participants
- I-total-participants
four I-total-participants
patients O
were O
randomized O
to O
receive O
study O
treatment O
( O
n O
= O
35 B-intervention-participants
, O
vandetanib O
; O
n O
= O
29 B-control-participants
, O
placebo O
) O
. O
A O
slightly O
greater O
number O
of O
patients O
had O
experienced O
a O
progression B-outcome
event I-outcome
by O
the O
data O
cut O
- O
off O
in O
the O
vandetanib O
group O
( O
24 B-iv-bin-abs
[ O
69 B-iv-bin-percent
% I-iv-bin-percent
] O
) O
compared O
with O
the O
placebo O
group O
( O
18 B-cv-bin-abs
[ O
62 B-cv-bin-percent
% I-cv-bin-percent
] O
) O
; O
HR O
= O
1.19 O
, O
two O
- O
sided O
80 O
% O
CI O
: O
0.79 O
- O
1.81 O
; O
two O
- O
sided O
P O
= O
0.59 O
) O
, O
suggesting O
that O
the O
addition O
of O
vandetanib O
to O
docetaxel O
did O
not O
affect O
the O
risk O
of O
disease O
progression O
compared O
with O
placebo O
plus O
docetaxel O
. O
The O
safety B-outcome
and I-outcome
tolerability I-outcome
profile I-outcome
of O
the O
combination O
therapy O
reflected O
those O
of O
both O
drugs O
as O
monotherapy O
agents O
. O
In O
patients O
with O
advanced O
breast O
cancer O
, O
vandetanib O
plus O
docetaxel O
was O
generally O
well B-outcome
tolerated I-outcome
. O
Clinical B-outcome
benefit I-outcome
was O
not O
different O
to O
that O
observed O
with O
placebo O
plus O
docetaxel O
. O
However O
, O
due O
to O
the O
small O
patient O
number O
it O
was O
not O
possible O
to O
yield O
robust O
results O
, O
further O
research O
is O
required O
to O
identify O
predictive O
factors O
for O
patient O
selection O
. O

No O
effect O
of O
exercise B-intervention
on O
insulin O
- O
like O
growth O
factor O
- O
I O
, O
insulin O
, O
and O
glucose O
in O
young O
women O
participating O
in O
a O
16 O
- O
week O
randomized O
controlled O
trial O
. O
Insulin O
- O
like O
growth O
factor O
I O
( O
IGF O
- O
I O
) O
and O
IGF O
binding O
protein O
3 O
( O
IGFBP-3 O
) O
have O
been O
associated O
with O
increased O
risk O
of O
breast O
cancer O
. O
We O
report O
our O
findings O
on O
the O
effects O
of O
16 O
weeks O
of O
aerobic O
exercise O
on O
IGF O
axis O
proteins O
, O
insulin O
, O
glucose O
, O
and O
insulin O
resistance O
of O
319 B-total-participants
young B-eligibility
sedentary I-eligibility
women I-eligibility
. O
Demographics O
, O
health O
surveys O
, O
body O
composition O
, O
dietary O
intake O
, O
and O
blood O
samples O
were O
collected O
at O
baseline O
and O
16 O
weeks O
. O
IGF O
- O
I O
and O
IGFBP-1 O
, O
IGFBP-2 O
, O
and O
IGFBP-3 O
were O
measured O
by O
ELISA O
. O
Exercise B-outcome
adherence I-outcome
was O
88 O
% O
. O
The O
dropout B-outcome
rates I-outcome
for O
the O
exercise O
and O
control B-control
groups I-control
were O
21.7 B-iv-bin-percent
% I-iv-bin-percent
and O
14.5 B-cv-bin-percent
% I-cv-bin-percent
, O
respectively O
. O
There O
was O
a O
small O
significant O
change B-outcome
from I-outcome
baseline I-outcome
in I-outcome
IGFBP-3 I-outcome
concentrations I-outcome
. O
IGFBP-3 B-outcome
levels I-outcome
decreased O
in O
controls O
and O
increased O
in O
exercisers O
. O
The O
between O
- O
group O
difference O
was O
significant O
. O
No O
other O
changes O
were O
noted O
. O
Sixteen O
weeks O
of O
exercise O
had O
minimum O
or O
no O
effect B-outcome
on I-outcome
IGF I-outcome
proteins I-outcome
of O
young O
women O
. O
Our O
study O
supports O
findings O
from O
previous O
studies O
conducted O
in O
older O
populations O
and O
raises O
the O
question O
of O
what O
type O
of O
intervention O
is O
needed O
to O
change O
circulating O
levels O
of O
IGF O
proteins O
in O
humans O
. O
  O

Brief B-intervention
smoking I-intervention
cessation I-intervention
intervention O
in O
relation O
to O
breast O
cancer O
surgery O
: O
a O
randomized O
controlled O
trial O
. O
Smokers O
are O
more O
prone O
to O
develop O
postoperative O
complications O
. O
Smoking O
cessation O
intervention O
beginning O
4 O
- O
8 O
weeks O
prior O
to O
surgery O
improves O
the O
postoperative O
outcome O
. O
Cancer O
patients O
, O
however O
, O
often O
undergo O
surgery O
less O
than O
4 O
weeks O
after O
diagnosis O
. O
The O
primary O
objective O
of O
this O
study O
was O
therefore O
to O
examine O
if O
a O
brief O
smoking O
cessation O
intervention O
shortly O
before O
breast O
cancer O
surgery O
would O
influence O
postoperative O
complications O
and O
smoking O
cessation O
. O
A O
randomized O
controlled O
multicentre O
trial O
with O
blinded O
outcome O
assessment O
conducted O
at O
3 O
hospitals O
in O
Denmark B-location
. O
One B-total-participants
hundred I-total-participants
and I-total-participants
thirty I-total-participants
patients O
were O
randomly O
assigned O
to O
brief O
smoking O
intervention O
( O
n O
= O
65 B-intervention-participants
) O
or O
standard B-control
care I-control
( O
n O
= O
65 B-control-participants
) O
. O
The O
intervention O
followed O
the O
principles O
of O
motivational O
interviewing O
and O
included O
personalized O
nicotine O
replacement O
therapy O
aimed O
at O
supporting O
smoking O
cessation O
from O
2 O
days O
before O
to O
10 O
days O
after O
surgery O
. O
The O
overall B-outcome
postoperative I-outcome
complication I-outcome
rate I-outcome
( O
including O
seroma O
requiring O
aspiration O
) O
was O
61 B-iv-bin-percent
% I-iv-bin-percent
in O
both O
groups O
risk O
ratio O
( O
RR O
) O
1.00 O
( O
95 O
% O
CI O
0.75 O
- O
1.33 O
) O
. O
The O
wound B-outcome
complication I-outcome
rate I-outcome
was O
44 B-iv-bin-percent
% I-iv-bin-percent
versus O
45 B-cv-bin-percent
% I-cv-bin-percent
. O
The O
effect B-outcome
on I-outcome
perioperative I-outcome
smoking I-outcome
cessation I-outcome
was O
modest O
, O
28 B-iv-bin-percent
% I-iv-bin-percent
intervention O
versus O
11 B-cv-bin-percent
% I-cv-bin-percent
control O
group O
patients O
, O
RR O
2.49 O
( O
95 O
% O
CI O
1.10 O
- O
5.60 O
) O
. O
There O
was O
no O
effect B-outcome
on I-outcome
smoking I-outcome
cessation I-outcome
at O
12 O
months O
, O
13 B-iv-bin-percent
% I-iv-bin-percent
versus O
9 B-cv-bin-percent
% I-cv-bin-percent
. O
Brief O
smoking O
intervention O
administered O
shortly O
before O
breast O
cancer O
surgery O
modestly O
increased O
self O
- O
reported O
perioperative O
smoking O
cessation O
without O
having O
any O
clinical O
impact O
on O
postoperative O
complications O
. O
The O
study O
adds O
to O
the O
body O
of O
evidence O
indicating O
that O
brief O
intervention O
has O
no O
clinical O
importance O
for O
surgical O
patients O
in O
regard O
to O
postoperative O
morbidity O
. O
Future O
studies O
should O
be O
designed O
to O
determine O
the O
optimal O
time O
of O
smoking O
cessation O
before O
surgery O
. O

Results O
of O
the O
CONFIRM O
phase O
III O
trial O
comparing O
fulvestrant B-control
250 I-control
mg I-control
with O
fulvestrant B-intervention
500 I-intervention
mg I-intervention
in O
postmenopausal O
women O
with O
estrogen O
receptor O
- O
positive O
advanced O
breast O
cancer O
. O
We O
compared O
fulvestrant O
500 O
mg O
regimen O
with O
the O
approved O
dose O
of O
fulvestrant O
250 O
mg O
per O
month O
for O
treatment O
of O
postmenopausal B-eligibility
women I-eligibility
with I-eligibility
estrogen I-eligibility
receptor I-eligibility
- I-eligibility
positive I-eligibility
advanced I-eligibility
breast I-eligibility
cancer I-eligibility
who I-eligibility
experienced I-eligibility
progression I-eligibility
after I-eligibility
prior I-eligibility
endocrine I-eligibility
therapy I-eligibility
. O
Comparison O
of O
Faslodex O
in O
Recurrent O
or O
Metastatic O
Breast O
Cancer O
( O
CONFIRM O
) O
is O
a O
double O
- O
blind O
, O
parallel O
- O
group O
, O
multicenter O
, O
phase O
III O
study O
. O
Patients O
were O
randomly O
assigned O
to O
fulvestrant O
500 O
mg O
( O
500 O
mg O
intramuscularly O
[ O
IM O
] O
on O
day O
0 O
, O
then O
500 O
mg O
IM O
on O
days O
14 O
and O
28 O
and O
every O
28 O
days O
thereafter O
) O
or O
250 O
mg O
every O
28 O
days O
. O
Primary O
end O
point O
was O
progression B-outcome-measure
- I-outcome-measure
free I-outcome-measure
survival I-outcome-measure
( I-outcome-measure
PFS I-outcome-measure
) I-outcome-measure
. O
Secondary O
end O
points O
included O
objective B-outcome-measure
response I-outcome-measure
rate I-outcome-measure
, O
clinical B-outcome-measure
benefit I-outcome-measure
rate I-outcome-measure
( I-outcome-measure
CBR I-outcome-measure
) I-outcome-measure
, O
duration B-outcome-measure
of I-outcome-measure
clinical I-outcome-measure
benefit I-outcome-measure
( I-outcome-measure
DoCB I-outcome-measure
) I-outcome-measure
, O
overall B-outcome-measure
survival I-outcome-measure
( I-outcome-measure
OS I-outcome-measure
) I-outcome-measure
, O
and O
quality B-outcome-measure
of I-outcome-measure
life I-outcome-measure
( I-outcome-measure
QOL I-outcome-measure
) I-outcome-measure
. O
PFS B-outcome
was O
significantly O
longer O
for O
fulvestrant O
500 O
mg O
( O
n O
= O
362 B-intervention-participants
) O
than O
250 O
mg O
( O
n O
= O
374 B-control-participants
) O
( O
hazard O
ratio O
[ O
HR O
] O
= O
0.80 O
; O
95 O
% O
CI O
, O
0.68 O
to O
0.94 O
; O
P O
= O
.006 O
) O
, O
corresponding O
to O
a O
20 O
% O
reduction O
in O
risk O
of O
progression O
. O
Objective B-outcome
response I-outcome
rate I-outcome
was O
similar O
for O
fulvestrant O
500 O
mg O
and O
250 O
mg O
( O
9.1 B-iv-bin-percent
% I-iv-bin-percent
v O
10.2 B-cv-bin-percent
% I-cv-bin-percent
, O
respectively O
) O
. O
CBR B-outcome
was O
45.6 B-iv-bin-percent
% I-iv-bin-percent
for O
fulvestrant O
500 O
mg O
and O
39.6 B-cv-bin-percent
% I-cv-bin-percent
for O
fulvestrant O
250 O
mg O
. O
DoCB B-outcome
and O
OS B-outcome
were O
16.6 B-iv-cont-median
and O
25.1 B-cv-cont-median
months I-cv-cont-median
, O
respectively O
, O
for O
the O
500 O
- O
mg O
group O
, O
whereas O
DoCB B-outcome
and O
OS B-outcome
were O
13.9 B-cv-cont-median
and O
22.8 B-cv-cont-median
months I-cv-cont-median
, O
respectively O
, O
in O
the O
250 O
- O
mg O
group O
. O
Fulvestrant O
500 O
mg O
was O
well B-outcome
tolerated I-outcome
with O
no O
dose O
- O
dependent O
adverse B-outcome
events I-outcome
. O
QOL B-outcome
was O
similar O
for O
both O
arms O
. O
Fulvestrant O
500 O
mg O
was O
associated O
with O
a O
statistically O
significant O
increase O
in O
PFS O
and O
not O
associated O
with O
increased O
toxicity O
, O
corresponding O
to O
a O
clinically O
meaningful O
improvement O
in O
benefit O
versus O
risk O
compared O
with O
fulvestrant O
250 O
mg O
. O

Randomized O
clinical O
trial O
of O
Chinese B-intervention
herbal I-intervention
medications I-intervention
to O
reduce O
wound B-condition
complications I-condition
after O
mastectomy O
for O
breast O
carcinoma O
. O
Ischaemia O
and O
necrosis O
of O
skin O
flaps O
is O
a O
common O
complication O
after O
mastectomy O
. O
This O
study O
evaluated O
the O
influence O
of O
anisodamine B-intervention
and I-intervention
Salvia I-intervention
miltiorrhiza I-intervention
on O
wound O
complications O
after O
mastectomy O
for O
breast O
cancer O
. O
Ninety B-total-participants
patients B-eligibility
undergoing I-eligibility
mastectomy I-eligibility
for I-eligibility
breast I-eligibility
carcinoma I-eligibility
were O
divided O
into O
three O
groups O
. O
Group O
1 O
received O
routine B-control
wound I-control
care I-control
, O
group O
2 O
received O
intravenous O
Salvia O
miltiorrhiza O
after O
surgery O
for O
3 O
days O
and O
group O
3 O
similarly O
received O
intravenous O
anisodamine O
. O
Skin O
flaps O
were O
observed O
on O
postoperative O
days O
4 O
and O
8 O
; O
areas O
of O
wound O
ischaemia O
and O
necrosis O
were O
graded O
and O
adverse O
events O
recorded O
. O
There O
was O
no O
difference O
in O
demographic O
characteristics O
between O
the O
groups O
. O
At O
4 O
days O
after O
surgery O
the O
rate B-outcome
of I-outcome
ischaemia I-outcome
and I-outcome
necrosis I-outcome
in O
groups O
2 O
and O
3 O
was O
significantly O
reduced O
compared O
with O
that O
in O
control O
group O
1 O
( O
median B-outcome
wound I-outcome
score I-outcome
680 B-iv-cont-median
versus O
2338 B-cv-cont-median
, O
P O
= O
0002 O
, O
and O
376 B-iv-cont-median
versus O
2338 B-cv-cont-median
, O
P O
< O
0001 O
, O
respectively O
) O
. O
This O
improvement O
in O
groups O
2 O
and O
3 O
continued O
to O
postoperative B-outcome
day I-outcome
8 I-outcome
( O
both O
P O
< O
0001 O
) O
, O
but O
wound B-outcome
scores I-outcome
at O
this O
stage O
were O
better O
in O
group O
3 O
than O
in O
group O
2 O
( O
182 B-iv-cont-median
versus O
692 B-iv-cont-median
respectively O
; O
P O
= O
0022 O
) O
. O
The O
volume B-outcome
of I-outcome
wound I-outcome
drainage I-outcome
was O
lower O
in O
group O
3 O
than O
in O
group O
1 O
( O
P O
= O
0004 O
) O
. O
The O
incidence B-outcome
of I-outcome
adverse I-outcome
effects I-outcome
was O
highest O
in O
group O
3 O
, O
and O
two O
patients O
in O
this O
group O
discontinued O
treatment O
. O
No O
significant O
complications B-outcome
were O
noted O
in O
group O
2 O
. O
Anisodamine O
and O
S. O
miltiorrhiza O
were O
both O
effective O
in O
reducing O
skin O
flap O
ischaemia O
and O
necrosis O
after O
mastectomy O
, O
although O
anisodamine O
was O
associated O
with O
a O
higher O
rate O
of O
adverse O
effects O
. O
  O

A O
cluster O
- O
randomized O
trial O
of O
a O
primary O
care O
informatics B-intervention
- I-intervention
based I-intervention
system I-intervention
for O
breast O
cancer O
screening O
. O
Information O
technology O
offers O
the O
promise O
, O
as O
yet O
unfulfilled O
, O
of O
delivering O
efficient O
, O
evidence O
- O
based O
health O
care O
. O
To O
evaluate O
whether O
a O
primary O
care O
network O
- O
based O
informatics O
intervention O
can O
improve O
breast O
cancer O
screening O
rates O
. O
Cluster O
- O
randomized O
controlled O
trial O
of O
12 O
primary O
care O
practices O
conducted O
from O
March O
20 O
, O
2007 O
to O
March O
19 O
, O
2008 O
. O
Women O
42 B-age
- I-age
69 I-age
years I-age
old O
with B-eligibility
no I-eligibility
record I-eligibility
of I-eligibility
a I-eligibility
mammogram I-eligibility
in I-eligibility
the I-eligibility
prior I-eligibility
2 I-eligibility
years I-eligibility
. O
In O
intervention O
practices O
, O
a O
population O
- O
based O
informatics O
system O
was O
implemented O
that O
: O
connected O
overdue O
patients O
to O
appropriate O
care O
providers O
, O
presented O
providers O
with O
a O
Web O
- O
based O
list O
of O
their O
overdue O
patients O
in O
a O
non O
- O
visit O
- O
based O
setting O
, O
and O
enabled O
" O
one O
- O
click O
" O
mammography O
ordering O
or O
documented O
deferral O
reasons O
. O
Patients O
selected O
for O
mammography O
received O
automatically O
generated O
letters O
and O
follow O
- O
up O
phone O
calls O
. O
All O
practices O
had O
electronic O
health O
record O
reminders O
about O
breast O
cancer O
screening O
available O
during O
clinical O
encounters O
. O
The O
primary O
outcome O
was O
the O
proportion B-outcome-measure
of I-outcome-measure
overdue I-outcome-measure
women I-outcome-measure
undergoing I-outcome-measure
mammography I-outcome-measure
at I-outcome-measure
1 I-outcome-measure
- I-outcome-measure
year I-outcome-measure
follow I-outcome-measure
- I-outcome-measure
up I-outcome-measure
. O
Baseline B-outcome
mammography I-outcome
rates I-outcome
in O
intervention O
and O
control B-control
practices I-control
did O
not O
differ O
( O
79.5 B-iv-bin-percent
% I-iv-bin-percent
vs O
79.3 B-cv-bin-percent
% I-cv-bin-percent
, O
p O
= O
0.73 O
) O
. O
Among O
3,054 B-intervention-participants
women O
in O
intervention O
practices O
and O
3,676 B-control-participants
women O
in O
control O
practices O
overdue O
for O
mammograms O
, O
intervention O
patients O
were O
somewhat O
younger O
, O
more O
likely O
to O
be O
non B-ethinicity
- I-ethinicity
Hispanic I-ethinicity
white I-ethinicity
, O
and O
have O
health O
insurance O
. O
Most O
intervention O
providers O
used O
the O
system O
( O
65 O
of O
70 O
providers O
, O
92.9 O
% O
) O
. O
Action B-outcome
was I-outcome
taken I-outcome
for O
2,652 B-iv-bin-abs
( O
86.8 B-iv-bin-percent
% I-iv-bin-percent
) O
intervention O
patients O
[ O
2,274 O
( O
74.5 O
% O
) O
contacted O
and O
378 O
( O
12.4 O
% O
) O
deferred O
] O
. O
After B-outcome
1 I-outcome
year I-outcome
, I-outcome
mammography I-outcome
rates I-outcome
were O
significantly O
higher O
in O
the O
intervention O
arm O
( O
31.4 B-iv-bin-percent
% I-iv-bin-percent
vs O
23.3 B-cv-bin-percent
% I-cv-bin-percent
in O
control O
arm O
, O
p O
< O
0.001 O
after O
adjustment O
for O
baseline O
differences O
; O
8.1 O
% O
absolute O
difference O
, O
95 O
% O
CI O
5.1 O
- O
11.2 O
% O
) O
. O
All O
demographic O
subgroups O
benefited O
from O
the O
intervention O
. O
Intervention O
patients O
completed O
screening O
sooner O
than O
control O
patients O
( O
p O
< O
0.001 O
) O
. O
A O
novel O
population O
- O
based O
informatics O
system O
functioning O
as O
part O
of O
a O
non O
- O
visit O
- O
based O
care O
model O
increased O
mammography O
screening O
rates O
in O
intervention O
practices O
. O
ClinicalTrials O
. O
gov O
; O
NCT00462891 O
. O

Phase O
III O
double O
- O
blind O
, O
placebo O
- O
controlled O
, O
prospective O
randomized O
trial O
of O
adjuvant O
tamoxifen B-intervention
vs. O
tamoxifen B-control
and I-control
fenretinide I-control
in O
postmenopausal O
women O
with O
positive O
receptors O
( O
EB193 O
): O
an O
intergroup O
trial O
coordinated O
by O
the O
Eastern O
Cooperative O
Oncology O
Group O
. O
Fenretinide O
and O
tamoxifen O
have O
additive O
antitumor O
effects O
preclinically O
. O
We O
performed O
a O
randomized O
, O
placebo O
- O
controlled O
, O
double O
- O
blind O
adjuvant O
trial O
in O
breast O
cancer O
patients O
treated O
for O
5 O
years O
with O
tamoxifen O
, O
with O
or O
without O
fenretinide O
. O
Between O
October O
1995 O
and O
October O
1999 O
, O
426 B-total-participants
postmenopausal B-eligibility
women I-eligibility
with I-eligibility
hormone I-eligibility
receptor I-eligibility
- I-eligibility
positive I-eligibility
breast I-eligibility
cancer I-eligibility
were O
randomized O
. O
Patients O
were O
monitored O
for O
efficacy O
and O
toxicity O
. O
Four B-total-participants
hundred I-total-participants
and I-total-participants
nineteen I-total-participants
patients O
were O
evaluable O
. O
The O
study O
was O
terminated O
early O
due O
to O
slow O
accrual O
. O
There O
were O
no O
significant O
differences O
between O
treatment O
groups O
in O
DFS B-outcome
, I-outcome
TTR I-outcome
or I-outcome
survival I-outcome
. O
More O
patients O
stopped B-outcome
treatment I-outcome
early O
on O
the O
fenretinide O
arm O
than O
on O
placebo O
( O
P O
= O
0.02 O
) O
. O
Grade B-outcome
3 I-outcome
/ I-outcome
4 I-outcome
toxicities I-outcome
, O
including O
visual B-outcome
problems I-outcome
and O
musculoskeletal B-outcome
complaints I-outcome
were O
more O
common O
in O
patients O
receiving O
fenretinide O
( O
P O
= O
0.007 O
) O
. O
A O
Night O
Blindness O
Questionnaire O
was O
used O
to O
monitor O
nyctalopia O
, O
which O
was O
slightly O
, O
but O
not O
significantly O
, O
more O
common O
on O
fenretinide O
. O
In O
this O
underpowered O
study O
, O
no O
significant O
difference O
was O
observed O
in O
efficacy O
between O
treatment O
groups O
. O
This O
trial O
provides O
important O
toxicity O
information O
about O
fenretinide O
, O
a O
retinoid O
that O
has O
been O
used O
in O
the O
prevention O
setting O
, O
because O
it O
is O
the O
only O
placebo O
- O
controlled O
, O
double O
- O
blind O
randomized O
study O
ever O
performed O
. O

Predictive O
factors O
of O
pathologic O
complete O
response O
and O
clinical O
tumor O
progression O
after O
preoperative B-intervention
chemotherapy I-intervention
in O
patients B-eligibility
with I-eligibility
stage I-eligibility
II I-eligibility
and I-eligibility
III I-eligibility
breast I-eligibility
cancer I-eligibility
. O
This O
study O
aimed O
to O
define O
predictive O
factors O
of O
pathologic O
complete O
response O
( O
pCR O
) O
and O
disease O
progression O
in O
stage B-eligibility
II I-eligibility
and I-eligibility
III I-eligibility
breast I-eligibility
cancer I-eligibility
patients I-eligibility
. O
Three B-total-participants
hundred I-total-participants
thirty I-total-participants
- I-total-participants
eight I-total-participants
patients O
were O
included O
in O
the O
study O
. O
Patients O
had O
received O
preoperative O
chemotherapy O
as O
follows O
: O
101 B-intervention-participants
had O
doxorubicin O
plus O
cyclophosphamide O
( O
AC O
) O
; O
91 B-intervention-participants
had O
doxorubicin O
plus O
docetaxel O
; O
103 B-intervention-participants
had O
docetaxel O
plus O
capecitabine O
; O
and O
43 B-intervention-participants
had O
paclitaxel O
plus O
gemcitabine O
. O
A O
pCR O
was O
defined O
as O
the O
absence O
of O
residual O
invasive O
carcinoma O
in O
the O
breast O
. O
The O
majority O
of O
patients O
( O
73 O
% O
) O
were O
premenopausal O
with O
a O
median O
age O
of O
44 B-age
( I-age
range I-age
, I-age
21 I-age
- I-age
76 I-age
) I-age
years I-age
. O
Fifty O
- O
four O
patients O
( O
16 O
% O
) O
achieved B-outcome
pCR I-outcome
and O
were O
distributed O
among O
the O
4 O
breast O
cancer O
subtypes O
as O
follows O
: O
10 O
% O
of O
patients O
with O
-ER O
or O
PR+/HER2- O
, O
13 O
% O
with O
ER O
or O
PR+/HER2 O
+ O
, O
33 O
% O
with O
ER-/PR-/HER2 O
+ O
, O
and O
19 O
% O
with O
ER-/PR-/HER2- O
( O
p O
 O
= O
 O
0.001 O
) O
. O
Taxane O
- O
containing O
regimen O
( O
p O
 O
= O
 O
0.042 O
) O
and O
Breast O
cancer O
subtype O
( O
p O
 O
= O
 O
0.005 O
) O
were O
significant O
predictive O
variables O
for O
pCR B-outcome
. O
On O
the O
other O
hand O
, O
significantly O
more O
patients O
who O
received O
non O
- O
taxane O
- O
containing O
regimen O
( O
AC O
) O
experienced O
no B-outcome
response I-outcome
( O
p O
 O
= O
 O
0.001 O
) O
or O
progression B-outcome
( O
p O
 O
= O
 O
0.006 O
) O
. O
Patients O
with O
ER-/PR-/HER2 O
+ O
tumors O
and O
those O
who O
received O
taxane O
- O
containing O
regimen O
achieved O
a O
higher O
pCR O
rate O
, O
while O
significantly O
more O
patients O
developed O
tumor O
progression O
by O
preoperative O
non O
- O
taxane O
- O
containing O
regimen O
( O
AC O
) O
compared O
to O
those O
who O
received O
taxane O
- O
containing O
chemotherapy O
. O

Comparison O
of O
pegfilgrastim B-intervention
on I-intervention
day I-intervention
2 I-intervention
vs. O
day B-control
4 I-control
as O
primary O
prophylaxis O
of O
intense O
dose O
- O
dense O
chemotherapy O
in O
patients O
with O
node O
- O
positive O
primary O
breast O
cancer O
within O
the O
prospective O
, O
multi O
- O
center O
GAIN O
study O
: O
( O
GBG O
33 O
) O
. O
Preliminary O
data O
suggest O
that O
pegfilgrastim O
given O
on O
day O
4 O
( O
P4 O
) O
might O
be O
superior O
to O
pegfilgrastim O
on O
day O
2 O
( O
P2 O
) O
in O
reducing O
grade O
4 O
leucopenia O
. O
Patients B-eligibility
with I-eligibility
node I-eligibility
- I-eligibility
positive I-eligibility
primary I-eligibility
breast I-eligibility
cancer I-eligibility
receiving I-eligibility
epirubicin I-eligibility
- I-eligibility
paclitaxel I-eligibility
- I-eligibility
cyclophosphamide I-eligibility
chemotherapy I-eligibility
were O
randomized O
to O
receive O
P2 O
versus O
P4 O
. O
Primary O
endpoint O
was O
leucopenia B-outcome-measure
grade I-outcome-measure
4 I-outcome-measure
, O
assuming O
a O
risk O
reduction O
of O
50 O
% O
with O
P4 O
from O
50 O
% O
in O
P2 O
to O
25 O
% O
with O
P4 O
. O
Three B-total-participants
- I-total-participants
hundred I-total-participants
fifty I-total-participants
- I-total-participants
one I-total-participants
patients O
were O
randomized O
to O
P2 O
( O
n O
 O
= O
 O
174 B-intervention-participants
) O
versus O
P4 O
( O
n O
 O
= O
 O
177 B-control-participants
) O
. O
The O
rate B-outcome
of I-outcome
leucopenia I-outcome
( I-outcome
grade I-outcome
4 I-outcome
) I-outcome
was O
47.1 B-iv-bin-percent
% I-iv-bin-percent
with O
P2 O
and O
42.0 B-cv-bin-percent
% I-cv-bin-percent
with O
P4 O
( O
p O
 O
= O
 O
0.387 O
) O
, O
neutropenia B-outcome
( I-outcome
grade I-outcome
3 I-outcome
 I-outcome
+ I-outcome
 I-outcome
4 I-outcome
) I-outcome
was O
47.9 B-iv-bin-percent
% I-iv-bin-percent
versus O
40.8 B-cv-bin-percent
% I-cv-bin-percent
( O
p O
 O
= O
 O
0.337 O
) O
, O
FN B-outcome
was O
4.7 B-iv-bin-percent
% I-iv-bin-percent
versus O
8.0 B-cv-bin-percent
% I-cv-bin-percent
( O
p O
 O
= O
 O
0.271 O
) O
, O
and O
infections B-outcome
was O
29.9 B-iv-bin-percent
% I-iv-bin-percent
versus O
25.4 B-cv-bin-percent
% I-cv-bin-percent
( O
p O
 O
= O
 O
0.404 O
) O
, O
respectively O
. O
This O
study O
failed O
to O
demonstrate O
that O
pegfilgrastim O
on O
day O
4 O
was O
more O
efficacious O
than O
on O
day O
2 O
with O
respect O
to O
grade O
4 O
leucopenia O
( O
the O
primary O
endpoint O
) O
, O
febrile O
neutropenia O
, O
or O
infections O
. O

Overview O
of O
the O
randomized O
trials O
of O
radiotherapy B-intervention
in O
ductal B-condition
carcinoma I-condition
in I-condition
situ I-condition
of O
the O
breast O
. O
Individual O
patient O
data O
were O
available O
for O
all O
four O
of O
the O
randomized O
trials O
that O
began O
before O
1995 O
, O
and O
that O
compared O
adjuvant O
radiotherapy O
vs O
no B-control
radiotherapy I-control
following O
breast O
- O
conserving O
surgery O
for O
ductal O
carcinoma O
in O
situ O
( O
DCIS O
) O
. O
A O
total O
of O
3729 B-total-participants
women O
were O
eligible O
for O
analysis O
. O
Radiotherapy O
reduced O
the O
absolute O
10 B-outcome
- I-outcome
year I-outcome
risk I-outcome
of I-outcome
any I-outcome
ipsilateral I-outcome
breast I-outcome
event I-outcome
( O
ie O
, O
either O
recurrent O
DCIS O
or O
invasive O
cancer O
) O
by O
15.2 O
% O
( O
SE O
1.6 O
% O
, O
12.9 B-iv-bin-percent
% I-iv-bin-percent
vs O
28.1 B-cv-bin-percent
% I-cv-bin-percent
2 O
P O
< O
.00001 O
) O
, O
and O
it O
was O
effective O
regardless O
of O
the O
age O
at O
diagnosis O
, O
extent O
of O
breast O
- O
conserving O
surgery O
, O
use O
of O
tamoxifen O
, O
method O
of O
DCIS O
detection O
, O
margin O
status O
, O
focality O
, O
grade O
, O
comedonecrosis O
, O
architecture O
, O
or O
tumor O
size O
. O
The O
proportional O
reduction O
in O
ipsilateral B-outcome
breast I-outcome
events I-outcome
was O
greater O
in O
older O
than O
in O
younger O
women O
( O
2P O
< O
.0004 O
for O
difference O
between O
proportional O
reductions O
; O
10 O
- O
year O
absolute O
risks O
: O
18.5 B-iv-bin-percent
% I-iv-bin-percent
vs O
29.1 B-cv-bin-percent
% I-cv-bin-percent
at O
ages O
< O
50 O
years O
, O
10.8 O
% O
vs O
27.8 O
% O
at O
ages O
 O
50 O
years O
) O
but O
did O
not O
differ O
significantly O
according O
to O
any O
other O
available O
factor O
. O
Even O
for O
women O
with O
negative O
margins O
and O
small O
low O
- O
grade O
tumors O
, O
the O
absolute O
reduction O
in O
the O
10 B-outcome
- I-outcome
year I-outcome
risk I-outcome
of I-outcome
ipsilateral I-outcome
breast I-outcome
events I-outcome
was O
18.0 O
% O
( O
SE O
5.5 O
, O
12.1 B-iv-bin-percent
% I-iv-bin-percent
vs O
30.1 B-cv-bin-percent
% I-cv-bin-percent
, O
2P O
= O
.002 O
) O
. O
After O
10 O
years O
of O
follow O
- O
up O
, O
there O
was O
, O
however O
, O
no O
significant O
effect O
on O
breast O
cancer O
mortality O
, O
mortality O
from O
causes O
other O
than O
breast O
cancer O
, O
or O
all O
- O
cause O
mortality O
. O

[ O
A O
pilot O
study O
of O
weekly O
versus O
3 O
- O
week O
docetaxel B-intervention
in I-intervention
combination I-intervention
with I-intervention
capecitabine I-intervention
in O
patients O
with O
anthracycline O
- O
pretreated O
metastatic O
breast O
cancer O
] O
. O
To O
evaluate O
the O
efficacy O
and O
safety O
of O
weekly O
or O
3 O
- O
week O
docetaxel O
in O
combination O
with O
capecitabine O
. O
83 B-total-participants
Patients B-eligibility
with I-eligibility
at I-eligibility
least I-eligibility
one I-eligibility
measurable I-eligibility
lesion I-eligibility
were O
randomized O
to O
receive O
the O
treatment O
arms O
: O
docetaxel O
37.5 O
mg O
/ O
m O
( O
2 O
) O
on O
days O
1 O
and O
8 O
, O
oral O
capecitabine O
950 O
mg O
/ O
m O
( O
2 O
) O
twice O
daily O
on O
days O
1 O
- O
14 O
( O
Group O
A O
) O
; O
docetaxel O
75 O
mg O
/ O
m O
( O
2 O
) O
on O
days O
1 O
, O
oral O
capecitabine O
950 O
mg O
/ O
m O
( O
2 O
) O
twice O
daily O
on O
days O
1 O
- O
14 O
( O
Group B-control
B I-control
) O
. O
Each O
cycle O
was O
repeated O
every O
3 O
weeks O
. O
Eighty B-total-participants
- I-total-participants
three I-total-participants
patients O
were O
enrolled O
, O
78 B-total-participants
eligible O
for O
tumor O
assessment O
. O
The O
overall B-outcome
clinical I-outcome
response I-outcome
rate I-outcome
of O
all O
groups O
was O
61.4 O
% O
( O
51 O
/ O
83 O
) O
. O
There O
was O
no O
progressive B-outcome
disease I-outcome
( I-outcome
PD I-outcome
) I-outcome
after O
two O
cycles O
. O
Efficacy B-outcome
outcomes I-outcome
were O
similar O
in O
the O
two O
groups O
. O
The O
response B-outcome
rate I-outcome
of O
group O
A O
and O
B O
were O
61.8 B-iv-bin-percent
% I-iv-bin-percent
( O
21 B-iv-bin-abs
/ O
34 B-intervention-participants
) O
and O
61.2 B-cv-bin-percent
% I-cv-bin-percent
( O
30 B-cv-bin-abs
/ O
49 B-control-participants
) O
respectively O
. O
There O
were O
no O
drug B-outcome
- I-outcome
related I-outcome
deaths I-outcome
observed O
. O
Neutropenia B-outcome
was O
the O
most O
common O
toxicity O
. O
In O
all O
, O
the O
frequency O
of O
Grade B-outcome
3 I-outcome
/ I-outcome
4 I-outcome
neutropenia I-outcome
were O
45.8 O
% O
( O
38 O
/ O
83 O
) O
, O
but O
Grade O
3 O
/ O
4 O
neutropenia O
of O
Group O
B O
55.1 B-cv-bin-percent
% I-cv-bin-percent
( O
27 B-cv-bin-abs
/ O
49 B-control-participants
) O
was O
higher O
than O
Group O
A O
32.4 B-iv-bin-percent
% I-iv-bin-percent
( O
11 B-iv-bin-abs
/ O
34 B-intervention-participants
) O
, O
P O
= O
0.04 O
. O
The O
study O
confirmed O
the O
superior O
activity O
of O
docetaxe O
- O
capecitabine O
combination O
therapy O
in O
anthracycline O
resistant O
MBC O
, O
and O
comparing O
with O
3 O
- O
week O
schedule O
, O
weekly O
docetaxel O
plus O
capecitabine O
has O
same O
high O
efficacy O
with O
a O
favourable O
safety O
profile O
. O

Breast O
cancer O
incidence O
in O
the O
randomized O
PEARL O
trial O
of O
lasofoxifene B-intervention
in O
postmenopausal B-eligibility
osteoporotic I-eligibility
women I-eligibility
. O
Currently O
available O
selective O
estrogen O
receptor O
modulators O
reduce O
the O
risk O
of O
breast O
cancer O
, O
but O
they O
are O
not O
widely O
used O
. O
In O
the O
Postmenopausal O
Evaluation O
and O
Risk O
- O
Reduction O
with O
Lasofoxifene O
( O
PEARL O
) O
trial O
, O
lasofoxifene O
was O
shown O
to O
reduce O
the O
risk O
of O
estrogen O
receptor O
- O
positive O
( O
ER+ O
) O
breast O
cancer O
, O
nonvertebral O
and O
vertebral O
fractures O
, O
coronary O
artery O
disease O
, O
and O
stroke O
, O
but O
the O
effects O
on O
total O
breast O
cancer O
( O
invasive O
and O
ductal O
carcinoma O
in O
situ O
, O
ER+ O
and O
estrogen O
receptor O
- O
negative O
[ O
ER- O
] O
) O
and O
ER+ O
invasive O
breast O
cancer O
are O
unknown O
. O
Postmenopausal O
women O
( O
n O
= O
8556 B-total-participants
) O
aged O
59 B-age
- I-age
80 I-age
years I-age
with B-eligibility
low I-eligibility
bone I-eligibility
density I-eligibility
and I-eligibility
normal I-eligibility
mammograms I-eligibility
were O
randomly O
assigned O
to O
two O
doses O
of O
lasofoxifene O
( O
0.25 O
and O
0.5 O
mg O
) O
or O
placebo B-control
. O
The O
primary O
endpoints O
of O
the O
PEARL O
trial O
were O
incidence B-outcome-measure
of I-outcome-measure
ER+ I-outcome-measure
breast I-outcome-measure
cancer I-outcome-measure
and I-outcome-measure
nonvertebral I-outcome-measure
fractures I-outcome-measure
at O
5 O
years O
. O
A O
nested O
case O
- O
control O
study O
of O
49 O
incident O
breast O
cancer O
case O
patients O
and O
156 O
unaffected O
control O
subjects O
from O
the O
PEARL O
trial O
was O
performed O
to O
evaluate O
treatment O
effects O
on O
risk O
of O
total O
and O
ER+ O
invasive O
breast O
cancer O
by O
baseline O
serum O
estradiol O
and O
sex O
hormone O
- O
binding O
globulin O
levels O
using O
logistic O
regression O
models O
. O
Cox O
proportional O
hazards O
models O
were O
used O
to O
evaluate O
risk O
of O
total O
breast O
cancer O
and O
ER+ O
invasive O
breast O
cancer O
using O
intention O
- O
to O
- O
treat O
analysis O
. O
All O
statistical O
tests O
were O
two O
- O
sided O
. O
Breast B-outcome
cancer I-outcome
was O
confirmed O
in O
49 O
women O
. O
Compared O
with O
placebo O
, O
0.5 O
mg O
of O
lasofoxifene O
statistically O
significantly O
reduced O
the O
risk B-outcome
of I-outcome
total I-outcome
breast I-outcome
cancer I-outcome
by O
79 B-iv-bin-percent
% I-iv-bin-percent
( O
hazard O
ratio O
= O
0.21 O
; O
95 O
% O
confidence O
interval O
[ O
CI O
] O
= O
0.08 O
to O
0.55 O
) O
and O
ER+ B-outcome
invasive I-outcome
breast I-outcome
cancer I-outcome
by O
83 B-iv-bin-percent
% I-iv-bin-percent
( O
hazard O
ratio O
= O
0.17 O
; O
95 O
% O
CI O
= O
0.05 O
to O
0.57 O
) O
. O
The O
effects O
of O
0.5 O
mg O
of O
lasofoxifene O
on O
total B-outcome
breast I-outcome
cancer I-outcome
were O
similar O
regardless O
of O
Gail O
score O
, O
whereas O
the O
effects O
were O
markedly O
stronger O
for O
women O
with O
baseline O
estradiol O
levels O
greater O
than O
the O
median O
( O
odds O
ratio O
= O
0.11 O
; O
95 O
% O
CI O
= O
0.02 O
to O
0.51 O
) O
vs O
those O
with O
levels O
less O
than O
the O
median O
( O
odds O
ratio O
= O
0.78 O
; O
95 O
% O
CI O
= O
0.16 O
to O
3.79 O
; O
P O
( O
interaction O
) O
= O
.04 O
) O
. O
A O
0.5 O
- O
mg O
dose O
of O
lasofoxifene O
appears O
to O
reduce O
the O
risks O
of O
both O
total O
and O
ER+ O
invasive O
breast O
cancer O
in O
postmenopausal O
women O
with O
osteoporosis O
. O

Changes O
in O
body O
weight O
and O
metabolic O
indexes O
in O
overweight B-condition
breast O
cancer O
survivors O
enrolled O
in O
a O
randomized O
trial O
of O
low B-intervention
- I-intervention
fat I-intervention
vs. O
reduced B-control
carbohydrate I-control
diets I-control
. O
Overweight O
status O
is O
common O
among O
women O
breast O
cancer O
survivors O
and O
places O
them O
at O
greater O
risk O
for O
metabolic O
disorders O
, O
cardiovascular O
morbidity O
, O
and O
breast O
cancer O
recurrence O
than O
nonoverweight O
survivors O
. O
Efforts O
to O
promote O
weight O
control O
in O
this O
population O
are O
needed O
. O
The O
objective O
of O
this O
research O
was O
to O
evaluate O
the O
effect O
of O
low O
- O
fat O
or O
low O
- O
carbohydrate O
diet O
counseling O
on O
weight O
loss O
, O
body O
composition O
, O
and O
changes O
in O
metabolic O
indexes O
in O
overweight B-eligibility
postmenopausal I-eligibility
breast I-eligibility
cancer I-eligibility
survivors I-eligibility
. O
Survivors O
( O
n O
= O
40 B-total-participants
) O
were O
randomized O
to O
receive O
dietitian O
counseling O
for O
a O
low O
- O
fat O
or O
a O
reduced O
carbohydrate O
diet O
for O
6 O
mo O
. O
Weight O
and O
metabolic O
measures O
, O
including O
glucose O
, O
insulin O
, O
HbA1c O
, O
HOMA O
, O
lipids O
, O
hsCRP O
, O
as O
well O
as O
blood O
pressure O
were O
measured O
at O
baseline O
, O
6 O
, O
12 O
and O
24 O
wk O
. O
Dietary B-outcome
intake I-outcome
of I-outcome
fat I-outcome
and I-outcome
carbohydrate I-outcome
was O
reduced O
by O
24 B-iv-cont-mean
and O
76 B-cv-cont-mean
g I-cv-cont-mean
/ I-cv-cont-mean
day I-cv-cont-mean
, O
respectively O
. O
Weight B-outcome
loss I-outcome
averaged O
6.1 O
( O
 O
4.8 O
kg O
) O
at O
24 O
wk O
and O
was O
not O
significantly O
different O
by O
diet O
group O
; O
loss B-outcome
of I-outcome
lean I-outcome
mass I-outcome
was O
also O
demonstrated O
. O
All O
subjects O
demonstrated O
improvements O
in O
total B-outcome
/ I-outcome
HDL I-outcome
cholesterol I-outcome
ratio I-outcome
, O
and O
significant O
reductions B-outcome
in I-outcome
HbA1c I-outcome
, I-outcome
insulin I-outcome
, I-outcome
and I-outcome
HOMA I-outcome
. O
Triglycerides B-outcome
levels I-outcome
were O
significantly O
reduced O
only O
in O
the O
low O
- O
carbohydrate O
diet O
group O
( O
-31.1 B-cv-cont-mean
 O
36.6 B-cv-cont-sd
; O
P O
= O
0.01 O
) O
. O
Significant O
improvements O
in O
weight O
and O
metabolic O
indexes O
can O
be O
demonstrated O
among O
overweight O
breast O
cancer O
survivors O
adherent O
to O
either O
a O
carbohydrate- O
or O
fat O
- O
restricted O
diet O
. O

Denosumab B-intervention
compared O
with O
zoledronic B-control
acid I-control
for O
the O
treatment O
of O
bone B-condition
metastases I-condition
in O
patients O
with O
advanced O
breast O
cancer O
: O
a O
randomized O
, O
double O
- O
blind O
study O
. O
This O
randomized O
study O
compared O
denosumab O
, O
a O
fully O
human O
monoclonal O
antibody O
against O
receptor O
activator O
of O
nuclear O
factor O
 O
B O
( O
RANK O
) O
ligand O
, O
with O
zoledronic O
acid O
in O
delaying O
or O
preventing O
skeletal O
- O
related O
events O
( O
SREs O
) O
in O
patients B-eligibility
with I-eligibility
breast I-eligibility
cancer I-eligibility
with I-eligibility
bone I-eligibility
metastases I-eligibility
. O
Patients O
were O
randomly O
assigned O
to O
receive O
either O
subcutaneous O
denosumab O
120 O
mg O
and O
intravenous O
placebo O
( O
n O
= O
1,026 B-intervention-participants
) O
or O
intravenous O
zoledronic O
acid O
4 O
mg O
adjusted O
for O
creatinine O
clearance O
and O
subcutaneous O
placebo O
( O
n O
= O
1,020 B-control-participants
) O
every O
4 O
weeks O
. O
All O
patients O
were O
strongly O
recommended O
to O
take O
daily O
calcium O
and O
vitamin O
D O
supplements O
. O
The O
primary O
end O
point O
was O
time B-outcome-measure
to I-outcome-measure
first I-outcome-measure
on I-outcome-measure
- I-outcome-measure
study I-outcome-measure
SRE I-outcome-measure
( O
defined O
as O
pathologic O
fracture O
, O
radiation O
or O
surgery O
to O
bone O
, O
or O
spinal O
cord O
compression O
) O
. O
Denosumab O
was O
superior O
to O
zoledronic O
acid O
in O
delaying O
time B-outcome
to I-outcome
first I-outcome
on I-outcome
- I-outcome
study I-outcome
SRE I-outcome
( O
hazard O
ratio O
, O
0.82 O
; O
95 O
% O
CI O
, O
0.71 O
to O
0.95 O
; O
P O
= O
.01 O
superiority O
) O
and O
time O
to O
first O
and O
subsequent O
( O
multiple O
) O
on O
- O
study O
SREs O
( O
rate O
ratio O
, O
0.77 O
; O
95 O
% O
CI O
, O
0.66 O
to O
0.89 O
; O
P O
= O
.001 O
) O
. O
Reduction B-outcome
in I-outcome
bone I-outcome
turnover I-outcome
markers I-outcome
was O
greater O
with O
denosumab O
. O
Overall B-outcome
survival I-outcome
, O
disease B-outcome
progression I-outcome
, O
and O
rates O
of O
adverse B-outcome
events I-outcome
( I-outcome
AEs I-outcome
) I-outcome
and O
serious B-outcome
AEs I-outcome
were O
similar O
between O
groups O
. O
An O
excess O
of O
renal B-outcome
AEs I-outcome
and O
acute B-outcome
- I-outcome
phase I-outcome
reactions I-outcome
occurred O
with O
zoledronic O
acid O
; O
hypocalcemia B-outcome
occurred O
more O
frequently O
with O
denosumab O
. O
Osteonecrosis B-outcome
of I-outcome
the I-outcome
jaw I-outcome
occurred O
infrequently O
( O
2.0 B-iv-bin-percent
% I-iv-bin-percent
, O
denosumab O
; O
1.4 B-cv-bin-percent
% I-cv-bin-percent
, O
zoledronic O
acid O
; O
P O
= O
.39 O
) O
. O
Denosumab O
was O
superior O
to O
zoledronic O
acid O
in O
delaying B-outcome
or I-outcome
preventing I-outcome
SREs I-outcome
in O
patients O
with O
breast O
cancer O
metastatic O
to O
bone O
and O
was O
generally O
well O
tolerated O
. O
With O
the O
convenience O
of O
a O
subcutaneous O
injection O
and O
no O
requirement O
for O
renal O
monitoring O
, O
denosumab O
represents O
a O
potential O
treatment O
option O
for O
patients O
with O
bone O
metastases O
. O

A O
randomized O
, O
controlled O
, O
double O
- O
blind O
study O
of O
light B-intervention
emitting I-intervention
diode I-intervention
photomodulation I-intervention
for O
the O
prevention O
of O
radiation B-condition
dermatitis I-condition
in O
patients O
with O
breast O
cancer O
. O
Radiation O
dermatitis O
occurs O
in O
a O
majority O
of O
patients O
with O
breast O
cancer O
who O
receive O
radiation O
therapy O
( O
RT O
) O
, O
causes O
significant O
pain O
, O
and O
may O
necessitate O
treatment O
delay O
. O
Light O
emitting O
diode O
( O
LED O
) O
photomodulation O
has O
been O
reported O
to O
minimize O
radiation O
dermatitis O
. O
This O
study O
sought O
to O
further O
evaluate O
the O
efficacy O
of O
LED O
photomodulation O
in O
lessening O
radiation O
dermatitis O
. O
After O
surgery O
, O
patients O
with O
breast O
cancer O
received O
LED O
photomodulation O
or O
sham B-control
treatments I-control
in O
conjunction O
with O
three O
- O
dimensional O
conformal O
RT O
. O
Reactions O
were O
evaluated O
using O
standardized O
photographs O
graded O
according O
to O
National O
Cancer O
Institute O
criteria O
. O
In O
the O
LED O
treatment O
group O
( O
n O
= O
18 B-total-participants
) O
, O
no B-iv-bin-abs
patients O
had O
grade B-outcome
0 I-outcome
reactions I-outcome
, O
six B-iv-bin-abs
( O
33.3 B-iv-bin-percent
% I-iv-bin-percent
) O
had O
grade B-outcome
1 I-outcome
reactions I-outcome
, O
12 B-iv-bin-abs
( O
66.7 B-iv-bin-percent
% I-iv-bin-percent
) O
had O
grade B-outcome
2 I-outcome
reactions I-outcome
, O
and O
none B-iv-bin-abs
had O
a O
grade B-outcome
3 I-outcome
reaction I-outcome
. O
In O
the O
sham O
treatment O
group O
( O
n O
= O
15 B-control-participants
) O
, O
one B-cv-bin-abs
( O
6.6 B-cv-bin-percent
% I-cv-bin-percent
) O
patient O
had O
a O
grade B-outcome
0 I-outcome
reaction I-outcome
, O
four B-cv-bin-abs
( O
26.7 B-cv-bin-percent
% I-cv-bin-percent
) O
had O
grade B-outcome
1 I-outcome
reactions I-outcome
, O
9 B-cv-bin-abs
( O
60.0 B-cv-bin-percent
% I-cv-bin-percent
) O
had O
grade B-outcome
2 I-outcome
reactions I-outcome
, O
and O
one B-cv-bin-abs
( O
6.7 B-cv-bin-percent
% I-cv-bin-percent
) O
had O
a O
grade B-outcome
3 I-outcome
reaction I-outcome
. O
Two B-iv-bin-abs
( O
11.1 B-iv-bin-percent
% I-iv-bin-percent
) O
patients O
in O
the O
LED O
treatment O
group O
and O
one B-cv-bin-abs
( O
6.7 B-cv-bin-percent
% I-cv-bin-percent
) O
in O
the O
control O
group O
had O
to O
interrupt B-outcome
treatment I-outcome
. O
Differences O
between O
groups O
were O
not O
statistically O
significant O
. O
LED O
photomodulation O
did O
not O
reduce O
the O
incidence O
of O
radiation O
- O
induced O
skin O
reactions O
or O
interruptions O
in O
therapy O
. O
. O
  O

Phase O
III O
trial O
of O
gemcitabine B-intervention
plus I-intervention
docetaxel I-intervention
versus O
capecitabine B-control
plus I-control
docetaxel I-control
with O
planned O
crossover O
to O
the O
alternate O
single O
agent O
in O
metastatic O
breast O
cancer O
. O
Safety O
and O
efficacy O
of O
gemcitabine O
plus O
docetaxel O
( O
GD O
) O
and O
capecitabine O
plus O
docetaxel O
( O
CD O
) O
were O
compared O
in O
patients B-eligibility
with I-eligibility
metastatic I-eligibility
breast I-eligibility
cancer I-eligibility
, O
where O
the O
alternate O
crossover O
monotherapy O
( O
GDC O
or O
CDG O
) O
was O
predetermined O
. O
Patients O
were O
randomly O
assigned O
to O
3 O
- O
week O
cycles O
of O
either O
gemcitabine O
1000 O
mg O
/ O
m O
( O
2 O
) O
on O
days O
1 O
and O
8 O
plus O
docetaxel O
75 O
mg O
/ O
m O
( O
2 O
) O
on O
day O
1 O
or O
capecitabine O
1000 O
mg O
/ O
m O
( O
2 O
) O
twice O
daily O
on O
days O
1 O
- O
14 O
plus O
docetaxel O
75 O
mg O
/ O
m O
( O
2 O
) O
day O
1 O
. O
Upon O
progression O
, O
patients O
received O
crossover O
monotherapy O
. O
Primary O
end O
point O
was O
time B-outcome-measure
to I-outcome-measure
progression I-outcome-measure
( I-outcome-measure
TtP I-outcome-measure
) I-outcome-measure
. O
Secondary O
end O
points O
evaluated O
overall B-outcome-measure
response I-outcome-measure
rate I-outcome-measure
( I-outcome-measure
ORR I-outcome-measure
) I-outcome-measure
, O
overall B-outcome-measure
survival I-outcome-measure
( I-outcome-measure
OS I-outcome-measure
) I-outcome-measure
, O
and O
adverse B-outcome-measure
events I-outcome-measure
( I-outcome-measure
AEs I-outcome-measure
) I-outcome-measure
. O
Despite O
over O
- O
accrual O
of O
475 B-total-participants
patients O
, O
the O
trial O
matured O
with O
only O
324 B-total-participants
of O
385 O
planned O
TtP O
events O
due O
to O
patient O
discontinuations O
. O
Human O
epidermal O
growth O
factor O
receptor O
2 O
status O
was O
not O
captured O
in O
this O
study O
. O
More O
CD O
patients O
( O
28 B-cv-bin-percent
% I-cv-bin-percent
) O
discontinued B-outcome
due I-outcome
to I-outcome
AEs I-outcome
than O
GD O
patients O
( O
18.0 B-iv-bin-percent
% I-iv-bin-percent
, O
P O
= O
0.009 O
) O
. O
TtP B-outcome
[ O
hazard O
ratio O
( O
HR O
) O
= O
1.101 O
, O
95 O
% O
confidence O
interval O
( O
CI O
) O
0.885 O
- O
1.370 O
, O
P O
= O
0.387 O
] O
and O
OS B-outcome
( O
HR O
= O
1.031 O
, O
95 O
% O
CI O
0.830 O
- O
1.280 O
, O
P O
= O
0.785 O
) O
were O
not O
significantly O
different O
comparing O
GD O
and O
CD O
. O
ORR B-outcome
was O
not O
statistically O
different O
( O
P O
= O
0.239 O
) O
comparing O
GD O
( O
72 B-iv-bin-abs
of O
207 B-intervention-participants
, O
34.8 B-iv-bin-percent
% I-iv-bin-percent
) O
and O
CD O
( O
78 B-cv-bin-abs
of O
191 B-control-participants
, O
40.8 B-cv-bin-percent
% I-cv-bin-percent
) O
. O
TtP B-outcome
, I-outcome
OS I-outcome
, I-outcome
and I-outcome
ORR I-outcome
were O
not O
significantly O
different O
comparing O
crossover O
groups O
. O
GD O
caused O
greater O
fatigue B-outcome
, O
hepatotoxicity B-outcome
, O
neutropenia B-outcome
, O
and O
thrombocytopenia B-outcome
but O
not O
febrile B-outcome
neutropenia I-outcome
; O
CD O
caused O
more O
hand B-outcome
- I-outcome
foot I-outcome
syndrome I-outcome
, O
gastrointestinal B-outcome
toxicity I-outcome
, O
and O
mucositis B-outcome
. O
GD O
and O
CD O
produced O
similar O
efficacy O
and O
toxicity O
profiles O
consistent O
with O
prior O
clinical O
experience O
. O

Ixabepilone B-intervention
plus I-intervention
capecitabine I-intervention
in O
metastatic O
breast O
cancer O
patients O
with O
reduced O
performance O
status O
previously O
treated O
with O
anthracyclines O
and O
taxanes O
: O
a O
pooled O
analysis O
by O
performance O
status O
of O
efficacy O
and O
safety O
data O
from O
2 O
phase O
III O
studies O
. O
Patients O
with O
metastatic O
breast O
cancer O
( O
MBC O
) O
previously O
treated O
with O
anthracyclines O
and O
taxanes O
often O
have O
decreased O
performance O
status O
secondary O
to O
extensive O
tumor O
involvement O
. O
Here O
, O
we O
report O
the O
pooled O
analysis O
of O
efficacy O
and O
safety O
data O
from O
two O
similarly O
designed O
phase O
III O
studies O
to O
provide O
a O
more O
precise O
estimate O
of O
benefit O
of O
ixabepilone O
plus O
capecitabine O
in O
MBC O
patients O
with O
Karnofsky O
's O
performance O
status O
( O
KPS O
) O
70 O
- O
80 O
. O
Across O
the O
studies O
, O
anthracycline B-eligibility
/ I-eligibility
taxane I-eligibility
- I-eligibility
pretreated I-eligibility
MBC I-eligibility
patients I-eligibility
were O
randomized O
to O
receive O
ixabepilone O
plus O
capecitabine O
or O
capecitabine B-control
alone I-control
. O
Individual O
patient O
data O
for O
KPS O
70 O
- O
80 O
subset O
( O
n O
 O
= O
 O
606 B-total-participants
) O
or O
KPS O
90 O
- O
100 O
subset O
( O
n O
 O
= O
 O
1349 B-total-participants
) O
from O
the O
two O
studies O
were O
pooled O
by O
treatment O
. O
Analysis O
included O
overall O
survival O
( O
OS O
) O
, O
progression O
- O
free O
survival O
( O
PFS O
) O
, O
objective O
response O
rate O
( O
ORR O
) O
, O
and O
safety O
. O
In O
patients O
with O
reduced O
performance O
status O
( O
KPS O
70 O
- O
80 O
) O
, O
ixabepilone O
plus O
capecitabine O
was O
associated O
with O
improvements O
in O
OS B-outcome
( O
median O
: O
12.3 B-iv-cont-median
vs. O
9.5 B-cv-cont-mean
 I-cv-cont-mean
months I-cv-cont-mean
; O
HR O
, O
0.75 O
; O
P O
 O
= O
 O
0.0015 O
) O
, O
PFS B-outcome
( O
median O
: O
4.6 B-iv-cont-median
vs. O
3.1 B-cv-cont-median
 I-cv-cont-median
months I-cv-cont-median
; O
HR O
, O
0.76 O
; O
P O
 O
= O
 O
0.0021 O
) O
and O
ORR B-outcome
( O
35 B-iv-bin-percent
vs. O
19 B-cv-bin-percent
% I-cv-bin-percent
) O
over O
capecitabine O
alone O
. O
Corresponding O
results O
in O
patients O
with O
high O
performance O
status O
( O
KPS O
90 O
- O
100 O
) O
were O
median B-outcome
OS I-outcome
of O
16.7 B-iv-cont-median
versus O
16.2 B-cv-cont-median
 I-cv-cont-median
months I-cv-cont-median
( O
HR O
, O
0.98 O
; O
P O
 O
= O
 O
0.8111 O
) O
, O
median B-outcome
PFS I-outcome
of O
6.0 B-iv-cont-median
versus O
4.4 B-cv-cont-median
 I-cv-cont-median
months I-cv-cont-median
( O
HR O
, O
0.58 O
; O
P O
 O
= O
 O
0.0009 O
) O
, O
and O
ORR B-outcome
of O
45 B-iv-bin-percent
versus O
28 B-cv-bin-percent
% I-cv-bin-percent
. O
The O
safety B-outcome
profile I-outcome
of O
combination O
therapy O
was O
similar O
between O
the O
subgroups O
. O
Ixabepilone O
plus O
capecitabine O
appeared O
to O
show O
superior O
efficacy O
compared O
to O
capecitabine O
alone O
in O
MBC O
patients O
previously O
treated O
with O
anthracyclines O
and O
taxanes O
, O
regardless O
of O
performance O
status O
, O
with O
a O
possible O
OS O
benefit O
favoring O
KPS O
70 O
- O
80 O
patients O
( O
ClinicalTrials O
. O
gov O
identifiers O
: O
NCT00080301 O
and O
NCT00082433 O
) O
. O

Randomized O
controlled O
trial O
on O
effectiveness O
of O
ultrasonography B-intervention
screening I-intervention
for O
breast O
cancer O
in O
women O
aged B-age
40 I-age
- I-age
49 I-age
( O
J O
- O
START O
): O
research O
design O
. O
In O
cancer O
screening O
, O
it O
is O
essential O
to O
undertake O
effective O
screening O
with O
appropriate O
methodology O
, O
which O
should O
be O
supported O
by O
evidence O
of O
a O
reduced O
mortality O
rate O
. O
At O
present O
, O
mammography O
is O
the O
only O
method O
for O
breast O
cancer O
screening O
with O
such O
evidence O
. O
However O
, O
mammography O
does O
not O
achieve O
sufficient O
accuracy O
in O
breasts O
with O
high O
density O
at O
ages O
below O
50 O
. O
Although O
ultrasonography O
achieves O
better O
accuracy O
in O
Breast O
Cancer O
detection O
even O
in O
dense O
breasts O
, O
the O
effectiveness O
has O
not O
been O
verified O
. O
We O
have O
planned O
a O
randomized O
controlled O
trial O
to O
assess O
the O
effectiveness O
of O
ultrasonography O
in O
women O
aged O
40 O
- O
49 O
, O
with O
a O
design O
to O
study O
50,000 B-intervention-participants
women O
with O
mammography O
and O
ultrasonography O
( O
intervention O
group O
) O
, O
and O
50,000 B-control-participants
controls O
with O
mammography B-control
only I-control
( I-control
control I-control
group I-control
) I-control
. O
The O
participants O
are O
scheduled O
to O
take O
second O
round O
screening O
with O
the O
same O
modality O
2 O
years O
on O
. O
The O
primary O
endpoints O
are O
sensitivity B-outcome-measure
and I-outcome-measure
specificity I-outcome-measure
, O
and O
the O
secondary O
endpoint O
is O
the O
rate B-outcome-measure
of I-outcome-measure
advanced I-outcome-measure
breast I-outcome-measure
cancers I-outcome-measure
. O

Randomized O
phase O
III O
trial O
of O
adjuvant B-intervention
epirubicin I-intervention
followed I-intervention
by I-intervention
cyclophosphamide I-intervention
, I-intervention
methotrexate I-intervention
, I-intervention
and I-intervention
5 I-intervention
- I-intervention
fluorouracil I-intervention
( I-intervention
CMF I-intervention
) I-intervention
versus O
CMF B-control
followed O
by O
epirubicin O
in O
patients O
with O
node O
- O
negative O
or O
1 O
- O
3 O
node O
- O
positive O
rapidly O
proliferating O
breast O
cancer O
. O
Adjuvant O
cyclophosphamide O
, O
methotrexate O
, O
and O
5 O
- O
fluorouracil O
( O
CMF O
) O
have O
proven O
highly O
effective O
in O
rapidly O
proliferating O
breast O
cancer O
( O
RPBC O
) O
. O
It O
has O
also O
been O
seen O
that O
sequential O
administration O
of O
doxorubicin O
and O
CMF O
is O
superior O
to O
their O
alternation O
, O
especially O
in O
indolent O
tumors O
. O
In O
a O
phase O
III O
study O
, O
we O
evaluated O
whether O
adjuvant O
epirubicin O
( O
E O
) O
followed O
by O
CMF O
is O
superior O
to O
the O
inverse O
sequence O
in O
RPBC O
. O
Patients B-eligibility
with I-eligibility
node I-eligibility
- I-eligibility
negative I-eligibility
or I-eligibility
1 I-eligibility
- I-eligibility
3 I-eligibility
node I-eligibility
- I-eligibility
positive I-eligibility
RPBC I-eligibility
( I-eligibility
Thymidine I-eligibility
Labeling I-eligibility
Index I-eligibility
 I-eligibility
> I-eligibility
 I-eligibility
3 I-eligibility
% I-eligibility
or I-eligibility
histological I-eligibility
grade I-eligibility
3 I-eligibility
or I-eligibility
S I-eligibility
- I-eligibility
phase I-eligibility
 I-eligibility
> I-eligibility
 I-eligibility
10 I-eligibility
% I-eligibility
or I-eligibility
Ki67 I-eligibility
 I-eligibility
> I-eligibility
 I-eligibility
20 I-eligibility
% I-eligibility
) I-eligibility
were O
randomized O
to O
receive O
E O
( O
100 O
mg O
/ O
m O
( O
2 O
) O
i. O
v. O
d1 O
, O
q21 O
days O
for O
4 O
cycles O
) O
followed O
by O
CMF O
( O
600 O
, O
40 O
, O
600 O
 O
mg O
/ O
m O
( O
2 O
) O
i. O
v. O
d1 O
and O
8 O
, O
q28 O
days O
for O
4 O
cycles O
) O
( O
E O
 O
 O
 O
CMF O
) O
or O
CMF O
followed O
by O
E O
( O
CMF O
 O
 O
 O
E O
) O
or O
CMF O
for O
6 O
cycles O
. O
From O
November O
1997 O
to O
December O
2004 O
, O
1066 B-total-participants
patients O
were O
enrolled O
: O
E O
 O
 O
 O
CMF O
440 B-intervention-participants
, O
CMF O
 O
 O
 O
E O
438 B-intervention-participants
, O
and O
CMF O
188 B-control-participants
. O
At O
a O
median O
follow O
- O
up O
of O
69 O
 O
months O
, O
5 B-outcome
- I-outcome
year I-outcome
OS I-outcome
was O
91 B-iv-bin-percent
% I-iv-bin-percent
( O
95 O
% O
CI O
88 O
- O
94 O
) O
for O
E O
 O
 O
 O
CMF O
and O
93 B-iv-bin-percent
% I-iv-bin-percent
( O
95 O
% O
CI O
90 O
- O
95 O
) O
for O
CMF O
 O
 O
 O
E O
, O
with O
adjusted O
hazard O
ratio O
of O
0.88 O
( O
95 O
% O
CI O
0.58 O
- O
1.35 O
) O
, O
and O
DFS B-outcome
was O
80 B-iv-bin-percent
% I-iv-bin-percent
in O
both O
arms O
, O
with O
adjusted O
hazard O
ratio O
of O
0.99 O
( O
95 O
% O
CI O
0.73 O
- O
1.33 O
, O
Cox O
model O
) O
. O
Adverse B-outcome
events I-outcome
were O
similar O
, O
apart O
from O
a O
higher O
rate O
of O
neutropenia O
in O
the O
CMF O
 O
 O
 O
E O
arm O
. O
No O
important O
differences O
in O
clinical O
outcome O
were O
observed O
between O
the O
two O
different O
sequences O
, O
making O
both O
a O
valid O
option O
in O
early O
breast O
cancer O
. O
Further O
molecular O
characterization O
of O
the O
tumors O
might O
help O
to O
identify O
subgroups O
achieving O
higher O
benefit O
from O
either O
sequence O
. O

A O
phase O
II O
randomized O
study O
comparing O
navelbine B-intervention
and I-intervention
capecitabine I-intervention
( O
Navcap O
) O
followed O
either O
by O
Navcap O
or O
by O
weekly O
docetaxel B-control
in O
the O
first O
- O
line O
treatment O
of O
HER-2 O
/ O
neu O
negative O
metastatic O
breast O
cancer O
. O
Following O
the O
proven O
efficacy O
and O
tolerability O
of O
Navcap O
and O
Navcap O
followed O
by O
docetaxel O
in O
the O
treatment O
of O
MBC O
, O
a O
phase O
II O
randomized O
study O
was O
initiated O
to O
assess O
the O
ORR O
of O
both O
arms O
in O
the O
first O
- O
line O
setting O
of O
MBC O
. O
Patients B-eligibility
with I-eligibility
no I-eligibility
prior I-eligibility
chemotherapy I-eligibility
for I-eligibility
MBC I-eligibility
and I-eligibility
HER-2 I-eligibility
/ I-eligibility
neu I-eligibility
negative I-eligibility
were O
eligible O
. O
All O
patients O
received O
Navcap O
( O
V O
25 O
mg O
/ O
m2 O
on O
d1 O
and O
d8 O
and O
C O
825 O
mg O
/ O
m2 O
bid O
D1 O
- O
14 O
q3w O
) O
for O
a O
total O
of O
4 O
cycles O
. O
Patients O
progressing O
under O
Navcap O
were O
withdrawn O
and O
received O
docetaxel O
as O
second O
- O
line O
treatment O
. O
Patients O
responding O
or O
stable O
were O
randomized O
to O
2 O
arms O
: O
4 O
cycles O
of O
Navcap O
( O
A O
) O
or O
12 O
weekly O
docetaxel O
( O
25 O
mg O
/ O
m/week O
) O
( O
B O
) O
. O
From O
July O
2004 O
to O
July O
2008 O
, O
a O
total O
of O
106 B-total-participants
patients O
were O
enrolled O
. O
Ninety B-total-participants
- I-total-participants
four I-total-participants
patients O
were O
evaluable O
before O
randomization O
, O
with O
a O
clinical O
benefit O
of O
58 O
% O
. O
Twenty O
- O
one O
patients O
( O
22 O
% O
) O
had O
disease O
progression O
and O
were O
therefore O
not O
randomized O
. O
Forty B-intervention-participants
- I-intervention-participants
one I-intervention-participants
patients O
were O
randomized O
to O
arm O
A O
and O
29 B-control-participants
patients O
to O
arm O
B O
. O
ORRs B-outcome
were O
56 B-iv-bin-percent
and O
71 B-cv-bin-percent
% I-cv-bin-percent
in O
arms O
A O
and O
B O
, O
respectively O
. O
The O
median B-outcome
time I-outcome
to I-outcome
progression I-outcome
and O
overall B-outcome
survival I-outcome
were O
10 B-iv-cont-median
and O
35 B-iv-cont-median
months I-iv-cont-median
in O
arm O
A O
and O
12 B-cv-cont-median
and O
37 B-cv-cont-median
months I-cv-cont-median
in O
arm O
B O
. O
Adverse O
events O
were O
mild O
. O
Arm O
A O
: O
grade B-outcome
3 I-outcome
- I-outcome
4 I-outcome
neutropenia I-outcome
( O
10 B-iv-bin-percent
% I-iv-bin-percent
) O
, O
grade B-outcome
3 I-outcome
anemia I-outcome
( O
5 B-iv-bin-percent
% I-iv-bin-percent
) O
. O
Arm O
B O
: O
grade B-outcome
3 I-outcome
neutropenia I-outcome
( O
6 B-cv-bin-percent
% I-cv-bin-percent
) O
, O
grade B-outcome
3 I-outcome
anemia I-outcome
( O
6.2 B-cv-bin-percent
% I-cv-bin-percent
) O
, O
and O
grade B-outcome
2 I-outcome
alopecia I-outcome
( O
12 B-cv-bin-percent
% I-cv-bin-percent
) O
. O
Both O
Navcap O
and O
Navcap O
followed O
by O
Docetaxel O
regimens O
were B-outcome
tolerated I-outcome
with O
manageable O
toxicity O
, O
offering O
consistent O
activities O
in O
terms O
of O
response O
rate O
for O
metastatic O
breast O
cancer O
patients O
. O

[ O
Preventing O
lymphoedema B-condition
after O
breast O
cancer O
surgery O
by O
elastic B-intervention
restraint I-intervention
orthotic I-intervention
and I-intervention
manual I-intervention
lymphatic I-intervention
drainage I-intervention
: O
a O
randomized O
clinical O
trial O
] O
. O
Secondary O
lymphoedema O
is O
considered O
one O
of O
the O
most O
common O
complications O
after O
breast O
cancer O
surgery O
. O
The O
aim O
of O
the O
present O
study O
was O
to O
analyze O
the O
effectiveness O
of O
containment O
elastic O
orthosis O
and O
manual O
lymphatic O
drainage O
in O
the O
prevention O
of O
lymphoedema O
secondary O
to O
mastectomy O
. O
An O
experimental O
study O
was O
performed O
with O
a O
control O
group O
. O
Forty B-total-participants
- I-total-participants
eight I-total-participants
patients O
were O
randomly O
assigned O
to O
experimental O
( O
containment O
elastic O
orthosis O
and O
manual O
lymphatic O
drainage O
) O
and O
control B-control
( I-control
postural I-control
measures I-control
) I-control
groups O
. O
Outcomes O
measures O
were O
quality B-outcome-measure
of I-outcome-measure
life I-outcome-measure
, O
body B-outcome-measure
composition I-outcome-measure
, O
temperature B-outcome-measure
, O
functional B-outcome-measure
assessment I-outcome-measure
of I-outcome-measure
the I-outcome-measure
shoulder I-outcome-measure
, O
pain B-outcome-measure
and O
limb B-outcome-measure
volume I-outcome-measure
. O
Measures O
were O
performed O
at O
baseline O
and O
after O
8 O
- O
months O
intervention O
. O
After O
the O
intervention O
period O
, O
the O
experimental O
group O
showed O
significant O
differences O
( O
P<.05 O
) O
in O
the O
quality B-outcome
of I-outcome
life I-outcome
, O
extracellular B-outcome
water I-outcome
, O
and O
functional B-outcome
assessment I-outcome
of I-outcome
the I-outcome
volume I-outcome
of I-outcome
the I-outcome
limb I-outcome
of O
the O
mastectomized O
side O
. O
The O
application O
of O
containment O
elastic O
orthosis O
and O
manual O
lymphatic O
drainage O
contribute O
to O
prevent O
secondary O
lymphoedema O
after O
breast O
cancer O
surgery O
, O
improving O
the O
quality O
of O
life O
in O
these O
patients O
. O
  O

Weight B-intervention
lifting I-intervention
for O
women O
at O
risk O
for O
breast O
cancer O
- O
related O
lymphedema B-condition
: O
a O
randomized O
trial O
. O
Clinical O
guidelines O
for O
breast O
cancer O
survivors O
without O
lymphedema O
advise O
against O
upper O
body O
exercise O
, O
preventing O
them O
from O
obtaining O
established O
health O
benefits O
of O
weight O
lifting O
. O
To O
evaluate O
lymphedema O
onset O
after O
a O
1 O
- O
year O
weight O
lifting O
intervention O
vs O
no B-control
exercise I-control
( I-control
control I-control
) I-control
among O
survivors O
at O
risk O
for O
breast O
cancer O
- O
related O
lymphedema O
( O
BCRL O
) O
. O
A O
randomized O
controlled O
equivalence O
trial O
( O
Physical O
Activity O
and O
Lymphedema O
trial O
) O
in O
the O
Philadelphia B-location
metropolitan O
area O
of O
154 B-total-participants
breast B-eligibility
cancer I-eligibility
survivors I-eligibility
1 I-eligibility
to I-eligibility
5 I-eligibility
years I-eligibility
postunilateral I-eligibility
breast I-eligibility
cancer I-eligibility
, I-eligibility
with I-eligibility
at I-eligibility
least I-eligibility
2 I-eligibility
lymph I-eligibility
nodes I-eligibility
removed I-eligibility
and I-eligibility
without I-eligibility
clinical I-eligibility
signs I-eligibility
of I-eligibility
BCRL I-eligibility
at I-eligibility
study I-eligibility
entry I-eligibility
. O
Participants O
were O
recruited O
between O
October O
1 O
, O
2005 O
, O
and O
February O
2007 O
, O
with O
data O
collection O
ending O
in O
August O
2008 O
. O
Weight O
lifting O
intervention O
included O
a O
gym O
membership O
and O
13 O
weeks O
of O
supervised O
instruction O
, O
with O
the O
remaining O
9 O
months O
unsupervised O
, O
vs O
no O
exercise O
. O
Incident O
BCRL O
determined O
by O
increased O
arm O
swelling O
during O
12 O
months O
( O
5 O
% O
increase O
in O
interlimb O
difference O
) O
. O
Clinician O
- O
defined O
BCRL O
onset O
was O
also O
evaluated O
. O
Equivalence O
margin O
was O
defined O
as O
doubling O
of O
lymphedema O
incidence O
. O
A O
total O
of O
134 B-total-participants
participants O
completed O
follow O
- O
up O
measures O
at O
1 O
year O
. O
The O
proportion O
of O
women O
who O
experienced O
incident B-outcome
BCRL I-outcome
onset I-outcome
was O
11 B-iv-bin-percent
% I-iv-bin-percent
( O
8 B-iv-bin-abs
of O
72 B-intervention-participants
) O
in O
the O
weight O
lifting O
intervention O
group O
and O
17 B-cv-bin-percent
% I-cv-bin-percent
( O
13 B-cv-bin-abs
of O
75 B-control-participants
) O
in O
the O
control O
group O
( O
cumulative O
incidence O
difference O
[ O
CID O
] O
, O
-6.0 O
% O
; O
95 O
% O
confidence O
interval O
[ O
CI O
] O
, O
-17.2 O
% O
to O
5.2 O
% O
; O
P O
for O
equivalence O
= O
.04 O
) O
. O
Among O
women O
with O
5 O
or O
more O
lymph O
nodes O
removed O
, O
the O
proportion O
who O
experienced O
incident B-outcome
BCRL I-outcome
onset I-outcome
was O
7 B-iv-bin-percent
% I-iv-bin-percent
( O
3 B-iv-bin-abs
of O
45 B-intervention-participants
) O
in O
the O
weight O
lifting O
intervention O
group O
and O
22 B-cv-bin-percent
% I-cv-bin-percent
( O
11 B-cv-bin-abs
of O
49 B-control-participants
) O
in O
the O
control O
group O
( O
CID O
, O
-15.0 O
% O
; O
95 O
% O
CI O
, O
-18.6 O
% O
to O
-11.4 O
% O
; O
P O
for O
equivalence O
= O
.003 O
) O
. O
Clinician B-outcome
- I-outcome
defined I-outcome
BCRL I-outcome
onset I-outcome
occurred O
in O
1 B-iv-bin-abs
woman O
in O
the O
weight O
lifting O
intervention O
group O
and O
3 B-cv-bin-abs
women O
in O
the O
control O
group O
( O
1.5 B-iv-bin-percent
% I-iv-bin-percent
vs O
4.4 B-cv-bin-percent
% I-cv-bin-percent
, O
P O
for O
equivalence O
= O
.12 O
) O
. O
In O
breast O
cancer O
survivors O
at O
risk O
for O
lymphedema O
, O
a O
program O
of O
slowly O
progressive O
weight O
lifting O
compared O
with O
no O
exercise O
did O
not O
result O
in O
increased O
incidence O
of O
lymphedema O
. O
clinicaltrials.gov O
Identifier O
: O
NCT00194363 O
. O

Reducing O
vasomotor O
symptoms O
with O
acupuncture B-intervention
in O
breast O
cancer O
patients O
treated O
with O
adjuvant O
tamoxifen O
: O
a O
randomized O
controlled O
trial O
. O
To O
evaluate O
true O
acupuncture O
to O
control B-control
acupuncture I-control
( O
CTRL O
) O
( O
non O
- O
insertive O
stimulation O
at O
non O
- O
acupuncture O
points O
) O
in O
breast B-eligibility
cancer I-eligibility
patients I-eligibility
treated I-eligibility
with I-eligibility
adjuvant I-eligibility
tamoxifen I-eligibility
suffering I-eligibility
from I-eligibility
hot I-eligibility
flushes I-eligibility
and I-eligibility
sweatings I-eligibility
. O
Eighty B-total-participants
- I-total-participants
four I-total-participants
patients O
were O
randomized O
to O
receive O
either O
true O
acupuncture O
or O
CTRL O
twice O
a O
week O
for O
5 O
weeks O
. O
Seventy B-total-participants
- I-total-participants
four I-total-participants
patients O
were O
treated O
according O
to O
the O
protocol O
. O
In O
the O
true O
acupuncture O
group O
42 B-iv-bin-percent
% I-iv-bin-percent
( O
16 B-iv-bin-abs
/ O
38 B-intervention-participants
) O
reported O
improvements B-outcome
in I-outcome
hot I-outcome
flushes I-outcome
after I-outcome
6 I-outcome
weeks I-outcome
compared O
to O
47 B-cv-bin-percent
% I-cv-bin-percent
( O
17 B-cv-bin-abs
/ O
36 B-control-participants
) O
in O
the O
CTRL O
group O
( O
95 O
% O
CI O
, O
-28 O
to O
18 O
% O
) O
. O
Both O
groups O
reported O
improvement O
regarding O
severity B-outcome
and I-outcome
frequencies I-outcome
in I-outcome
hot I-outcome
flushes I-outcome
and I-outcome
sweatings I-outcome
but O
no O
statistical O
difference O
was O
found O
between O
the O
groups O
. O
In O
a O
subanalysis O
regarding O
the O
severity B-outcome
of I-outcome
sweatings I-outcome
at I-outcome
night I-outcome
a O
statistically O
significant O
difference O
P O
= O
0.03 O
was O
found O
in O
the O
true O
acupuncture O
group O
. O
Former O
experience O
of O
true O
acupuncture O
did O
not O
influence O
the O
perception O
of O
true O
acupuncture O
or O
CTRL O
. O
No O
significant O
differences O
in O
hormonal B-outcome
levels I-outcome
were O
found O
before O
and O
after O
treatment O
. O
In O
conclusion O
, O
convincing O
data O
that O
true O
acupuncture O
is O
more O
effective O
than O
CTRL O
in O
reducing O
vasomotor O
symptoms O
is O
still O
lacking O
. O
Our O
study O
shows O
that O
both O
true O
and O
CTRL O
reduce O
vasomotor O
symptoms O
in O
breast O
cancer O
patients O
treated O
with O
adjuvant O
tamoxifen O
. O

Preoperative B-intervention
dexamethasone I-intervention
reduces O
postoperative B-condition
pain I-condition
, I-condition
nausea I-condition
and I-condition
vomiting I-condition
following O
mastectomy O
for O
breast O
cancer O
. O
Dexamethasone O
has O
been O
reported O
to O
reduce O
postoperative O
symptoms O
after O
different O
surgical O
procedures O
. O
We O
evaluated O
the O
efficacy O
of O
preoperative O
dexamethasone O
in O
ameliorating O
postoperative O
nausea O
and O
vomiting O
( O
PONV O
) O
, O
and O
pain O
after O
mastectomy O
. O
In O
this O
prospective O
, O
double O
- O
blind O
, O
placebo O
- O
controlled O
study O
, O
70 B-total-participants
patients B-eligibility
scheduled I-eligibility
for I-eligibility
mastectomy I-eligibility
with I-eligibility
axillary I-eligibility
lymph I-eligibility
node I-eligibility
dissection I-eligibility
were O
analyzed O
after O
randomization O
to O
treatment O
with O
8 O
mg O
intravenous O
dexamethasone O
( O
n O
= O
35 B-intervention-participants
) O
or O
placebo B-control
( O
n O
= O
35 B-intervention-participants
) O
. O
All O
patients O
underwent O
standardized O
procedures O
for O
general O
anesthesia O
and O
surgery O
. O
Episodes O
of O
PONV O
and O
pain O
score O
were O
recorded O
on O
a O
visual O
analogue O
scale O
. O
Analgesic O
and O
antiemetic O
requirements O
were O
also O
recorded O
. O
Demographic O
and O
medical O
variables O
were O
similar O
between O
groups O
. O
The O
incidence B-outcome
of I-outcome
PONV I-outcome
was O
lower O
in O
the O
dexamethasone O
group O
at B-outcome
the I-outcome
early I-outcome
postoperative I-outcome
evaluation I-outcome
( O
28.6 B-iv-bin-percent
% I-iv-bin-percent
vs. O
60 B-cv-bin-percent
% I-cv-bin-percent
; O
p O
= O
0.02 O
) O
and O
at B-outcome
6 I-outcome
h I-outcome
( O
17.2 B-iv-bin-percent
% I-iv-bin-percent
vs. O
45.8 B-cv-bin-percent
% I-cv-bin-percent
; O
p O
= O
0.03 O
) O
. O
More O
patients O
in O
the O
placebo O
group O
required B-outcome
additional I-outcome
antiemetic I-outcome
medication I-outcome
( O
21 B-cv-bin-abs
vs. O
8 B-iv-bin-abs
; O
p O
= O
0.01 O
) O
. O
Dexamethasone O
treatment O
significantly O
reduced O
postoperative B-outcome
pain I-outcome
just I-outcome
after I-outcome
surgery I-outcome
( O
VAS O
score O
, O
4.54 B-iv-cont-mean
 O
1.55 B-iv-cont-sd
vs. O
5.83 B-cv-cont-mean
 O
2.00 B-cv-cont-sd
; O
p O
= O
0.004 O
) O
, O
at B-outcome
6 I-outcome
h I-outcome
( O
3.03 B-iv-cont-mean
 O
1.20 B-iv-cont-sd
vs. O
4.17 B-cv-cont-mean
 O
1.24 B-cv-cont-sd
; O
p O
< O
0.0005 O
) O
and O
at B-outcome
12 I-outcome
h I-outcome
( O
2.09 B-iv-cont-mean
 O
0.85 B-iv-cont-sd
vs. O
2.54 B-cv-cont-mean
 O
0.98 B-cv-cont-sd
; O
p O
= O
0.04 O
) O
. O
Analgesics B-outcome
were O
required O
in O
more O
patients O
of O
the O
control O
group O
( O
21 B-cv-bin-abs
vs. O
10 B-iv-bin-abs
; O
p O
= O
0.008 O
) O
. O
There O
were O
no O
adverse B-outcome
events I-outcome
, I-outcome
morbidity I-outcome
or I-outcome
mortality I-outcome
. O
Preoperative O
intravenous O
dexamethasone O
( O
8 O
mg O
) O
can O
significantly O
reduce O
the O
incidence O
of O
PONV O
and O
pain O
in O
patients O
undergoing O
mastectomy O
with O
axillary O
dissection O
for O
breast O
cancer O
. O
NCT01116713 O
. O

Preoperative B-intervention
MRI I-intervention
and O
surgical O
management O
in O
patients O
with O
nonpalpable O
breast O
cancer O
: O
the O
MONET O
- O
randomised O
controlled O
trial O
. O
We O
evaluated O
whether O
performing O
contrast O
- O
enhanced O
breast O
MRI O
in O
addition O
to O
mammography O
and/or O
ultrasound O
in O
patients B-eligibility
with I-eligibility
nonpalpable I-eligibility
suspicious I-eligibility
breast I-eligibility
lesions I-eligibility
improves O
breast O
cancer O
management O
. O
The O
MONET O
- O
study O
( O
MR O
mammography O
of O
nonpalpable O
breast O
tumours O
) O
is O
a O
randomised O
controlled O
trial O
in O
patients O
with O
a O
nonpalpable O
BIRADS O
3 O
- O
5 O
lesion O
. O
Patients O
were O
randomly O
assigned O
to O
receive O
routine B-control
medical I-control
care I-control
, O
including O
mammography O
, O
ultrasound O
and O
lesion O
sampling O
by O
large O
core O
needle O
biopsy O
or O
additional O
MRI O
preceding O
biopsy O
. O
Patients O
with O
cancer O
were O
referred O
for O
surgery O
. O
Primary O
end O
- O
point O
was O
the O
rate B-outcome-measure
of I-outcome-measure
additional I-outcome-measure
surgical I-outcome-measure
procedures I-outcome-measure
( I-outcome-measure
re I-outcome-measure
- I-outcome-measure
excisions I-outcome-measure
and I-outcome-measure
conversion I-outcome-measure
to I-outcome-measure
mastectomy I-outcome-measure
) I-outcome-measure
in O
patients O
with O
a O
nonpalpable O
breast O
cancer O
. O
Four B-total-participants
hundred I-total-participants
and I-total-participants
eighteen I-total-participants
patients O
were O
randomised O
, O
207 B-intervention-participants
patients O
were O
allocated O
to O
MRI O
, O
and O
211 B-control-participants
patients O
to O
the O
control O
group O
. O
In O
the O
MRI O
group O
74 B-iv-bin-abs
patients O
had O
83 O
malignant B-outcome
lesions I-outcome
, O
compared O
to O
75 B-cv-bin-abs
patients O
with O
80 O
malignant O
lesions O
in O
the O
control O
group O
. O
The O
primary B-outcome
breast I-outcome
conserving I-outcome
surgery I-outcome
( I-outcome
BCS I-outcome
) I-outcome
rate I-outcome
was O
similar O
in O
both O
groups O
; O
68 B-iv-bin-percent
% I-iv-bin-percent
in O
the O
MRI O
group O
versus O
66 B-cv-bin-percent
% I-cv-bin-percent
in O
the O
control O
group O
. O
The O
number B-outcome
of I-outcome
re I-outcome
- I-outcome
excisions I-outcome
performed O
because O
of O
positive O
resection O
margins O
after O
primary O
BCS O
was O
increased O
in O
the O
MRI O
group O
; O
18 B-iv-bin-abs
/ O
53 B-intervention-participants
( O
34 B-iv-bin-percent
% I-iv-bin-percent
) O
patients O
in O
the O
MRI O
group O
versus O
6 B-cv-bin-abs
/ O
50 B-control-participants
( O
12 B-cv-bin-percent
% I-cv-bin-percent
) O
in O
the O
control O
group O
( O
p O
= O
0.008 O
) O
. O
The O
number B-outcome
of I-outcome
conversions I-outcome
to I-outcome
mastectomy I-outcome
did O
not O
differ O
significantly O
between O
groups O
. O
Overall O
, O
the O
rate B-outcome
of I-outcome
an I-outcome
additional I-outcome
surgical I-outcome
intervention I-outcome
( O
BCS O
and O
mastectomy O
combined O
) O
after O
initial O
breast O
conserving O
surgery O
was O
24 B-iv-bin-abs
/ O
53 B-intervention-participants
( O
45 B-iv-bin-percent
% I-iv-bin-percent
) O
in O
the O
MRI O
group O
versus O
14 B-cv-bin-abs
/ O
50 B-control-participants
( O
28 B-cv-bin-percent
% I-cv-bin-percent
) O
in O
the O
control O
group O
( O
p O
= O
0.069 O
) O
. O
Addition O
of O
MRI O
to O
routine O
clinical O
care O
in O
patients O
with O
nonpalpable O
breast O
cancer O
was O
paradoxically O
associated O
with O
an O
increased O
re B-outcome
- I-outcome
excision I-outcome
rate I-outcome
. O
Breast O
MRI O
should O
not O
be O
used O
routinely O
for O
preoperative O
work O
- O
up O
of O
patients O
with O
nonpalpable O
breast O
cancer O
. O

A O
randomized O
trial O
of O
dietary B-intervention
intervention I-intervention
for O
breast O
cancer O
prevention O
. O
Epidemiologic O
data O
and O
animal O
experiments O
suggest O
that O
dietary O
fat O
may O
influence O
risk O
of O
breast O
cancer O
. O
To O
determine O
whether O
intervention O
with O
a O
low O
- O
fat O
, O
high O
- O
carbohydrate O
diet O
would O
reduce O
breast O
cancer O
incidence O
in O
women O
at O
increased O
risk O
of O
the O
disease O
, O
we O
carried O
out O
a O
randomized O
controlled O
trial O
in O
Canada B-location
. O
We O
recruited O
4,690 B-total-participants
women B-eligibility
with I-eligibility
extensive I-eligibility
mammographic I-eligibility
density I-eligibility
and O
randomized O
them O
to O
an O
intervention O
group O
or O
a O
comparison B-control
group I-control
. O
The O
intervention O
group O
received O
intensive O
dietary O
counseling O
to O
reduce O
fat O
intake O
to O
a O
target O
of O
15 O
% O
of O
calories O
and O
increase O
carbohydrate O
to O
65 O
% O
of O
calories O
. O
Dietary O
intakes O
were O
assessed O
throughout O
using O
food O
records O
. O
Subjects O
were O
followed O
for O
at O
least O
7 O
years O
and O
for O
an O
average O
of O
10 O
years O
. O
The O
main O
outcome O
was O
invasive B-outcome-measure
breast I-outcome-measure
cancer I-outcome-measure
. O
Percentage B-outcome
of I-outcome
calories I-outcome
from O
fat O
in O
the O
intervention O
group O
decreased O
from O
30 O
% O
at B-outcome
baseline I-outcome
to O
20 O
% O
after B-outcome
randomization I-outcome
and O
remained O
9 O
% O
to O
10 O
% O
lower O
than O
the O
comparison O
group O
throughout O
. O
There O
were O
118 B-iv-bin-abs
invasive B-outcome
breast I-outcome
cancers I-outcome
in O
the O
intervention O
group O
and O
102 B-cv-bin-abs
in O
the O
comparison O
group O
[ O
adjusted O
hazard O
ratio O
= O
1.19 O
( O
95 O
% O
CI O
: O
0.91 O
- O
1.55 O
) O
] O
. O
Analysis O
of O
food O
records O
showed O
that O
fat O
intake O
at O
baseline O
and O
after O
randomization O
was O
not O
associated O
with O
total O
breast B-outcome
cancer I-outcome
incidence I-outcome
. O
Greater O
weight B-outcome
and O
lower O
carbohydrate B-outcome
intake I-outcome
at O
baseline O
and O
after O
randomization O
were O
associated O
with O
an O
increased O
risk O
of O
estrogen O
receptor O
( O
ER O
) O
-positive O
breast O
cancer O
. O
Our O
findings O
suggest O
that O
a O
sustained O
reduction O
in O
dietary O
fat O
intake O
did O
not O
reduce O
risk B-outcome
of I-outcome
breast I-outcome
cancer I-outcome
in O
women O
with O
extensive O
mammographic O
density O
. O
Weight O
and O
carbohydrate O
intakes O
were O
associated O
with O
risk O
of O
ER O
- O
positive O
breast O
cancer O
. O
  O

Effects O
of O
pilates B-intervention
exercises I-intervention
on O
functional B-condition
capacity I-condition
, I-condition
flexibility I-condition
, I-condition
fatigue I-condition
, I-condition
depression I-condition
and I-condition
quality I-condition
of I-condition
life I-condition
in O
female O
breast O
cancer O
patients O
: O
a O
randomized O
controlled O
study O
. O
There O
are O
very O
few O
randomized O
controlled O
studies O
on O
exercise O
in O
cancer O
patients O
. O
Consequently O
, O
there O
are O
no O
guidelines O
available O
with O
regard O
to O
the O
exercises O
that O
can O
be O
recommended O
and O
difficulties O
are O
encountered O
in O
the O
clinical O
practice O
as O
to O
which O
exercise O
is O
more O
suitable O
to O
the O
patients O
. O
The O
purpose O
of O
this O
study O
was O
to O
investigate O
the O
impact O
of O
pilates O
exercises O
on O
physical O
performance O
, O
flexibility O
, O
fatigue O
, O
depression O
and O
quality O
of O
life O
in O
women B-eligibility
who I-eligibility
had I-eligibility
been I-eligibility
treated I-eligibility
for I-eligibility
breast I-eligibility
cancer I-eligibility
. O
Randomized O
controlled O
trial O
. O
Out O
patient O
group O
, O
Department O
of O
Physical O
Medicine O
and O
Rehabilitation O
and O
Medical O
Oncology O
Department O
, O
University O
Hospital O
. O
Fifty B-total-participants
- I-total-participants
two I-total-participants
patients O
with O
breast O
cancer O
were O
divided O
into O
either O
pilates O
exercise O
( O
group O
1 O
) O
and O
control B-control
group I-control
( O
group O
2 O
) O
. O
Patients O
in O
Group O
1 O
performed O
pilates O
and O
home O
exercises O
and O
patients O
in O
group O
2 O
performed O
only O
home O
exercises O
. O
Pilates O
exercise O
sessions O
were O
performed O
three O
times O
a O
week O
for O
a O
period O
of O
eight O
weeks O
in O
the O
rehabilitation O
unit O
. O
Subjects O
were O
assessed O
before O
and O
after O
rehabilitation O
program O
, O
with O
respect O
to O
, O
6 O
- O
min O
walk O
test O
( O
6MWT O
) O
, O
modified O
sit O
and O
reach O
test O
, O
Brief O
Fatigue O
Inventory O
( O
BFI O
) O
, O
Beck O
Depression O
Index O
( O
BDI O
) O
and O
the O
European O
Organisation O
for O
Research O
and O
Treatment O
of O
Cancer O
Quality O
of O
Life O
C30 O
( O
EORTC O
QLQ O
- O
C30 O
) O
and O
EORTC O
QLQ O
BR23 O
. O
After O
the O
exercise O
program O
, O
improvements O
were O
observed O
in O
Group O
1 O
in O
6 B-outcome
- I-outcome
minute I-outcome
walk I-outcome
test I-outcome
, O
BDI B-outcome
, O
EORTC B-outcome
QLQ I-outcome
- I-outcome
C30 I-outcome
functional I-outcome
, O
and O
EORTC B-outcome
QLQ I-outcome
- I-outcome
C30 I-outcome
BR23 I-outcome
functional I-outcome
scores I-outcome
( O
P<0.05 O
) O
. O
In O
contrast O
, O
no B-outcome
significant I-outcome
improvement I-outcome
was O
observed O
in O
Group O
2 O
after O
the O
exercise O
program O
in O
any O
of O
parameters O
in O
comparison O
to O
the O
pre O
- O
exercise O
period O
( O
P>0.05 O
) O
. O
When O
the O
two O
exercise O
groups O
were O
compared O
, O
there O
were O
significant O
differences B-outcome
in I-outcome
6MWT I-outcome
in I-outcome
pilates I-outcome
- I-outcome
exercise I-outcome
group I-outcome
( O
P<0.05 O
) O
. O
Pilates O
exercises O
are O
effective B-outcome
and I-outcome
safe I-outcome
in O
female O
breast O
cancer O
patients O
. O
There O
is O
a O
need O
for O
further O
studies O
so O
that O
its O
effect O
can O
be O
confirmed O
. O
This O
study O
addressed O
the O
effects O
of O
pilates O
exercise O
, O
as O
a O
new O
approach O
, O
on O
functional O
capacity O
, O
fatigue O
, O
depression O
and O
quality O
of O
life O
in O
breast O
cancer O
patients O
in O
whom O
there O
are O
doubts O
regarding O
the O
efficacy O
and O
usefulness O
of O
the O
exercise O
. O

Effect O
of O
adding O
gefitinib B-intervention
to O
neoadjuvant O
chemotherapy O
in O
estrogen O
receptor O
negative O
early O
breast O
cancer O
in O
a O
randomized O
phase O
II O
trial O
. O
Gefitinib O
, O
an O
epidermal O
growth O
factor O
receptor O
tyrosine O
kinase O
inhibitor O
, O
has O
shown O
both O
anti O
- O
proliferative O
and O
anti O
- O
tumoral O
activity O
in O
breast O
cancer O
. O
This O
study O
was O
designed O
to O
determine O
the O
effect O
of O
adding O
gefitinib O
to O
neoadjuvant O
epirubicin O
and O
cyclophosphamide O
( O
EC O
) O
on O
tumor O
response O
rates O
. O
Women B-eligibility
with I-eligibility
unilateral I-eligibility
, I-eligibility
primary I-eligibility
operable I-eligibility
, I-eligibility
estrogen I-eligibility
receptor I-eligibility
negative I-eligibility
invasive I-eligibility
breast I-eligibility
cancer I-eligibility
 I-eligibility
2 I-eligibility
cm I-eligibility
were O
eligible O
for O
inclusion O
. O
Randomized O
patients O
were O
to O
receive O
four O
cycles O
of O
neoadjuvant O
EC O
plus O
12 O
weeks O
of O
either O
gefitinib O
( O
250 O
mg O
daily O
) O
or O
placebo B-control
. O
Primary O
endpoint O
was O
pathologic B-outcome-measure
complete I-outcome-measure
response I-outcome-measure
( I-outcome-measure
pCR I-outcome-measure
) I-outcome-measure
, O
and O
secondary O
endpoints O
were O
complete B-outcome-measure
response I-outcome-measure
( I-outcome-measure
CR I-outcome-measure
) I-outcome-measure
and O
overall B-outcome-measure
objective I-outcome-measure
response I-outcome-measure
( I-outcome-measure
OR I-outcome-measure
) I-outcome-measure
. O
181 B-total-participants
patients O
were O
randomized O
. O
A O
pCR B-outcome
was O
observed O
in O
17 B-iv-bin-percent
% I-iv-bin-percent
( O
12 B-iv-bin-abs
/ O
71 B-intervention-participants
) O
of O
patients O
treated O
with O
gefitinib O
and O
in O
12 B-cv-bin-percent
% I-cv-bin-percent
( O
9 B-cv-bin-abs
/ O
73 B-control-participants
) O
of O
patients O
treated O
with O
placebo O
( O
4.57 O
% O
difference O
, O
95 O
% O
CI O
-7.19 O
to O
6.33 O
; O
P O
= O
0.44 O
) O
. O
CR B-outcome
was O
observed O
in O
10 B-iv-bin-percent
% I-iv-bin-percent
of O
patients O
in O
both O
the O
gefitinib O
( O
7 B-iv-bin-abs
/ O
71 B-intervention-participants
) O
and O
the O
placebo O
group O
( O
7 B-cv-bin-abs
/ O
73 B-control-participants
) O
( O
0.27 O
% O
difference O
, O
95 O
% O
CI O
-9.6 O
to O
10.2 O
; O
P O
= O
0.96 O
) O
. O
There O
was O
no O
significant O
difference O
in O
OR B-outcome
( O
5.96 O
% O
; O
95 O
% O
CI O
-9.9 O
to O
21.9 O
; O
P O
= O
0.45 O
) O
between O
the O
two O
groups O
. O
Post O
hoc O
subgroup O
analysis O
showed O
a O
significant O
difference O
in O
pCR O
between O
triple O
negative O
breast O
cancer O
( O
TNBC O
) O
and O
non O
- O
TNBC O
tumors O
( O
P O
= O
0.03 O
) O
. O
More O
patients O
in O
the O
gefitinib O
arm O
had O
hematological B-outcome
toxicity I-outcome
( O
P O
= O
0.15 O
) O
and O
discontinued B-outcome
treatment I-outcome
( O
9 B-iv-bin-abs
/ O
94 B-intervention-participants
vs. O
2 B-cv-bin-abs
/ O
86 B-control-participants
) O
because O
of O
adverse O
events O
( O
AE O
) O
. O
Tumor B-outcome
response I-outcome
rates I-outcome
were O
similar O
in O
the O
two O
groups O
. O
A O
significantly O
higher O
pCR B-outcome
rate I-outcome
was O
observed O
post O
hoc O
in O
TNBC O
versus O
non O
- O
TNBC O
independent O
of O
treatment O
. O
More O
patients O
in O
the O
gefitinib O
group O
discontinued B-outcome
treatment I-outcome
because O
of O
AE O
. O

Effects O
on O
quality O
of O
life O
of O
weekly O
docetaxel B-intervention
- I-intervention
based I-intervention
chemotherapy I-intervention
in O
patients B-eligibility
with I-eligibility
locally I-eligibility
advanced I-eligibility
or I-eligibility
metastatic I-eligibility
breast I-eligibility
cancer I-eligibility
: O
results O
of O
a O
single O
- O
centre O
randomized O
phase O
3 O
trial O
. O
To O
evaluate O
whether O
weekly O
schedules O
of O
docetaxel O
- O
based O
chemotherapy O
were O
superior O
to O
3 O
- O
weekly O
ones O
in O
terms O
of O
quality O
of O
life O
in O
locally O
advanced O
or O
metastatic O
breast O
cancer O
. O
Patients O
with O
locally O
advanced O
or O
metastatic O
breast O
cancer O
, O
aged O
 B-age
70 I-age
years I-age
, O
performance O
status O
0 O
- O
2 O
, O
chemotherapy O
- O
naive O
for O
metastatic O
disease O
, O
were O
eligible O
. O
They O
were O
randomized O
to O
weekly O
or O
3 O
- O
weekly O
combination O
of O
docetaxel O
and O
epirubicin O
, O
if O
they O
were O
not O
treated O
with O
adjuvant O
anthracyclines O
, O
or O
docetaxel O
and O
capecitabine O
, O
if O
treated O
with O
adjuvant O
anthracyclines O
. O
Primary O
end O
- O
point O
was O
global B-outcome-measure
quality I-outcome-measure
of I-outcome-measure
life I-outcome-measure
change I-outcome-measure
at I-outcome-measure
6 I-outcome-measure
- I-outcome-measure
weeks I-outcome-measure
, O
measured O
by O
EORTC O
QLQ O
- O
C30 O
. O
With O
two O
- O
sided O
alpha O
0.05 O
and O
80 O
% O
power O
for O
35 O
% O
effect O
size O
, O
130 O
patients O
per O
arm O
were O
needed O
. O
From O
February O
2004 O
to O
March O
2008 O
, O
139 B-total-participants
patients O
were O
randomized O
, O
70 B-intervention-participants
to O
weekly O
and O
69 B-control-participants
to O
3 B-control
- I-control
weekly I-control
arm I-control
; O
129 O
and O
89 O
patients O
filled O
baseline O
and O
6 O
- O
week O
questionnaires O
, O
respectively O
. O
Global O
quality B-outcome
of I-outcome
life I-outcome
was O
better O
in O
the O
3 O
- O
weekly O
arm O
( O
p O
= O
0.03 O
) O
; O
patients O
treated O
with O
weekly O
schedules O
presented O
a O
significantly O
worsening O
in O
role O
functioning O
and O
financial O
scores O
( O
p O
= O
0.02 O
and O
p O
< O
0.001 O
) O
. O
Neutropenia B-outcome
and I-outcome
stomatitis I-outcome
were O
worse O
in O
the O
3 O
- O
weekly O
arm O
, O
where O
two B-cv-bin-abs
toxic O
deaths B-outcome
were O
observed O
. O
Overall B-outcome
response I-outcome
rate I-outcome
was O
39.1 B-cv-bin-percent
% I-cv-bin-percent
and O
33.3 B-iv-bin-percent
% I-iv-bin-percent
in O
3 O
- O
weekly O
and O
weekly O
arms O
; O
hazard O
ratio O
of O
progression B-outcome
was O
1.29 O
( O
95 O
% O
CI O
: O
0.84 O
- O
1.97 O
) O
and O
hazard O
ratio O
of O
death B-outcome
was O
1.38 O
( O
95 O
% O
CI O
: O
0.82 O
- O
2.30 O
) O
in O
the O
weekly O
arm O
. O
In O
this O
trial O
, O
the O
weekly O
schedules O
of O
docetaxel O
- O
based O
chemotherapy O
appear O
to O
be O
inferior O
to O
the O
3 O
- O
weekly O
one O
in O
terms O
of O
quality O
of O
life O
in O
patients O
with O
locally O
advanced O
or O
metastatic O
breast O
cancer O
. O
ClinicalTrials O
. O
gov O
NCT00540800 O
. O

Long O
- O
term O
results O
of O
International O
Breast O
Cancer O
Study O
Group O
Trial O
VIII O
: O
adjuvant B-intervention
chemotherapy I-intervention
plus I-intervention
goserelin I-intervention
compared O
with O
either O
therapy B-control
alone I-control
for O
premenopausal B-eligibility
patients I-eligibility
with I-eligibility
node I-eligibility
- I-eligibility
negative I-eligibility
breast I-eligibility
cancer I-eligibility
. O
The O
International O
Breast O
Cancer O
Study O
Group O
Trial O
VIII O
compared O
long O
- O
term O
efficacy O
of O
endocrine O
therapy O
( O
goserelin O
) O
, O
chemotherapy O
[ O
cyclophosphamide O
, O
methotrexate O
and O
fluorouracil O
( O
CMF O
) O
] O
, O
and O
chemoendocrine O
therapy O
( O
CMF O
followed O
by O
goserelin O
) O
for O
pre O
/ O
perimenopausal O
women O
with O
lymph O
- O
node O
- O
negative O
breast O
cancer O
. O
From O
1990 O
to O
1999 O
, O
1063 B-total-participants
patients O
were O
randomized O
to O
receive O
( O
i O
) O
goserelin O
for O
24 O
months O
( O
n O
= O
346 B-intervention-participants
) O
, O
( O
ii O
) O
six O
courses O
of O
' O
classical O
' O
CMF O
( O
cyclophosphamide O
, O
methotrexate O
, O
5 O
- O
fluorouracil O
) O
chemotherapy O
( O
n O
= O
360 B-control-participants
) O
, O
or O
( O
iii O
) O
six O
courses O
of O
CMF O
plus O
18 O
months O
goserelin O
( O
CMF O
goserelin O
; O
n O
= O
357 B-intervention-participants
) O
. O
Tumors O
were O
classified O
as O
estrogen O
receptor O
( O
ER O
) O
negative O
( O
19 O
% O
) O
, O
ER O
positive O
( O
80 O
% O
) O
, O
or O
ER O
unknown O
( O
1 O
% O
) O
; O
19 O
% O
of O
patients O
were O
younger O
than O
40 O
. O
Median O
follow O
- O
up O
was O
12.1 O
years O
. O
For O
the O
ER B-outcome
- I-outcome
positive I-outcome
cohort I-outcome
, I-outcome
sequential O
therapy O
provided O
a O
statistically O
significant O
benefit O
in O
disease B-outcome
- I-outcome
free I-outcome
survival I-outcome
( I-outcome
DFS I-outcome
) I-outcome
( O
12 B-outcome
- I-outcome
year I-outcome
DFS I-outcome
= O
77 B-iv-bin-percent
% I-iv-bin-percent
) O
compared O
with O
CMF O
alone O
( O
69 B-cv-bin-percent
% I-cv-bin-percent
) O
and O
goserelin O
alone O
( O
68 B-iv-bin-percent
% I-iv-bin-percent
) O
( O
P O
= O
0.04 O
for O
each O
comparison O
) O
, O
due O
largely O
to O
the O
effect O
in O
younger O
patients O
. O
Patients O
with O
ER B-outcome
- I-outcome
negative I-outcome
tumors I-outcome
whose O
treatment O
included O
CMF O
had O
similar O
DFS B-outcome
( O
12 B-outcome
- I-outcome
year I-outcome
DFS I-outcome
CMF O
= O
67 B-cv-bin-percent
% I-cv-bin-percent
; O
12 O
- O
year O
DFS O
CMF O
goserelin O
= O
69 B-iv-bin-percent
% I-iv-bin-percent
) O
compared O
with O
goserelin O
alone O
( O
12 O
- O
year O
DFS O
= O
61 B-cv-bin-percent
% I-cv-bin-percent
, O
P O
= O
NS O
) O
. O
For O
pre O
/ O
perimenopausal O
women O
with O
lymph O
- O
node O
- O
negative O
ER O
- O
positive O
breast O
cancer O
, O
CMF O
followed O
by O
goserelin O
improved O
DFS O
in O
comparison O
with O
either O
modality O
alone O
. O
The O
improvement O
was O
the O
most O
pronounced O
in O
those O
aged O
below O
40 O
, O
suggesting O
an O
endocrine O
effect O
of O
prolonged O
CMF O
- O
induced O
amenorrhea O
. O

Prospective O
comparison O
of O
peritumoral B-intervention
and I-intervention
subareolar I-intervention
injection I-intervention
of I-intervention
blue I-intervention
dye I-intervention
alone I-intervention
, O
for O
identification O
of O
sentinel O
lymph O
nodes O
in O
patients O
with O
early O
stage O
breast O
cancer O
. O
Various O
techniques O
are O
used O
for O
the O
identification O
of O
the O
sentinel O
node O
( O
SLN O
) O
. O
We O
prospectively O
compare O
the O
efficacy O
of O
SLN O
biopsy O
and O
the O
number O
of O
SLNs O
identified O
, O
by O
injecting O
methylene O
blue O
( O
MB O
) O
alone O
in O
the O
subareolar O
area O
( O
SA O
) O
or O
peritumorally O
( O
PT O
) O
in O
patients B-eligibility
with I-eligibility
early I-eligibility
stage I-eligibility
breast I-eligibility
cancer I-eligibility
. O
Patients O
were O
randomized O
in O
two O
groups O
( O
SA O
or O
PT B-control
injection I-control
) O
. O
A O
linear O
regression O
model O
was O
used O
to O
estimate O
the O
effect O
of O
various O
parameters O
on O
the O
identification O
rate O
and O
on O
the O
number O
of O
SLNs O
retrieved O
. O
At O
least O
one O
SLN B-outcome
was O
identified O
in O
61 B-iv-bin-abs
of O
66 B-intervention-participants
( O
92.4 B-iv-bin-percent
% I-iv-bin-percent
) O
procedures O
in O
the O
SA O
group O
and O
in O
57 B-cv-bin-abs
of O
60 B-control-participants
( O
95 B-cv-bin-percent
% I-cv-bin-percent
) O
procedures O
in O
the O
PT O
group O
( O
P O
 O
= O
 O
0.55 O
) O
. O
The O
mean B-outcome
number I-outcome
of I-outcome
SLNs I-outcome
removed I-outcome
with O
the O
SA O
injection O
method O
was O
1.64 B-iv-cont-mean
 I-iv-cont-mean
 O
 O
0.6 B-iv-cont-sd
nodes O
compared O
with O
2.23 B-cv-cont-mean
 O
 O
 O
0.7 B-cv-cont-sd
nodes O
identified O
with O
the O
PT O
injection O
( O
range O
: O
1 O
- O
4 O
, O
P O
 O
< O
 O
0.001 O
) O
. O
The O
injection O
site O
was O
the O
only O
factor O
affecting O
the O
number O
of O
SLNs O
retrieved O
. O
The O
use O
of O
MB O
alone O
is O
an O
efficient O
method O
for O
identification O
of O
the O
SLN O
. O
The O
PT O
injection O
route O
yields O
a O
higher O
number O
of O
SLNs O
than O
the O
SA O
route O
, O
comparable O
with O
the O
number O
of O
SLNs O
retrieved O
, O
when O
combined O
tracing O
agents O
and O
multiple O
injection O
sites O
are O
used O
. O

Surgical O
prevention O
of O
arm B-condition
lymphedema I-condition
after O
breast O
cancer O
treatment O
. O
To O
prospectively O
assess O
the O
efficacy O
of O
the O
lymphatic B-intervention
microsurgical I-intervention
preventive I-intervention
healing I-intervention
approach I-intervention
( I-intervention
LYMPHA I-intervention
) I-intervention
to O
prevent O
lymphedema O
after O
axillary O
dissection O
( O
AD O
) O
for O
breast O
cancer O
treatment O
. O
Among O
49 B-total-participants
consecutive O
women O
referred O
from O
March O
2008 O
to O
September O
2009 O
to O
undergo O
complete O
AD O
, O
46 B-total-participants
were O
randomly O
divided O
in O
2 O
groups O
. O
Twenty B-intervention-participants
- I-intervention-participants
three I-intervention-participants
underwent O
the O
LYMPHA O
technique O
for O
the O
prevention O
of O
arm O
lymphedema O
. O
The O
other O
23 B-control-participants
patients O
had O
no B-control
preventive I-control
surgical I-control
approach I-control
( I-control
control I-control
group I-control
) I-control
. O
The O
LYMPHA O
procedure O
consisted O
of O
performing O
lymphatic O
- O
venous O
anastomoses O
( O
LVA O
) O
at O
the O
time O
of O
AD O
. O
All O
patients O
underwent O
preoperative O
lymphoscintigraphy O
( O
LS O
) O
. O
Patients O
were O
followed O
up O
clinically O
at O
1 O
, O
3 O
, O
6 O
, O
12 O
, O
and O
18 O
 O
months O
by O
volumetry O
. O
Postoperatively O
, O
LS O
was O
performed O
after O
18 O
 O
months O
in O
41 O
patients O
( O
21 B-intervention-participants
treatment O
group O
and O
20 B-control-participants
control O
group O
) O
. O
Arm O
volume O
and O
LS O
alterations O
were O
assessed O
. O
Lymphedema B-outcome
appeared O
in O
1 B-iv-bin-abs
patient O
in O
the O
treatment O
group O
6 O
 O
months O
after O
surgery O
( O
4.34 B-iv-bin-percent
% I-iv-bin-percent
) O
. O
In O
the O
control O
group O
, O
lymphedema B-outcome
occurred O
in O
7 B-cv-bin-abs
patients O
( O
30.43 B-cv-bin-percent
% I-cv-bin-percent
) O
. O
No O
statistically O
significant O
differences O
in O
the O
arm B-outcome
volume I-outcome
were O
observed O
in O
the O
treatment O
group O
during O
follow O
- O
up O
, O
while O
the O
arm O
volume O
in O
the O
control O
group O
showed O
a O
significant O
increase O
after O
1 O
, O
3 O
, O
and O
6 O
 O
months O
from O
operation O
. O
There O
was O
significant O
difference O
between O
the O
2 O
groups O
in O
the O
volume B-outcome
changes I-outcome
with O
respect O
to O
baseline O
after O
1 O
, O
3 O
, O
6 O
, O
12 O
, O
and O
18 O
 O
months O
after O
surgery O
( O
every O
timing O
P O
value O
 O
< O
 O
0.01 O
) O
. O
LYMPHA O
represents O
a O
valid O
technique O
for O
primary O
prevention O
of O
secondary O
arm O
lymphedema O
with O
no O
risk O
of O
leaving O
undetected O
malignant O
disease O
in O
the O
axilla O
. O

Axillary B-intervention
node I-intervention
sampling I-intervention
in I-intervention
conjunction I-intervention
with I-intervention
sentinel I-intervention
node I-intervention
biopsy I-intervention
in O
patients O
with O
breast O
cancer O
. O
A O
prospective O
preliminary O
study O
. O
In O
patients O
with O
breast O
cancer O
( O
BC O
) O
, O
axillary O
lymph O
node O
sampling O
( O
ALNS O
) O
is O
a O
reliable O
procedure O
with O
low O
morbidity O
, O
alternative O
or O
complementary O
to O
sentinel O
lymph O
node O
biopsy O
( O
SLNB O
) O
, O
which O
may O
improve O
the O
detection O
rate O
of O
axillary O
node O
metastases O
as O
compared O
to O
SLNB O
alone O
in O
staging O
the O
axilla O
. O
The O
aim O
of O
this O
study O
was O
to O
assess O
the O
usefulness O
of O
ALNS O
in O
conjunction O
with O
SLNB O
in O
improving O
the O
sensitivity O
of O
SLNB O
alone O
at O
frozen O
section O
examination O
. O
One B-total-participants
hundred I-total-participants
and I-total-participants
twelve I-total-participants
women O
( O
median O
age O
56 B-age
years I-age
, O
range O
29 O
- O
71 O
years O
) O
with B-eligibility
BC I-eligibility
underwent I-eligibility
SLNB I-eligibility
using I-eligibility
a I-eligibility
combined I-eligibility
radioisotope I-eligibility
and I-eligibility
isosulfan I-eligibility
blue I-eligibility
dye I-eligibility
technique I-eligibility
. O
Two O
groups O
of O
age- O
and O
tumor O
size O
- O
matched O
patients O
were O
prospectively O
randomized O
: O
Group O
A O
( O
SLNB B-control
alone I-control
, O
55 B-control-participants
women O
) O
and O
group O
B O
( O
SLNB O
plus O
ALNS O
, O
57 B-intervention-participants
women O
) O
. O
Intraoperative O
examination O
showed O
SN B-outcome
involvement I-outcome
in O
32 O
( O
28.6 O
% O
) O
patients O
: O
group O
A O
= O
14 B-cv-bin-abs
( O
25.5 B-cv-bin-percent
% I-cv-bin-percent
) O
, O
group O
B O
= O
18 B-iv-bin-abs
( O
31.6 B-iv-bin-percent
% I-iv-bin-percent
) O
, O
whilst O
the O
final O
pathology O
showed O
axillary B-outcome
node I-outcome
involvement I-outcome
in O
7 O
further O
cases O
( O
group O
A O
= O
5 B-cv-bin-abs
, O
group O
B O
= O
2 B-iv-bin-abs
) O
. O
The O
sensitivity B-outcome
and O
accuracy B-outcome
were O
73.7 B-cv-bin-percent
% I-cv-bin-percent
vs. O
90.0 B-iv-bin-percent
% I-iv-bin-percent
( O
p O
= O
0.23 O
) O
and O
90.9 B-cv-bin-percent
% I-cv-bin-percent
vs. O
94.7 B-iv-bin-percent
% I-iv-bin-percent
( O
p O
= O
0.49 O
) O
, O
group O
A O
vs. O
B O
, O
respectively O
. O
Multivariate O
analysis O
showed O
that O
age O
> O
65 O
years O
and O
body O
mass O
index O
independently O
correlated O
with O
the O
amount B-outcome
of I-outcome
axillary I-outcome
drainage I-outcome
in O
both O
groups O
, O
which O
was O
47.5 B-cv-cont-mean
 O
11.3 B-cv-cont-sd
and O
49.6 B-iv-cont-mean
 O
12.2 B-iv-cont-sd
ml I-iv-cont-sd
( O
A O
vs. O
B O
, O
p O
= O
NS O
) O
, O
respectively O
. O
In O
conclusion O
, O
in O
our O
preliminary O
study O
, O
ALNS O
in O
conjunction O
with O
SLNB O
is O
a O
low O
- O
risk O
procedure O
, O
useful O
to O
reduce O
the O
false O
- O
negative O
rate O
of O
SLNB O
and O
to O
improve O
the O
accuracy O
of O
intraoperative O
evaluation O
of O
the O
axillary O
nodes O
in O
patients O
with O
BC O
. O

Long O
- O
term O
outcomes O
of O
invasive O
ipsilateral O
breast O
tumor O
recurrences O
after O
lumpectomy B-intervention
in O
NSABP O
B-17 O
and O
B-24 O
randomized O
clinical O
trials O
for O
DCIS O
. O
Ipsilateral O
breast O
tumor O
recurrence O
( O
IBTR O
) O
is O
the O
most O
common O
failure O
event O
after O
lumpectomy O
for O
ductal O
carcinoma O
in O
situ O
( O
DCIS O
) O
. O
We O
evaluated O
invasive O
IBTR O
( O
I O
- O
IBTR O
) O
and O
its O
influence O
on O
survival O
among O
participants O
in O
two O
National O
Surgical O
Adjuvant O
Breast O
and O
Bowel O
Project O
( O
NSABP O
) O
randomized O
trials O
for O
DCIS O
. O
In O
the O
NSABP O
B-17 O
trial O
( O
accrual O
period O
: O
October O
1 O
, O
1985 O
, O
to O
December O
31 O
, O
1990 O
) O
, O
patients B-eligibility
with I-eligibility
localized I-eligibility
DCIS I-eligibility
were O
randomly O
assigned O
to O
the O
lumpectomy B-control
only I-control
( O
LO O
, O
n O
= O
403 B-control-participants
) O
group O
or O
to O
the O
lumpectomy B-intervention
followed I-intervention
by I-intervention
radiotherapy I-intervention
( O
LRT O
, O
n O
= O
410 B-intervention-participants
) O
group O
. O
In O
the O
NSABP O
B-24 O
double O
- O
blinded O
, O
placebo O
- O
controlled O
trial O
( O
accrual O
period O
: O
May O
9 O
, O
1991 O
, O
to O
April O
13 O
, O
1994 O
) O
, O
all O
accrued O
patients O
were O
randomly O
assigned O
to O
LRT+ B-control
placebo I-control
, O
( O
n O
= O
900 B-control-participants
) O
or O
LRT B-intervention
+ I-intervention
tamoxifen I-intervention
( O
LRT O
+ O
TAM O
, O
n O
= O
899 B-intervention-participants
) O
. O
Endpoints O
included O
I B-outcome-measure
- I-outcome-measure
IBTR I-outcome-measure
, I-outcome-measure
DCIS I-outcome-measure
- I-outcome-measure
IBTR I-outcome-measure
, O
contralateral B-outcome-measure
breast I-outcome-measure
cancers I-outcome-measure
( I-outcome-measure
CBC I-outcome-measure
) I-outcome-measure
, O
overall B-outcome-measure
and I-outcome-measure
breast I-outcome-measure
cancer I-outcome-measure
- I-outcome-measure
specific I-outcome-measure
survival I-outcome-measure
, O
and O
survival B-outcome-measure
after I-outcome-measure
I I-outcome-measure
- I-outcome-measure
IBTR I-outcome-measure
. O
Median O
follow O
- O
up O
was O
207 O
months O
for O
the O
B-17 O
trial O
( O
N O
= O
813 B-total-participants
patients O
) O
and O
163 O
months O
for O
the O
B-24 O
trial O
( O
N O
= O
1799 B-total-participants
patients O
) O
. O
Of O
490 O
IBTR B-outcome
events I-outcome
, O
263 O
( O
53.7 O
% O
) O
were O
invasive O
. O
Radiation O
reduced B-outcome
I I-outcome
- I-outcome
IBTR I-outcome
by O
52 B-iv-bin-percent
% I-iv-bin-percent
in O
the O
LRT O
group O
compared O
with O
LO O
( O
B-17 O
, O
hazard O
ratio O
[ O
HR O
] O
of O
risk O
of O
I O
- O
IBTR O
= O
0.48 O
, O
95 O
% O
confidence O
interval O
[ O
CI O
] O
= O
0.33 O
to O
0.69 O
, O
P O
< O
.001 O
) O
. O
LRT O
+ O
TAM O
reduced B-outcome
I I-outcome
- I-outcome
IBTR I-outcome
by O
32 B-iv-bin-percent
% I-iv-bin-percent
compared O
with O
LRT O
+ O
placebo O
( O
B-24 O
, O
HR O
of O
risk O
of O
I O
- O
IBTR O
= O
0.68 O
, O
95 O
% O
CI O
= O
0.49 O
to O
0.95 O
, O
P O
= O
.025 O
) O
. O
The O
15 B-outcome
- I-outcome
year I-outcome
cumulative I-outcome
incidence I-outcome
of I-outcome
I I-outcome
- I-outcome
IBTR I-outcome
was O
19.4 B-cv-bin-percent
% I-cv-bin-percent
for O
LO O
, O
8.9 B-iv-bin-percent
% I-iv-bin-percent
for O
LRT O
( O
B-17 O
) O
, O
10.0 B-cv-bin-percent
% I-cv-bin-percent
for O
LRT O
+ O
placebo O
( O
B-24 O
) O
, O
and O
8.5 B-iv-bin-percent
% I-iv-bin-percent
for O
LRT O
+ O
TAM O
. O
The O
15 B-outcome
- I-outcome
year I-outcome
cumulative I-outcome
incidence I-outcome
of I-outcome
all I-outcome
contralateral I-outcome
breast I-outcome
cancers I-outcome
was O
10.3 B-cv-bin-percent
% I-cv-bin-percent
for O
LO O
, O
10.2 B-iv-bin-percent
% I-iv-bin-percent
for O
LRT O
( O
B-17 O
) O
, O
10.8 B-cv-bin-percent
% I-cv-bin-percent
for O
LRT O
+ O
placebo O
( O
B-24 O
) O
, O
and O
7.3 B-iv-bin-percent
% I-iv-bin-percent
for O
LRT O
+ O
TAM O
. O
I O
- O
IBTR O
was O
associated O
with O
increased O
mortality B-outcome
risk I-outcome
( O
HR O
of O
death O
= O
1.75 O
, O
95 O
% O
CI O
= O
1.45 O
to O
2.96 O
, O
P O
< O
.001 O
) O
, O
whereas O
recurrence O
of O
DCIS O
was O
not O
. O
Twenty O
- O
two O
of O
39 O
deaths B-outcome
after O
I O
- O
IBTR O
were O
attributed O
to O
breast O
cancer O
. O
Among O
all O
patients O
( O
with O
or O
without O
I O
- O
IBTR O
) O
, O
the O
15 B-outcome
- I-outcome
year I-outcome
cumulative I-outcome
incidence I-outcome
of I-outcome
breast I-outcome
cancer I-outcome
death I-outcome
was O
3.1 B-cv-bin-percent
% I-cv-bin-percent
for O
LO O
, O
4.7 B-iv-bin-percent
% I-iv-bin-percent
for O
LRT O
( O
B-17 O
) O
, O
2.7 B-cv-bin-percent
% I-cv-bin-percent
for O
LRT O
+ O
placebo O
( O
B-24 O
) O
, O
and O
2.3 B-iv-bin-percent
% I-iv-bin-percent
for O
LRT O
+ O
TAM O
. O
Although O
I O
- O
IBTR O
increased O
the O
risk O
for O
breast O
cancer O
- O
related O
death O
, O
radiation O
therapy O
and O
tamoxifen O
reduced O
I O
- O
IBTR O
, O
and O
long O
- O
term O
prognosis O
remained O
excellent O
after O
breast O
- O
conserving O
surgery O
for O
DCIS O
. O

Vaginal B-intervention
pH I-intervention
- I-intervention
balanced I-intervention
gel I-intervention
for O
the O
control O
of O
atrophic O
vaginitis O
among O
breast O
cancer O
survivors O
: O
a O
randomized O
controlled O
trial O
. O
To O
estimate O
the O
effects O
of O
vaginal O
pH O
- O
balanced O
gel O
on O
vaginal O
symptoms O
and O
atrophy O
in O
breast O
cancer O
survivors O
treated O
with O
chemotherapy O
or O
endocrine O
therapy O
. O
This O
was O
a O
randomized O
, O
double O
- O
blind O
, O
placebo O
- O
controlled O
study O
. O
Breast B-eligibility
cancer I-eligibility
survivors I-eligibility
who I-eligibility
experienced I-eligibility
menopause I-eligibility
after I-eligibility
chemotherapy I-eligibility
or I-eligibility
endocrine I-eligibility
therapy I-eligibility
were O
voluntarily O
enrolled O
and O
randomly O
administered O
vaginal O
topical O
pH O
- O
balanced O
gel O
or O
placebo B-control
three O
times O
per O
week O
for O
12 O
weeks O
. O
Vaginal B-outcome-measure
dryness I-outcome-measure
and O
dyspareunia B-outcome-measure
were O
measured O
by O
visual O
analog O
scale O
, O
vaginal O
health O
index O
, O
and O
vaginal O
pH. O
The O
endometrium O
and O
ovary O
were O
evaluated O
by O
transvaginal O
ultrasonography O
. O
Among O
98 B-total-participants
enrolled O
women O
, O
86 B-total-participants
completed O
the O
treatment O
( O
n O
= O
44 B-intervention-participants
and O
n O
= O
42 B-control-participants
for O
the O
pH O
- O
balanced O
gel O
group O
and O
placebo O
group O
, O
respectively O
) O
. O
Vaginal B-outcome
dryness I-outcome
and O
dyspareunia B-outcome
improved O
more O
in O
the O
pH O
- O
balanced O
gel O
group O
than O
in O
the O
placebo O
group O
( O
baseline B-outcome
mean O
8.20 B-iv-cont-mean
compared O
with O
end B-outcome
- I-outcome
point I-outcome
mean O
4.23 B-cv-cont-mean
[ O
P O
= O
.001 O
] O
and O
8.23 B-iv-cont-mean
compared O
with O
5.48 B-cv-cont-mean
[ O
P O
= O
.040 O
] O
, O
respectively O
) O
. O
Vaginal O
pH O
- O
balanced O
gel O
reduced O
the O
vaginal B-outcome
pH I-outcome
( O
gel O
: O
baseline B-outcome
mean O
6.49 B-iv-cont-mean
compared O
with O
end B-outcome
- I-outcome
point I-outcome
mean O
5.00 B-iv-cont-mean
; O
placebo O
: O
6.22 O
compared O
with O
5.69 O
[ O
P<.001 O
] O
) O
, O
and O
enhanced O
vaginal B-outcome
maturation I-outcome
index I-outcome
( O
gel O
: O
45.5 B-iv-cont-mean
compared O
with O
51.2 B-iv-cont-mean
; O
placebo O
: O
46.4 B-cv-cont-mean
compared O
with O
47.9 B-cv-cont-mean
[ O
P<.001 O
] O
) O
and O
vaginal B-outcome
health I-outcome
index I-outcome
( O
gel O
: O
15.8 B-iv-cont-mean
compared O
with O
21.1 B-iv-cont-mean
; O
placebo O
14.3 B-cv-cont-mean
compared O
with O
16.98 B-cv-cont-mean
[ O
P O
= O
.002 O
] O
) O
. O
There O
was O
no O
significant O
difference O
in O
adverse B-outcome
effects I-outcome
between O
the O
two O
groups O
except O
for O
mild O
irritation O
at O
the O
early O
time O
of O
pH O
- O
balanced O
gel O
administration O
. O
Vaginal O
pH O
- O
balanced O
gel O
could O
relieve O
vaginal O
symptoms O
and O
improve O
vaginal O
health O
in O
breast O
cancer O
survivors O
who O
have O
experienced O
menopause O
after O
cancer O
treatment O
. O
ClinicalTrials O
. O
gov O
, O
www O
. O
clinicaltrials.gov O
, O
NCT00607295.I. O

A O
single O
- O
center O
, O
prospective O
and O
randomized O
controlled O
study O
: O
Can O
the O
prophylactic O
use O
of O
lamivudine B-intervention
prevent O
hepatitis B-condition
B I-condition
virus I-condition
reactivation I-condition
in O
hepatitis B-eligibility
B I-eligibility
s I-eligibility
- I-eligibility
antigen I-eligibility
seropositive I-eligibility
breast I-eligibility
cancer I-eligibility
patients I-eligibility
during O
chemotherapy O
? O
Over O
the O
past O
four O
decades O
, O
chemotherapy O
has O
played O
an O
important O
role O
in O
prolonging O
survival O
in O
breast O
cancer O
patients O
. O
However O
, O
it O
may O
also O
result O
in O
undesirable O
side O
effects O
such O
as O
hepatitis O
B O
virus O
( O
HBV O
) O
reactivation O
seen O
in O
this O
study O
. O
With O
the O
increasing O
use O
of O
chemotherapy O
paralleling O
the O
rise O
in O
breast O
cancer O
incidence O
, O
the O
occurrence O
of O
HBV O
reactivation O
is O
likely O
to O
further O
increase O
. O
Several O
strategies O
use O
lamivudine O
to O
deal O
with O
this O
problem O
. O
Initially O
, O
lamivudine O
had O
been O
used O
to O
treat O
patients O
who O
developed O
alanine O
transaminase O
elevation O
attributable O
to O
HBV O
reactivation O
during O
chemotherapy O
. O
However O
, O
using O
this O
strategy O
, O
fatal O
reactivation O
has O
also O
been O
reported O
. O
Later O
studies O
have O
suggested O
that O
prophylactic O
lamivudine O
significantly O
reduces O
HBV O
reactivation O
and O
its O
associated O
morbidity O
. O
However O
, O
these O
studies O
were O
based O
mainly O
on O
patients O
with O
lymphoma O
, O
whereas O
studies O
on O
breast O
cancer O
patients O
were O
few O
. O
Moreover O
, O
these O
studies O
were O
retrospective O
. O
Recently O
, O
a O
prospective O
study O
has O
recommended O
that O
deferred O
preemptive O
lamivudine O
could O
be O
a O
comparable O
alternative O
to O
the O
prophylactic O
strategy O
. O
However O
, O
it O
was O
not O
a O
randomized O
controlled O
study O
. O
In O
this O
study O
, O
it O
was O
examined O
the O
efficacy O
of O
the O
prophylactic O
strategy O
in O
hepatitis O
B O
s O
- O
antigen O
seropositive O
breast O
cancer O
patients O
during O
chemotherapy O
using O
a O
prospective O
, O
randomized O
controlled O
study O
. O
Two O
groups O
were O
studied O
. O
One O
group O
consisted O
of O
21 B-intervention-participants
patients O
who O
were O
treated O
with O
prophylactic O
lamivudine O
, O
the O
other O
group O
consisted O
of O
21 B-control-participants
patients O
who O
were O
not B-control
treated I-control
with I-control
prophylactic I-control
lamivudine I-control
. O
The O
results O
showed O
that O
the O
prophylactic O
lamivudine O
strategy O
significantly O
decreased O
the O
incidence B-outcome
of I-outcome
HBV I-outcome
reactivation I-outcome
( O
0 B-iv-bin-percent
vs. O
28.6 B-cv-bin-percent
% I-cv-bin-percent
, O
P O
= O
0.021 O
) O
. O
It O
was O
conclude O
that O
the O
prophylactic O
lamivudine O
strategy O
significantly O
reduces O
the O
incidence O
of O
HBV O
reactivation O
for O
hepatitis O
B O
s O
- O
antigen O
seropositive O
breast O
cancer O
undergoing O
chemotherapy O
. O

Value O
of O
post O
- O
operative O
reassessment O
of O
estrogen O
receptor O
 O
expression O
following O
neoadjuvant O
chemotherapy O
with O
or O
without O
gefitinib B-intervention
for O
estrogen O
receptor O
negative O
breast O
cancer O
. O
The O
NICE O
trial O
was O
designed O
to O
evaluate O
the O
possible O
benefits O
of O
adding O
epidermal O
growth O
factor O
receptor O
targeted O
therapy O
to O
neoadjuvant O
chemotherapy O
in O
patients O
with O
estrogen O
receptor O
 O
( O
ER O
) O
negative O
and O
operable O
breast O
cancer O
. O
Preclinical O
data O
have O
suggested O
that O
signalling O
through O
the O
ErbB O
receptors O
or O
downstream O
effectors O
may O
repress O
ER O
expression O
. O
Here O
the O
authors O
investigated O
whether O
gefitinib O
, O
given O
neoadjuvant O
in O
combination O
with O
epirubicin O
and O
cyclophosphamide O
( O
EC O
) O
, O
could O
restore O
ER O
expression O
. O
Eligible O
patients O
in O
the O
NICE O
trial O
were O
women B-eligibility
with I-eligibility
unilateral I-eligibility
, I-eligibility
primary I-eligibility
operable I-eligibility
, I-eligibility
ER I-eligibility
negative I-eligibility
invasive I-eligibility
breast I-eligibility
cancer I-eligibility
 I-eligibility
2 I-eligibility
cm I-eligibility
. O
Material O
from O
patients O
randomized O
and O
completing O
treatment O
( O
four O
cycles O
of O
neoadjuvant O
EC O
plus O
12 O
weeks O
of O
either O
gefitinib O
or O
placebo O
) O
in O
the O
NICE O
trial O
having O
available O
ER O
status O
both O
at O
baseline O
and O
after O
neoadjuvant O
treatment O
were O
eligible O
for O
this O
study O
. O
Tumors O
with O
indication O
of O
changed O
ER O
phenotype O
( O
based O
on O
collected O
pathology O
reports O
) O
were O
immunohistochemically O
reassessed O
centrally O
. O
115 B-total-participants
patients O
were O
eligible O
for O
this O
study O
; O
59 B-intervention-participants
patients O
in O
the O
gefitinib O
group O
and O
56 B-control-participants
patients O
in O
the O
placebo B-control
group O
. O
Five O
( O
4.3 O
% O
) O
of O
115 O
tumors O
changed O
ER O
phenotype O
from O
negative O
to O
positive O
. O
A O
change B-outcome
was I-outcome
seen I-outcome
in O
three B-iv-bin-abs
patients O
in O
the O
gefitinib O
( O
5.1 B-iv-bin-percent
% I-iv-bin-percent
) O
and O
in O
two B-cv-bin-abs
patients O
in O
the O
placebo O
( O
3.6 B-cv-bin-percent
% I-cv-bin-percent
) O
group O
with O
a O
difference O
of O
1.51 O
% O
( O
95 O
% O
CI O
, O
-6.1 O
- O
9.1 O
) O
. O
Results O
of O
the O
NICE O
trial O
have O
been O
reported O
previously O
. O
Post O
- O
operative O
reassessment O
of O
ER O
expression O
changed O
the O
assessment O
of O
ER O
status O
in O
a O
small O
but O
significant O
fraction O
of O
patients O
and O
should O
, O
whenever O
possible O
, O
be O
performed O
following O
neoadjuvant O
chemotherapy O
for O
ER O
negative O
breast O
cancer O
. O
Gefitinib O
did O
not O
affect O
the O
reversion O
rate O
of O
ER O
negative O
tumors O
. O

Cosmetic O
outcome O
and O
surgical O
site O
infection O
rates O
of O
antibacterial B-intervention
absorbable I-intervention
( I-intervention
Polyglactin I-intervention
910 I-intervention
) I-intervention
suture I-intervention
compared O
to O
Chinese B-control
silk I-control
suture I-control
in O
breast O
cancer O
surgery O
: O
a O
randomized O
pilot O
research O
. O
The O
primary O
objective O
of O
this O
multicenter O
post O
- O
market O
study O
was O
to O
compare O
the O
cosmetic O
outcome O
of O
triclosan O
- O
coated O
VICRYL O
Plus O
sutures O
with O
Chinese O
silk O
sutures O
for O
skin O
closure O
of O
modified O
radical O
mastectomy O
. O
A O
secondary O
objective O
was O
to O
assess O
the O
incidence O
of O
surgical O
site O
infection O
( O
SSI O
) O
. O
Patients B-eligibility
undergoing I-eligibility
modified I-eligibility
radical I-eligibility
mastectomy I-eligibility
were O
randomly O
assigned O
to O
coated O
VICRYL O
Plus O
antibacterial O
( O
Polyglactin O
910 O
) O
suture O
or O
Chinese O
silk O
suture O
. O
Cosmetic O
outcomes O
were O
evaluated O
postoperatively O
at O
days O
12 O
( O
 O
2 O
) O
and O
30 O
( O
 O
5 O
) O
, O
and O
the O
evidence O
of O
SSI O
was O
assessed O
at O
days O
3 O
, O
5 O
, O
7 O
, O
12 O
( O
 O
2 O
) O
, O
30 O
( O
 O
5 O
) O
, O
and O
90 O
( O
 O
7 O
) O
. O
Cosmetic B-outcome-measure
outcomes I-outcome-measure
were O
independently O
assessed O
via O
visual O
analogue O
scale O
( O
VAS O
) O
score O
evaluations O
of O
blinded O
incision O
photographs O
( O
primary O
endpoint O
) O
and O
surgeon B-outcome-measure
- I-outcome-measure
assessed I-outcome-measure
modified I-outcome-measure
Hollander I-outcome-measure
Scale I-outcome-measure
( I-outcome-measure
mHCS I-outcome-measure
) I-outcome-measure
scores I-outcome-measure
( O
secondary O
endpoint O
) O
. O
SSI O
assessments O
used O
both O
CDC O
criteria O
and O
ASEPSIS O
scores O
. O
Six O
Chinese O
hospitals O
randomized O
101 B-total-participants
women O
undergoing O
modified O
radical O
mastectomy O
to O
closure O
with O
coated O
VICRYL O
Plus O
suture O
( O
n O
= O
51 B-intervention-participants
) O
or O
Chinese O
silk O
suture O
( O
n O
= O
50 B-control-participants
) O
. O
Mean B-outcome
VAS I-outcome
cosmetic I-outcome
outcome I-outcome
scores I-outcome
for O
antibacterial O
suture O
( O
67.2 B-iv-cont-mean
) O
were O
better O
than O
for O
Chinese O
silk O
( O
45.4 B-cv-cont-mean
) O
at O
day O
30 O
( O
P O
< O
0.0001 O
) O
) O
. O
Mean B-outcome
mHCS I-outcome
cosmetic I-outcome
outcome I-outcome
total I-outcome
scores I-outcome
, O
were O
also O
higher O
for O
antibacterial O
suture O
( O
5.7 B-iv-cont-mean
) O
than O
for O
Chinese O
silk O
( O
5.0 B-cv-cont-mean
) O
at O
day O
30 O
( O
P O
= O
0.002 O
) O
. O
Patients O
using O
coated O
VICRYL O
Plus O
suture O
had O
significantly O
better O
cosmetic O
outcomes O
than O
those O
with O
Chinese O
silk O
sutures O
. O
Patients O
using O
coated O
VICRYL O
Plus O
suture O
had O
a O
lower O
SSI O
incidence O
compared O
to O
the O
Chinese O
silk O
sutures O
, O
although O
the O
difference O
did O
not O
reach O
statistical O
significance O
. O

Randomized O
, O
placebo O
- O
controlled O
, O
double O
- O
blind O
, O
phase O
II O
study O
of O
axitinib B-intervention
plus I-intervention
docetaxel I-intervention
versus O
docetaxel B-control
plus I-control
placebo I-control
in O
patients O
with O
metastatic O
breast O
cancer O
. O
This O
multicenter O
, O
randomized O
, O
double O
- O
blind O
, O
phase O
II O
study O
assessed O
safety O
and O
efficacy O
of O
axitinib O
plus O
docetaxel O
in O
metastatic O
breast O
cancer O
( O
MBC O
) O
. O
Women B-eligibility
with I-eligibility
MBC I-eligibility
were O
randomly O
assigned O
2 O
:1 O
to O
receive O
docetaxel O
80 O
mg O
/ O
m2 O
once O
every O
3 O
weeks O
plus O
axitinib O
5 O
mg O
twice O
per O
day O
( O
combination O
arm O
) O
or O
placebo O
( O
placebo O
arm O
) O
, O
following O
a O
lead O
- O
in O
phase O
I O
trial O
. O
The O
primary O
end O
point O
was O
time B-outcome-measure
to I-outcome-measure
progression I-outcome-measure
( I-outcome-measure
TTP I-outcome-measure
) I-outcome-measure
. O
In O
all O
, O
168 B-total-participants
patients O
were O
enrolled O
; O
112 B-intervention-participants
were O
randomly O
assigned O
to O
axitinib O
and O
56 B-control-participants
to O
placebo O
. O
Median B-outcome
TTP I-outcome
was O
numerically O
longer O
in O
the O
combination O
arm O
than O
in O
the O
placebo O
arm O
( O
8.1 B-iv-cont-median
v O
7.1 B-cv-cont-median
months I-cv-cont-median
) O
, O
but O
this O
difference O
was O
not O
statistically O
significant O
( O
hazard O
ratio O
, O
1.24 O
; O
95 O
% O
CI O
, O
0.82 O
to O
1.87 O
; O
one O
- O
sided O
P O
= O
.156 O
) O
. O
The O
difference O
in O
median B-outcome
TTP I-outcome
was O
greatest O
among O
patients O
who O
had O
received O
prior O
adjuvant O
chemotherapy O
( O
9.2 B-iv-cont-median
v O
7.0 B-cv-cont-median
months I-cv-cont-median
; O
P O
= O
.043 O
, O
prespecified O
subgroup O
analysis O
) O
. O
Objective B-outcome
response I-outcome
rate I-outcome
was O
higher O
in O
the O
combination O
arm O
( O
41.1 B-iv-bin-percent
% I-iv-bin-percent
v O
23.6 B-cv-bin-percent
% I-cv-bin-percent
; O
P O
= O
.011 O
) O
. O
The O
most O
common O
grades B-outcome
3 I-outcome
to I-outcome
4 I-outcome
treatment I-outcome
- I-outcome
related I-outcome
adverse I-outcome
events I-outcome
( O
combination O
/ O
placebo O
) O
included O
diarrhea B-outcome
( O
10.8% B-iv-bin-percent
/ O
0 B-cv-bin-percent
% I-cv-bin-percent
) O
, O
fatigue B-outcome
( O
10.8% B-iv-bin-percent
/ O
5.4 B-cv-bin-percent
% I-cv-bin-percent
) O
, O
stomatitis B-outcome
( O
12.6% B-iv-bin-percent
/ O
1.8 B-cv-bin-percent
% I-cv-bin-percent
) O
, O
mucositis B-outcome
( O
9.0% B-iv-bin-percent
/ O
0 B-cv-bin-percent
% I-cv-bin-percent
) O
, O
asthenia B-outcome
( O
7.2% B-iv-bin-percent
/ O
0 B-cv-bin-percent
% I-cv-bin-percent
) O
, O
and O
hypertension B-outcome
( O
4.5% B-iv-bin-percent
/ O
0 B-cv-bin-percent
% I-cv-bin-percent
) O
. O
Three B-iv-bin-abs
patients O
in O
the O
combination O
arm O
experienced O
serious B-outcome
thromboembolic I-outcome
events I-outcome
( O
one B-iv-bin-abs
death B-outcome
) O
. O
Febrile B-outcome
neutropenia I-outcome
was O
more O
frequent O
in O
the O
combination O
arm O
( O
15.3 B-iv-bin-percent
% I-iv-bin-percent
v O
7.1 B-cv-bin-percent
% I-cv-bin-percent
) O
; O
rates O
of O
other O
hematologic O
toxicities O
were O
comparable O
. O
Increased O
toxicity B-outcome
with O
axitinib O
was O
generally O
managed O
by O
dose O
reduction O
and/or O
growth O
factor O
support O
. O
The O
addition O
of O
axitinib O
to O
docetaxel O
did O
not O
improve O
TTP O
in O
first O
- O
line O
MBC O
treatment O
. O
Combination O
therapy O
may O
be O
more O
effective O
in O
patients O
previously O
exposed O
to O
adjuvant O
chemotherapy O
. O

Prevention O
of O
osteoporosis B-condition
as O
a O
consequence O
of O
aromatase O
inhibitor O
therapy O
in O
postmenopausal B-eligibility
women I-eligibility
with I-eligibility
early I-eligibility
breast I-eligibility
cancer I-eligibility
: O
rationale O
and O
design O
of O
a O
randomized O
controlled O
trial O
. O
Aromatase O
inhibitors O
( O
AIs O
) O
have O
improved O
the O
prognosis O
for O
breast O
cancer O
survivors O
and O
are O
now O
standard O
of O
care O
for O
postmenopausal O
women O
with O
hormone O
receptor O
positive O
early O
stage O
breast O
cancer O
. O
One O
side O
- O
effect O
, O
however O
, O
is O
a O
decrease O
in O
bone O
mineral O
density O
( O
BMD O
) O
and O
increased O
fracture O
risk O
. O
Since O
hormone O
replacement O
therapy O
( O
HRT O
) O
is O
contraindicated O
in O
these O
women O
, O
one O
prevention O
option O
is O
exercise O
combined O
with O
vitamin O
D O
and O
calcium O
. O
The O
effect O
of O
this O
intervention O
on O
drug O
- O
induced O
osteoporosis O
is O
unknown O
. O
A O
single O
- O
blind O
randomized O
controlled O
trial O
will O
be O
undertaken O
to O
test O
the O
hypothesis O
that O
exercise B-intervention
combined I-intervention
with I-intervention
vitamin I-intervention
D I-intervention
and I-intervention
calcium I-intervention
can O
prevent O
the O
decrease O
in O
BMD O
associated O
with O
the O
use O
of O
AIs O
. O
Sixty B-total-participants
postmenopausal O
women O
prescribed O
an O
AI O
for O
the O
treatment O
of O
breast O
cancer O
will O
be O
randomized O
into O
either O
an O
exercise O
or O
control B-control
group I-control
. O
Participants O
randomized O
to O
the O
exercise O
group O
will O
undertake O
a O
12 O
- O
month O
gym O
- O
based O
exercise O
program O
, O
3 O
times O
per O
week O
involving O
resistance O
and O
impact O
training O
. O
Participants O
in O
the O
control O
group O
will O
be O
advised O
on O
the O
benefits O
of O
exercise O
for O
preventing O
osteoporosis O
, O
but O
not O
prescribed O
exercise O
. O
Both O
groups O
will O
receive O
vitamin O
D O
and O
calcium O
supplements O
. O
The O
primary O
outcome O
will O
be O
total B-outcome-measure
hip I-outcome-measure
bone I-outcome-measure
mineral I-outcome-measure
density I-outcome-measure
measured O
via O
dual O
energy O
X O
- O
ray O
absorptiometry O
( O
DXA O
) O
. O
Study O
outcomes O
will O
be O
compared O
between O
groups O
at O
baseline O
, O
6months O
and O
12months O
. O
This O
study O
will O
investigate O
the O
effect O
of O
exercise O
in O
combination O
with O
vitamin O
D O
and O
calcium O
on O
prevention O
of O
drug O
- O
induced O
osteoporosis O
in O
postmenopausal O
women O
prescribed O
AIs O
for O
the O
treatment O
of O
breast O
cancer O
. O
  O

Light O
treatment O
prevents O
fatigue B-condition
in O
women O
undergoing O
chemotherapy O
for O
breast O
cancer O
. O
Fatigue O
is O
one O
of O
the O
most O
disturbing O
complaints O
of O
cancer O
patients O
and O
is O
often O
the O
reason O
for O
discontinuing O
treatment O
. O
This O
randomized O
controlled O
study O
tested O
the O
hypothesis O
that O
increased O
morning O
bright O
light O
, O
compared O
to O
dim O
light O
, O
would O
result O
in O
less O
fatigue O
in O
women B-eligibility
with I-eligibility
breast I-eligibility
cancer I-eligibility
undergoing I-eligibility
chemotherapy I-eligibility
. O
Thirty B-total-participants
- I-total-participants
nine I-total-participants
women O
newly O
diagnosed O
with O
stage O
I O
- O
III O
breast O
cancer O
were O
randomized O
to O
either O
bright B-intervention
white I-intervention
light I-intervention
( I-intervention
BWL I-intervention
) I-intervention
or O
dim B-control
red I-control
light I-control
( I-control
DRL I-control
) I-control
treatment O
and O
were O
instructed O
to O
use O
the O
light O
box O
for O
30 O
min O
every O
morning O
throughout O
the O
first O
four O
cycles O
of O
chemotherapy O
. O
The O
Multidimensional O
Fatigue O
Symptom O
Inventory O
was O
administered O
prior O
to O
the O
start O
of O
chemotherapy O
( O
baseline O
) O
, O
during O
the O
chemotherapy O
treatment O
week O
of O
cycle O
1 O
( O
C1TW O
) O
, O
the O
last O
week O
( O
recovery O
week O
) O
of O
cycle O
1 O
( O
C1RW O
) O
, O
the O
chemotherapy O
treatment O
week O
of O
cycle O
4 O
( O
C4TW O
) O
, O
and O
the O
last O
week O
( O
recovery O
week O
) O
of O
cycle O
4 O
( O
C4RW O
) O
. O
The O
DRL O
group O
reported O
increased O
fatigue B-outcome
at O
C1TW O
( O
p O
= O
0.003 O
) O
and O
C4TW O
( O
p O
< O
0.001 O
) O
compared O
to O
baseline O
, O
while O
there O
was O
no O
significant O
change O
from O
baseline O
in O
the O
BWL O
group O
. O
A O
secondary O
analysis O
showed O
that O
the O
increases O
in O
fatigue B-outcome
levels I-outcome
in O
the O
DRL O
group O
were O
not O
mediated O
through O
nor O
associated O
with O
changes O
in O
sleep O
or O
in O
circadian O
rhythms O
as O
measured O
with O
wrist O
actigraphy O
. O
The O
results O
of O
this O
study O
suggest O
that O
morning O
bright O
light O
treatment O
may O
prevent O
overall O
fatigue O
from O
worsening O
during O
chemotherapy O
. O
Although O
our O
hypothesis O
that O
overall O
fatigue O
would O
improve O
with O
bright O
light O
treatment O
was O
not O
supported O
, O
the O
lack O
of O
deterioration O
in O
total O
fatigue O
scores O
suggests O
that O
bright O
morning O
light O
may O
be O
a O
useful O
intervention O
during O
chemotherapy O
for O
breast O
cancer O
. O

Phase O
III O
randomized O
equivalence O
trial O
of O
early O
breast O
cancer O
treatments O
with O
or O
without O
axillary B-intervention
clearance I-intervention
in O
post O
- O
menopausal O
patients O
results O
after O
5 O
years O
of O
follow O
- O
up O
. O
Axillary O
lymph O
node O
clearance O
( O
ALNC O
) O
improves O
locoregional O
control O
and O
provides O
prognostic O
information O
for O
early O
breast O
cancer O
treatment O
, O
but O
effects O
on O
survival O
are O
controversial O
. O
This O
multicentre O
, O
randomized O
pragmatic O
equivalence O
trial O
compares O
outcomes O
for O
post O
- O
menopausal O
early O
invasive O
breast O
cancer O
patients O
after O
locoregional O
treatment O
with O
ALNC O
and O
adjuvant O
therapies O
to O
outcomes O
after O
locoregional O
treatment O
without O
ALNC O
and O
adjuvant O
therapies O
. O
From O
1995 O
- O
2005 O
, O
women O
aged O
 B-age
50 I-age
years I-age
with B-eligibility
early I-eligibility
breast I-eligibility
cancer I-eligibility
( I-eligibility
tumor I-eligibility
 I-eligibility
10 I-eligibility
mm I-eligibility
) I-eligibility
and I-eligibility
clinically I-eligibility
- I-eligibility
negative I-eligibility
axillary I-eligibility
nodes I-eligibility
were O
randomized O
to O
receive O
treatment O
with O
ALNC O
( O
Ax O
) O
or O
without B-control
( I-control
no I-control
- I-control
Ax I-control
) I-control
. O
Adjuvant O
therapies O
were O
prescribed O
according O
to O
hormonal O
receptor O
status O
and O
individual O
histological O
results O
. O
The O
primary O
endpoint O
was O
overall B-outcome-measure
survival I-outcome-measure
( I-outcome-measure
OS I-outcome-measure
) I-outcome-measure
; O
secondary O
endpoints O
were O
event B-outcome-measure
- I-outcome-measure
free I-outcome-measure
survival I-outcome-measure
( I-outcome-measure
EFS I-outcome-measure
) I-outcome-measure
and O
functional B-outcome-measure
outcomes I-outcome-measure
. O
The O
trial O
was O
terminated O
due O
to O
lack O
of O
equivalence O
and O
low O
accrual O
after O
first O
interim O
analyses O
. O
NCT00210236 O
. O
Of O
625 B-total-participants
patients O
, O
297 B-control-participants
no O
- O
Ax O
and O
310 B-intervention-participants
Ax O
patients O
were O
maintained O
for O
final O
per O
- O
protocol O
analyses O
. O
OS B-outcome
and O
EFS B-outcome
at O
five O
years O
were O
not O
equivalent O
( O
Ax O
vs. O
no O
- O
Ax O
: O
98 B-iv-bin-percent
% I-iv-bin-percent
vs. O
94 B-cv-bin-percent
% I-cv-bin-percent
and O
96 B-iv-bin-percent
% I-iv-bin-percent
vs. O
90 B-cv-bin-percent
% I-cv-bin-percent
respectively O
) O
. O
Recurrence B-outcome
was O
higher O
for O
no O
- O
Ax O
, O
particularly O
in O
the O
first O
five O
years O
after O
surgery O
. O
Axillary B-outcome
nodes I-outcome
were I-outcome
positive I-outcome
for O
14 B-iv-bin-percent
% I-iv-bin-percent
Ax O
patients O
but O
only O
2 B-cv-bin-percent
% I-cv-bin-percent
no O
- O
Ax O
patients O
experienced O
axillary O
node O
recurrence O
. O
Functional B-outcome
impairments I-outcome
were O
greater O
after O
ALNC O
. O
Our O
results O
fail O
to O
demonstrate O
equivalence O
of O
outcomes O
when O
ALNC O
is O
omitted O
from O
post O
- O
menopausal O
early O
breast O
cancer O
patient O
treatment O
. O
However O
the O
low O
locoregional O
recurrence O
rates O
warrant O
further O
examination O
over O
a O
longer O
duration O
, O
in O
particular O
to O
consider O
whether O
these O
would O
impact O
on O
survival O
. O

Effect O
of O
the O
gonadotropin B-intervention
- I-intervention
releasing I-intervention
hormone I-intervention
analogue I-intervention
triptorelin I-intervention
on O
the O
occurrence O
of O
chemotherapy B-condition
- I-condition
induced I-condition
early I-condition
menopause I-condition
in O
premenopausal O
women O
with O
breast O
cancer O
: O
a O
randomized O
trial O
. O
Premenopausal O
patients O
with O
breast O
cancer O
are O
at O
high O
risk O
of O
premature O
ovarian O
failure O
induced O
by O
systemic O
treatments O
, O
but O
no O
standard O
strategies O
for O
preventing O
this O
adverse O
effect O
are O
yet O
available O
. O
To O
determine O
the O
effect O
of O
the O
temporary O
ovarian O
suppression O
obtained O
by O
administering O
the O
gonadotropin O
- O
releasing O
hormone O
analogue O
triptorelin O
during O
chemotherapy O
on O
the O
incidence O
of O
early O
menopause O
in O
young B-eligibility
patients I-eligibility
with I-eligibility
breast I-eligibility
cancer I-eligibility
undergoing I-eligibility
adjuvant I-eligibility
or I-eligibility
neoadjuvant I-eligibility
chemotherapy I-eligibility
. O
The O
PROMISE O
- O
GIM6 O
( O
Prevention O
of O
Menopause O
Induced O
by O
Chemotherapy O
: O
A O
Study O
in O
Early O
Breast O
Cancer O
Patients O
- O
Gruppo O
Italiano O
Mammella O
6 O
) O
study O
, O
a O
parallel O
, O
randomized O
, O
open O
- O
label O
, O
phase O
3 O
superiority O
trial O
, O
was O
conducted O
at O
16 O
sites O
in O
Italy B-location
and O
enrolled O
281 B-total-participants
patients O
between O
October O
2003 O
and O
January O
2008 O
. O
The O
patients O
were O
premenopausal B-eligibility
women I-eligibility
with I-eligibility
stage I-eligibility
I I-eligibility
through I-eligibility
III I-eligibility
breast I-eligibility
cancer I-eligibility
who I-eligibility
were I-eligibility
candidates I-eligibility
for I-eligibility
adjuvant I-eligibility
or I-eligibility
neoadjuvant I-eligibility
chemotherapy I-eligibility
. O
Assuming O
a O
60 O
% O
rate O
of O
early O
menopause O
in O
the O
group O
treated O
with O
chemotherapy B-control
alone I-control
, O
it O
was O
estimated O
that O
280 O
patients O
had O
to O
be O
enrolled O
to O
detect O
a O
20 O
% O
absolute O
reduction O
in O
early O
menopause O
in O
the O
group O
treated O
with O
chemotherapy O
plus O
triptorelin O
. O
The O
intention O
- O
to O
- O
treat O
analysis O
was O
performed O
by O
including O
all O
randomized O
patients O
and O
using O
imputed O
values O
for O
missing O
data O
. O
Before O
beginning O
chemotherapy O
, O
patients O
were O
randomly O
allocated O
to O
receive O
chemotherapy O
alone O
or O
combined O
with O
triptorelin O
. O
Triptorelin O
was O
administered O
intramuscularly O
at O
a O
dose O
of O
3.75 O
mg O
at O
least O
1 O
week O
before O
the O
start O
of O
chemotherapy O
and O
then O
every O
4 O
weeks O
for O
the O
duration O
of O
chemotherapy O
. O
Incidence O
of O
early O
menopause O
( O
defined O
as O
no O
resumption O
of O
menstrual O
activity O
and O
postmenopausal O
levels O
of O
follicle O
- O
stimulating O
hormone O
and O
estradiol O
1 O
year O
after O
the O
last O
cycle O
of O
chemotherapy O
) O
. O
The O
clinical O
and O
tumor O
characteristics O
of O
the O
133 B-control-participants
patients O
randomized O
to O
chemotherapy O
alone O
and O
the O
148 B-intervention-participants
patients O
randomized O
to O
chemotherapy O
plus O
triptorelin O
were O
similar O
. O
Twelve O
months O
after O
the O
last O
cycle O
of O
chemotherapy O
( O
last O
follow O
- O
up O
, O
August O
18 O
, O
2009 O
) O
, O
the O
rate B-outcome
of I-outcome
early I-outcome
menopause I-outcome
was O
25.9 B-cv-bin-percent
% I-cv-bin-percent
in O
the O
chemotherapy O
- O
alone O
group O
and O
8.9 B-iv-bin-percent
% I-iv-bin-percent
in O
the O
chemotherapy O
plus O
triptorelin O
group O
, O
an O
absolute O
difference O
of O
-17 O
% O
( O
95 O
% O
confidence O
interval O
, O
-26 O
% O
to O
-7.9 O
% O
; O
P O
< O
.001 O
) O
. O
The O
odds O
ratio O
for O
treatment B-outcome
- I-outcome
related I-outcome
early I-outcome
menopause I-outcome
was O
0.28 O
( O
95 O
% O
confidence O
interval O
, O
0.14 O
to O
0.59 O
; O
P O
< O
.001 O
) O
. O
The O
use O
of O
triptorelin O
- O
induced O
temporary O
ovarian O
suppression O
during O
chemotherapy O
in O
premenopausal O
patients O
with O
early O
- O
stage O
breast O
cancer O
reduced O
the O
occurrence O
of O
chemotherapy O
- O
induced O
early O
menopause O
. O
clinicaltrials.gov O
Identifier O
: O
NCT00311636 O
. O

Rationale O
and O
design O
of O
the O
Multidisciplinary O
Approach O
to O
Novel O
Therapies O
in O
Cardiology O
Oncology O
Research O
Trial O
( O
MANTICORE O
101 O
- O
-Breast O
): O
a O
randomized O
, O
placebo O
- O
controlled O
trial O
to O
determine O
if O
conventional O
heart B-intervention
failure I-intervention
pharmacotherapy I-intervention
can O
prevent O
trastuzumab B-condition
- I-condition
mediated I-condition
left I-condition
ventricular I-condition
remodeling I-condition
among O
patients O
with O
HER2 O
+ O
early O
breast O
cancer O
using O
cardiac O
MRI O
. O
MANTICORE O
101 O
- O
Breast O
( O
Multidisciplinary O
Approach O
to O
Novel O
Therapies O
in O
Cardiology O
Oncology O
Research O
) O
is O
a O
randomized O
trial O
to O
determine O
if O
conventional O
heart O
failure O
pharmacotherapy O
( O
angiotensin O
converting O
enzyme O
inhibitor O
or O
beta O
- O
blocker O
) O
can O
prevent O
trastuzumab O
- O
mediated O
left O
ventricular O
remodeling O
, O
measured O
with O
cardiac O
MRI O
, O
among O
patients O
with O
HER2 O
+ O
early O
breast O
cancer O
. O
One B-total-participants
hundred I-total-participants
and I-total-participants
fifty I-total-participants
- I-total-participants
nine I-total-participants
patients B-eligibility
with I-eligibility
histologically I-eligibility
confirmed I-eligibility
HER2 I-eligibility
+ I-eligibility
breast I-eligibility
cancer I-eligibility
will O
be O
enrolled O
in O
a O
parallel O
3 O
- O
arm O
, O
randomized O
, O
placebo O
controlled O
, O
double O
- O
blind O
design O
. O
After O
baseline O
assessments O
, O
participants O
will O
be O
randomized O
in O
a O
1 O
:1 O
:1 O
ratio O
to O
an O
angiotensin O
- O
converting O
enzyme O
inhibitor O
( O
perindopril O
) O
, O
beta O
- O
blocker O
( O
bisoprolol O
) O
, O
or O
placebo B-control
. O
Participants O
will O
receive O
drug O
or O
placebo O
for O
1 O
year O
beginning O
7 O
days O
before O
trastuzumab O
therapy O
. O
Dosages O
for O
all O
groups O
will O
be O
systematically O
up O
- O
titrated O
, O
as O
tolerated O
, O
at O
1 O
week O
intervals O
for O
a O
total O
of O
3 O
weeks O
. O
The O
primary O
objective O
of O
this O
randomized O
clinical O
trial O
is O
to O
determine O
if O
conventional O
heart O
failure O
pharmacotherapy O
can O
prevent O
trastuzumab O
- O
mediated O
left O
ventricular O
remodeling O
among O
patients O
with O
HER2 O
+ O
early O
breast O
cancer O
, O
as O
measured O
by O
12 B-outcome-measure
month I-outcome-measure
change I-outcome-measure
in I-outcome-measure
left I-outcome-measure
ventricular I-outcome-measure
end I-outcome-measure
- I-outcome-measure
diastolic I-outcome-measure
volume I-outcome-measure
using O
cardiac O
MRI O
. O
Secondary O
objectives O
include O
1 O
) O
determine O
the O
evolution B-outcome-measure
of I-outcome-measure
left I-outcome-measure
ventricular I-outcome-measure
remodeling I-outcome-measure
on I-outcome-measure
cardiac I-outcome-measure
MRI I-outcome-measure
in O
patients O
with O
HER2 O
+ O
early O
breast O
cancer O
, O
2 O
) O
understand O
the O
mechanism O
of O
trastuzumab O
mediated O
cardiac O
toxicity O
by O
assessing O
for O
the O
presence B-outcome-measure
of I-outcome-measure
myocardial I-outcome-measure
injury I-outcome-measure
and I-outcome-measure
apoptosis I-outcome-measure
on I-outcome-measure
serum I-outcome-measure
biomarkers I-outcome-measure
and I-outcome-measure
cardiac I-outcome-measure
MRI I-outcome-measure
, O
and O
3 O
) O
correlate B-outcome-measure
cardiac I-outcome-measure
biomarkers I-outcome-measure
of I-outcome-measure
myocyte I-outcome-measure
injury I-outcome-measure
and I-outcome-measure
extra I-outcome-measure
- I-outcome-measure
cellular I-outcome-measure
matrix I-outcome-measure
remodeling I-outcome-measure
with I-outcome-measure
left I-outcome-measure
ventricular I-outcome-measure
remodeling I-outcome-measure
on I-outcome-measure
cardiac I-outcome-measure
MRI I-outcome-measure
in O
patients O
with O
HER2 O
+ O
early O
breast O
cancer O
. O
Cardiac O
toxicity O
as O
a O
result O
of O
cancer O
therapies O
is O
now O
recognized O
as O
a O
significant O
health O
problem O
of O
increasing O
prevalence O
. O
To O
our O
knowledge O
, O
MANTICORE O
will O
be O
the O
first O
randomized O
trial O
testing O
proven O
heart O
failure O
pharmacotherapy O
in O
the O
prevention O
of O
trastuzumab O
- O
mediated O
cardiotoxicity O
. O
We O
expect O
the O
findings O
of O
this O
trial O
to O
provide O
important O
evidence O
in O
the O
development O
of O
guidelines O
for O
preventive O
therapy O
. O
ClinicalTrials.gov O
: O
NCT01016886 O
. O

The O
GISS O
trial O
: O
a O
phase O
II O
prevention O
trial O
of O
screening B-intervention
plus I-intervention
goserelin I-intervention
, I-intervention
ibandronate I-intervention
, O
versus O
screening B-control
alone I-control
in O
premenopausal O
women O
at O
increased O
risk O
of O
breast O
cancer O
. O
Genetic O
testing O
for O
inherited O
mutations O
in O
breast O
cancer O
genes O
provides O
valuable O
information O
for O
disease O
prevention O
. O
Today O
, O
premenopausal B-eligibility
women I-eligibility
with I-eligibility
increased I-eligibility
risk I-eligibility
for I-eligibility
breast I-eligibility
cancer I-eligibility
have O
only O
limited O
nonsurgical O
options O
to O
reduce O
their O
risk O
. O
The O
GISS O
trial O
, O
a O
randomized O
, O
multicenter O
, O
open O
- O
label O
phase O
II O
trial O
, O
assessed O
the O
feasibility O
of O
a O
preventive O
treatment O
with O
goserelin O
and O
ibandronate O
for O
premenopausal O
women O
at O
increased O
risk O
for O
breast O
cancer O
. O
The O
primary O
endpoints O
were O
refusal B-outcome-measure
to I-outcome-measure
undergo I-outcome-measure
randomization I-outcome-measure
and O
discontinuation B-outcome-measure
of I-outcome-measure
treatment I-outcome-measure
. O
Safety B-outcome-measure
and I-outcome-measure
quality I-outcome-measure
of I-outcome-measure
life I-outcome-measure
were O
also O
evaluated O
. O
Between O
the O
years O
2001 O
and O
2003 O
, O
31 B-total-participants
of O
322 O
eligible O
women O
participated O
in O
the O
trial O
; O
15 B-intervention-participants
received O
goserelin O
/ O
ibandronate O
plus O
screening O
, O
15 B-control-participants
screening O
only O
, O
and O
1 O
withdrew O
her O
consent O
after O
randomization O
. O
The O
treatment O
duration O
was O
24 O
months O
. O
Here O
, O
mainly O
the O
results O
from O
the O
first O
12 O
months O
were O
evaluated O
because O
of O
the O
low O
compliance O
thereafter O
. O
Hot B-outcome
flushes I-outcome
, O
headache B-outcome
, O
and O
vaginal B-outcome
dryness I-outcome
/ I-outcome
discharge I-outcome
occurred O
more O
often O
in O
the O
goserelin O
arm O
. O
No O
difference O
was O
observed O
between O
the O
two O
arms O
in O
the O
agreement B-outcome
to I-outcome
randomization I-outcome
, O
compliance O
, O
or O
any O
other O
endpoints O
. O
Acceptance B-outcome
of I-outcome
chemoprevention I-outcome
with O
goserelin O
and O
ibandronate O
was O
low O
. O
Premenopausal O
women O
at O
increased O
risk O
for O
breast O
cancer O
should O
be O
better O
informed O
about O
chemoprevention O
through O
physician O
counseling O
and O
a O
more O
feasible O
study O
design O
( O
e.g. O
, O
oral O
medication O
) O
should O
be O
provided O
. O
This O
is O
the O
first O
chemoprevention O
trial O
in O
premenopausal O
women O
at O
increased O
risk O
for O
breast O
cancer O
. O
  O

Surgery O
following O
neoadjuvant O
therapy O
in O
patients O
with O
HER2 O
- O
positive O
locally O
advanced O
or O
inflammatory O
breast O
cancer O
participating O
in O
the O
NeOAdjuvant O
Herceptin O
( O
NOAH O
) O
study O
. O
To O
describe O
surgical O
outcomes O
in O
patients O
with O
HER2 O
- O
positive O
locally O
advanced O
( O
LABC O
) O
or O
inflammatory O
breast O
cancer O
( O
IBC O
) O
participating O
in O
the O
NeOAdjuvant O
Herceptin O
( O
NOAH O
) O
study O
( O
ISRCTN86043495 O
) O
. O
A O
total O
of O
235 B-total-participants
patients B-eligibility
with I-eligibility
HER2 I-eligibility
- I-eligibility
positive I-eligibility
disease I-eligibility
were O
randomized O
to O
neoadjuvant B-intervention
trastuzumab I-intervention
plus I-intervention
chemotherapy I-intervention
( O
doxorubicin O
plus O
paclitaxel O
, O
followed O
by O
paclitaxel O
, O
followed O
by O
cyclophosphamide O
, O
methotrexate O
and O
fluorouracil O
) O
or O
neoadjuvant B-control
chemotherapy I-control
alone I-control
. O
Of O
these O
patients O
, O
228 B-total-participants
received O
their O
allocated O
treatment O
( O
115 B-intervention-participants
received O
trastuzumab O
plus O
chemotherapy O
and O
113 B-control-participants
received O
chemotherapy O
alone O
) O
and O
were O
potentially O
eligible O
for O
surgery O
. O
Mastectomy O
was O
required O
for O
all O
patients O
with O
IBC O
and O
was O
recommended O
for O
all O
patients O
with O
LABC O
. O
However O
, O
breast O
- O
conserving O
therapy O
could O
be O
considered O
for O
patients O
with O
peripheral O
neoplasms O
measuring O
 O
4 O
cm O
in O
diameter O
at O
diagnosis O
, O
with O
a O
favorable O
ratio O
of O
tumor O
to O
breast O
volume O
, O
or O
at O
the O
patient O
's O
request O
if O
there O
had O
been O
a O
good O
response O
to O
treatment O
. O
As O
previously O
reported O
, O
the O
addition O
of O
trastuzumab O
to O
neoadjuvant O
chemotherapy O
improved O
the O
overall O
, O
complete O
and O
pathological O
complete O
response O
to O
therapy O
and O
significantly O
improved O
event B-outcome-measure
- I-outcome-measure
free I-outcome-measure
survival I-outcome-measure
( O
the O
primary O
endpoint O
of O
the O
study O
) O
. O
Trastuzumab O
also O
enabled O
more O
patients O
to O
have O
breast B-outcome
conserving I-outcome
surgery I-outcome
( I-outcome
BCS I-outcome
) I-outcome
( O
23 B-iv-bin-percent
% I-iv-bin-percent
versus O
13 B-cv-bin-percent
% I-cv-bin-percent
respectively O
) O
without O
an O
apparent O
detrimental O
effect O
on O
local O
disease O
control O
( O
no O
patient O
treated O
with O
trastuzumab O
plus O
chemotherapy O
had O
experienced O
a O
local O
recurrence O
after O
BCS O
at O
the O
time O
of O
analysis O
) O
. O
Although O
this O
was O
not O
an O
aim O
of O
the O
trial O
, O
neoadjuvant O
trastuzumab O
given O
concurrently O
with O
chemotherapy O
enabled O
23 O
% O
of O
patients O
with O
HER2 O
- O
positive O
LABC O
/ O
IBC O
to O
avoid O
mastectomy O
( O
including O
a O
small O
number O
of O
patients O
with O
IBC O
) O
. O

Dramatic O
dietary B-intervention
fat I-intervention
reduction I-intervention
is O
feasible O
for O
breast O
cancer O
patients O
: O
Results O
of O
the O
randomised O
study O
, O
WINS O
( O
UK B-location
) O
- O
stage O
1 O
. O
The O
influence O
of O
dietary O
fat O
on O
breast O
tumour O
growth O
( O
1 O
) O
and O
, O
more O
recently O
, O
on O
treatment O
outcomes, O
( O
2,3 O
) O
suggests O
an O
important O
role O
for O
dietary O
advice O
in O
the O
future O
health O
of O
breast O
cancer O
patients O
. O
The O
Women O
's O
Intervention O
Nutrition O
Study O
( O
UK O
) O
- O
Stage O
1 O
assessed O
the O
feasibility O
of O
achieving O
and O
maintaining O
a O
 O
50 O
% O
reduction O
in O
reported O
fat O
intake O
in O
postmenopausal B-eligibility
, I-eligibility
early I-eligibility
stage I-eligibility
breast I-eligibility
cancer I-eligibility
patients I-eligibility
in I-eligibility
the I-eligibility
UK I-eligibility
. O
This O
study O
recruited O
patients O
in O
South B-location
- I-location
east I-location
England I-location
between O
2000 O
and O
2005 O
. O
They O
were O
randomly O
allocated O
into O
two O
groups O
. O
Group O
1 O
( O
n O
= O
54 B-intervention-participants
) O
, O
received O
specific O
dietary O
counselling O
to O
halve O
their O
reported O
fat O
intake O
and O
maintain O
this O
low O
fat O
intake O
. O
Group O
2 O
( O
n O
= O
53 B-control
) O
received O
healthy B-control
eating I-control
advice I-control
only I-control
. O
Dietitian O
- O
led O
group O
sessions O
provided O
support O
for O
women O
in O
both O
groups O
over O
2 O
years O
. O
( O
4 O
) O
Validated O
four O
- O
day O
diaries O
were O
used O
to O
measure O
intake O
. O
Data O
analysis O
used O
Generalised O
Linear O
Model O
( O
GLM O
) O
for O
repeated O
measures O
and O
logistic O
regression O
. O
A O
significantly O
greater O
proportion O
of O
women O
in O
Group O
1 O
reported O
a O
fat B-outcome
intake I-outcome
reduction I-outcome
of O
 O
50 O
% O
at O
3 O
months O
( O
p O
< O
.001 O
) O
and O
24 O
months O
( O
p O
< O
.001 O
) O
than O
in O
Group O
2 O
. O
The O
size B-outcome
of I-outcome
the I-outcome
effect I-outcome
of I-outcome
active I-outcome
dietary I-outcome
counselling I-outcome
was O
37 B-iv-bin-percent
% I-iv-bin-percent
at B-outcome
3 I-outcome
months I-outcome
( O
95%CI O
: O
21 O
- O
54 O
% O
) O
and O
35 B-iv-bin-percent
% I-iv-bin-percent
at B-outcome
24 I-outcome
months I-outcome
( O
95%CI O
: O
17 O
- O
53 O
% O
) O
. O
Mean B-outcome
fat I-outcome
intake I-outcome
was O
halved O
at O
3 O
months O
and O
24 O
months O
in O
Group O
1 O
only O
. O
Demonstrating O
such O
feasibility O
is O
a O
key O
step O
towards O
defining O
diet O
's O
role O
in O
the O
secondary O
prevention O
of O
breast O
cancer O
. O
  O

Effect O
of O
manual B-intervention
lymph I-intervention
drainage I-intervention
in O
addition O
to O
guidelines O
and O
exercise B-intervention
therapy I-intervention
on O
arm B-condition
lymphoedema I-condition
related O
to O
breast O
cancer O
: O
randomised O
controlled O
trial O
. O
To O
determine O
the O
preventive O
effect O
of O
manual O
lymph O
drainage O
on O
the O
development O
of O
lymphoedema O
related O
to O
breast O
cancer O
. O
Randomised O
single O
blinded O
controlled O
trial O
. O
University O
Hospitals O
Leuven O
, O
Leuven B-location
, I-location
Belgium I-location
. O
160 B-total-participants
consecutive O
patients B-eligibility
with I-eligibility
breast I-eligibility
cancer I-eligibility
and I-eligibility
unilateral I-eligibility
axillary I-eligibility
lymph I-eligibility
node I-eligibility
dissection I-eligibility
. O
The O
randomisation O
was O
stratified O
for O
body O
mass O
index O
( O
BMI O
) O
and O
axillary O
irradiation O
and O
treatment O
allocation O
was O
concealed O
. O
Randomisation O
was O
done O
independently O
from O
recruitment O
and O
treatment O
. O
Baseline O
characteristics O
were O
comparable O
between O
the O
groups O
. O
For O
six O
months O
the O
intervention O
group O
( O
n O
= O
79 B-intervention-participants
) O
performed O
a O
treatment O
programme O
consisting O
of O
guidelines O
about O
the O
prevention O
of O
lymphoedema O
, O
exercise O
therapy O
, O
and O
manual O
lymph O
drainage O
. O
The O
control B-control
group I-control
( O
n O
= O
81 B-control-participants
) O
performed O
the O
same O
programme O
without O
manual O
lymph O
drainage O
. O
Cumulative O
incidence O
of O
arm O
lymphoedema O
and O
time O
to O
develop O
arm O
lymphoedema O
, O
defined O
as O
an O
increase O
in O
arm O
volume O
of O
200 O
mL O
or O
more O
in O
the O
value O
before O
surgery O
. O
Four B-iv-bin-abs
patients O
in O
the O
intervention O
group O
and O
two B-cv-bin-abs
in O
the O
control O
group O
were O
lost B-outcome
to I-outcome
follow I-outcome
- I-outcome
up I-outcome
. O
At O
12 O
months O
after O
surgery O
, O
the O
cumulative B-outcome
incidence I-outcome
rate I-outcome
for I-outcome
arm I-outcome
lymphoedema I-outcome
was O
comparable O
between O
the O
intervention O
group O
( O
24 B-iv-bin-percent
% I-iv-bin-percent
) O
and O
control O
group O
( O
19 B-cv-bin-percent
% I-cv-bin-percent
) O
( O
odds O
ratio O
1.3 O
, O
95 O
% O
confidence O
interval O
0.6 O
to O
2.9 O
; O
P O
= O
0.45 O
) O
. O
The O
time B-outcome
to I-outcome
develop I-outcome
arm I-outcome
lymphoedema I-outcome
was O
comparable O
between O
the O
two O
group O
during O
the O
first O
year O
after O
surgery O
( O
hazard O
ratio O
1.3 O
, O
0.6 O
to O
2.5 O
; O
P O
= O
0.49 O
) O
. O
The O
sample O
size O
calculation O
was O
based O
on O
a O
presumed O
odds O
ratio O
of O
0.3 O
, O
which O
is O
not O
included O
in O
the O
95 O
% O
confidence O
interval O
. O
This O
odds O
ratio O
was O
calculated O
as O
( O
presumed O
cumulative O
incidence O
of O
lymphoedema O
in O
intervention O
group O
/ O
presumed O
cumulative O
incidence O
of O
no O
lymphoedema O
in O
intervention O
group O
) O
 O
( O
presumed O
cumulative O
incidence O
of O
no O
lymphoedema O
in O
control O
group O
/ O
presumed O
cumulative O
incidence O
of O
lymphoedema O
in O
control O
group O
) O
or O
( O
10 O
/ O
90 O
) O
 O
( O
70 O
/ O
30 O
) O
. O
Manual O
lymph O
drainage O
in O
addition O
to O
guidelines O
and O
exercise O
therapy O
after O
axillary O
lymph O
node O
dissection O
for O
breast O
cancer O
is O
unlikely O
to O
have O
a O
medium O
to O
large O
effect O
in O
reducing O
the O
incidence O
of O
arm O
lymphoedema O
in O
the O
short O
term O
. O
Trial O
registration O
Netherlands O
Trial O
Register O
No O
NTR O
1055 O
. O

A O
phase O
III O
, O
randomized O
, O
placebo O
- O
controlled O
, O
double O
- O
blind O
trial O
of O
flaxseed B-intervention
for O
the O
treatment O
of O
hot B-condition
flashes I-condition
: O
  O
North O
Central O
Cancer O
Treatment O
Group O
N08C7 O
. O
Preliminary O
data O
suggest O
that O
flaxseed O
, O
a O
rich O
source O
of O
dietary O
lignans O
, O
may O
be O
a O
potentially O
effective O
treatment O
of O
hot O
flashes O
. O
A O
phase O
III O
, O
randomized O
, O
placebo O
, O
controlled O
trial O
was O
conducted O
to O
evaluate O
the O
efficacy O
of O
flaxseed O
in O
reducing O
hot O
flashes O
. O
Postmenopausal B-eligibility
women I-eligibility
with I-eligibility
or I-eligibility
without I-eligibility
breast I-eligibility
cancer I-eligibility
were O
randomly O
assigned O
to O
a O
flaxseed O
bar O
( O
providing O
410 O
mg O
of O
lignans O
) O
for O
6 O
weeks O
versus O
a O
placebo B-control
bar I-control
. O
Participants O
completed O
daily O
, O
prospective O
, O
hot O
flash O
diaries O
during O
the O
baseline O
week O
, O
and O
then O
ate O
one O
study O
bar O
per O
day O
for O
6 O
weeks O
while O
recording O
their O
daily O
hot O
flashes O
. O
The O
intraparticipant B-outcome-measure
difference I-outcome-measure
in I-outcome-measure
hot I-outcome-measure
flash I-outcome-measure
activity I-outcome-measure
between I-outcome-measure
baseline I-outcome-measure
and I-outcome-measure
the I-outcome-measure
last I-outcome-measure
treatment I-outcome-measure
week I-outcome-measure
was O
the O
primary O
endpoint O
. O
Adverse O
effects O
were O
evaluated O
through O
a O
self O
- O
report O
and O
the O
Common O
Terminology O
Criteria O
assessment O
. O
A O
total O
of O
188 B-total-participants
women O
were O
enrolled O
in O
this O
trial O
. O
The O
mean B-outcome
hot I-outcome
flash I-outcome
score I-outcome
was O
reduced O
4.9 B-iv-cont-mean
in O
the O
flaxseed O
group O
and O
3.5 B-cv-cont-mean
in O
the O
placebo O
group O
( O
P O
= O
0.29 O
) O
. O
In O
both O
groups O
, O
slightly O
more O
than O
a O
third O
of O
the O
women O
received O
a O
50 O
% O
reduction B-outcome
in I-outcome
their I-outcome
hot I-outcome
flash I-outcome
score I-outcome
. O
Only O
one O
adverse O
effect O
was O
significantly O
different O
between O
groups O
, O
grade B-outcome
1 I-outcome
pruritus I-outcome
, O
which O
was O
more O
common O
in O
the O
placebo O
group O
( O
8 B-cv-bin-percent
% I-cv-bin-percent
vs O
1 B-iv-bin-percent
% I-iv-bin-percent
) O
. O
Both O
groups O
reported O
abdominal B-outcome
distension I-outcome
, O
flatulence B-outcome
, O
diarrhea B-outcome
, O
and O
nausea B-outcome
. O
Adherence B-outcome
and I-outcome
ability I-outcome
to I-outcome
detect I-outcome
treatment I-outcome
assignment I-outcome
did O
not O
differ O
between O
groups O
. O
The O
results O
of O
this O
trial O
do O
not O
support O
the O
use O
of O
410 O
mg O
of O
lignans O
for O
the O
reduction O
of O
hot O
flashes O
. O
The O
bars O
were O
fairly O
well O
tolerated O
, O
with O
both O
groups O
reporting O
gastrointestinal O
effects O
, O
probably O
due O
to O
the O
fiber O
content O
. O

A O
randomised O
controlled O
trial O
of O
support B-intervention
group I-intervention
intervention I-intervention
after O
breast O
cancer O
treatment O
: O
results O
on O
anxiety B-condition
and I-condition
depression I-condition
. O
Previous O
studies O
have O
demonstrated O
that O
between O
20 O
and O
30 O
% O
of O
women O
treated O
for O
breast O
cancer O
have O
measurable O
signs O
of O
anxiety O
and O
depression O
compared O
with O
6 O
% O
in O
a O
population O
of O
healthy O
women O
. O
Depression O
has O
been O
proposed O
as O
a O
predictive O
factor O
for O
recurrence O
and O
survival O
. O
The O
aim O
of O
the O
present O
study O
was O
to O
evaluate O
if O
psychosocial O
support O
intervention O
could O
influence O
anxiety O
and O
depression O
during O
the O
first O
year O
after O
diagnosis O
. O
Newly B-eligibility
diagnosed I-eligibility
breast I-eligibility
cancer I-eligibility
patients I-eligibility
were O
randomised O
between O
April O
2002 O
and O
November O
2007 O
and O
stratified O
by O
adjuvant O
chemotherapy O
. O
Of O
382 B-total-participants
eligible O
patients O
, O
191 B-intervention-participants
+ O
191 B-control-participants
patients O
were O
randomised O
to O
intervention O
group O
or O
control B-control
group I-control
, O
respectively O
. O
Control O
patients O
were O
subjected O
to O
standard B-control
follow I-control
- I-control
up I-control
routines I-control
. O
The O
Intervention O
group O
had O
support O
intervention O
at O
the O
Foundation O
Lustgrden O
Mlardalen O
. O
The O
rehabilitation O
lasted O
one O
week O
on O
a O
residential O
basis O
followed O
by O
four O
days O
of O
follow O
- O
up O
two O
months O
later O
. O
We O
used O
the O
Swedish O
version O
of O
the O
HAD O
scale O
with O
a O
cut O
- O
off O
value O
greater O
than O
10 O
for O
clinical B-outcome
symptoms I-outcome
of I-outcome
depression I-outcome
and I-outcome
anxiety I-outcome
. O
Support O
group O
intervention O
lowered O
anxiety B-outcome
over I-outcome
time I-outcome
( O
p O
< O
0.001 O
) O
but O
depression B-outcome
was O
unaffected O
( O
p O
= O
0.610 O
) O
. O
This O
prospective O
randomised O
trial O
of O
support O
group O
intervention O
in O
a O
large O
homogenous O
group O
of O
breast O
cancer O
women O
showed O
a O
statistically O
significant O
effect O
on O
lowering O
anxiety O
over O
time O
. O
No O
statistically O
significant O
effect O
of O
intervention O
could O
be O
seen O
on O
depression O
. O

Electrothermal B-intervention
bipolar I-intervention
vessel I-intervention
sealing I-intervention
system I-intervention
in O
axillary O
dissection O
: O
a O
prospective O
randomized O
clinical O
study O
. O
We O
assessed O
whether O
axillary O
dissection O
using O
the O
electrothermal O
bipolar O
vessel O
sealing O
system O
( O
LigaSure O
) O
improved O
perioperative O
outcome O
when O
compared O
with O
conventional O
axillary O
dissection O
, O
in O
a O
prospective O
randomized O
study O
of O
100 B-total-participants
women O
with O
breast O
cancer O
. O
Those B-eligibility
needing I-eligibility
axillary I-eligibility
dissection I-eligibility
were O
randomized O
to O
the O
use O
of O
LigaSure O
or O
to O
conventional B-control
axillary I-control
dissection I-control
( O
with O
50 B-intervention-participants
patients O
in O
each O
group O
, O
all O
of O
whom O
had O
a O
closed O
suction O
drain O
in O
the O
axilla O
) O
. O
The O
LigaSure O
patients O
had O
less B-outcome
intraoperative I-outcome
blood I-outcome
loss I-outcome
( O
exceeding O
199 O
mL O
in O
30.8 B-iv-bin-percent
% I-iv-bin-percent
vs. O
69.2 B-cv-bin-percent
% I-cv-bin-percent
, O
P O
< O
0.001 O
) O
, O
quicker B-outcome
axillary I-outcome
dissection I-outcome
( O
mean O
48 B-iv-cont-mean
vs. O
63.2 B-cv-cont-mean
min I-cv-cont-mean
, O
P O
= O
0.004 O
) O
, O
fewer B-outcome
days I-outcome
of I-outcome
suction I-outcome
drainage I-outcome
( O
4.3 B-iv-cont-mean
vs. O
5.7 B-cv-cont-mean
days I-cv-cont-mean
, O
P O
= O
0.012 O
) O
, O
and O
shorter B-outcome
hospitalization I-outcome
( O
5.1 B-iv-cont-mean
vs. O
6.5 B-cv-cont-mean
days I-cv-cont-mean
, O
P O
= O
0.021 O
) O
. O
No O
difference O
was O
found O
in O
the O
rate B-outcome
of I-outcome
hematomas I-outcome
, I-outcome
reoperations I-outcome
or I-outcome
infection I-outcome
. O
The O
use O
of O
LigaSure O
in O
axillary O
surgery O
reduced O
the O
surgical B-outcome
time I-outcome
and I-outcome
length I-outcome
of I-outcome
hospital I-outcome
stay I-outcome
, O
favoring O
early O
drain O
removal O
without O
increasing O
postoperative O
complications O
. O
  O

A O
randomized O
, O
double O
- O
blind O
, O
placebo O
- O
controlled O
trial O
of O
preemptive B-intervention
analgesia I-intervention
with I-intervention
bupivacaine I-intervention
in O
patients O
undergoing O
mastectomy O
for O
carcinoma O
of O
the O
breast O
. O
In O
this O
prospective O
, O
randomized O
, O
placebo O
- O
controlled O
, O
double O
- O
blinded O
clinical O
trial O
we O
tested O
the O
hypothesis O
that O
preemptive O
analgesia O
with O
bupivacaine O
applied O
in O
the O
area O
of O
the O
surgical O
incision O
in O
patients O
undergoing O
mastectomy O
for O
breast O
cancer O
would O
reduce O
post B-condition
- I-condition
operative I-condition
acute I-condition
pain I-condition
and O
would O
reduce O
the O
amount O
of O
analgesics O
used O
during O
surgery O
and O
in O
the O
post O
- O
operative O
period O
. O
Participants O
were O
assigned O
into O
1 O
of O
2 O
groups O
-- O
with O
bupivacaine O
applied O
in O
the O
area O
of O
surgical O
incision O
or O
with O
placebo B-control
. O
We O
assessed O
the O
intraoperative O
consumption O
of O
fentanyl O
, O
the O
postoperative O
consumption O
of O
morphine O
delivered O
using O
a O
PCA O
method O
, O
and O
the O
subjective O
pain O
intensity O
according O
to O
VAS O
score O
reported O
by O
patients O
in O
the O
early O
post O
- O
operative O
period O
. O
Out O
of O
121 O
consecutive O
cases O
qualified O
for O
mastectomy O
, O
112 B-total-participants
women O
were O
allocated O
randomly O
to O
1 O
of O
2 O
groups O
-- O
group O
A O
( O
bupivacaine O
) O
and O
group O
B O
( O
placebo O
) O
. O
The O
final O
study O
group O
comprised O
106 O
breast O
cancer O
cases O
. O
Between O
the O
groups O
, O
a O
statistically O
significant O
difference O
was O
observed O
with O
respect O
to O
: O
lower O
fentanyl B-outcome
consumption I-outcome
during I-outcome
surgery I-outcome
( O
p O
= O
0.011 O
) O
, O
lower O
morphine B-outcome
( I-outcome
delivered I-outcome
by I-outcome
means I-outcome
of I-outcome
a I-outcome
PCA I-outcome
) I-outcome
consumption I-outcome
between I-outcome
the I-outcome
4 I-outcome
- I-outcome
12th I-outcome
postoperative I-outcome
hours I-outcome
( O
p O
= O
0.02 O
) O
and O
significantly O
lower O
pain B-outcome
intensity I-outcome
assessed O
according O
to O
VAS O
score O
at B-outcome
the I-outcome
4th I-outcome
and I-outcome
12th I-outcome
hours I-outcome
after I-outcome
surgery I-outcome
( O
p O
= O
0.004 O
and O
p O
= O
0.02 O
respectively O
) O
for O
the O
group O
A O
patients O
. O
Preemptive O
analgesia O
application O
in O
the O
form O
of O
infiltration O
of O
the O
area O
of O
planned O
surgical O
incisions O
with O
bupivacaine O
in O
breast O
cancer O
patients O
undergoing O
mastectomy O
decreases O
post O
- O
operative O
pain O
sensation O
, O
limits O
the O
amount O
of O
fentanyl O
used O
during O
surgery O
, O
and O
reduces O
the O
demand O
for O
opiates O
in O
the O
hours O
soon O
after O
surgery O
. O

Telephone B-intervention
counseling I-intervention
and O
attendance O
in O
a O
national O
mammography O
- O
screening O
program O
a O
randomized O
controlled O
trial O
. O
In O
Germany B-location
, O
a O
mammography O
- O
screening O
program O
( O
MSP O
) O
was O
implemented O
on O
a O
national O
level O
. O
It O
complies O
with O
all O
criteria O
of O
the O
European O
guidelines O
for O
quality O
assurance O
in O
screening O
mammography O
; O
however O
, O
the O
attendance O
rate O
is O
54 O
% O
, O
falling O
short O
of O
the O
target O
attendance O
rate O
of O
70 O
% O
. O
The O
aim O
of O
this O
study O
was O
to O
investigate O
whether O
additional O
telephone O
counseling O
improves O
attendance O
among O
nonresponders O
and O
the O
level O
of O
satisfaction O
with O
telephone O
counseling O
. O
In O
a O
prospective O
RCT O
, O
women O
identified O
as O
nonresponders O
in O
the O
MSP O
were O
randomized O
to O
a O
control B-control
group I-control
that O
received O
written O
reminders O
or O
to O
an O
intervention O
group O
that O
additionally O
received O
telephone O
counseling O
. O
In O
a O
follow O
- O
up O
, O
a O
subset O
of O
the O
intervention O
group O
was O
contacted O
by O
telephone O
regarding O
their O
satisfaction O
with O
telephone O
counseling O
. O
In O
2008 O
, O
a O
total O
of O
5477 B-total-participants
women O
aged O
50 B-age
- I-age
69 I-age
years I-age
who O
were O
eligible O
for O
the O
German O
MSP O
but O
had O
not O
participated O
up O
to O
6 O
weeks O
after O
the O
first O
invitation O
were O
included O
in O
the O
study O
. O
Individual O
telephone O
counseling O
consisted O
of O
scripted O
calls O
from O
a O
trained O
counselor O
who O
provided O
information O
on O
MSP O
and O
answered O
the O
woman O
's O
questions O
. O
Report O
of O
mammography O
use O
provided O
by O
the O
screening O
unit O
3 O
months O
after O
the O
reminder O
was O
sent O
. O
Analysis O
was O
conducted O
in O
2009 O
. O
Comparison O
of O
screening O
attendance O
revealed O
a O
significantly O
higher O
attendance B-outcome
rate I-outcome
in O
the O
intervention O
group O
compared O
with O
controls O
( O
29.7 B-iv-bin-percent
% I-iv-bin-percent
vs O
26.1 B-cv-bin-percent
% I-cv-bin-percent
, O
p O
= O
0.0035 O
) O
. O
When O
only O
women O
for O
whom O
telephone O
numbers O
were O
available O
were O
analyzed O
, O
attendance B-outcome
was O
even O
better O
( O
35.5 B-iv-bin-percent
% I-iv-bin-percent
vs O
29.7 B-cv-bin-percent
% I-cv-bin-percent
, O
p O
= O
0.0004 O
) O
. O
In O
the O
follow O
- O
up O
, O
278 B-total-participants
of O
404 O
women O
were O
actually O
surveyed O
. O
Of O
those O
, O
33 O
% O
stated O
that O
telephone O
counseling O
had O
influenced B-outcome
their I-outcome
decision I-outcome
, O
56 O
% O
stated O
that O
they O
had O
undergone B-outcome
screening I-outcome
mammography I-outcome
, O
and O
77 O
% O
agreed O
that O
personal O
telephone O
counseling O
should O
be O
used O
routinely O
to O
encourage O
nonresponders O
to O
go O
for O
screening B-outcome
. O
Individual O
telephone O
counseling O
for O
nonresponders O
to O
a O
national O
program O
for O
breast O
cancer O
screening O
was O
well O
accepted O
by O
participants O
and O
effective O
. O
This O
study O
is O
registered O
at O
the O
Australian O
New O
Zealand O
Clinical O
Trials O
Registry O
ACTRN12611000645954 O
. O
  O

Effects O
of O
music B-intervention
therapy I-intervention
on O
anxiety B-condition
of O
patients O
with O
breast O
cancer O
after O
radical O
mastectomy O
: O
a O
randomized O
clinical O
trial O
. O
  O
This O
paper O
is O
a O
report O
of O
a O
clinical O
trial O
of O
the O
effects O
of O
music O
therapy O
on O
anxiety O
of O
female B-eligibility
breast I-eligibility
cancer I-eligibility
patients I-eligibility
following I-eligibility
radical I-eligibility
mastectomy I-eligibility
. O
  O
There O
is O
insufficient O
evidence O
on O
the O
effects O
of O
music O
therapy O
on O
state O
anxiety O
of O
breast O
cancer O
patients O
following O
radical O
mastectomy O
. O
  O
A O
Hall O
's O
Core O
, O
Care O
, O
and O
Cure O
Model O
- O
based O
clinical O
trial O
was O
conducted O
in O
120 B-total-participants
female O
breast O
cancer O
patients O
from O
March O
to O
November O
2009 O
. O
A O
randomized O
controlled O
design O
was O
utilized O
. O
The O
patients O
were O
randomly O
allocated O
to O
the O
experimental O
group O
( O
n O
= O
60 B-intervention-participants
) O
received O
music O
therapy O
in O
addition O
to O
routine O
nursing O
care O
, O
and O
the O
control O
group O
( O
n O
= O
60 B-control-participants
) O
only O
received O
routine B-control
nursing I-control
care I-control
. O
A O
standardized O
questionnaire O
and O
the O
State O
Anxiety O
Inventory O
were O
applied O
. O
The O
primary O
endpoint O
was O
the O
state B-outcome-measure
anxiety I-outcome-measure
score I-outcome-measure
measured O
at O
pretest O
( O
on O
the O
day O
before O
radical O
mastectomy O
) O
and O
at O
three O
post O
- O
tests O
( O
on O
the O
day O
before O
patients O
were O
discharged O
from O
hospital O
, O
the O
second O
and O
third O
time O
of O
admission O
to O
hospital O
for O
chemotherapy O
respectively O
) O
. O
  O
The O
pretest O
score O
revealed O
that O
the O
majority O
of O
the O
patients O
had O
a O
moderate O
level O
( O
775 O
% O
) O
and O
15 O
% O
had O
severe O
level B-outcome
of I-outcome
state I-outcome
anxiety I-outcome
. O
The O
repeated O
- O
measure O
ancova O
model O
analysis O
indicated O
that O
the O
mean B-outcome
state I-outcome
anxiety I-outcome
score I-outcome
was O
significantly O
lower O
in O
the O
experimental O
group O
than O
those O
in O
the O
control O
group O
at O
each O
of O
the O
three O
post O
- O
test O
measurements O
. O
The O
mean B-outcome
difference I-outcome
between O
the O
experimental O
and O
control O
group O
together O
with O
95 O
% O
confidence O
intervals O
were O
-457 O
( O
-633 O
, O
-282 O
) O
, O
-891 O
( O
-1075 O
, O
-708 O
) O
and O
-969 O
( O
-1152 O
, O
-785 O
) O
at O
the O
1st B-outcome
post I-outcome
- I-outcome
test I-outcome
, O
2nd B-outcome
post I-outcome
- I-outcome
test I-outcome
and O
3rd B-outcome
post I-outcome
- I-outcome
test I-outcome
respectively O
. O
  O
Music O
therapy O
is O
found O
to O
have O
positive O
effects O
on O
decreasing O
state O
anxiety O
score O
. O
  O

The O
efficacy O
and O
safety O
of O
neoadjuvant B-intervention
chemotherapy I-intervention
 I-intervention
+ I-intervention
/- I-intervention
 I-intervention
letrozole I-intervention
in O
postmenopausal O
women O
with O
locally O
advanced O
breast O
cancer O
: O
a O
randomized O
phase O
III O
clinical O
trial O
. O
This O
two O
- O
arm O
randomized O
clinical O
study O
aimed O
to O
evaluate O
the O
efficacy O
and O
safety O
of O
neoadjuvant O
concurrent O
chemotherapy O
and O
letrozole O
in O
postmenopausal O
women O
with O
locally O
advanced O
breast O
carcinoma O
. O
One B-total-participants
hundred I-total-participants
and I-total-participants
one I-total-participants
postmenopausal O
women O
aged O
50 B-age
- I-age
83 I-age
years I-age
with B-eligibility
pathologically I-eligibility
proven I-eligibility
locally I-eligibility
advanced I-eligibility
( I-eligibility
clinical I-eligibility
stage I-eligibility
T3 I-eligibility
, I-eligibility
T4 I-eligibility
and/or I-eligibility
N2 I-eligibility
, I-eligibility
N3 I-eligibility
) I-eligibility
breast I-eligibility
cancer I-eligibility
were O
randomly O
assigned O
to O
receive O
neoadjuvant O
chemotherapy B-control
alone I-control
( I-control
control I-control
arm I-control
, O
n O
= O
51 B-control-participants
) O
or O
neoadjuvant O
chemotherapy O
concurrent O
with O
letrozole O
2.5 O
mg O
( O
study O
arm O
, O
n O
= O
50 B-intervention-participants
) O
. O
Chemotherapy O
consisted O
of O
a O
median O
4 O
( O
range O
3 O
- O
5 O
) O
cycles O
of O
intravenous O
5 O
- O
fluorouracil O
600 O
mg O
/ O
m O
( O
2 O
) O
, O
doxorubicin O
60 O
mg O
/ O
m O
( O
2 O
) O
, O
and O
cyclophosphamide O
600 O
mg O
/ O
m O
( O
2 O
) O
, O
every O
three O
weeks O
. O
All O
patients O
subsequently O
underwent O
modified O
radical O
mastectomy O
approximately O
two O
weeks O
after O
the O
last O
cycle O
of O
chemotherapy O
. O
Pathologic B-outcome
complete I-outcome
response I-outcome
rates I-outcome
were O
25.5 B-iv-bin-percent
% I-iv-bin-percent
and O
10.2 B-cv-bin-percent
% I-cv-bin-percent
in O
the O
study O
and O
the O
control O
group O
, O
respectively O
( O
P O
= O
0.049 O
) O
. O
Similarly O
, O
clinical B-outcome
complete I-outcome
response I-outcome
rates I-outcome
were O
27.6 B-iv-bin-percent
% I-iv-bin-percent
and O
10.2 B-cv-bin-percent
% I-cv-bin-percent
in O
the O
study O
and O
the O
control O
group O
, O
respectively O
( O
P O
= O
0.037 O
) O
. O
In O
the O
subgroup O
analysis O
of O
hormone O
receptor O
- O
positive O
cases O
, O
the O
complete O
response O
rates O
were O
more O
prominent O
in O
study O
group O
compared O
with O
control O
group O
. O
Common O
treatment O
- O
related O
side O
effects O
such O
as O
nausea B-outcome
, O
vomiting B-outcome
, O
bone B-outcome
marrow I-outcome
suppression I-outcome
, O
and O
mucositis B-outcome
were O
similar O
in O
both O
groups O
, O
but O
hot B-outcome
flush I-outcome
was O
more O
prevalent O
in O
study O
group O
compared O
with O
control O
group O
( O
P O
= O
0.023 O
) O
. O
The O
addition O
of O
letrozole O
concurrently O
with O
neoadjuvant O
chemotherapy O
provides O
a O
higher O
clinical O
and O
pathologic O
response O
rates O
with O
acceptable O
toxicity O
compared O
with O
chemotherapy O
alone O
in O
postmenopausal O
women O
with O
locally O
advanced O
sensitive O
breast O
cancer O
. O

Topical B-intervention
silver I-intervention
sulfadiazine I-intervention
for O
the O
prevention O
of O
acute B-condition
dermatitis I-condition
during O
irradiation O
for O
breast O
cancer O
. O
This O
study O
aimed O
to O
evaluate O
the O
effectiveness O
of O
topical O
silver O
sulfadiazine O
( O
SSD O
) O
in O
preventing O
acute O
radiation O
dermatitis O
in O
women O
receiving O
radiotherapy O
for O
breast O
cancer O
. O
A O
randomized O
controlled O
clinical O
trial O
was O
conducted O
on O
patients B-eligibility
with I-eligibility
breast I-eligibility
cancer I-eligibility
referred I-eligibility
for I-eligibility
radiotherapy I-eligibility
after I-eligibility
treatment I-eligibility
with I-eligibility
mastectomy I-eligibility
and I-eligibility
chemotherapy I-eligibility
. O
The O
patients O
were O
randomized O
into O
the O
intervention O
( O
n O
= O
51 B-intervention-participants
) O
and O
control B-control
( O
n O
= O
51 B-control-participants
) O
groups O
and O
were O
instructed O
on O
general O
skin O
care O
during O
radiotherapy O
. O
The O
intervention O
group O
received O
SSD O
cream O
1 O
% O
, O
three O
times O
a O
day O
, O
3 O
days O
a O
week O
, O
for O
5 O
weeks O
during O
radiotherapy O
and O
one O
week O
thereafter O
. O
A O
blinded O
observer O
assessed O
the O
severity O
of O
dermatitis O
weekly O
( O
for O
6 O
weeks O
) O
and O
graded O
it O
from O
0 O
to O
4 O
according O
to O
the O
Radiation O
Therapy O
Oncology O
Group O
criteria O
. O
The O
two O
groups O
were O
similar O
in O
baseline O
characteristics O
. O
Two B-cv-bin-abs
patients O
in O
the O
control O
group O
discontinued B-outcome
the O
radiotherapy O
course O
because O
of O
severe O
skin O
injuries O
( O
grades O
3 O
and O
4 O
) O
. O
The O
intervention O
group O
encountered O
significantly O
less O
severe B-outcome
dermatitis I-outcome
during O
radiotherapy O
compared O
to O
the O
controls O
. O
The O
total B-outcome
score I-outcome
of I-outcome
skin I-outcome
injury I-outcome
was O
also O
lower O
in O
the O
intervention O
group O
compared O
with O
controls O
( O
5.49 B-iv-cont-mean
 O
1.02 B-iv-cont-sd
vs. O
7.21 B-cv-cont-mean
 O
1.76 B-cv-cont-sd
, O
p O
< O
0.001 O
) O
. O
A O
multivariate O
analysis O
found O
that O
the O
use O
of O
SSD O
cream O
( O
p O
< O
0.001 O
) O
and O
flat O
chest O
wall O
anatomy O
( O
p O
= O
0.008 O
) O
were O
significantly O
associated O
with O
a O
decreased O
skin O
injury O
. O
SSD O
cream O
reduced O
the O
severity B-outcome
of I-outcome
radiation I-outcome
- I-outcome
induced I-outcome
skin I-outcome
injury I-outcome
compared O
with O
general O
skin O
care O
alone O
. O
Further O
studies O
in O
patients O
with O
other O
types O
of O
cancer O
and O
also O
comparing O
SSD O
cream O
with O
other O
topical O
agents O
are O
warranted O
. O

Sequential B-intervention
versus O
concurrent B-control
trastuzumab I-control
in O
adjuvant O
chemotherapy O
for O
breast O
cancer O
. O
NCCTG O
( O
North O
Central O
Cancer O
Treatment O
Group O
) O
N9831 O
is O
the O
only O
randomized O
phase O
III O
trial O
evaluating O
trastuzumab O
added O
sequentially O
or O
used O
concurrently O
with O
chemotherapy O
in O
resected B-eligibility
stages I-eligibility
I I-eligibility
to I-eligibility
III I-eligibility
invasive I-eligibility
human I-eligibility
epidermal I-eligibility
growth I-eligibility
factor I-eligibility
receptor I-eligibility
2 I-eligibility
- I-eligibility
positive I-eligibility
breast I-eligibility
cancer I-eligibility
. O
Patients O
received O
doxorubicin B-intervention
and I-intervention
cyclophosphamide I-intervention
every O
3 O
weeks O
for O
four O
cycles O
, O
followed O
by O
paclitaxel O
weekly O
for O
12 O
weeks O
( O
arm O
A O
) O
, O
paclitaxel B-intervention
plus I-intervention
sequential I-intervention
trastuzumab I-intervention
weekly O
for O
52 O
weeks O
( O
arm O
B O
) O
, O
or O
paclitaxel B-control
plus I-control
concurrent I-control
trastuzumab I-control
for O
12 O
weeks O
followed O
by O
trastuzumab O
for O
40 O
weeks O
( O
arm O
C O
) O
. O
The O
primary O
end O
point O
was O
disease B-outcome-measure
- I-outcome-measure
free I-outcome-measure
survival I-outcome-measure
( I-outcome-measure
DFS I-outcome-measure
) I-outcome-measure
. O
Comparison O
of O
arm O
A O
( O
n O
= O
1,087 B-intervention-participants
) O
and O
arm O
B O
( O
n O
= O
1,097 B-intervention-participants
) O
, O
with O
6 O
- O
year O
median O
follow O
- O
up O
and O
390 O
events O
, O
revealed O
5 B-outcome
- I-outcome
year I-outcome
DFS I-outcome
rates O
of O
71.8 B-iv-bin-percent
% I-iv-bin-percent
and O
80.1 B-iv-bin-percent
% I-iv-bin-percent
, O
respectively O
. O
DFS B-outcome
was O
significantly O
increased O
with O
trastuzumab O
added O
sequentially O
to O
paclitaxel O
( O
log O
- O
rank O
P O
< O
.001 O
; O
arm O
B O
/ O
arm O
A O
hazard O
ratio O
[ O
HR O
] O
, O
0.69 O
; O
95 O
% O
CI O
, O
0.57 O
to O
0.85 O
) O
. O
Comparison O
of O
arm O
B O
( O
n O
= O
954 B-intervention-participants
) O
and O
arm O
C O
( O
n O
= O
949 B-control-participants
) O
, O
with O
6 O
- O
year O
median O
follow O
- O
up O
and O
313 O
events O
, O
revealed O
5 B-outcome
- I-outcome
year I-outcome
DFS I-outcome
rates O
of O
80.1 B-iv-bin-percent
% I-iv-bin-percent
and O
84.4 B-cv-bin-percent
% I-cv-bin-percent
, O
respectively O
. O
There O
was O
an O
increase O
in O
DFS B-outcome
with O
concurrent O
trastuzumab O
and O
paclitaxel O
relative O
to O
sequential O
administration O
( O
arm O
C O
/ O
arm O
B O
HR O
, O
0.77 O
; O
99.9 O
% O
CI O
, O
0.53 O
to O
1.11 O
) O
, O
but O
the O
P O
value O
( O
.02 O
) O
did O
not O
cross O
the O
prespecified O
O'Brien O
- O
Fleming O
boundary O
( O
.00116 O
) O
for O
the O
interim O
analysis O
. O
DFS B-outcome
was O
significantly O
improved O
with O
52 O
weeks O
of O
trastuzumab O
added O
to O
adjuvant O
chemotherapy O
. O
On O
the O
basis O
of O
a O
positive O
risk O
- O
benefit O
ratio O
, O
we O
recommend O
that O
trastuzumab O
be O
incorporated O
into O
a O
concurrent O
regimen O
with O
taxane O
chemotherapy O
as O
an O
important O
standard O
- O
of O
- O
care O
treatment O
alternative O
to O
a O
sequential O
regimen O
. O

Uptake O
of O
a O
randomized O
breast O
cancer O
prevention O
trial O
comparing O
letrozole B-intervention
to O
placebo B-control
in O
BRCA1 O
/ O
2 O
mutations O
carriers O
: O
the O
LIBER O
trial O
. O
Women O
with O
germline O
BRCA1 O
or O
BRCA2 O
( O
BRCA1 O
/ O
2 O
) O
mutations O
are O
considered O
as O
an O
extreme O
risk O
population O
for O
developing O
breast O
cancer O
. O
Prophylactic O
mastectomy O
provides O
a O
valid O
option O
to O
reduce O
such O
risk O
, O
impacting O
however O
, O
the O
quality O
of O
life O
. O
Medical O
prevention O
by O
aromatase O
inhibitor O
that O
has O
also O
recently O
shown O
to O
have O
preventive O
effect O
may O
thus O
be O
considered O
as O
an O
alternative O
. O
LIBER O
is O
an O
ongoing O
double O
- O
blind O
, O
randomized O
phase O
III O
trial O
to O
evaluate O
the O
efficacy O
of O
5 O
- O
year O
letrozole O
versus O
placebo O
to O
decrease O
breast O
cancer O
incidence O
in O
post B-eligibility
- I-eligibility
menopausal I-eligibility
BRCA1 I-eligibility
/ I-eligibility
2 I-eligibility
mutation I-eligibility
carriers I-eligibility
( O
NCT00673335 O
) O
. O
We O
present O
data O
on O
the O
uptake O
of O
this O
trial O
. O
We O
compared O
characteristics O
of O
women O
in O
the O
LIBER O
trial O
( O
n O
 O
= O
 O
113 B-total-participants
) O
to O
those O
of O
women O
enrolled O
in O
the O
prospective O
ongoing O
national O
GENEPSO O
cohort O
( O
n O
 O
= O
 O
1,505 B-total-participants
) O
. O
Uptake O
was O
evaluated O
through O
a O
survey O
sent O
to O
all O
active O
centres O
, O
with O
responses O
obtained O
from O
17 O
to O
the O
20 O
( O
85 O
% O
) O
centres O
. O
According O
to O
the O
characteristics O
of O
the O
women O
enrolled O
in O
the O
GENEPSO O
cohort O
and O
the O
survey O
, O
approximately O
one O
- O
third O
of O
BRCA1 O
/ O
2 O
mutation O
carriers O
were O
eligible O
for O
the O
trial O
. O
Five B-total-participants
hundred I-total-participants
and I-total-participants
thirty I-total-participants
- I-total-participants
four I-total-participants
women O
eligible O
from O
chart O
review O
have O
been O
informed O
by O
mail O
about O
the O
prevention O
trial O
and O
were O
invited O
to O
an O
oral O
information O
by O
participating O
centres O
. O
Forty O
- O
four O
percentage O
of O
them O
came O
to O
the O
dedicated O
medical O
visit O
. O
Uptake B-outcome
of I-outcome
drug I-outcome
prevention I-outcome
trial I-outcome
was O
32 O
% O
among O
women O
informed O
orally O
and O
15 O
% O
of O
all O
the O
eligible O
women O
. O
The O
main O
reasons O
of O
refusal O
were O
: O
potential B-outcome
side I-outcome
effects I-outcome
, O
probability B-outcome
to I-outcome
receive I-outcome
the I-outcome
placebo I-outcome
and O
lack B-outcome
of I-outcome
support I-outcome
from I-outcome
their I-outcome
physicians I-outcome
. O
Additionally O
, O
we O
noticed O
that O
prior O
prophylactic O
oophorectomy O
and O
previous O
unilateral O
breast O
cancer O
were O
more O
frequent O
in O
women O
enrolled O
in O
the O
LIBER O
trial O
than O
in O
the O
French O
cohort O
( O
93 O
% O
vs. O
60 O
% O
and O
50 O
% O
vs. O
39 O
% O
, O
respectively O
) O
. O
Based O
on O
an O
overall O
15 O
% O
uptake B-outcome
among O
all O
eligible O
subjects O
, O
greater O
and O
wider O
information O
of O
the O
trial O
should O
be O
offered O
to O
women O
with O
BRCA1 O
/ O
2 O
mutation O
to O
improve O
recruitment O
. O
Women O
with O
previous O
unilateral O
breast O
cancer O
or O
prior O
prophylactic O
oophorectomy O
are O
more O
likely O
to O
enter O
a O
medical O
prevention O
trial O
. O

Manual B-intervention
lymph I-intervention
drainage I-intervention
when O
added O
to O
advice O
and O
exercise O
may O
not O
be O
effective O
in O
preventing O
lymphoedema B-condition
after O
surgery O
for O
breast O
cancer O
. O
Summary O
of O
: O
Devoogdt O
N O
et O
al O
( O
2011 O
) O
Effect O
of O
manual O
lymph O
drainage O
in O
addition O
to O
guidelines O
and O
exercise O
therapy O
on O
arm O
lymphoedema O
related O
to O
breast O
cancer O
: O
randomized O
controlled O
trial O
. O
BMJ O
343 O
: O
d5326 O
. O
[ O
Prepared O
by O
Nicholas O
Taylor O
, O
CAP O
Editor O
. O
] O
Does O
manual O
lymph O
drainage O
prevent O
lymphoedema O
in O
patients O
who O
have O
had O
surgery O
for O
breast O
cancer O
? O
. O
Randomised O
, O
controlled O
trial O
with O
concealed O
allocation O
and O
blinded O
outcome O
assessment O
. O
A O
multidisciplinary O
breast O
centre O
of O
a O
tertiary O
hospital O
in O
Belgium B-location
. O
Patients O
were O
eligible O
to O
be O
included O
if O
they B-eligibility
received I-eligibility
unilateral I-eligibility
surgery I-eligibility
with I-eligibility
axillary I-eligibility
node I-eligibility
dissection I-eligibility
for I-eligibility
breast I-eligibility
cancer I-eligibility
, O
and O
agreed O
to O
participate O
. O
Randomisation O
of O
160 B-total-participants
participants O
allocated O
79 B-intervention-participants
to O
the O
intervention O
group O
and O
81 B-control-participants
to O
a O
control B-control
group I-control
. O
Both O
groups O
received O
guidelines O
about O
the O
prevention O
of O
lymphoedema O
in O
the O
form O
of O
a O
brochure O
, O
and O
exercise O
therapy O
involving O
supervised O
individualised O
30 O
minute O
sessions O
- O
initially O
twice O
a O
week O
, O
reducing O
to O
once O
fortnightly O
as O
patients O
progressed O
. O
Participants O
in O
both O
groups O
were O
also O
asked O
to O
perform O
exercises O
at O
home O
twice O
/ O
day O
. O
In O
addition O
, O
the O
intervention O
group O
received O
40 O
sessions O
of O
manual O
lymph O
drainage O
over O
20 O
weeks O
with O
each O
session O
lasting O
30 O
minutes O
and O
performed O
by O
trained O
therapists O
. O
The O
primary O
outcomes O
were O
the O
cumulative B-outcome-measure
incidence I-outcome-measure
of I-outcome-measure
and I-outcome-measure
the I-outcome-measure
time I-outcome-measure
to I-outcome-measure
develop I-outcome-measure
arm I-outcome-measure
lymphoedema I-outcome-measure
( O
defined O
as O
a O
200 O
ml O
increase O
) O
as O
measured O
with O
the O
water O
displacement O
method O
with O
measures O
taken O
at O
baseline O
and O
1 O
, O
3 O
, O
6 O
, O
and O
12 O
months O
after O
surgery O
. O
Secondary O
outcome O
measures O
were O
lymphoedema B-outcome-measure
measured O
with O
the O
arm O
circumference O
method O
, O
health B-outcome-measure
- I-outcome-measure
related I-outcome-measure
quality I-outcome-measure
of I-outcome-measure
life I-outcome-measure
using I-outcome-measure
the I-outcome-measure
SF-36 I-outcome-measure
scale I-outcome-measure
, O
and O
a O
patient B-outcome-measure
reported I-outcome-measure
questionnaire I-outcome-measure
to O
score O
the O
presence O
of O
subjective O
arm O
lymphoedema O
. O
154 B-total-participants
participants O
( O
96 O
% O
) O
completed O
the O
study O
at O
12 O
months O
. O
At O
12 O
months O
the O
incidence B-outcome
of I-outcome
lymphoedema I-outcome
in O
the O
intervention O
group O
( O
n O
= O
18 B-iv-bin-abs
, O
24 B-iv-bin-percent
% I-iv-bin-percent
) O
was O
similar O
to O
the O
incidence O
of O
lymphoedema O
in O
the O
control O
group O
( O
n O
= O
15 B-cv-bin-abs
, O
19 B-cv-bin-percent
% I-cv-bin-percent
, O
OR O
1.3 O
, O
95 O
% O
CI O
0.6 O
to O
2.4 O
) O
; O
also O
there O
was O
no O
difference O
in O
incidence O
at O
3 O
or O
6 O
months O
. O
There O
was O
no O
difference O
between O
the O
groups O
in O
the O
time B-outcome
taken I-outcome
to I-outcome
develop I-outcome
lymphoedema I-outcome
, O
and O
no O
difference O
between O
the O
groups O
in O
any O
secondary O
outcome O
measure O
. O
The O
application O
of O
manual O
lymph O
drainage O
after O
axillary O
node O
dissection O
for O
breast O
cancer O
in O
addition O
to O
providing O
guidelines O
and O
exercise O
therapy O
did O
not O
prevent O
lymphoedema O
in O
the O
first O
year O
after O
surgery O
. O
  O

[ O
Clinical O
comparative O
study O
of O
neoadjuvant O
chemotherapy O
outcome O
in O
locally O
advanced O
breast O
cancer O
: O
docetaxel B-intervention
versus O
paclitaxel B-control
plus I-control
pirarubicin I-control
hydrochloride I-control
and I-control
cyclophosphamide I-control
] O
. O
To O
compare O
the O
efficacy O
and O
toxicity O
of O
neoadjuvant O
chemotherapy O
of O
docetaxel O
with O
paclitaxel O
plus O
pirarubicin O
hydrochloride O
( O
THP O
) O
and O
cyclophosphamide O
( O
CTX O
) O
in O
locally B-eligibility
advanced I-eligibility
breast I-eligibility
cancer I-eligibility
( I-eligibility
LABC I-eligibility
) I-eligibility
. O
A O
total O
of O
97 B-total-participants
LABC O
cases O
were O
randomly O
divided O
into O
2 O
groups O
: O
docetaxel O
group O
( O
n O
= O
49 B-intervention-participants
, O
taxotere O
plus O
THP O
& O
CTX O
) O
and O
paclitaxel O
group O
( O
n O
= O
48 B-control-participants
, O
paclitaxel O
plus O
THP O
& O
CTX O
) O
. O
Neoadjuvant O
chemotherapy O
had O
four O
cycles O
of O
21 O
days O
each O
. O
The O
clinical B-outcome
and O
pathological B-outcome
complete I-outcome
remission I-outcome
rates I-outcome
of O
docetaxel O
group O
was O
28.6 B-iv-bin-percent
% I-iv-bin-percent
and O
26.5 B-iv-bin-percent
% I-iv-bin-percent
respectively O
. O
They O
were O
significantly O
higher O
than O
those O
of O
paclitaxel O
group O
( O
10.4 B-cv-bin-percent
% I-cv-bin-percent
and O
8.3 B-cv-bin-percent
% I-cv-bin-percent
) O
. O
Furthermore O
the O
pathological B-outcome
negative I-outcome
rate I-outcome
of I-outcome
regional I-outcome
lymph I-outcome
node I-outcome
in O
docetaxel O
group O
was O
also O
significantly O
higher O
than O
that O
of O
paclitaxel O
group O
( O
40.6 B-iv-bin-percent
% I-iv-bin-percent
vs. O
12.9 B-cv-bin-percent
% I-cv-bin-percent
) O
. O
However O
, O
grade B-outcome
III I-outcome
- I-outcome
IV I-outcome
blood I-outcome
system I-outcome
toxic I-outcome
reaction I-outcome
was O
found O
in O
71.4 B-iv-bin-percent
% I-iv-bin-percent
cases O
, O
grade B-outcome
II I-outcome
- I-outcome
IV I-outcome
liver I-outcome
dysfunction I-outcome
in O
53.1 B-iv-bin-percent
% I-iv-bin-percent
cases O
and O
edema B-outcome
in O
24.5 B-iv-bin-percent
% I-iv-bin-percent
cases O
among O
docetaxel O
group O
. O
They O
were O
higher O
than O
those O
among O
paclitaxel O
group O
( O
46.9 B-cv-bin-percent
% I-cv-bin-percent
, O
27.1 B-cv-bin-percent
% I-cv-bin-percent
& O
4.2 B-cv-bin-percent
% I-cv-bin-percent
) O
. O
Compared O
with O
paclitaxel O
, O
the O
combined O
regimen O
of O
docetaxel O
plus O
THP O
and O
CTX O
offers O
better O
outcomes O
for O
locally O
advanced O
breast O
cancer O
. O

Adjuvant B-intervention
capecitabine I-intervention
, I-intervention
docetaxel I-intervention
, I-intervention
cyclophosphamide I-intervention
, I-intervention
and I-intervention
epirubicin I-intervention
for O
early O
breast O
cancer O
: O
final O
analysis O
of O
the O
randomized O
FinXX O
trial O
. O
Capecitabine O
is O
an O
active O
agent O
in O
the O
treatment O
of O
breast O
cancer O
. O
It O
is O
not O
known O
whether O
integration O
of O
capecitabine O
into O
an O
adjuvant O
regimen O
that O
contains O
a O
taxane O
, O
an O
anthracycline O
, O
and O
cyclophosphamide O
improves O
outcome O
in O
early O
breast O
cancer O
. O
Women B-eligibility
with I-eligibility
axillary I-eligibility
node I-eligibility
- I-eligibility
positive I-eligibility
or I-eligibility
high I-eligibility
- I-eligibility
risk I-eligibility
node I-eligibility
- I-eligibility
negative I-eligibility
breast I-eligibility
cancer I-eligibility
were O
randomly O
assigned O
to O
receive O
either O
three O
cycles O
of O
docetaxel O
and O
capecitabine O
( O
TX O
) O
followed O
by O
three O
cycles O
of O
cyclophosphamide O
, O
epirubicin O
, O
and O
capecitabine O
( O
CEX O
; O
n O
= O
753 B-intervention-participants
) O
or O
three O
cycles O
of O
docetaxel O
( O
T O
) O
followed O
by O
three O
cycles O
of O
cyclophosphamide O
, O
epirubicin O
, O
and O
fluorouracil O
( O
CEF B-control
; O
n O
= O
747 B-control-participants
) O
. O
The O
primary O
end O
point O
was O
recurrence B-outcome-measure
- I-outcome-measure
free I-outcome-measure
survival I-outcome-measure
( I-outcome-measure
RFS I-outcome-measure
) I-outcome-measure
. O
During O
a O
median O
follow O
- O
up O
time O
of O
59 O
months O
, O
214 O
RFS B-outcome
events I-outcome
occurred O
( O
local B-outcome
or I-outcome
distant I-outcome
recurrences I-outcome
or I-outcome
deaths I-outcome
; O
TX O
/ O
CEX O
, O
n O
= O
96 B-iv-bin-abs
; O
T O
/ O
CEF O
, O
n O
= O
118 B-cv-bin-abs
) O
. O
RFS B-outcome
was O
not O
significantly O
different O
between O
the O
groups O
( O
hazard O
ratio O
[ O
HR O
] O
, O
0.79 O
; O
95 O
% O
CI O
, O
0.60 O
to O
1.04 O
; O
P O
= O
.087 O
; O
5 B-outcome
- I-outcome
year I-outcome
RFS I-outcome
, O
86.6 B-iv-bin-percent
% I-iv-bin-percent
for O
TX O
/ O
CEX O
v O
84.1 B-cv-bin-percent
% I-cv-bin-percent
for O
T O
/ O
CEF O
) O
. O
Fifty B-iv-bin-abs
- I-iv-bin-abs
six I-iv-bin-abs
patients O
assigned O
to O
TX O
/ O
CEX O
died B-outcome
during O
the O
follow O
- O
up O
compared O
with O
75 B-cv-bin-abs
of O
patients O
assigned O
to O
T O
/ O
CEF O
( O
HR O
, O
0.73 O
; O
95 O
% O
CI O
, O
0.52 O
to O
1.04 O
; O
P O
= O
.080 O
) O
. O
In O
exploratory O
analyses O
, O
TX O
/ O
CEX O
improved O
breast B-outcome
cancer I-outcome
- I-outcome
specific I-outcome
survival I-outcome
( O
HR O
, O
0.64 O
; O
95 O
% O
CI O
, O
0.44 O
to O
0.95 O
; O
P O
= O
.027 O
) O
and O
RFS B-outcome
in O
women O
with O
triple O
- O
negative O
disease O
and O
in O
women O
who O
had O
more O
than O
three O
metastatic O
axillary O
lymph O
nodes O
at O
the O
time O
of O
diagnosis O
. O
We O
detected O
little O
severe O
late O
toxicity B-outcome
. O
Integration O
of O
capecitabine O
into O
a O
regimen O
that O
contains O
docetaxel O
, O
epirubicin O
, O
and O
cyclophosphamide O
did O
not O
improve O
RFS O
significantly O
compared O
with O
a O
similar O
regimen O
without O
capecitabine O
. O

A O
randomized O
trial O
of O
a O
telephone B-intervention
- I-intervention
delivered I-intervention
exercise I-intervention
intervention O
for O
non O
- O
urban O
dwelling O
women O
newly O
diagnosed O
with O
breast O
cancer O
: O
exercise O
for O
health O
. O
Physical O
activity O
is O
important O
following O
breast O
cancer O
. O
Trials O
of O
non O
- O
face O
- O
to O
- O
face O
interventions O
are O
needed O
to O
assist O
in O
reaching O
women O
living O
outside O
major O
metropolitan O
areas O
. O
This O
study O
seeks O
to O
evaluate O
the O
feasibility O
and O
effectiveness O
of O
a O
telephone O
- O
delivered O
, O
mixed O
aerobic O
and O
resistance O
exercise O
intervention O
for O
non O
- O
urban O
Australian B-ethinicity
women B-eligibility
with I-eligibility
breast I-eligibility
cancer I-eligibility
. O
A O
randomized O
controlled O
trial O
comparing O
an O
8 O
- O
month O
intervention O
delivered O
by O
exercise O
physiologists O
( O
n O
= O
73 B-intervention-participants
) O
to O
usual B-control
care I-control
( O
n O
= O
70 B-control-participants
) O
. O
Sixty O
- O
one O
percent O
recruitment O
rate O
and O
96 O
% O
retention B-outcome
at O
12 O
months O
; O
79 O
% O
of O
women O
in O
the O
intervention O
group O
received O
at O
least O
75 O
% O
of O
calls O
; O
odds O
( O
OR O
, O
95 O
% O
CI O
) O
of O
meeting B-outcome
intervention I-outcome
targets I-outcome
favored O
the O
intervention O
group O
for O
resistance O
training O
( O
OR O
3.2 O
; O
1.2 O
, O
8.9 O
) O
and O
aerobic O
( O
OR O
2.1 O
; O
0.8 O
, O
5.5 O
) O
activity O
. O
Given O
the O
limited O
availability O
of O
physical O
activity O
programs O
for O
non O
- O
urban O
women O
with O
breast O
cancer O
, O
results O
provide O
strong O
support O
for O
feasibility O
and O
modest O
support O
for O
the O
efficacy O
of O
telephone O
- O
delivered O
interventions O
. O

Outcomes O
of O
Japanese B-ethinicity
breast O
cancer O
patients O
treated O
with O
pre O
- O
operative O
and O
post O
- O
operative O
anastrozole B-intervention
or O
tamoxifen B-control
. O
The O
present O
study O
examined O
long O
- O
term O
efficacy O
outcomes O
in O
a O
subgroup O
of O
postmenopausal O
, O
estrogen O
receptor O
- O
positive O
Japanese O
breast O
cancer O
patients O
from O
the O
Pre O
- O
Operative O
" O
Arimidex O
" O
Compared O
with O
Tamoxifen O
trial O
, O
following O
pre O
- O
operative O
( O
3 O
months O
) O
and O
post O
- O
operative O
( O
5 O
years O
) O
adjuvant O
treatment O
with O
either O
anastrozole O
or O
tamoxifen O
. O
Patients B-eligibility
with I-eligibility
large I-eligibility
, I-eligibility
potentially I-eligibility
operable I-eligibility
, I-eligibility
locally I-eligibility
- I-eligibility
advanced I-eligibility
breast I-eligibility
cancer I-eligibility
were O
randomized O
to O
receive O
anastrozole O
( O
1 O
mg O
/ O
day O
) O
plus O
tamoxifen O
placebo O
or O
tamoxifen O
( O
20 O
mg O
/ O
day O
) O
plus O
anastrozole O
placebo O
pre O
- O
operatively O
. O
After O
surgery O
at O
3 O
months O
, O
patients O
continued O
on O
the O
same O
study O
medication O
as O
adjuvant O
therapy O
for O
up O
to O
5 O
years O
or O
until O
recurrence O
, O
intolerable O
toxicity O
or O
withdrawal O
of O
patient O
consent O
. O
Recurrence O
- O
free O
survival O
and O
overall O
survival O
were O
measured O
from O
the O
date O
of O
randomization O
to O
the O
date O
of O
recurrence O
or O
death O
, O
whichever O
occurred O
first O
. O
Patients O
were O
monitored O
for O
adverse O
events O
throughout O
the O
study O
period O
and O
up O
to O
30 O
days O
following O
administration O
of O
the O
last O
study O
medication O
. O
During O
post O
- O
operative O
adjuvant O
therapy O
, O
4 B-iv-bin-abs
/ O
48 B-intervention-participants
( O
8 B-iv-bin-percent
% I-iv-bin-percent
) O
anastrozole O
and O
25 B-cv-bin-abs
/ O
49 B-control-participants
( O
51 B-cv-bin-percent
% I-cv-bin-percent
) O
tamoxifen O
patients O
experienced O
recurrence B-outcome
. O
There O
was O
a O
significant O
difference O
in O
recurrence B-outcome
- I-outcome
free I-outcome
survival I-outcome
between O
the O
two O
groups O
( O
hazard O
ratio O
0.14 O
; O
95 O
% O
confidence O
interval O
0.05 O
- O
0.41 O
; O
P O
= O
0.0003 O
) O
. O
There O
was O
a O
significant O
increase O
in O
overall B-outcome
survival I-outcome
with O
anastrozole O
( O
0.21 O
; O
0.05 O
- O
0.96 O
; O
P O
= O
0.0436 O
) O
and O
there O
were O
2 B-iv-bin-abs
/ O
48 B-intervention-participants
( O
4 B-iv-bin-percent
% I-iv-bin-percent
) O
and O
10 B-cv-bin-abs
/ O
49 B-control-participants
( O
20 B-cv-bin-percent
% I-cv-bin-percent
) O
deaths B-outcome
with O
anastrozole O
and O
tamoxifen O
, O
respectively O
. O
Most O
patients O
responding O
to O
pre O
- O
operative O
therapy O
remained O
recurrence B-outcome
- I-outcome
free I-outcome
. O
Sequential O
pre O
- O
operative O
/ O
post O
- O
operative O
treatment O
with O
anastrozole O
resulted O
in O
lower O
recurrence O
and O
death O
rates O
, O
compared O
with O
tamoxifen O
. O

Randomized O
trial O
of O
antimicrobial B-intervention
- I-intervention
coated I-intervention
sutures I-intervention
to O
prevent O
surgical B-condition
site I-condition
infection I-condition
after O
breast O
cancer O
surgery O
. O
Surgical O
site O
infection O
( O
SSI O
) O
is O
the O
fourth O
commonest O
healthcare O
- O
associated O
infection O
and O
complicates O
at O
least O
5 O
% O
of O
open O
operations O
. O
In O
a O
randomized O
clinical O
trial O
, O
antimicrobial O
- O
coated O
sutures O
were O
compared O
with O
their O
conventional O
counterparts O
, O
polyglactin O
and O
poliglecaprone O
, O
for O
skin O
closure O
after O
breast O
cancer O
surgery O
to O
assess O
their O
role O
in O
reducing O
the O
rate O
of O
SSI O
. O
Between O
November O
2008 O
and O
February O
2011 O
, O
150 B-total-participants
female O
patients O
presenting O
with O
breast O
cancer O
to O
a O
single O
center O
were O
randomized O
to O
skin O
closure O
with O
antimicrobial O
- O
coated O
or O
plain B-control
sutures I-control
. O
Postoperatively O
, O
SSI O
was O
defined O
using O
the O
U.S. O
Centers O
for O
Disease O
Control O
and O
Prevention O
( O
CDC O
) O
definitions O
and O
scored O
using O
the O
ASEPSIS O
or O
Southampton O
systems O
by O
trained O
, O
blinded O
observers O
with O
close O
post O
- O
discharge O
surveillance O
and O
patient O
diaries O
. O
Surgeons O
and O
patients O
were O
blinded O
to O
the O
type O
of O
suture O
used O
. O
Using O
CDC O
criteria O
, O
the O
overall B-outcome
rate I-outcome
of I-outcome
SSI I-outcome
was O
18.9 O
% O
at O
six O
weeks O
. O
Six O
patients O
( O
4.7 O
% O
) O
needed B-outcome
intervention I-outcome
or I-outcome
readmission I-outcome
for I-outcome
SSI I-outcome
. O
Skin O
closure O
with O
antimicrobial O
sutures O
showed O
a O
non O
- O
statistically O
significant O
reduction B-outcome
in I-outcome
the I-outcome
SSI I-outcome
rate I-outcome
, O
to O
15.2 B-iv-bin-percent
% I-iv-bin-percent
, O
compared O
with O
conventional O
sutures O
( O
22.9 B-cv-bin-percent
% I-cv-bin-percent
) O
. O
A O
uniform O
tendency O
for O
fewer O
SSIs B-outcome
in O
the O
antimicrobial O
- O
coated O
suture O
group O
was O
found O
using O
ASEPSIS O
and O
Southampton O
scores O
, O
but O
again O
, O
the O
difference O
was O
not O
statistically O
significant O
. O
The O
previously O
reported O
high O
rate O
of O
SSI O
related O
to O
breast O
surgery O
was O
confirmed O
. O
Using O
statistical O
modeling O
and O
earlier O
reports O
, O
the O
study O
was O
powered O
to O
show O
a O
difference O
using O
ASEPSIS O
scores O
, O
but O
the O
modification O
used O
in O
this O
trial O
failed O
to O
find O
a O
difference O
. O
Finding O
a O
statistically O
significant O
difference O
would O
have O
needed O
two O
to O
three O
times O
the O
number O
of O
patients O
recruited O
. O
Further O
evaluation O
of O
antimicrobial O
- O
coated O
sutures O
is O
merited O
, O
particularly O
if O
used O
as O
part O
of O
a O
care O
bundle O
to O
reduce O
SSI O
after O
breast O
cancer O
surgery O
. O

Preventing O
seroma B-condition
formation I-condition
after O
axillary O
dissection O
for O
breast O
cancer O
: O
a O
randomized O
clinical O
trial O
. O
Seroma O
formation O
after O
axillary O
dissection O
remains O
the O
most O
common O
early O
sequel O
to O
breast O
cancer O
surgery O
. O
Different O
surgical O
approaches O
have O
been O
performed O
to O
reduce O
seroma O
collection O
. O
Therefore O
, O
we O
aimed O
to O
assess O
the O
outcome O
of O
patients O
operated O
on O
using O
an O
ultrasound O
scalpel O
according O
to O
a O
standardized O
operative O
technique O
before O
accepting O
it O
as O
a O
routine O
procedure O
. O
A O
randomized O
controlled O
trial O
was O
designed O
to O
compare O
the O
outcome O
of O
patients B-eligibility
undergoing I-eligibility
breast I-eligibility
surgery I-eligibility
and I-eligibility
axillary I-eligibility
dissection I-eligibility
using O
either O
standard B-intervention
scalpel I-intervention
blades I-intervention
, I-intervention
scissors I-intervention
, I-intervention
ligations I-intervention
, I-intervention
and I-intervention
electrocautery I-intervention
or O
the O
ultrasound B-control
scalpel I-control
only I-control
. O
Each O
arm O
of O
the O
trial O
consisted O
of O
30 B-intervention-participants
patients O
. O
A O
statistically O
significant O
benefit O
in O
terms O
of O
axillary B-outcome
and I-outcome
chest I-outcome
wall I-outcome
drainage I-outcome
volume I-outcome
, O
the O
number B-outcome
of I-outcome
axilla I-outcome
seromas I-outcome
, O
intraoperative B-outcome
bleeding I-outcome
, O
and O
hospitalization B-outcome
stay I-outcome
was O
recorded O
in O
the O
harmonic O
scalpel O
group O
. O
No O
significant O
differences O
were O
found O
between O
the O
2 O
groups O
in O
terms O
of O
operative B-outcome
time I-outcome
. O
Finally O
, O
no B-outcome
postoperative I-outcome
hematoma I-outcome
, I-outcome
wound I-outcome
infections I-outcome
, I-outcome
and I-outcome
chest I-outcome
wall I-outcome
seroma I-outcome
were O
observed O
. O
The O
use O
of O
the O
harmonic O
scalpel O
was O
shown O
to O
reduce O
the O
magnitude B-outcome
of I-outcome
seromas I-outcome
in I-outcome
axilla I-outcome
and I-outcome
hospitalization I-outcome
stay I-outcome
. O
The O
harmonic O
scalpel O
can O
be O
used O
alone O
in O
axillary O
dissection O
with O
a O
safe O
and O
effective O
hemostasis O
. O
Our O
results O
must O
be O
confirmed O
by O
larger O
series O
. O
  O

The O
protective O
effect O
of O
zoledronic B-intervention
acid I-intervention
on O
bone B-condition
loss I-condition
in O
postmenopausal O
women O
with O
early O
breast O
cancer O
treated O
with O
sequential O
tamoxifen O
and O
letrozole O
: O
a O
prospective O
, O
randomized O
, O
phase O
II O
trial O
. O
This O
study O
reports O
the O
efficacy O
and O
safety O
of O
zoledronic O
acid O
( O
ZOL O
) O
in O
preventing O
bone O
loss O
in O
postmenopausal O
patients O
receiving O
an O
aromatase O
inhibitor O
( O
AI O
) O
following O
tamoxifen O
. O
Postmenopausal B-eligibility
patients I-eligibility
with I-eligibility
stage I-eligibility
I I-eligibility
- I-eligibility
III I-eligibility
hormone I-eligibility
receptor I-eligibility
- I-eligibility
positive I-eligibility
breast I-eligibility
cancer I-eligibility
who I-eligibility
received I-eligibility
tamoxifen I-eligibility
for I-eligibility
2.5 I-eligibility
- I-eligibility
3 I-eligibility
years I-eligibility
were O
randomized O
to O
receive O
letrozole B-intervention
( O
2.5 O
mg O
/ O
day O
) O
with O
( O
n O
= O
47 B-intervention-participants
) O
or O
without B-control
( O
n O
= O
43 B-control-participants
) O
ZOL O
( O
4 O
mg O
i.v O
. O
every O
6 O
months O
) O
for O
2 O
years O
. O
The O
primary O
endpoint O
was O
percent B-outcome-measure
change I-outcome-measure
from I-outcome-measure
baseline I-outcome-measure
in I-outcome-measure
lumbar I-outcome-measure
spine I-outcome-measure
( I-outcome-measure
LS I-outcome-measure
) I-outcome-measure
bone I-outcome-measure
mineral I-outcome-measure
density I-outcome-measure
( I-outcome-measure
BMD I-outcome-measure
) I-outcome-measure
up O
to O
60 O
months O
. O
Ninety B-total-participants
patients O
( O
86 B-total-participants
evaluable O
) O
with O
a O
median O
age O
of O
59 B-age
years I-age
( I-age
42.9 I-age
- I-age
83.6 I-age
) I-age
, O
50 O
/ O
86 O
of O
whom O
had O
previously O
been O
treated O
with O
chemotherapy O
, O
were O
followed O
for O
a O
median O
time O
of O
41.4 O
months O
. O
While O
the O
control O
group O
showed O
a O
significant O
decrease O
in O
LS B-outcome
T I-outcome
- I-outcome
score I-outcome
( O
p O
= O
0.0005 O
) O
, O
the O
ZOL O
group O
presented O
an O
increase O
over O
time O
( O
p O
= O
0.0143 O
) O
. O
Change B-outcome
over I-outcome
time I-outcome
in I-outcome
LS I-outcome
T I-outcome
- I-outcome
score I-outcome
was O
significantly O
different O
between O
groups O
, O
favoring O
ZOL O
( O
p O
< O
0.0001 O
at O
24 O
and O
48 O
months O
) O
. O
No O
fractures B-outcome
, I-outcome
renal I-outcome
dysfunction I-outcome
or I-outcome
osteonecrosis I-outcome
of I-outcome
the I-outcome
jaw I-outcome
were O
reported O
. O
The O
toxicity B-outcome
profile I-outcome
was O
similar O
to O
those O
previously O
reported O
for O
each O
drug O
. O
The O
addition O
of O
ZOL O
to O
letrozole O
was O
safe O
and O
efficacious O
in O
maintaining O
LS O
BMD O
in O
postmenopausal O
patients O
with O
hormone O
receptor O
- O
positive O
breast O
cancer O
and O
who O
were O
receiving O
letrozole O
following O
2.5 O
- O
3 O
years O
of O
tamoxifen O
. O
  O

A O
randomized O
trial O
of O
exercise O
on O
well B-condition
- I-condition
being I-condition
and I-condition
function I-condition
following O
breast O
cancer O
surgery O
: O
the O
RESTORE O
trial O
. O
This O
study O
aimed O
to O
determine O
the O
effect O
of O
a O
moderate O
, O
tailored O
exercise O
program O
on O
health O
- O
related O
quality O
of O
life O
, O
physical O
function O
, O
and O
arm O
volume O
in O
women O
receiving O
treatment O
for O
nonmetastatic O
breast O
cancer O
. O
Women B-eligibility
who I-eligibility
were I-eligibility
within I-eligibility
4 I-eligibility
- I-eligibility
12 I-eligibility
weeks I-eligibility
of I-eligibility
surgery I-eligibility
for I-eligibility
stage I-eligibility
I I-eligibility
- I-eligibility
III I-eligibility
breast I-eligibility
cancer I-eligibility
were O
randomized O
to O
center O
- O
based O
exercise B-intervention
and I-intervention
lymphedema I-intervention
education I-intervention
intervention O
or O
patient B-control
education I-control
. O
Functional O
assessment O
of O
cancer O
therapy O
- O
breast O
cancer O
( O
FACT O
- O
B O
) O
, O
6 O
- O
min O
walk O
, O
and O
arm O
volume O
were O
performed O
at O
3 O
- O
month O
intervals O
through O
18 O
months O
. O
Repeated O
measures O
analysis O
of O
covariance O
was O
used O
to O
model O
the O
total O
meters O
walked O
over O
time O
, O
FACT O
- O
B O
scores O
, O
and O
arm O
volume O
. O
Models O
were O
adjusted O
for O
baseline O
measurement O
, O
baseline O
affected O
arm O
volume O
, O
number O
of O
nodes O
removed O
, O
age O
, O
self O
- O
reported O
symptoms O
, O
baseline O
SF-12 O
mental O
and O
physical O
component O
scores O
, O
visit O
, O
and O
treatment O
group O
. O
Of O
the O
recruited O
104 B-total-participants
women O
, O
82 B-total-participants
completed O
all O
18 O
months O
. O
Mean O
age O
( O
range O
) O
was O
53.6 B-age
( I-age
32 I-age
- I-age
82 I-age
) I-age
years I-age
; O
88 O
% O
were O
Caucasian B-ethinicity
; O
45 O
% O
were O
employed O
full O
time O
; O
44 O
% O
were O
overweight O
; O
and O
28 O
% O
obese O
. O
Approximately O
, O
46 O
% O
had O
breast O
- O
conserving O
surgery O
; O
79 O
% O
had O
axillary O
node O
dissection O
; O
59 O
% O
received O
chemotherapy O
; O
and O
64 O
% O
received O
radiation O
. O
The O
intervention O
resulted O
in O
an O
average O
increase O
of O
34.3 O
ml O
( O
SD O
 O
= O
 O
12.8 O
) O
versus O
patient O
education O
( O
p O
 O
= O
 O
0.01 O
) O
. O
Changes B-outcome
in I-outcome
FACT I-outcome
- I-outcome
B I-outcome
scores I-outcome
and O
arm B-outcome
volumes I-outcome
were O
not O
significantly O
different O
. O
With O
this O
early O
exercise O
intervention O
after O
breast O
cancer O
diagnosis O
, O
a O
significant O
improvement O
was O
achieved O
in O
physical B-outcome
function I-outcome
, O
with O
no O
decline O
in O
health O
- O
related O
quality B-outcome
of I-outcome
life I-outcome
or O
detrimental O
effect O
on O
arm B-outcome
volume I-outcome
. O
Starting O
a O
supervised O
exercise O
regimen O
that O
is O
tailored O
to O
an O
individual O
's O
strength O
and O
stamina O
within O
3 O
months O
following O
breast O
cancer O
surgery O
appears O
safe O
and O
may O
hasten O
improvements O
in O
physical O
functioning O
. O

Prognostic O
effect O
of O
circulating O
adiponectin O
in O
a O
randomized O
2 O
x O
2 O
trial O
of O
low O
- O
dose O
tamoxifen B-intervention
and I-intervention
fenretinide I-intervention
in O
premenopausal O
women O
at O
risk O
for O
breast O
cancer O
. O
Adipokines O
are O
linked O
to O
obesity O
and O
insulin O
sensitivity O
and O
have O
recently O
been O
related O
to O
breast O
cancer O
risk O
and O
prognosis O
. O
We O
investigated O
the O
associations O
of O
plasma O
leptin O
and O
adiponectin O
with O
mammographic O
density O
and O
disease O
status O
and O
assessed O
their O
prognostic O
effect O
on O
recurrence O
- O
free O
survival O
in O
premenopausal B-eligibility
women I-eligibility
at I-eligibility
risk I-eligibility
for I-eligibility
breast I-eligibility
cancer I-eligibility
. O
We O
measured O
circulating O
lipids O
, O
insulin O
- O
like O
growth O
factor O
1 O
, O
glucose O
, O
insulin O
and O
insulin O
sensitivity O
( O
calculated O
by O
homeostasis O
model O
assessment O
[ O
HOMA O
] O
index O
) O
, O
leptin O
, O
adiponectin O
, O
and O
leptin O
- O
to O
- O
adiponectin O
ratio O
in O
235 B-total-participants
premenopausal B-eligibility
women I-eligibility
with I-eligibility
pT1mic I-eligibility
/ I-eligibility
pT1a I-eligibility
breast I-eligibility
cancer I-eligibility
( I-eligibility
n I-eligibility
= I-eligibility
21 I-eligibility
) I-eligibility
, I-eligibility
intraepithelial I-eligibility
neoplasia I-eligibility
( I-eligibility
n I-eligibility
= I-eligibility
160 I-eligibility
) I-eligibility
, I-eligibility
or I-eligibility
5 I-eligibility
- I-eligibility
year I-eligibility
Gail I-eligibility
risk I-eligibility
of I-eligibility
1.3 I-eligibility
% I-eligibility
or I-eligibility
greater I-eligibility
( O
n O
= O
54 O
) O
who O
participated O
in O
a O
2 O
 O
 O
2 O
trial O
of O
low O
- O
dose O
tamoxifen O
, O
fenretinide O
, O
both O
agents O
, O
or O
placebo B-control
over O
a O
2 O
- O
year O
period O
. O
At O
baseline O
, O
adiponectin O
levels O
were O
directly O
associated O
with O
mammographic B-outcome
density I-outcome
and I-outcome
HDL I-outcome
cholesterol I-outcome
and O
negatively O
associated O
with O
leptin O
, O
leptin O
- O
to O
- O
adiponectin O
ratio O
, O
body O
mass O
index O
( O
BMI O
) O
, O
and O
HOMA O
index O
. O
Median O
adiponectin B-outcome
levels I-outcome
were O
lower O
in O
affected O
than O
in O
unaffected O
women O
( O
P O
= O
.006 O
) O
. O
After O
a O
median O
of O
7.2 O
years O
and O
total O
of O
57 O
breast B-outcome
neoplastic I-outcome
events I-outcome
, O
there O
was O
a O
12 O
% O
reduction O
in O
the O
risk B-outcome
of I-outcome
breast I-outcome
neoplastic I-outcome
events I-outcome
per O
unit O
increase O
of O
adiponectin O
( O
adjusted O
hazard O
ratio O
, O
0.88 O
; O
95 O
% O
CI O
, O
0.81 O
to O
0.96 O
; O
P O
= O
.03 O
) O
. O
There O
was O
no O
interaction O
between O
treatment O
and O
adiponectin B-outcome
levels I-outcome
. O
Low O
adiponectin O
levels O
are O
associated O
with O
a O
history O
of O
prior O
intraepithelial O
neoplasia O
or O
pT1mic O
/ O
pT1a O
breast O
cancer O
and O
higher O
risk O
of O
second O
breast O
neoplastic O
events O
in O
premenopausal O
women O
. O
The O
associations O
are O
independent O
of O
BMI O
, O
mammographic O
density O
, O
and O
treatment O
. O
Our O
findings O
support O
the O
role O
of O
adiponectin O
as O
a O
potential O
target O
for O
premenopausal O
breast O
cancer O
prevention O
and O
treatment O
. O

Topical B-intervention
hyaluronic I-intervention
acid I-intervention
vs. O
standard B-control
of I-control
care I-control
for O
the O
prevention O
of O
radiation B-condition
dermatitis I-condition
after O
adjuvant O
radiotherapy O
for O
breast O
cancer O
: O
single O
- O
blind O
randomized O
phase O
III O
clinical O
trial O
. O
To O
determine O
the O
efficacy O
of O
an O
emulsion O
containing O
hyaluronic O
acid O
to O
reduce O
the O
development O
of O
 O
Grade O
2 O
radiation O
dermatitis O
after O
adjuvant O
breast O
radiation O
compared O
with O
best O
supportive O
care O
. O
Women B-eligibility
with I-eligibility
breast I-eligibility
cancer I-eligibility
who I-eligibility
had I-eligibility
undergone I-eligibility
lumpectomy I-eligibility
and I-eligibility
were I-eligibility
to I-eligibility
receive I-eligibility
whole I-eligibility
- I-eligibility
breast I-eligibility
radiotherapy I-eligibility
to I-eligibility
50 I-eligibility
Gy I-eligibility
with I-eligibility
a I-eligibility
10- I-eligibility
to I-eligibility
16 I-eligibility
- I-eligibility
Gy I-eligibility
surgical I-eligibility
bed I-eligibility
boost I-eligibility
were O
enrolled O
in O
a O
prospective O
randomized O
trial O
to O
compare O
the O
effectiveness O
of O
a O
hyaluronic O
acid O
- O
based O
gel O
( O
RadiaPlex O
) O
and O
a O
petrolatum O
- O
based O
gel O
( O
Aquaphor O
) O
for O
preventing O
the O
development O
of O
dermatitis O
. O
Each O
patient O
was O
randomly O
assigned O
to O
use O
hyaluronic O
acid O
gel O
on O
the O
medial O
half O
or O
the O
lateral O
half O
of O
the O
irradiated O
breast O
and O
to O
use O
the O
control O
gel O
on O
the O
other O
half O
. O
Dermatitis O
was O
graded O
weekly O
according O
to O
the O
Common O
Terminology O
Criteria O
v3.0 O
by O
the O
treating O
physician O
, O
who O
was O
blinded O
as O
to O
which O
gel O
was O
used O
on O
which O
area O
of O
the O
breast O
. O
The O
primary O
endpoint O
was O
development B-outcome-measure
of I-outcome-measure
 I-outcome-measure
Grade I-outcome-measure
2 I-outcome-measure
dermatitis I-outcome-measure
. O
The O
study O
closed O
early O
on O
the O
basis O
of O
a O
recommendation O
from O
the O
Data O
and O
Safety O
Monitoring O
Board O
after O
74 B-total-participants
of O
the O
planned O
92 O
patients O
were O
enrolled O
. O
Breast O
skin O
treated O
with O
the O
hyaluronic O
acid O
gel O
developed O
a O
significantly O
higher O
rate B-outcome
of I-outcome
 I-outcome
Grade I-outcome
2 I-outcome
dermatitis I-outcome
than O
did O
skin O
treated O
with O
petrolatum O
gel O
: O
61.5 B-iv-bin-percent
% I-iv-bin-percent
( O
40 B-iv-bin-abs
/ O
65 B-intervention-participants
) O
vs. O
47.7 B-cv-bin-percent
% I-cv-bin-percent
( O
31 B-cv-bin-abs
/ O
65 B-control-participants
) O
( O
p O
= O
0.027 O
) O
. O
Only O
one B-iv-bin-abs
patient O
developed O
Grade B-outcome
3 I-outcome
dermatitis I-outcome
using O
either O
gel O
. O
A O
higher O
proportion O
of O
patients O
had O
worse B-outcome
dermatitis I-outcome
in O
the O
breast O
segment O
treated O
with O
hyaluronic O
acid O
gel O
than O
in O
that O
treated O
with O
petrolatum O
gel O
at O
the O
end O
of O
radiotherapy O
( O
42 B-iv-bin-percent
% I-iv-bin-percent
vs. O
14 B-cv-bin-percent
% I-cv-bin-percent
, O
p O
= O
0.003 O
) O
. O
We O
found O
no O
benefit O
from O
the O
use O
of O
a O
topical O
hyaluronic O
acid O
- O
based O
gel O
for O
reducing O
the O
development O
of O
 O
Grade O
2 O
dermatitis O
after O
adjuvant O
radiotherapy O
for O
breast O
cancer O
. O
Additional O
studies O
are O
needed O
to O
determine O
the O
efficacy O
of O
hyaluronic O
acid O
- O
based O
gel O
in O
controlling O
radiation O
dermatitis O
symptoms O
after O
they O
develop O
. O
  O

Safety O
of O
bevacizumab B-intervention
in O
metastatic B-eligibility
breast I-eligibility
cancer I-eligibility
patients I-eligibility
undergoing I-eligibility
surgery I-eligibility
. O
Evaluate O
the O
safety O
of O
surgery O
in O
relation O
to O
bevacizumab O
in O
the O
first O
- O
line O
treatment O
of O
metastatic O
breast O
cancer O
( O
mBC O
) O
in O
two O
international O
trials O
. O
The O
incidence O
, O
type O
and O
timing O
of O
post O
- O
surgical O
bleeding O
events O
and O
wound O
- O
healing O
complications O
were O
assessed O
in O
surgical O
patients O
in O
the O
AVastin O
And O
DOcetaxel O
( O
AVADO O
) O
( O
NCT00333775 O
) O
and O
Avastin O
THErapy O
for O
advaNced O
breAst O
cancer O
( O
ATHENA O
) O
( O
NCT00448591 O
) O
trials O
. O
Both O
study O
protocols O
followed O
recommendations O
to O
withhold O
bevacizumab O
for O
at O
least O
6 O
weeks O
before O
elective O
surgery O
and O
to O
wait O
28 O
days O
( O
or O
until O
the O
wound O
was O
fully O
healed O
) O
after O
major O
surgery O
before O
recommencing O
bevacizumab O
therapy O
. O
In O
AVADO O
, O
221 O
surgical O
procedures O
( O
55 O
major O
, O
166 O
minor O
) O
were O
performed O
in O
155 B-total-participants
patients O
. O
In O
ATHENA O
, O
1190 O
surgical O
procedures O
( O
435 O
major O
, O
755 O
minor O
) O
were O
performed O
in O
672 B-total-participants
patients O
. O
One O
bevacizumab O
- O
treated O
AVADO O
patient O
( O
0.9 B-iv-bin-percent
% I-iv-bin-percent
) O
who O
underwent O
surgery O
experienced O
a O
grade B-outcome
3 I-outcome
bleeding I-outcome
event I-outcome
. O
In O
ATHENA O
, O
six O
patients O
( O
0.9 B-iv-bin-percent
% I-iv-bin-percent
) O
who O
underwent O
surgery O
experienced O
grade B-outcome
3 I-outcome
bleeding I-outcome
events I-outcome
and O
one B-iv-bin-abs
patient O
( O
0.1 B-iv-bin-percent
% I-iv-bin-percent
) O
experienced O
a O
grade B-outcome
4 I-outcome
bleeding I-outcome
event I-outcome
. O
No O
grade B-outcome
5 I-outcome
bleeding I-outcome
events I-outcome
in O
patients O
undergoing O
surgery O
were O
reported O
in O
either O
study O
. O
One O
grade B-outcome
3 I-outcome
wound I-outcome
- I-outcome
healing I-outcome
complication I-outcome
was O
reported O
in O
each O
of O
the O
AVADO O
arms O
: O
placebo B-control
( O
n O
= O
46 B-cv-bin-abs
, O
2.2 B-cv-bin-percent
% I-cv-bin-percent
) O
, O
bevacizumab O
7.5mg O
/ O
kg O
( O
n O
= O
57 B-iv-bin-abs
, O
1.8 B-iv-bin-percent
% I-iv-bin-percent
) O
and O
bevacizumab O
15mg O
/ O
kg O
( O
n O
= O
52 B-iv-bin-abs
, O
1.9 B-iv-bin-percent
% I-iv-bin-percent
) O
. O
Incidence O
of O
grade B-outcome
3 I-outcome
- I-outcome
4 I-outcome
wound I-outcome
- I-outcome
healing I-outcome
complications I-outcome
in O
ATHENA O
was O
2.2 B-iv-bin-percent
% I-iv-bin-percent
and O
1.3 B-iv-bin-percent
% I-iv-bin-percent
in O
patients O
undergoing O
minor O
or O
major O
surgery O
, O
respectively O
. O
Surgery O
can O
be O
performed O
on O
patients O
with O
mBC O
undergoing O
bevacizumab O
therapy O
with O
a O
low O
risk O
of O
severe O
bleeding O
or O
wound O
- O
healing O
complications O
post O
surgery O
, O
if O
current O
labelling O
recommendations O
are O
adhered O
to O
. O

Randomized O
trial O
using O
gonadotropin B-intervention
- I-intervention
releasing I-intervention
hormone I-intervention
agonist I-intervention
triptorelin I-intervention
for O
the O
preservation B-condition
of I-condition
ovarian I-condition
function I-condition
during O
( O
neo O
) O
adjuvant O
chemotherapy O
for O
breast O
cancer O
. O
Chemotherapy O
- O
induced O
amenorrhea O
is O
a O
serious O
concern O
for O
women O
undergoing O
cancer O
therapy O
. O
This O
prospective O
randomized O
trial O
evaluated O
the O
use O
of O
gonadotropin O
- O
releasing O
hormone O
( O
GnRH O
) O
analog O
triptorelin O
to O
preserve O
ovarian O
function O
in O
women O
treated O
with O
chemotherapy O
for O
early O
- O
stage O
breast O
cancer O
. O
Premenopausal B-eligibility
women I-eligibility
age I-eligibility
44 I-eligibility
years I-eligibility
or I-eligibility
younger I-eligibility
were O
randomly O
assigned O
to O
receive O
either O
triptorelin O
or O
no B-control
triptorelin I-control
during O
( O
neo O
) O
adjuvant O
chemotherapy O
and O
were O
further O
stratified O
by O
age O
( O
< O
35 O
, O
35 O
to O
39 O
, O
> O
39 O
years O
) O
, O
estrogen O
receptor O
status O
, O
and O
chemotherapy O
regimen O
. O
Objectives O
included O
the O
resumption O
of O
menses O
and O
serial O
monitoring O
of O
follicle O
- O
stimulating O
hormone O
( O
FSH O
) O
and O
inhibin O
A O
and O
B O
levels O
. O
Targeted O
for O
124 O
patients O
with O
a O
planned O
5 O
- O
year O
follow O
- O
up O
, O
the O
trial O
was O
stopped O
for O
futility O
after O
49 B-total-participants
patients O
were O
enrolled O
( O
median O
age O
, O
39 B-age
years I-age
; O
range O
, O
21 O
to O
43 O
years O
) O
; O
47 B-total-participants
patients O
were O
treated O
according O
to O
assigned O
groups O
with O
four O
cycles O
of O
adriamycin O
plus O
cyclophosphamide O
alone O
or O
followed O
by O
four O
cycles O
of O
paclitaxel O
or O
six O
cycles O
of O
fluorouracil O
, O
epirubicin O
, O
and O
cyclophosphamide O
. O
Menstruation B-outcome
resumed I-outcome
in O
19 B-cv-bin-abs
( O
90 B-cv-bin-percent
% I-cv-bin-percent
) O
of O
21 B-control-participants
patients O
in O
the O
control O
group O
and O
in O
23 B-iv-bin-abs
( O
88 B-iv-bin-percent
% I-iv-bin-percent
) O
of O
26 B-intervention-participants
in O
the O
triptorelin O
group O
( O
P O
= O
.36 O
) O
. O
Menses B-outcome
returned I-outcome
after O
a O
median O
of O
5.8 B-iv-cont-median
months I-iv-cont-median
( O
range O
, O
1 O
to O
19 O
months O
) O
after O
completion O
of O
chemotherapy O
in O
the O
triptorelin O
versus O
5.0 B-cv-cont-median
months I-cv-cont-median
( O
range O
, O
0 O
to O
28 O
months O
) O
in O
the O
control O
arm O
( O
P O
= O
.58 O
) O
. O
Two B-cv-bin-abs
patients O
( O
age O
26 O
and O
35 O
years O
at O
random O
assignment O
) O
in O
the O
control O
group O
had O
spontaneous B-outcome
pregnancies I-outcome
with I-outcome
term I-outcome
deliveries I-outcome
. O
FSH B-outcome
and I-outcome
inhibin I-outcome
B I-outcome
levels I-outcome
correlated O
with O
menstrual O
status O
. O
When O
stratified O
for O
age O
, O
estrogen O
receptor O
status O
, O
and O
treatment O
regimen O
, O
amenorrhea O
rates O
on O
triptorelin O
were O
comparable O
to O
those O
seen O
in O
the O
control O
group O
. O

Race O
and O
hormone O
receptor O
- O
positive O
breast O
cancer O
outcomes O
in O
a O
randomized O
chemotherapy B-intervention
trial O
. O
The O
association O
between O
black O
race O
and O
worse O
outcomes O
in O
operable O
breast O
cancer O
reported O
in O
previous O
studies O
has O
been O
attributed O
to O
a O
higher O
incidence O
of O
more O
aggressive O
triple O
- O
negative O
disease O
, O
disparities O
in O
care O
, O
and O
comorbidities O
. O
We O
evaluated O
associations O
between O
black B-ethinicity
race I-ethinicity
and O
outcomes O
, O
by O
tumor O
hormone O
receptor O
and O
HER2 O
expression O
, O
in O
patients B-eligibility
who I-eligibility
were I-eligibility
treated I-eligibility
with I-eligibility
contemporary I-eligibility
adjuvant I-eligibility
therapy I-eligibility
. O
The O
effect O
of O
black O
race O
on O
disease O
- O
free O
and O
overall O
survival O
was O
evaluated O
using O
Cox O
proportional O
hazards O
models O
adjusted O
for O
multiple O
covariates O
in O
a O
clinical O
trial O
population O
that O
was O
treated O
with O
anthracycline- O
and O
taxane O
- O
containing O
chemotherapy O
. O
Categorical O
variables O
were O
compared O
using O
the O
Fisher O
exact O
test O
. O
All O
P O
values O
are O
two O
- O
sided O
. O
Of O
4817 B-total-participants
eligible O
patients O
, O
405 B-intervention-participants
( O
8.4 O
% O
) O
were O
black B-ethinicity
. O
Compared O
with O
nonblack B-control
patients O
, O
black B-intervention
patients O
had O
a O
higher O
rate B-outcome
of I-outcome
triple I-outcome
- I-outcome
negative I-outcome
disease I-outcome
( O
31.9 B-iv-bin-percent
% I-iv-bin-percent
vs O
17.2 B-cv-bin-percent
% I-cv-bin-percent
; O
P O
< O
.001 O
) O
and O
a O
higher O
body O
mass O
index O
( O
median O
: O
31.7 O
vs O
27.4 O
kg O
/ O
m O
( O
2 O
) O
; O
P O
< O
.001 O
) O
. O
Black O
race O
was O
statistically O
significantly O
associated O
with O
worse O
disease B-outcome
- I-outcome
free I-outcome
survival I-outcome
( O
5 O
- O
year O
disease O
- O
free O
survival O
, O
black O
vs O
nonblack O
: O
76.7 B-iv-bin-percent
% I-iv-bin-percent
vs O
84.5 B-cv-bin-percent
% I-cv-bin-percent
; O
hazard O
ratio O
of O
recurrence O
or O
death O
= O
1.58 O
, O
95 O
% O
confidence O
interval O
= O
1.19 O
to O
2.10 O
, O
P O
= O
.0015 O
) O
and O
overall B-outcome
survival I-outcome
( O
5 B-outcome
- I-outcome
year I-outcome
overall I-outcome
survival I-outcome
, O
black O
vs O
nonblack O
: O
87.6 B-iv-bin-percent
% I-iv-bin-percent
vs O
91.9 B-cv-bin-percent
% I-cv-bin-percent
; O
hazard O
ratio O
of O
death O
= O
1.49 O
, O
95 O
% O
confidence O
interval O
= O
1.05 O
to O
2.12 O
, O
P O
= O
.025 O
) O
in O
patients O
with O
hormone O
receptor O
- O
positive O
HER2 O
- O
negative O
disease O
but O
not O
in O
patients O
with O
triple O
- O
negative O
or O
HER2 O
- O
positive O
disease O
. O
In O
a O
model O
that O
included O
black O
race O
, O
hormone O
receptor O
- O
positive O
HER2 O
- O
negative O
disease O
vs O
other O
subtypes O
, O
and O
their O
interaction O
, O
the O
interaction O
term O
was O
statistically O
significant O
for O
disease O
- O
free O
survival O
( O
P O
= O
.027 O
) O
but O
not O
for O
overall O
survival O
( O
P O
= O
.086 O
) O
. O
Factors O
other O
than O
disparities O
in O
care O
or O
aggressive O
disease O
contribute O
to O
increased O
recurrence O
in O
black O
women O
with O
hormone O
receptor O
- O
positive O
breast O
cancer O
. O

Low B-intervention
- I-intervention
molecular I-intervention
- I-intervention
weight I-intervention
heparin I-intervention
versus O
placebo B-control
for O
the O
prevention O
of O
venous B-condition
thromboembolism I-condition
in O
metastatic O
breast O
cancer O
or O
stage O
III O
/ O
IV O
lung O
cancer O
. O
In O
2 O
double O
- O
blind O
studies O
, O
ambulatory B-eligibility
patients I-eligibility
with I-eligibility
objectively I-eligibility
proven I-eligibility
, I-eligibility
disseminated I-eligibility
metastatic I-eligibility
breast I-eligibility
carcinoma I-eligibility
( I-eligibility
TOPIC-1 I-eligibility
) I-eligibility
or I-eligibility
stage I-eligibility
III I-eligibility
/ I-eligibility
IV I-eligibility
non I-eligibility
- I-eligibility
small I-eligibility
- I-eligibility
cell I-eligibility
lung I-eligibility
carcinoma I-eligibility
( I-eligibility
TOPIC-2 I-eligibility
) I-eligibility
were O
randomized O
to O
certoparin O
3000 O
IU O
or O
placebo O
subcutaneously O
once O
daily O
, O
for O
6 O
months O
. O
Primary O
efficacy O
outcome O
was O
objectively B-outcome-measure
confirmed I-outcome-measure
symptomatic I-outcome-measure
or I-outcome-measure
asymptomatic I-outcome-measure
venous I-outcome-measure
thromboembolism I-outcome-measure
( I-outcome-measure
VTE I-outcome-measure
) I-outcome-measure
. O
Safety O
outcomes O
included O
bleeding O
( O
major O
and O
minor O
) O
, O
and O
thrombocytopenia O
. O
TOPIC-1 O
was O
halted O
after O
an O
interim O
analysis O
. O
Venous B-outcome
thromboembolism I-outcome
occurrence O
was O
not O
different O
between O
treatment O
groups O
in O
TOPIC-1 O
( O
4 B-iv-bin-percent
% I-iv-bin-percent
treated O
with O
certoparin O
, O
7 B-iv-bin-abs
of O
174 B-intervention-participants
vs O
4 B-cv-bin-percent
% I-cv-bin-percent
receiving O
placebo O
, O
7 B-cv-bin-abs
of O
177 B-control-participants
, O
odds O
ratio O
[ O
OR O
] O
1.02 O
; O
95 O
% O
confidence O
interval O
[ O
CI O
] O
0.30 O
- O
3.48 O
) O
and O
in O
TOPIC-2 O
( O
4.5 B-iv-bin-percent
% I-iv-bin-percent
, O
12 B-iv-bin-abs
of O
268 B-intervention-participants
) O
vs O
8.3 B-cv-bin-percent
% I-cv-bin-percent
, O
22 B-cv-bin-abs
of O
264 B-control-participants
, O
respectively O
, O
OR O
0.52 O
; O
CI O
0.23 O
- O
1.12 O
) O
. O
Mortality B-outcome
was O
not O
different O
between O
groups O
. O
A O
post O
hoc O
analysis O
showed O
certoparin O
significantly O
reduced O
VTE B-outcome
in O
stage O
IV O
lung O
carcinoma O
( O
3.5 B-iv-bin-percent
% I-iv-bin-percent
vs O
10.2 B-cv-bin-percent
% I-cv-bin-percent
; O
P O
= O
.032 O
) O
without O
increased O
bleeding O
. O
In O
conclusion O
, O
thrombosis O
risk O
and O
prophylactic O
benefit O
was O
highest O
in O
stage O
IV O
lung O
carcinoma O
patients O
. O

The O
effect O
of O
transdermal B-intervention
estradiol I-intervention
or I-intervention
oral I-intervention
conjugated I-intervention
oestrogen I-intervention
and I-intervention
fenretinide I-intervention
versus O
placebo B-control
on O
haemostasis B-condition
and I-condition
cardiovascular I-condition
risk I-condition
biomarkers O
in O
a O
randomized O
breast O
cancer O
chemoprevention O
trial O
. O
We O
have O
previously O
reported O
the O
favourable O
effect O
of O
transdermal O
estradiol O
( O
E2 O
) O
, O
relative O
to O
oral O
conjugated O
equine O
oestrogen O
( O
CEE O
) O
, O
on O
ultrasensitive O
C O
- O
reactive O
protein O
after O
12 O
months O
of O
treatment O
in O
a O
retinoid O
- O
placebo O
controlled O
two O
- O
by O
- O
two O
randomized O
breast O
cancer O
prevention O
trial O
( O
Decensi O
A O
et O
al O
( O
2002 O
) O
Circulation106 O
10 O
1224 O
- O
8) O
. O
Here O
, O
we O
investigate O
the O
changes O
in O
lipids O
and O
clotting O
profile O
in O
patients O
of O
the O
same O
trial O
. O
Recent O
post B-eligibility
- I-eligibility
menopausal I-eligibility
women I-eligibility
were O
randomised O
to O
either O
oral O
CEE O
0.625 O
mg O
/ O
day O
and O
placebo O
( O
n O
= O
55 B-control-participants
) O
, O
CEE O
and O
fenretinide O
200 O
mg O
/ O
day O
( O
n O
= O
56 B-intervention-participants
) O
, O
transdermal O
E2 O
50 O
mg O
/ O
day O
and O
placebo O
( O
n O
= O
59 B-control-participants
) O
or O
E2 O
and O
fenretinide O
200 O
mg O
/ O
day O
( O
n O
= O
56 B-intervention-participants
) O
. O
Sequential O
medroxyprogesterone O
acetate O
10 O
mg O
/ O
day O
was O
given O
in O
each O
group O
. O
After O
12 O
months O
, O
there O
was O
a O
statistically O
significant O
effect O
of O
the O
route O
of O
administration O
of O
hormone O
replacement O
therapy O
( O
HRT O
) O
on O
fibrinogen B-outcome
levels I-outcome
; O
the O
median O
percentage O
change O
being O
-5.7 B-iv-cont-median
% I-iv-cont-median
with O
CEE O
and O
-1.1 B-iv-cont-median
% I-iv-cont-median
with O
E2 O
( O
p O
= O
0.012 O
) O
. O
Total B-outcome
cholesterol I-outcome
decreased O
in O
all O
arms O
( O
p O
< O
0.0001 O
) O
. O
HDL B-outcome
- I-outcome
C I-outcome
decreased O
significantly O
with O
transdermal O
E2 O
( O
p O
= O
0.006 O
) O
compared O
to O
oral O
CEE O
and O
with O
fenretinide O
relative O
to O
placebo O
( O
p<0.001 O
) O
. O
Triglycerides B-outcome
exhibited O
an O
opposite O
modulation O
in O
the O
HRT O
route O
, O
with O
a O
21.4 B-iv-cont-median
% I-iv-cont-median
median O
increase O
with O
oral O
CEE O
and O
an O
8.6 B-iv-cont-median
% I-iv-cont-median
reduction O
with O
transdermal O
E2 O
( O
p O
< O
0.0001 O
) O
. O
Antithrombin B-outcome
- I-outcome
III I-outcome
showed O
a O
4 O
% O
borderline O
significant O
reduction O
in O
the O
fenretinide O
arm O
relative O
to O
placebo O
, O
irrespective O
of O
the O
HRT O
administration O
route O
( O
p O
= O
0.055 O
) O
. O
Our O
data O
indicate O
that O
transdermal O
E2 O
may O
be O
preferable O
to O
oral O
CEE O
based O
on O
its O
safer O
cardiovascular O
risk O
profile O
. O
Fenretinide O
modified O
some O
cardiovascular O
risk O
biomarkers O
and O
confirmed O
a O
safer O
profile O
compared O
to O
other O
retinoids O
. O

Soy B-intervention
isoflavone I-intervention
supplementation O
for O
breast O
cancer O
risk O
reduction O
: O
a O
randomized O
phase O
II O
trial O
. O
Soy O
isoflavone O
consumption O
may O
protect O
against O
breast O
cancer O
development O
. O
We O
conducted O
a O
phase O
IIB O
trial O
of O
soy O
isoflavone O
supplementation O
to O
examine O
its O
effect O
on O
breast O
epithelial O
proliferation O
and O
other O
biomarkers O
in O
the O
healthy O
high O
- O
risk O
breast O
. O
One B-total-participants
hundred I-total-participants
and I-total-participants
twenty I-total-participants
- I-total-participants
six I-total-participants
consented O
women O
underwent O
a O
random O
fine O
- O
needle O
aspiration O
( O
rFNA O
) O
; O
those O
with O
4,000 O
or O
more O
epithelial O
cells O
were O
randomized O
to O
a O
double O
- O
blind O
6 O
- O
month O
intervention O
of O
mixed O
soy O
isoflavones O
( O
PTIG-2535 O
) O
or O
placebo B-control
, O
followed O
by O
repeat O
rFNA O
. O
Cells O
were O
examined O
for O
Ki-67 O
labeling O
index O
and O
atypia O
. O
Expression O
of O
28 O
genes O
related O
to O
proliferation O
, O
apoptosis O
, O
and O
estrogenic O
effect O
was O
measured O
using O
quantitative O
reverse O
transcriptase O
PCR O
. O
Hormone O
and O
protein O
levels O
were O
measured O
in O
nipple O
aspirate O
fluid O
( O
NAF O
) O
. O
All O
statistical O
tests O
were O
two O
- O
sided O
. O
Ninety B-total-participants
- I-total-participants
eight I-total-participants
women O
were O
evaluable O
for O
Ki-67 O
labeling O
index O
. O
In O
49 B-intervention-participants
treated O
women O
, O
the O
median B-outcome
Ki-67 I-outcome
labeling I-outcome
index I-outcome
was O
1.18 B-iv-cont-median
at O
entry O
and O
1.12 B-iv-cont-median
post O
intervention O
, O
whereas O
in O
49 B-control-participants
placebo O
subjects O
, O
it O
was O
0.97 B-cv-cont-median
and O
0.92 B-cv-cont-median
( O
P O
for O
between O
- O
group O
change O
: O
0.32 O
) O
. O
Menopausal B-outcome
stratification I-outcome
yielded O
similar O
results O
between O
groups O
, O
but O
within O
premenopausal O
soy O
- O
treated O
women O
, O
Ki-67 B-outcome
labeling I-outcome
index I-outcome
increased O
from O
1.71 O
to O
2.18 O
( O
P O
= O
0.04 O
) O
. O
We O
saw O
no O
treatment O
effect O
on O
cytologic B-outcome
atypia I-outcome
or I-outcome
NAF I-outcome
parameters I-outcome
. O
There O
were O
significant O
increases O
in O
the O
expression B-outcome
of I-outcome
14 I-outcome
of I-outcome
28 I-outcome
genes I-outcome
within O
the O
soy O
, O
but O
not O
the O
control O
group O
, O
without O
significant O
between O
- O
group O
differences O
. O
Plasma B-outcome
genistein I-outcome
values I-outcome
showed O
excellent O
compliance O
. O
A O
6 O
- O
month O
intervention O
of O
mixed O
soy O
isoflavones O
in O
healthy O
, O
high O
- O
risk O
adult O
Western O
women O
did O
not O
reduce O
breast O
epithelial O
proliferation O
, O
suggesting O
a O
lack O
of O
efficacy O
for O
breast O
cancer O
prevention O
and O
a O
possible O
adverse O
effect O
in O
premenopausal O
women O
. O
  O

Bone O
density O
and O
structure O
in O
healthy O
postmenopausal O
women O
treated O
with O
exemestane B-intervention
for O
the O
primary O
prevention O
of O
breast O
cancer O
: O
a O
nested O
substudy O
of O
the O
MAP.3 O
randomised O
controlled O
trial O
. O
Exemestane O
can O
prevent O
breast O
cancer O
in O
postmenopausal O
women O
. O
Because O
of O
potential O
widespread O
use O
, O
we O
examined O
the O
safety O
of O
exemestane O
on O
bone O
health O
. O
In O
this O
nested O
safety O
substudy O
of O
the O
MAP.3 O
trial O
( O
a O
randomised O
, O
placebo O
- O
controlled O
, O
double O
- O
blind O
trial O
of O
exemestane O
25 O
mg O
a O
day O
for O
the O
primary O
prevention O
of O
breast O
cancer O
) O
, O
we O
included O
postmenopausal B-eligibility
women I-eligibility
from I-eligibility
five I-eligibility
centres I-eligibility
who I-eligibility
were I-eligibility
eligible I-eligibility
to I-eligibility
participate I-eligibility
in I-eligibility
MAP.3 I-eligibility
, I-eligibility
not I-eligibility
osteoporotic I-eligibility
, I-eligibility
not I-eligibility
receiving I-eligibility
drugs I-eligibility
for I-eligibility
bone I-eligibility
- I-eligibility
related I-eligibility
disorders I-eligibility
, I-eligibility
with I-eligibility
baseline I-eligibility
lumbar I-eligibility
spine I-eligibility
, I-eligibility
total I-eligibility
hip I-eligibility
, I-eligibility
and I-eligibility
femoral I-eligibility
neck I-eligibility
T I-eligibility
- I-eligibility
scores I-eligibility
above I-eligibility
-20 I-eligibility
. O
The O
primary O
endpoint O
was O
percent B-outcome-measure
change I-outcome-measure
from I-outcome-measure
baseline I-outcome-measure
to I-outcome-measure
2 I-outcome-measure
years I-outcome-measure
in I-outcome-measure
total I-outcome-measure
volumetric I-outcome-measure
bone I-outcome-measure
mineral I-outcome-measure
density I-outcome-measure
( I-outcome-measure
BMD I-outcome-measure
) I-outcome-measure
at I-outcome-measure
the I-outcome-measure
distal I-outcome-measure
radius I-outcome-measure
by O
high O
- O
resolution O
peripheral O
quantitative O
CT O
. O
The O
primary O
analysis O
was O
per O
protocol O
using O
a O
non O
- O
inferiority O
margin O
. O
This O
analysis O
was O
done O
earlier O
than O
originally O
planned O
because O
of O
the O
impending O
announcement O
of O
MAP.3 O
results O
and O
subsequent O
unmasking O
of O
patients O
to O
treatment O
assignment O
. O
This O
study O
is O
registered O
with O
ClinicalTrials.gov O
, O
number O
NCT01144468 O
, O
and O
has O
been O
extended O
to O
5 O
years O
of O
unmasked O
follow O
- O
up O
. O
351 B-total-participants
women O
( O
176 B-intervention-participants
given O
exemestane O
, O
175 B-control-participants
given O
placebo B-control
; O
median O
age O
613 B-age
years I-age
[ O
IQR O
592 O
- O
649 O
] O
) O
met O
our O
inclusion O
criteria O
and O
completed O
baseline O
assessment O
. O
At O
the O
time O
of O
clinical O
cutoff O
, O
242 B-total-participants
women O
had O
completed O
2 O
- O
year O
follow O
- O
up O
( O
124 B-intervention-participants
given O
exemestane O
, O
118 B-control-participants
given O
placebo O
) O
. O
From O
baseline O
to O
2 O
years O
, O
the O
mean B-outcome
percent I-outcome
change I-outcome
in I-outcome
total I-outcome
volumetric I-outcome
BMD I-outcome
at I-outcome
the I-outcome
distal I-outcome
radius I-outcome
was O
-61 B-iv-cont-mean
% I-iv-cont-mean
( O
95 O
% O
CI O
-70 O
to O
-52 O
) O
in O
the O
exemestane O
group O
and O
-18 B-cv-cont-mean
% I-cv-cont-mean
( O
-24 O
to O
-12 O
) O
in O
the O
placebo O
group O
( O
difference O
-43 O
% O
, O
95 O
% O
CI O
-53 O
to O
-32 O
; O
p<00001 O
) O
. O
The O
lower O
limit O
of O
the O
95 O
% O
CI O
was O
lower O
than O
our O
non O
- O
inferiority O
margin O
of O
negative O
4 O
% O
( O
one O
- O
sided O
test O
for O
non O
- O
inferiority O
p O
= O
070 O
) O
, O
meaning O
the O
hypothesis O
that O
exemestane O
was O
inferior O
could O
not O
be O
rejected O
. O
At O
the O
distal O
tibia O
, O
the O
mean B-outcome
percent I-outcome
change I-outcome
in I-outcome
total I-outcome
volumetric I-outcome
BMD I-outcome
from I-outcome
baseline I-outcome
to I-outcome
2 I-outcome
years I-outcome
was O
-50 B-iv-cont-mean
% I-iv-cont-mean
( O
95 O
% O
CI O
-55 O
to O
-44 O
) O
in O
the O
exemestane O
group O
and O
-13 B-cv-cont-mean
% I-cv-cont-mean
( O
-17 O
to O
-10 O
) O
in O
the O
placebo O
group O
( O
difference O
-37 O
% O
, O
95 O
% O
CI O
-43 O
to O
-30 O
; O
p<00001 O
) O
. O
The O
mean B-outcome
percent I-outcome
change I-outcome
in I-outcome
cortical I-outcome
thickness I-outcome
was O
-79 B-iv-cont-mean
% I-iv-cont-mean
( O
SD O
73 B-iv-cont-sd
) O
in O
the O
exemestane O
group O
and O
-11 O
% O
( O
57 O
) O
in O
the O
placebo O
group O
at B-outcome
the I-outcome
distal I-outcome
radius I-outcome
( O
difference O
-68 O
% O
, O
95 O
% O
CI O
-85 O
to O
-50 O
; O
p<00001 O
) O
and O
-76 B-iv-cont-mean
% I-iv-cont-mean
( O
SD O
59 B-cv-cont-sd
) O
in O
the O
exemestane O
group O
and O
-07 B-cv-cont-mean
% I-cv-cont-mean
( O
49 O
) O
in O
the O
placebo O
group O
at B-outcome
the I-outcome
distal I-outcome
tibia I-outcome
( O
difference O
-69 O
% O
, O
-84 O
to O
-55 O
; O
p<00001 O
) O
. O
Decline O
in O
areal B-outcome
BMD I-outcome
, O
as O
measured O
by O
dual O
- O
energy O
x O
- O
ray O
absorptiometry O
, O
in O
the O
exemestane O
group O
compared O
with O
the O
placebo O
group O
occurred O
at B-outcome
the I-outcome
lumbar I-outcome
spine I-outcome
( O
-24 B-iv-cont-mean
% I-iv-cont-mean
[ O
95 O
% O
CI O
-31 O
to O
-17 O
] O
exemestane O
vs O
-05 B-cv-cont-mean
% I-cv-cont-mean
[ O
-11 O
to O
02 O
] O
placebo O
; O
difference O
-19 O
% O
, O
95 O
% O
CI O
-29 O
to O
-10 O
; O
p<00001 O
) O
, O
total B-outcome
hip I-outcome
( O
-18 B-iv-cont-mean
% I-iv-cont-mean
[ O
-23 O
to O
-12 O
] O
exemestane O
vs O
-06 B-cv-cont-mean
% I-cv-cont-mean
[ O
-11 O
to O
-01 O
] O
placebo O
; O
difference O
-12 O
% O
, O
-19 O
to O
-04 O
; O
p O
= O
0004 O
) O
, O
and O
femoral B-outcome
neck I-outcome
( O
-24 B-iv-cont-mean
% I-iv-cont-mean
[ O
-32 O
to O
-17 O
] O
exemestane O
vs O
-08 B-cv-cont-mean
% I-cv-cont-mean
[ O
-15 O
to O
01 O
] O
placebo O
; O
difference O
-16 O
% O
, O
-27 O
to O
-06 O
; O
p O
= O
0002 O
) O
. O
2 O
years O
of O
treatment O
with O
exemestane O
worsens O
age O
- O
related O
bone B-outcome
loss I-outcome
in O
postmenopausal O
women O
despite O
calcium O
and O
vitamin O
D O
supplementation O
. O
Women O
considering O
exemestane O
for O
the O
primary O
prevention O
of O
breast O
cancer O
should O
weigh O
their O
individual O
risks O
and O
benefits O
. O
For O
women O
taking O
exemestane O
, O
regular O
bone O
monitoring O
plus O
adequate O
calcium O
and O
vitamin O
D O
supplementation O
are O
important O
. O
To O
assess O
the O
effect O
of O
our O
findings O
on O
fracture O
risk O
, O
long O
- O
term O
follow O
- O
up O
is O
needed O
. O
Canadian O
Breast O
Cancer O
Research O
Alliance O
( O
Canadian O
Institutes O
of O
Health O
Research O
/ O
Canadian O
Cancer O
Society O
) O
. O
  O

First O
- O
line O
treatment O
of O
advanced O
breast O
cancer O
with O
sunitinib B-intervention
in I-intervention
combination I-intervention
with I-intervention
docetaxel I-intervention
versus O
docetaxel B-control
alone I-control
: O
results O
of O
a O
prospective O
, O
randomized O
phase O
III O
study O
. O
To O
investigate O
whether O
sunitinib O
plus O
docetaxel O
improves O
clinical O
outcomes O
for O
patients B-eligibility
with I-eligibility
human I-eligibility
epidermal I-eligibility
growth I-eligibility
factor I-eligibility
receptor I-eligibility
2 I-eligibility
( I-eligibility
HER2 I-eligibility
) I-eligibility
/neu I-eligibility
- I-eligibility
negative I-eligibility
advanced I-eligibility
breast I-eligibility
cancer I-eligibility
( I-eligibility
ABC I-eligibility
) I-eligibility
versus O
docetaxel O
alone O
. O
In O
this O
phase O
III O
study O
, O
patients O
were O
randomly O
assigned O
to O
open O
- O
label O
combination O
therapy O
( O
sunitinib O
37.5 O
mg O
/ O
d O
, O
days O
2 O
to O
15 O
every O
3 O
weeks O
; O
and O
docetaxel O
75 O
mg O
/ O
m O
( O
2 O
) O
, O
day O
1 O
every O
3 O
weeks O
) O
or O
monotherapy O
( O
docetaxel O
100 O
mg O
/ O
m O
( O
2 O
) O
every O
3 O
weeks O
) O
. O
Progression B-outcome-measure
- I-outcome-measure
free I-outcome-measure
survival I-outcome-measure
( I-outcome-measure
PFS I-outcome-measure
) I-outcome-measure
was O
the O
primary O
end O
point O
. O
Two B-intervention-participants
hundred I-intervention-participants
ninety I-intervention-participants
- I-intervention-participants
six I-intervention-participants
patients O
were O
randomly O
assigned O
to O
combination O
therapy O
, O
and O
297 B-control-participants
patients O
were O
assigned O
to O
monotherapy O
. O
Median B-outcome
PFS I-outcome
times I-outcome
were O
8.6 B-iv-cont-median
and O
8.3 B-cv-cont-median
months I-cv-cont-median
with O
combination O
therapy O
and O
monotherapy O
, O
respectively O
( O
hazard O
ratio O
, O
0.92 O
; O
one O
- O
sided O
P O
= O
.265 O
) O
. O
The O
objective B-outcome
response I-outcome
rate I-outcome
( I-outcome
ORR I-outcome
) I-outcome
was O
significantly O
higher O
with O
the O
combination O
( O
55 B-iv-bin-percent
% I-iv-bin-percent
) O
than O
with O
monotherapy O
( O
42 B-cv-bin-percent
% I-cv-bin-percent
; O
one O
- O
sided O
P O
= O
.001 O
) O
. O
Duration B-outcome
of I-outcome
response I-outcome
was O
similar O
in O
both O
arms O
( O
7.5 B-iv-cont-median
months I-iv-cont-median
with O
the O
combination O
v O
7.2 B-cv-cont-median
months I-cv-cont-median
with O
monotherapy O
) O
. O
Median B-outcome
overall I-outcome
survival I-outcome
( I-outcome
OS I-outcome
) I-outcome
times I-outcome
were O
24.8 B-iv-cont-median
and O
25.5 B-cv-cont-median
months I-cv-cont-median
with O
combination O
therapy O
and O
monotherapy O
, O
respectively O
( O
one O
- O
sided O
P O
= O
.904 O
) O
. O
There O
were O
107 B-iv-bin-abs
deaths B-outcome
with O
the O
combination O
and O
91 B-cv-bin-abs
deaths O
with O
monotherapy O
. O
The O
frequency O
of O
common O
adverse B-outcome
events I-outcome
( I-outcome
AEs I-outcome
) I-outcome
was O
higher O
with O
the O
combination O
, O
as O
were O
treatment O
discontinuations O
caused O
by O
AEs O
. O
The O
combination O
of O
sunitinib O
plus O
docetaxel O
improved O
ORR B-outcome
but O
did O
not O
prolong O
either O
PFS B-outcome
or I-outcome
OS I-outcome
compared O
with O
docetaxel O
alone O
when O
given O
to O
an O
unselected O
HER2 O
/ O
neu O
- O
negative O
cohort O
as O
first O
- O
line O
treatment O
for O
ABC O
. O
Sunitinib O
combination O
therapy O
may O
also O
have O
resulted O
in O
AEs B-outcome
that O
yield O
an O
unfavorable O
risk O
- O
benefit O
ratio O
. O
The O
sunitinib O
- O
docetaxel O
regimen O
evaluated O
in O
this O
study O
is O
not O
recommended O
for O
further O
use O
in O
ABC O
. O

FACT O
: O
an O
open O
- O
label O
randomized O
phase O
III O
study O
of O
fulvestrant B-intervention
and I-intervention
anastrozole I-intervention
in O
combination O
compared O
with O
anastrozole B-control
alone I-control
as O
first O
- O
line O
therapy O
for O
patients O
with O
receptor O
- O
positive O
postmenopausal O
breast O
cancer O
. O
To O
compare O
the O
effect O
of O
therapy O
with O
anastrozole O
versus O
a O
combination O
of O
fulvestrant O
and O
anastrozole O
in O
women O
in O
first O
relapse O
of O
endocrine O
- O
responsive O
breast O
cancer O
. O
Postmenopausal B-eligibility
women I-eligibility
, I-eligibility
or I-eligibility
premenopausal I-eligibility
women I-eligibility
receiving I-eligibility
a I-eligibility
gonadotropin I-eligibility
- I-eligibility
releasing I-eligibility
hormone I-eligibility
agonist I-eligibility
, I-eligibility
with I-eligibility
estrogen I-eligibility
receptor- I-eligibility
and/or I-eligibility
progesterone I-eligibility
receptor I-eligibility
- I-eligibility
positive I-eligibility
disease I-eligibility
at I-eligibility
first I-eligibility
relapse I-eligibility
after I-eligibility
primary I-eligibility
treatment I-eligibility
of I-eligibility
localized I-eligibility
disease I-eligibility
were O
open O
- O
label O
randomly O
assigned O
to O
a O
fulvestrant O
loading O
dose O
( O
LD O
) O
regimen O
followed O
by O
monthly O
injection O
plus O
1 O
mg O
of O
anastrozole O
daily O
or O
to O
1 O
mg O
of O
anastrozole O
daily O
alone O
. O
The O
primary O
end O
point O
was O
time B-outcome-measure
to I-outcome-measure
progression I-outcome-measure
( I-outcome-measure
TTP I-outcome-measure
) I-outcome-measure
. O
In O
all O
, O
514 B-total-participants
women O
were O
randomly O
assigned O
to O
fulvestrant O
plus O
anastrozole O
( O
experimental O
arm O
; O
n O
= O
258 B-intervention-participants
) O
or O
anastrozole O
( O
standard O
arm O
; O
n O
= O
256 B-control-participants
) O
. O
Approximately O
two O
thirds O
had O
received O
adjuvant O
antiestrogens O
, O
but O
only O
eight O
individuals O
had O
received O
an O
aromatase O
inhibitor O
. O
Median B-outcome
TTP I-outcome
was O
10.8 B-iv-cont-median
and O
10.2 B-cv-cont-median
months I-cv-cont-median
in O
the O
experimental O
versus O
standard O
arm O
, O
respectively O
( O
hazard O
ratio O
[ O
HR O
] O
= O
0.99 O
; O
95 O
% O
CI O
, O
0.81 O
to O
1.20 O
; O
P O
= O
.91 O
) O
; O
median B-outcome
overall I-outcome
survival I-outcome
was O
37.8 B-iv-cont-median
and O
38.2 B-cv-cont-median
months I-cv-cont-median
, O
respectively O
( O
HR O
= O
1.0 O
; O
95 O
% O
CI O
, O
0.76 O
to O
1.32 O
; O
P O
= O
1.00 O
) O
. O
Incidences O
of O
prespecified O
adverse B-outcome
events I-outcome
( I-outcome
AEs I-outcome
) I-outcome
were O
similar O
. O
Hot B-outcome
flashes I-outcome
were O
more O
common O
in O
the O
experimental O
arm O
: O
63 B-iv-bin-abs
patients O
( O
24.6 B-iv-bin-percent
% I-iv-bin-percent
) O
versus O
35 B-cv-bin-abs
patients O
( O
13.8 B-cv-bin-percent
% I-cv-bin-percent
) O
in O
the O
standard O
arm O
( O
P O
= O
.0023 O
) O
. O
Death B-outcome
owing I-outcome
to I-outcome
AEs I-outcome
was O
reported O
in O
11 B-iv-bin-abs
( O
4.3 B-iv-bin-percent
% I-iv-bin-percent
) O
and O
five B-cv-bin-abs
patients O
( O
2.0 B-cv-bin-percent
% I-cv-bin-percent
) O
in O
the O
experimental O
versus O
standard O
arm O
, O
respectively O
. O
Fulvestrant O
( O
250 O
mg O
+ O
LD O
regimen O
) O
in O
combination O
with O
anastrozole O
offered O
no O
clinical O
efficacy O
advantage O
over O
anastrozole O
monotherapy O
in O
this O
population O
of O
individuals O
with O
a O
relatively O
high O
proportion O
of O
previous O
adjuvant O
antiestrogen O
exposure O
. O

Trastuzumab B-intervention
decreases O
the O
incidence O
of O
clinical B-condition
relapses I-condition
in O
patients O
with O
early O
breast O
cancer O
presenting O
chemotherapy O
- O
resistant O
CK-19mRNA O
- O
positive O
circulating O
tumor O
cells O
: O
results O
of O
a O
randomized O
phase O
II O
study O
. O
Since O
the O
detection O
of O
circulating O
tumor O
cells O
( O
CTCs O
) O
which O
express O
HER2 O
is O
an O
adverse O
prognostic O
factor O
in O
early O
breast O
cancer O
patients O
, O
we O
investigated O
the O
effect O
of O
trastuzumab O
on O
patients O
' O
clinical O
outcome O
. O
Seventy B-total-participants
five I-total-participants
women B-eligibility
with I-eligibility
HER2 I-eligibility
( I-eligibility
- I-eligibility
) I-eligibility
breast I-eligibility
cancer I-eligibility
and I-eligibility
detectable I-eligibility
CK19 I-eligibility
mRNA I-eligibility
- I-eligibility
positive I-eligibility
CTCs I-eligibility
before I-eligibility
and I-eligibility
after I-eligibility
adjuvant I-eligibility
chemotherapy I-eligibility
, O
were O
randomized O
to O
receive O
either O
trastuzumab O
( O
n O
= O
36 B-intervention-participants
) O
or O
observation B-control
( O
n O
= O
39 B-control-participants
) O
. O
CK19 O
mRNA O
- O
positive O
CTCs O
were O
detected O
by O
RT O
- O
PCR O
and O
double O
stained O
CK O
( O
+ O
) O
/HER2 O
( O
+ O
) O
cells O
by O
immunofluorescence O
. O
The O
primary O
endpoint O
was O
the O
3 B-outcome-measure
- I-outcome-measure
year I-outcome-measure
disease I-outcome-measure
- I-outcome-measure
free I-outcome-measure
survival I-outcome-measure
rate I-outcome-measure
. O
Fifty O
- O
one O
( O
89 O
% O
) O
of O
the O
57 O
analyzed O
patients O
had O
HER2 O
- O
expressing O
CTCs O
. O
After O
trastuzumab O
administration O
, O
27 B-iv-bin-abs
of O
36 B-intervention-participants
( O
75 B-iv-bin-percent
% I-iv-bin-percent
) O
women O
became B-outcome
CK19 I-outcome
mRNA I-outcome
- I-outcome
negative I-outcome
compared O
to O
seven B-cv-bin-abs
of O
39 B-control-participants
( O
17.9 B-cv-bin-percent
% I-cv-bin-percent
) O
in O
the O
observation O
arm O
( O
p O
= O
0.001 O
) O
. O
After O
a O
median O
follow O
up O
time O
of O
67.2 O
months O
, O
four B-iv-bin-abs
( O
11 B-iv-bin-percent
% I-iv-bin-percent
) O
and O
15 B-cv-bin-abs
( O
38 B-cv-bin-percent
% I-cv-bin-percent
) O
relapses B-outcome
were O
observed O
in O
the O
trastuzumab O
and O
observation O
arm O
, O
respectively O
( O
p O
= O
0.008 O
) O
; O
subgroup O
analysis O
indicated O
that O
this O
effect O
was O
mainly O
confined O
to O
women O
with O
> O
3 O
involved O
axillary O
lymph O
nodes O
( O
p O
= O
0.004 O
) O
. O
The O
median B-outcome
DFS I-outcome
was O
also O
significantly O
higher O
for O
the O
trastuzumab O
- O
treated O
patients O
( O
p O
= O
0.008 O
) O
. O
Administration O
of O
trastuzumab O
can O
eliminate O
chemotherapy O
- O
resistant O
CK19 O
mRNA O
- O
positive O
CTCs O
, O
reduce O
the O
risk O
of O
disease O
recurrence O
and O
prolong O
the O
DFS O
. O

Influence O
of O
zoledronic B-intervention
acid I-intervention
on O
disseminated O
tumor O
cells O
in O
primary O
breast O
cancer O
patients O
. O
The O
presence O
of O
disseminated O
tumor O
cells O
( O
DTCs O
) O
in O
bone O
marrow O
of O
patients O
with O
early O
breast O
cancer O
( O
EBC O
) O
has O
been O
correlated O
with O
increased O
risk O
of O
metastatic O
disease O
or O
locoregional O
relapse O
. O
Zoledronic O
acid O
( O
ZOL O
) O
treatment O
has O
reduced O
DTCs O
in O
the O
bone O
marrow O
of O
patients O
with O
EBC O
in O
several O
studies O
. O
This O
controlled O
study O
sought O
to O
confirm O
these O
observations O
. O
Patients B-eligibility
with I-eligibility
EBC I-eligibility
and I-eligibility
DTC I-eligibility
- I-eligibility
positive I-eligibility
bone I-eligibility
marrow I-eligibility
were O
randomized O
( O
N O
= O
96 B-total-participants
) O
to O
treatment O
with O
ZOL O
plus O
adjuvant O
systemic O
therapy O
or O
adjuvant B-control
systemic I-control
therapy I-control
alone I-control
. O
The O
change O
in O
DTC O
numbers O
at O
12 O
months O
versus O
baseline O
was O
measured O
. O
DTC O
- O
positive O
patients O
treated O
with O
ZOL O
were O
more O
likely B-outcome
to I-outcome
become I-outcome
DTC I-outcome
- I-outcome
negative I-outcome
after O
12 O
months O
of O
treatment O
compared O
with O
the O
controls O
( O
67 B-iv-bin-percent
% I-iv-bin-percent
versus O
35 B-cv-bin-percent
% I-cv-bin-percent
; O
P O
= O
0.009 O
) O
. O
At O
12 O
months O
, O
DTC B-outcome
counts I-outcome
decreased O
to O
a O
mean O
of O
0.5 B-iv-cont-mean
 O
0.8 B-iv-cont-sd
DTCs I-iv-cont-sd
in O
the O
ZOL O
group O
and O
to O
0.9 B-cv-cont-mean
 O
0.8 B-cv-cont-sd
DTCs I-cv-cont-sd
in O
the O
control O
group O
. O
In O
addition O
, O
ZOL O
was O
generally O
well B-outcome
tolerated I-outcome
. O
Treatment O
with O
ZOL O
improves O
elimination B-outcome
of I-outcome
DTCs I-outcome
. O
Further O
studies O
are O
needed O
to O
determine O
whether O
the O
reduction O
in O
DTCs O
by O
ZOL O
provides O
clinical O
benefit O
. O

Longitudinal O
impact O
of O
yoga B-intervention
on O
chemotherapy B-condition
- I-condition
related I-condition
cognitive I-condition
impairment I-condition
and O
quality O
of O
life O
in O
women O
with O
early O
stage O
breast O
cancer O
: O
a O
case O
series O
. O
Adjuvant O
chemotherapy O
for O
women O
with O
breast O
cancer O
has O
significantly O
improved O
the O
cure O
rate O
; O
however O
, O
it O
has O
been O
associated O
with O
chemotherapy O
- O
related O
cognitive O
impact O
( O
CRCI O
) O
. O
The O
literature O
provides O
preliminary O
support O
for O
the O
feasibility O
and O
efficacy O
of O
yoga O
interventions O
for O
the O
general O
cancer O
population O
, O
however O
, O
controlled O
trials O
are O
scarce O
and O
no O
studies O
have O
examined O
the O
effect O
of O
yoga O
on O
cognition O
for O
women O
with O
breast O
cancer O
during O
chemotherapy O
. O
This O
case O
series O
aims O
to O
identify O
the O
impact O
of O
yoga O
on O
measures O
of O
cognition O
, O
functional O
outcomes O
, O
and O
quality O
of O
life O
( O
QOL O
) O
for O
breast O
cancer O
survivors O
( O
BCS O
) O
. O
Four B-total-participants
women B-eligibility
with I-eligibility
a I-eligibility
diagnosis I-eligibility
of I-eligibility
early I-eligibility
- I-eligibility
stage I-eligibility
breast I-eligibility
cancer I-eligibility
prior I-eligibility
to I-eligibility
chemotherapy I-eligibility
treatment I-eligibility
were O
administered O
the O
following O
physiologic O
measures O
at O
baseline O
, O
6 O
, O
and O
12 O
weeks O
during O
chemotherapy O
, O
and O
at O
one O
and O
three O
months O
after O
the O
conclusion O
of O
the O
study O
: O
Functional O
Reach O
test O
( O
balance O
) O
and O
Sit O
and O
Reach O
test O
( O
flexibility O
) O
, O
and O
QOL O
, O
POMS O
( O
Mood O
) O
and O
FACT O
- O
B O
( O
QOL O
) O
, O
at O
baseline O
. O
Primary O
outcomes O
of O
cognition B-outcome-measure
were O
measured O
with O
the O
Perceived O
Cognition O
Questionnaire O
( O
PCQ O
) O
and O
CogState O
, O
a O
computerized O
measurement O
of O
cognition O
. O
Women O
attended O
an O
Iyengar O
- O
inspired O
yoga O
program O
twice O
a O
week O
for O
12 O
weeks O
. O
Qualitative O
questionnaires O
were O
administered O
after O
the O
completion O
of O
the O
study O
to O
determine O
perceived O
benefits O
and O
challenges O
of O
the O
yoga O
program O
. O
Four B-total-participants
women O
with O
Stage O
II O
breast O
cancer O
ranged O
in O
age O
from O
44 B-age
- I-age
65 I-age
years I-age
. O
CogState O
computerized O
testing O
showed O
changes B-outcome
in I-outcome
varying I-outcome
domains I-outcome
of I-outcome
cognition I-outcome
through O
treatment O
and O
follow O
- O
up O
. O
Improved B-outcome
balance I-outcome
, I-outcome
flexibility I-outcome
, I-outcome
and I-outcome
QOL I-outcome
were O
also O
noted O
over O
time O
. O
No B-outcome
adverse I-outcome
events I-outcome
were O
observed O
. O
Analysis O
of O
qualitative O
data O
revealed O
the O
yoga O
classes O
were O
helpful O
and O
subjects O
continued O
the O
practice O
elements O
of O
yoga O
including O
relaxation O
, O
breathing O
, O
and O
stretching O
. O
The O
most O
challenging O
aspect O
of O
the O
study O
was O
physical O
limitations O
due O
to O
various O
medical O
complications O
and O
included O
fatigue O
, O
decreased O
range O
of O
motion O
, O
and O
pain O
. O
This O
case O
series O
suggests O
that O
yoga O
may O
impact O
various O
aspects O
of O
cognition O
during O
and O
after O
chemotherapy O
administration O
as O
noted O
through O
quantitative O
measures O
. O
Women O
describe O
yoga O
as O
improving O
various O
domains O
of O
QOL O
through O
the O
treatment O
trajectory O
. O
This O
mind O
- O
body O
intervention O
may O
stave O
off O
CRCI O
; O
however O
, O
further O
investigation O
is O
needed O
for O
additional O
randomized O
controlled O
trials O
on O
the O
effects O
of O
yoga O
on O
cognition O
for O
women O
with O
breast O
cancer O
undergoing O
adjuvant O
chemotherapy O
treatment O
. O
  O

CYP2D6 O
and O
UGT2B7 O
genotype O
and O
risk O
of O
recurrence O
in O
tamoxifen O
- O
treated O
breast O
cancer O
patients O
. O
Adjuvant O
tamoxifen O
therapy O
substantially O
decreases O
the O
risk O
of O
recurrence O
and O
mortality O
in O
women O
with O
hormone O
( O
estrogen O
and/or O
progesterone O
) O
receptor O
- O
positive O
breast O
cancer O
. O
Previous O
studies O
have O
suggested O
that O
metabolic O
conversion O
of O
tamoxifen O
to O
endoxifen O
by O
cytochrome O
P450 O
2D6 O
( O
CYP2D6 O
) O
is O
required O
for O
patient O
benefit O
from O
tamoxifen O
therapy O
. O
Tumor O
specimens O
from O
a O
subset O
of O
postmenopausal B-eligibility
patients I-eligibility
with I-eligibility
hormone I-eligibility
receptor I-eligibility
- I-eligibility
positive I-eligibility
early I-eligibility
- I-eligibility
stage I-eligibility
( I-eligibility
stages I-eligibility
I I-eligibility
, I-eligibility
II I-eligibility
, I-eligibility
and I-eligibility
IIIA I-eligibility
) I-eligibility
breast I-eligibility
cancer I-eligibility
, O
who O
were O
enrolled O
in O
the O
randomized O
double O
- O
blind O
Arimidex O
, O
Tamoxifen O
, O
Alone O
or O
in O
Combination O
( O
ATAC O
) O
clinical O
trial O
, O
were O
genotyped O
for O
variants O
in O
CYP2D6 O
( O
N O
= O
1203 B-total-participants
patients O
: O
anastrozole B-intervention
[ O
trade O
name O
: O
Arimidex O
] O
group O
, O
n O
= O
615 B-intervention-participants
patients O
; O
tamoxifen B-control
group O
, O
n O
= O
588 B-control-participants
patients O
) O
and O
UDP O
- O
glucuronosyltransferase-2B7 O
( O
UGT2B7 O
) O
, O
whose O
gene O
product O
inactivates O
endoxifen O
( O
N O
= O
1209 B-total-participants
patients O
; O
anastrozole O
group O
, O
n O
= O
606 B-intervention-participants
patients O
; O
tamoxifen O
group O
, O
n O
= O
603 B-control-participants
patients O
) O
. O
Genotyping O
was O
performed O
using O
polymerase O
chain O
reaction O
- O
based O
TaqMan O
assays O
. O
Based O
on O
the O
genotypes O
for O
CYP2D6 O
, O
patients O
were O
classified O
as O
poor O
metabolizer O
( O
PM O
) O
, O
intermediate O
metabolizer O
( O
IM O
) O
, O
or O
extensive O
metabolizer O
( O
EM O
) O
phenotypes O
. O
We O
evaluated O
the O
association O
of O
CYP2D6 O
and O
UGT2B7 O
genotype O
with O
distant B-outcome-measure
recurrence I-outcome-measure
( O
primary O
endpoint O
) O
and O
any B-outcome-measure
recurrence I-outcome-measure
( O
secondary O
endpoint O
) O
by O
estimating O
the O
hazard O
ratios O
( O
HRs O
) O
and O
corresponding O
95 O
% O
confidence O
intervals O
( O
CIs O
) O
using O
Cox O
proportional O
hazards O
models O
. O
All O
statistical O
tests O
were O
two O
- O
sided O
. O
After O
a O
median O
follow O
- O
up O
of O
10 O
years O
, O
no O
statistically O
significant O
associations O
were O
observed O
between O
CYP2D6 O
genotype O
and O
recurrence B-outcome
in O
tamoxifen O
- O
treated O
patients O
( O
PM O
vs O
EM O
: O
HR O
for O
distant O
recurrence O
= O
1.25 O
, O
95 O
% O
CI O
= O
0.55 O
to O
3.15 O
, O
P O
= O
.64 O
; O
HR O
for O
any O
recurrence O
= O
0.99 O
, O
95 O
% O
CI O
= O
0.48 O
to O
2.08 O
, O
P O
= O
.99 O
) O
. O
A O
near O
- O
null O
association O
was O
observed O
between O
UGT2B7 O
genotype O
and O
recurrence B-outcome
in O
tamoxifen O
- O
treated O
patients O
. O
No O
associations O
were O
observed O
between O
CYP2D6 O
and O
UGT2B7 O
genotypes O
and O
recurrence B-outcome
in O
anastrozole O
- O
treated O
patients O
. O
The O
results O
do O
not O
support O
the O
hypothesis O
that O
CYP2D6 O
genotype O
predicts O
clinical O
benefit O
of O
adjuvant O
tamoxifen O
treatment O
among O
postmenopausal O
breast O
cancer O
patients O
. O

Conjugated B-intervention
equine I-intervention
oestrogen I-intervention
and O
breast O
cancer O
incidence O
and O
mortality O
in O
postmenopausal O
women O
with O
hysterectomy O
: O
extended O
follow O
- O
up O
of O
the O
Women O
's O
Health O
Initiative O
randomised O
placebo O
- O
controlled O
trial O
. O
By O
contrast O
with O
many O
observational O
studies O
, O
women O
in O
the O
Women O
's O
Health O
Initiative O
( O
WHI O
) O
trial O
who O
were O
randomly O
allocated O
to O
receive O
oestrogen O
alone O
had O
a O
lower O
incidence O
of O
invasive O
breast O
cancer O
than O
did O
those O
who O
received O
placebo O
. O
We O
aimed O
to O
assess O
the O
influence O
of O
oestrogen O
use O
on O
longer O
term O
breast O
cancer O
incidence O
and O
mortality O
in O
extended O
follow O
- O
up O
of O
this O
cohort O
. O
Between O
1993 O
and O
1998 O
, O
the O
WHI O
enrolled O
10,739 B-total-participants
postmenopausal B-eligibility
women I-eligibility
from O
40 O
US B-location
clinical O
centres O
into O
a O
randomised O
, O
double O
- O
masked O
, O
placebo O
- O
controlled O
trial O
. O
Women O
aged O
50 B-age
- I-age
79 I-age
years I-age
who B-eligibility
had I-eligibility
undergone I-eligibility
hysterectomy I-eligibility
and I-eligibility
had I-eligibility
expected I-eligibility
3 I-eligibility
- I-eligibility
year I-eligibility
survival I-eligibility
and I-eligibility
mammography I-eligibility
clearance I-eligibility
were O
randomly O
allocated O
by O
a O
computerised O
, O
permuted O
block O
algorithm O
, O
stratified O
by O
age O
group O
and O
centre O
, O
to O
receive O
oral O
conjugated O
equine O
oestrogen O
( O
0625 O
mg O
per O
day O
; O
n O
= O
5310 B-intervention-participants
) O
or O
matched O
placebo B-control
( O
n O
= O
5429 B-control-participants
) O
. O
The O
trial O
intervention O
was O
terminated O
early O
on O
Feb O
29 O
, O
2004 O
, O
because O
of O
an O
adverse O
effect O
on O
stroke O
. O
Follow O
- O
up O
continued O
until O
planned O
termination O
( O
March O
31 O
, O
2005 O
) O
. O
Consent O
was O
sought O
for O
extended O
surveillance O
from O
the O
9786 O
living O
participants O
in O
active O
follow O
- O
up O
, O
of O
whom O
7645 O
agreed O
. O
Using O
data O
from O
this O
extended O
follow O
- O
up O
( O
to O
Aug O
14 O
, O
2009 O
) O
, O
we O
assessed O
long O
- O
term O
effects O
of O
oestrogen O
use O
on O
invasive O
breast O
cancer O
incidence O
, O
tumour O
characteristics O
, O
and O
mortality O
. O
We O
used O
Cox O
regression O
models O
to O
estimate O
hazard O
ratios O
( O
HRs O
) O
in O
the O
intention O
- O
to O
- O
treat O
population O
. O
This O
study O
is O
registered O
with O
ClinicalTrials.gov O
, O
number O
NCT00000611 O
. O
After O
a O
median O
follow O
- O
up O
of O
118 O
years O
( O
IQR O
91 O
- O
129 O
) O
, O
the O
use O
of O
oestrogen O
for O
a O
median O
of O
59 O
years O
( O
25 O
- O
73 O
) O
was O
associated O
with O
lower O
incidence B-outcome
of I-outcome
invasive I-outcome
breast I-outcome
cancer I-outcome
( O
151 B-iv-bin-abs
cases O
, O
027 O
% O
per O
year O
) O
compared O
with O
placebo O
( O
199 B-cv-bin-abs
cases O
, O
035 O
% O
per O
year O
; O
HR O
077 O
, O
95 O
% O
CI O
062 O
- O
095 O
; O
p O
= O
002 O
) O
with O
no O
difference O
( O
p O
= O
076 O
) O
between O
intervention O
phase O
( O
079 O
, O
061 O
- O
102 O
) O
and O
post O
- O
intervention O
phase O
effects O
( O
075 O
, O
051 O
- O
109 O
) O
. O
In O
subgroup O
analyses O
, O
we O
noted O
breast B-outcome
cancer I-outcome
risk I-outcome
reduction I-outcome
with O
oestrogen O
use O
was O
concentrated O
in O
women O
without O
benign O
breast O
disease O
( O
p O
= O
001 O
) O
or O
a O
family O
history O
of O
breast O
cancer O
( O
p O
= O
002 O
) O
. O
In O
the O
oestrogen O
group O
, O
fewer O
women O
died B-outcome
from I-outcome
breast I-outcome
cancer I-outcome
( O
six B-iv-bin-abs
deaths O
, O
0009 O
% O
per O
year O
) O
compared O
with O
controls O
( O
16 B-cv-bin-abs
deaths O
, O
0024 O
% O
per O
year O
; O
HR O
037 O
, O
95 O
% O
CI O
013 O
- O
091 O
; O
p O
= O
003 O
) O
. O
Fewer O
women O
in O
the O
oestrogen O
group O
died B-outcome
from I-outcome
any I-outcome
cause I-outcome
after I-outcome
a I-outcome
breast I-outcome
cancer I-outcome
diagnosis I-outcome
( O
30 B-iv-bin-abs
deaths O
, O
0046 O
% O
per O
year O
) O
than O
did O
controls O
( O
50 B-cv-bin-abs
deaths O
, O
0076 O
% O
; O
HR O
062 O
, O
95 O
% O
CI O
039 O
- O
097 O
; O
p O
= O
004 O
) O
. O
Our O
findings O
provide O
reassurance O
for O
women O
with O
hysterectomy O
seeking O
relief O
of O
climacteric O
symptoms O
in O
terms O
of O
the O
effects O
of O
oestrogen O
use O
for O
about O
5 O
years O
on O
breast O
cancer O
incidence O
and O
mortality O
. O
However O
, O
our O
data O
do O
not O
support O
use O
of O
oestrogen O
for O
breast O
cancer O
risk O
reduction O
because O
any O
noted O
benefit O
probably O
does O
not O
apply O
to O
populations O
at O
increased O
risk O
of O
such O
cancer O
. O
US O
National O
Heart O
, O
Lung O
, O
and O
Blood O
Institute O
; O
Wyeth O
. O
  O

Social O
cognitive O
influences O
on O
physical B-intervention
activity I-intervention
participation O
in O
long O
- O
term O
breast O
cancer O
survivors O
. O
Although O
physical O
activity O
is O
beneficial O
for O
breast O
cancer O
survivors O
, O
the O
majority O
do O
not O
meet O
public O
health O
physical O
activity O
recommendations O
. O
The O
purpose O
of O
this O
study O
was O
to O
test O
a O
social O
cognitive O
theory O
model O
of O
physical O
activity O
behavior O
in O
a O
sample O
of O
long B-eligibility
- I-eligibility
term I-eligibility
breast I-eligibility
cancer I-eligibility
survivors I-eligibility
using O
both O
self O
- O
report O
and O
objective O
measures O
of O
physical O
activity O
. O
Participants O
( O
N O
 O
= O
 O
1527 B-total-participants
) O
completed O
measures O
of O
physical O
activity O
, O
self O
- O
efficacy O
, O
goals O
, O
outcome O
expectations O
, O
fatigue O
, O
and O
social O
support O
at O
baseline O
and O
6 O
- O
month O
follow O
- O
up O
. O
A O
subsample O
( O
n O
 O
= O
 O
370 B-total-participants
) O
was O
randomly O
selected O
to O
wear O
an O
accelerometer O
. O
It O
was O
hypothesized O
that O
self O
- O
efficacy O
directly O
and O
indirectly O
influences O
physical O
activity O
through O
goals O
, O
social O
support O
, O
fatigue O
, O
and O
outcome O
expectations O
. O
Relationships O
were O
examined O
using O
panel O
analysis O
within O
a O
covariance O
modeling O
framework O
. O
The O
hypothesized O
model O
provided O
a O
good O
model O
- O
data O
fit O
( O
 O
( O
2 O
) O
 O
= O
 O
1168.73 O
, O
df O
 O
= O
 O
271 O
, O
p O
 O
= O
 O
< O
0.001 O
, O
CFI O
 O
= O
 O
0.96 O
, O
SRMR O
 O
= O
 O
0.04 O
) O
in O
the O
full O
sample O
when O
controlling O
for O
covariates O
. O
At O
baseline O
, O
self O
- O
efficacy O
directly O
and O
indirectly O
, O
via O
goals O
, O
outcome O
expectations O
, O
and O
social O
support O
, O
influenced O
physical O
activity O
. O
These O
relationships O
were O
also O
supported O
across O
time O
. O
Additionally O
, O
the O
hypothesized O
model O
was O
supported O
in O
the O
subsample O
with O
accelerometer O
data O
( O
2 O
 O
= O
 O
656.88 O
, O
df O
 O
= O
 O
330 O
, O
p O
 O
< O
 O
0.001 O
, O
CFI O
 O
= O
 O
0.95 O
, O
SRMR O
 O
= O
 O
0.05 O
) O
. O
This O
study O
validates O
a O
social O
cognitive O
model O
for O
understanding O
physical O
activity O
behavior O
in O
long O
- O
term O
breast O
cancer O
survivors O
. O
Future O
studies O
should O
be O
designed O
to O
replicate O
this O
model O
in O
other O
breast O
cancer O
survivor O
populations O
, O
and O
the O
findings O
should O
be O
applied O
to O
the O
development O
of O
future O
physical O
activity O
programs O
and O
studies O
for O
this O
population O
. O
  O

Expressive B-intervention
writing I-intervention
in O
early O
breast O
cancer O
survivors O
. O
This O
article O
is O
the O
report O
of O
a O
study O
aimed O
at O
determining O
whether O
or O
not O
expressive O
writing O
improves O
the O
quality O
- O
of O
- O
life O
of O
early B-eligibility
breast I-eligibility
cancer I-eligibility
survivors I-eligibility
. O
An O
additional O
aim O
is O
the O
investigation O
of O
whether O
or O
not O
the O
type O
of O
writing O
prompt O
makes O
a O
difference O
in O
results O
. O
The O
risk O
of O
distress O
can O
extend O
well O
beyond O
the O
time O
of O
a O
breast O
cancer O
diagnosis O
. O
Emotional O
expression O
may O
assist O
in O
dealing O
with O
this O
. O
Randomized O
controlled O
study O
. O
Participants O
( O
n O
= O
120 B-total-participants
) O
were O
randomized O
into O
one O
of O
four O
groups O
: O
a O
control B-control
group I-control
( I-control
no I-control
writing I-control
) I-control
or O
one O
of O
three O
expressive O
writing O
groups O
: O
breast O
cancer O
trauma O
, O
any O
self O
- O
selected O
trauma O
and O
facts O
related O
to O
breast O
cancer O
. O
Participants O
wrote O
20 O
minutes O
a O
day O
for O
4 O
consecutive O
days O
. O
Their O
quality O
- O
of O
- O
life O
was O
measured O
, O
using O
the O
' O
Functional O
Assessment O
of O
Cancer O
Therapy O
- O
Breast O
Cancer O
Version O
' O
, O
at O
baseline O
and O
at O
1 O
month O
and O
6 O
months O
after O
writing O
. O
Paired O
t O
- O
tests O
, O
multivariate O
analysis O
of O
variance O
and O
multiple O
regression O
were O
used O
to O
analyse O
the O
data O
of O
the O
97 B-total-participants
participants O
who O
completed O
the O
journaling O
assignment O
and O
at O
least O
the O
first O
assessment O
, O
collected O
in O
2006 O
. O
Intention O
- O
to O
- O
treat O
analysis O
was O
used O
. O
Expressive O
writing O
about O
one O
's O
breast O
cancer O
, O
breast O
cancer O
trauma O
and O
facts O
related O
to O
breast O
cancer O
, O
significantly O
improved O
the O
quality B-outcome
- I-outcome
of I-outcome
- I-outcome
life I-outcome
outcome I-outcome
. O
Expressive O
writing O
, O
focusing O
the O
instructions O
on O
writing O
about O
one O
's O
living O
and O
dealing O
with O
a O
diagnosis O
of O
breast O
cancer O
, O
is O
recommended O
for O
early O
breast O
cancer O
survivors O
as O
a O
feasible O
and O
easily O
implemented O
treatment O
approach O
to O
improve O
quality O
- O
of O
- O
life O
. O
  O

Lifestyle O
and O
breast O
cancer O
recurrences O
: O
the O
DIANA-5 O
trial O
. O
The O
DIANA O
( O
Diet O
and O
Androgens O
) O
-5 O
study O
is O
a O
multi O
- O
institutional O
randomized O
controlled O
trial O
of O
the O
effectiveness O
of O
a O
diet O
based O
on O
Mediterranean O
and O
macrobiotic O
recipes O
and O
principles O
, O
associated O
with O
moderate O
physical O
activity O
, O
in O
reducing O
additional O
breast O
cancer O
events O
in O
women B-eligibility
with I-eligibility
early I-eligibility
stage I-eligibility
invasive I-eligibility
breast I-eligibility
cancer I-eligibility
at I-eligibility
high I-eligibility
risk I-eligibility
of I-eligibility
recurrence I-eligibility
because I-eligibility
of I-eligibility
metabolic I-eligibility
or I-eligibility
endocrine I-eligibility
milieu I-eligibility
. O
The O
intervention O
is O
expected O
to O
reduce O
serum O
insulin O
and O
sex O
hormones O
, O
which O
were O
associated O
with O
breast O
prognosis O
in O
previous O
studies O
. O
Between O
2008 O
and O
2010 O
, O
the O
study O
randomly O
assigned O
1208 B-total-participants
patients O
to O
an O
intensive B-intervention
diet I-intervention
and I-intervention
exercise I-intervention
intervention O
or O
to O
a O
comparison B-control
group I-control
, O
to O
be O
followed O
- O
up O
through O
2015 O
. O
General O
lifestyle O
recommendations O
for O
the O
prevention O
of O
cancer O
are O
given O
to O
both O
groups O
, O
and O
the O
intervention O
group O
is O
being O
offered O
a O
comprehensive O
lifestyle O
intervention O
, O
including O
cooking O
classes O
, O
conferences O
, O
common O
meals O
and O
exercise O
sessions O
. O
Adherence O
assessments O
occurred O
at O
baseline O
and O
at O
12 O
months O
and O
are O
planned O
at O
36 O
and O
60 O
months O
. O
They O
include O
food O
frequency O
diaries O
, O
anthropometric O
measures O
, O
body O
fat O
distribution O
assessed O
with O
impedance O
scale O
, O
one O
week O
registration O
of O
physical O
activity O
with O
a O
multisensor O
arm O
- O
band O
monitor O
, O
metabolic O
and O
endocrine O
blood O
parameters O
. O
Outcome O
breast O
cancer O
events O
are O
assessed O
through O
self O
report O
at O
semi O
annual O
meetings O
or O
telephone O
interview O
and O
are O
validated O
through O
medical O
record O
verification O
. O
The O
randomized O
groups O
were O
comparable O
for O
age O
( O
51.8 B-age
years I-age
) O
, O
proportion O
of O
ER O
- O
negative O
tumors O
( O
22 O
% O
) O
, O
axillary O
node O
metastasis O
( O
42 O
% O
) O
, O
reproductive O
variables O
, O
tobacco O
smoking O
, O
blood O
pressure O
, O
anthropometric O
measurements O
and O
hormonal O
and O
metabolic O
parameters O
. O
DIANA-5 O
has O
the O
potential O
to O
establish O
whether O
a O
Mediterranean O
- O
macrobiotic O
lifestyle O
may O
reduce B-outcome
breast I-outcome
cancer I-outcome
recurrences I-outcome
. O
We O
will O
assess O
evidence O
of O
effectiveness O
, O
first O
by O
comparing O
the O
incidence O
of O
additional O
breast O
cancer O
events O
( O
local O
or O
distant O
recurrence O
, O
second O
ipsilateral O
or O
contralateral O
cancer O
) O
in O
the O
intervention O
and O
in O
the O
control O
group O
, O
by O
an O
intention O
- O
to O
- O
treat O
analysis O
, O
and O
second O
by O
analyzing O
the O
incidence O
of O
breast O
cancer O
events O
in O
the O
total O
study O
population O
by O
compliance O
assessment O
score O
. O

Prevention O
of O
pegfilgrastim B-condition
- I-condition
induced I-condition
bone I-condition
pain I-condition
: O
a O
phase O
III O
double O
- O
blind O
placebo O
- O
controlled O
randomized O
clinical O
trial O
of O
the O
university O
of O
rochester O
cancer O
center O
clinical O
community O
oncology O
program O
research O
base O
. O
Pegfilgrastim O
- O
induced O
bone O
pain O
is O
a O
significant O
clinical O
problem O
that O
may O
result O
in O
discontinuation O
of O
pegfilgrastim O
and O
lead O
to O
less O
effective O
chemotherapy O
dosing O
. O
Interventions O
for O
pegfilgrastim O
- O
induced O
bone O
pain O
are O
needed O
. O
The O
University O
of O
Rochester O
Cancer O
Center O
Clinical O
Community O
Oncology O
Program O
Research O
Base O
randomly O
assigned O
510 B-total-participants
patients O
at O
17 O
sites O
to O
receive O
either O
naproxen B-intervention
( O
500 O
mg O
two O
times O
per O
day O
) O
or O
placebo B-control
on O
the O
day O
of O
pegfilgrastim O
administration O
, O
continuing O
for O
5 O
to O
8 O
days O
after O
pegfilgrastim O
. O
Patients O
recorded O
pain O
severity O
( O
using O
a O
scale O
of O
0 O
to O
10 O
) O
and O
duration O
in O
daily O
diaries O
. O
The O
primary O
outcome O
measure O
was O
the O
area B-outcome-measure
under I-outcome-measure
the I-outcome-measure
curve I-outcome-measure
( I-outcome-measure
AUC I-outcome-measure
) I-outcome-measure
for I-outcome-measure
pain I-outcome-measure
for I-outcome-measure
days I-outcome-measure
1 I-outcome-measure
through I-outcome-measure
5 I-outcome-measure
. O
Secondary O
outcome O
measures O
included O
the O
identification O
of O
risk B-outcome-measure
factors I-outcome-measure
for I-outcome-measure
the I-outcome-measure
development I-outcome-measure
of I-outcome-measure
pain I-outcome-measure
and O
response B-outcome-measure
to I-outcome-measure
naproxen I-outcome-measure
. O
Patients O
' O
mean O
age O
was O
55.6 B-age
years I-age
and O
86 O
% O
were O
female O
. O
Sixty O
- O
eight O
percent O
of O
patients O
had O
breast O
cancer O
and O
10 O
% O
had O
lung O
cancer O
. O
Pain B-outcome
reached O
its O
peak O
at O
3 O
days O
for O
both O
groups O
. O
The O
mean B-outcome
AUC I-outcome
for I-outcome
pain I-outcome
was O
7.71 B-cv-cont-mean
for O
the O
placebo O
group O
and O
6.04 B-iv-cont-mean
for O
the O
naproxen O
group O
( O
P O
= O
.037 O
) O
. O
Naproxen O
reduced O
maximum B-outcome
pain I-outcome
from O
3.40 B-iv-cont-mean
to O
2.59 B-iv-cont-mean
( O
P O
= O
.005 O
) O
. O
Naproxen O
also O
reduced O
overall B-outcome
pain I-outcome
incidence I-outcome
from O
71.3 B-iv-cont-mean
% I-iv-cont-mean
to O
61.1 B-iv-cont-mean
% I-iv-cont-mean
( O
P O
= O
.020 O
) O
and O
duration B-outcome
from O
2.40 B-iv-cont-mean
to O
1.92 B-iv-cont-mean
days I-iv-cont-mean
( O
P O
= O
.009 O
) O
. O
The O
reduction B-outcome
in I-outcome
severe I-outcome
pain I-outcome
( O
> O
5 O
on O
a O
scale O
of O
1 O
to O
10 O
) O
from O
27.0 B-iv-cont-mean
% I-iv-cont-mean
to O
19.2 B-iv-cont-mean
% I-iv-cont-mean
was O
also O
significant O
( O
P O
= O
.048 O
) O
. O
Risk O
factors O
could O
not O
be O
identified O
to O
predict O
incidence O
, O
severity O
, O
or O
ability O
to O
prevent O
pegfilgrastim O
- O
induced O
bone O
pain O
. O
Our O
phase O
III O
randomized O
placebo O
- O
controlled O
clinical O
trial O
demonstrated O
that O
naproxen O
at O
a O
dose O
of O
500 O
mg O
twice O
per O
day O
is O
effective O
in O
reducing O
the O
incidence O
and O
severity O
of O
pegfilgrastim O
- O
induced O
bone O
pain O
. O

Randomized O
control O
trial O
: O
evaluating O
aluminum B-intervention
- I-intervention
based I-intervention
antiperspirant I-intervention
use O
, O
axilla O
skin O
toxicity O
, O
and O
reported O
quality O
of O
life O
in O
women B-eligibility
receiving I-eligibility
external I-eligibility
beam I-eligibility
radiotherapy I-eligibility
for I-eligibility
treatment I-eligibility
of I-eligibility
Stage I-eligibility
0 I-eligibility
, I-eligibility
I I-eligibility
, I-eligibility
and I-eligibility
II I-eligibility
breast I-eligibility
cancer I-eligibility
. O
Standard O
skin O
care O
instructions O
regarding O
the O
use O
of O
antiperspirants O
during O
radiotherapy O
to O
the O
breast O
varies O
across O
North B-location
America I-location
. O
Women O
have O
articulated O
that O
when O
instructed O
to O
not O
use O
antiperspirant O
, O
the O
potential O
for O
body O
odor O
is O
distressing O
. O
Historical O
practices O
and O
individual O
opinions O
have O
often O
guided O
practice O
in O
this O
field O
. O
The O
present O
study O
had O
2 O
purposes O
. O
To O
evaluate O
whether O
the O
use O
of O
aluminum O
- O
based O
antiperspirant O
while O
receiving O
external O
beam O
radiotherapy O
for O
stage O
0 O
, O
I O
, O
or O
II O
breast O
cancer O
will O
increase O
axilla O
skin O
toxicity O
and O
to O
evaluate O
whether O
the O
use O
of O
antiperspirant O
during O
external O
beam O
radiotherapy O
improves O
quality O
of O
life O
. O
A O
total O
of O
198 B-total-participants
participants O
were O
randomized O
to O
either O
the O
experimental O
group O
( O
antiperspirant O
) O
or O
control B-control
group I-control
( I-control
standard I-control
care I-control
- I-control
wash I-control
only I-control
) I-control
. O
The O
skin O
reactions O
in O
both O
groups O
were O
measured O
weekly O
and O
2 O
weeks O
after O
treatment O
using O
the O
National O
Cancer O
Institute O
Common O
Toxicity O
Criteria O
Adverse O
Events O
, O
version O
3 O
, O
toxicity O
grading O
criteria O
. O
Both O
groups O
completed O
the O
Functional O
Assessment O
for O
Chronic O
Illness O
Therapy O
's O
questionnaire O
for O
the O
breast O
population O
quality O
of O
life O
assessment O
tool O
, O
with O
additional O
questions O
evaluating O
the O
effect O
of O
underarm O
antiperspirant O
use O
on O
quality O
of O
life O
before O
treatment O
, O
immediately O
after O
treatment O
, O
and O
2 O
weeks O
after O
treatment O
during O
the O
study O
. O
The O
skin O
reaction O
data O
were O
analyzed O
using O
the O
generalized O
estimating O
equation O
. O
No O
statistically O
significant O
difference O
was O
seen O
in O
the O
skin B-outcome
reaction I-outcome
between O
the O
2 O
groups O
over O
time O
. O
The O
quality B-outcome
of I-outcome
life I-outcome
data O
also O
revealed O
no O
statistically O
significant O
difference O
between O
the O
2 O
groups O
over O
time O
. O
Data O
analysis O
indicates O
that O
using O
antiperspirant O
routinely O
during O
external O
beam O
radiotherapy O
for O
Stage O
0 O
, O
I O
, O
or O
II O
breast O
cancer O
does O
not O
affect O
the O
intensity O
of O
the O
skin O
reaction O
or O
the O
self O
- O
reported O
quality O
of O
life O
. O
This O
evidence O
supports O
that O
in O
this O
particular O
population O
, O
there O
is O
no O
purpose O
to O
restrict O
these O
women O
from O
using O
antiperspirants O
during O
their O
treatment O
, O
and O
the O
decision O
to O
use O
an O
antiperspirant O
or O
not O
in O
this O
setting O
should O
be O
left O
to O
the O
discretion O
of O
the O
patient O
. O
  O

A O
prospective O
, O
multicenter O
, O
controlled O
, O
observational O
study O
to O
evaluate O
the O
efficacy O
of O
a O
patient B-intervention
support I-intervention
program I-intervention
in O
improving O
patients O
' O
persistence O
to O
adjuvant O
aromatase O
inhibitor O
medication O
for O
postmenopausal O
, O
early O
stage O
breast O
cancer O
. O
Since O
the O
rate O
of O
persistence O
to O
adjuvant O
endocrine O
therapy O
such O
as O
5 O
- O
year O
aromatase O
inhibitors O
( O
AI O
) O
would O
decrease O
over O
time O
in O
patients O
with O
hormone O
- O
sensitive O
breast O
cancer O
, O
it O
is O
necessary O
to O
investigate O
if O
a O
patient O
support O
program O
could O
modify O
patients O
' O
beliefs O
and O
improve O
their O
persistence O
to O
AI O
treatment O
. O
This O
was O
a O
prospective O
, O
multicenter O
, O
controlled O
, O
observational O
study O
to O
evaluate O
the O
efficacy O
of O
a O
patient O
support O
program O
in O
improving O
postmenopausal O
patients O
' O
persistence O
to O
adjuvant O
AI O
medication O
for O
early O
stage O
breast O
cancer O
( O
NCT00769080 O
) O
. O
The O
primary O
objective O
was O
to O
compare O
the O
rates B-outcome-measure
of I-outcome-measure
1 I-outcome-measure
- I-outcome-measure
year I-outcome-measure
persistence I-outcome-measure
to O
upfront O
adjuvant O
AI O
for O
patients O
in O
the O
two O
observational O
arms O
( O
standard B-control
treatment I-control
group I-control
and O
standard O
treatment O
plus O
patient O
support O
program O
group O
) O
. O
In O
this O
study O
, O
262 B-control-participants
patients O
were O
enrolled O
in O
the O
standard O
treatment O
group O
and O
241 B-intervention-participants
patients O
in O
the O
standard O
treatment O
plus O
patient O
support O
program O
group O
. O
The O
mean B-outcome
1 I-outcome
- I-outcome
year I-outcome
persistence I-outcome
rates I-outcome
were O
95.9 B-cv-cont-mean
and O
95.8 B-iv-cont-mean
% I-iv-cont-mean
for O
the O
standard O
treatment O
group O
and O
the O
standard O
treatment O
plus O
patient O
support O
program O
group O
, O
respectively O
( O
P O
= O
0.95 O
) O
. O
The O
mean B-outcome
times I-outcome
to I-outcome
treatment I-outcome
discontinuation I-outcome
were O
231.2 B-cv-cont-mean
days I-cv-cont-mean
in O
the O
standard O
treatment O
group O
and O
227.8 B-iv-cont-mean
days I-iv-cont-mean
in O
the O
standard O
treatment O
plus O
patient O
support O
program O
group O
, O
with O
no O
statistically O
significant O
difference O
between O
the O
two O
groups O
( O
P O
= O
0.96 O
) O
. O
There O
was O
also O
no O
statistically O
significant O
difference O
in O
the O
reason O
for O
treatment B-outcome
discontinuation I-outcome
( O
P O
= O
0.32 O
) O
. O
There O
was O
a O
significant O
relationship O
between O
the O
patient O
centered O
care O
questionnaire O
and O
poor O
persistence O
( O
odds O
ratio O
= O
3.9 O
; O
95 O
% O
CI O
, O
1.1 O
- O
13.7 O
; O
P O
= O
0.035 O
) O
, O
suggesting O
that O
the O
persistence B-outcome
rate I-outcome
of O
patients O
with O
whom O
the O
doctor O
always O
or O
usually O
spends O
time O
is O
greater O
than O
that O
of O
patients O
with O
whom O
the O
doctor O
sometimes O
or O
never O
spends O
time O
. O
Patients O
' O
persistence O
to O
adjuvant O
AI O
medication O
for O
postmenopausal O
, O
early O
stage O
breast O
cancer O
is O
relatively O
high O
in O
the O
first O
year O
and O
is O
not O
significantly O
increased O
by O
adding O
a O
patient O
support O
program O
to O
standard O
treatment O
. O

Exemestane B-intervention
for O
breast O
cancer O
prevention O
: O
a O
critical O
shift O
? O
The O
Mammary O
Prevention O
3 O
( O
MAP.3 O
) O
placebo O
- O
controlled O
randomized O
trial O
in O
4,560 B-total-participants
high B-eligibility
- I-eligibility
risk I-eligibility
postmenopausal I-eligibility
women I-eligibility
showed O
a O
65 B-iv-bin-percent
% I-iv-bin-percent
reduction B-outcome
in I-outcome
invasive I-outcome
breast I-outcome
cancer I-outcome
with O
the O
use O
of O
exemestane O
at O
35 O
months O
median O
follow O
- O
up O
. O
Few O
differences O
in O
adverse B-outcome
events I-outcome
were O
observed O
between O
the O
arms O
, O
suggesting O
a O
promising O
risk O
: O
benefit O
balance O
with O
exemestane O
for O
use O
in O
chemoprevention O
. O
Yet O
, O
the O
MAP.3 O
design O
and O
implementation O
raise O
concerns O
regarding O
limited O
data O
maturity O
and O
not O
prospectively O
including O
key O
bone O
- O
related O
and O
other O
toxicities O
as O
study O
end O
points O
. O
Exemestane O
for O
prevention O
is O
juxtaposed O
against O
selective O
estrogen O
receptor O
modulators O
and O
the O
other O
aromatase O
inhibitors O
. O
Additional O
issues O
for O
prevention O
, O
including O
the O
influence O
of O
obesity O
, O
alternative O
dosing O
, O
and O
biomarker O
use O
in O
phase O
III O
trials O
, O
are O
addressed O
. O
The O
recently O
completed O
MAP.3 O
trial O
of O
exemestane O
for O
breast O
cancer O
prevention O
offers O
a O
potential O
new O
standard O
for O
pharmaceutical O
risk O
reduction O
in O
high O
- O
risk O
postmenopausal O
women O
. O
In O
addition O
to O
describing O
key O
findings O
from O
the O
publication O
of O
MAP.3 O
and O
related O
trials O
, O
our O
review O
undertakes O
a O
detailed O
analysis O
of O
the O
strengths O
and O
weaknesses O
of O
MAP.3 O
as O
well O
as O
the O
implications O
for O
future O
prevention O
research O
. O

Effect O
of O
different O
doses O
of O
metformin B-intervention
on O
serum B-condition
testosterone I-condition
and I-condition
insulin I-condition
in O
non O
- O
diabetic O
women O
with O
breast O
cancer O
: O
a O
randomized O
study O
. O
This O
is O
a O
randomized O
controlled O
trial O
to O
test O
the O
effect O
of O
different O
doses O
of O
metformin O
in O
patients O
with O
breast O
cancer O
and O
without O
diabetes O
, O
with O
the O
aim O
of O
modifying O
the O
hormonal O
and O
metabolic O
parameters O
linked O
to O
breast O
cancer O
prognosis O
. O
Analysis O
of O
the O
results O
suggest O
that O
the O
dose O
of O
1500 O
mg O
/ O
d O
of O
metformin O
causes O
a O
significant O
reduction O
of O
insulin O
and O
testosterone O
serum O
levels O
. O
Serum O
levels O
of O
insulin O
and O
testosterone O
may O
affect O
both O
breast O
cancer O
( O
BC O
) O
incidence O
and O
prognosis O
. O
Metformin O
reduces O
hyperglycemia O
and O
insulin O
levels O
in O
patients O
with O
diabetes O
. O
In O
women O
without O
diabetes O
and O
with O
polycystic O
ovary O
syndrome O
, O
metformin O
lowers O
both O
insulin O
and O
testosterone O
levels O
. O
Patients O
with O
diabetes O
who O
are O
treated O
with O
metformin O
showed O
a O
lower O
risk O
of O
cancer O
; O
a O
protective O
effect O
of O
metformin O
also O
was O
observed O
for O
BC O
. O
Recently O
, O
studies O
on O
metformin O
use O
for O
prevention O
or O
treatment O
of O
BC O
have O
been O
proposed O
in O
patients O
who O
are O
not O
diabetic O
. O
The O
aim O
of O
the O
present O
study O
was O
to O
test O
the O
effect O
of O
different O
doses O
of O
metformin O
on O
serum O
levels O
of O
insulin O
and O
testosterone O
in O
those O
postmenopausal B-eligibility
patients I-eligibility
with I-eligibility
breast I-eligibility
cancer I-eligibility
and I-eligibility
without I-eligibility
diabetes I-eligibility
who I-eligibility
have I-eligibility
basal I-eligibility
testosterone I-eligibility
levels I-eligibility
0.28 I-eligibility
ng I-eligibility
/ I-eligibility
mL I-eligibility
( O
median O
value O
) O
. O
A O
total O
of O
125 B-total-participants
eligible O
women O
were O
initially O
invited O
to O
take O
metformin O
500 O
mg O
/ O
d O
for O
3 O
months O
. O
The O
108 B-total-participants
women O
who O
completed O
the O
first O
3 O
months O
were O
invited O
to O
continue O
the O
study O
with O
metformin O
1000 O
mg O
/ O
d O
( O
500 O
mg O
twice O
a O
day O
[ O
b.i.d O
. O
] O
) O
for O
1 O
month O
. O
The O
women O
were O
then O
randomized O
into O
2 O
groups O
, O
and O
, O
for O
the O
subsequent O
5 O
months O
, O
1 O
group O
increased O
the O
dose O
by O
taking O
metformin O
1500 O
mg O
/ O
d O
( O
500 O
mg O
3 O
times O
a O
day O
[ O
t.i.d O
. O
] O
) O
, O
and O
the O
other O
group O
continued O
with O
metformin B-control
1000 I-control
mg I-control
/d I-control
( O
500 O
[ O
b.i.d O
. O
] O
) O
. O
A O
total O
of O
96 B-total-participants
women O
completed O
the O
study O
: O
43 B-intervention-participants
women O
received O
1500 O
mg O
/ O
d O
, O
and O
53 B-control-participants
women O
received O
1000 O
mg O
/ O
d. O
The O
women O
who O
took O
1500 O
mg O
/ O
d O
showed O
a O
significant O
reduction O
of O
insulin B-outcome
level I-outcome
, O
HOMA B-outcome
- I-outcome
IR I-outcome
index I-outcome
( O
homeostasis O
model O
assessment O
- O
insulin O
resistance O
index O
) O
, O
testosterone B-outcome
level I-outcome
, O
and O
free B-outcome
androgen I-outcome
index I-outcome
compared O
with O
women O
treated O
with O
1000 O
mg O
/ O
d. O
After O
treatment O
with O
1500 O
mg O
/ O
d O
, O
the O
insulin B-outcome
level I-outcome
decreased O
by O
25 O
% O
and O
the O
testosterone B-outcome
level I-outcome
decreased O
by O
23 O
% O
. O
Both O
these O
changes O
might O
have O
a O
prognostic O
importance O
. O
  O

Safety O
results O
from O
a O
phase O
III O
study O
( O
TURANDOT O
trial O
by O
CECOG O
) O
of O
first O
- O
line O
bevacizumab B-intervention
in I-intervention
combination I-intervention
with I-intervention
capecitabine I-intervention
or O
paclitaxel B-control
for O
HER-2 O
- O
negative O
locally O
recurrent O
or O
metastatic O
breast O
cancer O
. O
We O
report O
safety O
data O
from O
a O
randomised O
, O
phase O
III O
study O
( O
CECOG O
/ O
BC.1.3.005 O
) O
evaluating O
first O
- O
line O
bevacizumab O
plus O
paclitaxel O
or O
capecitabine O
for O
locally O
recurrent O
or O
metastatic O
breast O
cancer O
. O
Patients O
aged O
18 B-age
years I-age
with O
human O
epidermal O
growth O
factor O
receptor-2 O
- O
negative O
breast O
adenocarcinoma O
were O
randomised O
to O
Arm O
A O
: O
bevacizumab O
10 O
mg O
/ O
kg O
days O
1 O
and O
15 O
; O
paclitaxel O
90 O
mg O
/ O
m O
( O
2 O
) O
days O
1 O
, O
8 O
, O
and O
15 O
, O
every O
4 O
weeks O
; O
or O
Arm O
B O
: O
bevacizumab O
15 O
mg O
/ O
kg O
day O
1 O
; O
capecitabine O
1000 O
mg O
/ O
m O
( O
2 O
) O
b.i.d O
. O
, O
days O
1 O
- O
14 O
, O
every O
3 O
weeks O
, O
until O
disease O
progression O
, O
unacceptable O
toxicity O
or O
consent O
withdrawal O
. O
A O
post O
hoc O
interim O
safety O
analysis O
included O
561 B-total-participants
patients O
( O
Arm O
A O
: O
284 B-intervention-participants
, O
Arm O
B O
: O
277 B-control-participants
) O
. O
The O
regimens O
demonstrated O
similar O
frequencies O
of O
all O
- O
grade O
and O
serious O
adverse O
events O
( O
SAEs O
) O
, O
but O
different O
safety O
profiles O
. O
Treatment B-outcome
- I-outcome
related I-outcome
events I-outcome
occurred O
in O
85.2 B-iv-bin-percent
% I-iv-bin-percent
( O
Arm O
A O
) O
and O
78.0 B-cv-bin-percent
% I-cv-bin-percent
( O
Arm O
B O
) O
of O
patients O
. O
Fatigue B-outcome
was O
most O
common O
in O
Arm O
A O
( O
30.6 B-iv-bin-percent
% I-iv-bin-percent
versus O
23.5 B-cv-bin-percent
% I-cv-bin-percent
Arm O
B O
) O
, O
and O
hand B-outcome
- I-outcome
foot I-outcome
syndrome I-outcome
( I-outcome
HFS I-outcome
) I-outcome
most O
common O
in O
Arm O
B O
( O
49.5 B-cv-bin-percent
% I-cv-bin-percent
versus O
2.5 B-iv-bin-percent
% I-iv-bin-percent
Arm O
A O
) O
. O
Diarrhoea B-outcome
( O
Arm O
A O
: O
0.4 B-iv-bin-percent
% I-iv-bin-percent
, O
Arm O
B O
: O
1.4 B-cv-bin-percent
% I-cv-bin-percent
) O
and O
pulmonary B-outcome
embolism I-outcome
( O
Arm O
A O
: O
0.7 B-iv-bin-percent
% I-iv-bin-percent
, O
Arm O
B O
: O
1.1 B-cv-bin-percent
% I-cv-bin-percent
) O
were O
the O
most O
frequently O
reported O
SAEs O
. O
These O
findings O
are O
in O
- O
line O
with O
safety O
data O
for O
bevacizumab O
plus O
paclitaxel O
or O
capecitabine O
, O
reported O
in O
previous O
phase O
III O
trials O
. O

Administration O
of O
omega-3 B-intervention
fatty I-intervention
acids I-intervention
and I-intervention
Raloxifene I-intervention
to O
women O
at O
high O
risk O
of O
breast O
cancer O
: O
interim O
feasibility O
and O
biomarkers O
analysis O
from O
a O
clinical O
trial O
. O
The O
antiestrogen O
, O
Raloxifene O
( O
Ral O
) O
is O
an O
effective O
breast O
cancer O
chemopreventive O
agent O
. O
Omega-3 O
fatty O
acids O
( O
n-3FA O
) O
may O
inhibit O
mammary O
carcinogenesis O
. O
On O
the O
basis O
of O
their O
mechanisms O
of O
action O
, O
we O
test O
the O
hypothesis O
that O
a O
combination O
of O
n-3FA O
and O
Ral O
may O
be O
superior O
in O
reducing O
select O
biomarkers O
of O
breast O
cancer O
risk O
in O
women O
. O
Postmenopausal B-eligibility
women I-eligibility
at I-eligibility
increased I-eligibility
risk I-eligibility
for I-eligibility
breast I-eligibility
cancer I-eligibility
( O
breast O
density O
 O
25 O
% O
) O
were O
randomized O
to O
: O
( O
1 O
) O
no B-control
intervention I-control
; O
( O
2 O
) O
Ral O
60 O
mg O
; O
( O
3 O
) O
Ral O
30 O
mg O
; O
( O
4 O
) O
n-3FA O
( O
Lovaza O
) O
4 O
g O
and O
( O
5 O
) O
Lovaza O
4 O
g+Ral O
30 O
mg O
for O
2 O
years O
. O
Reduction B-outcome-measure
in I-outcome-measure
breast I-outcome-measure
density I-outcome-measure
is O
the O
primary O
end O
point O
of O
the O
study O
. O
We O
report O
preliminary O
data O
on O
feasibility O
, O
compliance O
and O
changes O
in O
secondary O
end O
points O
related O
to O
IGF O
- O
I O
signaling O
, O
estrogen O
metabolism O
, O
oxidative O
stress O
and O
inflammation O
in O
the O
first O
group O
of O
46 B-total-participants
women O
who O
completed O
1 O
year O
of O
the O
study O
. O
All O
interventions O
were O
well B-outcome
tolerated I-outcome
with O
excellent O
compliance B-outcome
( O
96 O
 O
1 O
% O
overall O
) O
by O
pill O
count O
and O
also O
supported O
by O
the O
expected O
rise O
in O
both O
serum B-outcome
n-3FA I-outcome
and I-outcome
n-3FA I-outcome
/ I-outcome
Omega-6 I-outcome
fatty I-outcome
acids I-outcome
( I-outcome
n-6FA I-outcome
) I-outcome
ratio I-outcome
in O
women O
randomized O
to O
groups O
4 O
and O
5 O
( O
P<0.05 O
) O
. O
Lovaza O
decreased O
serum B-outcome
triglycerides I-outcome
and O
increased O
high B-outcome
- I-outcome
density I-outcome
lipoprotein I-outcome
( I-outcome
HDL I-outcome
) I-outcome
cholesterol I-outcome
compared O
with O
control O
( O
P<0.05 O
for O
both O
) O
. O
Ral O
reduced O
serum B-outcome
IGF-1 I-outcome
in O
a O
dose O
- O
dependent O
manner O
( O
P<0.05 O
) O
while O
Lovaza O
did O
not O
. O
Lovaza O
had O
no O
effect O
on O
IGF-1 B-outcome
or I-outcome
IGFBP-3 I-outcome
. O
None O
of O
the O
other O
biomarkers O
were O
affected O
by O
our O
treatment O
. O
The O
combination O
of O
Lovaza O
and O
Ral O
is O
a O
feasible O
strategy O
that O
may O
be O
recommended O
in O
future O
breast O
cancer O
chemoprevention O
trials O
. O

Chemotherapy B-intervention
( I-intervention
CT I-intervention
) I-intervention
and O
hormonotherapy B-control
( I-control
HT I-control
) I-control
as O
neoadjuvant O
treatment O
in O
luminal B-eligibility
breast I-eligibility
cancer I-eligibility
patients I-eligibility
: O
results O
from O
the O
GEICAM O
/ O
2006 O
- O
03 O
, O
a O
multicenter O
, O
randomized O
, O
phase O
- O
II O
study O
. O
Luminal O
breast O
cancer O
is O
a O
highly O
endocrine O
responsive O
disease O
. O
However O
, O
the O
therapeutic O
benefit O
of O
chemotherapy O
( O
CT O
) O
in O
this O
population O
is O
not O
fully O
characterized O
. O
This O
study O
investigates O
the O
value O
of O
CT O
and O
hormone O
therapy O
( O
HT O
) O
in O
luminal O
breast O
cancer O
patients O
in O
the O
neoadjuvant O
setting O
. O
Patients O
with O
operable O
breast O
cancer O
and O
immunophenotypically O
defined O
luminal O
disease O
( O
ER+/PR+/HER2-/cytokeratin O
8 O
/ O
18 O
+ O
) O
were O
recruited O
. O
Patients O
were O
randomized O
to O
CT O
( O
epirubicin O
90 O
mg O
/ O
m O
( O
2 O
) O
plus O
cyclophosphamide O
600 O
mg O
/ O
m O
( O
2 O
) O
4 O
cycles O
followed O
by O
docetaxel O
100 O
mg O
/ O
m O
( O
2 O
) O
4 O
cycles O
[ O
EC O
- O
T O
] O
) O
or O
HT O
( O
exemestane O
25 O
mg O
daily O
24 O
weeks O
[ O
combined O
with O
goserelin O
in O
premenopausal O
patients O
] O
) O
. O
The O
primary O
end O
point O
was O
the O
clinical B-outcome-measure
response I-outcome-measure
measured O
by O
magnetic O
resonance O
imaging O
. O
Ninety B-total-participants
- I-total-participants
five I-total-participants
patients O
were O
randomized O
( O
47 B-intervention-participants
CT O
, O
48 B-control-participants
HT O
) O
. O
The O
clinical B-outcome
response I-outcome
rate I-outcome
was O
66 B-iv-bin-percent
% I-iv-bin-percent
for O
CT O
and O
48 B-cv-bin-percent
% I-cv-bin-percent
for O
HT O
( O
P O
= O
0.075 O
) O
. O
We O
performed O
an O
unplanned O
analysis O
based O
on O
Ki67 O
levels O
( O
cut O
- O
off O
of O
10 O
% O
) O
. O
Similar O
clinical B-outcome
response I-outcome
was O
seen O
between O
arms O
in O
patients B-outcome
with I-outcome
low I-outcome
Ki67 I-outcome
( O
CT O
: O
63 B-iv-bin-percent
% I-iv-bin-percent
, O
HT O
: O
58 B-cv-bin-percent
% I-cv-bin-percent
; O
P O
= O
0.74 O
) O
; O
patients B-outcome
with I-outcome
high I-outcome
Ki67 I-outcome
had O
a O
better O
response O
with O
CT O
( O
67 B-iv-bin-percent
versus O
42 B-cv-bin-percent
% I-cv-bin-percent
; O
P O
= O
0.075 O
) O
. O
Grade B-outcome
3 I-outcome
/ I-outcome
4 I-outcome
toxicity I-outcome
was O
more O
frequent O
with O
CT O
. O
Luminal O
immunophenotype O
is O
not O
enough O
to O
identify O
patients O
who O
do O
not O
benefit O
from O
neoadjuvant O
CT O
. O
Luminal O
patients O
with O
low O
proliferation O
index O
could O
potentially O
avoid O
CT O
. O

Perioperative B-intervention
intravenous I-intervention
lidocaine I-intervention
decreases O
the O
incidence B-condition
of I-condition
persistent I-condition
pain I-condition
after O
breast O
surgery O
. O
Breast O
cancer O
surgery O
is O
associated O
with O
a O
high O
incidence O
of O
persistent B-condition
postsurgical I-condition
pain I-condition
( I-condition
PPSP I-condition
) I-condition
. O
The O
aim O
of O
this O
study O
was O
to O
evaluate O
the O
impact O
of O
intravenous O
( O
IV O
) O
lidocaine O
on O
acute O
and O
PPSP O
, O
analgesic O
requirements O
, O
and O
sensation O
abnormalities O
in O
patients O
undergoing O
surgery O
for O
breast O
cancer O
. O
Thirty B-total-participants
- I-total-participants
six I-total-participants
patients O
participated O
in O
this O
randomized O
, O
double O
- O
blinded O
study O
. O
Before O
induction O
of O
general O
anesthesia O
, O
patients O
received O
a O
bolus O
of O
intravenous O
lidocaine O
1.5 O
mg O
/ O
kg O
followed O
by O
a O
continuous O
infusion O
of O
lidocaine O
1.5 O
mg O
/ O
kgh O
( O
lidocaine O
group O
) O
or O
an O
equal O
volume O
of O
saline B-control
( I-control
control I-control
group I-control
) I-control
. O
The O
infusion O
was O
stopped O
1 O
hour O
after O
the O
skin O
closure O
. O
Pain O
scores O
and O
analgesic O
consumption O
were O
recorded O
at O
2 O
, O
4 O
, O
24 O
hours O
, O
and O
then O
daily O
for O
1 O
week O
postoperatively O
. O
Three O
months O
later O
, O
patients O
were O
assessed O
for O
PPSP O
and O
secondary O
hyperalgesia O
. O
Two B-iv-bin-abs
( O
11.8 B-iv-bin-percent
% I-iv-bin-percent
) O
patients O
in O
the O
lidocaine O
group O
and O
9 B-cv-bin-abs
( O
47.4 B-cv-bin-percent
% I-cv-bin-percent
) O
patients O
in O
the O
control O
group O
reported O
PPSP B-outcome
at I-outcome
3 I-outcome
months I-outcome
follow I-outcome
- I-outcome
up I-outcome
( O
P O
= O
0.031 O
) O
. O
McGill O
Pain O
Questionnaire O
revealed O
greater O
present O
pain B-outcome
intensity I-outcome
- I-outcome
visual I-outcome
analog I-outcome
scale I-outcome
in O
the O
control O
group O
( O
14.6 B-iv-cont-mean
 O
22.5 B-iv-cont-sd
vs. O
2.6 B-cv-cont-mean
 O
7.5 B-cv-cont-sd
; O
P O
= O
0.025 O
) O
. O
Secondary B-outcome
hyperalgesia I-outcome
( O
area B-outcome
of I-outcome
hyperalgesia I-outcome
/ I-outcome
length I-outcome
of I-outcome
surgical I-outcome
incision I-outcome
) O
was O
significantly O
less O
in O
the O
lidocaine O
group O
compared O
with O
control O
group O
( O
0.2 B-iv-cont-mean
 O
0.8 B-iv-cont-sd
vs. O
3.2 B-cv-cont-mean
 O
4.5 B-cv-cont-sd
cm I-cv-cont-sd
; O
P O
= O
0.002 O
) O
. O
The O
2 O
groups O
were O
similar O
in O
terms O
of O
analgesic B-outcome
consumption I-outcome
during O
the O
early O
postoperative O
period O
. O
Intravenous O
perioperative O
lidocaine O
decreases O
the O
incidence B-outcome
and I-outcome
severity I-outcome
of I-outcome
PPSP I-outcome
after O
breast O
cancer O
surgery O
. O
Prevention O
of O
the O
induction O
of O
central O
hyperalgesia O
is O
a O
potential O
mechanism O
. O

Lanreotide B-intervention
Autogel I-intervention
90 O
mg O
and O
lymphorrhea B-condition
prevention O
after O
axillary O
node O
dissection O
in O
breast O
cancer O
: O
a O
phase O
III O
double O
blind O
, O
randomized O
, O
placebo O
- O
controlled O
trial O
. O
The O
aim O
of O
this O
study O
was O
to O
assess O
the O
efficacy O
of O
Lanreotide O
Autogel O
90 O
mg O
PR O
to O
prevent O
lymphorrhea O
after O
axillary O
dissection O
in O
breast O
cancer O
. O
A O
Phase O
III O
double O
- O
blind O
, O
randomized O
, O
placebo O
- O
controlled O
trial O
was O
performed O
between O
April O
1st O
, O
2008 O
, O
and O
December O
31st O
, O
2010 O
. O
The O
primary O
endpoint O
was O
the O
lymphorrhea B-outcome-measure
volume I-outcome-measure
( I-outcome-measure
ml I-outcome-measure
) I-outcome-measure
in I-outcome-measure
the I-outcome-measure
axillary I-outcome-measure
drain I-outcome-measure
during I-outcome-measure
the I-outcome-measure
first I-outcome-measure
four I-outcome-measure
postoperative I-outcome-measure
days I-outcome-measure
. O
The O
secondary O
end O
points O
were O
the O
number B-outcome-measure
of I-outcome-measure
days I-outcome-measure
until I-outcome-measure
axillary I-outcome-measure
drain I-outcome-measure
removal I-outcome-measure
, O
hospital B-outcome-measure
stay I-outcome-measure
duration I-outcome-measure
( I-outcome-measure
days I-outcome-measure
) I-outcome-measure
, O
lymphorrhea B-outcome-measure
volume I-outcome-measure
( I-outcome-measure
ml I-outcome-measure
) I-outcome-measure
up O
to O
days O
15 O
, O
30 O
and O
180 O
, O
number B-outcome-measure
of I-outcome-measure
cases I-outcome-measure
with I-outcome-measure
seroma I-outcome-measure
aspiration I-outcome-measure
and I-outcome-measure
number I-outcome-measure
of I-outcome-measure
seroma I-outcome-measure
aspirations I-outcome-measure
, O
evaluation B-outcome-measure
of I-outcome-measure
wound I-outcome-measure
, O
arm B-outcome-measure
pain I-outcome-measure
and O
mobility B-outcome-measure
on O
days O
15 O
, O
30 O
and O
180 O
. O
A O
total O
of O
148 B-total-participants
patients O
were O
recruited O
for O
the O
study O
. O
Altogether O
145 B-total-participants
patients O
were O
randomized O
and O
analysed O
on O
an O
intention O
- O
to O
- O
treat O
basis O
. O
On O
the O
day O
before O
surgery O
73 B-control-participants
patients O
received O
the O
placebo B-control
and O
72 B-intervention-participants
patients O
received O
lanreotide O
. O
At O
four O
postoperative O
days O
, O
there O
was O
a O
tendency O
towards O
a O
reduction B-outcome
of I-outcome
the I-outcome
lymphorrhea I-outcome
volume I-outcome
in O
the O
lanreotide O
group O
( O
median O
292 B-iv-cont-median
ml I-iv-cont-median
, O
range O
1 O
- O
965 O
ml O
) O
as O
compared O
to O
the O
placebo O
group O
( O
median O
337 B-cv-cont-median
ml I-cv-cont-median
, O
range O
0 O
- O
1230 O
ml O
) O
, O
although O
it O
was O
not O
statistically O
significant O
( O
p O
= O
0.18 O
) O
. O
There O
was O
no B-outcome
significant I-outcome
difference I-outcome
for I-outcome
the I-outcome
secondary I-outcome
end I-outcome
points I-outcome
. O
In O
the O
group O
with O
axillary O
dissection O
performed O
alone O
( O
n O
= O
24 O
) O
, O
the O
lymphorrhea B-outcome
volume I-outcome
was O
shown O
to O
be O
significantly O
reduced O
in O
the O
lanreotide O
group O
, O
( O
p O
= O
0.035 O
) O
as O
compared O
to O
the O
placebo O
group O
. O
Our O
study O
did O
not O
identify O
any O
overall O
significant O
reduction O
of O
lymphorrhea O
on O
lanreotide O
. O
  O

Impact O
of O
an O
educational B-intervention
intervention O
designed O
to O
reduce O
unnecessary O
recall O
during O
screening O
mammography O
. O
The O
aim O
of O
this O
study O
was O
to O
describe O
the O
impact O
of O
a O
tailored O
Web O
- O
based O
educational O
program O
designed O
to O
reduce O
excessive O
screening O
mammography O
recall O
. O
Radiologists B-eligibility
enrolled I-eligibility
in I-eligibility
one I-eligibility
of I-eligibility
four I-eligibility
mammography I-eligibility
registries I-eligibility
in O
the O
United B-location
States I-location
were O
invited O
to O
take O
part O
and O
were O
randomly O
assigned O
to O
receive O
the O
intervention O
or O
to O
serve O
as O
controls B-control
. O
The O
controls O
were O
offered O
the O
intervention O
at O
the O
end O
of O
the O
study O
, O
and O
data O
collection O
included O
an O
assessment O
of O
their O
clinical O
practice O
as O
well O
. O
The O
intervention O
provided O
each O
radiologist O
with O
individual O
audit O
data O
for O
his O
or O
her O
sensitivity O
, O
specificity O
, O
recall O
rate O
, O
positive O
predictive O
value O
, O
and O
cancer O
detection O
rate O
compared O
to O
national O
benchmarks O
and O
peer O
comparisons O
for O
the O
same O
measures O
; O
profiled O
breast O
cancer O
risk O
in O
each O
radiologist O
's O
respective O
patient O
populations O
to O
illustrate O
how O
low O
breast O
cancer O
risk O
is O
in O
population O
- O
based O
settings O
; O
and O
evaluated O
the O
possible O
impact O
of O
medical O
malpractice O
concerns O
on O
recall O
rates O
. O
Participants O
' O
recall O
rates O
from O
actual O
practice O
were O
evaluated O
for O
three O
time O
periods O
: O
the O
9 O
months O
before O
the O
intervention O
was O
delivered O
to O
the O
intervention O
group O
( O
baseline O
period O
) O
, O
the O
9 O
months O
between O
the O
intervention O
and O
control O
groups O
( O
T1 O
) O
, O
and O
the O
9 O
months O
after O
completion O
of O
the O
intervention O
by O
the O
controls O
( O
T2 O
) O
. O
Logistic O
regression O
models O
examining O
the O
probability O
that O
a O
mammogram O
was O
recalled O
included O
indication O
of O
intervention O
versus O
control O
and O
time O
period O
( O
baseline O
, O
T1 O
, O
and O
T2 O
) O
. O
Interactions O
between O
the O
groups O
and O
time O
period O
were O
also O
included O
to O
determine O
if O
the O
association O
between O
time O
period O
and O
the O
probability O
of O
a O
positive O
result O
differed O
across O
groups O
. O
Thirty B-total-participants
- I-total-participants
one I-total-participants
radiologists O
who O
completed O
the O
continuing O
medical O
education O
intervention O
were O
included O
in O
the O
adjusted O
model O
comparing O
radiologists O
in O
the O
intervention O
group O
( O
n O
= O
22 B-intervention-participants
) O
to O
radiologists O
who O
completed O
the O
intervention O
in O
the O
control O
group O
( O
n O
= O
9 B-control-participants
) O
. O
At O
T1 O
, O
the O
intervention O
group O
had O
12 O
% O
higher O
odds B-outcome
of I-outcome
positive I-outcome
mammographic I-outcome
results I-outcome
compared O
to O
the O
controls O
, O
after O
controlling O
for O
baseline O
( O
odds O
ratio O
, O
1.12 O
; O
95 O
% O
confidence O
interval O
, O
1.00 O
- O
1.27 O
; O
P O
= O
.0569 O
) O
. O
At O
T2 O
, O
a O
similar O
association O
was O
found O
, O
but O
it O
was O
not O
statistically O
significant O
( O
odds O
ratio O
, O
1.10 O
; O
95 O
% O
confidence O
interval O
, O
0.96 O
to O
1.25 O
) O
. O
No O
associations O
were O
found O
among O
radiologists O
in O
the O
control O
group O
when O
comparing O
those O
who O
completed B-outcome
the I-outcome
continuing I-outcome
medical I-outcome
education I-outcome
intervention I-outcome
( O
n O
= O
9 O
) O
to O
those O
who O
did O
not O
( O
n O
= O
10 O
) O
. O
In O
addition O
, O
no O
associations O
were O
found O
between O
time O
period O
and O
recall O
rate O
among O
radiologists O
who O
set O
realistic O
goals O
. O
This O
study O
resulted O
in O
a O
null O
effect O
, O
which O
may O
indicate O
that O
a O
single O
1 O
- O
hour O
intervention O
is O
not O
adequate O
to O
change O
excessive O
recall O
among O
radiologists O
who O
undertook O
the O
intervention O
being O
tested O
. O
  O

Protective O
effects O
of O
nebivolol B-intervention
against O
anthracycline B-condition
- I-condition
induced I-condition
cardiomyopathy I-condition
: O
a O
randomized O
control O
study O
. O
We O
aimed O
to O
evaluate O
the O
effect O
of O
prophylactic O
nebivolol O
use O
on O
prevention O
of O
antracycline O
- O
induced O
cardiotoxicity O
in O
breast O
cancer O
patients O
. O
In O
this O
small O
, O
prospective O
, O
double O
- O
blind O
study O
, O
we O
randomly O
assigned O
45 B-total-participants
consecutive O
patients O
with O
breast O
cancer O
and O
planned O
chemotheraphy O
to O
receive O
nebivolol O
5 O
mg O
daily O
( O
n O
= O
27 B-intervention-participants
) O
or O
placebo B-control
( O
n O
= O
18 B-control-participants
) O
. O
Echocardiographic O
measurements O
and O
N O
- O
terminal O
pro O
- O
brain O
natriuretic O
peptide O
( O
NT O
- O
pro O
- O
BNP O
) O
levels O
were O
obtained O
at O
baseline O
and O
at O
6 O
- O
month O
of O
chemotherapy O
. O
Both O
studied O
groups O
had O
comparable O
echocardiographic B-outcome
variables I-outcome
and O
NT O
- O
pro O
- O
BNP O
levels O
at O
baseline O
. O
At B-outcome
6 I-outcome
- I-outcome
month I-outcome
, O
the O
left B-outcome
ventricular I-outcome
( I-outcome
LV I-outcome
) I-outcome
end I-outcome
- I-outcome
systolic I-outcome
and O
end B-outcome
- I-outcome
diastolic I-outcome
diameters I-outcome
increased O
in O
the O
placebo O
group O
( O
LVESD B-outcome
: O
29.7 B-cv-cont-mean
 O
3.4 B-cv-cont-sd
to O
33.4 B-cv-cont-mean
 O
4.5 B-cv-cont-sd
mm I-cv-cont-sd
; O
LVEDD B-outcome
: O
47.2 B-cv-cont-mean
 O
3.8 B-cv-cont-sd
to O
52.0 B-cv-cont-mean
 O
4.6 B-cv-cont-sd
mm I-cv-cont-sd
, O
p O
= O
0.01 O
for O
both O
) O
but O
remained O
unchanged O
in O
the O
nebivolol O
group O
( O
LVESD B-outcome
: O
30.4 B-iv-cont-mean
 O
3.5 B-iv-cont-sd
to O
31.0 B-iv-cont-mean
 O
3.6 B-iv-cont-sd
mm I-iv-cont-sd
, O
p O
= O
0.20 O
; O
LVEDD B-outcome
: O
47.0 B-iv-cont-mean
 O
4.4 B-iv-cont-sd
to O
47.1 B-iv-cont-mean
 O
4.0 B-iv-cont-sd
mm I-iv-cont-sd
, O
p O
= O
0.93 O
) O
. O
The O
placebo O
group O
also O
had O
lower O
LVEF B-outcome
than O
the O
nebivolol O
group O
( O
57.5 B-cv-cont-mean
 O
5.6 B-cv-cont-sd
% I-cv-cont-sd
vs. O
63.8 B-iv-cont-mean
 O
3.9 B-iv-cont-sd
% I-iv-cont-sd
, O
p O
= O
0.01 O
) O
at B-outcome
6 I-outcome
- I-outcome
month I-outcome
. O
NT B-outcome
- I-outcome
pro I-outcome
- I-outcome
BNP I-outcome
level I-outcome
remained O
static O
in O
the O
nebivolol O
group O
( O
147 B-iv-cont-mean
 O
57 B-iv-cont-sd
to O
152 B-iv-cont-mean
 O
69 B-iv-cont-sd
pmol I-iv-cont-sd
/ I-iv-cont-sd
l I-iv-cont-sd
, O
p O
= O
0.77 O
) O
while O
it O
increased O
in O
the O
placebo O
group O
( O
144 B-cv-cont-mean
 O
66 B-cv-cont-sd
to O
204 B-cv-cont-mean
 O
73 B-cv-cont-sd
pmol I-cv-cont-sd
/ I-cv-cont-sd
l I-cv-cont-sd
, O
p O
= O
0.01 O
) O
. O
Prophylactic O
use O
of O
nebivolol O
treatment O
may O
protect O
the O
myocardium O
against O
antracycline O
- O
induced O
cardiotoxicity O
in O
breast O
cancer O
patients O
. O
  O

Protective O
effects O
of O
salidroside B-intervention
on O
epirubicin B-condition
- I-condition
induced I-condition
early I-condition
left I-condition
ventricular I-condition
regional I-condition
systolic I-condition
dysfunction I-condition
in O
patients O
with O
breast O
cancer O
. O
Salidroside O
[ O
2- O
( O
4 O
- O
hydroxyphenyl O
) O
ethyl O
- O
 O
- O
D O
- O
glucopyranoside O
] O
, O
one O
of O
the O
most O
potent O
ingredients O
extracted O
from O
the O
plant O
Rhodiola O
rosea O
L. O
, O
has O
been O
shown O
to O
have O
a O
cardiovascular O
protective O
effect O
as O
an O
antioxidant O
, O
and O
early O
treatment O
of O
epirubicin O
- O
induced O
cardiotoxicity O
has O
been O
the O
focus O
of O
clinical O
chemotherapy O
in O
patients O
with O
breast O
cancer O
. O
However O
, O
the O
cardioprotective O
effects O
of O
salidroside O
on O
epirubicin O
- O
induced O
cardiotoxicity O
, O
especially O
early O
left O
ventricular O
regional O
systolic O
dysfunction O
, O
have O
to O
date O
been O
sparsely O
investigated O
. O
The O
aim O
of O
this O
study O
was O
to O
investigate O
the O
protective O
effects O
of O
salidroside O
in O
preventing O
early O
left O
ventricular O
regional O
systolic O
dysfunction O
induced O
by O
epirubicin O
. O
Sixty B-total-participants
patients O
with O
histologically O
confirmed O
breast O
cancer O
were O
enrolled O
. O
Eligible O
patients O
were O
randomized O
to O
receive O
salidroside O
( O
600 O
 O
mg O
/ O
day O
; O
n O
 O
= O
 O
30 B-intervention-participants
) O
or O
placebo B-control
( O
n O
 O
= O
 O
30 B-control-participants
) O
starting O
1 O
week O
before O
chemotherapy O
. O
Patients O
were O
investigated O
by O
means O
of O
echocardiography O
and O
strain O
rate O
( O
SR O
) O
imaging O
. O
We O
also O
measured O
plasma O
concentrations O
of O
reactive O
oxygen O
species O
( O
ROS O
) O
. O
All O
parameters O
were O
assessed O
at O
baseline O
and O
7 O
days O
after O
each O
new O
epirubicin O
dose O
of O
100 O
 O
mg O
/ O
m2 O
. O
A O
decline B-outcome
of I-outcome
the I-outcome
SR I-outcome
peak I-outcome
was O
observed O
at O
an O
epirubicin O
dose O
of O
200 O
 O
mg O
/ O
m2 O
, O
with O
no O
significant O
differences O
between O
salidroside O
and O
placebo O
( O
1.35 B-iv-cont-mean
 O
 O
 O
0.36 B-iv-cont-sd
vs O
1.42 B-cv-cont-mean
 O
 O
 O
0.49 B-cv-cont-sd
/ I-cv-cont-sd
second I-cv-cont-sd
) O
. O
At O
growing O
cumulative B-outcome
doses I-outcome
of I-outcome
epirubicin I-outcome
, O
the O
SR O
normalized O
only O
with O
salidroside O
, O
showing O
a O
significant O
difference O
in O
comparison O
with O
placebo O
at O
epirubicin O
doses O
of O
300 O
 O
mg O
/ O
m2 O
( O
1.67 B-iv-cont-mean
 O
 O
 O
0.43 B-iv-cont-sd
vs O
1.32 B-cv-cont-mean
 O
 O
 O
0.53 B-cv-cont-sd
/ I-cv-cont-sd
second I-cv-cont-sd
, O
p O
 O
< O
 O
0.05 O
) O
and O
400 O
 O
mg O
/ O
m2 O
( O
1.68 B-iv-cont-mean
 O
 O
 O
0.29 B-iv-cont-sd
vs O
1.40 B-cv-cont-mean
 O
 O
 O
0.23 B-cv-cont-sd
/ I-cv-cont-sd
second I-cv-cont-sd
, O
p O
 O
< O
 O
0.05 O
) O
. O
Moreover O
, O
a O
significant O
increase O
in O
plasma B-outcome
concentrations I-outcome
of I-outcome
ROS I-outcome
was O
found O
with O
placebo O
, O
but O
they O
remained O
unchanged O
with O
salidroside O
. O
Salidroside O
can O
provide O
a O
protective O
effect O
on O
epirubicin O
- O
induced O
early O
left O
ventricular O
regional O
systolic O
dysfunction O
in O
patients O
with O
breast O
cancer O
. O

A O
double O
- O
blind O
placebo O
- O
controlled O
study O
to O
evaluate O
endometrial B-condition
safety I-condition
and I-condition
gynaecological I-condition
symptoms I-condition
in O
women O
treated O
for O
up O
to O
5 O
years O
with O
tamoxifen B-intervention
or O
placebo B-control
- O
a O
substudy O
for O
IBIS O
I O
Breast O
Cancer O
Prevention O
Trial O
. O
This O
prospective O
study O
was O
performed O
to O
investigate O
the O
effects O
of O
5 O
- O
year O
's O
use O
of O
tamoxifen O
in O
preventive O
setting O
on O
endometrium O
and O
gynaecological O
symptoms O
. O
Altogether O
96 B-total-participants
women O
were O
treated O
either O
with O
tamoxifen O
( O
TAM O
, O
n O
= O
45 B-intervention-participants
) O
or O
placebo B-control
( O
PLA O
, O
n O
= O
51 B-control-participants
) O
for O
up O
to O
5 O
years O
in O
a O
randomised O
, O
double O
- O
blind O
IBIS O
I O
breast O
cancer O
prevention O
trial O
, O
clinically O
followed O
- O
up O
for O
an O
additional O
year O
and O
for O
the O
occurrence O
of O
malignancies O
at O
least O
9 O
years O
between O
2 O
/ O
1995 O
and O
7 O
/ O
2009 O
in O
Finland B-location
. O
The O
gynaecological O
follow O
- O
up O
with O
trans O
- O
vaginal O
ultrasound O
and O
endometrial O
biopsies O
were O
performed O
at O
baseline O
, O
at O
2.5 O
and O
5 O
years O
and O
at O
the O
6 O
years O
follow O
- O
up O
visit O
. O
Women O
in O
the O
TAM O
group O
discontinued B-outcome
the I-outcome
treatment I-outcome
significantly O
more O
often O
( O
44 B-iv-bin-percent
% I-iv-bin-percent
versus O
22 B-cv-bin-percent
% I-cv-bin-percent
; O
p O
= O
0.017 O
) O
and O
earlier O
( O
at O
15 B-iv-cont-median
versus O
30 B-cv-cont-median
months I-cv-cont-median
; O
p O
= O
0.044 O
) O
, O
than O
those O
in O
the O
PLA O
group O
. O
In O
postmenopausal O
women O
the O
median O
endometrial B-outcome
thickness I-outcome
was O
significantly O
increased O
at O
five O
years O
in O
the O
TAM O
group O
( O
median O
4.3 B-iv-cont-median
versus O
2.0 B-cv-cont-median
mm I-cv-cont-median
, O
p O
= O
0.011 O
) O
, O
but O
there O
was O
no O
difference O
between O
the O
groups O
at O
one O
year O
after O
the O
treatment O
. O
There O
were O
also O
statistically O
significantly O
more O
referrals B-outcome
to I-outcome
hospitals I-outcome
due I-outcome
to I-outcome
gynaecological I-outcome
findings I-outcome
in O
the O
TAM O
group O
( O
risk O
rates O
( O
RR O
) O
3.15 O
; O
95 O
% O
confidence O
intervals O
( O
CI O
) O
1.12 O
- O
10.10 O
) O
, O
but O
no O
differences O
in O
hysterectomy B-outcome
rates I-outcome
or O
other O
serious B-outcome
adverse I-outcome
event I-outcome
rates I-outcome
were O
observed O
. O
The O
discontinuation B-outcome
rate I-outcome
in O
the O
TAM O
group O
was O
high O
, O
and O
the O
discontinuations O
also O
occurred O
early O
. O
Even O
though O
there O
were O
significantly O
more O
non O
- O
serious O
gynaecological O
events O
during O
the O
TAM O
treatment O
, O
routine O
gynaecological O
follow O
- O
up O
can O
not O
be O
recommended O
. O
  O

Late O
radiation O
toxicity O
after O
intraoperative B-intervention
radiotherapy I-intervention
( I-intervention
IORT I-intervention
) I-intervention
for O
breast O
cancer O
: O
results O
from O
the O
randomized O
phase O
III O
trial O
TARGIT O
A. O
The O
randomized O
phase O
III O
trial O
TARGIT O
A O
showed O
non O
- O
inferiority O
regarding O
local O
control O
after O
intraoperative O
radiotherapy O
( O
IORT O
20 O
Gy O
which O
was O
followed O
by O
whole O
breast O
radiotherapy O
( O
WBRT O
) O
in O
patients O
with O
risk O
factors O
only O
) O
in O
comparison O
to O
standard O
WBRT O
( O
50 O
- O
56 O
Gy O
) O
after O
breast O
- O
conserving O
surgery O
in O
selected O
patients O
. O
This O
is O
the O
first O
analysis O
of O
long O
- O
term O
toxicities O
in O
the O
setting O
of O
TARGIT O
. O
Between O
02 O
/ O
2002 O
and O
12 O
/ O
2008 O
, O
305 B-total-participants
patients O
were O
treated O
within O
TARGIT O
A O
( O
Arm O
A O
: O
n O
= O
34 B-intervention-participants
IORT O
, O
n O
= O
20 B-intervention-participants
IORT O
+ O
WBRT O
for O
risk O
factors O
; O
Arm O
B O
WBRT O
: O
n O
= O
55 B-intervention-participants
) O
or O
received O
IORT O
as O
a O
planned O
boost O
( O
control B-control
group I-control
: O
n O
= O
196 B-control-participants
) O
at O
a O
single O
center O
. O
Toxicity O
was O
assessed O
according O
to O
the O
LENT O
SOMA O
scales O
. O
No O
significant O
differences O
were O
seen O
between O
Arm O
A O
and O
Arm O
B O
regarding O
fibrosis B-outcome
, I-outcome
breast I-outcome
edema I-outcome
, I-outcome
retraction I-outcome
, I-outcome
ulceration I-outcome
, I-outcome
lymphedema I-outcome
, I-outcome
hyperpigmentation I-outcome
, I-outcome
and I-outcome
pain I-outcome
. O
Arm O
A O
had O
significantly O
less O
telangiectases B-outcome
compared O
to O
Arm O
B O
( O
p O
= O
0.049 O
) O
. O
In O
the O
subanalysis O
( O
Arm O
A O
IORT O
vs. O
Arm O
A O
IORT O
+ O
WBRT O
vs. O
Arm O
B O
) O
, O
fibrosis B-outcome
had O
a O
cumulative O
rate O
of O
5.9 B-iv-bin-percent
versus O
37.5 B-iv-bin-percent
versus O
18.4 B-iv-bin-percent
% I-iv-bin-percent
, O
respectively O
( O
38.2 B-cv-bin-percent
% I-cv-bin-percent
IORT O
boost O
control O
group O
) O
, O
at B-outcome
3 I-outcome
years I-outcome
. O
No O
telangiectases B-outcome
were O
seen O
after O
IORT O
alone O
( O
0 B-iv-bin-percent
% I-iv-bin-percent
Arm O
A O
IORT O
vs. O
17.5 B-iv-bin-percent
% I-iv-bin-percent
Arm O
A O
IORT O
+ O
WBRT O
vs. O
17.7 B-iv-bin-percent
% I-iv-bin-percent
Arm O
B O
) O
. O
The O
hazard O
ratio O
of O
higher B-outcome
grade I-outcome
toxicity I-outcome
as O
first O
event O
was O
0.46 O
( O
95 O
% O
CI O
, O
0.26 O
- O
0.83 O
) O
for O
Arm O
A O
IORT O
as O
compared O
to O
Arm O
B O
( O
p O
= O
0.010 O
) O
. O
No O
recurrences B-outcome
were O
seen O
after O
a O
median O
follow O
- O
up O
of O
40 B-iv-cont-median
months I-iv-cont-median
( O
Arm O
A O
) O
and O
42 B-cv-cont-median
months I-cv-cont-median
( O
Arm O
B O
) O
. O
With O
its O
very O
low O
chronic O
skin O
toxicity O
rates O
and O
outstanding O
long O
- O
term O
results O
regarding O
toxicity O
and O
local O
control O
, O
IORT O
with O
50 O
kV O
X O
- O
rays O
is O
a O
safe O
and O
effective O
method O
for O
treatment O
of O
selected O
breast O
cancer O
patients O
. O

Randomized O
trial O
of O
pentoxifylline B-intervention
and I-intervention
vitamin I-intervention
E I-intervention
vs O
standard B-control
follow I-control
- I-control
up I-control
after O
breast O
irradiation O
to O
prevent O
breast B-condition
fibrosis I-condition
, O
evaluated O
by O
tissue O
compliance O
meter O
. O
To O
conduct O
a O
randomized O
clinical O
trial O
to O
determine O
whether O
the O
combination O
of O
pentoxifylline O
( O
PTX O
) O
and O
vitamin O
E O
given O
for O
6 O
months O
after O
breast O
/ O
chest O
wall O
irradiation O
effectively O
prevents O
radiation O
- O
induced O
fibrosis O
( O
RIF O
) O
. O
Fifty B-total-participants
- I-total-participants
three I-total-participants
breast B-eligibility
cancer I-eligibility
patients I-eligibility
with I-eligibility
localized I-eligibility
disease I-eligibility
were O
enrolled O
and O
randomized O
to O
treatment O
with O
oral O
PTX O
400 O
mg O
3 O
times O
daily O
and O
oral O
vitamin O
E O
400 O
IU O
daily O
for O
6 O
months O
after O
radiation O
( O
n O
= O
26 B-intervention-participants
) O
, O
or O
standard O
follow O
up O
( O
n O
= O
27 B-control-participants
) O
. O
Tissue O
compliance O
meter O
( O
TCM O
) O
measurements O
were O
obtained O
at O
18 O
months O
to O
compare O
tissue O
compliance O
in O
the O
irradiated O
and O
untreated O
breast O
/ O
chest O
wall O
in O
treated O
subjects O
and O
controls O
. O
Measurements O
were O
obtained O
at O
2 O
mirror O
image O
sites O
on O
each O
breast O
/ O
chest O
wall O
, O
and O
the O
average O
difference O
in O
tissue O
compliance O
was O
scored O
. O
Differences O
in O
TCM O
measurements O
were O
compared O
using O
a O
t O
test O
. O
Subjects O
were O
followed O
a O
minimum O
of O
2 O
years O
for O
local O
recurrence O
, O
disease O
- O
free O
survival O
, O
and O
overall O
survival O
. O
The O
mean O
difference O
in O
TCM B-outcome
measurements I-outcome
in O
the O
2 O
groups O
was O
0.88 O
mm O
, O
median O
of O
1.00 B-iv-cont-median
mm I-iv-cont-median
( O
treated O
) O
and O
2.10 O
mm O
, O
median O
of O
2.4 B-cv-cont-median
mm I-cv-cont-median
( O
untreated O
) O
. O
The O
difference O
between O
the O
2 O
groups O
was O
significant O
( O
P O
= O
.0478 O
) O
. O
Overall B-outcome
survival I-outcome
( O
100 B-iv-bin-percent
% I-iv-bin-percent
treated O
, O
90.6 B-cv-bin-percent
% I-cv-bin-percent
controls O
at O
5 O
years O
) O
and O
disease B-outcome
- I-outcome
free I-outcome
survival I-outcome
( O
96.2 B-iv-bin-percent
% I-iv-bin-percent
treated O
, O
86.8 B-cv-bin-percent
% I-cv-bin-percent
controls O
at O
5 O
years O
) O
were O
not O
significantly O
different O
in O
the O
2 O
groups O
. O
This O
study O
of O
postirradiation O
breast O
cancer O
patients O
treated O
with O
PTX O
/ O
vitamin O
E O
or O
standard O
follow O
- O
up O
indicated O
a O
significant O
difference O
in O
radiation B-outcome
- I-outcome
induced I-outcome
fibrosis I-outcome
as O
measured O
by O
TCM O
. O
There O
was O
no O
observed O
impact O
on O
local B-outcome
control I-outcome
or I-outcome
survival I-outcome
within O
the O
first O
2 O
years O
of O
follow O
- O
up O
. O
The O
treatment O
was O
safe B-outcome
and O
well B-outcome
tolerated I-outcome
. O
Pentoxifylline O
/ O
vitamin O
E O
may O
be O
clinically O
useful O
in O
preventing O
fibrosis O
after O
radiation O
in O
high O
- O
risk O
patients O
. O
  O

Multidisciplinary B-intervention
rehabilitation I-intervention
in O
women O
following O
breast O
cancer O
treatment O
: O
a O
randomized O
controlled O
trial O
. O
To O
assess O
the O
effectiveness O
of O
a O
multidisciplinary O
ambulatory O
rehabilitation O
programme O
for O
women O
following O
definitive O
breast O
cancer O
treatment O
in O
an O
Australian B-ethinicity
community O
cohort O
. O
Eighty B-total-participants
- I-total-participants
five I-total-participants
women O
in O
the O
community O
randomized O
to O
a O
treatment O
group O
( O
n O
= O
43 B-intervention-participants
) O
for O
individualized O
high O
- O
intensity O
programme O
, O
or O
a O
control O
group O
( O
n O
= O
42 B-control-participants
) O
comprising O
usual B-control
activity I-control
. O
The O
primary O
outcome O
Depression B-outcome-measure
Anxiety I-outcome-measure
Stress I-outcome-measure
Scale I-outcome-measure
( I-outcome-measure
DASS I-outcome-measure
) I-outcome-measure
scale I-outcome-measure
measured O
restriction O
in O
participation O
. O
Secondary O
measures O
included O
Perceived B-outcome-measure
Impact I-outcome-measure
Problem I-outcome-measure
Profile I-outcome-measure
( I-outcome-measure
PIPP I-outcome-measure
) I-outcome-measure
and O
Cancer B-outcome-measure
Rehabilitation I-outcome-measure
Evaluation I-outcome-measure
System I-outcome-measure
Short I-outcome-measure
- I-outcome-measure
Form I-outcome-measure
( I-outcome-measure
CARES I-outcome-measure
- I-outcome-measure
SF I-outcome-measure
) I-outcome-measure
; O
and O
Functional B-outcome-measure
Independence I-outcome-measure
Measure I-outcome-measure
( I-outcome-measure
FIM I-outcome-measure
) I-outcome-measure
motor I-outcome-measure
subscale I-outcome-measure
for O
activity O
limitation O
. O
Assessments O
were O
at O
baseline O
and O
4 O
months O
. O
Intention O
- O
to O
- O
treat O
analysis O
of O
data O
showed O
a O
significant O
difference O
between O
both O
groups O
in O
DASS B-outcome
Depression I-outcome
scores I-outcome
( O
p O
= O
0.006 O
) O
( O
moderate O
effect O
size O
, O
r O
> O
0.3 O
) O
, O
PIPP B-outcome
Mobility I-outcome
( O
p O
= O
0.05 O
) O
and O
Participation B-outcome
( O
p O
= O
0.04 O
) O
scales O
, O
and O
CARES B-outcome
- I-outcome
SF I-outcome
Global I-outcome
score I-outcome
( O
p O
= O
0.02 O
) O
( O
small O
effect O
size O
, O
r O
< O
0.3 O
) O
. O
The O
treatment O
group O
, O
compared O
with O
control O
group O
, O
showed O
significant O
improvement B-outcome
in I-outcome
the I-outcome
DASS I-outcome
Depression I-outcome
scores I-outcome
: O
22 B-iv-bin-abs
/ O
42 B-intervention-participants
( O
52.4 B-iv-bin-percent
% I-iv-bin-percent
) O
vs O
12 B-cv-bin-abs
/ O
37 B-control-participants
( O
32.4 B-cv-bin-percent
% I-cv-bin-percent
) O
( O
p O
= O
0.02 O
) O
. O
No O
difference O
between O
groups O
was O
noted O
in O
the O
FIM B-outcome
scale I-outcome
. O
Rehabilitation O
can O
benefit O
participation O
in O
breast O
cancer O
survivors O
. O
Evidence O
for O
specific O
rehabilitation O
interventions O
is O
needed O
. O
Integrated O
cancer O
programmes O
allow O
opportunities O
to O
evaluate O
patients O
in O
various O
settings O
, O
but O
require O
outcome O
research O
to O
develop O
service O
models O
for O
survivorship O
issues O
. O

Hormone B-intervention
replacement I-intervention
therapy I-intervention
after O
breast O
cancer O
: O
10 O
year O
follow O
up O
of O
the O
Stockholm B-location
randomised O
trial O
. O
The O
management O
of O
hormonal O
deficiency O
symptoms O
in O
breast O
cancer O
survivors O
is O
an O
unsolved O
problem O
. O
While O
hormone O
replacement O
therapy O
( O
HRT O
) O
may O
increase O
the O
risk O
of O
breast O
cancer O
in O
healthy O
women O
, O
its O
effects O
on O
recurrence O
is O
unclear O
. O
Observational O
studies O
have O
suggested O
decreased O
recurrence O
rates O
from O
HRT O
. O
The O
few O
clinical O
trials O
in O
this O
field O
have O
all O
been O
closed O
preterm O
. O
The O
Stockholm O
trial O
was O
started O
in O
1997 O
and O
designed O
to O
minimise O
the O
dose O
of O
progestogen O
in O
the O
HRT O
arm O
. O
Disease O
- O
free O
women O
with O
a O
history O
of O
breast O
cancer O
were O
randomised O
to O
HRT O
( O
n O
= O
188 B-intervention-participants
) O
or O
no B-control
HRT I-control
( O
n O
= O
190 B-control-participants
) O
. O
The O
trial O
was O
stopped O
in O
2003 O
when O
another O
Swedish O
study O
( O
HABITS O
, O
the O
Hormonal O
Replacement O
After O
Breast O
Cancer O
- O
Is O
it O
Safe O
? O
) O
reported O
increased O
recurrence O
. O
However O
the O
Stockholm O
material O
showed O
no O
excess O
risk O
after O
4 O
years O
of O
follow O
- O
up O
. O
A O
long O
term O
follow O
- O
up O
has O
now O
been O
performed O
. O
After O
10.8 O
years O
of O
follow O
- O
up O
, O
there O
was O
no O
difference O
in O
new B-outcome
breast I-outcome
cancer I-outcome
events I-outcome
: O
60 B-iv-bin-abs
in O
the O
HRT O
group O
versus O
48 B-cv-bin-abs
among O
controls O
( O
hazard O
ratio O
( O
HR O
) O
= O
1.3 O
; O
95 O
% O
confidence O
interval O
( O
CI O
) O
= O
0.9 O
- O
1.9 O
) O
. O
Among O
women O
on O
HRT O
, O
11 B-iv-bin-abs
had O
local B-outcome
recurrence I-outcome
and O
12 B-iv-bin-abs
distant B-outcome
metastases I-outcome
versus O
15 B-cv-bin-abs
and O
12 B-cv-bin-abs
for O
the O
controls O
. O
There O
were O
14 B-iv-bin-abs
contra B-outcome
- I-outcome
lateral I-outcome
breast I-outcome
cancers I-outcome
in O
the O
HRT O
group O
and O
four B-cv-bin-abs
in O
the O
control O
group O
( O
HR O
= O
3.6 O
; O
95 O
% O
CI O
= O
1.2 O
- O
10.9 O
; O
p O
= O
0.013 O
) O
. O
No O
differences O
in O
mortality B-outcome
or I-outcome
new I-outcome
primary I-outcome
malignancies I-outcome
were O
found O
. O
The O
number B-outcome
of I-outcome
new I-outcome
events I-outcome
did O
not O
differ O
significantly O
between O
groups O
, O
in O
contrast O
to O
previous O
reports O
. O
The O
increased O
recurrence B-outcome
in O
HABITS O
has O
been O
attributed O
to O
higher O
progestogen O
exposure O
. O
As O
both O
trials O
were O
prematurely O
closed O
, O
data O
do O
not O
allow O
firm O
conclusions O
. O
Both O
studies O
found O
no O
increased O
mortality B-outcome
from O
breast O
cancer O
or O
other O
causes O
from O
HRT O
. O
Current O
guidelines O
typically O
consider O
HRT O
contraindicated O
in O
breast O
cancer O
survivors O
. O
Findings O
suggest O
that O
, O
in O
some O
women O
symptom O
relief O
may O
outweigh O
the O
potential O
risks O
of O
HRT O
. O

Bone B-condition
- I-condition
related I-condition
complications I-condition
and I-condition
quality I-condition
of I-condition
life I-condition
in O
advanced O
breast O
cancer O
: O
results O
from O
a O
randomized O
phase O
III O
trial O
of O
denosumab B-intervention
versus O
zoledronic B-control
acid I-control
. O
Denosumab O
was O
shown O
to O
be O
superior O
to O
zoledronic O
acid O
in O
preventing O
skeletal O
related O
events O
( O
SRE O
) O
in O
patients O
with O
breast O
cancer O
and O
bone O
metastases O
in O
a O
randomized O
, O
double O
- O
blind O
phase O
III O
study O
. O
We O
evaluated O
further O
results O
from O
this O
study O
related O
to O
skeletal O
complications O
and O
health O
- O
related O
quality O
of O
life O
( O
HRQoL O
) O
. O
Patients O
were O
randomized O
1 O
:1 O
to O
receive O
subcutaneous O
denosumab O
120 O
mg O
( O
n O
= O
1,026 B-intervention-participants
) O
and O
intravenous O
placebo O
, O
or O
intravenous O
zoledronic O
acid O
4 O
mg O
( O
n O
= O
1,020 B-control-participants
) O
and O
subcutaneous O
placebo O
every O
4 O
weeks O
. O
Analyses O
reported O
here O
include O
the O
proportion O
of O
patients O
with O
one O
or O
multiple O
on O
- O
study O
SREs O
, O
time O
to O
first O
radiation O
to O
bone O
, O
time O
to O
first O
SRE O
or O
hypercalcemia O
of O
malignancy O
, O
and O
change O
in O
HRQoL O
( O
functional O
assessment O
of O
cancer O
therapy O
- O
general O
) O
. O
Fewer O
patients O
receiving O
denosumab O
than O
zoledronic O
acid O
had O
an O
on O
- O
study O
SRE B-outcome
( O
31 B-iv-bin-percent
% I-iv-bin-percent
vs. O
36 B-cv-bin-percent
% I-cv-bin-percent
, O
P O
= O
0.006 O
) O
. O
The O
incidence B-outcome
of I-outcome
first I-outcome
radiation I-outcome
to I-outcome
bone I-outcome
was O
12 B-iv-bin-percent
% I-iv-bin-percent
( O
n O
= O
123 B-iv-bin-abs
) O
with O
denosumab O
versus O
16 B-cv-bin-percent
% I-cv-bin-percent
( O
n O
= O
162 B-cv-bin-abs
) O
with O
zoledronic O
acid O
. O
Denosumab O
prolonged O
the O
time B-outcome
to I-outcome
first I-outcome
radiation I-outcome
to I-outcome
bone I-outcome
by O
26 O
% O
versus O
zoledronic O
acid O
( O
HR O
, O
0.74 O
; O
95 O
% O
confidence O
interval O
[ O
CI O
] O
, O
0.59 O
- O
0.94 O
, O
P O
= O
0.012 O
) O
and O
prolonged O
the O
time B-outcome
to I-outcome
first I-outcome
SRE I-outcome
or I-outcome
hypercalcemia I-outcome
of I-outcome
malignancy I-outcome
by O
18 O
% O
( O
HR O
, O
0.82 O
; O
95 O
% O
CI O
, O
0.70 O
- O
0.95 O
; O
P O
= O
0.007 O
) O
. O
Ten B-iv-bin-percent
percent I-iv-bin-percent
more O
patients O
had O
a O
clinically O
meaningful O
improvement B-outcome
in I-outcome
HRQoL I-outcome
with O
denosumab O
relative O
to O
zoledronic O
acid O
, O
regardless O
of O
baseline O
pain O
levels O
. O
Denosumab O
was O
superior O
to O
zoledronic O
acid O
in O
reducing O
bone O
- O
related O
complications O
of O
metastatic O
breast O
cancer O
and O
maintained O
HRQoL O
, O
providing O
an O
efficacious O
, O
well O
- O
tolerated O
treatment O
option O
for O
patients O
with O
bone O
metastases O
from O
breast O
cancer O
. O

Omega-3 B-intervention
fatty I-intervention
acids I-intervention
are O
protective O
against O
paclitaxel B-condition
- I-condition
induced I-condition
peripheral I-condition
neuropathy I-condition
: O
a O
randomized O
double O
- O
blind O
placebo O
controlled O
trial O
. O
Axonal O
sensory O
peripheral O
neuropathy O
is O
the O
major O
dose O
- O
limiting O
side O
effect O
of O
paclitaxel O
. O

 O
Omega-3 O
fatty O
acids O
have O
beneficial O
effects O
on O
neurological O
disorders O
from O
their O
effects O
on O
neurons O
cells O
and O
inhibition O
of O
the O
formation O
of O
proinflammatory O
cytokines O
involved O
in O
peripheral O
neuropathy O
. O
This O
study O
was O
a O
randomized O
double O
blind O
placebo O
controlled O
trial O
to O
investigate O
the O
efficacy O
of O
omega-3 O
fatty O
acids O
in O
reducing O
incidence O
and O
severity O
of O
paclitaxel O
- O
induced O
peripheral O
neuropathy O
( O
PIPN O
) O
. O
Eligible O
patients B-eligibility
with I-eligibility
breast I-eligibility
cancer I-eligibility
randomly O
assigned O
to O
take O
omega-3 O
fatty O
acid O
pearls O
, O
640 O
mg O
t.i.d O
during O
chemotherapy O
with O
paclitaxel O
and O
one O
month O
after O
the O
end O
of O
the O
treatment O
or O
placebo B-control
. O
Clinical O
and O
electrophysiological O
studies O
were O
performed O
before O
the O
onset O
of O
chemotherapy O
and O
one O
month O
after O
cessation O
of O
therapy O
to O
evaluate O
PIPN O
based O
on O
" O
reduced O
Total O
Neuropathy O
Score O
" O
. O
Twenty B-iv-bin-abs
one I-iv-bin-abs
patients O
( O
70 B-iv-bin-percent
% I-iv-bin-percent
) O
of O
the O
group O
taking O
omega-3 O
fatty O
acid O
supplement O
( O
n O
= O
30 B-intervention-participants
) O
did O
not O
develop O
PN B-outcome
while O
it O
was O
40.7 B-cv-bin-percent
% I-cv-bin-percent
( O
11 B-cv-bin-abs
patients O
) O
in O
the O
placebo O
group O
( O
n O
= O
27 B-control-participants
) O
. O
A O
significant O
difference O
was O
seen O
in O
PN B-outcome
incidence I-outcome
( O
OR O
= O
0.3 O
, O
.95 O
% O
CI O
= O
( O
0.10 O
- O
0.88 O
) O
, O
p O
= O
0.029 O
) O
. O
There O
was O
a O
non O
- O
significant O
trend O
for O
differences O
of O
PIPN O
severity O
between O
the O
two O
study O
groups O
but O
the O
frequencies B-outcome
of I-outcome
PN I-outcome
in O
all O
scoring O
categories O
were O
higher O
in O
the O
placebo O
group O
( O
0.95 O
% O
CI O
= O
( O
-2.06 O
-0.02 O
) O
, O
p O
= O
0.054 O
) O
. O
Omega-3 O
fatty O
acids O
may O
be O
an O
efficient O
neuroprotective O
agent O
for O
prophylaxis O
against O
PIPN O
. O
Patients O
with O
breast O
cancer O
have O
a O
longer O
disease B-outcome
free I-outcome
survival I-outcome
rate I-outcome
with O
the O
aid O
of O
therapeutical O
agents O
. O
Finding O
a O
way O
to O
solve O
the O
disabling O
effects O
of O
PIPN O
would O
significantly O
improve O
the O
patients O
' O
quality O
of O
life O
. O
This O
trial O
was O
registered O
at O
ClinicalTrials.gov O
( O
NCT01049295 O
) O
. O

Acupuncture B-intervention
relieves O
menopausal B-condition
discomfort I-condition
in O
breast O
cancer O
patients O
: O
a O
prospective O
, O
double O
blinded O
, O
randomized O
study O
. O
This O
study O
evaluates O
the O
effect O
of O
acupuncture O
on O
hot O
flashes O
and O
disturbed O
night O
sleep O
in O
patients O
treated O
for O
breast O
cancer O
. O
The O
effect O
of O
acupuncture O
was O
tested O
against O
a O
sham O
- O
acupuncture O
group O
and O
a O
no O
- O
treatment O
control O
group O
. O
Plasma O
estradiol O
was O
measured O
to O
rule O
out O
this O
as O
cause O
of O
effect O
. O
Side O
effects O
of O
the O
treatment O
were O
registered O
. O
We O
randomized O
94 B-total-participants
women O
into O
the O
study O
: O
31 B-intervention-participants
had O
acupuncture O
, O
29 B-intervention-participants
had O
sham O
acupuncture O
and O
34 B-control-participants
had O
no B-control
treatment I-control
. O
In O
the O
acupuncture O
group O
, O
16 B-iv-bin-abs
patients O
( O
52 B-iv-bin-percent
% I-iv-bin-percent
) O
experienced O
a O
significant O
effect B-outcome
on I-outcome
hot I-outcome
flashes I-outcome
compared O
with O
seven B-iv-bin-abs
patients O
( O
24 B-iv-bin-percent
% I-iv-bin-percent
) O
in O
the O
sham O
group O
( O
p O
< O
0.05 O
) O
. O
The O
effect O
came O
after O
the O
second O
acupuncture O
session O
and O
lasted O
for O
at O
least O
12 O
weeks O
after O
last O
treatment O
. O
A O
statistically O
significant O
positive B-outcome
effect I-outcome
was O
seen O
on O
sleep O
in O
the O
acupuncture O
group O
compared O
with O
the O
sham O
- O
acupuncture O
and O
no O
- O
treatment O
groups O
. O
The O
effect O
was O
not O
correlated O
with O
increased O
levels B-outcome
of I-outcome
plasma I-outcome
estradiol I-outcome
. O
No O
side B-outcome
effects I-outcome
of O
acupuncture O
were O
registered O
. O
We O
find O
that O
acupuncture O
significantly O
relieves O
hot O
flashes O
and O
sleep O
disturbances O
and O
is O
a O
good O
and O
safe O
treatment O
in O
women O
treated O
for O
breast O
cancer O
. O

Pain B-condition
outcomes O
in O
patients O
with O
advanced O
breast O
cancer O
and O
bone O
metastases O
: O
results O
from O
a O
randomized O
, O
double O
- O
blind O
study O
of O
denosumab O
and O
zoledronic O
acid O
. O
In O
this O
study O
, O
the O
authors O
evaluated O
the O
effect O
of O
denosumab B-intervention
versus O
zoledronic B-control
acid I-control
( I-control
ZA I-control
) I-control
on O
pain O
in O
patients B-eligibility
with I-eligibility
advanced I-eligibility
breast I-eligibility
cancer I-eligibility
and I-eligibility
bone I-eligibility
metastases I-eligibility
. O
The O
prevention O
of O
pain O
, O
reduction O
in O
pain O
interference O
with O
daily O
life O
activities O
, O
and O
the O
proportion O
of O
patients O
requiring O
strong O
opioid O
analgesics O
were O
assessed O
in O
a O
randomized O
, O
double O
- O
blind O
, O
double O
- O
dummy O
phase O
3 O
study O
comparing O
denosumab O
with O
ZA O
for O
preventing O
skeletal O
- O
related O
events O
in O
2046 B-total-participants
patients O
who O
had O
breast O
cancer O
and O
bone O
metastases O
. O
Patients O
completed O
the O
Brief O
Pain O
Inventory O
- O
Short O
Form O
at O
baseline O
and O
monthly O
thereafter O
. O
Fewer O
patients O
who O
received O
denosumab O
reported O
a O
clinically O
meaningful O
worsening O
of O
pain B-outcome
severity I-outcome
( O
2 O
- O
point O
increase O
) O
from O
baseline O
compared O
with O
patients O
who O
received O
ZA O
, O
and O
a O
trend O
was O
observed O
toward O
delayed O
time B-outcome
to I-outcome
pain I-outcome
worsening I-outcome
with O
denosumab O
versus O
ZA O
( O
denosumab O
, O
8.5 B-iv-cont-mean
months I-iv-cont-mean
; O
ZA O
, O
7.4 B-cv-cont-mean
months I-cv-cont-mean
; O
P O
= O
.08 O
) O
. O
In O
patients O
who O
had O
no O
/ O
mild O
pain O
at O
baseline O
, O
a O
4 O
- O
month O
delay O
in O
progression B-outcome
to I-outcome
moderate I-outcome
/ I-outcome
severe I-outcome
pain I-outcome
was O
observed O
with O
denosumab O
compared O
with O
ZA O
( O
9.7 B-iv-cont-mean
months I-iv-cont-mean
vs O
5.8 B-cv-cont-mean
months I-cv-cont-mean
; O
P O
= O
.002 O
) O
. O
Denosumab O
delayed O
the O
time B-outcome
to I-outcome
increased I-outcome
pain I-outcome
interference I-outcome
by O
approximately O
1 O
month O
compared O
with O
ZA O
( O
denosumab O
, O
16.0 B-iv-cont-mean
months I-iv-cont-mean
; O
ZA O
, O
14.9 B-cv-cont-mean
months I-cv-cont-mean
; O
P O
= O
.09 O
) O
. O
The O
time B-outcome
to I-outcome
pain I-outcome
improvement I-outcome
( O
P O
= O
.72 O
) O
and O
the O
time B-outcome
to I-outcome
decreased I-outcome
pain I-outcome
interference I-outcome
( O
P O
= O
.92 O
) O
were O
similar O
between O
the O
groups O
. O
Fewer O
denosumab O
- O
treated O
patients O
reported O
increased O
analgesic B-outcome
use I-outcome
from O
no O
/ O
low O
use O
at O
baseline O
to O
strong O
opioid O
use O
. O
Denosumab O
demonstrated O
improved O
pain O
prevention O
and O
comparable O
pain O
palliation O
compared O
with O
ZA O
. O
In O
addition O
, O
fewer O
denosumab O
- O
treated O
patients O
shifted O
to O
strong O
opioid O
analgesic O
use O
. O
  O

Complete B-intervention
axillary I-intervention
lymph I-intervention
node I-intervention
dissection I-intervention
versus O
clinical B-control
follow I-control
- I-control
up I-control
in O
breast O
cancer O
patients O
with O
sentinel O
node O
micrometastasis O
: O
final O
results O
from O
the O
multicenter O
clinical O
trial O
AATRM O
048 O
/ O
13 O
/ O
2000 O
. O
It O
has O
been O
suggested O
that O
selective O
sentinel O
node O
( O
SN O
) O
biopsy O
alone O
can O
be O
used O
to O
manage O
early O
breast O
cancer O
, O
but O
definite O
evidence O
to O
support O
this O
notion O
is O
lacking O
. O
The O
aim O
of O
this O
study O
was O
to O
investigate O
whether O
refraining O
from O
completion O
axillary O
lymph O
node O
dissection O
( O
ALND O
) O
suffices O
to O
produce O
the O
same O
prognostic O
information O
and O
disease O
control O
as O
proceeding O
with O
completion O
ALND O
in O
early O
breast O
cancer O
patients O
showing O
micrometastasis O
at O
SN O
biopsy O
. O
This O
prospective O
, O
randomized O
clinical O
trial O
included O
patients B-eligibility
with I-eligibility
newly I-eligibility
diagnosed I-eligibility
early I-eligibility
- I-eligibility
stage I-eligibility
breast I-eligibility
cancer I-eligibility
( I-eligibility
T<3.5 I-eligibility
cm I-eligibility
, I-eligibility
clinical I-eligibility
N0 I-eligibility
, I-eligibility
M0 I-eligibility
) I-eligibility
who I-eligibility
underwent I-eligibility
surgical I-eligibility
excision I-eligibility
as I-eligibility
primary I-eligibility
treatment I-eligibility
. O
All O
had O
micrometastatic O
SN O
. O
Patients O
were O
randomly O
assigned O
to O
one O
of O
the O
two O
study O
arms O
: O
complete O
ALND O
( O
control O
arm O
) O
or O
clinical O
follow O
- O
up O
( O
experimental O
arm O
) O
. O
Median O
follow O
- O
up O
was O
5 O
years O
, O
recurrence O
was O
assessed O
, O
and O
the O
primary O
end O
point O
was O
disease B-outcome-measure
- I-outcome-measure
free I-outcome-measure
survival I-outcome-measure
. O
From O
a O
total O
sample O
of O
247 B-total-participants
patients O
, O
14 O
withdrew O
, O
leaving O
112 B-control-participants
in O
the O
control O
arm O
and O
121 B-intervention-participants
in O
the O
experimental O
arm O
. O
In O
15 B-cv-bin-abs
control O
subjects O
( O
13 B-cv-bin-percent
% I-cv-bin-percent
) O
, O
completion B-outcome
ALND I-outcome
was I-outcome
positive I-outcome
, O
with O
a O
low O
tumor O
burden O
. O
Four O
patients O
experienced O
disease B-outcome
recurrence I-outcome
: O
1 B-cv-bin-abs
( O
1 B-cv-bin-percent
% I-cv-bin-percent
) O
of O
108 B-control-participants
control O
subjects O
and O
3 B-iv-bin-abs
( O
2.5 B-iv-bin-percent
% I-iv-bin-percent
) O
of O
119 B-intervention-participants
experimental O
patients O
. O
There O
were O
no O
differences O
in O
disease B-outcome
- I-outcome
free I-outcome
survival I-outcome
( O
p O
= O
0.325 O
) O
between O
arms O
and O
no O
cancer B-outcome
- I-outcome
related I-outcome
deaths I-outcome
. O
Our O
results O
strongly O
suggest O
that O
in O
early O
breast O
cancer O
patients O
with O
SN O
micrometastasis O
, O
selective O
SN O
lymphadenectomy O
suffices O
to O
control O
locoregional O
and O
distant O
disease O
, O
with O
no O
significant O
effects O
on O
survival O
. O

Axillary O
lymphadenectomy O
for O
breast O
cancer O
. O
A O
randomized O
controlled O
trial O
comparing O
a O
bipolar B-intervention
vessel I-intervention
sealing I-intervention
system I-intervention
to O
the O
conventional B-control
technique I-control
. O
To O
compare O
safety O
and O
efficacy O
of O
a O
bipolar O
vessel O
sealing O
system O
( O
BVSS O
) O
to O
the O
conventional O
technique O
in O
axillary O
node O
dissection O
. O
116 B-total-participants
women B-eligibility
with I-eligibility
breast I-eligibility
cancer I-eligibility
were O
randomized O
to O
conventional O
node O
dissection O
surgical O
technique O
( O
control O
; O
n O
= O
58 B-control-participants
) O
by O
scalpel O
and O
monopolar O
cautery O
or O
using O
an O
electrothermal O
BVSS O
( O
study O
group O
; O
n O
= O
58 B-intervention-participants
) O
. O
The O
median O
( O
range O
) O
total B-outcome
volume I-outcome
of I-outcome
fluid I-outcome
collected I-outcome
by I-outcome
drain I-outcome
and I-outcome
aspirations I-outcome
was O
305 B-iv-cont-median
( O
30 O
- O
1420 O
) O
mL O
in O
the O
study O
group O
and O
335 B-cv-cont-median
( O
80 O
- O
1070 O
) O
mL O
in O
the O
control O
group O
( O
p O
= O
0.325 O
) O
. O
The O
median O
( O
range O
) O
total B-outcome
volume I-outcome
of I-outcome
lymph I-outcome
collected I-outcome
by I-outcome
percutaneous I-outcome
aspirations I-outcome
was O
207.5 B-iv-cont-median
( O
40 O
- O
1050 O
) O
mL O
in O
the O
study O
group O
and O
505 B-cv-cont-median
( O
270 O
- O
705 O
) O
mL O
in O
the O
control O
group O
( O
p O
= O
0.010 O
) O
. O
The O
incidence B-outcome
of I-outcome
seroma I-outcome
was O
similar O
in O
both O
groups O
( O
p O
= O
0.845 O
) O
. O
The O
axillary B-outcome
drain I-outcome
was I-outcome
removed I-outcome
earlier O
in O
the O
study O
group O
than O
in O
controls O
( O
p O
= O
0.046 O
) O
. O
The O
use O
of O
a O
BVSS O
offers O
marginal O
advantages O
when O
compared O
to O
the O
conventional O
technique O
. O
  O

Seven O
- O
year O
follow O
- O
up O
assessment O
of O
cardiac O
function O
in O
NSABP O
B-31 O
, O
a O
randomized O
trial O
comparing O
doxorubicin B-intervention
and I-intervention
cyclophosphamide I-intervention
followed I-intervention
by I-intervention
paclitaxel I-intervention
( I-intervention
ACP I-intervention
) I-intervention
with I-intervention
ACP I-intervention
plus I-intervention
trastuzumab I-intervention
as O
adjuvant O
therapy O
for O
patients B-eligibility
with I-eligibility
node I-eligibility
- I-eligibility
positive I-eligibility
, I-eligibility
human I-eligibility
epidermal I-eligibility
growth I-eligibility
factor I-eligibility
receptor I-eligibility
2 I-eligibility
- I-eligibility
positive I-eligibility
breast I-eligibility
cancer I-eligibility
. O
Cardiac O
dysfunction O
( O
CD O
) O
is O
a O
recognized O
risk O
associated O
with O
the O
addition O
of O
trastuzumab O
to O
adjuvant O
chemotherapy O
for O
human O
epidermal O
growth O
factor O
receptor O
2 O
- O
positive O
breast O
cancer O
, O
especially O
when O
the O
treatment O
regimen O
includes O
anthracyclines O
. O
Given O
the O
demonstrated O
efficacy O
of O
trastuzumab O
, O
ongoing O
assessment O
of O
cardiac O
safety O
and O
identification O
of O
risk O
factors O
for O
CD O
are O
important O
for O
optimal O
patient O
care O
. O
In O
National O
Surgical O
Adjuvant O
Breast O
and O
Bowel O
Project O
B-31 O
, O
a O
phase O
III O
adjuvant O
trial O
, O
1,830 B-total-participants
patients O
who O
met O
eligibility O
criteria O
for O
initiation O
of O
trastuzumab O
were O
evaluated O
for O
CD O
. O
Recovery O
from O
CD O
was O
also O
assessed O
. O
A O
statistical O
model O
was O
developed O
to O
estimate O
the O
risk O
of O
severe O
congestive O
heart O
failure O
( O
CHF O
) O
. O
Baseline O
patient O
characteristics O
associated O
with O
anthracycline O
- O
related O
decline O
in O
cardiac O
function O
were O
also O
identified O
. O
At O
7 O
- O
year O
follow O
- O
up O
, O
37 B-iv-bin-abs
( O
4.0 B-iv-bin-percent
% I-iv-bin-percent
) O
of O
944 B-intervention-participants
patients O
who O
received O
trastuzumab O
experienced O
a O
cardiac B-outcome
event I-outcome
( I-outcome
CE I-outcome
) I-outcome
versus O
10 B-cv-bin-abs
( O
1.3 B-cv-bin-percent
% I-cv-bin-percent
) O
of O
743 B-control-participants
patients O
in O
the O
control B-control
arm O
. O
One B-iv-bin-abs
cardiac B-outcome
- I-outcome
related I-outcome
death I-outcome
has O
occurred O
in O
each O
arm O
of O
the O
protocol O
. O
A O
Cardiac O
Risk O
Score O
, O
calculated O
using O
patient O
age O
and O
baseline O
left O
ventricular O
ejection O
fraction O
( O
LVEF O
) O
by O
multiple O
- O
gated O
acquisition O
scan O
, O
statistically O
correlates O
with O
the O
risk O
of O
a O
CE O
. O
After O
stopping O
trastuzumab O
, O
the O
majority O
of O
patients O
who O
experienced O
CD O
recovered O
LVEF O
in O
the O
normal O
range O
, O
although O
some O
decline O
from O
baseline O
often O
persists O
. O
Only O
two O
CEs B-outcome
occurred O
more O
than O
2 O
years O
after O
initiation O
of O
trastuzumab O
. O
The O
late O
development O
of O
CHF O
after O
the O
addition O
of O
trastuzumab O
to O
paclitaxel O
after O
doxorubicin/ O
cyclophosphamide O
chemotherapy O
is O
uncommon O
. O
The O
risk O
versus O
benefit O
of O
trastuzumab O
as O
given O
in O
this O
regimen O
remains O
strongly O
in O
favor O
of O
trastuzumab O
. O

Impact B-intervention
+ I-intervention
resistance I-intervention
training I-intervention
improves O
bone O
health O
and O
body O
composition O
in O
prematurely B-eligibility
menopausal I-eligibility
breast I-eligibility
cancer I-eligibility
survivors I-eligibility
: O
a O
randomized O
controlled O
trial O
. O
Our O
randomized O
controlled O
trial O
in O
prematurely O
menopausal O
breast O
cancer O
survivors O
showed O
that O
impact O
+ O
resistance O
training O
prevented O
increases O
in O
percentage O
of O
body O
fat O
compared O
with O
controls O
and O
also O
improved O
BMD O
at O
the O
hip O
and O
prevented O
BMD O
loss O
at O
the O
spine O
among O
exercise O
- O
trained O
women O
who O
were O
menopausal O
for O
> O
1 O
year O
. O
Cancer O
treatment O
- O
related O
menopause O
worsens O
bone O
health O
and O
body O
composition O
in O
breast O
cancer O
survivors O
( O
BCS O
) O
. O
We O
investigated O
whether O
impact O
+ O
resistance O
training O
could O
improve O
bone O
mineral O
density O
( O
BMD O
) O
, O
reduce O
bone O
turnover O
, O
build O
muscle O
, O
and O
decrease O
fat O
mass O
in O
BCS O
with O
premature O
menopause O
. O
We O
conducted O
a O
randomized O
controlled O
trial O
in O
71 B-total-participants
BCS O
( O
mean O
age O
, O
46.5 B-age
years I-age
) O
within O
5 O
years O
of O
treatment O
- O
related O
menopause O
. O
Women O
were O
randomly O
assigned O
to O
one O
of O
two O
groups O
: O
( O
1 O
) O
impact O
+ O
resistance O
training O
( O
prevent O
osteoporosis O
with O
impact O
+ O
resistance O
( O
POWIR O
) O
) O
or O
( O
2 O
) O
exercise B-control
placebo I-control
( O
FLEX O
) O
3/week O
for O
1 O
year O
. O
Outcomes O
were O
hip B-outcome-measure
and I-outcome-measure
spine I-outcome-measure
BMD I-outcome-measure
( O
in O
grams O
per O
square O
centimeter O
) O
and O
body B-outcome-measure
composition I-outcome-measure
( O
percent O
body O
fat O
( O
% O
BF O
) O
and O
lean B-outcome-measure
and I-outcome-measure
fat I-outcome-measure
mass I-outcome-measure
( O
in O
kilograms O
) O
) O
by O
DXA O
and O
bone B-outcome-measure
turnover I-outcome-measure
markers I-outcome-measure
( O
serum O
osteocalcin O
( O
in O
nanograms O
per O
milliliter O
) O
and O
urinary B-outcome-measure
deoxypryrodinoline I-outcome-measure
( O
in O
nanomoles O
per O
milliliter O
) O
. O
There O
were O
no O
significant O
group B-outcome
 I-outcome
time I-outcome
interactions I-outcome
for O
bone O
outcomes O
when O
using O
an O
intent O
- O
to O
- O
treat O
approach O
on O
the O
full O
sample O
. O
In O
analyses O
restricted O
to O
BCS O
who O
were O
menopausal O
for O
1 O
year O
, O
POWIR O
increased O
BMD B-outcome
at I-outcome
the I-outcome
hip I-outcome
and O
slowed O
BMD B-outcome
loss I-outcome
at I-outcome
the I-outcome
spine I-outcome
compared O
with O
FLEX O
( O
femoral B-outcome
neck I-outcome
- I-outcome
POWIR I-outcome
, O
0.004 B-iv-cont-mean
 O
 O
 O
0.093 B-iv-cont-sd
g I-iv-cont-sd
/ I-iv-cont-sd
cm I-iv-cont-sd
( O
2 O
) O
vs. O
FLEX O
, O
-0.010 B-cv-cont-mean
 O
 O
 O
0.089 B-cv-cont-sd
g I-cv-cont-sd
/ I-cv-cont-sd
cm I-cv-cont-sd
( O
2 O
) O
; O
p O
 O
< O
 O
0.01 O
; O
spine B-outcome
- I-outcome
POWIR I-outcome
, O
-0.003 B-iv-cont-mean
 O
 O
 O
0.114 B-iv-cont-sd
g I-iv-cont-sd
/ I-iv-cont-sd
cm I-iv-cont-sd
( O
2 O
) O
vs. O
FLEX O
, O
-0.020 B-cv-cont-mean
 O
 O
 O
0.110 B-cv-cont-sd
g I-cv-cont-sd
/ I-cv-cont-sd
cm I-cv-cont-sd
( O
2 O
) O
; O
p O
 O
= O
 O
0.03 O
) O
. O
POWIR O
prevented O
increases B-outcome
in I-outcome
% I-outcome
BF I-outcome
( O
POWIR O
, O
0.01 B-iv-bin-percent
% I-iv-bin-percent
vs. O
FLEX O
, O
1.3 B-cv-bin-percent
% I-cv-bin-percent
; O
p O
 O
< O
 O
0.04 O
) O
. O
Women O
with O
attendance O
to O
POWIR O
at O
64 O
% O
had O
better O
improvements B-outcome
in I-outcome
% I-outcome
BF I-outcome
than O
women O
attending O
less O
often O
( O
p O
 O
< O
 O
0.03 O
) O
. O
Impact O
+ O
resistance O
training O
may O
effectively O
combat O
bone O
loss O
and O
worsening O
body O
composition O
from O
premature O
menopause O
in O
BCS O
. O

Efficacy O
of O
prophylactic B-intervention
antibiotic I-intervention
administration O
for O
breast O
cancer O
surgery O
in O
overweight O
or O
obese O
patients O
: O
a O
randomized O
controlled O
trial O
. O
To O
assess O
the O
impact O
of O
prophylactic O
antibiotics O
on O
the O
prevention O
of O
surgical B-condition
site I-condition
infection I-condition
( I-condition
SSI I-condition
) I-condition
and O
the O
cost O
- O
effectiveness O
of O
this O
prophylaxis O
for O
breast O
cancer O
surgery O
in O
overweight O
or O
obese O
women O
. O
SSI O
is O
higher O
than O
expected O
after O
breast O
surgery O
. O
Obesity O
was O
found O
to O
be O
one O
of O
the O
risk O
factors O
. O
The O
trial O
was O
designed O
as O
a O
phase O
IV O
randomized O
, O
controlled O
, O
parallel O
- O
group O
efficacy O
trial O
. O
It O
was O
conducted O
at O
a O
tertiary O
university O
hospital O
. O
Overweight B-eligibility
or I-eligibility
obese I-eligibility
women I-eligibility
with I-eligibility
clinically I-eligibility
early I-eligibility
- I-eligibility
stage I-eligibility
breast I-eligibility
cancer I-eligibility
who I-eligibility
had I-eligibility
been I-eligibility
assigned I-eligibility
to I-eligibility
undergo I-eligibility
surgery I-eligibility
were O
eligible O
. O
Patients O
were O
randomly O
allocated O
to O
either O
a O
prophylaxis O
or O
a O
control O
group O
by O
using O
a O
computer O
- O
generated O
list O
. O
The O
prophylaxis O
group O
received O
1 O
g O
ampicillin O
- O
sulbactam O
intravenously O
at O
anesthesia O
. O
The O
control O
group O
received O
no O
intervention O
. O
Patients O
and O
observers O
were O
blinded O
to O
the O
assignments O
. O
The O
primary O
outcome O
was O
the O
comparison O
of O
SSI B-outcome-measure
incidences I-outcome-measure
of O
the O
2 O
groups O
. O
Patients O
were O
monitored O
for O
30 O
days O
. O
A O
total O
of O
369 B-total-participants
patients O
were O
included O
in O
final O
analysis O
, O
out O
of O
which O
187 B-intervention-participants
were O
allocated O
for O
prophylaxis O
and O
182 B-control-participants
were O
randomly O
assigned O
to O
the O
control B-control
group I-control
. O
Analysis O
was O
done O
according O
to O
the O
intention O
- O
to O
- O
treat O
principle O
. O
Prophylaxis O
significantly O
reduced O
the O
SSI B-outcome
rate I-outcome
( O
4.8 B-iv-bin-percent
% I-iv-bin-percent
) O
in O
the O
prophylaxis O
group O
when O
compared O
with O
that O
in O
the O
control O
group O
[ O
13.7 B-cv-bin-percent
% I-cv-bin-percent
; O
relative O
risk O
( O
RR O
) O
0.35 O
; O
95 O
% O
CI O
: O
0.17 O
- O
0.73 O
] O
. O
No O
adverse B-outcome
reaction I-outcome
was O
observed O
. O
The O
mean B-outcome
SSI I-outcome
- I-outcome
related I-outcome
cost I-outcome
( B-cv-cont-mean
20.26 I-cv-cont-mean
USD I-cv-cont-mean
) O
was O
found O
to O
be O
significantly O
higher O
in O
the O
control O
group O
when O
compared O
with O
that O
( O
8.48 B-iv-cont-mean
USD I-iv-cont-mean
) O
in O
the O
prophylaxis O
group O
. O
Antibiotic O
prophylaxis O
significantly O
decreased O
SSI O
incidence O
after O
elective O
surgery O
and O
was O
shown O
to O
be O
cost O
- O
effective O
in O
obese O
breast O
cancer O
patients O
. O
ClinicalTrials.gov O
Identifier O
: O
NCT00356148 O
. O

Bupropion B-intervention
for O
control O
of O
hot B-condition
flashes I-condition
in O
breast O
cancer O
survivors O
: O
a O
prospective O
, O
double O
- O
blind O
, O
randomized O
, O
crossover O
, O
pilot O
phase O
II O
trial O
. O
Hot O
flashes O
( O
HFs O
) O
and O
sexual O
dysfunction O
often O
affect O
breast O
cancer O
( O
BC O
) O
survivors O
and O
compromise O
their O
quality O
of O
life O
. O
Bupropion O
is O
an O
antidepressive O
medication O
used O
for O
smoking O
cessation O
and O
also O
has O
been O
previously O
studied O
for O
the O
treatment O
of O
sexual O
dysfunction O
. O
We O
aimed O
to O
evaluate O
bupropion O
's O
efficacy O
in O
controlling O
HFs O
in O
BC O
 O
survivors O
. O
This O
was O
a O
randomized O
, O
double O
- O
blind O
, O
crossover O
, O
placebo O
- O
controlled O
pilot O
study O
that O
enrolled O
55 B-total-participants
BC B-eligibility
survivors I-eligibility
who I-eligibility
reported I-eligibility
more I-eligibility
than I-eligibility
seven I-eligibility
HFs I-eligibility
per I-eligibility
week I-eligibility
. O
Subjects O
were O
randomized O
to O
receive O
either O
bupropion O
150 O
mg O
twice O
daily O
for O
four O
weeks O
followed O
by O
one O
week O
of O
washout O
and O
four O
more O
weeks O
of O
placebo B-control
twice O
daily O
or O
vice O
versa O
. O
The O
primary O
end O
point O
was O
average B-outcome-measure
daily I-outcome-measure
HF I-outcome-measure
 I-outcome-measure
activity I-outcome-measure
( O
number O
of O
HFs O
and O
a O
score O
combining O
number O
and O
severity O
) O
reported O
while O
on O
bupropion O
or O
on O
placebo O
. O
Secondary O
end O
points O
were O
sexual B-outcome-measure
dysfunction I-outcome-measure
, O
depression B-outcome-measure
, O
and O
quality B-outcome-measure
of I-outcome-measure
life I-outcome-measure
evaluated O
with O
the O
Arizona O
Sexual O
Experience O
Scale O
, O
Beck O
Depression O
Inventory O
, O
and O
European O
Organization O
for O
 O
Research O
and O
Treatment O
of O
Cancer O
Quality O
of O
Life O
Questionnaire O
- O
C30 O
, O
respectively O
. O
Bupropion O
reduced O
HFs B-outcome
by O
1.26 B-iv-cont-mean
per I-iv-cont-mean
day I-iv-cont-mean
and O
the O
HF B-outcome
score I-outcome
by O
6.31 B-iv-bin-percent
% I-iv-bin-percent
, O
whereas O
placebo O
reduced O
HFs B-outcome
by O
2.11 B-cv-cont-mean
per I-cv-cont-mean
day I-cv-cont-mean
( O
P>0.05 O
) O
and O
the O
HF B-outcome
score I-outcome
by O
30.47 B-cv-bin-percent
% I-cv-bin-percent
( O
P>0.05 O
) O
. O
There O
were O
no O
statistically O
significant O
differences O
between O
bupropion O
and O
placebo O
in O
the O
Arizona B-outcome
Sexual I-outcome
Experience I-outcome
Scale I-outcome
, O
Beck B-outcome
Depression I-outcome
Inventory I-outcome
, O
and O
European O
Organization O
for O
Research O
and O
Treatment O
of O
Cancer O
Quality B-outcome
of I-outcome
Life I-outcome
Questionnaire O
- O
C30 O
. O
At O
the O
end O
of O
the O
study O
, O
47 B-iv-bin-percent
% I-iv-bin-percent
of O
the O
patients B-outcome
preferred I-outcome
bupropion I-outcome
, O
whereas O
53 B-cv-bin-percent
% I-cv-bin-percent
preferred B-outcome
placebo I-outcome
. O
There O
were O
no O
statistically O
significant O
differences O
in O
side O
effects O
between O
the O
study O
groups O
. O
Compared O
with O
placebo O
, O
bupropion O
did O
not O
control O
HFs O
in O
this O
group O
of O
BC O
survivors O
. O
  O

A O
randomised O
controlled O
trial O
to O
evaluate O
both O
the O
role O
and O
the O
optimal B-intervention
fractionation I-intervention
of I-intervention
radiotherapy I-intervention
in O
the O
conservative O
management O
of O
early O
breast O
cancer O
. O
Postoperative O
radiotherapy O
is O
routinely O
used O
in O
early O
breast O
cancer O
employing O
either O
50 O
Gy O
in O
25 O
daily O
fractions O
( O
long O
course O
) O
or O
40 O
Gy O
in O
15 O
daily O
fractions O
( O
short O
course O
) O
. O
The O
role O
of O
radiotherapy O
and O
shorter O
fractionation O
regimens O
require O
validation O
. O
Patients B-eligibility
with I-eligibility
clinical I-eligibility
stage I-eligibility
I I-eligibility
and I-eligibility
II I-eligibility
disease I-eligibility
were O
randomised O
to O
receive O
immediate O
radiotherapy O
or O
delayed O
salvage O
treatment O
( O
no B-control
radiotherapy I-control
) O
. O
Patients O
receiving O
radiotherapy O
were O
further O
randomised O
between O
long O
( O
50 O
Gy O
in O
25 O
daily O
fractions O
) O
or O
short O
( O
40 O
Gy O
in O
15 O
daily O
fractions O
) O
regimens O
. O
The O
primary O
outcome O
measure O
was O
time B-outcome-measure
to I-outcome-measure
first I-outcome-measure
locoregional I-outcome-measure
relapse I-outcome-measure
. O
Reported O
results O
are O
at O
a O
median O
follow O
- O
up O
of O
16.9 O
years O
( O
interquartile O
range O
15.4 O
- O
18.8 O
) O
. O
In O
total O
, O
707 B-total-participants
women O
were O
recruited O
between O
1985 O
and O
1992 O
: O
median O
age O
59 B-age
years I-age
( O
range O
28 O
- O
80 O
) O
, O
68 O
% O
postmenopausal O
, O
median O
tumour O
size O
2.0 O
cm O
( O
range O
0.12 O
- O
8.0 O
) O
; O
271 O
patients O
have O
relapsed B-outcome
: O
110 B-iv-bin-abs
radiotherapy O
, O
161 B-cv-bin-abs
no O
radiotherapy O
. O
The O
site B-outcome
of I-outcome
first I-outcome
relapse I-outcome
was I-outcome
locoregional I-outcome
158 O
( O
64 O
% O
) O
and O
distant B-outcome
87 O
( O
36 O
% O
) O
. O
There O
was O
an O
estimated O
24 B-iv-bin-percent
% I-iv-bin-percent
reduction O
in O
the O
risk B-outcome
of I-outcome
any I-outcome
competing I-outcome
event I-outcome
( I-outcome
local I-outcome
relapse I-outcome
, I-outcome
distant I-outcome
relapse I-outcome
or I-outcome
death I-outcome
) I-outcome
with O
radiotherapy O
( O
hazard O
ratio O
= O
0.76 O
; O
95 O
% O
confidence O
interval O
0.65 O
, O
0.88 O
) O
. O
The O
benefit O
of O
radiotherapy O
treatment O
for O
all O
competing O
event O
types O
was O
statistically O
significant O
( O
X O
( O
Wald O
) O
( O
2 O
) O
= O
36.04 O
, O
P O
< O
0.001 O
) O
. O
Immediate O
radiotherapy O
reduced O
the O
risk B-outcome
of I-outcome
locoregional I-outcome
relapse I-outcome
by O
62 B-iv-bin-percent
% I-iv-bin-percent
( O
hazard O
ratio O
= O
0.38 O
; O
95 O
% O
confidence O
interval O
0.27 O
, O
0.53 O
) O
, O
consistent O
across O
prognostic O
subgroups O
. O
No O
differences O
were O
seen O
between O
either O
radiotherapy O
fractionation O
schedules O
. O
This O
study O
confirmed O
better O
locoregional O
control O
for O
patients O
with O
early O
breast O
cancer O
receiving O
radiotherapy O
. O
A O
radiotherapy O
schedule O
of O
40 O
Gy O
in O
15 O
daily O
fractions O
is O
an O
efficient O
and O
effective O
regimen O
that O
is O
at O
least O
as O
good O
as O
the O
international O
conventional O
regimen O
of O
50 O
Gy O
in O
25 O
daily O
fractions O
. O

A O
randomized O
, O
double O
- O
blinded O
placebo O
- O
controlled O
clinical O
trial O
of O
the O
routine O
use O
of O
preoperative B-intervention
antibiotic I-intervention
prophylaxis I-intervention
in O
modified O
radical O
mastectomy O
. O
The O
effectiveness O
of O
antibiotic O
prophylaxis O
for O
prevention O
of O
surgical B-condition
site I-condition
infection I-condition
( I-condition
SSI I-condition
) I-condition
following O
specific O
types O
of O
breast O
cancer O
surgery O
remains O
uncertain O
. O
This O
study O
assessed O
the O
effectiveness O
of O
prophylaxis O
in O
modified O
radical O
mastectomy O
( O
MRM O
) O
. O
Women B-eligibility
undergoing I-eligibility
MRM I-eligibility
for I-eligibility
breast I-eligibility
cancer I-eligibility
were O
recruited O
. O
Women O
were O
excluded O
who O
had O
diabetes O
mellitus O
, O
severe O
malnutrition O
or O
known O
allergy O
to O
cephalosporins O
; O
were O
receiving O
corticosteroid O
therapy O
or O
were O
treated O
with O
antibiotics O
within O
one O
week O
prior O
to O
surgery O
; O
were O
scheduled O
for O
simultaneous O
breast O
reconstruction O
or O
bilateral O
oophorectomy O
; O
had O
existing O
local O
infection O
. O
Participants O
were O
randomized O
to O
receive O
either O
intravenous B-intervention
cefazolin I-intervention
1 O
g O
or O
placebo B-control
within O
30 O
min O
prior O
to O
skin O
incision O
. O
Standard O
skin O
preparation O
and O
operative O
technique O
for O
MRM O
were O
carried O
out O
. O
Wounds O
were O
assessed O
for O
SSI O
and O
other O
complications O
weekly O
for O
30 O
days O
. O
A O
total O
of O
254 B-total-participants
women O
were O
recruited O
. O
Age O
, O
clinical O
stage O
, O
prior O
chemotherapy O
, O
and O
operative O
time O
were O
similar O
for O
antibiotic O
and O
placebo O
groups O
. O
The O
overall B-outcome
incidence I-outcome
of I-outcome
SSI I-outcome
was O
14.2 O
% O
. O
There O
were O
no O
significant O
differences O
in O
the O
infection B-outcome
rate I-outcome
over O
the O
30 O
- O
day O
follow O
- O
up O
period O
between O
the O
placebo O
and O
antibiotic O
groups O
( O
15 B-cv-bin-percent
% I-cv-bin-percent
vs O
13.4 B-iv-bin-percent
% I-iv-bin-percent
; O
p O
= O
0.719 O
) O
or O
at O
each O
week O
. O
The O
majority O
of O
SSI O
were O
either O
cellulitis O
or O
superficial O
infection O
for O
both O
groups O
. O
There O
were O
no O
significant O
differences O
between O
groups O
in O
treatments O
required O
for O
SSI B-outcome
, O
incidence B-outcome
of I-outcome
hematoma I-outcome
or O
seroma B-outcome
. O
The O
findings O
of O
this O
study O
, O
alone O
and O
when O
meta O
- O
analyzed O
with O
data O
from O
studies O
in O
similar O
surgical O
populations O
, O
do O
not O
support O
the O
use O
of O
antibiotic O
prophylaxis O
in O
MRM O
. O

A O
randomized O
phase O
II O
trial O
of O
platinum B-intervention
salts I-intervention
in O
basal O
- O
like O
breast O
cancer O
patients O
in O
the O
neoadjuvant O
setting O
. O
Results O
from O
the O
GEICAM O
/ O
2006 O
- O
03 O
, O
multicenter O
study O
. O
Chemotherapy O
remains O
as O
the O
only O
systemic O
treatment O
option O
available O
for O
basal O
- O
like O
breast O
cancer O
( O
BC O
) O
patients O
. O
Preclinical O
models O
and O
several O
phase O
II O
studies O
suggested O
that O
platinum O
salts O
are O
active O
drugs O
in O
this O
BC O
subtype O
though O
there O
is O
no O
randomized O
study O
supporting O
this O
hypothesis O
. O
This O
study O
investigates O
if O
the O
addition O
of O
carboplatin O
to O
a O
combination O
of O
an O
alkylating O
agent O
together O
with O
anthracyclines O
and O
taxanes O
is O
able O
to O
increase O
the O
efficacy O
in O
the O
neoadjuvant O
treatment O
context O
. O
Patients B-eligibility
with I-eligibility
operable I-eligibility
breast I-eligibility
cancer I-eligibility
and I-eligibility
immunophenotypically I-eligibility
defined I-eligibility
basal I-eligibility
- I-eligibility
like I-eligibility
disease I-eligibility
( I-eligibility
ER-/PR-/HER2- I-eligibility
and I-eligibility
cytokeratin I-eligibility
5 I-eligibility
/ I-eligibility
6 I-eligibility
+ I-eligibility
or I-eligibility
EGFR+ I-eligibility
) I-eligibility
were O
recruited O
. O
Patients O
were O
randomized O
to O
receive O
EC O
( O
epirubicin O
90 O
mg O
/ O
m O
( O
2 O
) O
plus O
cyclophosphamide O
600 O
mg O
/ O
m O
( O
2 O
) O
for O
4 O
cycles O
) O
followed O
either O
by O
D B-intervention
( I-intervention
docetaxel I-intervention
100 O
mg O
/ O
m O
( O
2 O
) O
 O
4 O
cycles O
; O
EC B-intervention
- I-intervention
D I-intervention
) O
or O
DCb O
( O
docetaxel O
75 O
mg O
/ O
m O
( O
2 O
) O
plus O
carboplatin O
AUC O
6 O
 O
4 O
cycles O
; O
EC B-control
- I-control
DCb I-control
) O
. O
The O
primary O
end O
point O
was O
pathological B-outcome-measure
complete I-outcome-measure
response I-outcome-measure
( I-outcome-measure
pCR I-outcome-measure
) I-outcome-measure
in O
the O
breast O
following O
the O
Miller O
and O
Payne O
criteria O
. O
Ninety B-total-participants
- I-total-participants
four I-total-participants
patients O
were O
randomized O
( O
46 O
EC O
- O
D O
, O
48 O
EC O
- O
DCb O
) O
. O
pCR B-outcome
rate I-outcome
in I-outcome
the I-outcome
breast I-outcome
was O
seen O
in O
16 B-iv-bin-abs
patients O
( O
35 B-iv-bin-percent
% I-iv-bin-percent
) O
with O
EC O
- O
D O
and O
14 B-cv-bin-abs
patients O
( O
30 B-cv-bin-percent
% I-cv-bin-percent
) O
with O
EC O
- O
DCb O
( O
P O
value O
= O
0.61 O
) O
. O
pCR B-outcome
in I-outcome
the I-outcome
breast I-outcome
and I-outcome
axilla I-outcome
was O
seen O
in O
30 B-iv-bin-percent
% I-iv-bin-percent
of O
patients O
in O
both O
arms O
. O
The O
overall B-outcome
clinical I-outcome
response I-outcome
rate I-outcome
was O
70 B-iv-bin-percent
% I-iv-bin-percent
( O
95 O
% O
CI O
56 O
- O
83 O
) O
in O
the O
EC O
- O
D O
arm O
and O
77 B-cv-bin-percent
% I-cv-bin-percent
( O
95 O
% O
CI O
65 O
- O
87 O
) O
in O
the O
EC O
- O
DCb O
arm O
. O
Grade B-outcome
3 I-outcome
/ I-outcome
4 I-outcome
toxicity I-outcome
was O
similar O
in O
both O
arms O
. O
The O
addition O
of O
carboplatin O
to O
conventional O
chemotherapy O
with O
EC O
- O
D O
in O
basal O
- O
like O
breast O
cancer O
patients O
did O
not O
improve O
the O
efficacy O
probably O
because O
they O
had O
already O
received O
an O
alkylating O
agent O
. O
These O
findings O
should O
be O
taken O
into O
consideration O
when O
developing O
new O
agents O
for O
this O
disease O
. O

Effect O
of O
a O
mixed O
solution O
of O
sodium B-intervention
hyaluronate I-intervention
and I-intervention
carboxymethyl I-intervention
cellulose I-intervention
on O
upper B-condition
limb I-condition
dysfunction I-condition
after O
total O
mastectomy O
: O
a O
double O
- O
blind O
, O
randomized O
clinical O
trial O
. O
Restricted O
shoulder O
mobility O
is O
a O
major O
upper O
limb O
dysfunction O
related O
to O
lower O
quality O
of O
life O
and O
disability O
after O
breast O
cancer O
surgery O
. O
We O
hypothesized O
that O
sodium O
hyaluronate O
- O
carboxymethyl O
cellulose O
( O
HA O
- O
CMC O
) O
applied O
to O
the O
surface O
of O
the O
pectoralis O
major O
muscle O
after O
mastectomy O
would O
significantly O
reduce O
pain O
and O
improve O
range O
of O
motion O
( O
ROM O
) O
of O
the O
shoulder O
in O
breast O
cancer O
patients O
. O
We O
conducted O
a O
double O
- O
blind O
, O
randomized O
controlled O
study O
to O
evaluate O
the O
clinical O
efficacy O
and O
safety O
of O
HA O
- O
CMC O
in O
the O
prevention O
of O
upper O
limb O
dysfunction O
after O
total O
mastectomy O
( O
TM O
) O
. O
A O
total O
of O
99 B-total-participants
women O
with O
breast O
cancer O
were O
randomly O
assigned O
to O
one O
of O
two O
groups O
. O
In O
the O
HA O
- O
CMC O
group O
( O
n O
 O
= O
 O
50 B-intervention-participants
) O
, O
a O
mixed O
HA O
- O
CMC O
was O
applied O
to O
the O
surface O
of O
the O
pectoralis O
major O
and O
serratus O
anterior O
muscle O
after O
TM O
. O
In O
the O
control B-control
group I-control
( O
n O
 O
= O
 O
49 B-control-participants
) O
, O
TM O
was O
performed O
without B-control
the I-control
use I-control
of I-control
HA I-control
- I-control
CMC I-control
. O
The O
primary O
outcomes O
were O
ROM B-outcome-measure
of I-outcome-measure
the I-outcome-measure
shoulder I-outcome-measure
and O
motion B-outcome-measure
- I-outcome-measure
related I-outcome-measure
pain I-outcome-measure
assessed O
using O
a O
numeric O
rating O
scale O
measured O
before O
surgery O
( O
T0 O
) O
and O
3 O
( O
T1 O
) O
and O
6 O
 O
months O
( O
T2 O
) O
after O
surgery O
. O
Secondary O
outcomes O
included O
disabilities B-outcome-measure
of I-outcome-measure
the I-outcome-measure
arm I-outcome-measure
, I-outcome-measure
shoulder I-outcome-measure
, I-outcome-measure
and I-outcome-measure
hand I-outcome-measure
( I-outcome-measure
DASH I-outcome-measure
) I-outcome-measure
and O
the O
pectoralis B-outcome-measure
minor I-outcome-measure
length I-outcome-measure
test I-outcome-measure
. O
Compared O
with O
the O
control O
group O
, O
the O
HA O
- O
CMC O
group O
showed O
greater O
reductions B-outcome
in I-outcome
postoperative I-outcome
restriction I-outcome
of I-outcome
total I-outcome
shoulder I-outcome
ROM I-outcome
( O
sum O
of O
flexion O
and O
horizontal O
abduction O
) O
at O
3 O
 O
months O
( O
10.20 O
 O
, O
P O
 O
= O
 O
0.004 O
) O
. O
Mean B-outcome
pain I-outcome
levels I-outcome
related O
to O
flexion O
and O
horizontal O
abduction O
were O
significantly O
lower O
in O
the O
HA O
- O
CMC O
group O
( O
-1.32 B-iv-cont-mean
and O
-0.93 B-cv-cont-mean
, O
respectively O
, O
P O
 O
< O
 O
0.05 O
) O
. O
The O
DASH B-outcome
score I-outcome
was O
lower O
( O
-4.94 O
; O
P O
 O
= O
 O
0.057 O
) O
in O
the O
HA O
- O
CMC O
group O
at O
T2 O
. O
No O
adverse B-outcome
effect I-outcome
was O
observed O
in O
either O
group O
. O
These O
results O
provide O
evidence O
that O
HA O
- O
CMC O
may O
provide O
pain O
relief O
and O
improve O
ROM O
of O
the O
shoulder O
without O
causing O
adverse O
effects O
. O
The O
effect O
on O
pectoralis O
tightness O
should O
be O
investigated O
in O
further O
studies O
. O

Efficacy O
of O
a O
combined O
alendronate B-intervention
and I-intervention
calcitriol I-intervention
agent I-intervention
( I-intervention
Maxmarvil I-intervention
 I-intervention
) I-intervention
in O
Korean B-ethinicity
postmenopausal B-eligibility
women I-eligibility
with I-eligibility
early I-eligibility
breast I-eligibility
cancer I-eligibility
receiving I-eligibility
aromatase I-eligibility
inhibitor I-eligibility
: O
a O
double O
- O
blind O
, O
randomized O
, O
placebo O
- O
controlled O
study O
. O
The O
use O
of O
aromatase O
inhibitor O
( O
AI O
) O
in O
postmenopausal O
women O
with O
hormone O
receptor O
( O
HR O
) O
-positive O
early O
breast O
cancer O
( O
EBC O
) O
produces O
a O
deleterious O
effect O
on O
bone O
mass O
and O
an O
increase O
in O
fractures O
. O
Several O
studies O
using O
intravenous O
bisphosphonates O
have O
shown O
effective O
management O
of O
AI O
- O
induced O
bone O
loss O
. O
To O
determine O
whether O
a O
lower O
dosage O
in O
oral O
form O
combined O
with O
calcitriol O
can O
effectively O
manage O
AI B-condition
- I-condition
induced I-condition
bone I-condition
loss I-condition
, O
we O
performed O
a O
randomized O
, O
double O
- O
blind O
, O
prospective O
, O
placebo O
- O
controlled O
24 O
- O
week O
trial O
with O
a O
combination O
of O
alendronate O
and O
0.5-g O
of O
calcitriol O
daily O
to O
HR O
- O
positive O
EBC O
patients O
. O
A O
total O
of O
98 B-total-participants
Korean O
postmenopausal O
women O
with O
HR O
- O
positive O
EBC O
who O
received O
daily O
AI O
, O
calcium O
and O
vitamin O
D O
were O
randomly O
assigned O
to O
5 O
- O
mg O
of O
alendronate O
and O
0.5-g O
of O
calcitriol O
( O
Maxmarvil O
 O
) O
or O
placebo B-control
groups O
. O
The O
bone O
mineral O
density O
( O
BMD O
) O
and O
turnover O
markers O
were O
measured O
. O
At B-outcome
week I-outcome
24 I-outcome
, O
the O
difference O
in O
lumbar B-outcome
BMD I-outcome
between O
the O
groups O
was O
3.0 O
% O
( O
p O
< O
0.005 O
) O
. O
The O
increase B-outcome
in I-outcome
C I-outcome
- I-outcome
telopeptide I-outcome
after B-outcome
24 I-outcome
weeks I-outcome
was O
significantly O
less O
in O
the O
Maxmarvil O
group O
compared O
to O
that O
in O
the O
placebo O
group O
( O
35.2 B-iv-cont-mean
 O
17.5 B-iv-cont-sd
% I-iv-cont-sd
vs. O
109.8 B-cv-cont-mean
 O
28.6 B-cv-cont-sd
% I-cv-cont-sd
, O
p O
< O
0.05 O
) O
. O
Our O
study O
demonstrates O
that O
a O
combination O
of O
5 O
- O
mg O
alendronate O
and O
0.5-g O
calcitriol O
is O
effective O
to O
prevent O
bone O
loss O
due O
to O
AI O
in O
Korean O
postmenopausal O
women O
with O
EBC O
. O

Problem B-intervention
- I-intervention
solving I-intervention
therapy I-intervention
for O
psychological B-condition
distress I-condition
in O
Japanese B-ethinicity
early O
- O
stage O
breast O
cancer O
patients O
. O
The O
current O
report O
provides O
the O
result O
of O
a O
Phase O
II O
clinical O
trial O
regarding O
the O
effectiveness O
and O
feasibility O
of O
problem O
- O
solving O
therapy O
for O
psychological O
distress O
experienced O
by O
Japanese O
early O
- O
stage O
breast O
cancer O
patients O
. O
Participants O
were O
36 B-total-participants
post B-eligibility
- I-eligibility
surgery I-eligibility
Japanese I-eligibility
breast I-eligibility
cancer I-eligibility
patients I-eligibility
in O
a O
university O
hospital O
located O
in O
Osaka B-location
Prefecture I-location
, I-location
Japan I-location
. O
After O
screening O
for O
psychological O
distress O
using O
the O
Distress O
and O
Impact O
Thermometer O
and O
the O
Hospital O
Anxiety O
and O
Depression O
Scale O
, O
highly O
distressed O
patients O
were O
exposed O
to O
5 O
weekly O
sessions O
of O
the O
problem O
- O
solving O
therapy O
program O
. O
Nineteen B-intervention-participants
patients O
completed O
the O
intervention O
and O
follow O
- O
up O
. O
There O
was O
a O
significant O
difference O
between O
the O
pre O
- O
intervention O
and O
the O
3 O
- O
month O
follow O
- O
up O
in O
the O
total B-outcome
Hospital I-outcome
Anxiety I-outcome
and I-outcome
Depression I-outcome
Scale I-outcome
score O
( O
P O
= O
0.02 O
) O
, O
and O
the O
mean O
change O
score O
from O
the O
pre O
- O
intervention O
to O
the O
follow O
- O
up O
was O
6.05 O
( O
SD O
= O
1.94 O
) O
. O
The O
intervention O
had O
a O
large O
effect O
size O
( O
d O
= O
0.82 O
) O
. O
There O
were O
also O
significant O
changes B-outcome
in I-outcome
worry I-outcome
, I-outcome
self I-outcome
- I-outcome
efficacy I-outcome
and I-outcome
quality I-outcome
of I-outcome
life I-outcome
measures I-outcome
. O
The O
findings O
of O
our O
study O
suggest O
that O
the O
problem O
- O
solving O
therapy O
program O
has O
potential O
to O
be O
effective O
for O
alleviating O
psychological O
distress O
experienced O
by O
Japanese O
early O
- O
stage O
breast O
cancer O
patients O
. O
The O
true O
effectiveness O
of O
the O
program O
should O
be O
confirmed O
by O
a O
future O
randomized O
control O
trial O
. O

Progressive B-intervention
resistance I-intervention
versus O
relaxation B-control
training I-control
for O
breast O
cancer O
patients O
during O
adjuvant O
chemotherapy O
: O
design O
and O
rationale O
of O
a O
randomized O
controlled O
trial O
( O
BEATE O
study O
) O
. O
Cancer O
- O
related O
fatigue O
is O
a O
common O
severe O
symptom O
in O
breast O
cancer O
patients O
, O
especially O
during O
chemotherapy O
. O
Exercise O
appears O
to O
be O
promising O
in O
prevention O
or O
treatment O
of O
fatigue O
. O
Resistance O
training O
as O
an O
accompanying O
treatment O
to O
chemotherapy O
has O
been O
minimally O
investigated O
, O
yet O
might O
counteract O
muscle O
degradation O
and O
inflammation O
caused O
by O
many O
chemotherapeutics O
, O
and O
thus O
forestall O
or O
reduce O
fatigue O
. O
Previous O
exercise O
trials O
mostly O
compared O
the O
intervention O
with O
' O
usual O
care O
' O
. O
Therefore O
, O
it O
is O
unclear O
to O
what O
extent O
the O
observed O
effects O
on O
fatigue O
are O
based O
on O
physical O
adaptations O
by O
exercise O
itself O
, O
or O
rather O
on O
psycho O
- O
social O
factors O
linked O
to O
the O
group O
support O
or O
attention O
by O
the O
trainer O
. O
The O
BEATE O
study O
is O
a O
randomized O
, O
controlled O
intervention O
trial O
comparing O
a O
12 O
- O
week O
supervised O
progressive O
resistance O
training O
program O
with O
a O
supervised O
group O
- O
based O
progressive O
muscle O
relaxation O
training O
in O
100 B-total-participants
patients B-eligibility
with I-eligibility
breast I-eligibility
cancer I-eligibility
under I-eligibility
adjuvant I-eligibility
chemotherapy I-eligibility
. O
The O
primary O
endpoint O
is O
cancer B-outcome-measure
- I-outcome-measure
related I-outcome-measure
fatigue I-outcome-measure
; O
secondary O
endpoints O
include O
quality B-outcome-measure
of I-outcome-measure
life I-outcome-measure
, O
depression B-outcome-measure
, O
and O
cognitive B-outcome-measure
capacity I-outcome-measure
. O
In O
addition O
, O
isokinetic B-outcome-measure
and I-outcome-measure
isometric I-outcome-measure
muscle I-outcome-measure
strength I-outcome-measure
, O
cardiorespiratory B-outcome-measure
fitness I-outcome-measure
, O
and O
body B-outcome-measure
composition I-outcome-measure
are O
measured O
, O
and O
biomarkers B-outcome-measure
, O
such O
as O
inflammatory O
parameters O
, O
cortisol O
, O
and O
oxidative O
stress O
are O
analyzed O
in O
blood O
, O
saliva O
and O
urine O
. O
Safety B-outcome-measure
of O
the O
resistance O
training O
during O
chemotherapy O
is O
monitored O
. O
Strengths O
of O
the O
BEATE O
study O
include O
the O
investigation O
of O
progressive O
resistance O
training O
parallel O
with O
chemotherapy O
, O
the O
choice O
of O
a O
control O
group O
that O
enables O
an O
evaluation O
of O
the O
physiological O
effects O
of O
exercise O
beyond O
potential O
psycho O
- O
social O
effects O
, O
and O
the O
comprehensive O
and O
high O
- O
quality O
assessment O
of O
physiological O
factors O
and O
biomarkers O
potentially O
related O
to O
fatigue O
. O
  O

Effectiveness O
of O
OK-432 B-intervention
( I-intervention
Sapylin I-intervention
) I-intervention
to O
reduce O
seroma B-condition
formation I-condition
after O
axillary O
lymphadenectomy O
for O
breast O
cancer O
. O
The O
occurrence O
of O
seroma O
formation O
after O
axillary O
lymphadenectomy O
for O
breast O
cancer O
can O
not O
be O
ignored O
. O
Various O
approaches O
have O
been O
used O
in O
an O
effort O
to O
reduce O
it O
, O
but O
these O
results O
are O
still O
controversial O
. O
We O
aimed O
to O
describe O
a O
new O
method O
of O
application O
of O
OK-432 O
( O
Sapylin O
, O
heat O
- O
treated O
Su O
strain O
of O
Streptococcus O
) O
to O
reduce O
seroma O
formation O
after O
axillary O
lymphadenectomy O
for O
breast O
cancer O
and O
to O
verify O
the O
safety O
and O
efficacy O
of O
it O
as O
a O
beneficial O
supplement O
for O
conventional O
surgery O
. O
A O
prospective O
, O
randomized O
analysis O
of O
consecutive O
quadrantectomy O
or O
mastectomy O
plus O
axillary O
lymphadenectomy O
using O
or O
not O
using O
OK-432 O
was O
designed O
. O
From O
July O
2010 O
to O
November O
2011 O
, O
a O
total O
of O
111 B-total-participants
patients O
were O
enrolled O
in O
this O
prospective O
, O
randomized O
study O
and O
completed O
the O
follow O
- O
up O
. O
OK-432 O
applied O
to O
the O
axillary O
fossa O
plus O
placement O
of O
closed O
suction O
drainage O
was O
used O
in O
54 B-intervention-participants
patients O
( O
the O
experimental O
group O
) O
; O
placement O
of O
closed O
suction O
drainage O
was O
used O
in O
57 B-control-participants
patients O
( O
the O
control B-control
group I-control
) O
. O
There O
were O
no O
statistical O
significance O
between O
the O
two O
groups O
in O
terms O
of O
age O
, O
body O
mass O
index O
, O
treatment O
received O
, O
tumor O
size O
, O
number O
of O
removed O
lymph O
nodes O
, O
and O
lymph O
node O
status O
. O
Postoperative B-outcome
drainage I-outcome
magnitude I-outcome
and I-outcome
duration I-outcome
were O
significantly O
reduced O
in O
the O
experimental O
group O
( O
P O
= O
0.008 O
and O
0.003 O
, O
respectively O
) O
. O
One O
week O
after O
hospital O
discharge O
, O
fewer O
patients O
developed O
a O
palpable B-outcome
seroma I-outcome
in O
the O
experimental O
group O
: O
10 B-iv-bin-abs
in O
the O
experimental O
group O
versus O
28 B-cv-bin-abs
in O
the O
control O
group O
( O
P O
= O
0.001 O
) O
. O
Fewer O
seromas B-outcome
needed I-outcome
aspiration I-outcome
( O
mean O
1 B-iv-cont-mean
[ O
range O
0 O
- O
3 O
] O
in O
the O
experimental O
group O
vs. O
mean O
4 B-cv-cont-mean
[ O
range O
1 O
- O
5 O
] O
in O
the O
control O
group O
; O
P O
< O
0.001 O
) O
. O
There O
were O
no O
significant O
differences O
in O
terms O
of O
the O
incidence B-outcome
of I-outcome
complications I-outcome
associated I-outcome
with I-outcome
axillary I-outcome
lymphadenectomy I-outcome
( O
P O
= O
0.941 O
) O
. O
OK-432 O
is O
a O
feasible O
and O
safe O
option O
for O
axillary O
lymphadenectomy O
for O
breast O
cancer O
. O
The O
use O
of O
it O
does O
not O
always O
prevent O
seroma O
formation O
, O
but O
it O
can O
reduce O
drainage O
magnitude O
and O
duration O
, O
as O
well O
as O
decrease O
the O
incidence O
of O
seroma O
after O
the O
removal O
of O
drainage O
. O
It O
may O
be O
increasingly O
conducted O
in O
day O
surgery O
clinics O
. O

The O
use O
of O
Ginkgo B-intervention
biloba I-intervention
for O
the O
prevention O
of O
chemotherapy B-condition
- I-condition
related I-condition
cognitive I-condition
dysfunction I-condition
in O
women O
receiving O
adjuvant O
treatment O
for O
breast O
cancer O
, O
N00C9 O
. O
Patients O
undergoing O
treatment O
for O
cancer O
often O
report O
problems O
with O
their O
cognitive O
function O
, O
which O
is O
an O
essential O
component O
of O
health O
- O
related O
quality O
of O
life O
. O
Pursuant O
to O
this O
, O
a O
two O
- O
arm O
randomized O
, O
placebo O
- O
controlled O
, O
double O
- O
blind O
, O
phase O
III O
clinical O
trial O
was O
conducted O
to O
evaluate O
Ginkgo O
biloba O
( O
EGB O
761 O
) O
for O
the O
prevention O
of O
chemotherapy O
- O
related O
cognitive O
dysfunction O
in O
patients O
with O
breast O
cancer O
. O
Previously B-eligibility
chemotherapy I-eligibility
nave I-eligibility
women I-eligibility
about I-eligibility
to I-eligibility
receive I-eligibility
adjuvant I-eligibility
chemotherapy I-eligibility
for I-eligibility
breast I-eligibility
cancer I-eligibility
were O
randomized O
to O
receive O
60 O
mg O
of O
EGB O
761 O
or O
a O
matching O
placebo B-control
twice O
daily O
. O
The O
study O
agent O
was O
to O
begin O
before O
their O
second O
 O
cycle O
of O
chemotherapy O
and O
to O
be O
taken O
throughout O
chemotherapy O
and O
1 O
month O
beyond O
completion O
. O
The O
primary O
measure O
for O
cognitive O
function O
was O
the O
High B-outcome-measure
Sensitivity I-outcome-measure
Cognitive I-outcome-measure
Screen I-outcome-measure
( I-outcome-measure
HSCS I-outcome-measure
) I-outcome-measure
, O
with O
a O
secondary O
measure O
being O
the O
Trail B-outcome-measure
Making I-outcome-measure
Tests I-outcome-measure
( I-outcome-measure
TMT I-outcome-measure
) I-outcome-measure
A I-outcome-measure
and I-outcome-measure
B I-outcome-measure
. O
Subjective O
assessment O
of O
cognitive O
function O
was O
evaluated O
by O
the O
cognitive O
subscale O
of O
the O
Perceived O
Health O
Scale O
( O
PHS O
) O
and O
the O
Profile O
of O
Mood O
States O
( O
POMS O
) O
. O
Data O
were O
collected O
at O
baseline O
and O
at O
intervals O
throughout O
and O
after O
chemotherapy O
, O
up O
to O
24 O
months O
after O
completion O
of O
adjuvant O
treatment O
. O
The O
primary O
statistical O
analysis O
included O
normalized O
area O
under O
the O
curve O
( O
AUC O
) O
comparisons O
of O
the O
HSCS O
, O
between O
the O
arms O
. O
Secondary O
analyses O
included O
evaluation O
of O
the O
other O
measures O
of O
cognition O
as O
well O
as O
correlational O
analyses O
between O
self O
- O
report O
and O
cognitive O
testing O
. O
One B-total-participants
hundred I-total-participants
and I-total-participants
sixty I-total-participants
- I-total-participants
six I-total-participants
women O
provided O
evaluable O
data O
. O
There O
were O
no O
significant O
differences B-outcome
in I-outcome
AUC I-outcome
up O
to O
12 O
months O
on O
the O
HSCS O
between O
arms O
at O
the O
end O
of O
chemotherapy O
or O
at O
any O
other O
time O
point O
after O
adjuvant O
treatment O
. O
There O
were O
also O
no O
significant O
differences B-outcome
in I-outcome
TMT I-outcome
A I-outcome
or I-outcome
B I-outcome
at O
any O
data O
point O
. O
Perceived B-outcome
cognitive I-outcome
functions I-outcome
, O
as O
measured O
by O
the O
PHS O
and O
confusion O
/ O
bewilderment O
subscale O
of O
the O
POMS O
, O
were O
not O
different O
between O
arms O
at O
the O
end O
of O
chemotherapy O
. O
There O
was O
also O
little O
correlation O
between O
self B-outcome
- I-outcome
reported I-outcome
cognition I-outcome
and I-outcome
cognitive I-outcome
testing I-outcome
. O
No O
differences O
were O
observed O
in O
toxicities B-outcome
per O
Common O
Terminology O
Criteria O
for O
Adverse O
Events O
( O
CTCAE O
) O
assessment O
between O
Ginkgo O
biloba O
and O
placebo O
throughout O
the O
study O
; O
however O
, O
after O
chemotherapy O
, O
the O
placebo O
group O
reported O
worse O
nausea O
( O
p O
 O
= O
 O
.05 O
) O
. O
This O
study O
did O
not O
provide O
any O
support O
for O
the O
notion O
that O
Ginkgo O
biloba O
, O
at O
a O
dose O
of O
60 O
mg O
twice O
a O
day O
, O
can O
help O
prevent O
cognitive O
changes O
from O
chemotherapy O
. O
These O
analyses O
do O
provide O
data O
to O
further O
support O
the O
low O
associations O
between O
patients O
' O
self O
- O
report O
of O
cognition O
and O
cognitive O
performance O
, O
based O
on O
more O
formal O
testing O
. O

Are O
mammographic O
changes O
in O
the O
tumor O
bed O
more O
pronounced O
after O
intraoperative O
radiotherapy O
for O
breast O
cancer O
? O
Subgroup O
analysis O
from O
a O
randomized O
trial O
( O
TARGIT O
- O
A O
) O
. O
Intraoperative O
radiotherapy O
( O
IORT O
) O
with O
low O
- O
energy O
x O
- O
rays O
is O
increasingly O
used O
in O
breast O
- O
conserving O
therapy O
( O
BCT O
) O
. O
Previous O
non O
- O
randomized O
studies O
have O
observed O
mammographic O
changes O
in O
the O
tumor O
bed O
to O
be O
more O
pronounced O
after O
IORT O
. O
The O
purpose O
of O
this O
study O
was O
to O
reassess O
the O
postoperative O
changes O
in O
a O
randomized O
single O
- O
center O
subgroup O
of O
patients O
from O
a O
multicenter O
trial O
( O
TARGIT O
- O
A O
) O
. O
In O
this O
subgroup O
( O
n O
= O
48 B-total-participants
) O
27 B-intervention-participants
patients O
received O
BCT B-intervention
with I-intervention
IORT I-intervention
, O
21 B-control-participants
patients O
had O
BCT B-control
with I-control
standard I-control
whole I-control
- I-control
breast I-control
radiotherapy I-control
serving O
as O
controls O
. O
Overall O
258 O
postoperative O
mammograms O
( O
median O
follow O
- O
up O
4.3 O
years O
, O
range O
3 O
- O
8) O
were O
retrospectively O
evaluated O
by O
two O
radiologists O
in O
consensus O
focusing O
on O
changes O
in O
the O
tumor O
bed O
. O
Fat B-outcome
necroses I-outcome
showed O
to O
be O
significantly O
more O
frequent B-outcome
( O
56 B-iv-bin-percent
% I-iv-bin-percent
versus O
24 B-cv-bin-percent
% I-cv-bin-percent
) O
and O
larger B-outcome
( O
8.7 B-iv-cont-median
versus O
1.6 B-cv-cont-median
sq I-cv-cont-median
cm I-cv-cont-median
, O
median O
) O
after O
IORT O
than O
those O
in O
controls O
. O
Scar B-outcome
calcifications I-outcome
were O
also O
significantly O
more O
frequent O
after O
IORT O
( O
63 B-iv-bin-percent
% I-iv-bin-percent
versus O
19 B-cv-bin-percent
% I-cv-bin-percent
) O
. O
The O
high O
incidence B-outcome
of I-outcome
large I-outcome
fat I-outcome
necroses I-outcome
in O
our O
study O
confirms O
previous O
study O
findings O
. O
However O
, O
the O
overall O
higher O
incidence O
of O
calcifications O
in O
the O
tumor O
bed O
after O
IORT O
represents O
a O
new O
finding O
, O
requiring O
further O
attention O
. O

Mindfulness B-intervention
based I-intervention
stress I-intervention
reduction I-intervention
( I-intervention
MBSR I-intervention
( I-intervention
BC I-intervention
) I-intervention
) I-intervention
in O
breast O
cancer O
: O
evaluating O
fear O
of O
recurrence O
( O
FOR O
) O
as O
a O
mediator O
of O
psychological O
and O
physical O
symptoms O
in O
a O
randomized O
control O
trial O
( O
RCT O
) O
. O
To O
investigate O
the O
mechanism O
( O
s O
) O
of O
action O
of O
mindfulness O
based O
stress O
reduction O
( O
MBSR O
( O
BC O
) O
) O
including O
reductions O
in O
fear O
of O
recurrence O
and O
other O
potential O
mediators O
. O
Eighty B-total-participants
- I-total-participants
two I-total-participants
post B-eligibility
- I-eligibility
treatment I-eligibility
breast I-eligibility
cancer I-eligibility
survivors I-eligibility
( I-eligibility
stages I-eligibility
0 I-eligibility
- I-eligibility
III I-eligibility
) I-eligibility
were O
randomly O
assigned O
to O
a O
6 O
- O
week O
MBSR O
( O
BC O
) O
program O
( O
n O
 O
= O
 O
40 B-intervention-participants
) O
or O
to O
usual B-control
care I-control
group I-control
( I-control
UC I-control
) I-control
( O
n O
 O
= O
 O
42 B-control-participants
) O
. O
Psychological O
and O
physical O
variables O
were O
assessed O
as O
potential O
mediators O
at O
baseline O
and O
at O
6 O
 O
weeks O
. O
MBSR O
( O
BC O
) O
compared O
to O
UC O
experienced O
favorable O
changes O
for O
five O
potential O
mediators O
: O
( O
1 O
) O
change B-outcome
in I-outcome
fear I-outcome
of I-outcome
recurrence I-outcome
problems I-outcome
mediated O
the O
effect O
of O
MBSR O
( O
BC O
) O
on O
6 O
- O
week O
change O
in O
perceived B-outcome
stress I-outcome
( O
z O
 O
= O
 O
2.12 O
, O
p O
 O
= O
 O
0.03 O
) O
and O
state B-outcome
anxiety I-outcome
( O
z O
 O
= O
 O
2.03 O
, O
p O
 O
= O
 O
0.04 O
) O
; O
and O
( O
2 O
) O
change B-outcome
in I-outcome
physical I-outcome
functioning I-outcome
mediated O
the O
effect O
of O
MBSR O
( O
BC O
) O
on O
6 O
- O
week O
change O
in O
perceived B-outcome
stress I-outcome
( O
z O
 O
= O
 O
2.27 O
, O
p O
 O
= O
 O
0.02 O
) O
and O
trait B-outcome
anxiety I-outcome
( O
z O
 O
= O
 O
1.98 O
, O
p O
 O
= O
 O
0.05 O
) O
. O
MBSR O
( O
BC O
) O
reduces O
fear B-outcome
of I-outcome
recurrence I-outcome
and O
improves O
physical B-outcome
functioning I-outcome
which O
reduces O
perceived B-outcome
stress I-outcome
and I-outcome
anxiety I-outcome
. O
Findings O
support O
the O
beneficial O
effects O
of O
MBSR O
( O
BC O
) O
and O
provide O
insight O
into O
the O
possible O
cognitive O
mechanism O
of O
action O
. O
  O

Breast B-intervention
ductal I-intervention
lavage I-intervention
for O
biomarker O
assessment O
in O
high O
risk O
women O
: O
rationale O
, O
design O
and O
methodology O
of O
a O
randomized O
phase O
II O
clinical O
trial O
with O
nimesulide O
, O
simvastatin O
and O
placebo O
. O
Despite O
positive O
results O
from O
large O
phase O
III O
clinical O
trials O
proved O
that O
it O
is O
possible O
to O
prevent O
estrogen O
- O
responsive O
breast O
cancers O
with O
selective O
estrogen O
receptor O
modulators O
and O
aromatase O
inhibitors O
, O
no O
significant O
results O
have O
been O
reached O
so O
far O
to O
prevent O
hormone O
non O
- O
responsive O
tumors O
. O
The O
Ductal O
Lavage O
( O
DL O
) O
procedure O
offers O
a O
minimally O
invasive O
method O
to O
obtain O
breast O
epithelial O
cells O
from O
the O
ductal O
system O
for O
cytopathologic O
analysis O
. O
Several O
studies O
with O
long O
- O
term O
follow O
- O
up O
have O
shown O
that O
women O
with O
atypical O
hyperplasia O
have O
an O
elevated O
risk O
of O
developing O
breast O
cancer O
. O
The O
objective O
of O
the O
proposed O
trial O
is O
to O
assess O
the O
efficacy O
and O
safety O
of O
a O
daily O
administration O
of O
nimesulide O
or O
simvastatin O
in O
women O
at O
higher O
risk O
for O
breast O
cancer O
, O
focused O
particularly O
on O
hormone O
non O
- O
responsive O
tumor O
risk O
. O
The O
primary O
endpoint O
is O
the O
change B-outcome-measure
in I-outcome-measure
prevalence I-outcome-measure
of I-outcome-measure
atypical I-outcome-measure
cells I-outcome-measure
and I-outcome-measure
cell I-outcome-measure
proliferation I-outcome-measure
( O
measured O
by O
Ki67 O
) O
in O
DL O
or O
fine O
needle O
aspirate O
samples O
, O
after O
12 O
months O
of O
treatment O
and O
12 O
months O
after O
treatment O
cessation O
. O
METHODS O
- O
DESIGN O
: O
From O
2005 O
to O
2011 O
, O
150 B-total-participants
women B-eligibility
with I-eligibility
a I-eligibility
history I-eligibility
of I-eligibility
estrogen I-eligibility
receptor I-eligibility
negative I-eligibility
ductal I-eligibility
intraepithelial I-eligibility
neoplasia I-eligibility
or I-eligibility
lobular I-eligibility
intraepithelial I-eligibility
neoplasia I-eligibility
or I-eligibility
atypical I-eligibility
hyperplasia I-eligibility
, I-eligibility
or I-eligibility
unaffected I-eligibility
subjects I-eligibility
carrying I-eligibility
a I-eligibility
mutation I-eligibility
of I-eligibility
BRCA1 I-eligibility
or I-eligibility
with I-eligibility
a I-eligibility
probability I-eligibility
of I-eligibility
mutation I-eligibility
> I-eligibility
10 I-eligibility
% I-eligibility
( I-eligibility
according I-eligibility
to I-eligibility
BRCAPRO I-eligibility
) I-eligibility
were O
randomized O
to O
receive O
nimesulide O
100mg O
/ O
day O
versus O
simvastatin O
20mg O
/ O
day O
versus O
placebo B-control
for O
one O
year O
followed O
by O
a O
second O
year O
of O
follow O
- O
up O
. O
This O
is O
the O
first O
randomized O
placebo O
controlled O
trial O
to O
evaluate O
the O
role O
of O
DL O
to O
study O
surrogate O
endpoints O
biomarkers O
and O
the O
effects O
of O
these O
drugs O
on O
breast O
carcinogenesis O
. O
In O
2007 O
the O
European O
Medicines O
Agency O
limited O
the O
use O
of O
systemic O
formulations O
of O
nimesulide O
to O
15 O
days O
. O
According O
to O
the O
European O
Institute O
of O
Oncology O
Ethics O
Committee O
communication O
, O
we O
are O
now O
performing O
an O
even O
more O
careful O
monitoring O
of O
the O
study O
participants O
. O
Preliminary O
results O
showed O
that O
DL B-outcome
is I-outcome
a I-outcome
feasible I-outcome
procedure I-outcome
, O
the O
treatment B-outcome
is I-outcome
well I-outcome
tolerated I-outcome
and O
the O
safety O
blood O
tests O
do O
not O
show O
any O
significant O
liver B-outcome
toxicity I-outcome
. O
There O
is O
an O
urgent O
need O
to O
confirm O
in O
the O
clinical O
setting O
the O
potential O
efficacy O
of O
other O
compounds O
in O
contrasting O
hormone O
non O
- O
responsive O
breast O
cancer O
. O
This O
paper O
is O
focused O
on O
the O
methodology O
and O
operational O
aspects O
of O
the O
clinical O
trial O
. O
( O
ClinicalTrials.gov O
Identifier O
: O
NCT01500577 O
) O
. O

Exercise B-intervention
effects O
on O
hip B-condition
bone I-condition
mineral I-condition
density I-condition
in O
older O
, O
post O
- O
menopausal O
breast O
cancer O
survivors O
are O
age O
dependent O
. O
We O
evaluated O
whether O
age O
moderated O
the O
effect O
of O
impact O
+ O
resistance O
exercise O
on O
hip O
BMD O
in O
older O
post O
- O
menopausal O
breast O
cancer O
survivors O
( O
BCS O
) O
. O
Exercise O
was O
more O
beneficial O
among O
younger O
than O
older O
women O
within O
our O
sample O
, O
suggesting O
that O
much O
older O
BCS O
may O
require O
different O
training O
programs O
to O
improve O
hip O
health O
. O
Previously O
, O
we O
reported O
that O
a O
program O
of O
resistance O
+ O
impact O
training O
stopped O
bone O
loss O
at O
the O
spine O
in O
older O
, O
post O
- O
menopausal O
BCS O
but O
had O
no O
effect O
on O
bone O
mineral O
density O
( O
BMD O
) O
at O
the O
hip O
. O
Aging O
may O
blunt O
the O
responsiveness O
of O
the O
hip O
to O
mechanical O
loading O
, O
so O
we O
conducted O
a O
secondary O
data O
analysis O
to O
evaluate O
whether O
age O
moderated O
the O
effect O
of O
exercise O
on O
hip O
BMD O
. O
We O
analyzed O
data O
from O
our O
randomized O
, O
controlled O
trial O
in O
older O
( O
 B-age
50 I-age
 I-age
years I-age
of O
age O
at O
diagnosis O
) O
, O
post B-eligibility
- I-eligibility
menopausal I-eligibility
, I-eligibility
post I-eligibility
- I-eligibility
adjuvant I-eligibility
treatment I-eligibility
BCS I-eligibility
( O
n O
 O
= O
 O
106 B-total-participants
) O
comparing O
women O
assigned O
to O
impact O
+ O
resistance O
exercise O
( O
POWIR O
) O
or O
to O
a O
control B-control
program I-control
of O
low O
- O
intensity O
stretching O
( O
FLEX O
) O
. O
We O
examined O
effect O
modification O
by O
age O
on O
BMD O
at O
three O
hip O
sites O
( O
greater O
trochanter O
, O
femoral O
neck O
, O
and O
total O
hip O
) O
using O
hierarchical O
linear O
modeling O
adjusting O
for O
time O
since O
diagnosis O
and O
use O
of O
adjuvant O
hormone O
therapy O
. O
Age O
moderated O
the O
effect O
of O
exercise O
on O
total B-outcome
hip I-outcome
BMD I-outcome
such O
that O
younger O
women O
in O
POWIR O
were O
more O
likely O
to O
see O
a O
positive O
net O
benefit O
than O
FLEX O
compared O
to O
older O
women O
where O
there O
was O
little O
difference O
between O
groups O
( O
p O
 O
= O
 O
0.02 O
) O
. O
The O
skeletal B-outcome
response I-outcome
to I-outcome
loading I-outcome
at I-outcome
the I-outcome
hip I-outcome
within O
post O
- O
menopausal O
BCS O
diminishes O
with O
age O
. O
Whether O
more O
vigorous O
exercise O
programs O
and/or O
longer O
training O
periods O
are O
required O
to O
favorably O
change O
hip O
health O
in O
older O
BCS O
will O
require O
future O
study O
and O
careful O
thought O
about O
the O
risks O
and O
benefits O
of O
tougher O
training O
programs O
. O

Effect O
of O
penehyclidine B-intervention
hydrochloride I-intervention
on O
the O
incidence B-condition
of I-condition
intra I-condition
- I-condition
operative I-condition
awareness I-condition
in O
Chinese B-ethinicity
patients O
undergoing O
breast O
cancer O
surgery O
during O
general O
anaesthesia O
. O
Intra O
- O
operative O
awareness O
can O
lead O
to O
serious O
adverse O
psychological O
consequences O
. O
We O
conducted O
a O
prospective O
, O
randomised O
, O
double O
- O
blinded O
trial O
in O
920 B-total-participants
patients B-eligibility
undergoing I-eligibility
breast I-eligibility
cancer I-eligibility
surgery I-eligibility
under I-eligibility
bispectral I-eligibility
index I-eligibility
- I-eligibility
guided I-eligibility
total I-eligibility
intravenous I-eligibility
anaesthesia I-eligibility
to O
evaluate O
the O
effect O
of O
penehyclidine O
hydrochloride O
on O
intra O
- O
operative O
awareness O
. O
Patients O
were O
randomly O
divided O
to O
receive O
0.01 O
 O
mg.kg O
( O
-1 O
) O
  O
penehyclidine O
hydrochloride O
or O
saline B-control
intravenously O
30 O
 O
min O
before O
surgery O
. O
The O
pre O
- O
administration O
, O
pre O
- O
operative O
anxiety O
levels O
were O
assessed O
using O
a O
100 O
- O
mm O
visual O
analogue O
scale O
. O
Intra O
- O
operative O
awareness O
was O
defined O
as O
recall O
of O
intra O
- O
operative O
events O
using O
a O
modified O
Brice O
interview O
administered O
2 O
- O
6 O
 O
h O
postoperatively O
, O
and O
in O
the O
next O
24 O
- O
48 O
 O
h. O
A O
committee O
of O
three O
experts O
, O
blinded O
to O
the O
study O
conditions O
, O
independently O
scrutinised O
all O
reported O
recollections O
. O
We O
found O
no O
differences O
in O
depth O
of O
anaesthesia O
and O
patients O
' O
pre O
- O
operative O
anxiety B-outcome
levels I-outcome
between O
the O
two O
groups O
. O
The O
incidence B-outcome
of I-outcome
awareness I-outcome
with O
penehyclidine O
hydrochloride O
( O
0 B-iv-bin-abs
/ O
456 B-intervention-participants
patients O
; O
0 B-iv-bin-percent
% I-iv-bin-percent
) O
was O
significantly O
lower O
than O
with O
saline O
( O
5 B-cv-bin-abs
/ O
452 B-control-participants
; O
1.1 B-cv-bin-percent
% I-cv-bin-percent
) O
, O
p O
 O
= O
 O
0.030 O
. O
We O
conclude O
that O
penehyclidine O
hydrochloride O
reduced O
the O
incidence O
of O
intra O
- O
operative O
awareness O
in O
patients O
undergoing O
breast O
cancer O
surgery O
during O
general O
anaesthesia O
. O

Can O
treatment O
with O
Cocculine B-intervention
improve O
the O
control O
of O
chemotherapy B-condition
- I-condition
induced I-condition
emesis I-condition
in O
early O
breast O
cancer O
patients O
? O
A O
randomized O
, O
multi O
- O
centered O
, O
double O
- O
blind O
, O
placebo O
- O
controlled O
Phase O
III O
trial O
. O
Chemotherapy O
induced O
nausea O
and O
vomiting O
( O
CINV O
) O
remains O
a O
major O
problem O
that O
seriously O
impairs O
the O
quality O
of O
life O
( O
QoL O
) O
in O
cancer O
patients O
receiving O
chemotherapy O
regimens O
. O
Complementary O
medicines O
, O
including O
homeopathy O
, O
are O
used O
by O
many O
patients O
with O
cancer O
, O
usually O
alongside O
with O
conventional O
treatment O
. O
A O
randomized O
, O
placebo O
- O
controlled O
Phase O
III O
study O
was O
conducted O
to O
evaluate O
the O
efficacy O
of O
a O
complex O
homeopathic O
medicine O
, O
Cocculine O
, O
in O
the O
control O
of O
CINV O
in O
non O
- O
metastatic O
breast O
cancer O
patients O
treated O
by O
standard O
chemotherapy O
regimens O
. O
Chemotherapy B-eligibility
- I-eligibility
nave I-eligibility
patients I-eligibility
with I-eligibility
non I-eligibility
- I-eligibility
metastatic I-eligibility
breast I-eligibility
cancer I-eligibility
scheduled O
to O
receive O
6 O
cycles O
of O
chemotherapy O
including O
at O
least O
three O
initial O
cycles O
of O
FAC O
50 O
, O
FEC O
100 O
or O
TAC O
were O
randomized O
to O
receive O
standard O
anti O
- O
emetic O
treatment O
plus O
either O
a O
complex O
homeopathic O
remedy O
( O
Cocculine O
, O
registered O
in O
France O
for O
treatment O
of O
nausea O
and O
travel O
sickness O
) O
or O
the O
matching O
placebo O
( O
NCT00409071 O
clinicaltrials.gov O
) O
. O
The O
primary O
endpoint O
was O
nausea B-outcome-measure
score I-outcome-measure
measured O
after O
the O
1st O
chemotherapy O
course O
using O
the O
FLIE O
questionnaire O
( O
Functional O
Living O
Index O
for O
Emesis O
) O
with O
5 O
- O
day O
recall O
. O
Secondary O
endpoints O
were O
: O
vomiting B-outcome-measure
measured O
by O
the O
FLIE O
score O
, O
nausea B-outcome-measure
and I-outcome-measure
vomiting I-outcome-measure
measured O
by O
patient O
self O
- O
evaluation O
( O
EVA O
) O
and O
investigator O
recording O
( O
NCI O
- O
CTC O
AE O
V3.0 O
) O
and O
treatment B-outcome-measure
compliance I-outcome-measure
. O
From O
September O
2005 O
to O
January O
2008 O
, O
431 B-total-participants
patients O
were O
randomized O
: O
214 B-intervention-participants
to O
Cocculine O
( O
C O
) O
and O
217 B-control-participants
to O
placebo B-control
( I-control
P I-control
) I-control
. O
Patient O
characteristics O
were O
well O
- O
balanced O
between O
the O
2 O
arms O
. O
Overall O
, O
compliance B-outcome
to O
study O
treatments O
was O
excellent O
and O
similar O
between O
the O
2 O
arms O
. O
A O
total O
of O
205 O
patients O
( O
50.9 O
% O
; O
103 B-cv-bin-abs
patients O
in O
the O
placebo O
and O
102 B-iv-bin-abs
in O
the O
homeopathy O
arms O
) O
had O
nausea B-outcome
FLIE I-outcome
scores I-outcome
> I-outcome
6 I-outcome
indicative O
of O
no O
impact O
of O
nausea O
on O
quality O
of O
life O
during O
the O
1st O
chemotherapy O
course O
. O
There O
was O
no O
difference O
between O
the O
2 O
arms O
when O
primary O
endpoint O
analysis O
was O
performed O
by O
chemotherapy O
stratum O
; O
or O
in O
the O
subgroup O
of O
patients O
with O
susceptibility O
to O
nausea O
and O
vomiting O
before O
inclusion O
. O
In O
addition O
, O
nausea B-outcome
, O
vomiting B-outcome
and O
global B-outcome
emesis I-outcome
FLIE I-outcome
scores I-outcome
were O
not O
statistically O
different O
at O
any O
time O
between O
the O
two O
study O
arms O
. O
The O
frequencies O
of O
severe B-outcome
( I-outcome
Grade I-outcome
 I-outcome
2 I-outcome
) I-outcome
nausea I-outcome
and O
vomiting B-outcome
were O
low O
in O
our O
study O
( O
nausea B-outcome
: O
P O
: O
17.6 B-cv-bin-percent
% I-cv-bin-percent
vs O
C O
: O
15.7 B-iv-bin-percent
% I-iv-bin-percent
, O
p O
= O
0.62 O
; O
vomiting B-outcome
: O
P O
: O
10.8 B-cv-bin-percent
% I-cv-bin-percent
vs O
C O
: O
12.0 B-iv-bin-percent
% I-iv-bin-percent
, O
p O
= O
0.72 O
during O
the O
first O
course O
) O
. O
This O
double O
- O
blinded O
, O
placebo O
- O
controlled O
, O
randomised O
Phase O
III O
study O
showed O
that O
adding O
a O
complex O
homeopathic O
medicine O
( O
Cocculine O
) O
to O
standard O
anti O
- O
emetic O
prophylaxis O
does O
not O
improve O
the O
control O
of O
CINV O
in O
early O
breast O
cancer O
patients O
. O

No O
differences O
between O
Calendula B-intervention
cream I-intervention
and O
aqueous B-control
cream I-control
in O
the O
prevention O
of O
acute B-condition
radiation I-condition
skin I-condition
reactions I-condition
-- O
results O
from O
a O
randomised O
blinded O
trial O
. O
The O
purpose O
of O
this O
blinded O
, O
randomized O
clinical O
trial O
was O
to O
compare O
two O
topical O
agents O
( O
Calendula B-intervention
Weleda I-intervention
cream I-intervention
vs. O
Essex B-intervention
cream I-intervention
) O
in O
reducing O
the O
risk O
of O
severe O
acute O
radiation O
skin O
reactions O
( O
ARSR O
) O
in O
relation O
to O
adjuvant O
radiotherapy O
( O
RT O
) O
for O
breast O
cancer O
. O
The O
primary O
endpoint O
was O
the O
difference B-outcome-measure
in I-outcome-measure
proportion I-outcome-measure
of I-outcome-measure
patients I-outcome-measure
with I-outcome-measure
ARSR I-outcome-measure
, O
assessed O
with O
the O
Radiation O
Therapy O
Oncology O
Group O
/ O
The O
Organization O
for O
Research O
and O
Treatment O
of O
Cancer O
Acute O
Radiation O
Morbidity O
Scoring O
Criteria O
( O
RTOG O
/ O
EORTC O
scale O
) O
at O
follow O
- O
up O
. O
The O
secondary O
endpoints O
included O
patient O
reported O
outcome O
measures O
; O
Quality B-outcome-measure
of I-outcome-measure
Life I-outcome-measure
Questionnaire I-outcome-measure
( O
QLQ O
- O
C30 O
) O
, O
Sleep B-outcome-measure
disturbances I-outcome-measure
( O
MOS O
- O
sleep O
questionnaire O
) O
and O
symptoms B-outcome-measure
from I-outcome-measure
the I-outcome-measure
irradiated I-outcome-measure
area I-outcome-measure
( O
visual O
analogue O
scale O
) O
. O
Patients O
' O
experiences O
and O
adherence O
to O
the O
topical O
agents O
were O
also O
evaluated O
. O
A O
total O
of O
420 B-total-participants
patients O
were O
randomised O
and O
411 B-total-participants
were O
analysed O
. O
With O
the O
exception O
of O
previous O
chemotherapy O
, O
the O
treatment O
groups O
were O
well O
balanced O
, O
both O
regarding O
treatment- O
and O
patient O
- O
related O
factors O
. O
The O
incidence B-outcome
of I-outcome
severe I-outcome
ARSR I-outcome
( O
RTOG O
/ O
EORTC O
grade O
2 O
) O
at O
the O
follow O
- O
up O
visit O
was O
23 B-iv-bin-percent
% I-iv-bin-percent
( O
n O
= O
45 B-intervention-participants
) O
in O
the O
Calendula O
group O
and O
19 B-cv-bin-percent
% I-cv-bin-percent
( O
n O
= O
38 B-control-participants
) O
in O
the O
Essex O
group O
. O
We O
found O
no O
difference O
in O
severe B-outcome
ARSR I-outcome
between O
the O
groups O
at O
any O
point O
of O
assessment O
. O
The O
patients O
reported O
low O
levels B-outcome
of I-outcome
skin I-outcome
related I-outcome
symptoms I-outcome
and O
no O
statistically O
significant O
differences O
between O
the O
groups O
were O
found O
. O
No O
differences O
in O
ARSR O
between O
patients O
randomised O
to O
Calendula O
or O
Essex O
cream O
was O
found O
. O
ARSR O
seem O
to O
be O
a O
relatively O
limited O
problem O
, O
probably O
more O
influenced O
by O
treatment O
related O
factors O
than O
by O
choice O
of O
skin O
care O
products O
in O
this O
patient O
group O
. O
  O

Gonadatrophin B-intervention
suppression I-intervention
to O
prevent O
chemotherapy B-condition
- I-condition
induced I-condition
ovarian I-condition
damage I-condition
: O
a O
randomized O
controlled O
trial O
. O
To O
estimate O
the O
effectiveness O
of O
gonadotropin O
- O
releasing O
hormone O
( O
GnRH O
) O
analogues O
cotreatment O
in O
preventing O
chemotherapy O
- O
induced O
amenorrhea O
in O
young O
breast O
cancer O
patients O
undergoing O
cyclophosphamide O
- O
based O
chemotherapy O
. O
One B-total-participants
hundred I-total-participants
hormone B-eligibility
- I-eligibility
insensitive I-eligibility
breast I-eligibility
cancer I-eligibility
participants I-eligibility
( O
aged O
18 B-age
- I-age
40 I-age
years I-age
) O
were O
recruited O
from O
two O
university O
- O
affiliated O
oncology O
centers O
in O
Egypt B-location
. O
Opting O
for O
type O
of O
cotreatment O
was O
based O
on O
available O
timeframe O
until O
start O
of O
chemotherapy O
. O
Fifty B-total-participants
women O
ready O
for O
early O
chemotherapy O
were O
randomized O
to O
receive O
either O
chemotherapy B-control
alone I-control
( O
arm O
I O
) O
or O
chemotherapy O
after O
downregulation O
( O
estradiol O
less O
than O
50 O
pg O
/ O
mL O
) O
by O
GnRH O
antagonist O
and O
agonist O
( O
arm O
II O
) O
. O
Then O
, O
GnRH O
antagonist O
was O
discontinued O
and O
agonist O
was O
continued O
until O
the O
end O
of O
chemotherapy O
. O
When O
chemotherapy O
was O
to O
start O
later O
than O
10 O
days O
after O
study O
inclusion O
, O
50 B-total-participants
women O
were O
randomized O
to O
receive O
either O
chemotherapy O
alone O
( O
arm O
III O
) O
or O
chemotherapy O
after O
downregulation O
with O
GnRH O
agonist O
( O
arm O
IV O
) O
. O
Resumption B-outcome-measure
of I-outcome-measure
menstruation I-outcome-measure
at I-outcome-measure
12 I-outcome-measure
months I-outcome-measure
after I-outcome-measure
end I-outcome-measure
of I-outcome-measure
chemotherapy I-outcome-measure
was O
the O
primary O
outcome O
. O
Postchemotherapy B-outcome-measure
hormonal I-outcome-measure
and O
ultrasound B-outcome-measure
changes I-outcome-measure
were O
secondary O
outcomes O
. O
Twelve O
months O
after O
termination O
of O
chemotherapy O
, O
there O
were O
no O
differences O
in O
menstruation B-outcome
resumption I-outcome
rates I-outcome
between O
GnRH O
- O
treated O
patients O
and O
control O
group O
individuals O
in O
either O
early O
( O
80 B-iv-bin-percent
% I-iv-bin-percent
in O
arms O
I O
and O
II O
, O
risk O
ratio O
1 O
, O
95 O
% O
confidence O
interval O
0.7-.32 O
; O
P O
= O
1.00 O
) O
or O
delayed O
chemotherapy O
groups O
( O
80 B-cv-bin-percent
% I-cv-bin-percent
and O
84 B-iv-bin-percent
% I-iv-bin-percent
in O
arms O
III O
and O
IV O
, O
risk O
ratio O
0.95 O
, O
95 O
% O
confidence O
interval O
0.73 O
- O
1.235 O
; O
P O
= O
.71 O
) O
. O
There O
were O
no O
differences O
in O
hormonal B-outcome
and I-outcome
ultrasound I-outcome
markers I-outcome
between O
GnRH O
analogue O
users O
and O
control O
group O
individuals O
. O
The O
use O
of O
GnRH O
analogue O
cotreatment O
did O
not O
predict O
independently O
the O
odds O
of O
menstruating O
at O
12 O
months O
. O
GnRH O
analogue O
cotreatment O
does O
not O
offer O
a O
significant O
protective O
effect O
on O
ovarian O
function O
in O
patients O
treated O
by O
cyclophosphamide O
- O
based O
chemotherapy O
. O
Australian O
New O
Zealand O
Clinical O
Trials O
Registry O
. O
www.anzctr.org.au O
, O
ACTRN12609001059257 O
. O
I. O

Breast O
density O
changes O
in O
a O
randomized O
controlled O
trial O
evaluating O
bazedoxifene B-intervention
/ I-intervention
conjugated I-intervention
estrogens I-intervention
. O
Breast O
density O
is O
associated O
with O
an O
increased O
risk O
of O
breast O
cancer O
. O
This O
study O
assessed O
changes O
in O
mammographic O
breast O
density O
after O
24 O
months O
of O
treatment O
with O
bazedoxifene O
( O
BZA O
) O
/conjugated O
estrogens O
( O
CE O
) O
in O
postmenopausal B-eligibility
women I-eligibility
. O
This O
was O
an O
ancillary O
study O
in O
a O
subset O
of O
nonhysterectomized O
postmenopausal O
women O
enrolled O
in O
a O
randomized O
, O
double O
- O
blind O
, O
placebo O
- O
controlled O
, O
and O
active O
- O
controlled O
phase O
3 O
study O
. O
Treatments O
evaluated O
were O
BZA O
20 O
mg O
/ O
CE O
0.45 O
mg O
, O
BZA O
20 O
mg O
/ O
CE O
0.625 O
mg O
, O
raloxifene O
60 O
mg O
, O
and O
placebo B-control
. O
Women O
who O
were O
eligible O
for O
participation O
in O
the O
ancillary O
study O
must O
have O
completed O
24 O
months O
of O
treatment O
and O
have O
mammograms O
at O
baseline O
and O
24 O
months O
. O
The O
left O
craniocaudal O
views O
from O
each O
mammogram O
pair O
were O
digitized O
and O
analyzed O
by O
a O
radiologist O
who O
was O
blinded O
to O
treatment O
arm O
and O
mammogram O
date O
. O
The O
percent O
breast O
density O
was O
determined O
using O
validated O
software O
. O
Mammogram O
pairs O
were O
obtained O
from O
507 B-total-participants
evaluable O
participants O
( O
mean O
age O
range O
, O
55.2 B-age
- I-age
56.3 I-age
y I-age
) O
. O
The O
mean O
changes O
( O
95 O
% O
CI O
) O
in O
mammographic B-outcome
breast I-outcome
density I-outcome
from I-outcome
baseline I-outcome
to I-outcome
24 I-outcome
months I-outcome
were O
comparable O
among O
groups O
( O
-0.39 B-iv-cont-mean
% I-iv-cont-mean
[ O
-0.69 O
to O
-0.08 O
] O
, O
-0.05 B-iv-cont-mean
% I-iv-cont-mean
[ O
-0.38 O
to O
0.27 O
] O
, O
-0.23 B-iv-cont-mean
% I-iv-cont-mean
[ O
-0.54 O
to O
0.08 O
] O
, O
and O
-0.42 B-cv-cont-mean
% I-cv-cont-mean
[ O
-0.72 O
to O
-0.11 O
] O
for O
BZA O
20 O
mg O
/ O
CE O
0.45 O
mg O
, O
BZA O
20 O
mg O
/ O
CE O
0.625 O
mg O
, O
raloxifene O
60 O
mg O
, O
and O
placebo O
, O
respectively O
) O
. O
These O
reductions O
from O
baseline O
were O
statistically O
significant O
for O
BZA O
20 O
mg O
/ O
CE O
0.45 O
mg O
and O
placebo O
. O
The O
effect O
of O
both O
BZA O
/ O
CE O
doses O
on O
breast O
density O
was O
generally O
consistent O
among O
subgroups O
based O
on O
age O
, O
body O
mass O
index O
, O
and O
years O
since O
menopause O
. O
Treatment O
with O
BZA O
20 O
mg O
/ O
CE O
0.45 O
mg O
or O
BZA O
20 O
mg O
/ O
CE O
0.625 O
mg O
for O
24 O
months O
did O
not O
affect O
mammographic O
breast O
density O
in O
this O
population O
of O
postmenopausal O
women O
. O

Effect O
of O
mindfulness B-intervention
- I-intervention
based I-intervention
stress I-intervention
reduction I-intervention
on O
sleep B-condition
quality I-condition
: O
results O
of O
a O
randomized O
trial O
among O
Danish B-ethinicity
breast O
cancer O
patients O
. O
The O
prevalence O
of O
sleep O
disturbance O
is O
high O
among O
cancer O
patients O
, O
and O
the O
sleep O
problems O
tend O
to O
last O
for O
years O
after O
the O
end O
of O
treatment O
. O
As O
part O
of O
a O
large O
randomized O
controlled O
clinical O
trial O
( O
the O
MICA O
trial O
, O
NCT00990977 O
) O
of O
the O
effect O
of O
mindfulness O
- O
based O
stress O
reduction O
( O
MBSR O
) O
on O
psychological O
and O
somatic O
symptoms O
among O
breast O
cancer O
patients O
, O
the O
aim O
of O
the O
current O
study O
was O
to O
evaluate O
the O
effect O
of O
MBSR O
on O
the O
secondary O
outcome O
, O
' B-outcome-measure
sleep I-outcome-measure
quality I-outcome-measure
' I-outcome-measure
. O
A O
total O
of O
336 B-total-participants
women B-eligibility
operated I-eligibility
on I-eligibility
for I-eligibility
breast I-eligibility
cancer I-eligibility
stage I-eligibility
I I-eligibility
- I-eligibility
III I-eligibility
3 I-eligibility
- I-eligibility
18 I-eligibility
months I-eligibility
previously I-eligibility
were O
randomized O
to O
MBSR O
( O
n O
= O
168 B-intervention-participants
) O
or O
treatment B-control
as I-control
usual I-control
( O
n O
= O
168 B-control-participants
) O
; O
both O
groups O
received O
standard O
clinical O
care O
. O
The O
intervention O
consisted O
of O
an O
eight O
- O
week O
MBSR O
program O
( O
psycho O
- O
education O
, O
meditation O
and O
gentle O
yoga O
) O
. O
Sleep O
quality O
was O
assessed O
on O
the O
Medical O
Outcome O
Study O
sleep O
scale O
at O
baseline O
, O
after O
the O
intervention O
and O
at O
six- O
and O
12 O
- O
months O
' O
follow O
- O
up O
. O
The O
mean B-outcome
sleep I-outcome
problem I-outcome
scores I-outcome
were O
significantly O
lower O
in O
the O
MBSR O
group O
than O
in O
controls O
immediately O
after O
the O
intervention O
. O
Quantile O
regression O
analyses O
showed O
that O
the O
effect O
was O
statistically O
significant O
only O
for O
the O
participants O
represented O
by O
the O
lower O
percentile O
of O
change O
between O
baseline O
and O
post O
- O
intervention O
, O
i.e. O
those O
who O
had O
more O
sleep O
problems O
; O
the O
MBSR O
group O
had O
a O
significantly O
smaller O
increase O
in O
sleep B-outcome
problems I-outcome
than O
the O
control O
group O
. O
After O
the O
12 O
- O
month O
follow O
- O
up O
, O
there O
was O
no O
significant O
between O
- O
group O
effect O
of O
MBSR O
on O
sleep B-outcome
quality I-outcome
in O
intention O
- O
to O
- O
treat O
analyses O
. O
MBSR O
had O
a O
statistically O
significant O
effect O
on O
sleep B-outcome
quality I-outcome
just O
after O
the O
intervention O
but O
no O
long O
- O
term O
effect O
among O
breast O
cancer O
patients O
. O
Future O
trials O
in O
which O
participation O
is O
restricted O
to O
patients O
with O
significant O
sleep O
problems O
are O
recommended O
for O
evaluating O
the O
effect O
of O
MBSR O
on O
sleep O
quality O
. O

Population O
- O
based O
breast O
cancer O
screening O
in O
a O
primary O
care O
network O
. O
To O
assess O
the O
ability O
of O
a O
health B-intervention
information I-intervention
technology I-intervention
system I-intervention
to O
facilitate O
population- O
based O
breast O
cancer O
screening O
. O
Cohort O
study O
with O
2 O
- O
year O
follow O
- O
up O
after O
a O
1 O
- O
year O
cluster O
randomized O
trial O
. O
Study O
population O
was O
women O
42 B-age
to I-age
69 I-age
years I-age
old O
receiving O
care O
within O
a O
12 O
- O
practice O
primary O
care O
network O
. O
The O
management O
informatics O
system O
( O
1 O
) O
identified O
women O
overdue O
for O
mammograms O
, O
( O
2 O
) O
connected O
them O
to O
primary O
care O
providers O
using O
a O
web O
- O
based O
tool O
, O
( O
3 O
) O
created O
automatically O
generated O
outreach O
letters O
for O
patients O
specified O
by O
providers O
, O
( O
4 O
) O
monitored O
for O
subsequent O
mammography O
scheduling O
and O
completion O
, O
and O
( O
5 O
) O
provided O
practice O
delegates O
with O
a O
list O
of O
women O
remaining O
unscreened O
for O
reminder O
phone O
calls O
. O
Eligible O
women B-eligibility
overdue I-eligibility
for I-eligibility
a I-eligibility
mammogram I-eligibility
during O
a O
1 O
- O
year O
study O
period O
included O
those O
overdue O
at O
study O
start O
( O
prevalent O
cohort O
) O
and O
those O
who O
became O
overdue O
during O
follow O
- O
up O
( O
incident O
cohort O
) O
. O
The O
main O
outcome O
measure O
was O
mammography B-outcome-measure
completion I-outcome-measure
rates I-outcome-measure
over I-outcome-measure
3 I-outcome-measure
years I-outcome-measure
. O
Among O
32,688 B-total-participants
eligible O
women O
, O
9795 B-total-participants
( O
30 O
% O
) O
were O
overdue O
for O
screening O
( O
4487 B-intervention-participants
intervention O
, O
5308 B-control-participants
control B-control
) O
. O
Intervention O
patients O
were O
somewhat O
younger O
, O
more O
likely O
to O
be O
non B-ethinicity
- I-ethinicity
Hispanic I-ethinicity
white O
, O
and O
more O
likely O
to O
have O
health O
insurance O
compared O
with O
control O
patients O
. O
Adjusted O
completion B-outcome
rates I-outcome
in O
the O
prevalent O
cohort O
( O
n O
= O
6697 B-total-participants
) O
were O
significantly O
higher O
among O
intervention O
patients O
after O
3 O
years O
( O
51.7 B-iv-bin-percent
% I-iv-bin-percent
vs O
45.8 B-cv-bin-percent
% I-cv-bin-percent
; O
P O
= O
.002 O
) O
. O
For O
patients O
in O
the O
incident O
cohort O
( O
n O
= O
3098 B-total-participants
) O
, O
adjusted O
completion B-outcome
rates I-outcome
after O
2 O
years O
were O
53.8 B-iv-bin-percent
% I-iv-bin-percent
versus O
48.7 B-cv-bin-percent
% I-cv-bin-percent
, O
respectively O
( O
P O
= O
.052 O
) O
. O
Population O
- O
based O
informatics O
systems O
can O
enable O
sustained O
increases O
in O
mammography O
screening O
rates O
beyond O
rates O
seen O
with O
office O
- O
based O
visit O
reminders O
. O

A O
Nonrandomized O
, O
Phase O
II O
Study O
of O
Sequential B-intervention
Irinotecan I-intervention
and I-intervention
Flavopiridol I-intervention
in O
Patients O
With O
Advanced O
Hepatocellular O
Carcinoma O
. O
Flavopiridol O
, O
a O
Cdk O
inhibitor O
, O
potentiates O
irinotecan O
- O
induced O
apoptosis O
. O
In O
a O
phase O
I O
trial O
of O
sequential O
irinotecan O
and O
flavopiridol O
, O
2 O
patients O
with O
advanced O
hepatocellular O
carcinoma O
( O
HCC O
) O
had O
stable O
disease O
( O
SD O
) O
for O
14 O
months O
. O
We O
thus O
studied O
the O
sequential O
combination O
of O
irinotecan O
and O
flavopiridol O
in O
patients O
with O
HCC O
. O
Patients B-eligibility
with I-eligibility
advanced I-eligibility
HCC I-eligibility
nave I-eligibility
to I-eligibility
systemic I-eligibility
therapy I-eligibility
, O
Child O
- O
Pugh O
B8 O
, O
and O
Karnofsky O
performance O
score O
( O
KPS O
) O
70 O
% O
received O
100 O
mg O
/ O
m O
( O
2 O
) O
irinotecan O
followed O
7 O
hours O
later O
by O
flavopiridol O
60 O
mg O
/ O
m O
( O
2 O
) O
weekly O
for O
4 O
of O
6 O
weeks O
. O
The O
primary O
end O
point O
was O
an O
improvement B-outcome-measure
in I-outcome-measure
progression I-outcome-measure
- I-outcome-measure
free I-outcome-measure
survival I-outcome-measure
at I-outcome-measure
4 I-outcome-measure
months I-outcome-measure
( I-outcome-measure
PFS-4 I-outcome-measure
) I-outcome-measure
from O
33 O
% O
to O
54 O
% O
, O
using O
a O
Simon O
's O
two O
- O
stage O
design O
. O
Tumors O
were O
stained O
for O
p53 O
. O
Only O
16 B-total-participants
patients O
in O
the O
first O
stage O
were O
enrolled O
: O
median O
age O
, O
64 B-age
years I-age
; O
median O
KPS O
, O
80 O
% O
; O
Child O
- O
Pugh O
A O
, O
87.5 O
% O
; O
and O
stage O
III O
/ O
IV O
, O
25% O
/ O
75 O
% O
. O
The O
primary O
end O
point O
was O
not O
met O
; O
PFS-4 B-outcome
was O
20 O
% O
, O
leading O
to O
early O
termination O
of O
the O
study O
. O
Ten O
patients O
were O
evaluable O
for O
response O
: O
1 B-iv-bin-abs
had O
SD B-outcome
> I-outcome
1 I-outcome
year O
and O
9 B-iv-bin-abs
had O
disease B-outcome
progression I-outcome
. O
Grade B-outcome
3 I-outcome
fatigue I-outcome
, O
dehydration B-outcome
, O
diarrhea B-outcome
, O
neutropenia B-outcome
with I-outcome
or I-outcome
without I-outcome
fever I-outcome
, O
lymphopenia B-outcome
, O
anemia B-outcome
, O
hyperbilirubinemia B-outcome
, O
and O
transaminitis B-outcome
occurred O
in O
10 O
% O
of O
the O
patients O
. O
Of O
the O
9 B-total-participants
patients O
who O
progressed O
, O
5 B-iv-bin-abs
had O
mutant B-outcome
p53 I-outcome
and O
4 B-iv-bin-abs
had O
wild B-outcome
- I-outcome
type I-outcome
p53 I-outcome
. O
The O
patient O
with O
stable O
disease O
had O
wild O
- O
type O
p53 O
. O
Sequential O
irinotecan O
and O
flavopiridol O
are O
ineffective O
and O
poorly O
tolerated O
in O
patients O
with O
advanced O
HCC O
. O
Despite O
our O
limited O
assessments O
, O
it O
is O
possible O
that O
the O
presence O
of O
wild O
- O
type O
p53 O
is O
necessary O
but O
not O
sufficient O
to O
predict O
response O
in O
HCC O
. O

Radiation O
- O
related O
quality O
of O
life O
parameters O
after O
targeted B-intervention
intraoperative I-intervention
radiotherapy I-intervention
versus O
whole B-control
breast I-control
radiotherapy I-control
in O
patients O
with O
breast O
cancer O
: O
results O
from O
the O
randomized O
phase O
III O
trial O
TARGIT O
- O
A. O
Intraoperative O
radiotherapy O
( O
IORT O
) O
is O
a O
new O
treatment O
approach O
for O
early O
stage O
breast O
cancer O
. O
This O
study O
reports O
on O
the O
effects O
of O
IORT O
on O
radiation O
- O
related O
quality O
of O
life O
( O
QoL O
) O
parameters O
. O
Two B-total-participants
hundred I-total-participants
and I-total-participants
thirty I-total-participants
women B-eligibility
with I-eligibility
stage I-eligibility
I I-eligibility
- I-eligibility
III I-eligibility
breast I-eligibility
cancer I-eligibility
( O
age O
, O
31 B-age
to I-age
84 I-age
years I-age
) O
were O
entered O
into O
the O
study O
. O
A O
single O
- O
center O
subgroup O
of O
87 B-total-participants
women O
from O
the O
two O
arms O
of O
the O
randomized O
phase O
III O
trial O
TARGIT O
- O
A O
( O
TARGeted O
Intra O
- O
operative O
radioTherapy O
versus O
whole O
breast O
radiotherapy O
for O
breast O
cancer O
) O
was O
analyzed O
. O
Furthermore O
, O
results O
were O
compared O
to O
non O
- O
randomized O
control O
groups O
: O
n O
= O
90 B-intervention-participants
receiving O
IORT O
as O
a O
tumor O
bed O
boost O
followed O
by O
external O
beam O
whole O
breast O
radiotherapy O
( O
EBRT O
) O
outside O
of O
TARGIT O
- O
A O
( O
IORT O
- O
boost O
) O
, O
and O
n O
= O
53 B-control-participants
treated O
with O
EBRT O
followed O
by O
an O
external O
- O
beam O
boost O
( O
EBRT O
- O
boost O
) O
. O
QoL O
was O
collected O
using O
the O
European O
Organization O
for O
Research O
and O
Treatment O
of O
Cancer O
Quality O
of O
Life O
Questionnaires O
C30 O
( O
QLQ O
- O
C30 O
) O
and O
BR23 O
( O
QLQ O
- O
BR23 O
) O
. O
The O
mean B-outcome
follow I-outcome
- I-outcome
up I-outcome
period I-outcome
in O
the O
TARGIT O
- O
A O
groups O
was O
32 B-iv-cont-mean
versus O
39 B-cv-cont-mean
months I-cv-cont-mean
in O
the O
non O
- O
randomized O
control O
groups O
. O
Patients O
receiving O
IORT O
alone O
reported O
less O
general O
pain B-outcome
( O
21.3 B-iv-cont-mean
points I-iv-cont-mean
) O
, O
breast B-outcome
( O
7.0 B-iv-cont-mean
points I-iv-cont-mean
) O
and O
arm B-outcome
( O
15.1 B-iv-cont-mean
points I-iv-cont-mean
) O
symptoms O
, O
and O
better O
role B-outcome
functioning I-outcome
( O
78.7 B-iv-cont-mean
points I-iv-cont-mean
) O
as O
patients O
receiving O
EBRT O
( O
40.9 B-cv-cont-mean
; O
19.0 B-cv-cont-mean
; O
32.8 B-cv-cont-mean
; O
and O
60.5 B-cv-cont-mean
points I-cv-cont-mean
, O
respectively O
, O
P O
< O
0.01 O
) O
. O
Patients O
receiving O
IORT O
alone O
also O
had O
fewer O
breast B-outcome
symptoms I-outcome
than O
TARGIT O
- O
A O
patients O
receiving O
IORT O
followed O
by O
EBRT O
for O
high O
risk O
features O
on O
final O
pathology O
( O
IORT O
- O
EBRT O
; O
7.0 B-iv-cont-mean
versus O
29.7 B-cv-cont-mean
points I-cv-cont-mean
, O
P O
< O
0.01 O
) O
. O
There O
were O
no O
significant O
differences O
between O
TARGIT O
- O
A O
patients O
receiving O
IORT O
- O
EBRT O
compared O
to O
non O
- O
randomized O
IORT O
- O
boost O
or O
EBRT O
- O
boost O
patients O
and O
patients O
receiving O
EBRT O
without O
a O
boost O
. O
In O
the O
randomized O
setting O
, O
important O
radiation O
- O
related O
QoL O
parameters O
after O
IORT O
were O
superior O
to O
EBRT O
. O
Non O
- O
randomized O
comparisons O
showed O
equivalent O
parameters O
in O
the O
IORT O
- O
EBRT O
group O
and O
the O
control O
groups O
. O

Partial B-intervention
lower I-intervention
axillary I-intervention
dissection I-intervention
for O
patients B-eligibility
with I-eligibility
clinically I-eligibility
node I-eligibility
- I-eligibility
negative I-eligibility
breast I-eligibility
cancer I-eligibility
. O
To O
evaluate O
retrospectively O
the O
outcomes O
of O
partial O
lower O
axillary O
lymph O
node O
dissection O
caudal O
to O
the O
intercostobrachial O
nerve O
in O
patients O
with O
clinically O
node O
- O
negative O
( O
N O
( O
0 O
) O
) O
breast O
cancer O
. O
Numbers O
of O
dissected O
and O
metastatic O
nodes O
, O
overall O
and O
disease O
- O
free O
  O
survival O
rates O
, O
postoperative O
complication O
rates O
, O
and O
axillary O
recurrence O
were O
compared O
between O
patients O
who O
underwent O
breast O
cancer O
surgery O
with O
partial O
axillary O
node O
dissection O
( O
n O
= O
1043 B-intervention-participants
) O
and O
historical B-control
controls I-control
who O
underwent O
conventional O
dissection O
( O
n O
= O
1084 B-control-participants
) O
. O
The O
  O
5 B-outcome
- I-outcome
year I-outcome
overall I-outcome
and O
disease B-outcome
- I-outcome
free I-outcome
survival I-outcome
rates I-outcome
were O
95.6 B-iv-bin-percent
% I-iv-bin-percent
and O
89.7 B-cv-bin-percent
% I-cv-bin-percent
, O
and O
94.9 B-iv-bin-percent
% I-iv-bin-percent
and O
88.4 B-cv-bin-percent
% I-cv-bin-percent
, O
respectively O
, O
in O
the O
partial O
dissection O
and O
conventional O
dissection O
groups O
; O
the O
differences O
were O
not O
significant O
. O
Mean B-outcome
duration I-outcome
of I-outcome
surgery I-outcome
( O
41.6 B-iv-cont-mean
min I-iv-cont-mean
versus O
60.9 B-cv-cont-mean
min I-cv-cont-mean
) O
, O
intraoperative B-outcome
blood I-outcome
loss I-outcome
( O
28.0 B-iv-cont-mean
ml I-iv-cont-mean
  O
versus O
51.3 B-cv-cont-mean
ml I-cv-cont-mean
) O
, O
volume B-outcome
of I-outcome
lymphatic I-outcome
drainage I-outcome
at I-outcome
2 I-outcome
weeks I-outcome
postoperatively I-outcome
( O
488 B-iv-cont-mean
ml I-iv-cont-mean
versus O
836 B-cv-cont-mean
ml I-cv-cont-mean
) O
, O
and O
persistent B-outcome
arm I-outcome
lymphoedema I-outcome
( O
0.0 B-iv-bin-percent
% I-iv-bin-percent
versus O
11.8 B-cv-bin-percent
% I-cv-bin-percent
) O
were O
significantly O
different O
between O
the O
partial O
and O
conventional O
dissection O
groups O
, O
respectively O
. O
Partial O
axillary O
lymph O
node O
dissection O
  O
was O
associated O
with O
similar O
survival O
rates O
( O
but O
lower O
postoperative O
complication O
rates O
) O
compared O
with O
conventional O
axillary O
dissection O
and O
is O
recommended O
in O
patients O
with O
N O
( O
0 O
) O
breast O
cancer O
. O

[ O
Chinese O
HER2 O
positive O
early O
breast O
cancer O
trastuzumab B-intervention
adjuvant I-intervention
therapy I-intervention
: O
preliminary O
outcomes O
] O
. O
To O
evaluate O
the O
efficacy O
and O
safety O
of O
1 O
- O
year O
adjuvant O
trastuzumab O
( O
herceptin O
) O
versus O
1 O
- O
year O
non B-control
- I-control
trastuzumab I-control
observation I-control
in O
Chinese B-ethinicity
patients B-eligibility
with I-eligibility
HER2 I-eligibility
- I-eligibility
positive I-eligibility
early I-eligibility
breast I-eligibility
cancer I-eligibility
during O
a O
median O
follow O
- O
up O
of O
1 O
year O
. O
The O
HERA O
trial O
was O
an O
international O
, O
multicenter O
, O
randomized O
, O
open O
- O
label O
, O
phase O
III O
trial O
comparing O
treatment O
with O
trastuzumab O
for O
1 O
and O
2 O
years O
with O
observation O
after O
standard O
adjuvant O
chemotherapy O
, O
radiotherapy O
or O
both O
in O
patients O
with O
HER2 O
- O
positive O
node O
- O
positive O
or O
high O
- O
risk O
node O
- O
negative O
early O
breast O
cancer O
. O
The O
primary O
endpoint O
was O
disease B-outcome-measure
- I-outcome-measure
free I-outcome-measure
survival I-outcome-measure
. O
Secondary O
end O
points O
included O
recurrence B-outcome-measure
- I-outcome-measure
free I-outcome-measure
survival I-outcome-measure
, O
distant B-outcome-measure
disease I-outcome-measure
- I-outcome-measure
free I-outcome-measure
survival I-outcome-measure
, O
overall B-outcome-measure
survival I-outcome-measure
and O
cardiac B-outcome-measure
safety I-outcome-measure
. O
The O
first O
planned O
interim O
analysis O
comparing O
the O
efficacy O
and O
safety O
of O
treatment O
with O
trastuzumab O
for O
1 O
year O
versus O
observation O
were O
completed O
in O
April O
2005 O
. O
Only O
the O
outcomes O
of O
recruited O
Chinese O
patients O
were O
reported O
. O
A O
total O
of O
122 B-total-participants
Chinese O
patients O
from O
8 O
participating O
centers O
were O
included O
for O
planned O
interim O
analysis O
. O
And O
they O
were O
divided O
into O
trastuzumab O
( O
n O
= O
68 B-intervention-participants
) O
and O
observation O
( O
n O
= O
54 B-control-participants
) O
groups O
. O
Three B-iv-bin-abs
and O
eight B-cv-bin-abs
disease B-outcome
- I-outcome
free I-outcome
survival I-outcome
events I-outcome
were O
observed O
in O
the O
trastuzumab O
and O
observation O
groups O
respectively O
. O
Two B-outcome
- I-outcome
year I-outcome
disease I-outcome
- I-outcome
free I-outcome
survival I-outcome
rates I-outcome
were O
92.9 B-iv-bin-percent
% I-iv-bin-percent
and O
81.4 B-cv-bin-percent
% I-cv-bin-percent
respectively O
( O
P O
= O
0.0489 O
) O
; O
2 B-outcome
- I-outcome
year I-outcome
recurrence I-outcome
- I-outcome
free I-outcome
survival I-outcome
and O
distant B-outcome
disease I-outcome
- I-outcome
free I-outcome
survivals I-outcome
were O
98.1 B-iv-bin-percent
% I-iv-bin-percent
vs O
81.4 B-cv-bin-percent
% I-cv-bin-percent
( O
P O
= O
0.0064 O
) O
and O
98.1 B-iv-bin-percent
% I-iv-bin-percent
vs O
83.3 B-cv-bin-percent
% I-cv-bin-percent
( O
P O
= O
0.0117 O
) O
respectively O
. O
Trastuzumab O
was O
generally O
well O
- O
tolerated O
with O
a O
decent O
safety B-outcome
profile I-outcome
. O
Severe B-outcome
cardiotoxicity I-outcome
was O
not O
observed O
. O
One O
- O
year O
treatment O
with O
adjuvant O
trastuzumab O
improves O
disease O
- O
free O
survival O
, O
recurrence O
- O
free O
survival O
and O
distant O
disease O
- O
free O
survival O
in O
Chinese O
patients O
with O
HER2 O
- O
positive O
early O
breast O
cancer O
. O

A O
double O
- O
blind O
randomized O
trial O
of O
wound B-intervention
and I-intervention
intercostal I-intervention
space I-intervention
infiltration I-intervention
with I-intervention
ropivacaine I-intervention
during O
breast O
cancer O
surgery O
: O
effects O
on O
chronic B-condition
postoperative I-condition
pain I-condition
. O
The O
efficacy O
of O
local O
anesthetic O
wound O
infiltration O
for O
the O
treatment O
of O
acute O
and O
chronic O
postoperative O
pain O
is O
controversial O
and O
there O
are O
no O
detailed O
studies O
. O
The O
primary O
objective O
of O
this O
study O
was O
to O
evaluate O
the O
influence O
of O
ropivacaine O
wound O
infiltration O
on O
chronic O
pain O
after O
breast O
surgery O
. O
In O
this O
prospective O
, O
randomized O
, O
double O
- O
blind O
, O
parallel O
- O
group O
, O
placebo O
- O
controlled O
study O
, O
236 B-total-participants
patients O
scheduled O
for O
breast O
cancer O
surgery O
were O
randomized O
( O
1 O
:1 O
) O
to O
receive O
ropivacaine O
or O
placebo B-control
infiltration O
of O
the O
wound O
, O
the O
second O
and O
third O
intercostal O
spaces O
and O
the O
humeral O
insertion O
of O
major O
pectoralis O
. O
Acute B-outcome-measure
pain I-outcome-measure
, O
analgesic B-outcome-measure
consumption I-outcome-measure
, O
nausea B-outcome-measure
and I-outcome-measure
vomiting I-outcome-measure
were O
assessed O
every O
30 O
min O
for O
2 O
h O
in O
the O
postanesthesia O
care O
unit O
and O
every O
6 O
h O
for O
48 O
h. O
Chronic O
pain O
was O
evaluated O
3 O
months O
, O
6 O
months O
, O
and O
1 O
yr O
after O
surgery O
by O
the O
brief O
pain O
inventory O
, O
hospital O
anxiety O
and O
depression O
, O
and O
neuropathic O
pain O
questionnaires O
. O
Ropivacaine O
wound O
infiltration O
significantly O
decreased O
immediate O
postoperative B-outcome
pain I-outcome
for O
the O
first O
90 O
min O
, O
but O
did O
not O
decrease O
chronic O
pain O
at O
3 O
months O
( O
primary O
endpoint O
) O
, O
or O
at O
6 O
and O
12 O
months O
postoperatively O
. O
At O
3 O
months O
, O
the O
incidence B-outcome
of I-outcome
chronic I-outcome
pain I-outcome
was O
33 B-iv-bin-percent
% I-iv-bin-percent
and O
27 B-cv-bin-percent
% I-cv-bin-percent
( O
P O
= O
0.37 O
) O
in O
the O
ropivacaine O
and O
placebo O
groups O
, O
respectively O
. O
During O
follow O
- O
up O
, O
brief B-outcome
pain I-outcome
inventory I-outcome
, O
neuropathic B-outcome
pain I-outcome
, O
and O
anxiety B-outcome
increased O
over O
time O
in O
both O
groups O
( O
P O
< O
0.001 O
) O
while O
depression O
remained O
stable O
. O
No O
complications B-outcome
occurred O
. O
This O
multicenter O
, O
prospective O
study O
shows O
that O
ropivacaine O
wound O
infiltration O
after O
breast O
cancer O
surgery O
decreased O
immediate O
postoperative O
pain O
but O
did O
not O
decrease O
chronic O
pain O
at O
3 O
, O
6 O
, O
and O
12 O
months O
postoperatively O
. O

The O
prevalence O
of O
immunohistochemically O
determined O
oestrogen O
receptor O
positivity O
in O
primary O
breast O
cancer O
is O
dependent O
on O
the O
choice O
of O
antibody O
and O
method O
of O
heat O
- O
induced O
epitope O
retrieval O
- O
prognostic O
implications O
? O
Oestrogen O
receptor O
( O
ER O
) O
status O
is O
important O
for O
the O
choice O
of O
systemic O
treatment O
of O
breast O
cancer O
patients O
. O
However O
, O
most O
data O
from O
randomised O
trials O
on O
the O
effect O
of O
adjuvant O
endocrine O
therapy O
according O
to O
ER O
status O
are O
based O
on O
the O
cytosol O
methods O
. O
Comparisons O
with O
immunohistochemical O
methods O
have O
given O
similar O
results O
. O
The O
aim O
of O
the O
present O
study O
was O
to O
examine O
whether O
different O
ER O
antibodies O
and O
heat O
- O
induced O
epitope O
retrieval O
( O
HIER O
) O
methods O
influence O
the O
prevalence O
of O
ER O
- O
positivity O
in O
primary O
breast O
cancer O
. O
This O
study O
is O
based O
on O
patients O
included O
in O
a O
clinical O
trial O
designed O
to O
compare O
the O
effect O
of O
two O
years O
of O
adjuvant B-intervention
tamoxifen I-intervention
versus O
no O
adjuvant B-control
systemic I-control
treatment I-control
in O
premenopausal B-eligibility
women I-eligibility
. O
From O
1986 O
to O
1991 O
, O
564 B-total-participants
patients O
from O
two O
study O
centres O
in O
Sweden B-location
were O
enrolled O
and O
randomised O
. O
Patients O
were O
randomised O
independently O
of O
ER O
status O
. O
In O
the O
present O
study O
, O
ER O
status O
was O
assessed O
on O
tissue O
microarrays O
with O
the O
three O
different O
ER O
antibody O
/ O
HIER O
combinations O
: O
1D5 O
in O
citrate O
pH O
6 O
( O
n O
= O
390 B-intervention-participants
) O
, O
SP1 O
in O
Tris O
pH O
9 O
( O
n O
= O
390 B-intervention-participants
) O
and O
PharmDx O
in O
citrate O
pH O
6 O
( O
n O
= O
361 B-intervention-participants
) O
. O
At O
cut O
- O
offs O
of O
1 O
% O
and O
10 O
% O
, O
respectively O
, O
the O
prevalence B-outcome
of I-outcome
ER I-outcome
- I-outcome
positivity I-outcome
was O
higher O
with O
SP1 O
( O
75 B-iv-bin-percent
% I-iv-bin-percent
and O
72 B-iv-bin-percent
% I-iv-bin-percent
) O
compared O
with O
1D5 O
( O
68 B-iv-bin-percent
% I-iv-bin-percent
and O
66 B-iv-bin-percent
% I-iv-bin-percent
) O
and O
PharmDx O
( O
66 B-iv-bin-percent
% I-iv-bin-percent
and O
62 B-iv-bin-percent
% I-iv-bin-percent
) O
. O
At O
these O
cut O
- O
offs O
, O
patients O
in O
the O
discordant O
groups O
( O
SP1 O
- O
positive O
and O
1D5 O
- O
negative O
) O
seem O
to O
have O
a O
prognosis O
intermediate O
between O
those O
of O
the O
double O
- O
positive O
and O
double O
- O
negative O
groups O
. O
Comparison O
with O
the O
ER O
status O
determined O
by O
the O
cytosol O
- O
based O
methods O
in O
the O
discordant O
group O
also O
showed O
an O
intermediate O
pattern O
. O
The O
repeatability O
was O
good O
for O
all O
antibodies O
and O
cut O
- O
offs O
, O
with O
overall O
agreement O
 O
93 O
% O
. O
The O
present O
study O
shows O
that O
the O
choice O
of O
antibody O
and O
HIER O
method O
influences O
the O
prevalence O
of O
ER O
- O
positivity O
. O
We O
suggest O
that O
this O
be O
taken O
into O
consideration O
when O
choosing O
a O
cut O
- O
off O
for O
clinical O
decision O
making O
. O

The O
Patient O
's O
Anastrozole O
Compliance O
to O
Therapy O
( O
PACT O
) O
Program O
: O
a O
randomized O
, O
in O
- O
practice O
study O
on O
the O
impact O
of O
a O
standardized B-intervention
information I-intervention
program I-intervention
on O
persistence O
and O
compliance O
to O
adjuvant O
endocrine O
therapy O
in O
postmenopausal O
women O
with O
early O
breast O
cancer O
. O
Compliance O
and O
persistence O
are O
often O
overlooked O
in O
adjuvant O
breast O
cancer O
treatment O
. O
PACT O
was O
a O
prospective O
, O
multicenter O
, O
randomized O
, O
open O
, O
parallel O
- O
group O
study O
assessing O
whether O
educational O
materials O
( O
EMs O
) O
enhanced O
compliance O
with O
aromatase O
inhibitor O
( O
AI O
) O
therapy O
in O
postmenopausal O
women O
with O
early O
, O
hormone O
- O
receptor O
- O
positive O
( O
HR+ O
) O
breast O
cancer O
. O
The O
primary O
end O
points O
were O
compliance B-outcome-measure
( O
proportion O
taking O
 O
80 O
% O
anastrozole O
) O
at O
12 O
months O
and O
persistence B-outcome-measure
( O
proportion O
reporting O
anastrozole O
intake O
during O
the O
study O
period O
) O
. O
Four B-total-participants
thousand I-total-participants
eight I-total-participants
hundred I-total-participants
and I-total-participants
forty I-total-participants
- I-total-participants
four I-total-participants
patients O
were O
randomly O
assigned O
1 O
:1 O
to O
receive O
standard B-control
therapy I-control
or O
standard O
therapy O
with O
EMs O
. O
There O
was O
no O
difference O
between O
arms O
in O
compliance B-outcome
( O
N O
= O
2740 O
; O
88.5% B-cv-bin-percent
/ O
88.8 B-iv-bin-percent
% I-iv-bin-percent
, O
respectively O
, O
P O
= O
0.81 O
) O
or O
persistence B-outcome
rates I-outcome
( O
N O
= O
2740 O
; O
40.5% B-cv-bin-percent
/ O
43.0 B-iv-bin-percent
% I-iv-bin-percent
, O
respectively O
, O
P O
= O
0.18 O
) O
. O
Modified O
end O
point O
analyses O
found O
no O
differences O
in O
compliance B-outcome
between O
arms O
based O
on O
the O
classification O
of O
: O
( O
i O
) O
patients B-outcome
with I-outcome
missing I-outcome
documentation I-outcome
or I-outcome
follow I-outcome
- I-outcome
up I-outcome
visit I-outcome
< O
9 O
months O
as O
non O
- O
compliant O
( O
N O
= O
4397 O
, O
P O
= O
0.15 O
) O
; O
( O
ii O
) O
patients B-outcome
with I-outcome
early I-outcome
( I-outcome
 I-outcome
292 I-outcome
days I-outcome
) I-outcome
12 I-outcome
- I-outcome
month I-outcome
follow I-outcome
- I-outcome
up I-outcome
documentation I-outcome
excluded I-outcome
( O
N O
= O
4091 O
, O
P O
= O
0.19 O
) O
; O
( O
iii O
) O
patients B-outcome
reaching I-outcome
 I-outcome
80 I-outcome
% I-outcome
compliance I-outcome
during O
individual O
follow O
- O
up O
as O
compliant O
( O
N O
= O
4397 O
, O
P O
= O
0.26 O
) O
. O
Modified O
persistence O
analyses O
found O
no O
difference O
between O
arms O
( O
N O
= O
4397 O
, O
P O
= O
0.37 O
) O
. O
Addition O
of O
EMs O
to O
standard O
therapy O
did O
not O
significantly O
affect O
compliance O
and O
persistence O
with O
adjuvant O
anastrozole O
. O
CLINICALTRIALS O
ID O
: O
NCT00555867 O
. O

Pilot O
randomised O
controlled O
trial O
of O
a O
radiation B-intervention
therapist I-intervention
- I-intervention
led I-intervention
educational I-intervention
intervention O
for O
breast O
cancer O
patients O
prior O
to O
commencing O
radiotherapy O
. O
Although O
patients O
receive O
information O
prior O
to O
commencing O
radiotherapy O
, O
they O
often O
experience O
anxiety O
and O
distress O
. O
We O
conducted O
a O
pilot O
randomised O
controlled O
trial O
to O
determine O
whether O
a O
radiation O
therapist O
led O
psycho O
- O
educational O
intervention O
for O
breast B-eligibility
cancer I-eligibility
patients I-eligibility
prior I-eligibility
to I-eligibility
radiotherapy I-eligibility
is O
likely O
to O
be O
effective O
in O
reducing O
radiotherapy B-condition
- I-condition
related I-condition
concerns I-condition
, I-condition
patient I-condition
anxiety I-condition
and I-condition
depression I-condition
. O
The O
intervention O
comprised O
two O
face O
- O
to O
- O
face O
consultations O
with O
a O
radiation O
therapist O
( O
one O
prior O
to O
radiation O
planning O
and O
the O
other O
prior O
to O
treatment O
) O
. O
Patients O
completed O
surveys O
at O
baseline O
, O
prior O
to O
treatment O
planning O
and O
on O
the O
first O
day O
of O
treatment O
. O
Outcome O
measures O
included O
the O
Hospital B-outcome-measure
Anxiety I-outcome-measure
and I-outcome-measure
Depression I-outcome-measure
Scale I-outcome-measure
, O
Radiation B-outcome-measure
Therapy I-outcome-measure
Related I-outcome-measure
Patient I-outcome-measure
Concerns I-outcome-measure
and O
Radiation B-outcome-measure
Therapy I-outcome-measure
Knowledge I-outcome-measure
Scales I-outcome-measure
. O
One B-total-participants
hundred I-total-participants
and I-total-participants
twenty I-total-participants
two I-total-participants
patients O
completed O
baseline O
measures O
. O
Fifty B-control-participants
- I-control-participants
eight I-control-participants
patients O
received O
usual B-control
care I-control
, O
and O
64 B-intervention-participants
received O
the O
intervention O
. O
After O
the O
first O
consultation O
, O
patient B-outcome
anxiety I-outcome
was O
significantly O
lower O
in O
the O
intervention O
group O
( O
p O
 O
= O
 O
0.048 O
) O
, O
as O
were O
concerns B-outcome
about I-outcome
radiotherapy I-outcome
( O
p O
 O
= O
 O
0.001 O
) O
. O
There O
were O
no O
differences O
between O
groups O
for O
depression B-outcome
. O
Patient B-outcome
knowledge I-outcome
for O
the O
intervention O
group O
was O
higher O
after O
the O
first O
consultation O
( O
p O
 O
< O
 O
0.001 O
) O
. O
This O
intervention O
is O
likely O
to O
be O
effective O
in O
reducing O
patient O
anxiety O
and O
concerns O
and O
increasing O
knowledge O
. O
Future O
research O
is O
required O
to O
test O
this O
intervention O
with O
a O
larger O
population O
. O

Phase O
II O
randomized O
study O
of O
trastuzumab B-intervention
emtansine I-intervention
versus O
trastuzumab B-control
plus I-control
docetaxel I-control
in O
patients O
with O
human O
epidermal O
growth O
factor O
receptor O
2 O
- O
positive O
metastatic O
breast O
cancer O
. O
Trastuzumab O
emtansine O
( O
T O
- O
DM1 O
) O
, O
an O
antibody O
- O
drug O
conjugate O
composed O
of O
the O
cytotoxic O
agent O
DM1 O
conjugated O
to O
trastuzumab O
via O
a O
stable O
thioether O
linker O
, O
has O
shown O
clinical O
activity O
in O
single O
- O
arm O
studies O
enrolling O
patients O
with O
human O
epidermal O
growth O
factor O
receptor O
2 O
( O
HER2 O
) O
-positive O
metastatic O
breast O
cancer O
( O
MBC O
) O
whose O
disease O
had O
progressed O
on O
HER2 O
- O
targeted O
therapy O
in O
the O
metastatic O
setting O
. O
Patients O
( O
N O
= O
137 B-total-participants
) O
with B-eligibility
HER2 I-eligibility
- I-eligibility
positive I-eligibility
MBC I-eligibility
or I-eligibility
recurrent I-eligibility
locally I-eligibility
advanced I-eligibility
breast I-eligibility
cancer I-eligibility
were O
randomly O
assigned O
to O
trastuzumab O
plus O
docetaxel O
( O
HT O
; O
n O
= O
70 B-control-participants
) O
or O
T O
- O
DM1 O
( O
n O
= O
67 B-intervention-participants
) O
as O
first O
- O
line O
treatment O
until O
disease O
progression O
or O
unacceptable O
toxicity O
. O
Primary O
end O
points O
were O
investigator O
- O
assessed O
progression B-outcome-measure
- I-outcome-measure
free I-outcome-measure
survival I-outcome-measure
( I-outcome-measure
PFS I-outcome-measure
) I-outcome-measure
and O
safety B-outcome-measure
. O
Key O
secondary O
end O
points O
included O
overall B-outcome-measure
survival I-outcome-measure
( I-outcome-measure
OS I-outcome-measure
) I-outcome-measure
, O
objective B-outcome-measure
response I-outcome-measure
rate I-outcome-measure
( I-outcome-measure
ORR I-outcome-measure
) I-outcome-measure
, O
duration B-outcome-measure
of I-outcome-measure
objective I-outcome-measure
response I-outcome-measure
, O
clinical B-outcome-measure
benefit I-outcome-measure
rate I-outcome-measure
, O
and O
quality B-outcome-measure
of I-outcome-measure
life I-outcome-measure
. O
Median B-outcome
PFS I-outcome
was O
9.2 B-cv-cont-median
months I-cv-cont-median
with O
HT O
and O
14.2 B-iv-cont-median
months I-iv-cont-median
with O
T O
- O
DM1 O
( O
hazard O
ratio O
, O
0.59 O
; O
95 O
% O
CI O
, O
0.36 O
to O
0.97 O
) O
; O
median B-outcome
follow I-outcome
- I-outcome
up I-outcome
was O
approximately O
14 B-iv-cont-median
months I-iv-cont-median
in O
both O
arms O
. O
ORR B-outcome
was O
58.0 B-cv-bin-percent
% I-cv-bin-percent
( O
95 O
% O
CI O
, O
45.5 O
% O
to O
69.2 O
% O
) O
with O
HT O
and O
64.2 B-iv-bin-percent
% I-iv-bin-percent
( O
95 O
% O
CI O
, O
51.8 O
% O
to O
74.8 O
% O
) O
with O
T O
- O
DM1 O
. O
T O
- O
DM1 O
had O
a O
favorable O
safety B-outcome
profile I-outcome
versus O
HT O
, O
with O
fewer O
grade B-outcome
 I-outcome
3 I-outcome
adverse I-outcome
events I-outcome
( O
AEs O
; O
46.4 B-iv-bin-percent
% I-iv-bin-percent
v O
90.9 B-cv-bin-percent
% I-cv-bin-percent
) O
, O
AEs O
leading O
to O
treatment B-outcome
discontinuations I-outcome
( O
7.2 B-iv-bin-percent
% I-iv-bin-percent
v O
34.8 B-cv-bin-percent
% I-cv-bin-percent
) O
, O
[ O
corrected O
] O
and O
serious B-outcome
AEs I-outcome
( O
20.3 B-iv-bin-percent
% I-iv-bin-percent
v O
25.8 B-cv-bin-percent
% I-cv-bin-percent
) O
. O
Preliminary O
OS B-outcome
results O
were O
similar O
between O
treatment O
arms O
; O
median O
follow O
- O
up O
was O
approximately O
23 B-iv-cont-median
months I-iv-cont-median
in O
both O
arms O
. O
In O
this O
randomized O
phase O
II O
study O
, O
first O
- O
line O
treatment O
with O
T O
- O
DM1 O
for O
patients O
with O
HER2 O
- O
positive O
MBC O
provided O
a O
significant O
improvement O
in O
PFS O
, O
with O
a O
favorable O
safety O
profile O
, O
versus O
HT O
. O

Results O
from O
a O
randomized O
trial O
of O
a O
web B-intervention
- I-intervention
based I-intervention
, I-intervention
tailored I-intervention
decision I-intervention
aid I-intervention
for O
women B-eligibility
at I-eligibility
high I-eligibility
risk I-eligibility
for I-eligibility
breast I-eligibility
cancer I-eligibility
. O
To O
assess O
the O
impact O
of O
Guide O
to O
Decide O
( O
GtD O
) O
, O
a O
web O
- O
based O
, O
personally O
- O
tailored O
decision O
aid O
designed O
to O
inform O
women O
's O
decisions O
about O
prophylactic O
tamoxifen O
and O
raloxifene O
use O
. O
Postmenopausal O
women O
, O
age B-age
46 I-age
- I-age
74 I-age
, O
with B-eligibility
BCRAT I-eligibility
5 I-eligibility
- I-eligibility
year I-eligibility
risk I-eligibility
 I-eligibility
1.66 I-eligibility
% I-eligibility
and I-eligibility
no I-eligibility
prior I-eligibility
history I-eligibility
of I-eligibility
breast I-eligibility
cancer I-eligibility
were O
randomized O
to O
one O
of O
three O
study O
arms O
: O
intervention O
( O
n O
= O
690 B-intervention-participants
) O
, O
Time O
1 O
control O
( O
n O
= O
160 B-intervention-participants
) O
, O
or O
3 O
- O
month O
control B-control
( O
n O
= O
162 B-control-participants
) O
. O
Intervention O
participants O
viewed O
GtD O
prior O
to O
completing O
a O
post O
- O
test O
and O
3 O
month O
follow O
- O
up O
assessment O
. O
Controls O
did O
not O
. O
We O
assessed O
the O
impact O
of O
GtD O
on O
women O
's O
decisional O
conflict O
levels O
and O
treatment O
decision O
behavior O
at O
post O
- O
test O
and O
at O
3 O
months O
, O
respectively O
. O
Intervention O
participants O
had O
significantly O
lower O
decisional B-outcome
conflict I-outcome
levels I-outcome
at O
post O
- O
test O
( O
p<0.001 O
) O
and O
significantly O
higher O
odds O
of O
making O
a O
decision O
about O
whether O
or O
not O
to O
take O
prophylactic O
tamoxifen O
or O
raloxifene O
at O
3 O
- O
month O
follow O
- O
up O
( O
p<0.001 O
) O
compared O
to O
control O
participants O
. O
GtD O
lowered O
decisional B-outcome
conflict I-outcome
and O
helped O
women O
at O
high O
risk O
of O
breast O
cancer O
decide O
whether O
to O
take O
prophylactic O
tamoxifen O
or O
raloxifene O
to O
reduce O
their O
cancer O
risk O
. O
Web O
- O
based O
, O
tailored O
decision O
aids O
should O
be O
used O
more O
routinely O
to O
facilitate O
informed O
medical O
decisions O
, O
reduce O
patients O
' O
decisional O
conflict O
, O
and O
empower O
patients O
to O
choose O
the O
treatment O
strategy O
that O
best O
reflects O
their O
own O
values O
. O
  O

Efficacy O
of O
everolimus B-intervention
with I-intervention
exemestane I-intervention
versus O
exemestane B-control
alone I-control
in O
Asian B-ethinicity
patients B-eligibility
with I-eligibility
HER2 I-eligibility
- I-eligibility
negative I-eligibility
, I-eligibility
hormone I-eligibility
- I-eligibility
receptor I-eligibility
- I-eligibility
positive I-eligibility
breast I-eligibility
cancer I-eligibility
in O
BOLERO-2 O
. O
The O
addition O
of O
mTOR O
inhibitor O
everolimus O
( O
EVE O
) O
to O
exemestane O
( O
EXE O
) O
was O
evaluated O
in O
an O
international O
, O
phase O
3 O
study O
( O
BOLERO-2 O
) O
in O
patients O
with O
hormone O
- O
receptor O
- O
positive O
( O
HR O
( O
+ O
) O
) O
breast O
cancer O
refractory O
to O
letrozole O
or O
anastrozole O
. O
The O
safety O
and O
efficacy O
of O
anticancer O
treatments O
may O
be O
influenced O
by O
ethnicity O
( O
Sekine O
et O
al O
. O
in O
Br O
J O
Cancer O
99 O
: O
1757 O
- O
62 O
, O
2008 O
) O
. O
Safety O
and O
efficacy O
results O
from O
Asian O
versus O
non B-ethinicity
- I-ethinicity
Asian I-ethinicity
patients O
in O
BOLERO-2 O
are O
reported O
. O
Patients O
were O
randomized O
( O
2 O
:1 O
) O
to O
10 O
mg O
/ O
day O
EVE O
+ O
EXE O
or O
placebo B-control
( I-control
PBO I-control
) I-control
+ I-control
EXE I-control
. O
Primary O
endpoint O
was O
progression B-outcome-measure
- I-outcome-measure
free I-outcome-measure
survival I-outcome-measure
( I-outcome-measure
PFS I-outcome-measure
) I-outcome-measure
. O
Secondary O
endpoints O
included O
overall B-outcome-measure
survival I-outcome-measure
, O
response B-outcome-measure
rate I-outcome-measure
, O
clinical B-outcome-measure
benefit I-outcome-measure
rate I-outcome-measure
, O
and O
safety B-outcome-measure
. O
Of O
143 B-total-participants
Asian O
patients O
, O
98 B-intervention-participants
received O
EVE O
+ O
EXE O
and O
45 B-control-participants
received O
PBO O
+ O
EXE O
. O
Treatment O
with O
EVE O
+ O
EXE O
significantly O
improved O
median B-outcome
PFS I-outcome
versus O
PBO O
+ O
EXE O
among O
Asian O
patients O
by O
38 O
% O
( O
HR O
= O
0.62 O
; O
95 O
% O
CI O
, O
0.41 O
- O
0.94 O
) O
. O
Median B-outcome
PFS I-outcome
was O
also O
improved O
among O
non O
- O
Asian O
patients O
by O
59 O
% O
( O
HR O
= O
0.41 O
; O
95 O
% O
CI O
, O
0.33 O
- O
0.50 O
) O
. O
Median B-outcome
PFS I-outcome
duration O
among O
EVE O
- O
treated O
Asian O
patients O
was O
8.48 B-iv-cont-median
versus O
4.14 B-cv-cont-median
months I-cv-cont-median
for O
PBO O
+ O
EXE O
, O
and O
7.33 B-iv-cont-median
versus O
2.83 B-cv-cont-median
months I-cv-cont-median
, O
respectively O
, O
in B-outcome
non I-outcome
- I-outcome
Asian I-outcome
patients I-outcome
. O
The O
most O
common O
grade B-outcome
3 I-outcome
/ I-outcome
4 I-outcome
adverse I-outcome
events I-outcome
( O
stomatitis O
, O
anemia O
, O
elevated O
liver O
enzymes O
, O
hyperglycemia O
, O
and O
dyspnea O
) O
occurred O
at O
similar O
frequencies O
in O
Asian O
and O
non O
- O
Asian O
patients O
. O
Grade B-outcome
1 I-outcome
/ I-outcome
2 I-outcome
interstitial I-outcome
lung I-outcome
disease I-outcome
occurred O
more O
frequently O
in O
Asian O
patients O
. O
Quality B-outcome
of I-outcome
life I-outcome
was O
similar O
between O
treatment O
arms O
in O
Asian O
patients O
. O
Adding O
EVE O
to O
EXE O
provided O
substantial O
clinical O
benefit O
in O
both O
Asian O
and O
non O
- O
Asian O
patients O
with O
similar O
safety O
profiles O
. O
This O
combination O
represents O
an O
improvement O
in O
the O
management O
of O
postmenopausal O
women O
with O
HR O
( O
+ O
) O
/HER2 O
( O
- O
) O
advanced O
breast O
cancer O
progressing O
on O
nonsteroidal O
aromatase O
inhibitors O
, O
regardless O
of O
ethnicity O
. O

Effect O
of O
everolimus B-intervention
on O
bone O
marker O
levels O
and O
progressive O
disease O
in O
bone O
in O
BOLERO-2 O
. O
Breast O
Cancer O
Trials O
of O
Oral O
Everolimus O
2 O
( O
BOLERO-2 O
) O
, O
a O
phase O
III O
study O
in O
postmenopausal B-eligibility
women I-eligibility
with I-eligibility
estrogen I-eligibility
receptor I-eligibility
- I-eligibility
positive I-eligibility
breast I-eligibility
cancer I-eligibility
progressing I-eligibility
despite I-eligibility
nonsteroidal I-eligibility
aromatase I-eligibility
inhibitor I-eligibility
therapy I-eligibility
, O
showed O
statistically O
significant O
benefits O
with O
adding O
everolimus O
to O
exemestane O
. O
Moreover O
, O
in O
preclinical O
studies O
, O
mammalian O
target O
of O
rapamycin O
inhibition O
was O
associated O
with O
decreased O
osteoclast O
survival O
and O
activity O
. O
Exploratory O
analyses O
in O
BOLERO-2 O
evaluated O
the O
effect O
of O
everolimus O
on O
bone O
marker O
levels O
and O
progressive O
disease O
in O
bone O
. O
Patients O
were O
treated O
with O
exemestane O
( O
25mg O
/ O
day O
) O
and O
randomized O
( O
2 O
:1 O
) O
to O
everolimus O
( O
10mg O
/ O
day O
; O
combination O
) O
or O
placebo B-control
( I-control
exemestane I-control
only I-control
) I-control
. O
Exploratory O
endpoints O
included O
changes B-outcome-measure
in I-outcome-measure
bone I-outcome-measure
turnover I-outcome-measure
marker I-outcome-measure
levels I-outcome-measure
vs O
baseline B-outcome-measure
and I-outcome-measure
progressive I-outcome-measure
disease I-outcome-measure
in I-outcome-measure
bone I-outcome-measure
, O
defined O
as O
unequivocal O
progression O
of O
a O
preexisting O
bone O
lesion O
or O
the O
appearance O
of O
a O
new O
bone O
lesion O
. O
Baseline B-outcome
disease I-outcome
characteristics I-outcome
were O
well O
balanced O
between O
arms O
( O
N O
= O
724 B-total-participants
) O
; O
baseline O
bisphosphonate O
use O
was O
not O
( O
43.9 B-iv-bin-percent
% I-iv-bin-percent
combination O
vs O
54.0 B-cv-bin-percent
% I-cv-bin-percent
exemestane O
only O
) O
. O
At O
a O
median O
of O
18 O
months O
of O
follow O
- O
up O
, O
median O
progression B-outcome
- I-outcome
free I-outcome
survival I-outcome
( O
primary O
endpoint O
) O
was O
statistically O
significantly O
longer O
with O
the O
combination O
vs O
exemestane O
only O
( O
Cox O
proportional O
hazard O
ratio O
= O
0.45 O
, O
95 O
% O
confidence O
interval O
= O
0.38 O
to O
0.54 O
; O
log O
- O
rank O
, O
1 O
- O
sided O
P O
< O
.0001 O
) O
. O
Bone B-outcome
marker I-outcome
levels I-outcome
at B-outcome
6 I-outcome
and I-outcome
12 I-outcome
weeks I-outcome
increased O
with O
exemestane O
only O
, O
as O
expected O
, O
but O
decreased O
with O
the O
combination O
. O
The O
cumulative B-outcome
incidence I-outcome
rate I-outcome
of I-outcome
progressive I-outcome
disease I-outcome
in I-outcome
bone I-outcome
was O
lower O
in O
the O
combination O
arm O
. O
Bone B-outcome
- I-outcome
related I-outcome
adverse I-outcome
events I-outcome
occurred O
with O
similar O
frequency O
in O
both O
arms O
( O
3.3 B-iv-bin-percent
% I-iv-bin-percent
combination O
vs O
4.2 B-cv-bin-percent
% I-cv-bin-percent
exemestane O
only O
) O
. O
These O
exploratory O
analyses O
suggest O
that O
everolimus O
has O
beneficial O
effects O
on O
bone O
turnover O
and O
progressive O
disease O
in O
bone O
in O
patients O
receiving O
exemestane O
for O
hormone O
receptor O
- O
positive O
breast O
cancer O
progressing O
during O
/ O
after O
nonsteroidal O
aromatase O
inhibitor O
therapy O
. O

Dressing B-intervention
wear I-intervention
time I-intervention
after O
breast O
reconstruction O
: O
study O
protocol O
for O
a O
randomized O
controlled O
trial O
. O
One O
of O
the O
major O
risk O
variables O
for O
surgical O
site O
infection O
is O
wound O
management O
. O
Understanding O
infection O
risk O
factors O
for O
breast O
operations O
is O
essential O
in O
order O
to O
develop O
infection O
- O
prevention O
strategies O
and O
improve O
surgical O
outcomes O
. O
The O
aim O
of O
this O
trial O
is O
to O
assess O
the O
influence O
of O
dressing O
wear O
time O
on O
surgical B-condition
site I-condition
infection I-condition
rates I-condition
and I-condition
skin I-condition
colonization I-condition
. O
Patients O
' O
perception O
at O
self O
- O
assessment O
will O
also O
be O
analyzed O
. O
This O
is O
a O
two O
- O
arm O
randomized O
controlled O
trial O
. O
Two B-total-participants
hundred I-total-participants
breast B-eligibility
cancer I-eligibility
patients I-eligibility
undergoing I-eligibility
immediate I-eligibility
or I-eligibility
delayed I-eligibility
breast I-eligibility
reconstruction I-eligibility
will O
be O
prospectively O
enrolled O
. O
Patients O
will O
be O
randomly O
allocated O
to O
group O
I O
( O
dressing O
removed O
on O
postoperative O
day O
one O
) O
or O
group B-control
II I-control
( I-control
dressing I-control
removed I-control
on I-control
postoperative I-control
day I-control
six I-control
) I-control
. O
Surgical O
site O
infections O
will O
be O
defined O
by O
standard O
criteria O
from O
the O
Centers O
for O
Disease O
Control O
and O
Prevention O
( O
CDC O
) O
. O
Skin O
colonization O
will O
be O
assessed O
by O
culture O
of O
samples O
collected O
at O
predefined O
time O
points O
. O
Patients O
will O
score O
dressing O
wear O
time O
with O
regard O
to O
safety O
, O
comfort O
and O
convenience O
. O
The O
evidence O
to O
support O
dressing O
standards O
for O
breast O
surgery O
wounds O
is O
empiric O
and O
scarce O
. O
CDC O
recommends O
protecting O
, O
with O
a O
sterile O
dressing O
for O
24 O
to O
48 O
hours O
postoperatively O
, O
a O
primarily O
closed O
incision O
, O
but O
there O
is O
no O
recommendation O
to O
cover O
this O
kind O
of O
incision O
beyond O
48 O
hours O
, O
or O
on O
the O
appropriate O
time O
to O
shower O
or O
bathe O
with O
an O
uncovered O
incision O
. O
The O
results O
of O
the O
ongoing O
trial O
may O
support O
standard O
recommendations O
regarding O
dressing O
wear O
time O
after O
breast O
reconstruction O
. O
ClinicalTrials.gov O
identifier O
: O
http O
: O
//NCT01148823 O
. O

Association O
between O
allergies B-intervention
, I-intervention
asthma I-intervention
, O
and O
breast O
cancer O
risk O
among O
women O
in O
Ontario B-location
, I-location
Canada I-location
. O
To O
investigate O
the O
association O
between O
allergies O
, O
asthma O
, O
and O
breast O
cancer O
risk O
in O
a O
large O
, O
population O
- O
based O
case O
- O
control O
study O
. O
Breast O
cancer O
cases O
( O
n O
= O
3,101 B-intervention-participants
) O
were O
identified O
using O
the O
Ontario O
Cancer O
Registry O
and O
population O
controls B-control
( O
n O
= O
3,471 B-control-participants
) O
through O
random O
digit O
dialing O
. O
Self O
- O
reported O
histories O
of O
allergies O
, O
hay O
fever O
, O
and O
asthma O
were O
collected O
by O
questionnaire O
. O
Logistic O
regression O
was O
used O
to O
assess O
associations O
between O
breast O
cancer O
risk O
and O
history O
of O
allergy O
/ O
hay O
fever O
and O
asthma O
, O
with O
16 O
possible O
confounders O
examined O
. O
Analyses O
were O
stratified O
by O
menopausal O
status O
. O
A O
history O
of O
allergies O
or O
hay O
fever O
was O
associated O
with O
a O
small O
reduction O
in O
breast B-outcome
cancer I-outcome
risk I-outcome
[ O
age O
- O
adjusted O
odds O
ratio O
( O
AOR O
) O
= O
0.86 O
, O
95 O
% O
confidence O
interval O
( O
CI O
) O
0.77 O
- O
0.96 O
] O
and O
did O
not O
differ O
by O
menopausal O
status O
. O
Asthma O
was O
not O
associated O
with O
breast B-outcome
cancer I-outcome
risk I-outcome
overall I-outcome
; O
however O
, O
among O
premenopausal O
women O
, O
asthma O
was O
associated O
with O
a O
reduced O
risk B-outcome
of I-outcome
breast I-outcome
cancer I-outcome
( O
AOR O
= O
0.72 O
, O
95 O
% O
CI O
0.54 O
- O
0.97 O
) O
. O
A O
history O
of O
allergies O
may O
be O
associated O
with O
a O
modest O
reduction O
in O
breast B-outcome
cancer I-outcome
risk I-outcome
. O
Asthma O
does O
not O
appear O
to O
be O
associated O
with O
breast O
cancer O
risk O
overall O
; O
however O
, O
asthma O
may O
be O
associated O
with O
reduced O
breast O
cancer O
risk O
among O
premenopausal O
women O
. O

Technical O
effects O
of O
adding O
1 B-intervention
% I-intervention
lidocaine I-intervention
to I-intervention
technetium I-intervention
sulfur I-intervention
colloid I-intervention
for O
sentinel O
lymphatic O
mapping O
in O
early O
breast O
cancer O
: O
analysis O
of O
data O
from O
a O
double O
- O
blind O
randomized O
controlled O
trial O
. O
A O
practice O
standard O
in O
sentinel O
lymph O
node O
( O
SLN O
) O
mapping O
in O
breast O
cancer O
is O
intradermal O
injection O
of O
technetium-99 O
m O
sulfur O
colloid O
( O
Tc-99 O
m O
) O
, O
resulting O
in O
significant O
patient O
discomfort O
and O
pain O
. O
A O
previous O
randomized O
controlled O
trial O
showed O
that O
adding O
lidocaine O
to O
Tc-99 O
m O
significantly O
reduced O
radioisotope O
injection O
- O
related O
pain O
. O
We O
tested O
whether O
1 O
 O
% O
lidocaine O
admixed O
with O
Tc-99 O
m O
affects O
feasibility O
of O
SLN O
mapping O
. O
Between O
January O
2006 O
and O
April O
2009 O
, O
140 B-total-participants
patients B-eligibility
with I-eligibility
early I-eligibility
breast I-eligibility
cancer I-eligibility
were O
randomly O
assigned O
( O
1 O
:1 O
:1 O
:1 O
) O
to O
receive O
standard O
topical O
4 O
 O
% O
lidocaine O
cream O
and O
intradermal O
Tc-99 O
m O
( O
control B-control
) O
or O
to O
one O
of O
three O
other O
study O
groups O
: O
topical B-control
placebo I-control
cream I-control
and O
injection O
of O
Tc-99 O
m O
containing O
sodium O
bicarbonate O
( O
NaHCO3 O
) O
, O
1 O
 O
% O
lidocaine O
, O
or O
both O
. O
All O
SLN O
data O
were O
collected O
prospectively O
. O
Study O
groups O
were O
comparable O
for O
clinicopathological O
parameters O
. O
As O
previously O
reported O
, O
the O
addition O
of O
1 O
 O
% O
lidocaine O
to O
the O
radioisotope O
solution O
significantly O
improved O
patient B-outcome
comfort I-outcome
. O
Overall B-outcome
SLN I-outcome
identification I-outcome
rate I-outcome
in O
the O
trial O
was O
93 O
 O
% O
. O
Technical B-outcome
aspects I-outcome
of I-outcome
SLN I-outcome
biopsy I-outcome
were O
similar O
for O
all O
groups O
, O
including O
time B-outcome
from I-outcome
injection I-outcome
to I-outcome
operation I-outcome
, O
first B-outcome
SLN I-outcome
( I-outcome
SLN I-outcome
1 I-outcome
) I-outcome
gamma O
probe O
counts O
, O
ex B-outcome
vivo I-outcome
counts I-outcome
for O
SLN O
1 O
and O
SLN O
2 O
, O
and O
axillary B-outcome
bed I-outcome
counts I-outcome
. O
SLN B-outcome
identification I-outcome
rates I-outcome
were O
comparable O
statistically O
: O
control O
( O
96 B-cv-bin-percent
 I-cv-bin-percent
% I-cv-bin-percent
) O
, O
lidocaine O
( O
90 B-iv-bin-percent
 I-iv-bin-percent
% I-iv-bin-percent
) O
, O
sodium O
bicarbonate O
( O
97 B-iv-bin-percent
 I-iv-bin-percent
% I-iv-bin-percent
) O
, O
and O
sodium O
bicarbonate O
- O
lidocaine O
( O
90 B-iv-bin-percent
 I-iv-bin-percent
% I-iv-bin-percent
) O
. O
The O
control O
group O
had O
a O
significantly O
higher O
SLN B-outcome
2 I-outcome
/ I-outcome
SLN I-outcome
1 I-outcome
ex I-outcome
vivo I-outcome
count I-outcome
ratio I-outcome
, O
and O
the O
number B-outcome
of I-outcome
SLNs I-outcome
detected I-outcome
was O
significantly O
reduced O
in O
the O
lidocaine O
versus O
no O
- O
lidocaine O
groups O
( O
p O
 O
< O
 O
0.05 O
) O
. O
Addition O
of O
1 O
 O
% O
lidocaine O
to O
standard O
radioisotope O
solution O
for O
SLN O
mapping O
in O
breast O
cancer O
is O
associated O
with O
fewer O
SLNs O
detected O
, O
but O
it O
does O
not O
appear O
to O
compromise O
SLN O
identification O
. O

Comparison O
of O
the O
sentinel B-intervention
node I-intervention
procedure I-intervention
between O
patients B-eligibility
with I-eligibility
multifocal I-eligibility
and I-eligibility
unifocal I-eligibility
breast I-eligibility
cancer I-eligibility
in O
the O
EORTC O
10981 O
- O
22023 O
AMAROS O
Trial O
: O
identification O
rate O
and O
nodal O
outcome O
. O
Multifocal O
breast O
cancer O
is O
associated O
with O
a O
higher O
risk O
of O
nodal O
involvement O
compared O
to O
unifocal O
breast O
cancer O
and O
the O
drainage O
pattern O
from O
multifocal O
localisations O
may O
be O
different O
. O
For O
this O
reason O
, O
the O
value O
of O
the O
sentinel O
node O
biopsy O
( O
SNB O
) O
procedure O
for O
this O
indication O
is O
debated O
. O
The O
aim O
of O
the O
current O
analysis O
was O
to O
evaluate O
the O
sentinel O
node O
identification O
rate O
and O
nodal O
involvement O
in O
patients O
with O
a O
multifocal O
tumour O
in O
the O
EORTC O
10981 O
- O
22023 O
AMAROS O
trial O
. O
From O
the O
first O
4000 B-total-participants
registered O
patients O
, O
342 B-intervention-participants
were O
identified O
with O
a O
multifocal O
tumour O
on O
histological O
examination O
and O
compared O
to O
a O
randomly O
selected O
control B-control
group I-control
of O
684 B-control-participants
patients O
with O
a O
unifocal O
tumour O
. O
The O
outcome O
of O
the O
SNB O
was O
assessed O
. O
The O
sentinel B-outcome
node I-outcome
was O
identified O
in O
96 B-iv-bin-percent
% I-iv-bin-percent
of O
the O
patients O
with O
a O
multifocal O
tumour O
and O
in O
98 B-cv-bin-percent
% I-cv-bin-percent
of O
those O
with O
unifocal O
disease O
. O
In O
the O
multifocal O
group O
, O
51 B-iv-bin-percent
% I-iv-bin-percent
had O
a O
metastasis B-outcome
in O
the O
sentinel O
node O
compared O
to O
28 B-cv-bin-percent
% I-cv-bin-percent
in O
the O
unifocal O
group O
; O
and O
further O
nodal B-outcome
involvement I-outcome
after I-outcome
a I-outcome
positive I-outcome
sentinel I-outcome
node I-outcome
was O
found O
in O
40 B-iv-bin-percent
% I-iv-bin-percent
( O
38 B-iv-bin-abs
/ O
95 B-intervention-participants
) O
and O
39 B-cv-bin-percent
% I-cv-bin-percent
( O
39 B-cv-bin-abs
/ O
101 B-control-participants
) O
respectively O
. O
In O
this O
prospective O
international O
multicentre O
study O
, O
the O
96 O
% O
detection O
rate O
indicates O
that O
the O
SNB O
procedure O
can O
be O
highly O
effective O
in O
patients O
with O
a O
multifocal O
tumour O
. O
Though O
the O
tumour O
- O
positive O
rate O
of O
the O
sentinel O
node O
was O
twice O
as O
high O
in O
the O
multifocal O
group O
compared O
to O
the O
unifocal O
group O
, O
further O
nodal O
involvement O
after O
a O
positive O
sentinel O
node O
was O
similar O
in O
both O
groups O
. O
This O
suggests O
that O
the O
SNB O
procedure O
is O
safe O
in O
patients O
with O
multifocal O
breast O
cancer O
. O

Phase O
III O
, O
multicenter O
, O
randomized O
trial O
of O
maintenance B-intervention
chemotherapy I-intervention
versus O
observation B-control
in O
patients O
with O
metastatic O
breast O
cancer O
after O
achieving O
disease O
control O
with O
six O
cycles O
of O
gemcitabine O
plus O
paclitaxel O
as O
first O
- O
line O
chemotherapy O
: O
KCSG O
- O
BR07 O
- O
02 O
. O
The O
primary O
purpose O
of O
our O
study O
was O
to O
evaluate O
whether O
maintenance O
chemotherapy O
with O
paclitaxel O
/ O
gemcitabine O
( O
PG O
) O
was O
superior O
to O
observation O
in O
improving O
progression O
- O
free O
survival O
( O
PFS O
) O
in O
patients O
with O
metastatic O
breast O
cancer O
( O
MBC O
) O
who O
achieved O
disease O
control O
with O
an O
initial O
six O
cycles O
of O
PG O
as O
their O
first O
- O
line O
treatment O
. O
The O
study O
was O
a O
prospective O
, O
randomized O
, O
multicenter O
, O
phase O
III O
trial O
. O
Patients B-eligibility
MBC I-eligibility
with I-eligibility
who I-eligibility
achieved I-eligibility
disease I-eligibility
control I-eligibility
after I-eligibility
six I-eligibility
cycles I-eligibility
of I-eligibility
PG I-eligibility
chemotherapy I-eligibility
were O
randomly O
assigned O
to O
maintenance O
chemotherapy O
or O
observation O
until O
progression O
. O
Of O
324 B-total-participants
patients O
from O
10 O
centers O
enrolled O
, O
231 B-total-participants
patients O
with O
MBC O
exhibited O
disease O
control O
( O
complete O
response O
+ O
partial O
response O
+ O
stable O
disease O
) O
with O
first O
- O
line O
PG O
and O
were O
randomly O
assigned O
to O
maintenance O
chemotherapy O
( O
n O
= O
116 B-intervention-participants
) O
or O
observation O
( O
n O
= O
115 B-control-participants
) O
. O
The O
median O
age O
was O
48 B-age
years I-age
( O
range O
, O
28 O
to O
76 O
years O
) O
, O
median O
follow O
- O
up O
was O
33 O
months O
, O
and O
median O
number O
of O
chemotherapy O
cycles O
in O
the O
maintenance O
group O
after O
random O
assignment O
was O
six O
. O
The O
median B-outcome
PFS I-outcome
time I-outcome
after O
random O
assignment O
was O
longer O
in O
the O
maintenance O
group O
than O
in O
the O
observation O
group O
( O
7.5 B-iv-cont-median
v O
3.8 B-cv-cont-median
months I-cv-cont-median
, O
respectively O
; O
P O
= O
.026 O
) O
. O
The O
median B-outcome
overall I-outcome
survival I-outcome
( I-outcome
OS I-outcome
) I-outcome
time I-outcome
was O
longer O
in O
the O
maintenance O
group O
than O
in O
the O
observation O
group O
( O
32.3 B-iv-cont-median
v O
23.5 B-cv-cont-median
months I-cv-cont-median
, O
respectively O
; O
P O
= O
.047 O
) O
. O
The O
rate B-outcome
of I-outcome
grade I-outcome
3 I-outcome
or I-outcome
higher I-outcome
neutropenia I-outcome
after O
random O
assignment O
was O
higher O
in O
the O
maintenance O
group O
than O
in O
the O
observation O
group O
( O
61 B-iv-bin-percent
% I-iv-bin-percent
v O
0.9 B-cv-bin-percent
% I-cv-bin-percent
, O
respectively O
; O
P O
< O
.001 O
) O
. O
In O
patients O
with O
MBC O
who O
achieved O
disease O
control O
with O
an O
initial O
six O
cycles O
of O
PG O
chemotherapy O
, O
maintenance O
PG O
chemotherapy O
resulted O
in O
better O
PFS O
and O
OS O
compared O
with O
observation O
. O

Evaluation O
of O
Short O
- O
Term O
Use O
of O
N B-intervention
- I-intervention
Acetylcysteine I-intervention
as O
a O
Strategy O
for O
Prevention O
of O
Anthracycline B-condition
- I-condition
Induced I-condition
Cardiomyopathy I-condition
: O
EPOCH O
Trial O
- O
A O
Prospective O
Randomized O
Study O
. O
We O
investigate O
to O
determine O
whether O
N O
- O
acetylcysteine O
( O
NAC O
) O
can O
prevent O
anthracycline O
- O
induced O
cardiotoxicity O
. O
A O
total O
of O
103 B-total-participants
patients O
were O
enrolled O
in O
this O
prospective O
randomized O
open O
label O
controlled O
trial O
. O
They O
are O
patients B-eligibility
first I-eligibility
diagnosed I-eligibility
with I-eligibility
breast I-eligibility
cancer I-eligibility
or I-eligibility
lymphoma I-eligibility
, I-eligibility
who I-eligibility
require I-eligibility
chemotherapy I-eligibility
, I-eligibility
including I-eligibility
anthracycline I-eligibility
like I-eligibility
adriamycine I-eligibility
or I-eligibility
epirubicine I-eligibility
. O
Patients O
were O
randomized O
to O
the O
NAC O
group O
{ O
n O
= O
50 B-intervention-participants
; O
1200 O
mg O
orally O
every O
8 O
hours O
starting O
before O
and O
ending O
after O
the O
intravenous O
infusion O
of O
anthracycline O
in O
all O
chemotherapy O
cycles O
( O
3 O
- O
6 O
) O
} O
or O
the O
control B-control
group I-control
( O
n O
= O
53 B-control-participants
) O
. O
Primary O
outcome O
was O
the O
decrease B-outcome-measure
in I-outcome-measure
left I-outcome-measure
ventricular I-outcome-measure
ejection I-outcome-measure
fraction I-outcome-measure
( I-outcome-measure
LVEF I-outcome-measure
) I-outcome-measure
absolutely O
10 O
% O
from O
the O
baseline O
and O
concomitantly O
< O
50 O
% O
at O
6 O
- O
month O
. O
Composite O
of O
all O
- O
cause O
death O
, O
heart O
failure O
and O
readmission O
were O
compared O
. O
The O
primary B-outcome
outcome I-outcome
was O
not O
significantly O
different O
in O
the O
NAC O
and O
control O
groups O
{ O
3 B-iv-bin-abs
/ O
47 B-intervention-participants
( O
6.4 B-iv-bin-percent
% I-iv-bin-percent
) O
vs. O
1 B-cv-bin-abs
/ O
52 B-control-participants
( O
1.9 B-cv-bin-percent
% I-cv-bin-percent
) O
, O
p O
= O
0.343 O
} O
. O
The O
mean B-outcome
LVEF I-outcome
significantly O
decreased O
in O
both O
the O
NAC O
( O
from O
64.5 O
to O
60.8 B-iv-cont-mean
% I-iv-cont-mean
, O
p O
= O
0.001 O
) O
and O
control O
groups O
( O
from O
64.1 O
to O
61.3 B-cv-cont-mean
% I-cv-cont-mean
, O
p<0.001 O
) O
after O
the O
completion O
of O
whole O
chemotherapy O
. O
The O
mean B-outcome
LVEF I-outcome
change I-outcome
did O
not O
differ O
between O
the O
two O
groups O
( O
-3.64 B-iv-cont-mean
% I-iv-cont-mean
in O
NAC O
vs. O
-2.78 B-cv-cont-mean
% I-cv-cont-mean
in O
control O
group O
, O
p O
= O
0.502 O
) O
. O
Left B-outcome
ventricular I-outcome
( I-outcome
LV I-outcome
) I-outcome
end I-outcome
systolic I-outcome
dimension I-outcome
increased O
with O
higher O
trend O
in O
NAC O
by O
3.08 B-iv-cont-mean
 O
4.56 B-iv-cont-sd
mm I-iv-cont-sd
as O
compared O
with O
1.47 B-cv-cont-mean
 O
1.83 B-cv-cont-sd
mm I-cv-cont-sd
in O
the O
control O
group O
( O
p O
= O
0.064 O
) O
. O
LV B-outcome
end I-outcome
diastolic I-outcome
dimension I-outcome
did O
not O
change O
in O
each O
group O
and O
change O
does O
not O
differ O
in O
both O
. O
Peak B-outcome
E I-outcome
, O
A B-outcome
and I-outcome
E I-outcome
/ I-outcome
A I-outcome
ratio I-outcome
change I-outcome
and O
cardiac B-outcome
enzymes I-outcome
were O
comparable O
in O
two O
groups O
. O
Cumulative B-outcome
12 I-outcome
- I-outcome
month I-outcome
event I-outcome
rate I-outcome
was O
6 B-iv-bin-percent
% I-iv-bin-percent
and O
3.8 B-cv-bin-percent
% I-cv-bin-percent
in O
the O
NAC O
group O
and O
the O
control O
group O
, O
respectively O
, O
with O
no O
difference O
( O
p O
= O
0.672 O
) O
. O
We O
can O
not O
prove O
that O
NAC O
prevents O
anthracycline O
- O
induced O
cardiomyopathy O
. O

Primary O
granulocyte B-intervention
colony I-intervention
- I-intervention
stimulating I-intervention
factor I-intervention
prophylaxis I-intervention
during O
the O
first O
two O
cycles O
only O
or O
throughout O
all O
chemotherapy O
cycles O
in O
patients O
with O
breast O
cancer O
at O
risk O
for O
febrile B-condition
neutropenia I-condition
. O
Early O
breast O
cancer O
is O
commonly O
treated O
with O
anthracyclines O
and O
taxanes O
. O
However O
, O
combining O
these O
drugs O
increases O
the O
risk O
of O
myelotoxicity O
and O
may O
require O
granulocyte O
colony O
- O
stimulating O
factor O
( O
G O
- O
CSF O
) O
support O
. O
The O
highest O
incidence O
of O
febrile O
neutropenia O
( O
FN O
) O
and O
largest O
benefit O
of O
G O
- O
CSF O
during O
the O
first O
cycles O
of O
chemotherapy O
lead O
to O
questions O
about O
the O
effectiveness O
of O
continued O
use O
of O
G O
- O
CSF O
throughout O
later O
cycles O
of O
chemotherapy O
. O
In O
a O
multicenter O
study O
, O
patients B-eligibility
with I-eligibility
breast I-eligibility
cancer I-eligibility
who I-eligibility
were I-eligibility
considered I-eligibility
fit I-eligibility
enough I-eligibility
to I-eligibility
receive I-eligibility
3 I-eligibility
- I-eligibility
weekly I-eligibility
polychemotherapy I-eligibility
, I-eligibility
but I-eligibility
also I-eligibility
had I-eligibility
> I-eligibility
20 I-eligibility
% I-eligibility
risk I-eligibility
for I-eligibility
FN I-eligibility
, O
were O
randomly O
assigned O
to O
primary O
G O
- O
CSF O
prophylaxis O
during O
the O
first O
two O
chemotherapy O
cycles O
only O
( O
experimental O
arm O
) O
or O
to O
primary O
G O
- O
CSF O
prophylaxis O
throughout O
all O
chemotherapy O
cycles O
( O
standard B-control
arm I-control
) O
. O
The O
noninferiority O
hypothesis O
was O
that O
the O
incidence O
of O
FN O
would O
be O
maximally O
7.5 O
% O
higher O
in O
the O
experimental O
compared O
with O
the O
standard O
arm O
. O
After O
inclusion O
of O
167 B-total-participants
eligible O
patients O
, O
the O
independent O
data O
monitoring O
committee O
advised O
premature O
study O
closure O
. O
Of O
84 B-control-participants
patients O
randomly O
assigned O
to O
G O
- O
CSF O
throughout O
all O
chemotherapy O
cycles O
, O
eight B-cv-bin-abs
( O
10 B-cv-bin-percent
% I-cv-bin-percent
) O
experienced O
an O
episode B-outcome
of I-outcome
FN I-outcome
. O
In O
contrast O
, O
of O
83 B-intervention-participants
patients O
randomly O
assigned O
to O
G O
- O
CSF O
during O
the O
first O
two O
cycles O
only O
, O
30 B-iv-bin-abs
( O
36 B-iv-bin-percent
% I-iv-bin-percent
) O
had O
an O
FN B-outcome
episode I-outcome
( O
95 O
% O
CI O
, O
0.13 O
to O
0.54 O
) O
, O
with O
a O
peak O
incidence O
of O
24 O
% O
in O
the O
third O
cycle O
( O
ie O
, O
first O
cycle O
without O
G O
- O
CSF O
prophylaxis O
) O
. O
In O
patients O
with O
early O
breast O
cancer O
at O
high O
risk O
for O
FN O
, O
continued O
use O
of O
primary O
G O
- O
CSF O
prophylaxis O
during O
all O
chemotherapy O
cycles O
is O
of O
clinical O
relevance O
and O
thus O
can O
not O
be O
abandoned O
. O

Guided B-intervention
paravertebral I-intervention
blocks I-intervention
with O
versus O
without B-control
clonidine I-control
for O
women O
undergoing O
breast O
surgery O
: O
a O
prospective O
double O
- O
blinded O
randomized O
study O
. O
Paravertebral O
blocks O
( O
PVBs O
) O
have O
been O
introduced O
as O
an O
alternative O
to O
general O
anesthesia O
for O
breast O
cancer O
surgeries O
. O
The O
addition O
of O
clonidine O
as O
an O
adjuvant O
in O
PVBs O
may O
enhance O
quality O
and O
duration O
of O
analgesia O
and O
significantly O
reduce O
the O
consumption O
of O
analgesics O
after O
breast O
surgery O
. O
In O
this O
prospective O
randomized O
double O
- O
blind O
study O
, O
we O
assessed O
the O
significance O
of O
adding O
clonidine O
to O
the O
anesthetic O
mixture O
for O
women B-eligibility
undergoing I-eligibility
mastectomy I-eligibility
. O
Sixty B-total-participants
patients O
were O
randomized O
equally O
into O
2 O
groups O
, O
both O
of O
which O
received O
PVB O
block O
, O
either O
with O
or O
without O
clonidine O
. O
Analgesic O
consumption O
was O
noted O
up O
to O
2 O
weeks O
after O
the O
operation O
. O
A O
visual O
analog O
scale O
was O
used O
to O
assess O
pain O
postoperatively O
during O
the O
hospital O
stay O
, O
and O
a O
numeric O
rating O
scale O
was O
used O
when O
patients O
were O
discharged O
. O
Analgesic B-outcome
consumption I-outcome
was O
significantly O
lower O
in O
the O
clonidine O
group O
48 O
hours O
postoperatively O
with O
95 O
% O
confidence O
interval O
( O
CI O
) O
for O
the O
difference O
( O
-69.5 O
% O
to O
-6.6 O
% O
) O
. O
Pain B-outcome
scores I-outcome
at O
rest O
showed O
significant O
reduction O
in O
the O
clonidine O
group O
during O
the O
period O
from O
24 O
to O
72 O
hours O
postoperatively O
with O
95 O
% O
CI O
for O
the O
ratios O
of O
2 O
means O
( O
1.09 O
- O
3.61 O
) O
, O
( O
2.04 O
- O
9.04 O
) O
, O
and O
( O
2.54 O
- O
16.55 O
) O
, O
respectively O
, O
with O
shoulder B-outcome
movement I-outcome
at O
24 O
, O
48 O
, O
and O
72 O
hours O
postoperatively O
95 O
% O
CI O
for O
the O
ratio O
of O
2 O
means O
( O
1.10 O
- O
3.15 O
) O
, O
( O
1.32 O
- O
6.38 O
) O
, O
and O
( O
1.33 O
- O
8.42 O
) O
, O
respectively O
. O
The O
time B-outcome
needed I-outcome
to I-outcome
resume I-outcome
daily I-outcome
activity I-outcome
was O
shorter O
in O
the O
clonidine O
group O
compared O
with O
the O
control O
group O
with O
95 O
% O
CI O
for O
the O
ratio O
of O
2 O
means O
( O
1.14 O
- O
1.62 O
) O
. O
The O
addition O
of O
clonidine O
enhanced O
the O
analgesic O
efficacy O
of O
PVB O
up O
to O
3 O
days O
postoperatively O
for O
patients O
undergoing O
breast O
surgery O
. O

Weekly B-intervention
paclitaxel I-intervention
/ I-intervention
carboplatin I-intervention
/ I-intervention
trastuzumab I-intervention
therapy I-intervention
improves O
pathologic O
complete O
remission O
in O
aggressive O
HER2 O
- O
positive O
breast O
cancers O
, O
especially O
in O
luminal O
- O
B O
subtype O
, O
compared O
with O
a O
once O
- O
every-3 O
- O
weeks O
schedule O
. O
The O
efficacy O
and O
tolerability O
of O
two O
different O
schedules O
of O
paclitaxel O
, O
carboplatin O
, O
and O
trastuzumab O
( O
PCarH O
) O
for O
HER2 O
- O
positive O
, O
locally O
aggressive O
( O
stage O
IIB O
- O
IIIC O
) O
breast O
cancers O
were O
evaluated O
in O
this O
phase O
II O
trial O
. O
Patients O
were O
randomly O
assigned O
to O
receive O
either O
weekly O
( O
12 O
doses O
over O
16 O
weeks O
) O
or O
once O
- O
every-3 O
- O
weeks O
( O
4 O
doses O
over O
12 O
weeks O
) O
treatment O
. O
The O
primary O
endpoint O
was O
pathologic B-outcome-measure
complete I-outcome-measure
remission I-outcome-measure
( I-outcome-measure
pCR I-outcome-measure
) I-outcome-measure
in I-outcome-measure
the I-outcome-measure
breast I-outcome-measure
and I-outcome-measure
axilla I-outcome-measure
. O
To O
detect O
an O
assumed O
35 O
% O
pCR O
absolute O
difference O
between O
the O
two O
schedules O
, O
a O
minimum O
of O
26 O
assessable O
patients O
in O
each O
group O
was O
required O
( O
two O
- O
sided O
 O
= O
0.05 O
, O
 O
= O
0.2 O
) O
. O
A O
total O
of O
56 B-total-participants
patients O
were O
enrolled O
( O
weekly O
group O
, O
n O
= O
29 B-intervention-participants
; O
every-3 B-control
- I-control
weeks I-control
group I-control
, O
n O
= O
27 B-control-participants
) O
. O
In O
the O
intent O
- O
to O
- O
treat O
analysis O
, O
pCR B-outcome
in I-outcome
the I-outcome
breast I-outcome
/ I-outcome
axilla I-outcome
were O
found O
in O
31 O
patients O
( O
55 O
% O
; O
95 O
% O
confidence O
interval O
[ O
CI O
] O
: O
41%-69 O
% O
) O
. O
Compared O
with O
the O
every-3 O
- O
weeks O
schedule O
, O
the O
weekly O
administration O
achieved O
higher O
pCR B-outcome
( O
41 B-cv-bin-percent
% I-cv-bin-percent
vs. O
69 B-iv-bin-percent
% I-iv-bin-percent
; O
p O
= O
.03 O
) O
. O
After O
adjustment O
for O
clinical O
and O
pathological O
factors O
, O
the O
weekly O
administration O
was O
more O
effective B-outcome
than O
the O
every-3 O
- O
weeks O
schedule O
, O
with O
hazard O
ratio O
of O
0.3 O
( O
95 O
% O
CI O
: O
0.1 O
- O
0.9 O
; O
p O
= O
.03 O
) O
. O
Interestingly O
, O
weekly O
administration O
resulted O
in O
high O
pCR B-outcome
rates I-outcome
in O
both O
luminal O
- O
B O
( O
HER2 O
- O
positive O
) O
and O
ERBB2 O
+ O
tumors O
( O
67 B-cv-bin-percent
% I-cv-bin-percent
vs. O
71 B-iv-bin-percent
% I-iv-bin-percent
; O
p O
= O
.78 O
) O
, O
whereas O
luminal B-outcome
- I-outcome
B I-outcome
( I-outcome
HER2 I-outcome
- I-outcome
positive I-outcome
) I-outcome
tumors I-outcome
benefited O
less O
from O
the O
every-3 O
- O
weeks O
schedule O
compared O
with O
the O
ERBB2 O
+ O
tumors O
( O
21 B-cv-bin-percent
% I-cv-bin-percent
vs. O
62 B-iv-bin-percent
% I-iv-bin-percent
, O
p O
= O
.03 O
) O
. O
These O
results O
remain O
after O
multivariate O
adjustment O
, O
showing O
weekly O
administration O
was O
more O
effective O
in O
the O
luminal O
- O
B O
( O
HER2 O
- O
positive O
) O
subgroup O
( O
p O
= O
.02 O
) O
but O
not O
in O
the O
ERBB2 O
+ O
subgroup O
( O
p O
= O
.50 O
) O
. O
A O
more O
frequent O
administration O
might O
improve O
the O
possibility O
of O
eradicating O
invasive O
cancer O
in O
the O
breast O
and O
axilla O
, O
especially O
in O
the O
luminal O
- O
B O
( O
HER2 O
- O
positive O
) O
subtype O
. O
Further O
studies O
to O
validate O
our O
findings O
are O
warranted O
. O

Prophylactic O
use O
of O
levonorgestrel B-intervention
- I-intervention
releasing I-intervention
intrauterine I-intervention
system I-intervention
in O
women O
with O
breast O
cancer O
treated O
with O
tamoxifen O
: O
a O
randomized O
controlled O
trial O
. O
To O
estimate O
the O
rate O
of O
endometrial O
pathology O
with O
the O
prophylactic O
use O
of O
levonorgestrel O
- O
releasing O
intrauterine O
system O
in O
women O
with O
breast O
cancer O
treated O
with O
tamoxifen O
. O
This O
was O
a O
randomized O
contro O
- O
lled O
trial O
of O
129 B-total-participants
Chinese B-ethinicity
women O
who O
attended O
a O
university O
hospital O
in O
Hong B-ethinicity
Kong I-ethinicity
and O
required B-eligibility
adjuvant I-eligibility
tamoxifen I-eligibility
for I-eligibility
breast I-eligibility
cancer I-eligibility
after I-eligibility
the I-eligibility
completion I-eligibility
of I-eligibility
postoperative I-eligibility
radiotherapy I-eligibility
and I-eligibility
chemotherapy I-eligibility
. O
Women O
were O
randomized O
to O
treatment O
( O
prophylactic O
levonorgestrel O
- O
releasing O
intrauterine O
system O
insertion O
before O
the O
commencement O
of O
tamoxifen O
) O
or O
control B-control
group I-control
. O
The O
uterine O
cavity O
was O
examined O
by O
hysteroscopy O
and O
endometrial O
sampling O
before O
the O
commencement O
of O
tamoxifen O
and O
at O
12 O
, O
24 O
, O
45 O
, O
and O
60 O
months O
afterward O
. O
Any O
endometrial O
polyps O
or O
submucosal O
fibroids O
were O
resected O
through O
hysteroscopy O
at O
each O
assessment O
and O
specimens O
were O
sent O
for O
histologic O
confirmation O
. O
A O
total O
of O
94 B-total-participants
women O
completed O
5 O
- O
year O
follow O
- O
up O
. O
There O
was O
no O
significant O
difference O
in O
the O
occurrence B-outcome
of I-outcome
submucosal I-outcome
fibroids I-outcome
( O
1 B-iv-bin-abs
[ O
1.8 B-iv-bin-percent
% I-iv-bin-percent
] O
compared O
with O
2 B-cv-bin-abs
[ O
3.4 B-cv-bin-percent
% I-cv-bin-percent
] O
) O
and O
endometrial B-outcome
hyperplasia I-outcome
( O
both O
0 B-iv-bin-abs
) O
in O
the O
treatment O
and O
control O
groups O
, O
respectively O
. O
Levonorgestrel O
- O
releasing O
intrauterine O
system O
significantly O
reduced O
de B-outcome
novo I-outcome
endometrial I-outcome
polyps I-outcome
( O
hazard O
ratio O
0.19 O
, O
95 O
% O
confidence O
interval O
0.07 O
- O
0.48 O
) O
over O
the O
course O
of O
5 O
years O
on O
an O
intention O
- O
to O
- O
treat O
basis O
. O
There O
was O
no O
statistically O
significant O
increase O
in O
breast B-outcome
cancer I-outcome
recurrence I-outcome
rate I-outcome
( O
10 B-cv-bin-abs
[ O
17.2 B-cv-bin-percent
% I-cv-bin-percent
] O
compared O
with O
6 B-iv-bin-abs
[ O
10.0 B-iv-bin-percent
% I-iv-bin-percent
] O
) O
or O
cancer B-outcome
- I-outcome
related I-outcome
deaths I-outcome
( O
6 B-cv-bin-abs
[ O
10.3 B-cv-bin-percent
% I-cv-bin-percent
] O
compared O
with O
5 B-iv-bin-abs
[ O
8.3 B-iv-bin-percent
% I-iv-bin-percent
] O
) O
in O
the O
treatment O
group O
, O
but O
the O
study O
was O
underpowered O
in O
this O
regard O
. O
Prophylactic O
levonorgestrel O
- O
releasing O
intrauterine O
system O
prevents O
de O
novo O
endometrial O
polyps O
in O
women O
using O
tamoxifen O
. O
However O
, O
its O
role O
in O
the O
prevention O
of O
endometrial O
hyperplasia O
and O
adenocarcinoma O
as O
well O
as O
its O
effect O
on O
risk O
of O
breast O
cancer O
recurrence O
remain O
uncertain O
. O
Chinese O
Clinical O
Trial O
Registry O
, O
http://www.chictr.org/en/ O
, O
ChiCTR O
- O
TRC-09000625 O
. O
I. O

A O
randomized O
, O
phase O
II O
, O
three O
- O
arm O
study O
of O
two O
schedules O
of O
ixabepilone B-intervention
or O
paclitaxel B-control
plus I-control
bevacizumab I-control
as O
first O
- O
line O
therapy O
for O
metastatic O
breast O
cancer O
. O
The O
aim O
of O
this O
phase O
II O
trial O
was O
to O
estimate O
the O
objective O
response O
rate O
( O
ORR O
) O
of O
two O
different O
schedules O
of O
ixabepilone O
[ O
weekly O
or O
every O
3 O
weeks O
( O
Q3W O
) O
] O
combined O
with O
bevacizumab O
, O
relative O
to O
a O
reference O
arm O
of O
weekly O
paclitaxel O
and O
bevacizumab O
. O
Patients B-eligibility
with I-eligibility
human I-eligibility
epidermal I-eligibility
growth I-eligibility
factor I-eligibility
receptor I-eligibility
2 I-eligibility
- I-eligibility
normal I-eligibility
, I-eligibility
chemotherapy I-eligibility
- I-eligibility
nave I-eligibility
metastatic I-eligibility
breast I-eligibility
cancer I-eligibility
( I-eligibility
MBC I-eligibility
) I-eligibility
were O
randomized O
3 O
:3 O
: O
2 O
to O
ixabepilone O
16 O
mg O
/ O
m O
( O
2 O
) O
weekly O
plus O
bevacizumab O
10 O
mg O
/ O
kg O
Q2W O
( O
Arm O
A O
: O
n O
= O
46 O
) O
; O
ixabepilone O
40 O
mg O
/ O
m O
( O
2 O
) O
Q3W O
( O
reduced O
to O
32 O
mg O
/ O
m O
( O
2 O
) O
after O
four O
cycles O
of O
treatment O
) O
plus O
bevacizumab O
15 O
mg O
/ O
kg O
Q3W O
( O
Arm O
B O
: O
n O
= O
45 O
) O
; O
or O
paclitaxel O
90 O
mg O
/ O
m O
( O
2 O
) O
weekly O
plus O
bevacizumab O
10 O
mg O
/ O
kg O
intravenous O
infusion O
Q2W O
( O
Arm O
C O
: O
n O
= O
32 O
) O
. O
Of O
123 B-total-participants
randomized O
patients O
, O
122 B-total-participants
were O
treated O
. O
All O
were O
followed O
for O
19 O
months O
; O
5 O
% O
of O
patients O
remained O
on O
study O
treatment O
at O
the O
time O
of O
this O
analysis O
. O
Grade B-outcome
3 I-outcome
or I-outcome
4 I-outcome
neutropenia I-outcome
was O
more O
common O
in O
Arm O
B O
( O
60 B-iv-bin-percent
% I-iv-bin-percent
) O
than O
Arms O
A O
( O
16 B-iv-bin-percent
% I-iv-bin-percent
) O
or O
C O
( O
22 B-cv-bin-percent
% I-cv-bin-percent
) O
; O
other O
adverse O
events O
were O
similar O
. O
The O
investigator O
- O
assessed O
ORR B-outcome
was O
48 B-iv-bin-percent
, O
71 B-iv-bin-percent
, O
and O
63 B-cv-bin-percent
% I-cv-bin-percent
for O
Arms O
A O
, O
B O
, O
and O
C O
, O
respectively O
. O
Median B-outcome
progression I-outcome
- I-outcome
free I-outcome
survival I-outcome
( O
randomized O
patients O
) O
was O
9.6 B-iv-cont-median
months I-iv-cont-median
in O
Arm O
A O
, O
11.9 B-iv-cont-median
months I-iv-cont-median
in O
Arm O
B O
, O
and O
13.5 B-cv-cont-median
months I-cv-cont-median
in O
Arm O
C. O
In O
conclusion O
, O
ixabepilone O
Q3W O
plus O
bevacizumab O
has O
clinical O
activity O
as O
first O
- O
line O
therapy O
for O
MBC O
relative O
to O
paclitaxel O
plus O
bevacizumab O
, O
but O
with O
significantly O
greater O
risk O
of O
grade O
3 O
or O
4 O
neutropenia O
. O
In O
addition O
, O
these O
data O
suggest O
that O
weekly O
dosing O
of O
ixabepilone O
may O
be O
less O
active O
than O
Q3W O
dosing O
, O
but O
with O
less O
neutropenia O
. O

Randomized O
phase O
II O
, O
double O
- O
blind O
, O
placebo O
- O
controlled O
study O
of O
exemestane B-intervention
with I-intervention
or I-intervention
without I-intervention
entinostat I-intervention
in O
postmenopausal O
women O
with O
locally O
recurrent O
or O
metastatic O
estrogen O
receptor O
- O
positive O
breast O
cancer O
progressing O
on O
treatment O
with O
a O
nonsteroidal O
aromatase O
inhibitor O
. O
Entinostat O
is O
an O
oral O
isoform O
selective O
histone O
deacetylase O
inhibitor O
that O
targets O
resistance O
to O
hormonal O
therapies O
in O
estrogen O
receptor O
- O
positive O
( O
ER+ O
) O
breast O
cancer O
. O
This O
randomized O
, O
placebo O
- O
controlled O
, O
phase O
II O
study O
evaluated O
entinostat O
combined O
with O
the O
aromatase O
inhibitor O
exemestane O
versus O
exemestane O
alone O
. O
Postmenopausal B-eligibility
women I-eligibility
with I-eligibility
ER+ I-eligibility
advanced I-eligibility
breast I-eligibility
cancer I-eligibility
progressing I-eligibility
on I-eligibility
a I-eligibility
nonsteroidal I-eligibility
aromatase I-eligibility
inhibitor I-eligibility
were O
randomly O
assigned O
to O
exemestane O
25 O
mg O
daily O
plus O
entinostat O
5 O
mg O
once O
per O
week O
( O
EE O
) O
or O
exemestane B-control
plus I-control
placebo I-control
( I-control
EP I-control
) I-control
. O
The O
primary O
end O
point O
was O
progression B-outcome-measure
- I-outcome-measure
free I-outcome-measure
survival I-outcome-measure
( I-outcome-measure
PFS I-outcome-measure
) I-outcome-measure
. O
Blood O
was O
collected O
in O
a O
subset O
of O
patients O
for O
evaluation O
of O
protein O
lysine O
acetylation O
as O
a O
biomarker O
of O
entinostat O
activity O
. O
One B-total-participants
hundred I-total-participants
thirty I-total-participants
patients O
were O
randomly O
assigned O
( O
EE O
group O
, O
n O
= O
64 B-intervention-participants
; O
EP O
group O
, O
n O
= O
66 B-control-participants
) O
. O
Based O
on O
intent O
- O
to O
- O
treat O
analysis O
, O
treatment O
with O
EE O
improved O
median B-outcome
PFS I-outcome
to O
4.3 B-iv-cont-median
months I-iv-cont-median
versus O
2.3 B-cv-cont-median
months I-cv-cont-median
with O
EP O
( O
hazard O
ratio O
[ O
HR O
] O
, O
0.73 O
; O
95 O
% O
CI O
, O
0.50 O
to O
1.07 O
; O
one O
- O
sided O
P O
= O
.055 O
; O
two O
- O
sided O
P O
= O
.11 O
[ O
predefined O
significance O
level O
of O
.10 O
, O
one O
- O
sided O
] O
) O
. O
Median B-outcome
overall I-outcome
survival I-outcome
was O
an O
exploratory O
end O
point O
and O
improved O
to O
28.1 B-iv-cont-median
months I-iv-cont-median
with O
EE O
versus O
19.8 B-cv-cont-median
months I-cv-cont-median
with O
EP O
( O
HR O
, O
0.59 O
; O
95 O
% O
CI O
, O
0.36 O
to O
0.97 O
; O
P O
= O
.036 O
) O
. O
Fatigue B-outcome
and I-outcome
neutropenia I-outcome
were O
the O
most O
frequent O
grade B-outcome
3 I-outcome
/ I-outcome
4 I-outcome
toxicities I-outcome
. O
Treatment B-outcome
discontinuation I-outcome
because O
of O
adverse B-outcome
events I-outcome
was O
higher O
in O
the O
EE O
group O
versus O
the O
EP O
group O
( O
11 B-iv-bin-percent
% I-iv-bin-percent
v O
2 B-cv-bin-percent
% I-cv-bin-percent
) O
. O
Protein O
lysine O
hyperacetylation O
in O
the O
EE O
biomarker O
subset O
was O
associated O
with O
prolonged O
PFS O
. O
Entinostat O
added O
to O
exemestane O
is O
generally O
well O
tolerated O
and O
demonstrated O
activity O
in O
patients O
with O
ER+ O
advanced O
breast O
cancer O
in O
this O
signal O
- O
finding O
phase O
II O
study O
. O
Acetylation O
changes O
may O
provide O
an O
opportunity O
to O
maximize O
clinical O
benefit O
with O
entinostat O
. O
Plans O
for O
a O
confirmatory O
study O
are O
underway O
. O

Randomized O
controlled O
trial O
of O
toremifene B-intervention
120 O
mg O
compared O
with O
exemestane B-control
25 O
mg O
after O
prior O
treatment O
with O
a O
non O
- O
steroidal O
aromatase O
inhibitor O
in O
postmenopausal B-eligibility
women I-eligibility
with I-eligibility
hormone I-eligibility
receptor I-eligibility
- I-eligibility
positive I-eligibility
metastatic I-eligibility
breast I-eligibility
cancer I-eligibility
. O
After O
the O
failure O
of O
a O
non O
- O
steroidal O
aromatase O
inhibitor O
( O
nsAI O
) O
for O
postmenopausal O
patients O
with O
metastatic O
breast O
cancer O
( O
mBC O
) O
, O
it O
is O
unclear O
which O
of O
various O
kinds O
of O
endocrine O
therapy O
is O
the O
most O
appropriate O
. O
A O
randomized O
controlled O
trial O
was O
performed O
to O
compare O
the O
efficacy O
and O
safety O
of O
daily O
toremifene O
120 O
 O
mg O
( O
TOR120 O
) O
, O
a O
selective O
estrogen O
receptor O
modulator O
, O
and O
exemestane O
25 O
 O
mg O
( O
EXE O
) O
, O
a O
steroidal O
aromatase O
inhibitor O
. O
The O
primary O
end O
point O
was O
the O
clinical B-outcome-measure
benefit I-outcome-measure
rate I-outcome-measure
( I-outcome-measure
CBR I-outcome-measure
) I-outcome-measure
. O
The O
secondary O
end O
points O
were O
objective B-outcome-measure
response I-outcome-measure
rate I-outcome-measure
( I-outcome-measure
ORR I-outcome-measure
) I-outcome-measure
, O
progression B-outcome-measure
- I-outcome-measure
free I-outcome-measure
survival I-outcome-measure
( I-outcome-measure
PFS I-outcome-measure
) I-outcome-measure
, O
overall B-outcome-measure
survival I-outcome-measure
( I-outcome-measure
OS I-outcome-measure
) I-outcome-measure
and O
toxicity B-outcome-measure
. O
Initially O
, O
a O
total O
of O
91 B-total-participants
women O
was O
registered O
in O
the O
study O
and O
randomly O
assigned O
to O
either O
TOR120 O
( O
n O
 O
= O
 O
46 B-intervention-participants
) O
or O
EXE O
( O
n O
 O
= O
 O
45 B-control-participants
) O
from O
October O
2008 O
to O
November O
2011 O
. O
Three O
of O
the O
46 O
patients O
in O
the O
TOR120 O
arm O
were O
not O
received O
treatment O
, O
2 O
patients O
having O
withdrawn O
from O
the O
trial O
by O
their O
preference O
and O
one O
having O
been O
dropped O
due O
to O
administration O
of O
another O
SERM O
. O
When O
analyzed O
after O
a O
median O
observation O
period O
of O
16.9 O
 O
months O
, O
the O
intention O
- O
to O
- O
treat O
analysis O
showed O
that O
there O
were O
no O
statistical O
difference O
between O
TOR120 O
( O
N O
 O
= O
 O
46 B-intervention-participants
) O
and O
EXE O
( O
n O
 O
= O
 O
45 B-control-participants
) O
in O
terms O
of O
CBR B-outcome
( O
41.3 B-iv-bin-percent
% I-iv-bin-percent
vs. O
26.7 B-cv-bin-percent
% I-cv-bin-percent
; O
P O
 O
= O
 O
0.14 O
) O
, O
ORR B-outcome
( O
10.8 B-iv-bin-percent
% I-iv-bin-percent
vs. O
2.2 B-cv-bin-percent
% I-cv-bin-percent
; O
P O
 O
= O
 O
0.083 O
) O
, O
and O
OS B-outcome
( O
Hazard O
ratio O
, O
0.60 O
; O
P O
 O
= O
 O
0.22 O
) O
. O
The O
PFS B-outcome
of O
TOR120 O
was O
longer O
than O
that O
of O
EXE O
, O
the O
difference O
being O
statistically O
significant O
( O
Hazard O
ratio O
, O
0.61 O
, O
P O
 O
= O
 O
0.045 O
) O
. O
The O
results O
in O
treatment O
- O
received O
cohort O
( O
N O
 O
= O
 O
88 O
) O
were O
similar O
to O
those O
in O
ITT O
cohort O
. O
Both O
treatments O
were O
well O
- O
tolerated O
with O
no O
severe O
adverse B-outcome
events I-outcome
, O
although O
the O
treatment O
of O
3 B-iv-bin-abs
of O
43 B-intervention-participants
women O
administered O
TOR120 O
was O
stopped O
after O
a O
few O
days O
because O
of O
nausea O
, O
general O
fatigue O
, O
hot O
flush O
and O
night O
sweating O
. O
TOR120 O
, O
as O
a O
subsequent O
endocrine O
therapy O
for O
mBC O
patients O
who O
failed O
non O
- O
steroidal O
AI O
treatment O
, O
could O
potentially O
be O
more O
beneficial O
than O
EXE O
. O
UMIN000001841 O
. O

Lumpectomy B-intervention
plus I-intervention
tamoxifen I-intervention
with I-intervention
or I-intervention
without I-intervention
irradiation I-intervention
in O
women O
age O
70 O
years O
or O
older O
with O
early O
breast O
cancer O
: O
long O
- O
term O
follow O
- O
up O
of O
CALGB O
9343 O
. O
To O
determine O
whether O
there O
is O
a O
benefit O
to O
adjuvant O
radiation O
therapy O
after O
breast O
- O
conserving O
surgery O
and O
tamoxifen O
in O
women O
age O
 O
70 O
years O
with O
early O
- O
stage O
breast O
cancer O
. O
Between O
July O
1994 O
and O
February O
1999 O
, O
636 B-total-participants
women O
( O
age O
 B-age
70 I-age
years I-age
) O
who B-eligibility
had I-eligibility
clinical I-eligibility
stage I-eligibility
I I-eligibility
( I-eligibility
T1N0M0 I-eligibility
according I-eligibility
to I-eligibility
TNM I-eligibility
classification I-eligibility
) I-eligibility
estrogen I-eligibility
receptor I-eligibility
( I-eligibility
ER I-eligibility
) I-eligibility
-positive I-eligibility
breast I-eligibility
carcinoma I-eligibility
treated I-eligibility
by I-eligibility
lumpectomy I-eligibility
were O
randomly O
assigned O
to O
receive O
tamoxifen O
plus O
radiation O
therapy O
( O
TamRT O
; O
317 B-intervention-participants
women O
) O
or O
tamoxifen B-control
alone I-control
( O
Tam O
; O
319 B-control-participants
women O
) O
. O
Primary O
end O
points O
were O
time B-outcome-measure
to I-outcome-measure
local I-outcome-measure
or I-outcome-measure
regional I-outcome-measure
recurrence I-outcome-measure
, O
frequency B-outcome-measure
of I-outcome-measure
mastectomy I-outcome-measure
, O
breast B-outcome-measure
cancer I-outcome-measure
- I-outcome-measure
specific I-outcome-measure
survival I-outcome-measure
, O
time B-outcome-measure
to I-outcome-measure
distant I-outcome-measure
metastasis I-outcome-measure
, O
and O
overall B-outcome-measure
survival I-outcome-measure
( I-outcome-measure
OS I-outcome-measure
) I-outcome-measure
. O
Median O
follow O
- O
up O
for O
treated O
patients O
is O
now O
12.6 O
years O
. O
At O
10 O
years O
, O
98 B-iv-bin-percent
% I-iv-bin-percent
of O
patients O
receiving O
TamRT O
( O
95 O
% O
CI O
, O
96 O
% O
to O
99 O
% O
) O
compared O
with O
90 B-cv-bin-percent
% I-cv-bin-percent
of O
those O
receiving O
Tam O
( O
95 O
% O
CI O
, O
85 O
% O
to O
93 O
% O
) O
were O
free B-outcome
from I-outcome
local I-outcome
and I-outcome
regional I-outcome
recurrences I-outcome
. O
There O
were O
no O
significant O
differences O
in O
time B-outcome
to I-outcome
mastectomy I-outcome
, O
time B-outcome
to I-outcome
distant I-outcome
metastasis I-outcome
, O
breast B-outcome
cancer I-outcome
- I-outcome
specific I-outcome
survival I-outcome
, O
or O
OS B-outcome
between O
the O
two O
groups O
. O
Ten B-outcome
- I-outcome
year I-outcome
OS I-outcome
was O
67 B-iv-bin-percent
% I-iv-bin-percent
( O
95 O
% O
CI O
, O
62 O
% O
to O
72 O
% O
) O
and O
66 B-cv-bin-percent
% I-cv-bin-percent
( O
95 O
% O
CI O
, O
61 O
% O
to O
71 O
% O
) O
in O
the O
TamRT O
and O
Tam O
groups O
, O
respectively O
. O
With O
long O
- O
term O
follow O
- O
up O
, O
the O
previously O
observed O
small O
improvement O
in O
locoregional B-outcome
recurrence I-outcome
with O
the O
addition O
of O
radiation O
therapy O
remains O
. O
However O
, O
this O
does O
not O
translate O
into O
an O
advantage O
in O
OS O
, O
distant O
disease O
- O
free O
survival O
, O
or O
breast O
preservation O
. O
Depending O
on O
the O
value O
placed O
on O
local O
recurrence O
, O
Tam O
remains O
a O
reasonable O
option O
for O
women O
age O
 O
70 O
years O
with O
ER O
- O
positive O
early O
- O
stage O
breast O
cancer O
. O

Randomized O
double O
- O
blind O
placebo O
- O
controlled O
trial O
of O
acetyl B-intervention
- I-intervention
L I-intervention
- I-intervention
carnitine I-intervention
for O
the O
prevention O
of O
taxane B-condition
- I-condition
induced I-condition
neuropathy I-condition
in O
women B-eligibility
undergoing I-eligibility
adjuvant I-eligibility
breast I-eligibility
cancer I-eligibility
therapy I-eligibility
. O
Chemotherapy O
- O
induced O
peripheral O
neuropathy O
( O
CIPN O
) O
is O
common O
and O
leads O
to O
suboptimal O
treatment O
. O
Acetyl O
- O
L O
- O
carnitine O
( O
ALC O
) O
is O
a O
natural O
compound O
involved O
in O
neuronal O
protection O
. O
Studies O
have O
suggested O
ALC O
may O
be O
effective O
for O
the O
prevention O
and O
treatment O
of O
CIPN O
. O
A O
24 O
- O
week O
randomized O
double O
- O
blind O
trial O
comparing O
ALC O
( O
3,000 O
mg O
per O
day O
) O
with O
placebo B-control
in O
women O
undergoing O
adjuvant O
taxane O
- O
based O
chemotherapy O
was O
conducted O
. O
The O
primary O
objective O
was O
to O
determine B-outcome-measure
if I-outcome-measure
ALC I-outcome-measure
prevents I-outcome-measure
CIPN I-outcome-measure
as O
measured O
by O
the O
11 O
- O
item O
neurotoxicity O
( O
NTX O
) O
component O
of O
the O
Functional O
Assessment O
of O
Cancer O
Therapy O
( O
FACT O
) O
-Taxane O
scale O
at O
12 O
weeks O
. O
Secondary O
objectives O
included O
changes B-outcome-measure
in I-outcome-measure
24 I-outcome-measure
- I-outcome-measure
week I-outcome-measure
end I-outcome-measure
points I-outcome-measure
, O
functional B-outcome-measure
status I-outcome-measure
( O
FACT O
- O
Trial O
Outcome O
Index O
[ O
TOI O
] O
) O
, O
fatigue B-outcome-measure
( O
Functional O
Assessment O
of O
Chronic O
Illness O
Therapy O
[ O
FACIT O
] O
-Fatigue O
) O
, O
and O
NTX B-outcome-measure
grade I-outcome-measure
. O
A O
total O
of O
409 B-total-participants
patients O
were O
evaluable O
( O
208 B-intervention-participants
received O
ALC O
; O
201 B-control-participants
, O
placebo O
) O
. O
In O
a O
multivariate O
linear O
regression O
, O
week-12 O
scores O
were O
0.9 O
points O
lower O
( O
more O
CIPN O
) O
with O
ALC O
than O
placebo O
( O
95 O
% O
CI O
, O
-2.2 O
to O
0.4 O
; O
P O
= O
.17 O
) O
, O
whereas O
week-24 O
scores O
were O
1.8 O
points O
lower O
with O
ALC O
( O
95 O
% O
CI O
, O
-3.2 O
to O
-0.4 O
; O
P O
= O
.01 O
) O
. O
Patients O
receiving O
ALC O
were O
more O
likely O
to O
have O
a O
> B-outcome
5 I-outcome
- I-outcome
point I-outcome
decrease I-outcome
in I-outcome
FACT I-outcome
- I-outcome
NTX I-outcome
scores I-outcome
( O
38 B-iv-bin-percent
% I-iv-bin-percent
v O
28 B-cv-bin-percent
% I-cv-bin-percent
; O
P O
= O
.05 O
) O
, O
and O
FACT O
- O
TOI O
scores O
were O
3.5 O
points O
lower O
with O
ALC O
( O
P O
= O
.03 O
) O
. O
Grade B-outcome
3 I-outcome
to I-outcome
4 I-outcome
neurotoxicity I-outcome
was O
more O
frequent O
in O
the O
ALC O
arm O
( O
eight B-iv-bin-abs
v O
one B-cv-bin-abs
) O
. O
No O
differences O
between O
arms O
were O
observed O
for O
FACIT B-outcome
- I-outcome
Fatigue I-outcome
or I-outcome
other I-outcome
toxicities I-outcome
. O
Serum B-outcome
carnitine I-outcome
level I-outcome
increased O
with O
ALC O
but O
remained O
stable O
with O
placebo O
. O
There O
was O
no O
evidence O
that O
ALC O
affected O
CIPN O
at O
12 O
weeks O
; O
however O
, O
ALC O
significantly O
increased O
CIPN O
by O
24 O
weeks O
. O
This O
is O
the O
first O
study O
to O
our O
knowledge O
showing O
that O
a O
nutritional O
supplement O
increased O
CIPN O
. O
Patients O
should O
be O
discouraged O
from O
using O
supplements O
without O
proven O
efficacy O
. O

Randomized O
phase O
II O
study O
of O
the O
anti O
- O
epidermal O
growth O
factor O
receptor O
monoclonal O
antibody O
cetuximab B-intervention
with I-intervention
cisplatin I-intervention
versus O
cisplatin B-control
alone I-control
in O
patients O
with O
metastatic O
triple O
- O
negative O
breast O
cancer O
. O
Epidermal O
growth O
factor O
receptor O
is O
overexpressed O
in O
metastatic O
triple O
- O
negative O
breast O
cancers O
( O
mTNBCs O
) O
, O
an O
aggressive O
subtype O
of O
breast O
cancer O
. O
Our O
randomized O
phase O
II O
study O
investigated O
cisplatin O
with O
or O
without O
cetuximab O
in O
this O
setting O
. O
Patients B-eligibility
who I-eligibility
had I-eligibility
received I-eligibility
no I-eligibility
more I-eligibility
than I-eligibility
one I-eligibility
previous I-eligibility
chemotherapy I-eligibility
regimen I-eligibility
were O
randomly O
assigned O
on O
a O
2 O
:1 O
schedule O
to O
receive O
no O
more O
than O
six O
cycles O
of O
cisplatin O
plus O
cetuximab O
or O
cisplatin O
alone O
. O
Patients O
receiving O
cisplatin O
alone O
could O
switch O
to O
cisplatin O
plus O
cetuximab O
or O
cetuximab O
alone O
on O
disease O
progression O
. O
The O
primary O
end O
point O
was O
overall B-outcome-measure
response I-outcome-measure
rate I-outcome-measure
( I-outcome-measure
ORR I-outcome-measure
) I-outcome-measure
. O
Secondary O
end O
points O
studied O
included O
progression B-outcome-measure
- I-outcome-measure
free I-outcome-measure
survival I-outcome-measure
( I-outcome-measure
PFS I-outcome-measure
) I-outcome-measure
, O
overall B-outcome-measure
survival I-outcome-measure
( I-outcome-measure
OS I-outcome-measure
) I-outcome-measure
, O
and O
safety B-outcome-measure
profiles I-outcome-measure
. O
Analyses O
included O
a O
significance O
level O
of O
 O
= O
.10 O
with O
no O
adjustments O
for O
multiplicity O
. O
The O
full O
analysis O
set O
comprised O
115 B-intervention-participants
patients O
receiving O
cisplatin O
plus O
cetuximab O
and O
58 B-control-participants
receiving O
cisplatin O
alone O
; O
31 O
patients O
whose O
disease O
progressed O
on O
cisplatin O
alone O
switched O
to O
cetuximab O
- O
containing O
therapy O
. O
The O
ORR B-outcome
was O
20 B-iv-bin-percent
% I-iv-bin-percent
( O
95 O
% O
CI O
, O
13 O
to O
29 O
) O
with O
cisplatin O
plus O
cetuximab O
and O
10 B-cv-bin-percent
% I-cv-bin-percent
( O
95 O
% O
CI O
, O
4 O
to O
21 O
) O
with O
cisplatin O
alone O
( O
odds O
ratio O
, O
2.13 O
; O
95 O
% O
CI O
, O
0.81 O
to O
5.59 O
; O
P O
= O
.11 O
) O
. O
Cisplatin O
plus O
cetuximab O
resulted O
in O
longer O
PFS B-outcome
compared O
with O
cisplatin O
alone O
( O
median O
, O
3.7 B-iv-cont-median
v O
1.5 B-cv-cont-median
months I-cv-cont-median
; O
hazard O
ratio O
[ O
HR O
] O
, O
0.67 O
; O
95 O
% O
CI O
, O
0.47 O
to O
0.97 O
; O
P O
= O
.032 O
) O
. O
Corresponding O
median B-outcome
OS I-outcome
was O
12.9 B-iv-cont-median
versus O
9.4 B-cv-cont-median
months I-cv-cont-median
( O
HR O
, O
0.82 O
; O
95 O
% O
CI O
, O
0.56 O
to O
1.20 O
; O
P O
= O
.31 O
) O
. O
Common O
grade B-outcome
3 I-outcome
/ I-outcome
4 I-outcome
adverse I-outcome
events I-outcome
included O
acne B-outcome
- I-outcome
like I-outcome
rash I-outcome
, I-outcome
neutropenia I-outcome
, I-outcome
and I-outcome
fatigue I-outcome
. O
While O
the O
primary O
study O
end O
point O
was O
not O
met O
, O
adding O
cetuximab O
to O
cisplatin O
doubled O
the O
ORR O
and O
appeared O
to O
prolong O
PFS O
and O
OS O
, O
warranting O
further O
investigation O
in O
mTNBC O
. O

Soluble O
human O
epidermal O
growth O
factor O
receptor O
2 O
( O
HER2 O
) O
levels O
in O
patients O
with O
HER2 O
- O
positive O
breast O
cancer O
receiving O
chemotherapy B-intervention
with I-intervention
or I-intervention
without I-intervention
trastuzumab I-intervention
: O
results O
from O
North O
Central O
Cancer O
Treatment O
Group O
adjuvant O
trial O
N9831 O
. O
Increased O
soluble O
human O
epidermal O
growth O
factor O
receptor O
2 O
( O
sHER2 O
) O
is O
an O
indicator O
of O
a O
poor O
prognosis O
in O
HER2 O
- O
positive O
metastatic O
breast O
cancer O
. O
In O
this O
study O
, O
the O
authors O
evaluated O
levels O
of O
sHER2 O
during O
treatment O
and O
at O
the O
time O
of O
disease O
recurrence O
in O
the O
adjuvant O
North O
Central O
Cancer O
Treatment O
Group O
N9831 O
clinical O
trial O
. O
The O
objectives O
were O
to O
describe O
sHER2 O
levels O
during O
treatment O
and O
at O
the O
time O
of O
recurrence O
in O
patients O
who O
were O
randomized O
to O
treatment O
arms O
A O
( O
standard B-control
chemotherapy I-control
) O
, O
B O
( O
standard O
chemotherapy O
with O
sequential O
trastuzumab O
) O
, O
and O
C O
( O
standard O
chemotherapy O
with O
concurrent O
trastuzumab O
) O
. O
Baseline O
samples O
were O
available O
from O
2318 B-total-participants
patients O
, O
serial O
samples O
were O
available O
from O
105 O
patients O
, O
and O
recurrence O
samples O
were O
available O
from O
124 O
patients O
. O
The O
cutoff O
sHER2 O
value O
for O
the O
assay O
was O
15 O
ng O
/ O
mL. O
Statistical O
methods O
included O
repeated O
measures O
linear O
models O
, O
Wilcoxon O
rank O
- O
sum O
tests O
, O
and O
Cox O
regression O
models O
. O
There O
were O
differences O
between O
groups O
in O
terms O
of O
age O
, O
menopausal O
status O
, O
and O
hormone O
receptor O
status O
. O
Within O
treatment O
arms O
A O
, O
B O
, O
and O
C O
, O
patients O
who O
had O
baseline O
sHER2 O
levels O
15 O
ng O
/ O
mL O
had O
worse O
disease B-outcome
- I-outcome
free I-outcome
survival I-outcome
than O
patients O
who O
had O
baseline O
sHER2 O
levels O
< O
15 O
ng O
/ O
mL O
( O
arm O
A O
: O
hazard O
ratio O
, O
1.81 O
; O
P O
= O
.0014 O
; O
arm O
B O
: O
hazard O
ratio O
, O
2.08 O
; O
P O
= O
.0015 O
; O
arm O
C O
: O
hazard O
ratio O
, O
1.96 O
; O
P O
= O
.01 O
) O
. O
Among O
the O
124 O
patients O
who O
experienced O
disease O
recurrence O
, O
sHER2 B-outcome
levels I-outcome
increased O
from O
baseline O
to O
the O
time O
of O
recurrence O
in O
arms O
A O
and O
B O
but O
remained O
unchanged O
in O
arm O
C. O
Patients O
who O
had O
recurrence O
sHER2 O
levels O
15 O
ng O
/ O
mL O
had O
a O
shorter O
survival B-outcome
after I-outcome
recurrence I-outcome
with O
a O
3 B-outcome
- I-outcome
year I-outcome
overall I-outcome
survival I-outcome
rate I-outcome
of O
51 O
% O
compared O
with O
77 O
% O
for O
those O
who O
had O
recurrence O
sHER2 O
levels O
< O
15 O
ng O
/ O
mL O
( O
hazard O
ratio O
, O
2.36 O
; O
95 O
% O
confidence O
interval O
, O
1.19 O
- O
4.70 O
; O
P O
= O
.01 O
) O
. O
In O
patients O
with O
early O
stage O
, O
HER2 O
- O
positive O
breast O
cancer O
, O
a O
high O
baseline O
sHER2 O
level O
was O
identified O
as O
a O
prognostic O
marker O
associated O
with O
shorter O
disease O
- O
free O
survival O
, O
and O
a O
high O
sHER2 O
level O
at O
recurrence O
was O
predictive O
of O
shorter O
survival O
. O

High O
Ki67 O
predicts O
unfavourable O
outcomes O
in O
early O
breast O
cancer O
patients O
with O
a O
clinically O
clear O
axilla O
who O
do O
not O
receive O
axillary B-intervention
dissection I-intervention
or O
axillary B-control
radiotherapy I-control
. O
Axillary O
dissection O
is O
increasingly O
forgone O
in O
early O
breast O
cancer O
patients O
with O
a O
clinically O
negative O
axilla O
. O
The O
GRISO O
053 O
randomised O
trial O
recruited O
435 B-total-participants
patients O
of O
age O
over B-age
45 I-age
years I-age
, O
tumour B-eligibility
1.4 I-eligibility
cm I-eligibility
and I-eligibility
clinically I-eligibility
negative I-eligibility
axilla I-eligibility
, O
to O
assess O
the O
importance O
of O
axillary O
radiotherapy O
versus O
no O
axillary O
radiotherapy O
in O
patients O
not O
given O
axillary O
dissection O
. O
In O
the O
present O
study O
on O
a O
subgroup O
GRISO O
cases O
our O
aim O
was O
to O
assess O
the O
prognostic O
importance O
of O
tumour O
biological O
factors O
after O
more O
than O
10 O
years O
of O
follow O
- O
up O
. O
We O
retrospectively O
assessed O
biological O
factors O
in O
a O
subgroup O
of O
285 O
GRISO O
cases O
( O
145 B-control-participants
given O
axillary O
radiotherapy O
; O
140 B-intervention-participants
not O
given O
axillary O
radiotherapy O
) O
with O
complete O
biologic O
, O
therapeutic O
and O
follow O
- O
up O
information O
, O
using O
multivariable O
Cox O
proportional O
hazards O
regression O
modelling O
. O
Only O
10 B-outcome
- I-outcome
year I-outcome
cumulative I-outcome
incidence I-outcome
of I-outcome
distant I-outcome
metastasis I-outcome
was O
lower O
in O
the O
axillary O
radiotherapy O
( O
1 B-cv-bin-percent
% I-cv-bin-percent
) O
than O
no O
axillary O
radiotherapy O
arm O
( O
7 B-iv-bin-percent
% I-iv-bin-percent
) O
( O
p O
= O
0.037 O
) O
. O
Irrespective O
of O
study O
arm O
, O
hormone O
receptor O
positivity O
had O
significantly O
favourable O
effects O
on O
10 B-outcome
- I-outcome
year I-outcome
disease I-outcome
- I-outcome
free I-outcome
survival I-outcome
( I-outcome
DFS I-outcome
) I-outcome
and O
overall B-outcome
survival I-outcome
. O
human O
epidermal O
growth O
factor O
receptor O
2 O
( O
HER2 O
) O
-positive O
and O
triple O
- O
negative O
subtypes O
were O
associated O
with O
lower O
10 B-outcome
- I-outcome
year I-outcome
DFS I-outcome
( O
60 O
% O
and O
76 O
% O
, O
respectively O
) O
than O
luminal O
A O
( O
96 O
% O
) O
and O
B O
( O
91 O
% O
) O
( O
p O
= O
0.001 O
) O
. O
Ten B-outcome
- I-outcome
year I-outcome
DFS I-outcome
for O
high O
( O
14 O
% O
) O
Ki67 O
cancers O
was O
lower O
than O
for O
low O
Ki67 O
cancers O
( O
p O
= O
0.027 O
) O
; O
however O
, O
this O
effect O
was O
mainly O
confined O
to O
the O
no O
axillary O
radiotherapy O
arm O
. O
For O
patients O
with O
clinically O
node O
- O
negative O
small O
breast O
cancer O
not O
given O
axillary O
dissection O
, O
10 O
- O
year O
DFS O
is O
worsened O
by O
HER2 O
positivity O
, O
triple O
- O
negative O
phenotype O
and O
high O
Ki67 O
. O
Axillary O
radiotherapy O
counteracts O
the O
negative O
prognostic O
effect O
of O
high O
Ki67 O
in O
patients O
not O
receiving O
axillary O
dissection O
. O

